<!DOCTYPE html>

<html lang="en">
<head><meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>project</title><script src="https://cdnjs.cloudflare.com/ajax/libs/require.js/2.1.10/require.min.js"></script>
<style type="text/css">
    pre { line-height: 125%; }
td.linenos .normal { color: inherit; background-color: transparent; padding-left: 5px; padding-right: 5px; }
span.linenos { color: inherit; background-color: transparent; padding-left: 5px; padding-right: 5px; }
td.linenos .special { color: #000000; background-color: #ffffc0; padding-left: 5px; padding-right: 5px; }
span.linenos.special { color: #000000; background-color: #ffffc0; padding-left: 5px; padding-right: 5px; }
.highlight .hll { background-color: var(--jp-cell-editor-active-background) }
.highlight { background: var(--jp-cell-editor-background); color: var(--jp-mirror-editor-variable-color) }
.highlight .c { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment */
.highlight .err { color: var(--jp-mirror-editor-error-color) } /* Error */
.highlight .k { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword */
.highlight .o { color: var(--jp-mirror-editor-operator-color); font-weight: bold } /* Operator */
.highlight .p { color: var(--jp-mirror-editor-punctuation-color) } /* Punctuation */
.highlight .ch { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Hashbang */
.highlight .cm { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Multiline */
.highlight .cp { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Preproc */
.highlight .cpf { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.PreprocFile */
.highlight .c1 { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Single */
.highlight .cs { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Special */
.highlight .kc { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Constant */
.highlight .kd { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Declaration */
.highlight .kn { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Namespace */
.highlight .kp { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Pseudo */
.highlight .kr { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Reserved */
.highlight .kt { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Type */
.highlight .m { color: var(--jp-mirror-editor-number-color) } /* Literal.Number */
.highlight .s { color: var(--jp-mirror-editor-string-color) } /* Literal.String */
.highlight .ow { color: var(--jp-mirror-editor-operator-color); font-weight: bold } /* Operator.Word */
.highlight .pm { color: var(--jp-mirror-editor-punctuation-color) } /* Punctuation.Marker */
.highlight .w { color: var(--jp-mirror-editor-variable-color) } /* Text.Whitespace */
.highlight .mb { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Bin */
.highlight .mf { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Float */
.highlight .mh { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Hex */
.highlight .mi { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Integer */
.highlight .mo { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Oct */
.highlight .sa { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Affix */
.highlight .sb { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Backtick */
.highlight .sc { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Char */
.highlight .dl { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Delimiter */
.highlight .sd { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Doc */
.highlight .s2 { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Double */
.highlight .se { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Escape */
.highlight .sh { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Heredoc */
.highlight .si { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Interpol */
.highlight .sx { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Other */
.highlight .sr { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Regex */
.highlight .s1 { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Single */
.highlight .ss { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Symbol */
.highlight .il { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Integer.Long */
  </style>
<style type="text/css">
/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*
 * Mozilla scrollbar styling
 */

/* use standard opaque scrollbars for most nodes */
[data-jp-theme-scrollbars='true'] {
  scrollbar-color: rgb(var(--jp-scrollbar-thumb-color))
    var(--jp-scrollbar-background-color);
}

/* for code nodes, use a transparent style of scrollbar. These selectors
 * will match lower in the tree, and so will override the above */
[data-jp-theme-scrollbars='true'] .CodeMirror-hscrollbar,
[data-jp-theme-scrollbars='true'] .CodeMirror-vscrollbar {
  scrollbar-color: rgba(var(--jp-scrollbar-thumb-color), 0.5) transparent;
}

/* tiny scrollbar */

.jp-scrollbar-tiny {
  scrollbar-color: rgba(var(--jp-scrollbar-thumb-color), 0.5) transparent;
  scrollbar-width: thin;
}

/* tiny scrollbar */

.jp-scrollbar-tiny::-webkit-scrollbar,
.jp-scrollbar-tiny::-webkit-scrollbar-corner {
  background-color: transparent;
  height: 4px;
  width: 4px;
}

.jp-scrollbar-tiny::-webkit-scrollbar-thumb {
  background: rgba(var(--jp-scrollbar-thumb-color), 0.5);
}

.jp-scrollbar-tiny::-webkit-scrollbar-track:horizontal {
  border-left: 0 solid transparent;
  border-right: 0 solid transparent;
}

.jp-scrollbar-tiny::-webkit-scrollbar-track:vertical {
  border-top: 0 solid transparent;
  border-bottom: 0 solid transparent;
}

/*
 * Lumino
 */

.lm-ScrollBar[data-orientation='horizontal'] {
  min-height: 16px;
  max-height: 16px;
  min-width: 45px;
  border-top: 1px solid #a0a0a0;
}

.lm-ScrollBar[data-orientation='vertical'] {
  min-width: 16px;
  max-width: 16px;
  min-height: 45px;
  border-left: 1px solid #a0a0a0;
}

.lm-ScrollBar-button {
  background-color: #f0f0f0;
  background-position: center center;
  min-height: 15px;
  max-height: 15px;
  min-width: 15px;
  max-width: 15px;
}

.lm-ScrollBar-button:hover {
  background-color: #dadada;
}

.lm-ScrollBar-button.lm-mod-active {
  background-color: #cdcdcd;
}

.lm-ScrollBar-track {
  background: #f0f0f0;
}

.lm-ScrollBar-thumb {
  background: #cdcdcd;
}

.lm-ScrollBar-thumb:hover {
  background: #bababa;
}

.lm-ScrollBar-thumb.lm-mod-active {
  background: #a0a0a0;
}

.lm-ScrollBar[data-orientation='horizontal'] .lm-ScrollBar-thumb {
  height: 100%;
  min-width: 15px;
  border-left: 1px solid #a0a0a0;
  border-right: 1px solid #a0a0a0;
}

.lm-ScrollBar[data-orientation='vertical'] .lm-ScrollBar-thumb {
  width: 100%;
  min-height: 15px;
  border-top: 1px solid #a0a0a0;
  border-bottom: 1px solid #a0a0a0;
}

.lm-ScrollBar[data-orientation='horizontal']
  .lm-ScrollBar-button[data-action='decrement'] {
  background-image: var(--jp-icon-caret-left);
  background-size: 17px;
}

.lm-ScrollBar[data-orientation='horizontal']
  .lm-ScrollBar-button[data-action='increment'] {
  background-image: var(--jp-icon-caret-right);
  background-size: 17px;
}

.lm-ScrollBar[data-orientation='vertical']
  .lm-ScrollBar-button[data-action='decrement'] {
  background-image: var(--jp-icon-caret-up);
  background-size: 17px;
}

.lm-ScrollBar[data-orientation='vertical']
  .lm-ScrollBar-button[data-action='increment'] {
  background-image: var(--jp-icon-caret-down);
  background-size: 17px;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

.lm-Widget {
  box-sizing: border-box;
  position: relative;
  overflow: hidden;
}

.lm-Widget.lm-mod-hidden {
  display: none !important;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

.lm-AccordionPanel[data-orientation='horizontal'] > .lm-AccordionPanel-title {
  /* Title is rotated for horizontal accordion panel using CSS */
  display: block;
  transform-origin: top left;
  transform: rotate(-90deg) translate(-100%);
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

.lm-CommandPalette {
  display: flex;
  flex-direction: column;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.lm-CommandPalette-search {
  flex: 0 0 auto;
}

.lm-CommandPalette-content {
  flex: 1 1 auto;
  margin: 0;
  padding: 0;
  min-height: 0;
  overflow: auto;
  list-style-type: none;
}

.lm-CommandPalette-header {
  overflow: hidden;
  white-space: nowrap;
  text-overflow: ellipsis;
}

.lm-CommandPalette-item {
  display: flex;
  flex-direction: row;
}

.lm-CommandPalette-itemIcon {
  flex: 0 0 auto;
}

.lm-CommandPalette-itemContent {
  flex: 1 1 auto;
  overflow: hidden;
}

.lm-CommandPalette-itemShortcut {
  flex: 0 0 auto;
}

.lm-CommandPalette-itemLabel {
  overflow: hidden;
  white-space: nowrap;
  text-overflow: ellipsis;
}

.lm-close-icon {
  border: 1px solid transparent;
  background-color: transparent;
  position: absolute;
  z-index: 1;
  right: 3%;
  top: 0;
  bottom: 0;
  margin: auto;
  padding: 7px 0;
  display: none;
  vertical-align: middle;
  outline: 0;
  cursor: pointer;
}
.lm-close-icon:after {
  content: 'X';
  display: block;
  width: 15px;
  height: 15px;
  text-align: center;
  color: #000;
  font-weight: normal;
  font-size: 12px;
  cursor: pointer;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

.lm-DockPanel {
  z-index: 0;
}

.lm-DockPanel-widget {
  z-index: 0;
}

.lm-DockPanel-tabBar {
  z-index: 1;
}

.lm-DockPanel-handle {
  z-index: 2;
}

.lm-DockPanel-handle.lm-mod-hidden {
  display: none !important;
}

.lm-DockPanel-handle:after {
  position: absolute;
  top: 0;
  left: 0;
  width: 100%;
  height: 100%;
  content: '';
}

.lm-DockPanel-handle[data-orientation='horizontal'] {
  cursor: ew-resize;
}

.lm-DockPanel-handle[data-orientation='vertical'] {
  cursor: ns-resize;
}

.lm-DockPanel-handle[data-orientation='horizontal']:after {
  left: 50%;
  min-width: 8px;
  transform: translateX(-50%);
}

.lm-DockPanel-handle[data-orientation='vertical']:after {
  top: 50%;
  min-height: 8px;
  transform: translateY(-50%);
}

.lm-DockPanel-overlay {
  z-index: 3;
  box-sizing: border-box;
  pointer-events: none;
}

.lm-DockPanel-overlay.lm-mod-hidden {
  display: none !important;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

.lm-Menu {
  z-index: 10000;
  position: absolute;
  white-space: nowrap;
  overflow-x: hidden;
  overflow-y: auto;
  outline: none;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.lm-Menu-content {
  margin: 0;
  padding: 0;
  display: table;
  list-style-type: none;
}

.lm-Menu-item {
  display: table-row;
}

.lm-Menu-item.lm-mod-hidden,
.lm-Menu-item.lm-mod-collapsed {
  display: none !important;
}

.lm-Menu-itemIcon,
.lm-Menu-itemSubmenuIcon {
  display: table-cell;
  text-align: center;
}

.lm-Menu-itemLabel {
  display: table-cell;
  text-align: left;
}

.lm-Menu-itemShortcut {
  display: table-cell;
  text-align: right;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

.lm-MenuBar {
  outline: none;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.lm-MenuBar-content {
  margin: 0;
  padding: 0;
  display: flex;
  flex-direction: row;
  list-style-type: none;
}

.lm-MenuBar-item {
  box-sizing: border-box;
}

.lm-MenuBar-itemIcon,
.lm-MenuBar-itemLabel {
  display: inline-block;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

.lm-ScrollBar {
  display: flex;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.lm-ScrollBar[data-orientation='horizontal'] {
  flex-direction: row;
}

.lm-ScrollBar[data-orientation='vertical'] {
  flex-direction: column;
}

.lm-ScrollBar-button {
  box-sizing: border-box;
  flex: 0 0 auto;
}

.lm-ScrollBar-track {
  box-sizing: border-box;
  position: relative;
  overflow: hidden;
  flex: 1 1 auto;
}

.lm-ScrollBar-thumb {
  box-sizing: border-box;
  position: absolute;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

.lm-SplitPanel-child {
  z-index: 0;
}

.lm-SplitPanel-handle {
  z-index: 1;
}

.lm-SplitPanel-handle.lm-mod-hidden {
  display: none !important;
}

.lm-SplitPanel-handle:after {
  position: absolute;
  top: 0;
  left: 0;
  width: 100%;
  height: 100%;
  content: '';
}

.lm-SplitPanel[data-orientation='horizontal'] > .lm-SplitPanel-handle {
  cursor: ew-resize;
}

.lm-SplitPanel[data-orientation='vertical'] > .lm-SplitPanel-handle {
  cursor: ns-resize;
}

.lm-SplitPanel[data-orientation='horizontal'] > .lm-SplitPanel-handle:after {
  left: 50%;
  min-width: 8px;
  transform: translateX(-50%);
}

.lm-SplitPanel[data-orientation='vertical'] > .lm-SplitPanel-handle:after {
  top: 50%;
  min-height: 8px;
  transform: translateY(-50%);
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

.lm-TabBar {
  display: flex;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.lm-TabBar[data-orientation='horizontal'] {
  flex-direction: row;
  align-items: flex-end;
}

.lm-TabBar[data-orientation='vertical'] {
  flex-direction: column;
  align-items: flex-end;
}

.lm-TabBar-content {
  margin: 0;
  padding: 0;
  display: flex;
  flex: 1 1 auto;
  list-style-type: none;
}

.lm-TabBar[data-orientation='horizontal'] > .lm-TabBar-content {
  flex-direction: row;
}

.lm-TabBar[data-orientation='vertical'] > .lm-TabBar-content {
  flex-direction: column;
}

.lm-TabBar-tab {
  display: flex;
  flex-direction: row;
  box-sizing: border-box;
  overflow: hidden;
  touch-action: none; /* Disable native Drag/Drop */
}

.lm-TabBar-tabIcon,
.lm-TabBar-tabCloseIcon {
  flex: 0 0 auto;
}

.lm-TabBar-tabLabel {
  flex: 1 1 auto;
  overflow: hidden;
  white-space: nowrap;
}

.lm-TabBar-tabInput {
  user-select: all;
  width: 100%;
  box-sizing: border-box;
}

.lm-TabBar-tab.lm-mod-hidden {
  display: none !important;
}

.lm-TabBar-addButton.lm-mod-hidden {
  display: none !important;
}

.lm-TabBar.lm-mod-dragging .lm-TabBar-tab {
  position: relative;
}

.lm-TabBar.lm-mod-dragging[data-orientation='horizontal'] .lm-TabBar-tab {
  left: 0;
  transition: left 150ms ease;
}

.lm-TabBar.lm-mod-dragging[data-orientation='vertical'] .lm-TabBar-tab {
  top: 0;
  transition: top 150ms ease;
}

.lm-TabBar.lm-mod-dragging .lm-TabBar-tab.lm-mod-dragging {
  transition: none;
}

.lm-TabBar-tabLabel .lm-TabBar-tabInput {
  user-select: all;
  width: 100%;
  box-sizing: border-box;
  background: inherit;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

.lm-TabPanel-tabBar {
  z-index: 1;
}

.lm-TabPanel-stackedPanel {
  z-index: 0;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-Collapse {
  display: flex;
  flex-direction: column;
  align-items: stretch;
}

.jp-Collapse-header {
  padding: 1px 12px;
  background-color: var(--jp-layout-color1);
  border-bottom: solid var(--jp-border-width) var(--jp-border-color2);
  color: var(--jp-ui-font-color1);
  cursor: pointer;
  display: flex;
  align-items: center;
  font-size: var(--jp-ui-font-size0);
  font-weight: 600;
  text-transform: uppercase;
  user-select: none;
}

.jp-Collapser-icon {
  height: 16px;
}

.jp-Collapse-header-collapsed .jp-Collapser-icon {
  transform: rotate(-90deg);
  margin: auto 0;
}

.jp-Collapser-title {
  line-height: 25px;
}

.jp-Collapse-contents {
  padding: 0 12px;
  background-color: var(--jp-layout-color1);
  color: var(--jp-ui-font-color1);
  overflow: auto;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensureUiComponents() in @jupyterlab/buildutils */

/**
 * (DEPRECATED) Support for consuming icons as CSS background images
 */

/* Icons urls */

:root {
  --jp-icon-add-above: url(data:image/svg+xml;base64,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);
  --jp-icon-add-below: url(data:image/svg+xml;base64,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);
  --jp-icon-add: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTE5IDEzaC02djZoLTJ2LTZINXYtMmg2VjVoMnY2aDZ2MnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-bell: url(data:image/svg+xml;base64,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);
  --jp-icon-bug-dot: url(data:image/svg+xml;base64,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);
  --jp-icon-bug: url(data:image/svg+xml;base64,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);
  --jp-icon-build: url(data:image/svg+xml;base64,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);
  --jp-icon-caret-down-empty-thin: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIwIDIwIj4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSIgc2hhcGUtcmVuZGVyaW5nPSJnZW9tZXRyaWNQcmVjaXNpb24iPgoJCTxwb2x5Z29uIGNsYXNzPSJzdDEiIHBvaW50cz0iOS45LDEzLjYgMy42LDcuNCA0LjQsNi42IDkuOSwxMi4yIDE1LjQsNi43IDE2LjEsNy40ICIvPgoJPC9nPgo8L3N2Zz4K);
  --jp-icon-caret-down-empty: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiIHNoYXBlLXJlbmRlcmluZz0iZ2VvbWV0cmljUHJlY2lzaW9uIj4KICAgIDxwYXRoIGQ9Ik01LjIsNS45TDksOS43bDMuOC0zLjhsMS4yLDEuMmwtNC45LDVsLTQuOS01TDUuMiw1Ljl6Ii8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-caret-down: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiIHNoYXBlLXJlbmRlcmluZz0iZ2VvbWV0cmljUHJlY2lzaW9uIj4KICAgIDxwYXRoIGQ9Ik01LjIsNy41TDksMTEuMmwzLjgtMy44SDUuMnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-caret-left: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSIgc2hhcGUtcmVuZGVyaW5nPSJnZW9tZXRyaWNQcmVjaXNpb24iPgoJCTxwYXRoIGQ9Ik0xMC44LDEyLjhMNy4xLDlsMy44LTMuOGwwLDcuNkgxMC44eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-caret-right: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiIHNoYXBlLXJlbmRlcmluZz0iZ2VvbWV0cmljUHJlY2lzaW9uIj4KICAgIDxwYXRoIGQ9Ik03LjIsNS4yTDEwLjksOWwtMy44LDMuOFY1LjJINy4yeiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-caret-up-empty-thin: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIwIDIwIj4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSIgc2hhcGUtcmVuZGVyaW5nPSJnZW9tZXRyaWNQcmVjaXNpb24iPgoJCTxwb2x5Z29uIGNsYXNzPSJzdDEiIHBvaW50cz0iMTUuNCwxMy4zIDkuOSw3LjcgNC40LDEzLjIgMy42LDEyLjUgOS45LDYuMyAxNi4xLDEyLjYgIi8+Cgk8L2c+Cjwvc3ZnPgo=);
  --jp-icon-caret-up: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSIgc2hhcGUtcmVuZGVyaW5nPSJnZW9tZXRyaWNQcmVjaXNpb24iPgoJCTxwYXRoIGQ9Ik01LjIsMTAuNUw5LDYuOGwzLjgsMy44SDUuMnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-case-sensitive: url(data:image/svg+xml;base64,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);
  --jp-icon-check: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIj4KICAgIDxwYXRoIGQ9Ik05IDE2LjE3TDQuODMgMTJsLTEuNDIgMS40MUw5IDE5IDIxIDdsLTEuNDEtMS40MXoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-circle-empty: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTEyIDJDNi40NyAyIDIgNi40NyAyIDEyczQuNDcgMTAgMTAgMTAgMTAtNC40NyAxMC0xMFMxNy41MyAyIDEyIDJ6bTAgMThjLTQuNDEgMC04LTMuNTktOC04czMuNTktOCA4LTggOCAzLjU5IDggOC0zLjU5IDgtOCA4eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-circle: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMTggMTgiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPGNpcmNsZSBjeD0iOSIgY3k9IjkiIHI9IjgiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-clear: url(data:image/svg+xml;base64,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);
  --jp-icon-close: url(data:image/svg+xml;base64,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);
  --jp-icon-code-check: url(data:image/svg+xml;base64,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);
  --jp-icon-code: url(data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMjIiIGhlaWdodD0iMjIiIHZpZXdCb3g9IjAgMCAyOCAyOCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CgkJPHBhdGggZD0iTTExLjQgMTguNkw2LjggMTRMMTEuNCA5LjRMMTAgOEw0IDE0TDEwIDIwTDExLjQgMTguNlpNMTYuNiAxOC42TDIxLjIgMTRMMTYuNiA5LjRMMTggOEwyNCAxNEwxOCAyMEwxNi42IDE4LjZWMTguNloiLz4KCTwvZz4KPC9zdmc+Cg==);
  --jp-icon-collapse-all: url(data:image/svg+xml;base64,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);
  --jp-icon-console: url(data:image/svg+xml;base64,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);
  --jp-icon-copy: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMTggMTgiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTExLjksMUgzLjJDMi40LDEsMS43LDEuNywxLjcsMi41djEwLjJoMS41VjIuNWg4LjdWMXogTTE0LjEsMy45aC04Yy0wLjgsMC0xLjUsMC43LTEuNSwxLjV2MTAuMmMwLDAuOCwwLjcsMS41LDEuNSwxLjVoOCBjMC44LDAsMS41LTAuNywxLjUtMS41VjUuNEMxNS41LDQuNiwxNC45LDMuOSwxNC4xLDMuOXogTTE0LjEsMTUuNWgtOFY1LjRoOFYxNS41eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-copyright: url(data:image/svg+xml;base64,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);
  --jp-icon-cut: url(data:image/svg+xml;base64,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);
  --jp-icon-delete: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjE2cHgiIGhlaWdodD0iMTZweCI+CiAgICA8cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIiAvPgogICAgPHBhdGggY2xhc3M9ImpwLWljb24zIiBmaWxsPSIjNjI2MjYyIiBkPSJNNiAxOWMwIDEuMS45IDIgMiAyaDhjMS4xIDAgMi0uOSAyLTJWN0g2djEyek0xOSA0aC0zLjVsLTEtMWgtNWwtMSAxSDV2MmgxNFY0eiIgLz4KPC9zdmc+Cg==);
  --jp-icon-download: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTE5IDloLTRWM0g5djZINWw3IDcgNy03ek01IDE4djJoMTR2LTJINXoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-duplicate: url(data:image/svg+xml;base64,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);
  --jp-icon-edit: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTMgMTcuMjVWMjFoMy43NUwxNy44MSA5Ljk0bC0zLjc1LTMuNzVMMyAxNy4yNXpNMjAuNzEgNy4wNGMuMzktLjM5LjM5LTEuMDIgMC0xLjQxbC0yLjM0LTIuMzRjLS4zOS0uMzktMS4wMi0uMzktMS40MSAwbC0xLjgzIDEuODMgMy43NSAzLjc1IDEuODMtMS44M3oiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-ellipses: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPGNpcmNsZSBjeD0iNSIgY3k9IjEyIiByPSIyIi8+CiAgICA8Y2lyY2xlIGN4PSIxMiIgY3k9IjEyIiByPSIyIi8+CiAgICA8Y2lyY2xlIGN4PSIxOSIgY3k9IjEyIiByPSIyIi8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-error: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KPGcgY2xhc3M9ImpwLWljb24zIiBmaWxsPSIjNjE2MTYxIj48Y2lyY2xlIGN4PSIxMiIgY3k9IjE5IiByPSIyIi8+PHBhdGggZD0iTTEwIDNoNHYxMmgtNHoiLz48L2c+CjxwYXRoIGZpbGw9Im5vbmUiIGQ9Ik0wIDBoMjR2MjRIMHoiLz4KPC9zdmc+Cg==);
  --jp-icon-expand-all: url(data:image/svg+xml;base64,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);
  --jp-icon-extension: url(data:image/svg+xml;base64,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);
  --jp-icon-fast-forward: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIyNCIgaGVpZ2h0PSIyNCIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTQgMThsOC41LTZMNCA2djEyem05LTEydjEybDguNS02TDEzIDZ6Ii8+CiAgICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-file-upload: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTkgMTZoNnYtNmg0bC03LTctNyA3aDR6bS00IDJoMTR2Mkg1eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-file: url(data:image/svg+xml;base64,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);
  --jp-icon-filter-dot: url(data:image/svg+xml;base64,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);
  --jp-icon-filter-list: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTEwIDE4aDR2LTJoLTR2MnpNMyA2djJoMThWNkgzem0zIDdoMTJ2LTJINnYyeiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-filter: url(data:image/svg+xml;base64,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);
  --jp-icon-folder-favorite: url(data:image/svg+xml;base64,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);
  --jp-icon-folder: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIiBkPSJNMTAgNEg0Yy0xLjEgMC0xLjk5LjktMS45OSAyTDIgMThjMCAxLjEuOSAyIDIgMmgxNmMxLjEgMCAyLS45IDItMlY4YzAtMS4xLS45LTItMi0yaC04bC0yLTJ6Ii8+Cjwvc3ZnPgo=);
  --jp-icon-home: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjRweCIgdmlld0JveD0iMCAwIDI0IDI0IiB3aWR0aD0iMjRweCIgZmlsbD0iIzAwMDAwMCI+CiAgPHBhdGggZD0iTTAgMGgyNHYyNEgweiIgZmlsbD0ibm9uZSIvPjxwYXRoIGNsYXNzPSJqcC1pY29uMyBqcC1pY29uLXNlbGVjdGFibGUiIGZpbGw9IiM2MTYxNjEiIGQ9Ik0xMCAyMHYtNmg0djZoNXYtOGgzTDEyIDMgMiAxMmgzdjh6Ii8+Cjwvc3ZnPgo=);
  --jp-icon-html5: url(data:image/svg+xml;base64,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);
  --jp-icon-image: url(data:image/svg+xml;base64,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);
  --jp-icon-info: url(data:image/svg+xml;base64,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);
  --jp-icon-inspector: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtaW5zcGVjdG9yLWljb24tY29sb3IganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIiBkPSJNMjAgNEg0Yy0xLjEgMC0xLjk5LjktMS45OSAyTDIgMThjMCAxLjEuOSAyIDIgMmgxNmMxLjEgMCAyLS45IDItMlY2YzAtMS4xLS45LTItMi0yem0tNSAxNEg0di00aDExdjR6bTAtNUg0VjloMTF2NHptNSA1aC00VjloNHY5eiIvPgo8L3N2Zz4K);
  --jp-icon-json: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIyIDIyIj4KICA8ZyBjbGFzcz0ianAtanNvbi1pY29uLWNvbG9yIGpwLWljb24tc2VsZWN0YWJsZSIgZmlsbD0iI0Y5QTgyNSI+CiAgICA8cGF0aCBkPSJNMjAuMiAxMS44Yy0xLjYgMC0xLjcuNS0xLjcgMSAwIC40LjEuOS4xIDEuMy4xLjUuMS45LjEgMS4zIDAgMS43LTEuNCAyLjMtMy41IDIuM2gtLjl2LTEuOWguNWMxLjEgMCAxLjQgMCAxLjQtLjggMC0uMyAwLS42LS4xLTEgMC0uNC0uMS0uOC0uMS0xLjIgMC0xLjMgMC0xLjggMS4zLTItMS4zLS4yLTEuMy0uNy0xLjMtMiAwLS40LjEtLjguMS0xLjIuMS0uNC4xLS43LjEtMSAwLS44LS40LS43LTEuNC0uOGgtLjVWNC4xaC45YzIuMiAwIDMuNS43IDMuNSAyLjMgMCAuNC0uMS45LS4xIDEuMy0uMS41LS4xLjktLjEgMS4zIDAgLjUuMiAxIDEuNyAxdjEuOHpNMS44IDEwLjFjMS42IDAgMS43LS41IDEuNy0xIDAtLjQtLjEtLjktLjEtMS4zLS4xLS41LS4xLS45LS4xLTEuMyAwLTEuNiAxLjQtMi4zIDMuNS0yLjNoLjl2MS45aC0uNWMtMSAwLTEuNCAwLTEuNC44IDAgLjMgMCAuNi4xIDEgMCAuMi4xLjYuMSAxIDAgMS4zIDAgMS44LTEuMyAyQzYgMTEuMiA2IDExLjcgNiAxM2MwIC40LS4xLjgtLjEgMS4yLS4xLjMtLjEuNy0uMSAxIDAgLjguMy44IDEuNC44aC41djEuOWgtLjljLTIuMSAwLTMuNS0uNi0zLjUtMi4zIDAtLjQuMS0uOS4xLTEuMy4xLS41LjEtLjkuMS0xLjMgMC0uNS0uMi0xLTEuNy0xdi0xLjl6Ii8+CiAgICA8Y2lyY2xlIGN4PSIxMSIgY3k9IjEzLjgiIHI9IjIuMSIvPgogICAgPGNpcmNsZSBjeD0iMTEiIGN5PSI4LjIiIHI9IjIuMSIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-julia: url(data:image/svg+xml;base64,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);
  --jp-icon-jupyter-favicon: url(data:image/svg+xml;base64,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);
  --jp-icon-jupyter: url(data:image/svg+xml;base64,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);
  --jp-icon-jupyterlab-wordmark: url(data:image/svg+xml;base64,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);
  --jp-icon-kernel: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICAgIDxwYXRoIGNsYXNzPSJqcC1pY29uMiIgZmlsbD0iIzYxNjE2MSIgZD0iTTE1IDlIOXY2aDZWOXptLTIgNGgtMnYtMmgydjJ6bTgtMlY5aC0yVjdjMC0xLjEtLjktMi0yLTJoLTJWM2gtMnYyaC0yVjNIOXYySDdjLTEuMSAwLTIgLjktMiAydjJIM3YyaDJ2MkgzdjJoMnYyYzAgMS4xLjkgMiAyIDJoMnYyaDJ2LTJoMnYyaDJ2LTJoMmMxLjEgMCAyLS45IDItMnYtMmgydi0yaC0ydi0yaDJ6bS00IDZIN1Y3aDEwdjEweiIvPgo8L3N2Zz4K);
  --jp-icon-keyboard: url(data:image/svg+xml;base64,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);
  --jp-icon-launch: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMzIgMzIiIHdpZHRoPSIzMiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIj4KICAgIDxwYXRoIGQ9Ik0yNiwyOEg2YTIuMDAyNywyLjAwMjcsMCwwLDEtMi0yVjZBMi4wMDI3LDIuMDAyNywwLDAsMSw2LDRIMTZWNkg2VjI2SDI2VjE2aDJWMjZBMi4wMDI3LDIuMDAyNywwLDAsMSwyNiwyOFoiLz4KICAgIDxwb2x5Z29uIHBvaW50cz0iMjAgMiAyMCA0IDI2LjU4NiA0IDE4IDEyLjU4NiAxOS40MTQgMTQgMjggNS40MTQgMjggMTIgMzAgMTIgMzAgMiAyMCAyIi8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-launcher: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIiBkPSJNMTkgMTlINVY1aDdWM0g1YTIgMiAwIDAwLTIgMnYxNGEyIDIgMCAwMDIgMmgxNGMxLjEgMCAyLS45IDItMnYtN2gtMnY3ek0xNCAzdjJoMy41OWwtOS44MyA5LjgzIDEuNDEgMS40MUwxOSA2LjQxVjEwaDJWM2gtN3oiLz4KPC9zdmc+Cg==);
  --jp-icon-line-form: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICAgIDxwYXRoIGZpbGw9IndoaXRlIiBkPSJNNS44OCA0LjEyTDEzLjc2IDEybC03Ljg4IDcuODhMOCAyMmwxMC0xMEw4IDJ6Ii8+Cjwvc3ZnPgo=);
  --jp-icon-link: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTMuOSAxMmMwLTEuNzEgMS4zOS0zLjEgMy4xLTMuMWg0VjdIN2MtMi43NiAwLTUgMi4yNC01IDVzMi4yNCA1IDUgNWg0di0xLjlIN2MtMS43MSAwLTMuMS0xLjM5LTMuMS0zLjF6TTggMTNoOHYtMkg4djJ6bTktNmgtNHYxLjloNGMxLjcxIDAgMy4xIDEuMzkgMy4xIDMuMXMtMS4zOSAzLjEtMy4xIDMuMWgtNFYxN2g0YzIuNzYgMCA1LTIuMjQgNS01cy0yLjI0LTUtNS01eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-list: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICAgIDxwYXRoIGNsYXNzPSJqcC1pY29uMiBqcC1pY29uLXNlbGVjdGFibGUiIGZpbGw9IiM2MTYxNjEiIGQ9Ik0xOSA1djE0SDVWNWgxNG0xLjEtMkgzLjljLS41IDAtLjkuNC0uOS45djE2LjJjMCAuNC40LjkuOS45aDE2LjJjLjQgMCAuOS0uNS45LS45VjMuOWMwLS41LS41LS45LS45LS45ek0xMSA3aDZ2MmgtNlY3em0wIDRoNnYyaC02di0yem0wIDRoNnYyaC02ek03IDdoMnYySDd6bTAgNGgydjJIN3ptMCA0aDJ2Mkg3eiIvPgo8L3N2Zz4K);
  --jp-icon-markdown: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIyIDIyIj4KICA8cGF0aCBjbGFzcz0ianAtaWNvbi1jb250cmFzdDAganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjN0IxRkEyIiBkPSJNNSAxNC45aDEybC02LjEgNnptOS40LTYuOGMwLTEuMy0uMS0yLjktLjEtNC41LS40IDEuNC0uOSAyLjktMS4zIDQuM2wtMS4zIDQuM2gtMkw4LjUgNy45Yy0uNC0xLjMtLjctMi45LTEtNC4zLS4xIDEuNi0uMSAzLjItLjIgNC42TDcgMTIuNEg0LjhsLjctMTFoMy4zTDEwIDVjLjQgMS4yLjcgMi43IDEgMy45LjMtMS4yLjctMi42IDEtMy45bDEuMi0zLjdoMy4zbC42IDExaC0yLjRsLS4zLTQuMnoiLz4KPC9zdmc+Cg==);
  --jp-icon-move-down: url(data:image/svg+xml;base64,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);
  --jp-icon-move-up: url(data:image/svg+xml;base64,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);
  --jp-icon-new-folder: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTIwIDZoLThsLTItMkg0Yy0xLjExIDAtMS45OS44OS0xLjk5IDJMMiAxOGMwIDEuMTEuODkgMiAyIDJoMTZjMS4xMSAwIDItLjg5IDItMlY4YzAtMS4xMS0uODktMi0yLTJ6bS0xIDhoLTN2M2gtMnYtM2gtM3YtMmgzVjloMnYzaDN2MnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-not-trusted: url(data:image/svg+xml;base64,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);
  --jp-icon-notebook: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIyIDIyIj4KICA8ZyBjbGFzcz0ianAtbm90ZWJvb2staWNvbi1jb2xvciBqcC1pY29uLXNlbGVjdGFibGUiIGZpbGw9IiNFRjZDMDAiPgogICAgPHBhdGggZD0iTTE4LjcgMy4zdjE1LjRIMy4zVjMuM2gxNS40bTEuNS0xLjVIMS44djE4LjNoMTguM2wuMS0xOC4zeiIvPgogICAgPHBhdGggZD0iTTE2LjUgMTYuNWwtNS40LTQuMy01LjYgNC4zdi0xMWgxMXoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-numbering: url(data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMjIiIGhlaWdodD0iMjIiIHZpZXdCb3g9IjAgMCAyOCAyOCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CgkJPHBhdGggZD0iTTQgMTlINlYxOS41SDVWMjAuNUg2VjIxSDRWMjJIN1YxOEg0VjE5Wk01IDEwSDZWNkg0VjdINVYxMFpNNCAxM0g1LjhMNCAxNS4xVjE2SDdWMTVINS4yTDcgMTIuOVYxMkg0VjEzWk05IDdWOUgyM1Y3SDlaTTkgMjFIMjNWMTlIOVYyMVpNOSAxNUgyM1YxM0g5VjE1WiIvPgoJPC9nPgo8L3N2Zz4K);
  --jp-icon-offline-bolt: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjE2Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTEyIDIuMDJjLTUuNTEgMC05Ljk4IDQuNDctOS45OCA5Ljk4czQuNDcgOS45OCA5Ljk4IDkuOTggOS45OC00LjQ3IDkuOTgtOS45OFMxNy41MSAyLjAyIDEyIDIuMDJ6TTExLjQ4IDIwdi02LjI2SDhMMTMgNHY2LjI2aDMuMzVMMTEuNDggMjB6Ii8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-palette: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTE4IDEzVjIwSDRWNkg5LjAyQzkuMDcgNS4yOSA5LjI0IDQuNjIgOS41IDRINEMyLjkgNCAyIDQuOSAyIDZWMjBDMiAyMS4xIDIuOSAyMiA0IDIySDE4QzE5LjEgMjIgMjAgMjEuMSAyMCAyMFYxNUwxOCAxM1pNMTkuMyA4Ljg5QzE5Ljc0IDguMTkgMjAgNy4zOCAyMCA2LjVDMjAgNC4wMSAxNy45OSAyIDE1LjUgMkMxMy4wMSAyIDExIDQuMDEgMTEgNi41QzExIDguOTkgMTMuMDEgMTEgMTUuNDkgMTFDMTYuMzcgMTEgMTcuMTkgMTAuNzQgMTcuODggMTAuM0wyMSAxMy40MkwyMi40MiAxMkwxOS4zIDguODlaTTE1LjUgOUMxNC4xMiA5IDEzIDcuODggMTMgNi41QzEzIDUuMTIgMTQuMTIgNCAxNS41IDRDMTYuODggNCAxOCA1LjEyIDE4IDYuNUMxOCA3Ljg4IDE2Ljg4IDkgMTUuNSA5WiIvPgogICAgPHBhdGggZmlsbC1ydWxlPSJldmVub2RkIiBjbGlwLXJ1bGU9ImV2ZW5vZGQiIGQ9Ik00IDZIOS4wMTg5NEM5LjAwNjM5IDYuMTY1MDIgOSA2LjMzMTc2IDkgNi41QzkgOC44MTU3NyAxMC4yMTEgMTAuODQ4NyAxMi4wMzQzIDEySDlWMTRIMTZWMTIuOTgxMUMxNi41NzAzIDEyLjkzNzcgMTcuMTIgMTIuODIwNyAxNy42Mzk2IDEyLjYzOTZMMTggMTNWMjBINFY2Wk04IDhINlYxMEg4VjhaTTYgMTJIOFYxNEg2VjEyWk04IDE2SDZWMThIOFYxNlpNOSAxNkgxNlYxOEg5VjE2WiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-paste: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTE5IDJoLTQuMThDMTQuNC44NCAxMy4zIDAgMTIgMGMtMS4zIDAtMi40Ljg0LTIuODIgMkg1Yy0xLjEgMC0yIC45LTIgMnYxNmMwIDEuMS45IDIgMiAyaDE0YzEuMSAwIDItLjkgMi0yVjRjMC0xLjEtLjktMi0yLTJ6bS03IDBjLjU1IDAgMSAuNDUgMSAxcy0uNDUgMS0xIDEtMS0uNDUtMS0xIC40NS0xIDEtMXptNyAxOEg1VjRoMnYzaDEwVjRoMnYxNnoiLz4KICAgIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-pdf: url(data:image/svg+xml;base64,PHN2ZwogICB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAyMiAyMiIgd2lkdGg9IjE2Ij4KICAgIDxwYXRoIHRyYW5zZm9ybT0icm90YXRlKDQ1KSIgY2xhc3M9ImpwLWljb24tc2VsZWN0YWJsZSIgZmlsbD0iI0ZGMkEyQSIKICAgICAgIGQ9Im0gMjIuMzQ0MzY5LC0zLjAxNjM2NDIgaCA1LjYzODYwNCB2IDEuNTc5MjQzMyBoIC0zLjU0OTIyNyB2IDEuNTA4NjkyOTkgaCAzLjMzNzU3NiBWIDEuNjUwODE1NCBoIC0zLjMzNzU3NiB2IDMuNDM1MjYxMyBoIC0yLjA4OTM3NyB6IG0gLTcuMTM2NDQ0LDEuNTc5MjQzMyB2IDQuOTQzOTU0MyBoIDAuNzQ4OTIgcSAxLjI4MDc2MSwwIDEuOTUzNzAzLC0wLjYzNDk1MzUgMC42NzgzNjksLTAuNjM0OTUzNSAwLjY3ODM2OSwtMS44NDUxNjQxIDAsLTEuMjA0NzgzNTUgLTAuNjcyOTQyLC0xLjgzNDMxMDExIC0wLjY3Mjk0MiwtMC42Mjk1MjY1OSAtMS45NTkxMywtMC42Mjk1MjY1OSB6IG0gLTIuMDg5Mzc3LC0xLjU3OTI0MzMgaCAyLjIwMzM0MyBxIDEuODQ1MTY0LDAgMi43NDYwMzksMC4yNjU5MjA3IDAuOTA2MzAxLDAuMjYwNDkzNyAxLjU1MjEwOCwwLjg5MDAyMDMgMC41Njk4MywwLjU0ODEyMjMgMC44NDY2MDUsMS4yNjQ0ODAwNiAwLjI3Njc3NCwwLjcxNjM1NzgxIDAuMjc2Nzc0LDEuNjIyNjU4OTQgMCwwLjkxNzE1NTEgLTAuMjc2Nzc0LDEuNjM4OTM5OSAtMC4yNzY3NzUsMC43MTYzNTc4IC0wLjg0NjYwNSwxLjI2NDQ4IC0wLjY1MTIzNCwwLjYyOTUyNjYgLTEuNTYyOTYyLDAuODk1NDQ3MyAtMC45MTE3MjgsMC4yNjA0OTM3IC0yLjczNTE4NSwwLjI2MDQ5MzcgaCAtMi4yMDMzNDMgeiBtIC04LjE0NTg1NjUsMCBoIDMuNDY3ODIzIHEgMS41NDY2ODE2LDAgMi4zNzE1Nzg1LDAuNjg5MjIzIDAuODMwMzI0LDAuNjgzNzk2MSAwLjgzMDMyNCwxLjk1MzcwMzE0IDAsMS4yNzUzMzM5NyAtMC44MzAzMjQsMS45NjQ1NTcwNiBRIDkuOTg3MTk2MSwyLjI3NDkxNSA4LjQ0MDUxNDUsMi4yNzQ5MTUgSCA3LjA2MjA2ODQgViA1LjA4NjA3NjcgSCA0Ljk3MjY5MTUgWiBtIDIuMDg5Mzc2OSwxLjUxNDExOTkgdiAyLjI2MzAzOTQzIGggMS4xNTU5NDEgcSAwLjYwNzgxODgsMCAwLjkzODg2MjksLTAuMjkzMDU1NDcgMC4zMzEwNDQxLC0wLjI5ODQ4MjQxIDAuMzMxMDQ0MSwtMC44NDExNzc3MiAwLC0wLjU0MjY5NTMxIC0wLjMzMTA0NDEsLTAuODM1NzUwNzQgLTAuMzMxMDQ0MSwtMC4yOTMwNTU1IC0wLjkzODg2MjksLTAuMjkzMDU1NSB6IgovPgo8L3N2Zz4K);
  --jp-icon-python: url(data:image/svg+xml;base64,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);
  --jp-icon-r-kernel: url(data:image/svg+xml;base64,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);
  --jp-icon-react: url(data:image/svg+xml;base64,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);
  --jp-icon-redo: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjE2Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgICA8cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZD0iTTE4LjQgMTAuNkMxNi41NSA4Ljk5IDE0LjE1IDggMTEuNSA4Yy00LjY1IDAtOC41OCAzLjAzLTkuOTYgNy4yMkwzLjkgMTZjMS4wNS0zLjE5IDQuMDUtNS41IDcuNi01LjUgMS45NSAwIDMuNzMuNzIgNS4xMiAxLjg4TDEzIDE2aDlWN2wtMy42IDMuNnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-refresh: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTkgMTMuNWMtMi40OSAwLTQuNS0yLjAxLTQuNS00LjVTNi41MSA0LjUgOSA0LjVjMS4yNCAwIDIuMzYuNTIgMy4xNyAxLjMzTDEwIDhoNVYzbC0xLjc2IDEuNzZDMTIuMTUgMy42OCAxMC42NiAzIDkgMyA1LjY5IDMgMy4wMSA1LjY5IDMuMDEgOVM1LjY5IDE1IDkgMTVjMi45NyAwIDUuNDMtMi4xNiA1LjktNWgtMS41MmMtLjQ2IDItMi4yNCAzLjUtNC4zOCAzLjV6Ii8+CiAgICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-regex: url(data:image/svg+xml;base64,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);
  --jp-icon-run: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTggNXYxNGwxMS03eiIvPgogICAgPC9nPgo8L3N2Zz4K);
  --jp-icon-running: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDUxMiA1MTIiPgogIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICA8cGF0aCBkPSJNMjU2IDhDMTE5IDggOCAxMTkgOCAyNTZzMTExIDI0OCAyNDggMjQ4IDI0OC0xMTEgMjQ4LTI0OFMzOTMgOCAyNTYgOHptOTYgMzI4YzAgOC44LTcuMiAxNi0xNiAxNkgxNzZjLTguOCAwLTE2LTcuMi0xNi0xNlYxNzZjMC04LjggNy4yLTE2IDE2LTE2aDE2MGM4LjggMCAxNiA3LjIgMTYgMTZ2MTYweiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-save: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTE3IDNINWMtMS4xMSAwLTIgLjktMiAydjE0YzAgMS4xLjg5IDIgMiAyaDE0YzEuMSAwIDItLjkgMi0yVjdsLTQtNHptLTUgMTZjLTEuNjYgMC0zLTEuMzQtMy0zczEuMzQtMyAzLTMgMyAxLjM0IDMgMy0xLjM0IDMtMyAzem0zLTEwSDVWNWgxMHY0eiIvPgogICAgPC9nPgo8L3N2Zz4K);
  --jp-icon-search: url(data:image/svg+xml;base64,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);
  --jp-icon-settings: url(data:image/svg+xml;base64,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);
  --jp-icon-share: url(data:image/svg+xml;base64,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);
  --jp-icon-spreadsheet: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIyIDIyIj4KICA8cGF0aCBjbGFzcz0ianAtaWNvbi1jb250cmFzdDEganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNENBRjUwIiBkPSJNMi4yIDIuMnYxNy42aDE3LjZWMi4ySDIuMnptMTUuNCA3LjdoLTUuNVY0LjRoNS41djUuNXpNOS45IDQuNHY1LjVINC40VjQuNGg1LjV6bS01LjUgNy43aDUuNXY1LjVINC40di01LjV6bTcuNyA1LjV2LTUuNWg1LjV2NS41aC01LjV6Ii8+Cjwvc3ZnPgo=);
  --jp-icon-stop: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTAgMGgyNHYyNEgweiIgZmlsbD0ibm9uZSIvPgogICAgICAgIDxwYXRoIGQ9Ik02IDZoMTJ2MTJINnoiLz4KICAgIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-tab: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTIxIDNIM2MtMS4xIDAtMiAuOS0yIDJ2MTRjMCAxLjEuOSAyIDIgMmgxOGMxLjEgMCAyLS45IDItMlY1YzAtMS4xLS45LTItMi0yem0wIDE2SDNWNWgxMHY0aDh2MTB6Ii8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-table-rows: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTAgMGgyNHYyNEgweiIgZmlsbD0ibm9uZSIvPgogICAgICAgIDxwYXRoIGQ9Ik0yMSw4SDNWNGgxOFY4eiBNMjEsMTBIM3Y0aDE4VjEweiBNMjEsMTZIM3Y0aDE4VjE2eiIvPgogICAgPC9nPgo8L3N2Zz4K);
  --jp-icon-tag: url(data:image/svg+xml;base64,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);
  --jp-icon-terminal: url(data:image/svg+xml;base64,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);
  --jp-icon-text-editor: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtdGV4dC1lZGl0b3ItaWNvbi1jb2xvciBqcC1pY29uLXNlbGVjdGFibGUiIGZpbGw9IiM2MTYxNjEiIGQ9Ik0xNSAxNUgzdjJoMTJ2LTJ6bTAtOEgzdjJoMTJWN3pNMyAxM2gxOHYtMkgzdjJ6bTAgOGgxOHYtMkgzdjJ6TTMgM3YyaDE4VjNIM3oiLz4KPC9zdmc+Cg==);
  --jp-icon-toc: url(data:image/svg+xml;base64,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);
  --jp-icon-tree-view: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTAgMGgyNHYyNEgweiIgZmlsbD0ibm9uZSIvPgogICAgICAgIDxwYXRoIGQ9Ik0yMiAxMVYzaC03djNIOVYzSDJ2OGg3VjhoMnYxMGg0djNoN3YtOGgtN3YzaC0yVjhoMnYzeiIvPgogICAgPC9nPgo8L3N2Zz4K);
  --jp-icon-trusted: url(data:image/svg+xml;base64,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);
  --jp-icon-undo: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTEyLjUgOGMtMi42NSAwLTUuMDUuOTktNi45IDIuNkwyIDd2OWg5bC0zLjYyLTMuNjJjMS4zOS0xLjE2IDMuMTYtMS44OCA1LjEyLTEuODggMy41NCAwIDYuNTUgMi4zMSA3LjYgNS41bDIuMzctLjc4QzIxLjA4IDExLjAzIDE3LjE1IDggMTIuNSA4eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-user: url(data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMTYiIHZpZXdCb3g9IjAgMCAyNCAyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTE2IDdhNCA0IDAgMTEtOCAwIDQgNCAwIDAxOCAwek0xMiAxNGE3IDcgMCAwMC03IDdoMTRhNyA3IDAgMDAtNy03eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-users: url(data:image/svg+xml;base64,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);
  --jp-icon-vega: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIyIDIyIj4KICA8ZyBjbGFzcz0ianAtaWNvbjEganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjMjEyMTIxIj4KICAgIDxwYXRoIGQ9Ik0xMC42IDUuNGwyLjItMy4ySDIuMnY3LjNsNC02LjZ6Ii8+CiAgICA8cGF0aCBkPSJNMTUuOCAyLjJsLTQuNCA2LjZMNyA2LjNsLTQuOCA4djUuNWgxNy42VjIuMmgtNHptLTcgMTUuNEg1LjV2LTQuNGgzLjN2NC40em00LjQgMEg5LjhWOS44aDMuNHY3Ljh6bTQuNCAwaC0zLjRWNi41aDMuNHYxMS4xeiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-word: url(data:image/svg+xml;base64,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);
  --jp-icon-yaml: url(data:image/svg+xml;base64,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);
}

/* Icon CSS class declarations */

.jp-AddAboveIcon {
  background-image: var(--jp-icon-add-above);
}

.jp-AddBelowIcon {
  background-image: var(--jp-icon-add-below);
}

.jp-AddIcon {
  background-image: var(--jp-icon-add);
}

.jp-BellIcon {
  background-image: var(--jp-icon-bell);
}

.jp-BugDotIcon {
  background-image: var(--jp-icon-bug-dot);
}

.jp-BugIcon {
  background-image: var(--jp-icon-bug);
}

.jp-BuildIcon {
  background-image: var(--jp-icon-build);
}

.jp-CaretDownEmptyIcon {
  background-image: var(--jp-icon-caret-down-empty);
}

.jp-CaretDownEmptyThinIcon {
  background-image: var(--jp-icon-caret-down-empty-thin);
}

.jp-CaretDownIcon {
  background-image: var(--jp-icon-caret-down);
}

.jp-CaretLeftIcon {
  background-image: var(--jp-icon-caret-left);
}

.jp-CaretRightIcon {
  background-image: var(--jp-icon-caret-right);
}

.jp-CaretUpEmptyThinIcon {
  background-image: var(--jp-icon-caret-up-empty-thin);
}

.jp-CaretUpIcon {
  background-image: var(--jp-icon-caret-up);
}

.jp-CaseSensitiveIcon {
  background-image: var(--jp-icon-case-sensitive);
}

.jp-CheckIcon {
  background-image: var(--jp-icon-check);
}

.jp-CircleEmptyIcon {
  background-image: var(--jp-icon-circle-empty);
}

.jp-CircleIcon {
  background-image: var(--jp-icon-circle);
}

.jp-ClearIcon {
  background-image: var(--jp-icon-clear);
}

.jp-CloseIcon {
  background-image: var(--jp-icon-close);
}

.jp-CodeCheckIcon {
  background-image: var(--jp-icon-code-check);
}

.jp-CodeIcon {
  background-image: var(--jp-icon-code);
}

.jp-CollapseAllIcon {
  background-image: var(--jp-icon-collapse-all);
}

.jp-ConsoleIcon {
  background-image: var(--jp-icon-console);
}

.jp-CopyIcon {
  background-image: var(--jp-icon-copy);
}

.jp-CopyrightIcon {
  background-image: var(--jp-icon-copyright);
}

.jp-CutIcon {
  background-image: var(--jp-icon-cut);
}

.jp-DeleteIcon {
  background-image: var(--jp-icon-delete);
}

.jp-DownloadIcon {
  background-image: var(--jp-icon-download);
}

.jp-DuplicateIcon {
  background-image: var(--jp-icon-duplicate);
}

.jp-EditIcon {
  background-image: var(--jp-icon-edit);
}

.jp-EllipsesIcon {
  background-image: var(--jp-icon-ellipses);
}

.jp-ErrorIcon {
  background-image: var(--jp-icon-error);
}

.jp-ExpandAllIcon {
  background-image: var(--jp-icon-expand-all);
}

.jp-ExtensionIcon {
  background-image: var(--jp-icon-extension);
}

.jp-FastForwardIcon {
  background-image: var(--jp-icon-fast-forward);
}

.jp-FileIcon {
  background-image: var(--jp-icon-file);
}

.jp-FileUploadIcon {
  background-image: var(--jp-icon-file-upload);
}

.jp-FilterDotIcon {
  background-image: var(--jp-icon-filter-dot);
}

.jp-FilterIcon {
  background-image: var(--jp-icon-filter);
}

.jp-FilterListIcon {
  background-image: var(--jp-icon-filter-list);
}

.jp-FolderFavoriteIcon {
  background-image: var(--jp-icon-folder-favorite);
}

.jp-FolderIcon {
  background-image: var(--jp-icon-folder);
}

.jp-HomeIcon {
  background-image: var(--jp-icon-home);
}

.jp-Html5Icon {
  background-image: var(--jp-icon-html5);
}

.jp-ImageIcon {
  background-image: var(--jp-icon-image);
}

.jp-InfoIcon {
  background-image: var(--jp-icon-info);
}

.jp-InspectorIcon {
  background-image: var(--jp-icon-inspector);
}

.jp-JsonIcon {
  background-image: var(--jp-icon-json);
}

.jp-JuliaIcon {
  background-image: var(--jp-icon-julia);
}

.jp-JupyterFaviconIcon {
  background-image: var(--jp-icon-jupyter-favicon);
}

.jp-JupyterIcon {
  background-image: var(--jp-icon-jupyter);
}

.jp-JupyterlabWordmarkIcon {
  background-image: var(--jp-icon-jupyterlab-wordmark);
}

.jp-KernelIcon {
  background-image: var(--jp-icon-kernel);
}

.jp-KeyboardIcon {
  background-image: var(--jp-icon-keyboard);
}

.jp-LaunchIcon {
  background-image: var(--jp-icon-launch);
}

.jp-LauncherIcon {
  background-image: var(--jp-icon-launcher);
}

.jp-LineFormIcon {
  background-image: var(--jp-icon-line-form);
}

.jp-LinkIcon {
  background-image: var(--jp-icon-link);
}

.jp-ListIcon {
  background-image: var(--jp-icon-list);
}

.jp-MarkdownIcon {
  background-image: var(--jp-icon-markdown);
}

.jp-MoveDownIcon {
  background-image: var(--jp-icon-move-down);
}

.jp-MoveUpIcon {
  background-image: var(--jp-icon-move-up);
}

.jp-NewFolderIcon {
  background-image: var(--jp-icon-new-folder);
}

.jp-NotTrustedIcon {
  background-image: var(--jp-icon-not-trusted);
}

.jp-NotebookIcon {
  background-image: var(--jp-icon-notebook);
}

.jp-NumberingIcon {
  background-image: var(--jp-icon-numbering);
}

.jp-OfflineBoltIcon {
  background-image: var(--jp-icon-offline-bolt);
}

.jp-PaletteIcon {
  background-image: var(--jp-icon-palette);
}

.jp-PasteIcon {
  background-image: var(--jp-icon-paste);
}

.jp-PdfIcon {
  background-image: var(--jp-icon-pdf);
}

.jp-PythonIcon {
  background-image: var(--jp-icon-python);
}

.jp-RKernelIcon {
  background-image: var(--jp-icon-r-kernel);
}

.jp-ReactIcon {
  background-image: var(--jp-icon-react);
}

.jp-RedoIcon {
  background-image: var(--jp-icon-redo);
}

.jp-RefreshIcon {
  background-image: var(--jp-icon-refresh);
}

.jp-RegexIcon {
  background-image: var(--jp-icon-regex);
}

.jp-RunIcon {
  background-image: var(--jp-icon-run);
}

.jp-RunningIcon {
  background-image: var(--jp-icon-running);
}

.jp-SaveIcon {
  background-image: var(--jp-icon-save);
}

.jp-SearchIcon {
  background-image: var(--jp-icon-search);
}

.jp-SettingsIcon {
  background-image: var(--jp-icon-settings);
}

.jp-ShareIcon {
  background-image: var(--jp-icon-share);
}

.jp-SpreadsheetIcon {
  background-image: var(--jp-icon-spreadsheet);
}

.jp-StopIcon {
  background-image: var(--jp-icon-stop);
}

.jp-TabIcon {
  background-image: var(--jp-icon-tab);
}

.jp-TableRowsIcon {
  background-image: var(--jp-icon-table-rows);
}

.jp-TagIcon {
  background-image: var(--jp-icon-tag);
}

.jp-TerminalIcon {
  background-image: var(--jp-icon-terminal);
}

.jp-TextEditorIcon {
  background-image: var(--jp-icon-text-editor);
}

.jp-TocIcon {
  background-image: var(--jp-icon-toc);
}

.jp-TreeViewIcon {
  background-image: var(--jp-icon-tree-view);
}

.jp-TrustedIcon {
  background-image: var(--jp-icon-trusted);
}

.jp-UndoIcon {
  background-image: var(--jp-icon-undo);
}

.jp-UserIcon {
  background-image: var(--jp-icon-user);
}

.jp-UsersIcon {
  background-image: var(--jp-icon-users);
}

.jp-VegaIcon {
  background-image: var(--jp-icon-vega);
}

.jp-WordIcon {
  background-image: var(--jp-icon-word);
}

.jp-YamlIcon {
  background-image: var(--jp-icon-yaml);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/**
 * (DEPRECATED) Support for consuming icons as CSS background images
 */

.jp-Icon,
.jp-MaterialIcon {
  background-position: center;
  background-repeat: no-repeat;
  background-size: 16px;
  min-width: 16px;
  min-height: 16px;
}

.jp-Icon-cover {
  background-position: center;
  background-repeat: no-repeat;
  background-size: cover;
}

/**
 * (DEPRECATED) Support for specific CSS icon sizes
 */

.jp-Icon-16 {
  background-size: 16px;
  min-width: 16px;
  min-height: 16px;
}

.jp-Icon-18 {
  background-size: 18px;
  min-width: 18px;
  min-height: 18px;
}

.jp-Icon-20 {
  background-size: 20px;
  min-width: 20px;
  min-height: 20px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.lm-TabBar .lm-TabBar-addButton {
  align-items: center;
  display: flex;
  padding: 4px;
  padding-bottom: 5px;
  margin-right: 1px;
  background-color: var(--jp-layout-color2);
}

.lm-TabBar .lm-TabBar-addButton:hover {
  background-color: var(--jp-layout-color1);
}

.lm-DockPanel-tabBar .lm-TabBar-tab {
  width: var(--jp-private-horizontal-tab-width);
}

.lm-DockPanel-tabBar .lm-TabBar-content {
  flex: unset;
}

.lm-DockPanel-tabBar[data-orientation='horizontal'] {
  flex: 1 1 auto;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/**
 * Support for icons as inline SVG HTMLElements
 */

/* recolor the primary elements of an icon */
.jp-icon0[fill] {
  fill: var(--jp-inverse-layout-color0);
}

.jp-icon1[fill] {
  fill: var(--jp-inverse-layout-color1);
}

.jp-icon2[fill] {
  fill: var(--jp-inverse-layout-color2);
}

.jp-icon3[fill] {
  fill: var(--jp-inverse-layout-color3);
}

.jp-icon4[fill] {
  fill: var(--jp-inverse-layout-color4);
}

.jp-icon0[stroke] {
  stroke: var(--jp-inverse-layout-color0);
}

.jp-icon1[stroke] {
  stroke: var(--jp-inverse-layout-color1);
}

.jp-icon2[stroke] {
  stroke: var(--jp-inverse-layout-color2);
}

.jp-icon3[stroke] {
  stroke: var(--jp-inverse-layout-color3);
}

.jp-icon4[stroke] {
  stroke: var(--jp-inverse-layout-color4);
}

/* recolor the accent elements of an icon */
.jp-icon-accent0[fill] {
  fill: var(--jp-layout-color0);
}

.jp-icon-accent1[fill] {
  fill: var(--jp-layout-color1);
}

.jp-icon-accent2[fill] {
  fill: var(--jp-layout-color2);
}

.jp-icon-accent3[fill] {
  fill: var(--jp-layout-color3);
}

.jp-icon-accent4[fill] {
  fill: var(--jp-layout-color4);
}

.jp-icon-accent0[stroke] {
  stroke: var(--jp-layout-color0);
}

.jp-icon-accent1[stroke] {
  stroke: var(--jp-layout-color1);
}

.jp-icon-accent2[stroke] {
  stroke: var(--jp-layout-color2);
}

.jp-icon-accent3[stroke] {
  stroke: var(--jp-layout-color3);
}

.jp-icon-accent4[stroke] {
  stroke: var(--jp-layout-color4);
}

/* set the color of an icon to transparent */
.jp-icon-none[fill] {
  fill: none;
}

.jp-icon-none[stroke] {
  stroke: none;
}

/* brand icon colors. Same for light and dark */
.jp-icon-brand0[fill] {
  fill: var(--jp-brand-color0);
}

.jp-icon-brand1[fill] {
  fill: var(--jp-brand-color1);
}

.jp-icon-brand2[fill] {
  fill: var(--jp-brand-color2);
}

.jp-icon-brand3[fill] {
  fill: var(--jp-brand-color3);
}

.jp-icon-brand4[fill] {
  fill: var(--jp-brand-color4);
}

.jp-icon-brand0[stroke] {
  stroke: var(--jp-brand-color0);
}

.jp-icon-brand1[stroke] {
  stroke: var(--jp-brand-color1);
}

.jp-icon-brand2[stroke] {
  stroke: var(--jp-brand-color2);
}

.jp-icon-brand3[stroke] {
  stroke: var(--jp-brand-color3);
}

.jp-icon-brand4[stroke] {
  stroke: var(--jp-brand-color4);
}

/* warn icon colors. Same for light and dark */
.jp-icon-warn0[fill] {
  fill: var(--jp-warn-color0);
}

.jp-icon-warn1[fill] {
  fill: var(--jp-warn-color1);
}

.jp-icon-warn2[fill] {
  fill: var(--jp-warn-color2);
}

.jp-icon-warn3[fill] {
  fill: var(--jp-warn-color3);
}

.jp-icon-warn0[stroke] {
  stroke: var(--jp-warn-color0);
}

.jp-icon-warn1[stroke] {
  stroke: var(--jp-warn-color1);
}

.jp-icon-warn2[stroke] {
  stroke: var(--jp-warn-color2);
}

.jp-icon-warn3[stroke] {
  stroke: var(--jp-warn-color3);
}

/* icon colors that contrast well with each other and most backgrounds */
.jp-icon-contrast0[fill] {
  fill: var(--jp-icon-contrast-color0);
}

.jp-icon-contrast1[fill] {
  fill: var(--jp-icon-contrast-color1);
}

.jp-icon-contrast2[fill] {
  fill: var(--jp-icon-contrast-color2);
}

.jp-icon-contrast3[fill] {
  fill: var(--jp-icon-contrast-color3);
}

.jp-icon-contrast0[stroke] {
  stroke: var(--jp-icon-contrast-color0);
}

.jp-icon-contrast1[stroke] {
  stroke: var(--jp-icon-contrast-color1);
}

.jp-icon-contrast2[stroke] {
  stroke: var(--jp-icon-contrast-color2);
}

.jp-icon-contrast3[stroke] {
  stroke: var(--jp-icon-contrast-color3);
}

.jp-icon-dot[fill] {
  fill: var(--jp-warn-color0);
}

.jp-jupyter-icon-color[fill] {
  fill: var(--jp-jupyter-icon-color, var(--jp-warn-color0));
}

.jp-notebook-icon-color[fill] {
  fill: var(--jp-notebook-icon-color, var(--jp-warn-color0));
}

.jp-json-icon-color[fill] {
  fill: var(--jp-json-icon-color, var(--jp-warn-color1));
}

.jp-console-icon-color[fill] {
  fill: var(--jp-console-icon-color, white);
}

.jp-console-icon-background-color[fill] {
  fill: var(--jp-console-icon-background-color, var(--jp-brand-color1));
}

.jp-terminal-icon-color[fill] {
  fill: var(--jp-terminal-icon-color, var(--jp-layout-color2));
}

.jp-terminal-icon-background-color[fill] {
  fill: var(
    --jp-terminal-icon-background-color,
    var(--jp-inverse-layout-color2)
  );
}

.jp-text-editor-icon-color[fill] {
  fill: var(--jp-text-editor-icon-color, var(--jp-inverse-layout-color3));
}

.jp-inspector-icon-color[fill] {
  fill: var(--jp-inspector-icon-color, var(--jp-inverse-layout-color3));
}

/* CSS for icons in selected filebrowser listing items */
.jp-DirListing-item.jp-mod-selected .jp-icon-selectable[fill] {
  fill: #fff;
}

.jp-DirListing-item.jp-mod-selected .jp-icon-selectable-inverse[fill] {
  fill: var(--jp-brand-color1);
}

/* stylelint-disable selector-max-class, selector-max-compound-selectors */

/**
* TODO: come up with non css-hack solution for showing the busy icon on top
*  of the close icon
* CSS for complex behavior of close icon of tabs in the main area tabbar
*/
.lm-DockPanel-tabBar
  .lm-TabBar-tab.lm-mod-closable.jp-mod-dirty
  > .lm-TabBar-tabCloseIcon
  > :not(:hover)
  > .jp-icon3[fill] {
  fill: none;
}

.lm-DockPanel-tabBar
  .lm-TabBar-tab.lm-mod-closable.jp-mod-dirty
  > .lm-TabBar-tabCloseIcon
  > :not(:hover)
  > .jp-icon-busy[fill] {
  fill: var(--jp-inverse-layout-color3);
}

/* stylelint-enable selector-max-class, selector-max-compound-selectors */

/* CSS for icons in status bar */
#jp-main-statusbar .jp-mod-selected .jp-icon-selectable[fill] {
  fill: #fff;
}

#jp-main-statusbar .jp-mod-selected .jp-icon-selectable-inverse[fill] {
  fill: var(--jp-brand-color1);
}

/* special handling for splash icon CSS. While the theme CSS reloads during
   splash, the splash icon can loose theming. To prevent that, we set a
   default for its color variable */
:root {
  --jp-warn-color0: var(--md-orange-700);
}

/* not sure what to do with this one, used in filebrowser listing */
.jp-DragIcon {
  margin-right: 4px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/**
 * Support for alt colors for icons as inline SVG HTMLElements
 */

/* alt recolor the primary elements of an icon */
.jp-icon-alt .jp-icon0[fill] {
  fill: var(--jp-layout-color0);
}

.jp-icon-alt .jp-icon1[fill] {
  fill: var(--jp-layout-color1);
}

.jp-icon-alt .jp-icon2[fill] {
  fill: var(--jp-layout-color2);
}

.jp-icon-alt .jp-icon3[fill] {
  fill: var(--jp-layout-color3);
}

.jp-icon-alt .jp-icon4[fill] {
  fill: var(--jp-layout-color4);
}

.jp-icon-alt .jp-icon0[stroke] {
  stroke: var(--jp-layout-color0);
}

.jp-icon-alt .jp-icon1[stroke] {
  stroke: var(--jp-layout-color1);
}

.jp-icon-alt .jp-icon2[stroke] {
  stroke: var(--jp-layout-color2);
}

.jp-icon-alt .jp-icon3[stroke] {
  stroke: var(--jp-layout-color3);
}

.jp-icon-alt .jp-icon4[stroke] {
  stroke: var(--jp-layout-color4);
}

/* alt recolor the accent elements of an icon */
.jp-icon-alt .jp-icon-accent0[fill] {
  fill: var(--jp-inverse-layout-color0);
}

.jp-icon-alt .jp-icon-accent1[fill] {
  fill: var(--jp-inverse-layout-color1);
}

.jp-icon-alt .jp-icon-accent2[fill] {
  fill: var(--jp-inverse-layout-color2);
}

.jp-icon-alt .jp-icon-accent3[fill] {
  fill: var(--jp-inverse-layout-color3);
}

.jp-icon-alt .jp-icon-accent4[fill] {
  fill: var(--jp-inverse-layout-color4);
}

.jp-icon-alt .jp-icon-accent0[stroke] {
  stroke: var(--jp-inverse-layout-color0);
}

.jp-icon-alt .jp-icon-accent1[stroke] {
  stroke: var(--jp-inverse-layout-color1);
}

.jp-icon-alt .jp-icon-accent2[stroke] {
  stroke: var(--jp-inverse-layout-color2);
}

.jp-icon-alt .jp-icon-accent3[stroke] {
  stroke: var(--jp-inverse-layout-color3);
}

.jp-icon-alt .jp-icon-accent4[stroke] {
  stroke: var(--jp-inverse-layout-color4);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-icon-hoverShow:not(:hover) .jp-icon-hoverShow-content {
  display: none !important;
}

/**
 * Support for hover colors for icons as inline SVG HTMLElements
 */

/**
 * regular colors
 */

/* recolor the primary elements of an icon */
.jp-icon-hover :hover .jp-icon0-hover[fill] {
  fill: var(--jp-inverse-layout-color0);
}

.jp-icon-hover :hover .jp-icon1-hover[fill] {
  fill: var(--jp-inverse-layout-color1);
}

.jp-icon-hover :hover .jp-icon2-hover[fill] {
  fill: var(--jp-inverse-layout-color2);
}

.jp-icon-hover :hover .jp-icon3-hover[fill] {
  fill: var(--jp-inverse-layout-color3);
}

.jp-icon-hover :hover .jp-icon4-hover[fill] {
  fill: var(--jp-inverse-layout-color4);
}

.jp-icon-hover :hover .jp-icon0-hover[stroke] {
  stroke: var(--jp-inverse-layout-color0);
}

.jp-icon-hover :hover .jp-icon1-hover[stroke] {
  stroke: var(--jp-inverse-layout-color1);
}

.jp-icon-hover :hover .jp-icon2-hover[stroke] {
  stroke: var(--jp-inverse-layout-color2);
}

.jp-icon-hover :hover .jp-icon3-hover[stroke] {
  stroke: var(--jp-inverse-layout-color3);
}

.jp-icon-hover :hover .jp-icon4-hover[stroke] {
  stroke: var(--jp-inverse-layout-color4);
}

/* recolor the accent elements of an icon */
.jp-icon-hover :hover .jp-icon-accent0-hover[fill] {
  fill: var(--jp-layout-color0);
}

.jp-icon-hover :hover .jp-icon-accent1-hover[fill] {
  fill: var(--jp-layout-color1);
}

.jp-icon-hover :hover .jp-icon-accent2-hover[fill] {
  fill: var(--jp-layout-color2);
}

.jp-icon-hover :hover .jp-icon-accent3-hover[fill] {
  fill: var(--jp-layout-color3);
}

.jp-icon-hover :hover .jp-icon-accent4-hover[fill] {
  fill: var(--jp-layout-color4);
}

.jp-icon-hover :hover .jp-icon-accent0-hover[stroke] {
  stroke: var(--jp-layout-color0);
}

.jp-icon-hover :hover .jp-icon-accent1-hover[stroke] {
  stroke: var(--jp-layout-color1);
}

.jp-icon-hover :hover .jp-icon-accent2-hover[stroke] {
  stroke: var(--jp-layout-color2);
}

.jp-icon-hover :hover .jp-icon-accent3-hover[stroke] {
  stroke: var(--jp-layout-color3);
}

.jp-icon-hover :hover .jp-icon-accent4-hover[stroke] {
  stroke: var(--jp-layout-color4);
}

/* set the color of an icon to transparent */
.jp-icon-hover :hover .jp-icon-none-hover[fill] {
  fill: none;
}

.jp-icon-hover :hover .jp-icon-none-hover[stroke] {
  stroke: none;
}

/**
 * inverse colors
 */

/* inverse recolor the primary elements of an icon */
.jp-icon-hover.jp-icon-alt :hover .jp-icon0-hover[fill] {
  fill: var(--jp-layout-color0);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon1-hover[fill] {
  fill: var(--jp-layout-color1);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon2-hover[fill] {
  fill: var(--jp-layout-color2);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon3-hover[fill] {
  fill: var(--jp-layout-color3);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon4-hover[fill] {
  fill: var(--jp-layout-color4);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon0-hover[stroke] {
  stroke: var(--jp-layout-color0);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon1-hover[stroke] {
  stroke: var(--jp-layout-color1);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon2-hover[stroke] {
  stroke: var(--jp-layout-color2);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon3-hover[stroke] {
  stroke: var(--jp-layout-color3);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon4-hover[stroke] {
  stroke: var(--jp-layout-color4);
}

/* inverse recolor the accent elements of an icon */
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent0-hover[fill] {
  fill: var(--jp-inverse-layout-color0);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent1-hover[fill] {
  fill: var(--jp-inverse-layout-color1);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent2-hover[fill] {
  fill: var(--jp-inverse-layout-color2);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent3-hover[fill] {
  fill: var(--jp-inverse-layout-color3);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent4-hover[fill] {
  fill: var(--jp-inverse-layout-color4);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent0-hover[stroke] {
  stroke: var(--jp-inverse-layout-color0);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent1-hover[stroke] {
  stroke: var(--jp-inverse-layout-color1);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent2-hover[stroke] {
  stroke: var(--jp-inverse-layout-color2);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent3-hover[stroke] {
  stroke: var(--jp-inverse-layout-color3);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent4-hover[stroke] {
  stroke: var(--jp-inverse-layout-color4);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-IFrame {
  width: 100%;
  height: 100%;
}

.jp-IFrame > iframe {
  border: none;
}

/*
When drag events occur, `lm-mod-override-cursor` is added to the body.
Because iframes steal all cursor events, the following two rules are necessary
to suppress pointer events while resize drags are occurring. There may be a
better solution to this problem.
*/
body.lm-mod-override-cursor .jp-IFrame {
  position: relative;
}

body.lm-mod-override-cursor .jp-IFrame::before {
  content: '';
  position: absolute;
  top: 0;
  left: 0;
  right: 0;
  bottom: 0;
  background: transparent;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2016, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-HoverBox {
  position: fixed;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-FormGroup-content fieldset {
  border: none;
  padding: 0;
  min-width: 0;
  width: 100%;
}

/* stylelint-disable selector-max-type */

.jp-FormGroup-content fieldset .jp-inputFieldWrapper input,
.jp-FormGroup-content fieldset .jp-inputFieldWrapper select,
.jp-FormGroup-content fieldset .jp-inputFieldWrapper textarea {
  font-size: var(--jp-content-font-size2);
  border-color: var(--jp-input-border-color);
  border-style: solid;
  border-radius: var(--jp-border-radius);
  border-width: 1px;
  padding: 6px 8px;
  background: none;
  color: var(--jp-ui-font-color0);
  height: inherit;
}

.jp-FormGroup-content fieldset input[type='checkbox'] {
  position: relative;
  top: 2px;
  margin-left: 0;
}

.jp-FormGroup-content button.jp-mod-styled {
  cursor: pointer;
}

.jp-FormGroup-content .checkbox label {
  cursor: pointer;
  font-size: var(--jp-content-font-size1);
}

.jp-FormGroup-content .jp-root > fieldset > legend {
  display: none;
}

.jp-FormGroup-content .jp-root > fieldset > p {
  display: none;
}

/** copy of `input.jp-mod-styled:focus` style */
.jp-FormGroup-content fieldset input:focus,
.jp-FormGroup-content fieldset select:focus {
  -moz-outline-radius: unset;
  outline: var(--jp-border-width) solid var(--md-blue-500);
  outline-offset: -1px;
  box-shadow: inset 0 0 4px var(--md-blue-300);
}

.jp-FormGroup-content fieldset input:hover:not(:focus),
.jp-FormGroup-content fieldset select:hover:not(:focus) {
  background-color: var(--jp-border-color2);
}

/* stylelint-enable selector-max-type */

.jp-FormGroup-content .checkbox .field-description {
  /* Disable default description field for checkbox:
   because other widgets do not have description fields,
   we add descriptions to each widget on the field level.
  */
  display: none;
}

.jp-FormGroup-content #root__description {
  display: none;
}

.jp-FormGroup-content .jp-modifiedIndicator {
  width: 5px;
  background-color: var(--jp-brand-color2);
  margin-top: 0;
  margin-left: calc(var(--jp-private-settingeditor-modifier-indent) * -1);
  flex-shrink: 0;
}

.jp-FormGroup-content .jp-modifiedIndicator.jp-errorIndicator {
  background-color: var(--jp-error-color0);
  margin-right: 0.5em;
}

/* RJSF ARRAY style */

.jp-arrayFieldWrapper legend {
  font-size: var(--jp-content-font-size2);
  color: var(--jp-ui-font-color0);
  flex-basis: 100%;
  padding: 4px 0;
  font-weight: var(--jp-content-heading-font-weight);
  border-bottom: 1px solid var(--jp-border-color2);
}

.jp-arrayFieldWrapper .field-description {
  padding: 4px 0;
  white-space: pre-wrap;
}

.jp-arrayFieldWrapper .array-item {
  width: 100%;
  border: 1px solid var(--jp-border-color2);
  border-radius: 4px;
  margin: 4px;
}

.jp-ArrayOperations {
  display: flex;
  margin-left: 8px;
}

.jp-ArrayOperationsButton {
  margin: 2px;
}

.jp-ArrayOperationsButton .jp-icon3[fill] {
  fill: var(--jp-ui-font-color0);
}

button.jp-ArrayOperationsButton.jp-mod-styled:disabled {
  cursor: not-allowed;
  opacity: 0.5;
}

/* RJSF form validation error */

.jp-FormGroup-content .validationErrors {
  color: var(--jp-error-color0);
}

/* Hide panel level error as duplicated the field level error */
.jp-FormGroup-content .panel.errors {
  display: none;
}

/* RJSF normal content (settings-editor) */

.jp-FormGroup-contentNormal {
  display: flex;
  align-items: center;
  flex-wrap: wrap;
}

.jp-FormGroup-contentNormal .jp-FormGroup-contentItem {
  margin-left: 7px;
  color: var(--jp-ui-font-color0);
}

.jp-FormGroup-contentNormal .jp-FormGroup-description {
  flex-basis: 100%;
  padding: 4px 7px;
}

.jp-FormGroup-contentNormal .jp-FormGroup-default {
  flex-basis: 100%;
  padding: 4px 7px;
}

.jp-FormGroup-contentNormal .jp-FormGroup-fieldLabel {
  font-size: var(--jp-content-font-size1);
  font-weight: normal;
  min-width: 120px;
}

.jp-FormGroup-contentNormal fieldset:not(:first-child) {
  margin-left: 7px;
}

.jp-FormGroup-contentNormal .field-array-of-string .array-item {
  /* Display `jp-ArrayOperations` buttons side-by-side with content except
    for small screens where flex-wrap will place them one below the other.
  */
  display: flex;
  align-items: center;
  flex-wrap: wrap;
}

.jp-FormGroup-contentNormal .jp-objectFieldWrapper .form-group {
  padding: 2px 8px 2px var(--jp-private-settingeditor-modifier-indent);
  margin-top: 2px;
}

/* RJSF compact content (metadata-form) */

.jp-FormGroup-content.jp-FormGroup-contentCompact {
  width: 100%;
}

.jp-FormGroup-contentCompact .form-group {
  display: flex;
  padding: 0.5em 0.2em 0.5em 0;
}

.jp-FormGroup-contentCompact
  .jp-FormGroup-compactTitle
  .jp-FormGroup-description {
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color2);
}

.jp-FormGroup-contentCompact .jp-FormGroup-fieldLabel {
  padding-bottom: 0.3em;
}

.jp-FormGroup-contentCompact .jp-inputFieldWrapper .form-control {
  width: 100%;
  box-sizing: border-box;
}

.jp-FormGroup-contentCompact .jp-arrayFieldWrapper .jp-FormGroup-compactTitle {
  padding-bottom: 7px;
}

.jp-FormGroup-contentCompact
  .jp-objectFieldWrapper
  .jp-objectFieldWrapper
  .form-group {
  padding: 2px 8px 2px var(--jp-private-settingeditor-modifier-indent);
  margin-top: 2px;
}

.jp-FormGroup-contentCompact ul.error-detail {
  margin-block-start: 0.5em;
  margin-block-end: 0.5em;
  padding-inline-start: 1em;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

.jp-SidePanel {
  display: flex;
  flex-direction: column;
  min-width: var(--jp-sidebar-min-width);
  overflow-y: auto;
  color: var(--jp-ui-font-color1);
  background: var(--jp-layout-color1);
  font-size: var(--jp-ui-font-size1);
}

.jp-SidePanel-header {
  flex: 0 0 auto;
  display: flex;
  border-bottom: var(--jp-border-width) solid var(--jp-border-color2);
  font-size: var(--jp-ui-font-size0);
  font-weight: 600;
  letter-spacing: 1px;
  margin: 0;
  padding: 2px;
  text-transform: uppercase;
}

.jp-SidePanel-toolbar {
  flex: 0 0 auto;
}

.jp-SidePanel-content {
  flex: 1 1 auto;
}

.jp-SidePanel-toolbar,
.jp-AccordionPanel-toolbar {
  height: var(--jp-private-toolbar-height);
}

.jp-SidePanel-toolbar.jp-Toolbar-micro {
  display: none;
}

.lm-AccordionPanel .jp-AccordionPanel-title {
  box-sizing: border-box;
  line-height: 25px;
  margin: 0;
  display: flex;
  align-items: center;
  background: var(--jp-layout-color1);
  color: var(--jp-ui-font-color1);
  border-bottom: var(--jp-border-width) solid var(--jp-toolbar-border-color);
  box-shadow: var(--jp-toolbar-box-shadow);
  font-size: var(--jp-ui-font-size0);
}

.jp-AccordionPanel-title {
  cursor: pointer;
  user-select: none;
  -moz-user-select: none;
  -webkit-user-select: none;
  text-transform: uppercase;
}

.lm-AccordionPanel[data-orientation='horizontal'] > .jp-AccordionPanel-title {
  /* Title is rotated for horizontal accordion panel using CSS */
  display: block;
  transform-origin: top left;
  transform: rotate(-90deg) translate(-100%);
}

.jp-AccordionPanel-title .lm-AccordionPanel-titleLabel {
  user-select: none;
  text-overflow: ellipsis;
  white-space: nowrap;
  overflow: hidden;
}

.jp-AccordionPanel-title .lm-AccordionPanel-titleCollapser {
  transform: rotate(-90deg);
  margin: auto 0;
  height: 16px;
}

.jp-AccordionPanel-title.lm-mod-expanded .lm-AccordionPanel-titleCollapser {
  transform: rotate(0deg);
}

.lm-AccordionPanel .jp-AccordionPanel-toolbar {
  background: none;
  box-shadow: none;
  border: none;
  margin-left: auto;
}

.lm-AccordionPanel .lm-SplitPanel-handle:hover {
  background: var(--jp-layout-color3);
}

.jp-text-truncated {
  overflow: hidden;
  text-overflow: ellipsis;
  white-space: nowrap;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2017, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-Spinner {
  position: absolute;
  display: flex;
  justify-content: center;
  align-items: center;
  z-index: 10;
  left: 0;
  top: 0;
  width: 100%;
  height: 100%;
  background: var(--jp-layout-color0);
  outline: none;
}

.jp-SpinnerContent {
  font-size: 10px;
  margin: 50px auto;
  text-indent: -9999em;
  width: 3em;
  height: 3em;
  border-radius: 50%;
  background: var(--jp-brand-color3);
  background: linear-gradient(
    to right,
    #f37626 10%,
    rgba(255, 255, 255, 0) 42%
  );
  position: relative;
  animation: load3 1s infinite linear, fadeIn 1s;
}

.jp-SpinnerContent::before {
  width: 50%;
  height: 50%;
  background: #f37626;
  border-radius: 100% 0 0;
  position: absolute;
  top: 0;
  left: 0;
  content: '';
}

.jp-SpinnerContent::after {
  background: var(--jp-layout-color0);
  width: 75%;
  height: 75%;
  border-radius: 50%;
  content: '';
  margin: auto;
  position: absolute;
  top: 0;
  left: 0;
  bottom: 0;
  right: 0;
}

@keyframes fadeIn {
  0% {
    opacity: 0;
  }

  100% {
    opacity: 1;
  }
}

@keyframes load3 {
  0% {
    transform: rotate(0deg);
  }

  100% {
    transform: rotate(360deg);
  }
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2017, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

button.jp-mod-styled {
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color0);
  border: none;
  box-sizing: border-box;
  text-align: center;
  line-height: 32px;
  height: 32px;
  padding: 0 12px;
  letter-spacing: 0.8px;
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
}

input.jp-mod-styled {
  background: var(--jp-input-background);
  height: 28px;
  box-sizing: border-box;
  border: var(--jp-border-width) solid var(--jp-border-color1);
  padding-left: 7px;
  padding-right: 7px;
  font-size: var(--jp-ui-font-size2);
  color: var(--jp-ui-font-color0);
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
}

input[type='checkbox'].jp-mod-styled {
  appearance: checkbox;
  -webkit-appearance: checkbox;
  -moz-appearance: checkbox;
  height: auto;
}

input.jp-mod-styled:focus {
  border: var(--jp-border-width) solid var(--md-blue-500);
  box-shadow: inset 0 0 4px var(--md-blue-300);
}

.jp-select-wrapper {
  display: flex;
  position: relative;
  flex-direction: column;
  padding: 1px;
  background-color: var(--jp-layout-color1);
  box-sizing: border-box;
  margin-bottom: 12px;
}

.jp-select-wrapper:not(.multiple) {
  height: 28px;
}

.jp-select-wrapper.jp-mod-focused select.jp-mod-styled {
  border: var(--jp-border-width) solid var(--jp-input-active-border-color);
  box-shadow: var(--jp-input-box-shadow);
  background-color: var(--jp-input-active-background);
}

select.jp-mod-styled:hover {
  cursor: pointer;
  color: var(--jp-ui-font-color0);
  background-color: var(--jp-input-hover-background);
  box-shadow: inset 0 0 1px rgba(0, 0, 0, 0.5);
}

select.jp-mod-styled {
  flex: 1 1 auto;
  width: 100%;
  font-size: var(--jp-ui-font-size2);
  background: var(--jp-input-background);
  color: var(--jp-ui-font-color0);
  padding: 0 25px 0 8px;
  border: var(--jp-border-width) solid var(--jp-input-border-color);
  border-radius: 0;
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
}

select.jp-mod-styled:not([multiple]) {
  height: 32px;
}

select.jp-mod-styled[multiple] {
  max-height: 200px;
  overflow-y: auto;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-switch {
  display: flex;
  align-items: center;
  padding-left: 4px;
  padding-right: 4px;
  font-size: var(--jp-ui-font-size1);
  background-color: transparent;
  color: var(--jp-ui-font-color1);
  border: none;
  height: 20px;
}

.jp-switch:hover {
  background-color: var(--jp-layout-color2);
}

.jp-switch-label {
  margin-right: 5px;
  font-family: var(--jp-ui-font-family);
}

.jp-switch-track {
  cursor: pointer;
  background-color: var(--jp-switch-color, var(--jp-border-color1));
  -webkit-transition: 0.4s;
  transition: 0.4s;
  border-radius: 34px;
  height: 16px;
  width: 35px;
  position: relative;
}

.jp-switch-track::before {
  content: '';
  position: absolute;
  height: 10px;
  width: 10px;
  margin: 3px;
  left: 0;
  background-color: var(--jp-ui-inverse-font-color1);
  -webkit-transition: 0.4s;
  transition: 0.4s;
  border-radius: 50%;
}

.jp-switch[aria-checked='true'] .jp-switch-track {
  background-color: var(--jp-switch-true-position-color, var(--jp-warn-color0));
}

.jp-switch[aria-checked='true'] .jp-switch-track::before {
  /* track width (35) - margins (3 + 3) - thumb width (10) */
  left: 19px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2016, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

:root {
  --jp-private-toolbar-height: calc(
    28px + var(--jp-border-width)
  ); /* leave 28px for content */
}

.jp-Toolbar {
  color: var(--jp-ui-font-color1);
  flex: 0 0 auto;
  display: flex;
  flex-direction: row;
  border-bottom: var(--jp-border-width) solid var(--jp-toolbar-border-color);
  box-shadow: var(--jp-toolbar-box-shadow);
  background: var(--jp-toolbar-background);
  min-height: var(--jp-toolbar-micro-height);
  padding: 2px;
  z-index: 8;
  overflow-x: hidden;
}

/* Toolbar items */

.jp-Toolbar > .jp-Toolbar-item.jp-Toolbar-spacer {
  flex-grow: 1;
  flex-shrink: 1;
}

.jp-Toolbar-item.jp-Toolbar-kernelStatus {
  display: inline-block;
  width: 32px;
  background-repeat: no-repeat;
  background-position: center;
  background-size: 16px;
}

.jp-Toolbar > .jp-Toolbar-item {
  flex: 0 0 auto;
  display: flex;
  padding-left: 1px;
  padding-right: 1px;
  font-size: var(--jp-ui-font-size1);
  line-height: var(--jp-private-toolbar-height);
  height: 100%;
}

/* Toolbar buttons */

/* This is the div we use to wrap the react component into a Widget */
div.jp-ToolbarButton {
  color: transparent;
  border: none;
  box-sizing: border-box;
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
  padding: 0;
  margin: 0;
}

button.jp-ToolbarButtonComponent {
  background: var(--jp-layout-color1);
  border: none;
  box-sizing: border-box;
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
  padding: 0 6px;
  margin: 0;
  height: 24px;
  border-radius: var(--jp-border-radius);
  display: flex;
  align-items: center;
  text-align: center;
  font-size: 14px;
  min-width: unset;
  min-height: unset;
}

button.jp-ToolbarButtonComponent:disabled {
  opacity: 0.4;
}

button.jp-ToolbarButtonComponent > span {
  padding: 0;
  flex: 0 0 auto;
}

button.jp-ToolbarButtonComponent .jp-ToolbarButtonComponent-label {
  font-size: var(--jp-ui-font-size1);
  line-height: 100%;
  padding-left: 2px;
  color: var(--jp-ui-font-color1);
  font-family: var(--jp-ui-font-family);
}

#jp-main-dock-panel[data-mode='single-document']
  .jp-MainAreaWidget
  > .jp-Toolbar.jp-Toolbar-micro {
  padding: 0;
  min-height: 0;
}

#jp-main-dock-panel[data-mode='single-document']
  .jp-MainAreaWidget
  > .jp-Toolbar {
  border: none;
  box-shadow: none;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

.jp-WindowedPanel-outer {
  position: relative;
  overflow-y: auto;
}

.jp-WindowedPanel-inner {
  position: relative;
}

.jp-WindowedPanel-window {
  position: absolute;
  left: 0;
  right: 0;
  overflow: visible;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* Sibling imports */

body {
  color: var(--jp-ui-font-color1);
  font-size: var(--jp-ui-font-size1);
}

/* Disable native link decoration styles everywhere outside of dialog boxes */
a {
  text-decoration: unset;
  color: unset;
}

a:hover {
  text-decoration: unset;
  color: unset;
}

/* Accessibility for links inside dialog box text */
.jp-Dialog-content a {
  text-decoration: revert;
  color: var(--jp-content-link-color);
}

.jp-Dialog-content a:hover {
  text-decoration: revert;
}

/* Styles for ui-components */
.jp-Button {
  color: var(--jp-ui-font-color2);
  border-radius: var(--jp-border-radius);
  padding: 0 12px;
  font-size: var(--jp-ui-font-size1);

  /* Copy from blueprint 3 */
  display: inline-flex;
  flex-direction: row;
  border: none;
  cursor: pointer;
  align-items: center;
  justify-content: center;
  text-align: left;
  vertical-align: middle;
  min-height: 30px;
  min-width: 30px;
}

.jp-Button:disabled {
  cursor: not-allowed;
}

.jp-Button:empty {
  padding: 0 !important;
}

.jp-Button.jp-mod-small {
  min-height: 24px;
  min-width: 24px;
  font-size: 12px;
  padding: 0 7px;
}

/* Use our own theme for hover styles */
.jp-Button.jp-mod-minimal:hover {
  background-color: var(--jp-layout-color2);
}

.jp-Button.jp-mod-minimal {
  background: none;
}

.jp-InputGroup {
  display: block;
  position: relative;
}

.jp-InputGroup input {
  box-sizing: border-box;
  border: none;
  border-radius: 0;
  background-color: transparent;
  color: var(--jp-ui-font-color0);
  box-shadow: inset 0 0 0 var(--jp-border-width) var(--jp-input-border-color);
  padding-bottom: 0;
  padding-top: 0;
  padding-left: 10px;
  padding-right: 28px;
  position: relative;
  width: 100%;
  -webkit-appearance: none;
  -moz-appearance: none;
  appearance: none;
  font-size: 14px;
  font-weight: 400;
  height: 30px;
  line-height: 30px;
  outline: none;
  vertical-align: middle;
}

.jp-InputGroup input:focus {
  box-shadow: inset 0 0 0 var(--jp-border-width)
      var(--jp-input-active-box-shadow-color),
    inset 0 0 0 3px var(--jp-input-active-box-shadow-color);
}

.jp-InputGroup input:disabled {
  cursor: not-allowed;
  resize: block;
  background-color: var(--jp-layout-color2);
  color: var(--jp-ui-font-color2);
}

.jp-InputGroup input:disabled ~ span {
  cursor: not-allowed;
  color: var(--jp-ui-font-color2);
}

.jp-InputGroup input::placeholder,
input::placeholder {
  color: var(--jp-ui-font-color2);
}

.jp-InputGroupAction {
  position: absolute;
  bottom: 1px;
  right: 0;
  padding: 6px;
}

.jp-HTMLSelect.jp-DefaultStyle select {
  background-color: initial;
  border: none;
  border-radius: 0;
  box-shadow: none;
  color: var(--jp-ui-font-color0);
  display: block;
  font-size: var(--jp-ui-font-size1);
  font-family: var(--jp-ui-font-family);
  height: 24px;
  line-height: 14px;
  padding: 0 25px 0 10px;
  text-align: left;
  -moz-appearance: none;
  -webkit-appearance: none;
}

.jp-HTMLSelect.jp-DefaultStyle select:disabled {
  background-color: var(--jp-layout-color2);
  color: var(--jp-ui-font-color2);
  cursor: not-allowed;
  resize: block;
}

.jp-HTMLSelect.jp-DefaultStyle select:disabled ~ span {
  cursor: not-allowed;
}

/* Use our own theme for hover and option styles */
/* stylelint-disable-next-line selector-max-type */
.jp-HTMLSelect.jp-DefaultStyle select:hover,
.jp-HTMLSelect.jp-DefaultStyle select > option {
  background-color: var(--jp-layout-color2);
  color: var(--jp-ui-font-color0);
}

select {
  box-sizing: border-box;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Styles
|----------------------------------------------------------------------------*/

.jp-StatusBar-Widget {
  display: flex;
  align-items: center;
  background: var(--jp-layout-color2);
  min-height: var(--jp-statusbar-height);
  justify-content: space-between;
  padding: 0 10px;
}

.jp-StatusBar-Left {
  display: flex;
  align-items: center;
  flex-direction: row;
}

.jp-StatusBar-Middle {
  display: flex;
  align-items: center;
}

.jp-StatusBar-Right {
  display: flex;
  align-items: center;
  flex-direction: row-reverse;
}

.jp-StatusBar-Item {
  max-height: var(--jp-statusbar-height);
  margin: 0 2px;
  height: var(--jp-statusbar-height);
  white-space: nowrap;
  text-overflow: ellipsis;
  color: var(--jp-ui-font-color1);
  padding: 0 6px;
}

.jp-mod-highlighted:hover {
  background-color: var(--jp-layout-color3);
}

.jp-mod-clicked {
  background-color: var(--jp-brand-color1);
}

.jp-mod-clicked:hover {
  background-color: var(--jp-brand-color0);
}

.jp-mod-clicked .jp-StatusBar-TextItem {
  color: var(--jp-ui-inverse-font-color1);
}

.jp-StatusBar-HoverItem {
  box-shadow: '0px 4px 4px rgba(0, 0, 0, 0.25)';
}

.jp-StatusBar-TextItem {
  font-size: var(--jp-ui-font-size1);
  font-family: var(--jp-ui-font-family);
  line-height: 24px;
  color: var(--jp-ui-font-color1);
}

.jp-StatusBar-GroupItem {
  display: flex;
  align-items: center;
  flex-direction: row;
}

.jp-Statusbar-ProgressCircle svg {
  display: block;
  margin: 0 auto;
  width: 16px;
  height: 24px;
  align-self: normal;
}

.jp-Statusbar-ProgressCircle path {
  fill: var(--jp-inverse-layout-color3);
}

.jp-Statusbar-ProgressBar-progress-bar {
  height: 10px;
  width: 100px;
  border: solid 0.25px var(--jp-brand-color2);
  border-radius: 3px;
  overflow: hidden;
  align-self: center;
}

.jp-Statusbar-ProgressBar-progress-bar > div {
  background-color: var(--jp-brand-color2);
  background-image: linear-gradient(
    -45deg,
    rgba(255, 255, 255, 0.2) 25%,
    transparent 25%,
    transparent 50%,
    rgba(255, 255, 255, 0.2) 50%,
    rgba(255, 255, 255, 0.2) 75%,
    transparent 75%,
    transparent
  );
  background-size: 40px 40px;
  float: left;
  width: 0%;
  height: 100%;
  font-size: 12px;
  line-height: 14px;
  color: #fff;
  text-align: center;
  animation: jp-Statusbar-ExecutionTime-progress-bar 2s linear infinite;
}

.jp-Statusbar-ProgressBar-progress-bar p {
  color: var(--jp-ui-font-color1);
  font-family: var(--jp-ui-font-family);
  font-size: var(--jp-ui-font-size1);
  line-height: 10px;
  width: 100px;
}

@keyframes jp-Statusbar-ExecutionTime-progress-bar {
  0% {
    background-position: 0 0;
  }

  100% {
    background-position: 40px 40px;
  }
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Variables
|----------------------------------------------------------------------------*/

:root {
  --jp-private-commandpalette-search-height: 28px;
}

/*-----------------------------------------------------------------------------
| Overall styles
|----------------------------------------------------------------------------*/

.lm-CommandPalette {
  padding-bottom: 0;
  color: var(--jp-ui-font-color1);
  background: var(--jp-layout-color1);

  /* This is needed so that all font sizing of children done in ems is
   * relative to this base size */
  font-size: var(--jp-ui-font-size1);
}

/*-----------------------------------------------------------------------------
| Modal variant
|----------------------------------------------------------------------------*/

.jp-ModalCommandPalette {
  position: absolute;
  z-index: 10000;
  top: 38px;
  left: 30%;
  margin: 0;
  padding: 4px;
  width: 40%;
  box-shadow: var(--jp-elevation-z4);
  border-radius: 4px;
  background: var(--jp-layout-color0);
}

.jp-ModalCommandPalette .lm-CommandPalette {
  max-height: 40vh;
}

.jp-ModalCommandPalette .lm-CommandPalette .lm-close-icon::after {
  display: none;
}

.jp-ModalCommandPalette .lm-CommandPalette .lm-CommandPalette-header {
  display: none;
}

.jp-ModalCommandPalette .lm-CommandPalette .lm-CommandPalette-item {
  margin-left: 4px;
  margin-right: 4px;
}

.jp-ModalCommandPalette
  .lm-CommandPalette
  .lm-CommandPalette-item.lm-mod-disabled {
  display: none;
}

/*-----------------------------------------------------------------------------
| Search
|----------------------------------------------------------------------------*/

.lm-CommandPalette-search {
  padding: 4px;
  background-color: var(--jp-layout-color1);
  z-index: 2;
}

.lm-CommandPalette-wrapper {
  overflow: overlay;
  padding: 0 9px;
  background-color: var(--jp-input-active-background);
  height: 30px;
  box-shadow: inset 0 0 0 var(--jp-border-width) var(--jp-input-border-color);
}

.lm-CommandPalette.lm-mod-focused .lm-CommandPalette-wrapper {
  box-shadow: inset 0 0 0 1px var(--jp-input-active-box-shadow-color),
    inset 0 0 0 3px var(--jp-input-active-box-shadow-color);
}

.jp-SearchIconGroup {
  color: white;
  background-color: var(--jp-brand-color1);
  position: absolute;
  top: 4px;
  right: 4px;
  padding: 5px 5px 1px;
}

.jp-SearchIconGroup svg {
  height: 20px;
  width: 20px;
}

.jp-SearchIconGroup .jp-icon3[fill] {
  fill: var(--jp-layout-color0);
}

.lm-CommandPalette-input {
  background: transparent;
  width: calc(100% - 18px);
  float: left;
  border: none;
  outline: none;
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color0);
  line-height: var(--jp-private-commandpalette-search-height);
}

.lm-CommandPalette-input::-webkit-input-placeholder,
.lm-CommandPalette-input::-moz-placeholder,
.lm-CommandPalette-input:-ms-input-placeholder {
  color: var(--jp-ui-font-color2);
  font-size: var(--jp-ui-font-size1);
}

/*-----------------------------------------------------------------------------
| Results
|----------------------------------------------------------------------------*/

.lm-CommandPalette-header:first-child {
  margin-top: 0;
}

.lm-CommandPalette-header {
  border-bottom: solid var(--jp-border-width) var(--jp-border-color2);
  color: var(--jp-ui-font-color1);
  cursor: pointer;
  display: flex;
  font-size: var(--jp-ui-font-size0);
  font-weight: 600;
  letter-spacing: 1px;
  margin-top: 8px;
  padding: 8px 0 8px 12px;
  text-transform: uppercase;
}

.lm-CommandPalette-header.lm-mod-active {
  background: var(--jp-layout-color2);
}

.lm-CommandPalette-header > mark {
  background-color: transparent;
  font-weight: bold;
  color: var(--jp-ui-font-color1);
}

.lm-CommandPalette-item {
  padding: 4px 12px 4px 4px;
  color: var(--jp-ui-font-color1);
  font-size: var(--jp-ui-font-size1);
  font-weight: 400;
  display: flex;
}

.lm-CommandPalette-item.lm-mod-disabled {
  color: var(--jp-ui-font-color2);
}

.lm-CommandPalette-item.lm-mod-active {
  color: var(--jp-ui-inverse-font-color1);
  background: var(--jp-brand-color1);
}

.lm-CommandPalette-item.lm-mod-active .lm-CommandPalette-itemLabel > mark {
  color: var(--jp-ui-inverse-font-color0);
}

.lm-CommandPalette-item.lm-mod-active .jp-icon-selectable[fill] {
  fill: var(--jp-layout-color0);
}

.lm-CommandPalette-item.lm-mod-active:hover:not(.lm-mod-disabled) {
  color: var(--jp-ui-inverse-font-color1);
  background: var(--jp-brand-color1);
}

.lm-CommandPalette-item:hover:not(.lm-mod-active):not(.lm-mod-disabled) {
  background: var(--jp-layout-color2);
}

.lm-CommandPalette-itemContent {
  overflow: hidden;
}

.lm-CommandPalette-itemLabel > mark {
  color: var(--jp-ui-font-color0);
  background-color: transparent;
  font-weight: bold;
}

.lm-CommandPalette-item.lm-mod-disabled mark {
  color: var(--jp-ui-font-color2);
}

.lm-CommandPalette-item .lm-CommandPalette-itemIcon {
  margin: 0 4px 0 0;
  position: relative;
  width: 16px;
  top: 2px;
  flex: 0 0 auto;
}

.lm-CommandPalette-item.lm-mod-disabled .lm-CommandPalette-itemIcon {
  opacity: 0.6;
}

.lm-CommandPalette-item .lm-CommandPalette-itemShortcut {
  flex: 0 0 auto;
}

.lm-CommandPalette-itemCaption {
  display: none;
}

.lm-CommandPalette-content {
  background-color: var(--jp-layout-color1);
}

.lm-CommandPalette-content:empty::after {
  content: 'No results';
  margin: auto;
  margin-top: 20px;
  width: 100px;
  display: block;
  font-size: var(--jp-ui-font-size2);
  font-family: var(--jp-ui-font-family);
  font-weight: lighter;
}

.lm-CommandPalette-emptyMessage {
  text-align: center;
  margin-top: 24px;
  line-height: 1.32;
  padding: 0 8px;
  color: var(--jp-content-font-color3);
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2017, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-Dialog {
  position: absolute;
  z-index: 10000;
  display: flex;
  flex-direction: column;
  align-items: center;
  justify-content: center;
  top: 0;
  left: 0;
  margin: 0;
  padding: 0;
  width: 100%;
  height: 100%;
  background: var(--jp-dialog-background);
}

.jp-Dialog-content {
  display: flex;
  flex-direction: column;
  margin-left: auto;
  margin-right: auto;
  background: var(--jp-layout-color1);
  padding: 24px 24px 12px;
  min-width: 300px;
  min-height: 150px;
  max-width: 1000px;
  max-height: 500px;
  box-sizing: border-box;
  box-shadow: var(--jp-elevation-z20);
  word-wrap: break-word;
  border-radius: var(--jp-border-radius);

  /* This is needed so that all font sizing of children done in ems is
   * relative to this base size */
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color1);
  resize: both;
}

.jp-Dialog-content.jp-Dialog-content-small {
  max-width: 500px;
}

.jp-Dialog-button {
  overflow: visible;
}

button.jp-Dialog-button:focus {
  outline: 1px solid var(--jp-brand-color1);
  outline-offset: 4px;
  -moz-outline-radius: 0;
}

button.jp-Dialog-button:focus::-moz-focus-inner {
  border: 0;
}

button.jp-Dialog-button.jp-mod-styled.jp-mod-accept:focus,
button.jp-Dialog-button.jp-mod-styled.jp-mod-warn:focus,
button.jp-Dialog-button.jp-mod-styled.jp-mod-reject:focus {
  outline-offset: 4px;
  -moz-outline-radius: 0;
}

button.jp-Dialog-button.jp-mod-styled.jp-mod-accept:focus {
  outline: 1px solid var(--jp-accept-color-normal, var(--jp-brand-color1));
}

button.jp-Dialog-button.jp-mod-styled.jp-mod-warn:focus {
  outline: 1px solid var(--jp-warn-color-normal, var(--jp-error-color1));
}

button.jp-Dialog-button.jp-mod-styled.jp-mod-reject:focus {
  outline: 1px solid var(--jp-reject-color-normal, var(--md-grey-600));
}

button.jp-Dialog-close-button {
  padding: 0;
  height: 100%;
  min-width: unset;
  min-height: unset;
}

.jp-Dialog-header {
  display: flex;
  justify-content: space-between;
  flex: 0 0 auto;
  padding-bottom: 12px;
  font-size: var(--jp-ui-font-size3);
  font-weight: 400;
  color: var(--jp-ui-font-color1);
}

.jp-Dialog-body {
  display: flex;
  flex-direction: column;
  flex: 1 1 auto;
  font-size: var(--jp-ui-font-size1);
  background: var(--jp-layout-color1);
  color: var(--jp-ui-font-color1);
  overflow: auto;
}

.jp-Dialog-footer {
  display: flex;
  flex-direction: row;
  justify-content: flex-end;
  align-items: center;
  flex: 0 0 auto;
  margin-left: -12px;
  margin-right: -12px;
  padding: 12px;
}

.jp-Dialog-checkbox {
  padding-right: 5px;
}

.jp-Dialog-checkbox > input:focus-visible {
  outline: 1px solid var(--jp-input-active-border-color);
  outline-offset: 1px;
}

.jp-Dialog-spacer {
  flex: 1 1 auto;
}

.jp-Dialog-title {
  overflow: hidden;
  white-space: nowrap;
  text-overflow: ellipsis;
}

.jp-Dialog-body > .jp-select-wrapper {
  width: 100%;
}

.jp-Dialog-body > button {
  padding: 0 16px;
}

.jp-Dialog-body > label {
  line-height: 1.4;
  color: var(--jp-ui-font-color0);
}

.jp-Dialog-button.jp-mod-styled:not(:last-child) {
  margin-right: 12px;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

.jp-Input-Boolean-Dialog {
  flex-direction: row-reverse;
  align-items: end;
  width: 100%;
}

.jp-Input-Boolean-Dialog > label {
  flex: 1 1 auto;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2016, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-MainAreaWidget > :focus {
  outline: none;
}

.jp-MainAreaWidget .jp-MainAreaWidget-error {
  padding: 6px;
}

.jp-MainAreaWidget .jp-MainAreaWidget-error > pre {
  width: auto;
  padding: 10px;
  background: var(--jp-error-color3);
  border: var(--jp-border-width) solid var(--jp-error-color1);
  border-radius: var(--jp-border-radius);
  color: var(--jp-ui-font-color1);
  font-size: var(--jp-ui-font-size1);
  white-space: pre-wrap;
  word-wrap: break-word;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/**
 * google-material-color v1.2.6
 * https://github.com/danlevan/google-material-color
 */
:root {
  --md-red-50: #ffebee;
  --md-red-100: #ffcdd2;
  --md-red-200: #ef9a9a;
  --md-red-300: #e57373;
  --md-red-400: #ef5350;
  --md-red-500: #f44336;
  --md-red-600: #e53935;
  --md-red-700: #d32f2f;
  --md-red-800: #c62828;
  --md-red-900: #b71c1c;
  --md-red-A100: #ff8a80;
  --md-red-A200: #ff5252;
  --md-red-A400: #ff1744;
  --md-red-A700: #d50000;
  --md-pink-50: #fce4ec;
  --md-pink-100: #f8bbd0;
  --md-pink-200: #f48fb1;
  --md-pink-300: #f06292;
  --md-pink-400: #ec407a;
  --md-pink-500: #e91e63;
  --md-pink-600: #d81b60;
  --md-pink-700: #c2185b;
  --md-pink-800: #ad1457;
  --md-pink-900: #880e4f;
  --md-pink-A100: #ff80ab;
  --md-pink-A200: #ff4081;
  --md-pink-A400: #f50057;
  --md-pink-A700: #c51162;
  --md-purple-50: #f3e5f5;
  --md-purple-100: #e1bee7;
  --md-purple-200: #ce93d8;
  --md-purple-300: #ba68c8;
  --md-purple-400: #ab47bc;
  --md-purple-500: #9c27b0;
  --md-purple-600: #8e24aa;
  --md-purple-700: #7b1fa2;
  --md-purple-800: #6a1b9a;
  --md-purple-900: #4a148c;
  --md-purple-A100: #ea80fc;
  --md-purple-A200: #e040fb;
  --md-purple-A400: #d500f9;
  --md-purple-A700: #a0f;
  --md-deep-purple-50: #ede7f6;
  --md-deep-purple-100: #d1c4e9;
  --md-deep-purple-200: #b39ddb;
  --md-deep-purple-300: #9575cd;
  --md-deep-purple-400: #7e57c2;
  --md-deep-purple-500: #673ab7;
  --md-deep-purple-600: #5e35b1;
  --md-deep-purple-700: #512da8;
  --md-deep-purple-800: #4527a0;
  --md-deep-purple-900: #311b92;
  --md-deep-purple-A100: #b388ff;
  --md-deep-purple-A200: #7c4dff;
  --md-deep-purple-A400: #651fff;
  --md-deep-purple-A700: #6200ea;
  --md-indigo-50: #e8eaf6;
  --md-indigo-100: #c5cae9;
  --md-indigo-200: #9fa8da;
  --md-indigo-300: #7986cb;
  --md-indigo-400: #5c6bc0;
  --md-indigo-500: #3f51b5;
  --md-indigo-600: #3949ab;
  --md-indigo-700: #303f9f;
  --md-indigo-800: #283593;
  --md-indigo-900: #1a237e;
  --md-indigo-A100: #8c9eff;
  --md-indigo-A200: #536dfe;
  --md-indigo-A400: #3d5afe;
  --md-indigo-A700: #304ffe;
  --md-blue-50: #e3f2fd;
  --md-blue-100: #bbdefb;
  --md-blue-200: #90caf9;
  --md-blue-300: #64b5f6;
  --md-blue-400: #42a5f5;
  --md-blue-500: #2196f3;
  --md-blue-600: #1e88e5;
  --md-blue-700: #1976d2;
  --md-blue-800: #1565c0;
  --md-blue-900: #0d47a1;
  --md-blue-A100: #82b1ff;
  --md-blue-A200: #448aff;
  --md-blue-A400: #2979ff;
  --md-blue-A700: #2962ff;
  --md-light-blue-50: #e1f5fe;
  --md-light-blue-100: #b3e5fc;
  --md-light-blue-200: #81d4fa;
  --md-light-blue-300: #4fc3f7;
  --md-light-blue-400: #29b6f6;
  --md-light-blue-500: #03a9f4;
  --md-light-blue-600: #039be5;
  --md-light-blue-700: #0288d1;
  --md-light-blue-800: #0277bd;
  --md-light-blue-900: #01579b;
  --md-light-blue-A100: #80d8ff;
  --md-light-blue-A200: #40c4ff;
  --md-light-blue-A400: #00b0ff;
  --md-light-blue-A700: #0091ea;
  --md-cyan-50: #e0f7fa;
  --md-cyan-100: #b2ebf2;
  --md-cyan-200: #80deea;
  --md-cyan-300: #4dd0e1;
  --md-cyan-400: #26c6da;
  --md-cyan-500: #00bcd4;
  --md-cyan-600: #00acc1;
  --md-cyan-700: #0097a7;
  --md-cyan-800: #00838f;
  --md-cyan-900: #006064;
  --md-cyan-A100: #84ffff;
  --md-cyan-A200: #18ffff;
  --md-cyan-A400: #00e5ff;
  --md-cyan-A700: #00b8d4;
  --md-teal-50: #e0f2f1;
  --md-teal-100: #b2dfdb;
  --md-teal-200: #80cbc4;
  --md-teal-300: #4db6ac;
  --md-teal-400: #26a69a;
  --md-teal-500: #009688;
  --md-teal-600: #00897b;
  --md-teal-700: #00796b;
  --md-teal-800: #00695c;
  --md-teal-900: #004d40;
  --md-teal-A100: #a7ffeb;
  --md-teal-A200: #64ffda;
  --md-teal-A400: #1de9b6;
  --md-teal-A700: #00bfa5;
  --md-green-50: #e8f5e9;
  --md-green-100: #c8e6c9;
  --md-green-200: #a5d6a7;
  --md-green-300: #81c784;
  --md-green-400: #66bb6a;
  --md-green-500: #4caf50;
  --md-green-600: #43a047;
  --md-green-700: #388e3c;
  --md-green-800: #2e7d32;
  --md-green-900: #1b5e20;
  --md-green-A100: #b9f6ca;
  --md-green-A200: #69f0ae;
  --md-green-A400: #00e676;
  --md-green-A700: #00c853;
  --md-light-green-50: #f1f8e9;
  --md-light-green-100: #dcedc8;
  --md-light-green-200: #c5e1a5;
  --md-light-green-300: #aed581;
  --md-light-green-400: #9ccc65;
  --md-light-green-500: #8bc34a;
  --md-light-green-600: #7cb342;
  --md-light-green-700: #689f38;
  --md-light-green-800: #558b2f;
  --md-light-green-900: #33691e;
  --md-light-green-A100: #ccff90;
  --md-light-green-A200: #b2ff59;
  --md-light-green-A400: #76ff03;
  --md-light-green-A700: #64dd17;
  --md-lime-50: #f9fbe7;
  --md-lime-100: #f0f4c3;
  --md-lime-200: #e6ee9c;
  --md-lime-300: #dce775;
  --md-lime-400: #d4e157;
  --md-lime-500: #cddc39;
  --md-lime-600: #c0ca33;
  --md-lime-700: #afb42b;
  --md-lime-800: #9e9d24;
  --md-lime-900: #827717;
  --md-lime-A100: #f4ff81;
  --md-lime-A200: #eeff41;
  --md-lime-A400: #c6ff00;
  --md-lime-A700: #aeea00;
  --md-yellow-50: #fffde7;
  --md-yellow-100: #fff9c4;
  --md-yellow-200: #fff59d;
  --md-yellow-300: #fff176;
  --md-yellow-400: #ffee58;
  --md-yellow-500: #ffeb3b;
  --md-yellow-600: #fdd835;
  --md-yellow-700: #fbc02d;
  --md-yellow-800: #f9a825;
  --md-yellow-900: #f57f17;
  --md-yellow-A100: #ffff8d;
  --md-yellow-A200: #ff0;
  --md-yellow-A400: #ffea00;
  --md-yellow-A700: #ffd600;
  --md-amber-50: #fff8e1;
  --md-amber-100: #ffecb3;
  --md-amber-200: #ffe082;
  --md-amber-300: #ffd54f;
  --md-amber-400: #ffca28;
  --md-amber-500: #ffc107;
  --md-amber-600: #ffb300;
  --md-amber-700: #ffa000;
  --md-amber-800: #ff8f00;
  --md-amber-900: #ff6f00;
  --md-amber-A100: #ffe57f;
  --md-amber-A200: #ffd740;
  --md-amber-A400: #ffc400;
  --md-amber-A700: #ffab00;
  --md-orange-50: #fff3e0;
  --md-orange-100: #ffe0b2;
  --md-orange-200: #ffcc80;
  --md-orange-300: #ffb74d;
  --md-orange-400: #ffa726;
  --md-orange-500: #ff9800;
  --md-orange-600: #fb8c00;
  --md-orange-700: #f57c00;
  --md-orange-800: #ef6c00;
  --md-orange-900: #e65100;
  --md-orange-A100: #ffd180;
  --md-orange-A200: #ffab40;
  --md-orange-A400: #ff9100;
  --md-orange-A700: #ff6d00;
  --md-deep-orange-50: #fbe9e7;
  --md-deep-orange-100: #ffccbc;
  --md-deep-orange-200: #ffab91;
  --md-deep-orange-300: #ff8a65;
  --md-deep-orange-400: #ff7043;
  --md-deep-orange-500: #ff5722;
  --md-deep-orange-600: #f4511e;
  --md-deep-orange-700: #e64a19;
  --md-deep-orange-800: #d84315;
  --md-deep-orange-900: #bf360c;
  --md-deep-orange-A100: #ff9e80;
  --md-deep-orange-A200: #ff6e40;
  --md-deep-orange-A400: #ff3d00;
  --md-deep-orange-A700: #dd2c00;
  --md-brown-50: #efebe9;
  --md-brown-100: #d7ccc8;
  --md-brown-200: #bcaaa4;
  --md-brown-300: #a1887f;
  --md-brown-400: #8d6e63;
  --md-brown-500: #795548;
  --md-brown-600: #6d4c41;
  --md-brown-700: #5d4037;
  --md-brown-800: #4e342e;
  --md-brown-900: #3e2723;
  --md-grey-50: #fafafa;
  --md-grey-100: #f5f5f5;
  --md-grey-200: #eee;
  --md-grey-300: #e0e0e0;
  --md-grey-400: #bdbdbd;
  --md-grey-500: #9e9e9e;
  --md-grey-600: #757575;
  --md-grey-700: #616161;
  --md-grey-800: #424242;
  --md-grey-900: #212121;
  --md-blue-grey-50: #eceff1;
  --md-blue-grey-100: #cfd8dc;
  --md-blue-grey-200: #b0bec5;
  --md-blue-grey-300: #90a4ae;
  --md-blue-grey-400: #78909c;
  --md-blue-grey-500: #607d8b;
  --md-blue-grey-600: #546e7a;
  --md-blue-grey-700: #455a64;
  --md-blue-grey-800: #37474f;
  --md-blue-grey-900: #263238;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2017, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| RenderedText
|----------------------------------------------------------------------------*/

:root {
  /* This is the padding value to fill the gaps between lines containing spans with background color. */
  --jp-private-code-span-padding: calc(
    (var(--jp-code-line-height) - 1) * var(--jp-code-font-size) / 2
  );
}

.jp-RenderedText {
  text-align: left;
  padding-left: var(--jp-code-padding);
  line-height: var(--jp-code-line-height);
  font-family: var(--jp-code-font-family);
}

.jp-RenderedText pre,
.jp-RenderedJavaScript pre,
.jp-RenderedHTMLCommon pre {
  color: var(--jp-content-font-color1);
  font-size: var(--jp-code-font-size);
  border: none;
  margin: 0;
  padding: 0;
}

.jp-RenderedText pre a:link {
  text-decoration: none;
  color: var(--jp-content-link-color);
}

.jp-RenderedText pre a:hover {
  text-decoration: underline;
  color: var(--jp-content-link-color);
}

.jp-RenderedText pre a:visited {
  text-decoration: none;
  color: var(--jp-content-link-color);
}

/* console foregrounds and backgrounds */
.jp-RenderedText pre .ansi-black-fg {
  color: #3e424d;
}

.jp-RenderedText pre .ansi-red-fg {
  color: #e75c58;
}

.jp-RenderedText pre .ansi-green-fg {
  color: #00a250;
}

.jp-RenderedText pre .ansi-yellow-fg {
  color: #ddb62b;
}

.jp-RenderedText pre .ansi-blue-fg {
  color: #208ffb;
}

.jp-RenderedText pre .ansi-magenta-fg {
  color: #d160c4;
}

.jp-RenderedText pre .ansi-cyan-fg {
  color: #60c6c8;
}

.jp-RenderedText pre .ansi-white-fg {
  color: #c5c1b4;
}

.jp-RenderedText pre .ansi-black-bg {
  background-color: #3e424d;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-red-bg {
  background-color: #e75c58;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-green-bg {
  background-color: #00a250;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-yellow-bg {
  background-color: #ddb62b;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-blue-bg {
  background-color: #208ffb;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-magenta-bg {
  background-color: #d160c4;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-cyan-bg {
  background-color: #60c6c8;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-white-bg {
  background-color: #c5c1b4;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-black-intense-fg {
  color: #282c36;
}

.jp-RenderedText pre .ansi-red-intense-fg {
  color: #b22b31;
}

.jp-RenderedText pre .ansi-green-intense-fg {
  color: #007427;
}

.jp-RenderedText pre .ansi-yellow-intense-fg {
  color: #b27d12;
}

.jp-RenderedText pre .ansi-blue-intense-fg {
  color: #0065ca;
}

.jp-RenderedText pre .ansi-magenta-intense-fg {
  color: #a03196;
}

.jp-RenderedText pre .ansi-cyan-intense-fg {
  color: #258f8f;
}

.jp-RenderedText pre .ansi-white-intense-fg {
  color: #a1a6b2;
}

.jp-RenderedText pre .ansi-black-intense-bg {
  background-color: #282c36;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-red-intense-bg {
  background-color: #b22b31;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-green-intense-bg {
  background-color: #007427;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-yellow-intense-bg {
  background-color: #b27d12;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-blue-intense-bg {
  background-color: #0065ca;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-magenta-intense-bg {
  background-color: #a03196;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-cyan-intense-bg {
  background-color: #258f8f;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-white-intense-bg {
  background-color: #a1a6b2;
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-default-inverse-fg {
  color: var(--jp-ui-inverse-font-color0);
}

.jp-RenderedText pre .ansi-default-inverse-bg {
  background-color: var(--jp-inverse-layout-color0);
  padding: var(--jp-private-code-span-padding) 0;
}

.jp-RenderedText pre .ansi-bold {
  font-weight: bold;
}

.jp-RenderedText pre .ansi-underline {
  text-decoration: underline;
}

.jp-RenderedText[data-mime-type='application/vnd.jupyter.stderr'] {
  background: var(--jp-rendermime-error-background);
  padding-top: var(--jp-code-padding);
}

/*-----------------------------------------------------------------------------
| RenderedLatex
|----------------------------------------------------------------------------*/

.jp-RenderedLatex {
  color: var(--jp-content-font-color1);
  font-size: var(--jp-content-font-size1);
  line-height: var(--jp-content-line-height);
}

/* Left-justify outputs.*/
.jp-OutputArea-output.jp-RenderedLatex {
  padding: var(--jp-code-padding);
  text-align: left;
}

/*-----------------------------------------------------------------------------
| RenderedHTML
|----------------------------------------------------------------------------*/

.jp-RenderedHTMLCommon {
  color: var(--jp-content-font-color1);
  font-family: var(--jp-content-font-family);
  font-size: var(--jp-content-font-size1);
  line-height: var(--jp-content-line-height);

  /* Give a bit more R padding on Markdown text to keep line lengths reasonable */
  padding-right: 20px;
}

.jp-RenderedHTMLCommon em {
  font-style: italic;
}

.jp-RenderedHTMLCommon strong {
  font-weight: bold;
}

.jp-RenderedHTMLCommon u {
  text-decoration: underline;
}

.jp-RenderedHTMLCommon a:link {
  text-decoration: none;
  color: var(--jp-content-link-color);
}

.jp-RenderedHTMLCommon a:hover {
  text-decoration: underline;
  color: var(--jp-content-link-color);
}

.jp-RenderedHTMLCommon a:visited {
  text-decoration: none;
  color: var(--jp-content-link-color);
}

/* Headings */

.jp-RenderedHTMLCommon h1,
.jp-RenderedHTMLCommon h2,
.jp-RenderedHTMLCommon h3,
.jp-RenderedHTMLCommon h4,
.jp-RenderedHTMLCommon h5,
.jp-RenderedHTMLCommon h6 {
  line-height: var(--jp-content-heading-line-height);
  font-weight: var(--jp-content-heading-font-weight);
  font-style: normal;
  margin: var(--jp-content-heading-margin-top) 0
    var(--jp-content-heading-margin-bottom) 0;
}

.jp-RenderedHTMLCommon h1:first-child,
.jp-RenderedHTMLCommon h2:first-child,
.jp-RenderedHTMLCommon h3:first-child,
.jp-RenderedHTMLCommon h4:first-child,
.jp-RenderedHTMLCommon h5:first-child,
.jp-RenderedHTMLCommon h6:first-child {
  margin-top: calc(0.5 * var(--jp-content-heading-margin-top));
}

.jp-RenderedHTMLCommon h1:last-child,
.jp-RenderedHTMLCommon h2:last-child,
.jp-RenderedHTMLCommon h3:last-child,
.jp-RenderedHTMLCommon h4:last-child,
.jp-RenderedHTMLCommon h5:last-child,
.jp-RenderedHTMLCommon h6:last-child {
  margin-bottom: calc(0.5 * var(--jp-content-heading-margin-bottom));
}

.jp-RenderedHTMLCommon h1 {
  font-size: var(--jp-content-font-size5);
}

.jp-RenderedHTMLCommon h2 {
  font-size: var(--jp-content-font-size4);
}

.jp-RenderedHTMLCommon h3 {
  font-size: var(--jp-content-font-size3);
}

.jp-RenderedHTMLCommon h4 {
  font-size: var(--jp-content-font-size2);
}

.jp-RenderedHTMLCommon h5 {
  font-size: var(--jp-content-font-size1);
}

.jp-RenderedHTMLCommon h6 {
  font-size: var(--jp-content-font-size0);
}

/* Lists */

/* stylelint-disable selector-max-type, selector-max-compound-selectors */

.jp-RenderedHTMLCommon ul:not(.list-inline),
.jp-RenderedHTMLCommon ol:not(.list-inline) {
  padding-left: 2em;
}

.jp-RenderedHTMLCommon ul {
  list-style: disc;
}

.jp-RenderedHTMLCommon ul ul {
  list-style: square;
}

.jp-RenderedHTMLCommon ul ul ul {
  list-style: circle;
}

.jp-RenderedHTMLCommon ol {
  list-style: decimal;
}

.jp-RenderedHTMLCommon ol ol {
  list-style: upper-alpha;
}

.jp-RenderedHTMLCommon ol ol ol {
  list-style: lower-alpha;
}

.jp-RenderedHTMLCommon ol ol ol ol {
  list-style: lower-roman;
}

.jp-RenderedHTMLCommon ol ol ol ol ol {
  list-style: decimal;
}

.jp-RenderedHTMLCommon ol,
.jp-RenderedHTMLCommon ul {
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon ul ul,
.jp-RenderedHTMLCommon ul ol,
.jp-RenderedHTMLCommon ol ul,
.jp-RenderedHTMLCommon ol ol {
  margin-bottom: 0;
}

/* stylelint-enable selector-max-type, selector-max-compound-selectors */

.jp-RenderedHTMLCommon hr {
  color: var(--jp-border-color2);
  background-color: var(--jp-border-color1);
  margin-top: 1em;
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon > pre {
  margin: 1.5em 2em;
}

.jp-RenderedHTMLCommon pre,
.jp-RenderedHTMLCommon code {
  border: 0;
  background-color: var(--jp-layout-color0);
  color: var(--jp-content-font-color1);
  font-family: var(--jp-code-font-family);
  font-size: inherit;
  line-height: var(--jp-code-line-height);
  padding: 0;
  white-space: pre-wrap;
}

.jp-RenderedHTMLCommon :not(pre) > code {
  background-color: var(--jp-layout-color2);
  padding: 1px 5px;
}

/* Tables */

.jp-RenderedHTMLCommon table {
  border-collapse: collapse;
  border-spacing: 0;
  border: none;
  color: var(--jp-ui-font-color1);
  font-size: var(--jp-ui-font-size1);
  table-layout: fixed;
  margin-left: auto;
  margin-bottom: 1em;
  margin-right: auto;
}

.jp-RenderedHTMLCommon thead {
  border-bottom: var(--jp-border-width) solid var(--jp-border-color1);
  vertical-align: bottom;
}

.jp-RenderedHTMLCommon td,
.jp-RenderedHTMLCommon th,
.jp-RenderedHTMLCommon tr {
  vertical-align: middle;
  padding: 0.5em;
  line-height: normal;
  white-space: normal;
  max-width: none;
  border: none;
}

.jp-RenderedMarkdown.jp-RenderedHTMLCommon td,
.jp-RenderedMarkdown.jp-RenderedHTMLCommon th {
  max-width: none;
}

:not(.jp-RenderedMarkdown).jp-RenderedHTMLCommon td,
:not(.jp-RenderedMarkdown).jp-RenderedHTMLCommon th,
:not(.jp-RenderedMarkdown).jp-RenderedHTMLCommon tr {
  text-align: right;
}

.jp-RenderedHTMLCommon th {
  font-weight: bold;
}

.jp-RenderedHTMLCommon tbody tr:nth-child(odd) {
  background: var(--jp-layout-color0);
}

.jp-RenderedHTMLCommon tbody tr:nth-child(even) {
  background: var(--jp-rendermime-table-row-background);
}

.jp-RenderedHTMLCommon tbody tr:hover {
  background: var(--jp-rendermime-table-row-hover-background);
}

.jp-RenderedHTMLCommon p {
  text-align: left;
  margin: 0;
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon img {
  -moz-force-broken-image-icon: 1;
}

/* Restrict to direct children as other images could be nested in other content. */
.jp-RenderedHTMLCommon > img {
  display: block;
  margin-left: 0;
  margin-right: 0;
  margin-bottom: 1em;
}

/* Change color behind transparent images if they need it... */
[data-jp-theme-light='false'] .jp-RenderedImage img.jp-needs-light-background {
  background-color: var(--jp-inverse-layout-color1);
}

[data-jp-theme-light='true'] .jp-RenderedImage img.jp-needs-dark-background {
  background-color: var(--jp-inverse-layout-color1);
}

.jp-RenderedHTMLCommon img,
.jp-RenderedImage img,
.jp-RenderedHTMLCommon svg,
.jp-RenderedSVG svg {
  max-width: 100%;
  height: auto;
}

.jp-RenderedHTMLCommon img.jp-mod-unconfined,
.jp-RenderedImage img.jp-mod-unconfined,
.jp-RenderedHTMLCommon svg.jp-mod-unconfined,
.jp-RenderedSVG svg.jp-mod-unconfined {
  max-width: none;
}

.jp-RenderedHTMLCommon .alert {
  padding: var(--jp-notebook-padding);
  border: var(--jp-border-width) solid transparent;
  border-radius: var(--jp-border-radius);
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon .alert-info {
  color: var(--jp-info-color0);
  background-color: var(--jp-info-color3);
  border-color: var(--jp-info-color2);
}

.jp-RenderedHTMLCommon .alert-info hr {
  border-color: var(--jp-info-color3);
}

.jp-RenderedHTMLCommon .alert-info > p:last-child,
.jp-RenderedHTMLCommon .alert-info > ul:last-child {
  margin-bottom: 0;
}

.jp-RenderedHTMLCommon .alert-warning {
  color: var(--jp-warn-color0);
  background-color: var(--jp-warn-color3);
  border-color: var(--jp-warn-color2);
}

.jp-RenderedHTMLCommon .alert-warning hr {
  border-color: var(--jp-warn-color3);
}

.jp-RenderedHTMLCommon .alert-warning > p:last-child,
.jp-RenderedHTMLCommon .alert-warning > ul:last-child {
  margin-bottom: 0;
}

.jp-RenderedHTMLCommon .alert-success {
  color: var(--jp-success-color0);
  background-color: var(--jp-success-color3);
  border-color: var(--jp-success-color2);
}

.jp-RenderedHTMLCommon .alert-success hr {
  border-color: var(--jp-success-color3);
}

.jp-RenderedHTMLCommon .alert-success > p:last-child,
.jp-RenderedHTMLCommon .alert-success > ul:last-child {
  margin-bottom: 0;
}

.jp-RenderedHTMLCommon .alert-danger {
  color: var(--jp-error-color0);
  background-color: var(--jp-error-color3);
  border-color: var(--jp-error-color2);
}

.jp-RenderedHTMLCommon .alert-danger hr {
  border-color: var(--jp-error-color3);
}

.jp-RenderedHTMLCommon .alert-danger > p:last-child,
.jp-RenderedHTMLCommon .alert-danger > ul:last-child {
  margin-bottom: 0;
}

.jp-RenderedHTMLCommon blockquote {
  margin: 1em 2em;
  padding: 0 1em;
  border-left: 5px solid var(--jp-border-color2);
}

a.jp-InternalAnchorLink {
  visibility: hidden;
  margin-left: 8px;
  color: var(--md-blue-800);
}

h1:hover .jp-InternalAnchorLink,
h2:hover .jp-InternalAnchorLink,
h3:hover .jp-InternalAnchorLink,
h4:hover .jp-InternalAnchorLink,
h5:hover .jp-InternalAnchorLink,
h6:hover .jp-InternalAnchorLink {
  visibility: visible;
}

.jp-RenderedHTMLCommon kbd {
  background-color: var(--jp-rendermime-table-row-background);
  border: 1px solid var(--jp-border-color0);
  border-bottom-color: var(--jp-border-color2);
  border-radius: 3px;
  box-shadow: inset 0 -1px 0 rgba(0, 0, 0, 0.25);
  display: inline-block;
  font-size: var(--jp-ui-font-size0);
  line-height: 1em;
  padding: 0.2em 0.5em;
}

/* Most direct children of .jp-RenderedHTMLCommon have a margin-bottom of 1.0.
 * At the bottom of cells this is a bit too much as there is also spacing
 * between cells. Going all the way to 0 gets too tight between markdown and
 * code cells.
 */
.jp-RenderedHTMLCommon > *:last-child {
  margin-bottom: 0.5em;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

.lm-cursor-backdrop {
  position: fixed;
  width: 200px;
  height: 200px;
  margin-top: -100px;
  margin-left: -100px;
  will-change: transform;
  z-index: 100;
}

.lm-mod-drag-image {
  will-change: transform;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

.jp-lineFormSearch {
  padding: 4px 12px;
  background-color: var(--jp-layout-color2);
  box-shadow: var(--jp-toolbar-box-shadow);
  z-index: 2;
  font-size: var(--jp-ui-font-size1);
}

.jp-lineFormCaption {
  font-size: var(--jp-ui-font-size0);
  line-height: var(--jp-ui-font-size1);
  margin-top: 4px;
  color: var(--jp-ui-font-color0);
}

.jp-baseLineForm {
  border: none;
  border-radius: 0;
  position: absolute;
  background-size: 16px;
  background-repeat: no-repeat;
  background-position: center;
  outline: none;
}

.jp-lineFormButtonContainer {
  top: 4px;
  right: 8px;
  height: 24px;
  padding: 0 12px;
  width: 12px;
}

.jp-lineFormButtonIcon {
  top: 0;
  right: 0;
  background-color: var(--jp-brand-color1);
  height: 100%;
  width: 100%;
  box-sizing: border-box;
  padding: 4px 6px;
}

.jp-lineFormButton {
  top: 0;
  right: 0;
  background-color: transparent;
  height: 100%;
  width: 100%;
  box-sizing: border-box;
}

.jp-lineFormWrapper {
  overflow: hidden;
  padding: 0 8px;
  border: 1px solid var(--jp-border-color0);
  background-color: var(--jp-input-active-background);
  height: 22px;
}

.jp-lineFormWrapperFocusWithin {
  border: var(--jp-border-width) solid var(--md-blue-500);
  box-shadow: inset 0 0 4px var(--md-blue-300);
}

.jp-lineFormInput {
  background: transparent;
  width: 200px;
  height: 100%;
  border: none;
  outline: none;
  color: var(--jp-ui-font-color0);
  line-height: 28px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2016, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-JSONEditor {
  display: flex;
  flex-direction: column;
  width: 100%;
}

.jp-JSONEditor-host {
  flex: 1 1 auto;
  border: var(--jp-border-width) solid var(--jp-input-border-color);
  border-radius: 0;
  background: var(--jp-layout-color0);
  min-height: 50px;
  padding: 1px;
}

.jp-JSONEditor.jp-mod-error .jp-JSONEditor-host {
  border-color: red;
  outline-color: red;
}

.jp-JSONEditor-header {
  display: flex;
  flex: 1 0 auto;
  padding: 0 0 0 12px;
}

.jp-JSONEditor-header label {
  flex: 0 0 auto;
}

.jp-JSONEditor-commitButton {
  height: 16px;
  width: 16px;
  background-size: 18px;
  background-repeat: no-repeat;
  background-position: center;
}

.jp-JSONEditor-host.jp-mod-focused {
  background-color: var(--jp-input-active-background);
  border: 1px solid var(--jp-input-active-border-color);
  box-shadow: var(--jp-input-box-shadow);
}

.jp-Editor.jp-mod-dropTarget {
  border: var(--jp-border-width) solid var(--jp-input-active-border-color);
  box-shadow: var(--jp-input-box-shadow);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/
.jp-DocumentSearch-input {
  border: none;
  outline: none;
  color: var(--jp-ui-font-color0);
  font-size: var(--jp-ui-font-size1);
  background-color: var(--jp-layout-color0);
  font-family: var(--jp-ui-font-family);
  padding: 2px 1px;
  resize: none;
}

.jp-DocumentSearch-overlay {
  position: absolute;
  background-color: var(--jp-toolbar-background);
  border-bottom: var(--jp-border-width) solid var(--jp-toolbar-border-color);
  border-left: var(--jp-border-width) solid var(--jp-toolbar-border-color);
  top: 0;
  right: 0;
  z-index: 7;
  min-width: 405px;
  padding: 2px;
  font-size: var(--jp-ui-font-size1);

  --jp-private-document-search-button-height: 20px;
}

.jp-DocumentSearch-overlay button {
  background-color: var(--jp-toolbar-background);
  outline: 0;
}

.jp-DocumentSearch-overlay button:hover {
  background-color: var(--jp-layout-color2);
}

.jp-DocumentSearch-overlay button:active {
  background-color: var(--jp-layout-color3);
}

.jp-DocumentSearch-overlay-row {
  display: flex;
  align-items: center;
  margin-bottom: 2px;
}

.jp-DocumentSearch-button-content {
  display: inline-block;
  cursor: pointer;
  box-sizing: border-box;
  width: 100%;
  height: 100%;
}

.jp-DocumentSearch-button-content svg {
  width: 100%;
  height: 100%;
}

.jp-DocumentSearch-input-wrapper {
  border: var(--jp-border-width) solid var(--jp-border-color0);
  display: flex;
  background-color: var(--jp-layout-color0);
  margin: 2px;
}

.jp-DocumentSearch-input-wrapper:focus-within {
  border-color: var(--jp-cell-editor-active-border-color);
}

.jp-DocumentSearch-toggle-wrapper,
.jp-DocumentSearch-button-wrapper {
  all: initial;
  overflow: hidden;
  display: inline-block;
  border: none;
  box-sizing: border-box;
}

.jp-DocumentSearch-toggle-wrapper {
  width: 14px;
  height: 14px;
}

.jp-DocumentSearch-button-wrapper {
  width: var(--jp-private-document-search-button-height);
  height: var(--jp-private-document-search-button-height);
}

.jp-DocumentSearch-toggle-wrapper:focus,
.jp-DocumentSearch-button-wrapper:focus {
  outline: var(--jp-border-width) solid
    var(--jp-cell-editor-active-border-color);
  outline-offset: -1px;
}

.jp-DocumentSearch-toggle-wrapper,
.jp-DocumentSearch-button-wrapper,
.jp-DocumentSearch-button-content:focus {
  outline: none;
}

.jp-DocumentSearch-toggle-placeholder {
  width: 5px;
}

.jp-DocumentSearch-input-button::before {
  display: block;
  padding-top: 100%;
}

.jp-DocumentSearch-input-button-off {
  opacity: var(--jp-search-toggle-off-opacity);
}

.jp-DocumentSearch-input-button-off:hover {
  opacity: var(--jp-search-toggle-hover-opacity);
}

.jp-DocumentSearch-input-button-on {
  opacity: var(--jp-search-toggle-on-opacity);
}

.jp-DocumentSearch-index-counter {
  padding-left: 10px;
  padding-right: 10px;
  user-select: none;
  min-width: 35px;
  display: inline-block;
}

.jp-DocumentSearch-up-down-wrapper {
  display: inline-block;
  padding-right: 2px;
  margin-left: auto;
  white-space: nowrap;
}

.jp-DocumentSearch-spacer {
  margin-left: auto;
}

.jp-DocumentSearch-up-down-wrapper button {
  outline: 0;
  border: none;
  width: var(--jp-private-document-search-button-height);
  height: var(--jp-private-document-search-button-height);
  vertical-align: middle;
  margin: 1px 5px 2px;
}

.jp-DocumentSearch-up-down-button:hover {
  background-color: var(--jp-layout-color2);
}

.jp-DocumentSearch-up-down-button:active {
  background-color: var(--jp-layout-color3);
}

.jp-DocumentSearch-filter-button {
  border-radius: var(--jp-border-radius);
}

.jp-DocumentSearch-filter-button:hover {
  background-color: var(--jp-layout-color2);
}

.jp-DocumentSearch-filter-button-enabled {
  background-color: var(--jp-layout-color2);
}

.jp-DocumentSearch-filter-button-enabled:hover {
  background-color: var(--jp-layout-color3);
}

.jp-DocumentSearch-search-options {
  padding: 0 8px;
  margin-left: 3px;
  width: 100%;
  display: grid;
  justify-content: start;
  grid-template-columns: 1fr 1fr;
  align-items: center;
  justify-items: stretch;
}

.jp-DocumentSearch-search-filter-disabled {
  color: var(--jp-ui-font-color2);
}

.jp-DocumentSearch-search-filter {
  display: flex;
  align-items: center;
  user-select: none;
}

.jp-DocumentSearch-regex-error {
  color: var(--jp-error-color0);
}

.jp-DocumentSearch-replace-button-wrapper {
  overflow: hidden;
  display: inline-block;
  box-sizing: border-box;
  border: var(--jp-border-width) solid var(--jp-border-color0);
  margin: auto 2px;
  padding: 1px 4px;
  height: calc(var(--jp-private-document-search-button-height) + 2px);
}

.jp-DocumentSearch-replace-button-wrapper:focus {
  border: var(--jp-border-width) solid var(--jp-cell-editor-active-border-color);
}

.jp-DocumentSearch-replace-button {
  display: inline-block;
  text-align: center;
  cursor: pointer;
  box-sizing: border-box;
  color: var(--jp-ui-font-color1);

  /* height - 2 * (padding of wrapper) */
  line-height: calc(var(--jp-private-document-search-button-height) - 2px);
  width: 100%;
  height: 100%;
}

.jp-DocumentSearch-replace-button:focus {
  outline: none;
}

.jp-DocumentSearch-replace-wrapper-class {
  margin-left: 14px;
  display: flex;
}

.jp-DocumentSearch-replace-toggle {
  border: none;
  background-color: var(--jp-toolbar-background);
  border-radius: var(--jp-border-radius);
}

.jp-DocumentSearch-replace-toggle:hover {
  background-color: var(--jp-layout-color2);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.cm-editor {
  line-height: var(--jp-code-line-height);
  font-size: var(--jp-code-font-size);
  font-family: var(--jp-code-font-family);
  border: 0;
  border-radius: 0;
  height: auto;

  /* Changed to auto to autogrow */
}

.cm-editor pre {
  padding: 0 var(--jp-code-padding);
}

.jp-CodeMirrorEditor[data-type='inline'] .cm-dialog {
  background-color: var(--jp-layout-color0);
  color: var(--jp-content-font-color1);
}

.jp-CodeMirrorEditor {
  cursor: text;
}

/* When zoomed out 67% and 33% on a screen of 1440 width x 900 height */
@media screen and (min-width: 2138px) and (max-width: 4319px) {
  .jp-CodeMirrorEditor[data-type='inline'] .cm-cursor {
    border-left: var(--jp-code-cursor-width1) solid
      var(--jp-editor-cursor-color);
  }
}

/* When zoomed out less than 33% */
@media screen and (min-width: 4320px) {
  .jp-CodeMirrorEditor[data-type='inline'] .cm-cursor {
    border-left: var(--jp-code-cursor-width2) solid
      var(--jp-editor-cursor-color);
  }
}

.cm-editor.jp-mod-readOnly .cm-cursor {
  display: none;
}

.jp-CollaboratorCursor {
  border-left: 5px solid transparent;
  border-right: 5px solid transparent;
  border-top: none;
  border-bottom: 3px solid;
  background-clip: content-box;
  margin-left: -5px;
  margin-right: -5px;
}

.cm-searching,
.cm-searching span {
  /* `.cm-searching span`: we need to override syntax highlighting */
  background-color: var(--jp-search-unselected-match-background-color);
  color: var(--jp-search-unselected-match-color);
}

.cm-searching::selection,
.cm-searching span::selection {
  background-color: var(--jp-search-unselected-match-background-color);
  color: var(--jp-search-unselected-match-color);
}

.jp-current-match > .cm-searching,
.jp-current-match > .cm-searching span,
.cm-searching > .jp-current-match,
.cm-searching > .jp-current-match span {
  background-color: var(--jp-search-selected-match-background-color);
  color: var(--jp-search-selected-match-color);
}

.jp-current-match > .cm-searching::selection,
.cm-searching > .jp-current-match::selection,
.jp-current-match > .cm-searching span::selection {
  background-color: var(--jp-search-selected-match-background-color);
  color: var(--jp-search-selected-match-color);
}

.cm-trailingspace {
  background-image: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAgAAAAFCAYAAAB4ka1VAAAAsElEQVQIHQGlAFr/AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA7+r3zKmT0/+pk9P/7+r3zAAAAAAAAAAABAAAAAAAAAAA6OPzM+/q9wAAAAAA6OPzMwAAAAAAAAAAAgAAAAAAAAAAGR8NiRQaCgAZIA0AGR8NiQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAQyoYJ/SY80UAAAAASUVORK5CYII=);
  background-position: center left;
  background-repeat: repeat-x;
}

.jp-CollaboratorCursor-hover {
  position: absolute;
  z-index: 1;
  transform: translateX(-50%);
  color: white;
  border-radius: 3px;
  padding-left: 4px;
  padding-right: 4px;
  padding-top: 1px;
  padding-bottom: 1px;
  text-align: center;
  font-size: var(--jp-ui-font-size1);
  white-space: nowrap;
}

.jp-CodeMirror-ruler {
  border-left: 1px dashed var(--jp-border-color2);
}

/* Styles for shared cursors (remote cursor locations and selected ranges) */
.jp-CodeMirrorEditor .cm-ySelectionCaret {
  position: relative;
  border-left: 1px solid black;
  margin-left: -1px;
  margin-right: -1px;
  box-sizing: border-box;
}

.jp-CodeMirrorEditor .cm-ySelectionCaret > .cm-ySelectionInfo {
  white-space: nowrap;
  position: absolute;
  top: -1.15em;
  padding-bottom: 0.05em;
  left: -1px;
  font-size: 0.95em;
  font-family: var(--jp-ui-font-family);
  font-weight: bold;
  line-height: normal;
  user-select: none;
  color: white;
  padding-left: 2px;
  padding-right: 2px;
  z-index: 101;
  transition: opacity 0.3s ease-in-out;
}

.jp-CodeMirrorEditor .cm-ySelectionInfo {
  transition-delay: 0.7s;
  opacity: 0;
}

.jp-CodeMirrorEditor .cm-ySelectionCaret:hover > .cm-ySelectionInfo {
  opacity: 1;
  transition-delay: 0s;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-MimeDocument {
  outline: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Variables
|----------------------------------------------------------------------------*/

:root {
  --jp-private-filebrowser-button-height: 28px;
  --jp-private-filebrowser-button-width: 48px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-FileBrowser .jp-SidePanel-content {
  display: flex;
  flex-direction: column;
}

.jp-FileBrowser-toolbar.jp-Toolbar {
  flex-wrap: wrap;
  row-gap: 12px;
  border-bottom: none;
  height: auto;
  margin: 8px 12px 0;
  box-shadow: none;
  padding: 0;
  justify-content: flex-start;
}

.jp-FileBrowser-Panel {
  flex: 1 1 auto;
  display: flex;
  flex-direction: column;
}

.jp-BreadCrumbs {
  flex: 0 0 auto;
  margin: 8px 12px;
}

.jp-BreadCrumbs-item {
  margin: 0 2px;
  padding: 0 2px;
  border-radius: var(--jp-border-radius);
  cursor: pointer;
}

.jp-BreadCrumbs-item:hover {
  background-color: var(--jp-layout-color2);
}

.jp-BreadCrumbs-item:first-child {
  margin-left: 0;
}

.jp-BreadCrumbs-item.jp-mod-dropTarget {
  background-color: var(--jp-brand-color2);
  opacity: 0.7;
}

/*-----------------------------------------------------------------------------
| Buttons
|----------------------------------------------------------------------------*/

.jp-FileBrowser-toolbar > .jp-Toolbar-item {
  flex: 0 0 auto;
  padding-left: 0;
  padding-right: 2px;
  align-items: center;
  height: unset;
}

.jp-FileBrowser-toolbar > .jp-Toolbar-item .jp-ToolbarButtonComponent {
  width: 40px;
}

/*-----------------------------------------------------------------------------
| Other styles
|----------------------------------------------------------------------------*/

.jp-FileDialog.jp-mod-conflict input {
  color: var(--jp-error-color1);
}

.jp-FileDialog .jp-new-name-title {
  margin-top: 12px;
}

.jp-LastModified-hidden {
  display: none;
}

.jp-FileSize-hidden {
  display: none;
}

.jp-FileBrowser .lm-AccordionPanel > h3:first-child {
  display: none;
}

/*-----------------------------------------------------------------------------
| DirListing
|----------------------------------------------------------------------------*/

.jp-DirListing {
  flex: 1 1 auto;
  display: flex;
  flex-direction: column;
  outline: 0;
}

.jp-DirListing-header {
  flex: 0 0 auto;
  display: flex;
  flex-direction: row;
  align-items: center;
  overflow: hidden;
  border-top: var(--jp-border-width) solid var(--jp-border-color2);
  border-bottom: var(--jp-border-width) solid var(--jp-border-color1);
  box-shadow: var(--jp-toolbar-box-shadow);
  z-index: 2;
}

.jp-DirListing-headerItem {
  padding: 4px 12px 2px;
  font-weight: 500;
}

.jp-DirListing-headerItem:hover {
  background: var(--jp-layout-color2);
}

.jp-DirListing-headerItem.jp-id-name {
  flex: 1 0 84px;
}

.jp-DirListing-headerItem.jp-id-modified {
  flex: 0 0 112px;
  border-left: var(--jp-border-width) solid var(--jp-border-color2);
  text-align: right;
}

.jp-DirListing-headerItem.jp-id-filesize {
  flex: 0 0 75px;
  border-left: var(--jp-border-width) solid var(--jp-border-color2);
  text-align: right;
}

.jp-id-narrow {
  display: none;
  flex: 0 0 5px;
  padding: 4px;
  border-left: var(--jp-border-width) solid var(--jp-border-color2);
  text-align: right;
  color: var(--jp-border-color2);
}

.jp-DirListing-narrow .jp-id-narrow {
  display: block;
}

.jp-DirListing-narrow .jp-id-modified,
.jp-DirListing-narrow .jp-DirListing-itemModified {
  display: none;
}

.jp-DirListing-headerItem.jp-mod-selected {
  font-weight: 600;
}

/* increase specificity to override bundled default */
.jp-DirListing-content {
  flex: 1 1 auto;
  margin: 0;
  padding: 0;
  list-style-type: none;
  overflow: auto;
  background-color: var(--jp-layout-color1);
}

.jp-DirListing-content mark {
  color: var(--jp-ui-font-color0);
  background-color: transparent;
  font-weight: bold;
}

.jp-DirListing-content .jp-DirListing-item.jp-mod-selected mark {
  color: var(--jp-ui-inverse-font-color0);
}

/* Style the directory listing content when a user drops a file to upload */
.jp-DirListing.jp-mod-native-drop .jp-DirListing-content {
  outline: 5px dashed rgba(128, 128, 128, 0.5);
  outline-offset: -10px;
  cursor: copy;
}

.jp-DirListing-item {
  display: flex;
  flex-direction: row;
  align-items: center;
  padding: 4px 12px;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.jp-DirListing-checkboxWrapper {
  /* Increases hit area of checkbox. */
  padding: 4px;
}

.jp-DirListing-header
  .jp-DirListing-checkboxWrapper
  + .jp-DirListing-headerItem {
  padding-left: 4px;
}

.jp-DirListing-content .jp-DirListing-checkboxWrapper {
  position: relative;
  left: -4px;
  margin: -4px 0 -4px -8px;
}

.jp-DirListing-checkboxWrapper.jp-mod-visible {
  visibility: visible;
}

/* For devices that support hovering, hide checkboxes until hovered, selected...
*/
@media (hover: hover) {
  .jp-DirListing-checkboxWrapper {
    visibility: hidden;
  }

  .jp-DirListing-item:hover .jp-DirListing-checkboxWrapper,
  .jp-DirListing-item.jp-mod-selected .jp-DirListing-checkboxWrapper {
    visibility: visible;
  }
}

.jp-DirListing-item[data-is-dot] {
  opacity: 75%;
}

.jp-DirListing-item.jp-mod-selected {
  color: var(--jp-ui-inverse-font-color1);
  background: var(--jp-brand-color1);
}

.jp-DirListing-item.jp-mod-dropTarget {
  background: var(--jp-brand-color3);
}

.jp-DirListing-item:hover:not(.jp-mod-selected) {
  background: var(--jp-layout-color2);
}

.jp-DirListing-itemIcon {
  flex: 0 0 20px;
  margin-right: 4px;
}

.jp-DirListing-itemText {
  flex: 1 0 64px;
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  user-select: none;
}

.jp-DirListing-itemText:focus {
  outline-width: 2px;
  outline-color: var(--jp-inverse-layout-color1);
  outline-style: solid;
  outline-offset: 1px;
}

.jp-DirListing-item.jp-mod-selected .jp-DirListing-itemText:focus {
  outline-color: var(--jp-layout-color1);
}

.jp-DirListing-itemModified {
  flex: 0 0 125px;
  text-align: right;
}

.jp-DirListing-itemFileSize {
  flex: 0 0 90px;
  text-align: right;
}

.jp-DirListing-editor {
  flex: 1 0 64px;
  outline: none;
  border: none;
  color: var(--jp-ui-font-color1);
  background-color: var(--jp-layout-color1);
}

.jp-DirListing-item.jp-mod-running .jp-DirListing-itemIcon::before {
  color: var(--jp-success-color1);
  content: '\25CF';
  font-size: 8px;
  position: absolute;
  left: -8px;
}

.jp-DirListing-item.jp-mod-running.jp-mod-selected
  .jp-DirListing-itemIcon::before {
  color: var(--jp-ui-inverse-font-color1);
}

.jp-DirListing-item.lm-mod-drag-image,
.jp-DirListing-item.jp-mod-selected.lm-mod-drag-image {
  font-size: var(--jp-ui-font-size1);
  padding-left: 4px;
  margin-left: 4px;
  width: 160px;
  background-color: var(--jp-ui-inverse-font-color2);
  box-shadow: var(--jp-elevation-z2);
  border-radius: 0;
  color: var(--jp-ui-font-color1);
  transform: translateX(-40%) translateY(-58%);
}

.jp-Document {
  min-width: 120px;
  min-height: 120px;
  outline: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Main OutputArea
| OutputArea has a list of Outputs
|----------------------------------------------------------------------------*/

.jp-OutputArea {
  overflow-y: auto;
}

.jp-OutputArea-child {
  display: table;
  table-layout: fixed;
  width: 100%;
  overflow: hidden;
}

.jp-OutputPrompt {
  width: var(--jp-cell-prompt-width);
  color: var(--jp-cell-outprompt-font-color);
  font-family: var(--jp-cell-prompt-font-family);
  padding: var(--jp-code-padding);
  letter-spacing: var(--jp-cell-prompt-letter-spacing);
  line-height: var(--jp-code-line-height);
  font-size: var(--jp-code-font-size);
  border: var(--jp-border-width) solid transparent;
  opacity: var(--jp-cell-prompt-opacity);

  /* Right align prompt text, don't wrap to handle large prompt numbers */
  text-align: right;
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;

  /* Disable text selection */
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.jp-OutputArea-prompt {
  display: table-cell;
  vertical-align: top;
}

.jp-OutputArea-output {
  display: table-cell;
  width: 100%;
  height: auto;
  overflow: auto;
  user-select: text;
  -moz-user-select: text;
  -webkit-user-select: text;
  -ms-user-select: text;
}

.jp-OutputArea .jp-RenderedText {
  padding-left: 1ch;
}

/**
 * Prompt overlay.
 */

.jp-OutputArea-promptOverlay {
  position: absolute;
  top: 0;
  width: var(--jp-cell-prompt-width);
  height: 100%;
  opacity: 0.5;
}

.jp-OutputArea-promptOverlay:hover {
  background: var(--jp-layout-color2);
  box-shadow: inset 0 0 1px var(--jp-inverse-layout-color0);
  cursor: zoom-out;
}

.jp-mod-outputsScrolled .jp-OutputArea-promptOverlay:hover {
  cursor: zoom-in;
}

/**
 * Isolated output.
 */
.jp-OutputArea-output.jp-mod-isolated {
  width: 100%;
  display: block;
}

/*
When drag events occur, `lm-mod-override-cursor` is added to the body.
Because iframes steal all cursor events, the following two rules are necessary
to suppress pointer events while resize drags are occurring. There may be a
better solution to this problem.
*/
body.lm-mod-override-cursor .jp-OutputArea-output.jp-mod-isolated {
  position: relative;
}

body.lm-mod-override-cursor .jp-OutputArea-output.jp-mod-isolated::before {
  content: '';
  position: absolute;
  top: 0;
  left: 0;
  right: 0;
  bottom: 0;
  background: transparent;
}

/* pre */

.jp-OutputArea-output pre {
  border: none;
  margin: 0;
  padding: 0;
  overflow-x: auto;
  overflow-y: auto;
  word-break: break-all;
  word-wrap: break-word;
  white-space: pre-wrap;
}

/* tables */

.jp-OutputArea-output.jp-RenderedHTMLCommon table {
  margin-left: 0;
  margin-right: 0;
}

/* description lists */

.jp-OutputArea-output dl,
.jp-OutputArea-output dt,
.jp-OutputArea-output dd {
  display: block;
}

.jp-OutputArea-output dl {
  width: 100%;
  overflow: hidden;
  padding: 0;
  margin: 0;
}

.jp-OutputArea-output dt {
  font-weight: bold;
  float: left;
  width: 20%;
  padding: 0;
  margin: 0;
}

.jp-OutputArea-output dd {
  float: left;
  width: 80%;
  padding: 0;
  margin: 0;
}

.jp-TrimmedOutputs pre {
  background: var(--jp-layout-color3);
  font-size: calc(var(--jp-code-font-size) * 1.4);
  text-align: center;
  text-transform: uppercase;
}

/* Hide the gutter in case of
 *  - nested output areas (e.g. in the case of output widgets)
 *  - mirrored output areas
 */
.jp-OutputArea .jp-OutputArea .jp-OutputArea-prompt {
  display: none;
}

/* Hide empty lines in the output area, for instance due to cleared widgets */
.jp-OutputArea-prompt:empty {
  padding: 0;
  border: 0;
}

/*-----------------------------------------------------------------------------
| executeResult is added to any Output-result for the display of the object
| returned by a cell
|----------------------------------------------------------------------------*/

.jp-OutputArea-output.jp-OutputArea-executeResult {
  margin-left: 0;
  width: 100%;
}

/* Text output with the Out[] prompt needs a top padding to match the
 * alignment of the Out[] prompt itself.
 */
.jp-OutputArea-executeResult .jp-RenderedText.jp-OutputArea-output {
  padding-top: var(--jp-code-padding);
  border-top: var(--jp-border-width) solid transparent;
}

/*-----------------------------------------------------------------------------
| The Stdin output
|----------------------------------------------------------------------------*/

.jp-Stdin-prompt {
  color: var(--jp-content-font-color0);
  padding-right: var(--jp-code-padding);
  vertical-align: baseline;
  flex: 0 0 auto;
}

.jp-Stdin-input {
  font-family: var(--jp-code-font-family);
  font-size: inherit;
  color: inherit;
  background-color: inherit;
  width: 42%;
  min-width: 200px;

  /* make sure input baseline aligns with prompt */
  vertical-align: baseline;

  /* padding + margin = 0.5em between prompt and cursor */
  padding: 0 0.25em;
  margin: 0 0.25em;
  flex: 0 0 70%;
}

.jp-Stdin-input::placeholder {
  opacity: 0;
}

.jp-Stdin-input:focus {
  box-shadow: none;
}

.jp-Stdin-input:focus::placeholder {
  opacity: 1;
}

/*-----------------------------------------------------------------------------
| Output Area View
|----------------------------------------------------------------------------*/

.jp-LinkedOutputView .jp-OutputArea {
  height: 100%;
  display: block;
}

.jp-LinkedOutputView .jp-OutputArea-output:only-child {
  height: 100%;
}

/*-----------------------------------------------------------------------------
| Printing
|----------------------------------------------------------------------------*/

@media print {
  .jp-OutputArea-child {
    break-inside: avoid-page;
  }
}

/*-----------------------------------------------------------------------------
| Mobile
|----------------------------------------------------------------------------*/
@media only screen and (max-width: 760px) {
  .jp-OutputPrompt {
    display: table-row;
    text-align: left;
  }

  .jp-OutputArea-child .jp-OutputArea-output {
    display: table-row;
    margin-left: var(--jp-notebook-padding);
  }
}

/* Trimmed outputs warning */
.jp-TrimmedOutputs > a {
  margin: 10px;
  text-decoration: none;
  cursor: pointer;
}

.jp-TrimmedOutputs > a:hover {
  text-decoration: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Table of Contents
|----------------------------------------------------------------------------*/

:root {
  --jp-private-toc-active-width: 4px;
}

.jp-TableOfContents {
  display: flex;
  flex-direction: column;
  background: var(--jp-layout-color1);
  color: var(--jp-ui-font-color1);
  font-size: var(--jp-ui-font-size1);
  height: 100%;
}

.jp-TableOfContents-placeholder {
  text-align: center;
}

.jp-TableOfContents-placeholderContent {
  color: var(--jp-content-font-color2);
  padding: 8px;
}

.jp-TableOfContents-placeholderContent > h3 {
  margin-bottom: var(--jp-content-heading-margin-bottom);
}

.jp-TableOfContents .jp-SidePanel-content {
  overflow-y: auto;
}

.jp-TableOfContents-tree {
  margin: 4px;
}

.jp-TableOfContents ol {
  list-style-type: none;
}

/* stylelint-disable-next-line selector-max-type */
.jp-TableOfContents li > ol {
  /* Align left border with triangle icon center */
  padding-left: 11px;
}

.jp-TableOfContents-content {
  /* left margin for the active heading indicator */
  margin: 0 0 0 var(--jp-private-toc-active-width);
  padding: 0;
  background-color: var(--jp-layout-color1);
}

.jp-tocItem {
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.jp-tocItem-heading {
  display: flex;
  cursor: pointer;
}

.jp-tocItem-heading:hover {
  background-color: var(--jp-layout-color2);
}

.jp-tocItem-content {
  display: block;
  padding: 4px 0;
  white-space: nowrap;
  text-overflow: ellipsis;
  overflow-x: hidden;
}

.jp-tocItem-collapser {
  height: 20px;
  margin: 2px 2px 0;
  padding: 0;
  background: none;
  border: none;
  cursor: pointer;
}

.jp-tocItem-collapser:hover {
  background-color: var(--jp-layout-color3);
}

/* Active heading indicator */

.jp-tocItem-heading::before {
  content: ' ';
  background: transparent;
  width: var(--jp-private-toc-active-width);
  height: 24px;
  position: absolute;
  left: 0;
  border-radius: var(--jp-border-radius);
}

.jp-tocItem-heading.jp-tocItem-active::before {
  background-color: var(--jp-brand-color1);
}

.jp-tocItem-heading:hover.jp-tocItem-active::before {
  background: var(--jp-brand-color0);
  opacity: 1;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-Collapser {
  flex: 0 0 var(--jp-cell-collapser-width);
  padding: 0;
  margin: 0;
  border: none;
  outline: none;
  background: transparent;
  border-radius: var(--jp-border-radius);
  opacity: 1;
}

.jp-Collapser-child {
  display: block;
  width: 100%;
  box-sizing: border-box;

  /* height: 100% doesn't work because the height of its parent is computed from content */
  position: absolute;
  top: 0;
  bottom: 0;
}

/*-----------------------------------------------------------------------------
| Printing
|----------------------------------------------------------------------------*/

/*
Hiding collapsers in print mode.

Note: input and output wrappers have "display: block" propery in print mode.
*/

@media print {
  .jp-Collapser {
    display: none;
  }
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Header/Footer
|----------------------------------------------------------------------------*/

/* Hidden by zero height by default */
.jp-CellHeader,
.jp-CellFooter {
  height: 0;
  width: 100%;
  padding: 0;
  margin: 0;
  border: none;
  outline: none;
  background: transparent;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Input
|----------------------------------------------------------------------------*/

/* All input areas */
.jp-InputArea {
  display: table;
  table-layout: fixed;
  width: 100%;
  overflow: hidden;
}

.jp-InputArea-editor {
  display: table-cell;
  overflow: hidden;
  vertical-align: top;

  /* This is the non-active, default styling */
  border: var(--jp-border-width) solid var(--jp-cell-editor-border-color);
  border-radius: 0;
  background: var(--jp-cell-editor-background);
}

.jp-InputPrompt {
  display: table-cell;
  vertical-align: top;
  width: var(--jp-cell-prompt-width);
  color: var(--jp-cell-inprompt-font-color);
  font-family: var(--jp-cell-prompt-font-family);
  padding: var(--jp-code-padding);
  letter-spacing: var(--jp-cell-prompt-letter-spacing);
  opacity: var(--jp-cell-prompt-opacity);
  line-height: var(--jp-code-line-height);
  font-size: var(--jp-code-font-size);
  border: var(--jp-border-width) solid transparent;

  /* Right align prompt text, don't wrap to handle large prompt numbers */
  text-align: right;
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;

  /* Disable text selection */
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

/*-----------------------------------------------------------------------------
| Mobile
|----------------------------------------------------------------------------*/
@media only screen and (max-width: 760px) {
  .jp-InputArea-editor {
    display: table-row;
    margin-left: var(--jp-notebook-padding);
  }

  .jp-InputPrompt {
    display: table-row;
    text-align: left;
  }
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Placeholder
|----------------------------------------------------------------------------*/

.jp-Placeholder {
  display: table;
  table-layout: fixed;
  width: 100%;
}

.jp-Placeholder-prompt {
  display: table-cell;
  box-sizing: border-box;
}

.jp-Placeholder-content {
  display: table-cell;
  padding: 4px 6px;
  border: 1px solid transparent;
  border-radius: 0;
  background: none;
  box-sizing: border-box;
  cursor: pointer;
}

.jp-Placeholder-contentContainer {
  display: flex;
}

.jp-Placeholder-content:hover,
.jp-InputPlaceholder > .jp-Placeholder-content:hover {
  border-color: var(--jp-layout-color3);
}

.jp-Placeholder-content .jp-MoreHorizIcon {
  width: 32px;
  height: 16px;
  border: 1px solid transparent;
  border-radius: var(--jp-border-radius);
}

.jp-Placeholder-content .jp-MoreHorizIcon:hover {
  border: 1px solid var(--jp-border-color1);
  box-shadow: 0 0 2px 0 rgba(0, 0, 0, 0.25);
  background-color: var(--jp-layout-color0);
}

.jp-PlaceholderText {
  white-space: nowrap;
  overflow-x: hidden;
  color: var(--jp-inverse-layout-color3);
  font-family: var(--jp-code-font-family);
}

.jp-InputPlaceholder > .jp-Placeholder-content {
  border-color: var(--jp-cell-editor-border-color);
  background: var(--jp-cell-editor-background);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Private CSS variables
|----------------------------------------------------------------------------*/

:root {
  --jp-private-cell-scrolling-output-offset: 5px;
}

/*-----------------------------------------------------------------------------
| Cell
|----------------------------------------------------------------------------*/

.jp-Cell {
  padding: var(--jp-cell-padding);
  margin: 0;
  border: none;
  outline: none;
  background: transparent;
}

/*-----------------------------------------------------------------------------
| Common input/output
|----------------------------------------------------------------------------*/

.jp-Cell-inputWrapper,
.jp-Cell-outputWrapper {
  display: flex;
  flex-direction: row;
  padding: 0;
  margin: 0;

  /* Added to reveal the box-shadow on the input and output collapsers. */
  overflow: visible;
}

/* Only input/output areas inside cells */
.jp-Cell-inputArea,
.jp-Cell-outputArea {
  flex: 1 1 auto;
}

/*-----------------------------------------------------------------------------
| Collapser
|----------------------------------------------------------------------------*/

/* Make the output collapser disappear when there is not output, but do so
 * in a manner that leaves it in the layout and preserves its width.
 */
.jp-Cell.jp-mod-noOutputs .jp-Cell-outputCollapser {
  border: none !important;
  background: transparent !important;
}

.jp-Cell:not(.jp-mod-noOutputs) .jp-Cell-outputCollapser {
  min-height: var(--jp-cell-collapser-min-height);
}

/*-----------------------------------------------------------------------------
| Output
|----------------------------------------------------------------------------*/

/* Put a space between input and output when there IS output */
.jp-Cell:not(.jp-mod-noOutputs) .jp-Cell-outputWrapper {
  margin-top: 5px;
}

.jp-CodeCell.jp-mod-outputsScrolled .jp-Cell-outputArea {
  overflow-y: auto;
  max-height: 24em;
  margin-left: var(--jp-private-cell-scrolling-output-offset);
  resize: vertical;
}

.jp-CodeCell.jp-mod-outputsScrolled .jp-Cell-outputArea[style*='height'] {
  max-height: unset;
}

.jp-CodeCell.jp-mod-outputsScrolled .jp-Cell-outputArea::after {
  content: ' ';
  box-shadow: inset 0 0 6px 2px rgb(0 0 0 / 30%);
  width: 100%;
  height: 100%;
  position: sticky;
  bottom: 0;
  top: 0;
  margin-top: -50%;
  float: left;
  display: block;
  pointer-events: none;
}

.jp-CodeCell.jp-mod-outputsScrolled .jp-OutputArea-child {
  padding-top: 6px;
}

.jp-CodeCell.jp-mod-outputsScrolled .jp-OutputArea-prompt {
  width: calc(
    var(--jp-cell-prompt-width) - var(--jp-private-cell-scrolling-output-offset)
  );
}

.jp-CodeCell.jp-mod-outputsScrolled .jp-OutputArea-promptOverlay {
  left: calc(-1 * var(--jp-private-cell-scrolling-output-offset));
}

/*-----------------------------------------------------------------------------
| CodeCell
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| MarkdownCell
|----------------------------------------------------------------------------*/

.jp-MarkdownOutput {
  display: table-cell;
  width: 100%;
  margin-top: 0;
  margin-bottom: 0;
  padding-left: var(--jp-code-padding);
}

.jp-MarkdownOutput.jp-RenderedHTMLCommon {
  overflow: auto;
}

/* collapseHeadingButton (show always if hiddenCellsButton is _not_ shown) */
.jp-collapseHeadingButton {
  display: flex;
  min-height: var(--jp-cell-collapser-min-height);
  font-size: var(--jp-code-font-size);
  position: absolute;
  background-color: transparent;
  background-size: 25px;
  background-repeat: no-repeat;
  background-position-x: center;
  background-position-y: top;
  background-image: var(--jp-icon-caret-down);
  right: 0;
  top: 0;
  bottom: 0;
}

.jp-collapseHeadingButton.jp-mod-collapsed {
  background-image: var(--jp-icon-caret-right);
}

/*
 set the container font size to match that of content
 so that the nested collapse buttons have the right size
*/
.jp-MarkdownCell .jp-InputPrompt {
  font-size: var(--jp-content-font-size1);
}

/*
  Align collapseHeadingButton with cell top header
  The font sizes are identical to the ones in packages/rendermime/style/base.css
*/
.jp-mod-rendered .jp-collapseHeadingButton[data-heading-level='1'] {
  font-size: var(--jp-content-font-size5);
  background-position-y: calc(0.3 * var(--jp-content-font-size5));
}

.jp-mod-rendered .jp-collapseHeadingButton[data-heading-level='2'] {
  font-size: var(--jp-content-font-size4);
  background-position-y: calc(0.3 * var(--jp-content-font-size4));
}

.jp-mod-rendered .jp-collapseHeadingButton[data-heading-level='3'] {
  font-size: var(--jp-content-font-size3);
  background-position-y: calc(0.3 * var(--jp-content-font-size3));
}

.jp-mod-rendered .jp-collapseHeadingButton[data-heading-level='4'] {
  font-size: var(--jp-content-font-size2);
  background-position-y: calc(0.3 * var(--jp-content-font-size2));
}

.jp-mod-rendered .jp-collapseHeadingButton[data-heading-level='5'] {
  font-size: var(--jp-content-font-size1);
  background-position-y: top;
}

.jp-mod-rendered .jp-collapseHeadingButton[data-heading-level='6'] {
  font-size: var(--jp-content-font-size0);
  background-position-y: top;
}

/* collapseHeadingButton (show only on (hover,active) if hiddenCellsButton is shown) */
.jp-Notebook.jp-mod-showHiddenCellsButton .jp-collapseHeadingButton {
  display: none;
}

.jp-Notebook.jp-mod-showHiddenCellsButton
  :is(.jp-MarkdownCell:hover, .jp-mod-active)
  .jp-collapseHeadingButton {
  display: flex;
}

/* showHiddenCellsButton (only show if jp-mod-showHiddenCellsButton is set, which
is a consequence of the showHiddenCellsButton option in Notebook Settings)*/
.jp-Notebook.jp-mod-showHiddenCellsButton .jp-showHiddenCellsButton {
  margin-left: calc(var(--jp-cell-prompt-width) + 2 * var(--jp-code-padding));
  margin-top: var(--jp-code-padding);
  border: 1px solid var(--jp-border-color2);
  background-color: var(--jp-border-color3) !important;
  color: var(--jp-content-font-color0) !important;
  display: flex;
}

.jp-Notebook.jp-mod-showHiddenCellsButton .jp-showHiddenCellsButton:hover {
  background-color: var(--jp-border-color2) !important;
}

.jp-showHiddenCellsButton {
  display: none;
}

/*-----------------------------------------------------------------------------
| Printing
|----------------------------------------------------------------------------*/

/*
Using block instead of flex to allow the use of the break-inside CSS property for
cell outputs.
*/

@media print {
  .jp-Cell-inputWrapper,
  .jp-Cell-outputWrapper {
    display: block;
  }
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Variables
|----------------------------------------------------------------------------*/

:root {
  --jp-notebook-toolbar-padding: 2px 5px 2px 2px;
}

/*-----------------------------------------------------------------------------

/*-----------------------------------------------------------------------------
| Styles
|----------------------------------------------------------------------------*/

.jp-NotebookPanel-toolbar {
  padding: var(--jp-notebook-toolbar-padding);

  /* disable paint containment from lumino 2.0 default strict CSS containment */
  contain: style size !important;
}

.jp-Toolbar-item.jp-Notebook-toolbarCellType .jp-select-wrapper.jp-mod-focused {
  border: none;
  box-shadow: none;
}

.jp-Notebook-toolbarCellTypeDropdown select {
  height: 24px;
  font-size: var(--jp-ui-font-size1);
  line-height: 14px;
  border-radius: 0;
  display: block;
}

.jp-Notebook-toolbarCellTypeDropdown span {
  top: 5px !important;
}

.jp-Toolbar-responsive-popup {
  position: absolute;
  height: fit-content;
  display: flex;
  flex-direction: row;
  flex-wrap: wrap;
  justify-content: flex-end;
  border-bottom: var(--jp-border-width) solid var(--jp-toolbar-border-color);
  box-shadow: var(--jp-toolbar-box-shadow);
  background: var(--jp-toolbar-background);
  min-height: var(--jp-toolbar-micro-height);
  padding: var(--jp-notebook-toolbar-padding);
  z-index: 1;
  right: 0;
  top: 0;
}

.jp-Toolbar > .jp-Toolbar-responsive-opener {
  margin-left: auto;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Variables
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------

/*-----------------------------------------------------------------------------
| Styles
|----------------------------------------------------------------------------*/

.jp-Notebook-ExecutionIndicator {
  position: relative;
  display: inline-block;
  height: 100%;
  z-index: 9997;
}

.jp-Notebook-ExecutionIndicator-tooltip {
  visibility: hidden;
  height: auto;
  width: max-content;
  width: -moz-max-content;
  background-color: var(--jp-layout-color2);
  color: var(--jp-ui-font-color1);
  text-align: justify;
  border-radius: 6px;
  padding: 0 5px;
  position: fixed;
  display: table;
}

.jp-Notebook-ExecutionIndicator-tooltip.up {
  transform: translateX(-50%) translateY(-100%) translateY(-32px);
}

.jp-Notebook-ExecutionIndicator-tooltip.down {
  transform: translateX(calc(-100% + 16px)) translateY(5px);
}

.jp-Notebook-ExecutionIndicator-tooltip.hidden {
  display: none;
}

.jp-Notebook-ExecutionIndicator:hover .jp-Notebook-ExecutionIndicator-tooltip {
  visibility: visible;
}

.jp-Notebook-ExecutionIndicator span {
  font-size: var(--jp-ui-font-size1);
  font-family: var(--jp-ui-font-family);
  color: var(--jp-ui-font-color1);
  line-height: 24px;
  display: block;
}

.jp-Notebook-ExecutionIndicator-progress-bar {
  display: flex;
  justify-content: center;
  height: 100%;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

/*
 * Execution indicator
 */
.jp-tocItem-content::after {
  content: '';

  /* Must be identical to form a circle */
  width: 12px;
  height: 12px;
  background: none;
  border: none;
  position: absolute;
  right: 0;
}

.jp-tocItem-content[data-running='0']::after {
  border-radius: 50%;
  border: var(--jp-border-width) solid var(--jp-inverse-layout-color3);
  background: none;
}

.jp-tocItem-content[data-running='1']::after {
  border-radius: 50%;
  border: var(--jp-border-width) solid var(--jp-inverse-layout-color3);
  background-color: var(--jp-inverse-layout-color3);
}

.jp-tocItem-content[data-running='0'],
.jp-tocItem-content[data-running='1'] {
  margin-right: 12px;
}

/*
 * Copyright (c) Jupyter Development Team.
 * Distributed under the terms of the Modified BSD License.
 */

.jp-Notebook-footer {
  height: 27px;
  margin-left: calc(
    var(--jp-cell-prompt-width) + var(--jp-cell-collapser-width) +
      var(--jp-cell-padding)
  );
  width: calc(
    100% -
      (
        var(--jp-cell-prompt-width) + var(--jp-cell-collapser-width) +
          var(--jp-cell-padding) + var(--jp-cell-padding)
      )
  );
  border: var(--jp-border-width) solid var(--jp-cell-editor-border-color);
  color: var(--jp-ui-font-color3);
  margin-top: 6px;
  background: none;
  cursor: pointer;
}

.jp-Notebook-footer:focus {
  border-color: var(--jp-cell-editor-active-border-color);
}

/* For devices that support hovering, hide footer until hover */
@media (hover: hover) {
  .jp-Notebook-footer {
    opacity: 0;
  }

  .jp-Notebook-footer:focus,
  .jp-Notebook-footer:hover {
    opacity: 1;
  }
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Imports
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| CSS variables
|----------------------------------------------------------------------------*/

:root {
  --jp-side-by-side-output-size: 1fr;
  --jp-side-by-side-resized-cell: var(--jp-side-by-side-output-size);
  --jp-private-notebook-dragImage-width: 304px;
  --jp-private-notebook-dragImage-height: 36px;
  --jp-private-notebook-selected-color: var(--md-blue-400);
  --jp-private-notebook-active-color: var(--md-green-400);
}

/*-----------------------------------------------------------------------------
| Notebook
|----------------------------------------------------------------------------*/

/* stylelint-disable selector-max-class */

.jp-NotebookPanel {
  display: block;
  height: 100%;
}

.jp-NotebookPanel.jp-Document {
  min-width: 240px;
  min-height: 120px;
}

.jp-Notebook {
  padding: var(--jp-notebook-padding);
  outline: none;
  overflow: auto;
  background: var(--jp-layout-color0);
}

.jp-Notebook.jp-mod-scrollPastEnd::after {
  display: block;
  content: '';
  min-height: var(--jp-notebook-scroll-padding);
}

.jp-MainAreaWidget-ContainStrict .jp-Notebook * {
  contain: strict;
}

.jp-Notebook .jp-Cell {
  overflow: visible;
}

.jp-Notebook .jp-Cell .jp-InputPrompt {
  cursor: move;
}

/*-----------------------------------------------------------------------------
| Notebook state related styling
|
| The notebook and cells each have states, here are the possibilities:
|
| - Notebook
|   - Command
|   - Edit
| - Cell
|   - None
|   - Active (only one can be active)
|   - Selected (the cells actions are applied to)
|   - Multiselected (when multiple selected, the cursor)
|   - No outputs
|----------------------------------------------------------------------------*/

/* Command or edit modes */

.jp-Notebook .jp-Cell:not(.jp-mod-active) .jp-InputPrompt {
  opacity: var(--jp-cell-prompt-not-active-opacity);
  color: var(--jp-cell-prompt-not-active-font-color);
}

.jp-Notebook .jp-Cell:not(.jp-mod-active) .jp-OutputPrompt {
  opacity: var(--jp-cell-prompt-not-active-opacity);
  color: var(--jp-cell-prompt-not-active-font-color);
}

/* cell is active */
.jp-Notebook .jp-Cell.jp-mod-active .jp-Collapser {
  background: var(--jp-brand-color1);
}

/* cell is dirty */
.jp-Notebook .jp-Cell.jp-mod-dirty .jp-InputPrompt {
  color: var(--jp-warn-color1);
}

.jp-Notebook .jp-Cell.jp-mod-dirty .jp-InputPrompt::before {
  color: var(--jp-warn-color1);
  content: '';
}

.jp-Notebook .jp-Cell.jp-mod-active.jp-mod-dirty .jp-Collapser {
  background: var(--jp-warn-color1);
}

/* collapser is hovered */
.jp-Notebook .jp-Cell .jp-Collapser:hover {
  box-shadow: var(--jp-elevation-z2);
  background: var(--jp-brand-color1);
  opacity: var(--jp-cell-collapser-not-active-hover-opacity);
}

/* cell is active and collapser is hovered */
.jp-Notebook .jp-Cell.jp-mod-active .jp-Collapser:hover {
  background: var(--jp-brand-color0);
  opacity: 1;
}

/* Command mode */

.jp-Notebook.jp-mod-commandMode .jp-Cell.jp-mod-selected {
  background: var(--jp-notebook-multiselected-color);
}

.jp-Notebook.jp-mod-commandMode
  .jp-Cell.jp-mod-active.jp-mod-selected:not(.jp-mod-multiSelected) {
  background: transparent;
}

/* Edit mode */

.jp-Notebook.jp-mod-editMode .jp-Cell.jp-mod-active .jp-InputArea-editor {
  border: var(--jp-border-width) solid var(--jp-cell-editor-active-border-color);
  box-shadow: var(--jp-input-box-shadow);
  background-color: var(--jp-cell-editor-active-background);
}

/*-----------------------------------------------------------------------------
| Notebook drag and drop
|----------------------------------------------------------------------------*/

.jp-Notebook-cell.jp-mod-dropSource {
  opacity: 0.5;
}

.jp-Notebook-cell.jp-mod-dropTarget,
.jp-Notebook.jp-mod-commandMode
  .jp-Notebook-cell.jp-mod-active.jp-mod-selected.jp-mod-dropTarget {
  border-top-color: var(--jp-private-notebook-selected-color);
  border-top-style: solid;
  border-top-width: 2px;
}

.jp-dragImage {
  display: block;
  flex-direction: row;
  width: var(--jp-private-notebook-dragImage-width);
  height: var(--jp-private-notebook-dragImage-height);
  border: var(--jp-border-width) solid var(--jp-cell-editor-border-color);
  background: var(--jp-cell-editor-background);
  overflow: visible;
}

.jp-dragImage-singlePrompt {
  box-shadow: 2px 2px 4px 0 rgba(0, 0, 0, 0.12);
}

.jp-dragImage .jp-dragImage-content {
  flex: 1 1 auto;
  z-index: 2;
  font-size: var(--jp-code-font-size);
  font-family: var(--jp-code-font-family);
  line-height: var(--jp-code-line-height);
  padding: var(--jp-code-padding);
  border: var(--jp-border-width) solid var(--jp-cell-editor-border-color);
  background: var(--jp-cell-editor-background-color);
  color: var(--jp-content-font-color3);
  text-align: left;
  margin: 4px 4px 4px 0;
}

.jp-dragImage .jp-dragImage-prompt {
  flex: 0 0 auto;
  min-width: 36px;
  color: var(--jp-cell-inprompt-font-color);
  padding: var(--jp-code-padding);
  padding-left: 12px;
  font-family: var(--jp-cell-prompt-font-family);
  letter-spacing: var(--jp-cell-prompt-letter-spacing);
  line-height: 1.9;
  font-size: var(--jp-code-font-size);
  border: var(--jp-border-width) solid transparent;
}

.jp-dragImage-multipleBack {
  z-index: -1;
  position: absolute;
  height: 32px;
  width: 300px;
  top: 8px;
  left: 8px;
  background: var(--jp-layout-color2);
  border: var(--jp-border-width) solid var(--jp-input-border-color);
  box-shadow: 2px 2px 4px 0 rgba(0, 0, 0, 0.12);
}

/*-----------------------------------------------------------------------------
| Cell toolbar
|----------------------------------------------------------------------------*/

.jp-NotebookTools {
  display: block;
  min-width: var(--jp-sidebar-min-width);
  color: var(--jp-ui-font-color1);
  background: var(--jp-layout-color1);

  /* This is needed so that all font sizing of children done in ems is
    * relative to this base size */
  font-size: var(--jp-ui-font-size1);
  overflow: auto;
}

.jp-ActiveCellTool {
  padding: 12px 0;
  display: flex;
}

.jp-ActiveCellTool-Content {
  flex: 1 1 auto;
}

.jp-ActiveCellTool .jp-ActiveCellTool-CellContent {
  background: var(--jp-cell-editor-background);
  border: var(--jp-border-width) solid var(--jp-cell-editor-border-color);
  border-radius: 0;
  min-height: 29px;
}

.jp-ActiveCellTool .jp-InputPrompt {
  min-width: calc(var(--jp-cell-prompt-width) * 0.75);
}

.jp-ActiveCellTool-CellContent > pre {
  padding: 5px 4px;
  margin: 0;
  white-space: normal;
}

.jp-MetadataEditorTool {
  flex-direction: column;
  padding: 12px 0;
}

.jp-RankedPanel > :not(:first-child) {
  margin-top: 12px;
}

.jp-KeySelector select.jp-mod-styled {
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color0);
  border: var(--jp-border-width) solid var(--jp-border-color1);
}

.jp-KeySelector label,
.jp-MetadataEditorTool label,
.jp-NumberSetter label {
  line-height: 1.4;
}

.jp-NotebookTools .jp-select-wrapper {
  margin-top: 4px;
  margin-bottom: 0;
}

.jp-NumberSetter input {
  width: 100%;
  margin-top: 4px;
}

.jp-NotebookTools .jp-Collapse {
  margin-top: 16px;
}

/*-----------------------------------------------------------------------------
| Presentation Mode (.jp-mod-presentationMode)
|----------------------------------------------------------------------------*/

.jp-mod-presentationMode .jp-Notebook {
  --jp-content-font-size1: var(--jp-content-presentation-font-size1);
  --jp-code-font-size: var(--jp-code-presentation-font-size);
}

.jp-mod-presentationMode .jp-Notebook .jp-Cell .jp-InputPrompt,
.jp-mod-presentationMode .jp-Notebook .jp-Cell .jp-OutputPrompt {
  flex: 0 0 110px;
}

/*-----------------------------------------------------------------------------
| Side-by-side Mode (.jp-mod-sideBySide)
|----------------------------------------------------------------------------*/
.jp-mod-sideBySide.jp-Notebook .jp-Notebook-cell {
  margin-top: 3em;
  margin-bottom: 3em;
  margin-left: 5%;
  margin-right: 5%;
}

.jp-mod-sideBySide.jp-Notebook .jp-CodeCell {
  display: grid;
  grid-template-columns: minmax(0, 1fr) min-content minmax(
      0,
      var(--jp-side-by-side-output-size)
    );
  grid-template-rows: auto minmax(0, 1fr) auto;
  grid-template-areas:
    'header header header'
    'input handle output'
    'footer footer footer';
}

.jp-mod-sideBySide.jp-Notebook .jp-CodeCell.jp-mod-resizedCell {
  grid-template-columns: minmax(0, 1fr) min-content minmax(
      0,
      var(--jp-side-by-side-resized-cell)
    );
}

.jp-mod-sideBySide.jp-Notebook .jp-CodeCell .jp-CellHeader {
  grid-area: header;
}

.jp-mod-sideBySide.jp-Notebook .jp-CodeCell .jp-Cell-inputWrapper {
  grid-area: input;
}

.jp-mod-sideBySide.jp-Notebook .jp-CodeCell .jp-Cell-outputWrapper {
  /* overwrite the default margin (no vertical separation needed in side by side move */
  margin-top: 0;
  grid-area: output;
}

.jp-mod-sideBySide.jp-Notebook .jp-CodeCell .jp-CellFooter {
  grid-area: footer;
}

.jp-mod-sideBySide.jp-Notebook .jp-CodeCell .jp-CellResizeHandle {
  grid-area: handle;
  user-select: none;
  display: block;
  height: 100%;
  cursor: ew-resize;
  padding: 0 var(--jp-cell-padding);
}

.jp-mod-sideBySide.jp-Notebook .jp-CodeCell .jp-CellResizeHandle::after {
  content: '';
  display: block;
  background: var(--jp-border-color2);
  height: 100%;
  width: 5px;
}

.jp-mod-sideBySide.jp-Notebook
  .jp-CodeCell.jp-mod-resizedCell
  .jp-CellResizeHandle::after {
  background: var(--jp-border-color0);
}

.jp-CellResizeHandle {
  display: none;
}

/*-----------------------------------------------------------------------------
| Placeholder
|----------------------------------------------------------------------------*/

.jp-Cell-Placeholder {
  padding-left: 55px;
}

.jp-Cell-Placeholder-wrapper {
  background: #fff;
  border: 1px solid;
  border-color: #e5e6e9 #dfe0e4 #d0d1d5;
  border-radius: 4px;
  -webkit-border-radius: 4px;
  margin: 10px 15px;
}

.jp-Cell-Placeholder-wrapper-inner {
  padding: 15px;
  position: relative;
}

.jp-Cell-Placeholder-wrapper-body {
  background-repeat: repeat;
  background-size: 50% auto;
}

.jp-Cell-Placeholder-wrapper-body div {
  background: #f6f7f8;
  background-image: -webkit-linear-gradient(
    left,
    #f6f7f8 0%,
    #edeef1 20%,
    #f6f7f8 40%,
    #f6f7f8 100%
  );
  background-repeat: no-repeat;
  background-size: 800px 104px;
  height: 104px;
  position: absolute;
  right: 15px;
  left: 15px;
  top: 15px;
}

div.jp-Cell-Placeholder-h1 {
  top: 20px;
  height: 20px;
  left: 15px;
  width: 150px;
}

div.jp-Cell-Placeholder-h2 {
  left: 15px;
  top: 50px;
  height: 10px;
  width: 100px;
}

div.jp-Cell-Placeholder-content-1,
div.jp-Cell-Placeholder-content-2,
div.jp-Cell-Placeholder-content-3 {
  left: 15px;
  right: 15px;
  height: 10px;
}

div.jp-Cell-Placeholder-content-1 {
  top: 100px;
}

div.jp-Cell-Placeholder-content-2 {
  top: 120px;
}

div.jp-Cell-Placeholder-content-3 {
  top: 140px;
}

</style>
<style type="text/css">
/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*
The following CSS variables define the main, public API for styling JupyterLab.
These variables should be used by all plugins wherever possible. In other
words, plugins should not define custom colors, sizes, etc unless absolutely
necessary. This enables users to change the visual theme of JupyterLab
by changing these variables.

Many variables appear in an ordered sequence (0,1,2,3). These sequences
are designed to work well together, so for example, `--jp-border-color1` should
be used with `--jp-layout-color1`. The numbers have the following meanings:

* 0: super-primary, reserved for special emphasis
* 1: primary, most important under normal situations
* 2: secondary, next most important under normal situations
* 3: tertiary, next most important under normal situations

Throughout JupyterLab, we are mostly following principles from Google's
Material Design when selecting colors. We are not, however, following
all of MD as it is not optimized for dense, information rich UIs.
*/

:root {
  /* Elevation
   *
   * We style box-shadows using Material Design's idea of elevation. These particular numbers are taken from here:
   *
   * https://github.com/material-components/material-components-web
   * https://material-components-web.appspot.com/elevation.html
   */

  --jp-shadow-base-lightness: 0;
  --jp-shadow-umbra-color: rgba(
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    0.2
  );
  --jp-shadow-penumbra-color: rgba(
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    0.14
  );
  --jp-shadow-ambient-color: rgba(
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    0.12
  );
  --jp-elevation-z0: none;
  --jp-elevation-z1: 0 2px 1px -1px var(--jp-shadow-umbra-color),
    0 1px 1px 0 var(--jp-shadow-penumbra-color),
    0 1px 3px 0 var(--jp-shadow-ambient-color);
  --jp-elevation-z2: 0 3px 1px -2px var(--jp-shadow-umbra-color),
    0 2px 2px 0 var(--jp-shadow-penumbra-color),
    0 1px 5px 0 var(--jp-shadow-ambient-color);
  --jp-elevation-z4: 0 2px 4px -1px var(--jp-shadow-umbra-color),
    0 4px 5px 0 var(--jp-shadow-penumbra-color),
    0 1px 10px 0 var(--jp-shadow-ambient-color);
  --jp-elevation-z6: 0 3px 5px -1px var(--jp-shadow-umbra-color),
    0 6px 10px 0 var(--jp-shadow-penumbra-color),
    0 1px 18px 0 var(--jp-shadow-ambient-color);
  --jp-elevation-z8: 0 5px 5px -3px var(--jp-shadow-umbra-color),
    0 8px 10px 1px var(--jp-shadow-penumbra-color),
    0 3px 14px 2px var(--jp-shadow-ambient-color);
  --jp-elevation-z12: 0 7px 8px -4px var(--jp-shadow-umbra-color),
    0 12px 17px 2px var(--jp-shadow-penumbra-color),
    0 5px 22px 4px var(--jp-shadow-ambient-color);
  --jp-elevation-z16: 0 8px 10px -5px var(--jp-shadow-umbra-color),
    0 16px 24px 2px var(--jp-shadow-penumbra-color),
    0 6px 30px 5px var(--jp-shadow-ambient-color);
  --jp-elevation-z20: 0 10px 13px -6px var(--jp-shadow-umbra-color),
    0 20px 31px 3px var(--jp-shadow-penumbra-color),
    0 8px 38px 7px var(--jp-shadow-ambient-color);
  --jp-elevation-z24: 0 11px 15px -7px var(--jp-shadow-umbra-color),
    0 24px 38px 3px var(--jp-shadow-penumbra-color),
    0 9px 46px 8px var(--jp-shadow-ambient-color);

  /* Borders
   *
   * The following variables, specify the visual styling of borders in JupyterLab.
   */

  --jp-border-width: 1px;
  --jp-border-color0: var(--md-grey-400);
  --jp-border-color1: var(--md-grey-400);
  --jp-border-color2: var(--md-grey-300);
  --jp-border-color3: var(--md-grey-200);
  --jp-inverse-border-color: var(--md-grey-600);
  --jp-border-radius: 2px;

  /* UI Fonts
   *
   * The UI font CSS variables are used for the typography all of the JupyterLab
   * user interface elements that are not directly user generated content.
   *
   * The font sizing here is done assuming that the body font size of --jp-ui-font-size1
   * is applied to a parent element. When children elements, such as headings, are sized
   * in em all things will be computed relative to that body size.
   */

  --jp-ui-font-scale-factor: 1.2;
  --jp-ui-font-size0: 0.83333em;
  --jp-ui-font-size1: 13px; /* Base font size */
  --jp-ui-font-size2: 1.2em;
  --jp-ui-font-size3: 1.44em;
  --jp-ui-font-family: system-ui, -apple-system, blinkmacsystemfont, 'Segoe UI',
    helvetica, arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji',
    'Segoe UI Symbol';

  /*
   * Use these font colors against the corresponding main layout colors.
   * In a light theme, these go from dark to light.
   */

  /* Defaults use Material Design specification */
  --jp-ui-font-color0: rgba(0, 0, 0, 1);
  --jp-ui-font-color1: rgba(0, 0, 0, 0.87);
  --jp-ui-font-color2: rgba(0, 0, 0, 0.54);
  --jp-ui-font-color3: rgba(0, 0, 0, 0.38);

  /*
   * Use these against the brand/accent/warn/error colors.
   * These will typically go from light to darker, in both a dark and light theme.
   */

  --jp-ui-inverse-font-color0: rgba(255, 255, 255, 1);
  --jp-ui-inverse-font-color1: rgba(255, 255, 255, 1);
  --jp-ui-inverse-font-color2: rgba(255, 255, 255, 0.7);
  --jp-ui-inverse-font-color3: rgba(255, 255, 255, 0.5);

  /* Content Fonts
   *
   * Content font variables are used for typography of user generated content.
   *
   * The font sizing here is done assuming that the body font size of --jp-content-font-size1
   * is applied to a parent element. When children elements, such as headings, are sized
   * in em all things will be computed relative to that body size.
   */

  --jp-content-line-height: 1.6;
  --jp-content-font-scale-factor: 1.2;
  --jp-content-font-size0: 0.83333em;
  --jp-content-font-size1: 14px; /* Base font size */
  --jp-content-font-size2: 1.2em;
  --jp-content-font-size3: 1.44em;
  --jp-content-font-size4: 1.728em;
  --jp-content-font-size5: 2.0736em;

  /* This gives a magnification of about 125% in presentation mode over normal. */
  --jp-content-presentation-font-size1: 17px;
  --jp-content-heading-line-height: 1;
  --jp-content-heading-margin-top: 1.2em;
  --jp-content-heading-margin-bottom: 0.8em;
  --jp-content-heading-font-weight: 500;

  /* Defaults use Material Design specification */
  --jp-content-font-color0: rgba(0, 0, 0, 1);
  --jp-content-font-color1: rgba(0, 0, 0, 0.87);
  --jp-content-font-color2: rgba(0, 0, 0, 0.54);
  --jp-content-font-color3: rgba(0, 0, 0, 0.38);
  --jp-content-link-color: var(--md-blue-900);
  --jp-content-font-family: system-ui, -apple-system, blinkmacsystemfont,
    'Segoe UI', helvetica, arial, sans-serif, 'Apple Color Emoji',
    'Segoe UI Emoji', 'Segoe UI Symbol';

  /*
   * Code Fonts
   *
   * Code font variables are used for typography of code and other monospaces content.
   */

  --jp-code-font-size: 13px;
  --jp-code-line-height: 1.3077; /* 17px for 13px base */
  --jp-code-padding: 5px; /* 5px for 13px base, codemirror highlighting needs integer px value */
  --jp-code-font-family-default: menlo, consolas, 'DejaVu Sans Mono', monospace;
  --jp-code-font-family: var(--jp-code-font-family-default);

  /* This gives a magnification of about 125% in presentation mode over normal. */
  --jp-code-presentation-font-size: 16px;

  /* may need to tweak cursor width if you change font size */
  --jp-code-cursor-width0: 1.4px;
  --jp-code-cursor-width1: 2px;
  --jp-code-cursor-width2: 4px;

  /* Layout
   *
   * The following are the main layout colors use in JupyterLab. In a light
   * theme these would go from light to dark.
   */

  --jp-layout-color0: white;
  --jp-layout-color1: white;
  --jp-layout-color2: var(--md-grey-200);
  --jp-layout-color3: var(--md-grey-400);
  --jp-layout-color4: var(--md-grey-600);

  /* Inverse Layout
   *
   * The following are the inverse layout colors use in JupyterLab. In a light
   * theme these would go from dark to light.
   */

  --jp-inverse-layout-color0: #111;
  --jp-inverse-layout-color1: var(--md-grey-900);
  --jp-inverse-layout-color2: var(--md-grey-800);
  --jp-inverse-layout-color3: var(--md-grey-700);
  --jp-inverse-layout-color4: var(--md-grey-600);

  /* Brand/accent */

  --jp-brand-color0: var(--md-blue-900);
  --jp-brand-color1: var(--md-blue-700);
  --jp-brand-color2: var(--md-blue-300);
  --jp-brand-color3: var(--md-blue-100);
  --jp-brand-color4: var(--md-blue-50);
  --jp-accent-color0: var(--md-green-900);
  --jp-accent-color1: var(--md-green-700);
  --jp-accent-color2: var(--md-green-300);
  --jp-accent-color3: var(--md-green-100);

  /* State colors (warn, error, success, info) */

  --jp-warn-color0: var(--md-orange-900);
  --jp-warn-color1: var(--md-orange-700);
  --jp-warn-color2: var(--md-orange-300);
  --jp-warn-color3: var(--md-orange-100);
  --jp-error-color0: var(--md-red-900);
  --jp-error-color1: var(--md-red-700);
  --jp-error-color2: var(--md-red-300);
  --jp-error-color3: var(--md-red-100);
  --jp-success-color0: var(--md-green-900);
  --jp-success-color1: var(--md-green-700);
  --jp-success-color2: var(--md-green-300);
  --jp-success-color3: var(--md-green-100);
  --jp-info-color0: var(--md-cyan-900);
  --jp-info-color1: var(--md-cyan-700);
  --jp-info-color2: var(--md-cyan-300);
  --jp-info-color3: var(--md-cyan-100);

  /* Cell specific styles */

  --jp-cell-padding: 5px;
  --jp-cell-collapser-width: 8px;
  --jp-cell-collapser-min-height: 20px;
  --jp-cell-collapser-not-active-hover-opacity: 0.6;
  --jp-cell-editor-background: var(--md-grey-100);
  --jp-cell-editor-border-color: var(--md-grey-300);
  --jp-cell-editor-box-shadow: inset 0 0 2px var(--md-blue-300);
  --jp-cell-editor-active-background: var(--jp-layout-color0);
  --jp-cell-editor-active-border-color: var(--jp-brand-color1);
  --jp-cell-prompt-width: 64px;
  --jp-cell-prompt-font-family: var(--jp-code-font-family-default);
  --jp-cell-prompt-letter-spacing: 0;
  --jp-cell-prompt-opacity: 1;
  --jp-cell-prompt-not-active-opacity: 0.5;
  --jp-cell-prompt-not-active-font-color: var(--md-grey-700);

  /* A custom blend of MD grey and blue 600
   * See https://meyerweb.com/eric/tools/color-blend/#546E7A:1E88E5:5:hex */
  --jp-cell-inprompt-font-color: #307fc1;

  /* A custom blend of MD grey and orange 600
   * https://meyerweb.com/eric/tools/color-blend/#546E7A:F4511E:5:hex */
  --jp-cell-outprompt-font-color: #bf5b3d;

  /* Notebook specific styles */

  --jp-notebook-padding: 10px;
  --jp-notebook-select-background: var(--jp-layout-color1);
  --jp-notebook-multiselected-color: var(--md-blue-50);

  /* The scroll padding is calculated to fill enough space at the bottom of the
  notebook to show one single-line cell (with appropriate padding) at the top
  when the notebook is scrolled all the way to the bottom. We also subtract one
  pixel so that no scrollbar appears if we have just one single-line cell in the
  notebook. This padding is to enable a 'scroll past end' feature in a notebook.
  */
  --jp-notebook-scroll-padding: calc(
    100% - var(--jp-code-font-size) * var(--jp-code-line-height) -
      var(--jp-code-padding) - var(--jp-cell-padding) - 1px
  );

  /* Rendermime styles */

  --jp-rendermime-error-background: #fdd;
  --jp-rendermime-table-row-background: var(--md-grey-100);
  --jp-rendermime-table-row-hover-background: var(--md-light-blue-50);

  /* Dialog specific styles */

  --jp-dialog-background: rgba(0, 0, 0, 0.25);

  /* Console specific styles */

  --jp-console-padding: 10px;

  /* Toolbar specific styles */

  --jp-toolbar-border-color: var(--jp-border-color1);
  --jp-toolbar-micro-height: 8px;
  --jp-toolbar-background: var(--jp-layout-color1);
  --jp-toolbar-box-shadow: 0 0 2px 0 rgba(0, 0, 0, 0.24);
  --jp-toolbar-header-margin: 4px 4px 0 4px;
  --jp-toolbar-active-background: var(--md-grey-300);

  /* Statusbar specific styles */

  --jp-statusbar-height: 24px;

  /* Input field styles */

  --jp-input-box-shadow: inset 0 0 2px var(--md-blue-300);
  --jp-input-active-background: var(--jp-layout-color1);
  --jp-input-hover-background: var(--jp-layout-color1);
  --jp-input-background: var(--md-grey-100);
  --jp-input-border-color: var(--jp-inverse-border-color);
  --jp-input-active-border-color: var(--jp-brand-color1);
  --jp-input-active-box-shadow-color: rgba(19, 124, 189, 0.3);

  /* General editor styles */

  --jp-editor-selected-background: #d9d9d9;
  --jp-editor-selected-focused-background: #d7d4f0;
  --jp-editor-cursor-color: var(--jp-ui-font-color0);

  /* Code mirror specific styles */

  --jp-mirror-editor-keyword-color: #008000;
  --jp-mirror-editor-atom-color: #88f;
  --jp-mirror-editor-number-color: #080;
  --jp-mirror-editor-def-color: #00f;
  --jp-mirror-editor-variable-color: var(--md-grey-900);
  --jp-mirror-editor-variable-2-color: rgb(0, 54, 109);
  --jp-mirror-editor-variable-3-color: #085;
  --jp-mirror-editor-punctuation-color: #05a;
  --jp-mirror-editor-property-color: #05a;
  --jp-mirror-editor-operator-color: #a2f;
  --jp-mirror-editor-comment-color: #408080;
  --jp-mirror-editor-string-color: #ba2121;
  --jp-mirror-editor-string-2-color: #708;
  --jp-mirror-editor-meta-color: #a2f;
  --jp-mirror-editor-qualifier-color: #555;
  --jp-mirror-editor-builtin-color: #008000;
  --jp-mirror-editor-bracket-color: #997;
  --jp-mirror-editor-tag-color: #170;
  --jp-mirror-editor-attribute-color: #00c;
  --jp-mirror-editor-header-color: blue;
  --jp-mirror-editor-quote-color: #090;
  --jp-mirror-editor-link-color: #00c;
  --jp-mirror-editor-error-color: #f00;
  --jp-mirror-editor-hr-color: #999;

  /*
    RTC user specific colors.
    These colors are used for the cursor, username in the editor,
    and the icon of the user.
  */

  --jp-collaborator-color1: #ffad8e;
  --jp-collaborator-color2: #dac83d;
  --jp-collaborator-color3: #72dd76;
  --jp-collaborator-color4: #00e4d0;
  --jp-collaborator-color5: #45d4ff;
  --jp-collaborator-color6: #e2b1ff;
  --jp-collaborator-color7: #ff9de6;

  /* Vega extension styles */

  --jp-vega-background: white;

  /* Sidebar-related styles */

  --jp-sidebar-min-width: 250px;

  /* Search-related styles */

  --jp-search-toggle-off-opacity: 0.5;
  --jp-search-toggle-hover-opacity: 0.8;
  --jp-search-toggle-on-opacity: 1;
  --jp-search-selected-match-background-color: rgb(245, 200, 0);
  --jp-search-selected-match-color: black;
  --jp-search-unselected-match-background-color: var(
    --jp-inverse-layout-color0
  );
  --jp-search-unselected-match-color: var(--jp-ui-inverse-font-color0);

  /* Icon colors that work well with light or dark backgrounds */
  --jp-icon-contrast-color0: var(--md-purple-600);
  --jp-icon-contrast-color1: var(--md-green-600);
  --jp-icon-contrast-color2: var(--md-pink-600);
  --jp-icon-contrast-color3: var(--md-blue-600);

  /* Button colors */
  --jp-accept-color-normal: var(--md-blue-700);
  --jp-accept-color-hover: var(--md-blue-800);
  --jp-accept-color-active: var(--md-blue-900);
  --jp-warn-color-normal: var(--md-red-700);
  --jp-warn-color-hover: var(--md-red-800);
  --jp-warn-color-active: var(--md-red-900);
  --jp-reject-color-normal: var(--md-grey-600);
  --jp-reject-color-hover: var(--md-grey-700);
  --jp-reject-color-active: var(--md-grey-800);

  /* File or activity icons and switch semantic variables */
  --jp-jupyter-icon-color: #f37626;
  --jp-notebook-icon-color: #f37626;
  --jp-json-icon-color: var(--md-orange-700);
  --jp-console-icon-background-color: var(--md-blue-700);
  --jp-console-icon-color: white;
  --jp-terminal-icon-background-color: var(--md-grey-800);
  --jp-terminal-icon-color: var(--md-grey-200);
  --jp-text-editor-icon-color: var(--md-grey-700);
  --jp-inspector-icon-color: var(--md-grey-700);
  --jp-switch-color: var(--md-grey-400);
  --jp-switch-true-position-color: var(--md-orange-900);
}
</style>
<style type="text/css">
/* Force rendering true colors when outputing to pdf */
* {
  -webkit-print-color-adjust: exact;
}

/* Misc */
a.anchor-link {
  display: none;
}

/* Input area styling */
.jp-InputArea {
  overflow: hidden;
}

.jp-InputArea-editor {
  overflow: hidden;
}

.cm-editor.cm-s-jupyter .highlight pre {
/* weird, but --jp-code-padding defined to be 5px but 4px horizontal padding is hardcoded for pre.cm-line */
  padding: var(--jp-code-padding) 4px;
  margin: 0;

  font-family: inherit;
  font-size: inherit;
  line-height: inherit;
  color: inherit;

}

.jp-OutputArea-output pre {
  line-height: inherit;
  font-family: inherit;
}

.jp-RenderedText pre {
  color: var(--jp-content-font-color1);
  font-size: var(--jp-code-font-size);
}

/* Hiding the collapser by default */
.jp-Collapser {
  display: none;
}

@page {
    margin: 0.5in; /* Margin for each printed piece of paper */
}

@media print {
  .jp-Cell-inputWrapper,
  .jp-Cell-outputWrapper {
    display: block;
  }
}
</style>
<!-- Load mathjax -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.7/latest.js?config=TeX-AMS_CHTML-full,Safe"> </script>
<!-- MathJax configuration -->
<script type="text/x-mathjax-config">
    init_mathjax = function() {
        if (window.MathJax) {
        // MathJax loaded
            MathJax.Hub.Config({
                TeX: {
                    equationNumbers: {
                    autoNumber: "AMS",
                    useLabelIds: true
                    }
                },
                tex2jax: {
                    inlineMath: [ ['$','$'], ["\\(","\\)"] ],
                    displayMath: [ ['$$','$$'], ["\\[","\\]"] ],
                    processEscapes: true,
                    processEnvironments: true
                },
                displayAlign: 'center',
                messageStyle: 'none',
                CommonHTML: {
                    linebreaks: {
                    automatic: true
                    }
                }
            });

            MathJax.Hub.Queue(["Typeset", MathJax.Hub]);
        }
    }
    init_mathjax();
    </script>
<!-- End of mathjax configuration --><script type="module">
  document.addEventListener("DOMContentLoaded", async () => {
    const diagrams = document.querySelectorAll(".jp-Mermaid > pre.mermaid");
    // do not load mermaidjs if not needed
    if (!diagrams.length) {
      return;
    }
    const mermaid = (await import("https://cdnjs.cloudflare.com/ajax/libs/mermaid/10.7.0/mermaid.esm.min.mjs")).default;
    const parser = new DOMParser();

    mermaid.initialize({
      maxTextSize: 100000,
      maxEdges: 100000,
      startOnLoad: false,
      fontFamily: window
        .getComputedStyle(document.body)
        .getPropertyValue("--jp-ui-font-family"),
      theme: document.querySelector("body[data-jp-theme-light='true']")
        ? "default"
        : "dark",
    });

    let _nextMermaidId = 0;

    function makeMermaidImage(svg) {
      const img = document.createElement("img");
      const doc = parser.parseFromString(svg, "image/svg+xml");
      const svgEl = doc.querySelector("svg");
      const { maxWidth } = svgEl?.style || {};
      const firstTitle = doc.querySelector("title");
      const firstDesc = doc.querySelector("desc");

      img.setAttribute("src", `data:image/svg+xml,${encodeURIComponent(svg)}`);
      if (maxWidth) {
        img.width = parseInt(maxWidth);
      }
      if (firstTitle) {
        img.setAttribute("alt", firstTitle.textContent);
      }
      if (firstDesc) {
        const caption = document.createElement("figcaption");
        caption.className = "sr-only";
        caption.textContent = firstDesc.textContent;
        return [img, caption];
      }
      return [img];
    }

    async function makeMermaidError(text) {
      let errorMessage = "";
      try {
        await mermaid.parse(text);
      } catch (err) {
        errorMessage = `${err}`;
      }

      const result = document.createElement("details");
      result.className = 'jp-RenderedMermaid-Details';
      const summary = document.createElement("summary");
      summary.className = 'jp-RenderedMermaid-Summary';
      const pre = document.createElement("pre");
      const code = document.createElement("code");
      code.innerText = text;
      pre.appendChild(code);
      summary.appendChild(pre);
      result.appendChild(summary);

      const warning = document.createElement("pre");
      warning.innerText = errorMessage;
      result.appendChild(warning);
      return [result];
    }

    async function renderOneMarmaid(src) {
      const id = `jp-mermaid-${_nextMermaidId++}`;
      const parent = src.parentNode;
      let raw = src.textContent.trim();
      const el = document.createElement("div");
      el.style.visibility = "hidden";
      document.body.appendChild(el);
      let results = null;
      let output = null;
      try {
        let { svg } = await mermaid.render(id, raw, el);
        svg = cleanMermaidSvg(svg);
        results = makeMermaidImage(svg);
        output = document.createElement("figure");
        results.map(output.appendChild, output);
      } catch (err) {
        parent.classList.add("jp-mod-warning");
        results = await makeMermaidError(raw);
        output = results[0];
      } finally {
        el.remove();
      }
      parent.classList.add("jp-RenderedMermaid");
      parent.appendChild(output);
    }


    /**
     * Post-process to ensure mermaid diagrams contain only valid SVG and XHTML.
     */
    function cleanMermaidSvg(svg) {
      return svg.replace(RE_VOID_ELEMENT, replaceVoidElement);
    }


    /**
     * A regular expression for all void elements, which may include attributes and
     * a slash.
     *
     * @see https://developer.mozilla.org/en-US/docs/Glossary/Void_element
     *
     * Of these, only `<br>` is generated by Mermaid in place of `\n`,
     * but _any_ "malformed" tag will break the SVG rendering entirely.
     */
    const RE_VOID_ELEMENT =
      /<\s*(area|base|br|col|embed|hr|img|input|link|meta|param|source|track|wbr)\s*([^>]*?)\s*>/gi;

    /**
     * Ensure a void element is closed with a slash, preserving any attributes.
     */
    function replaceVoidElement(match, tag, rest) {
      rest = rest.trim();
      if (!rest.endsWith('/')) {
        rest = `${rest} /`;
      }
      return `<${tag} ${rest}>`;
    }

    void Promise.all([...diagrams].map(renderOneMarmaid));
  });
</script>
<style>
  .jp-Mermaid:not(.jp-RenderedMermaid) {
    display: none;
  }

  .jp-RenderedMermaid {
    overflow: auto;
    display: flex;
  }

  .jp-RenderedMermaid.jp-mod-warning {
    width: auto;
    padding: 0.5em;
    margin-top: 0.5em;
    border: var(--jp-border-width) solid var(--jp-warn-color2);
    border-radius: var(--jp-border-radius);
    color: var(--jp-ui-font-color1);
    font-size: var(--jp-ui-font-size1);
    white-space: pre-wrap;
    word-wrap: break-word;
  }

  .jp-RenderedMermaid figure {
    margin: 0;
    overflow: auto;
    max-width: 100%;
  }

  .jp-RenderedMermaid img {
    max-width: 100%;
  }

  .jp-RenderedMermaid-Details > pre {
    margin-top: 1em;
  }

  .jp-RenderedMermaid-Summary {
    color: var(--jp-warn-color2);
  }

  .jp-RenderedMermaid:not(.jp-mod-warning) pre {
    display: none;
  }

  .jp-RenderedMermaid-Summary > pre {
    display: inline-block;
    white-space: normal;
  }
</style>
<!-- End of mermaid configuration --></head>
<body class="jp-Notebook" data-jp-theme-light="true" data-jp-theme-name="JupyterLab Light">
<main>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h1 id="Project-3:-Smart-Nutrition-Disorder-Specialist-Bot"><strong>Project 3: Smart Nutrition Disorder Specialist Bot</strong><a class="anchor-link" href="#Project-3:-Smart-Nutrition-Disorder-Specialist-Bot"></a></h1><hr/>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h2 id="Business-Use-Case"><strong>Business Use Case</strong><a class="anchor-link" href="#Business-Use-Case"></a></h2>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="Problem-Statement:"><strong>Problem Statement:</strong><a class="anchor-link" href="#Problem-Statement:"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Global Nutrition Health Organization</strong>, a leading global institution dedicated to nutritional health, has collaborated with <strong>InnoviTech Solutions</strong>, a premier IT technology company, to develop an innovative application designed to assist  in diagnosing and managing nutritional disorders. This initiative addresses the escalating complexities in nutritional health, where the vast amount of dietary information, medical research, and patient data has made swift and precise decision-making increasingly challenging. The Global Nutrition Health Organization recognized the necessity for a robust, AI-powered tool that could provide clinicians with immediate access to well-structured and pertinent nutritional information.</p>
<p><strong>InnoviTech Solutions</strong> has proposed creating a Retrieval-Augmented Generation (RAG)-based chatbot that integrates comprehensive nutritional literature, including reliable resources such as the Nutritional Medical Reference. This tool is intended to empower healthcare professionals with instant, accurate, and contextually relevant responses to their queries about nutritional disorders. This collaboration signifies a major advancement in the intersection of healthcare and technology, leveraging state-of-the-art generative AI to enhance diagnostic efficiency and patient care outcomes.</p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="Objective:"><strong>Objective:</strong><a class="anchor-link" href="#Objective:"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>As a Gen AI Data Scientist at InnoviTech Solutions, the objective is to develop an Agentic Retrieval-Augmented Generation (RAG)-based system tailored for the Global Nutrition Health Organization. This system is designed to support users by streamlining the extraction and integration of vital nutritional information from extensive resources, such as the Nutritional Medical Reference.</p>
<p>The application aims to enable healthcare providers to quickly access information regarding symptoms, diagnoses, treatment plans, and more, thereby reducing the need for lengthy manual searches. The RAG-based chatbot will be built with a custom advanced workflow that includes the following key components:</p>
<ul>
<li><p><strong>Query Expansion:</strong> Enhancing user queries to improve retrieval accuracy without altering the original intent. This step ensures that the user's queries are refined to capture the most relevant information from the extensive nutritional resources.</p>
</li>
<li><p><strong>Context Retrieval:</strong> Fetching relevant documents from a vector store based on the expanded or original query. This step is crucial to provide contextually relevant information that the model can use to generate accurate responses.</p>
</li>
<li><p><strong>Response Generation:</strong> Crafting accurate and informative responses strictly adhering to the retrieved context. This ensures that the AI provides information directly from the trusted nutritional sources, maintaining reliability and relevance.</p>
</li>
<li><p><strong>Groundedness Evaluation:</strong> Assessing the factual alignment of the generated response with the retrieved context. This step ensures that the responses generated by the AI are factually correct and based on the provided context, enhancing the credibility of the information.</p>
</li>
<li><p><strong>Precision Evaluation:</strong> Scoring the precision of the response in addressing the user's query. This step evaluates how well the response addresses the specific query of the user, ensuring relevance and usefulness.</p>
</li>
<li><p><strong>Response Refinement:</strong> Providing constructive feedback to improve gaps, ambiguities, or missing details in the response. If the response does not meet the groundedness or precision criteria, it is refined to ensure it meets the required standards.</p>
</li>
<li><p><strong>Query Refinement:</strong> Suggesting improvements for the expanded query to enhance search precision. If the response needs further improvement, the query itself is refined to ensure better retrieval in subsequent iterations.</p>
</li>
</ul>
<p>The purpose of these operations is to ensure that the AI provides the best possible response from the context provided, strictly adhering to the nutritional disorder manuals. By performing these operations, we ensure that the responses are both accurate and relevant, meeting the high standards expected in healthcare.</p>
<p>The workflow diagram, included below, visually represents this advanced workflow, highlighting the iterative process of grounding, precision checking, and refinement to achieve the most accurate and useful responses:</p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><img alt="flow-1.jpg" src="data:image/jpeg;base64,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"/></p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="Learning-Objectives:"><strong>Learning Objectives:</strong><a class="anchor-link" href="#Learning-Objectives:"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>In this project, you will embark on an exciting journey to build an advanced AI Nutrition Disorder Specialist bot using Retrieval-Augmented Generation (RAG) and deploying it on Hugging Face Docker Spaces. Here's what you will be learning and implementing in each major section:</p>
<p><strong>Section 1: Comprehensive Data Parsing and Preparation for Efficient Nutritional Information Retrieval</strong></p>
<p>In this section, you will:</p>
<ul>
<li><p>Install and Import Required Libraries: Set up your environment by installing necessary libraries and importing essential modules for data parsing and processing.</p>
</li>
<li><p>Setting Up Data and LLM Configuration:</p>
<ul>
<li>Unzip nutritional documents.</li>
<li>Read configuration files to extract API keys and endpoints.</li>
<li>Initialize OpenAI embedding function and OpenAI models for embeddings and chat functionalities.</li>
</ul>
</li>
<li><p>Parsing and Extracting Tables from Nutritional Documents:</p>
<ul>
<li>Set up an asynchronous environment for LlamaParse.</li>
<li>Initialize LlamaParse and parse content from PDFs to extract JSON objects.</li>
<li>Inspect parsed JSON objects to validate parsing.</li>
<li>Extract tables from the parsed JSON objects and display them for validation.</li>
</ul>
</li>
<li><p>Semantic Chunking and Structured Retrieval:</p>
<ul>
<li>Initialize ChromaDB client and set up SemanticChunker for text chunking.</li>
<li>Split PDF documents into semantic chunks and store them in Chroma vectorstore.</li>
<li>Perform similarity search in the vectorstore and structured retrieval using Self-Query Retriever.</li>
</ul>
</li>
<li><p>Generating Hypothetical Questions and Storing:</p>
<ul>
<li>Generate hypothetical questions for text semantic chunks and tables.</li>
<li>Store these hypothetical questions in the Chroma vectorstore.</li>
<li>Initialize structured retriever for hypothetical questions and perform structured retrieval.</li>
</ul>
</li>
</ul>
<p><strong>Section 2: Building an Intelligent Nutrition Disorder Agent with Advanced Retrieval and Safety Mechanisms</strong></p>
<p>In this section, you will:</p>
<ul>
<li><p>Build an Advanced RAG Agent Tool:</p>
<ul>
<li>Import necessary libraries required for the advanced RAG agent tool.</li>
<li>Define the state of the AI agent using TypedDict to manage various workflow stages.</li>
<li>Expand user queries to improve retrieval accuracy.</li>
<li>Fetch relevant nutritional information from the vector store based on the query.</li>
<li>Generate responses based on the retrieved context.</li>
<li>Evaluate whether the response is grounded in the retrieved context.</li>
<li>Assess whether the response precisely addresses the users query.</li>
<li>Provide constructive feedback to identify and improve gaps in the response.</li>
<li>Suggest improvements for the expanded query to enhance search precision.</li>
<li>Determine if the response is grounded and decide the next step.</li>
<li>Determine if the response is precise and decide the next step.</li>
<li>Define the end-to-end workflow using a StateGraph.</li>
<li>Run the agent with a loop protection mechanism to prevent infinite loops.</li>
<li>Visualize the workflow to understand the sequence and logic of the steps involved.</li>
</ul>
</li>
<li><p>Guardrailing User Input:</p>
<ul>
<li>Import libraries for filtering user input and accessing user data securely.</li>
<li>Define a function to filter user input using Llama Guard and ensure it is safe.</li>
</ul>
</li>
<li><p>Adding Memory to the Chatbot:</p>
<ul>
<li>Integrate a memory component using the Mem0 API to store and retrieve customer interactions.</li>
<li>Implement methods for storing customer interactions with appropriate metadata (e.g., timestamp, conversation formatting).</li>
<li>Retrieve relevant past interactions to build context for handling user queries.</li>
<li>Manage multiple sessions using persona-based session management to ensure personalized responses.</li>
</ul>
</li>
<li><p>Initialize and Use the AI Nutrition Disorder Specialist Agent:</p>
<ul>
<li>Import libraries required to initialize and set up the AI agent.</li>
<li>Define and run a conversational agent for answering nutrition disorder-related questions using the RAG-based workflow. This includes handling user interaction, input filtering, query processing, and error handling.</li>
</ul>
</li>
</ul>
<p><strong>Section 3: Getting Your App Live on Hugging Face Docker Spaces</strong></p>
<p>In this section, you will:</p>
<ul>
<li><p>Set Up the Environment and Fetch Secrets:</p>
<ul>
<li>Initialize environment variables and fetch necessary API keys and secrets.</li>
<li>Configure the OpenAI embedding function and Chat OpenAI model.</li>
</ul>
</li>
<li><p>Create the LangGraph Agent:</p>
<ul>
<li>Reuse functions and workflow definitions from Section 2 to create the LangGraph agent.</li>
<li>Ensure the workflow follows a structured approach to query handling and response generation.</li>
</ul>
</li>
<li><p>Run the Agentic RAG Function:</p>
<ul>
<li>Use the advanced RAG function to handle user queries and generate responses.</li>
<li>Ensure context-aware interactions by leveraging conversation history.</li>
</ul>
</li>
<li><p>Create a User Interface using Streamlit:</p>
<ul>
<li>Set up a user-friendly interface for the agent using Streamlit.</li>
<li>Ensure seamless user experience with a clear UI, chat history management, input filtering, query processing, and error handling.</li>
</ul>
</li>
<li><p>Deploy the App using Docker:</p>
<ul>
<li>Create a Dockerfile to containerize the application.</li>
<li>Upload necessary files and initiate the deployment process to Hugging Face Docker Spaces.</li>
<li>Ensure the agent is live and accessible, ready to assist users with their queries.</li>
</ul>
</li>
</ul>
<p>By the end of this project, you will have built and deployed an advanced AI Nutrition Disorder Specialist agent, equipped with the ability to provide accurate, contextually relevant responses to user queries. This comprehensive approach will enhance your skills in data parsing, advanced retrieval mechanisms, AI model deployment, and user interface design. Let's get started!</p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h1 id="Section-1:-Comprehensive-Data-Parsing-and-Preparation-for-Efficient-Nutritional-Information-Retrieval"><strong>Section 1: Comprehensive Data Parsing and Preparation for Efficient Nutritional Information Retrieval</strong><a class="anchor-link" href="#Section-1:-Comprehensive-Data-Parsing-and-Preparation-for-Efficient-Nutritional-Information-Retrieval"></a></h1>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>In this section, we lay the groundwork for the AI Nutrition Disorder Specialist bot by meticulously parsing and preparing data from various nutritional disorder documents. We begin by installing and importing the necessary libraries, followed by unzipping the documents and setting up configurations for OpenAI models. Next, we parse PDF content using LlamaParse to extract tables and validate parsed JSON objects. We then perform semantic chunking of text for structured retrieval, and generate hypothetical questions and metadata for these text chunks and tables. Finally, we store everything in ChromaDB, ensuring efficient retrieval and processing of relevant information for the bot's responses. This structured approach equips the AI with the ability to provide accurate and contextually relevant answers to user queries related to nutritional disorders.</p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h2 id="1.1.-Install-and-Import-Required-Libraries"><strong>1.1. Install and Import Required Libraries</strong><a class="anchor-link" href="#1.1.-Install-and-Import-Required-Libraries"></a></h2>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[7]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="err">!</span><span class="n">pip</span> <span class="n">install</span> <span class="n">numpy</span><span class="o">==</span><span class="mf">1.25.2</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Requirement already satisfied: numpy==1.25.2 in /usr/local/lib/python3.11/dist-packages (1.25.2)
</pre>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[1]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Installing the required libraries</span>
<span class="err">!</span><span class="n">pip</span> <span class="n">install</span> <span class="n">openai</span><span class="o">==</span><span class="mf">1.55.3</span> \
            <span class="n">langchain</span><span class="o">==</span><span class="mf">0.2.7</span> \
            <span class="n">langchain</span><span class="o">-</span><span class="n">community</span><span class="o">==</span><span class="mf">0.2.7</span>\
             <span class="n">langchain</span><span class="o">-</span><span class="n">huggingface</span><span class="o">==</span><span class="mf">0.0.3</span> \
             <span class="n">langchain</span><span class="o">-</span><span class="n">experimental</span><span class="o">==</span><span class="mf">0.0.62</span> \
             <span class="n">langchain</span><span class="o">-</span><span class="n">openai</span><span class="o">==</span><span class="mf">0.1.14</span> \
             <span class="n">chromadb</span><span class="o">==</span><span class="mf">0.5.3</span> \
             <span class="n">sentence</span><span class="o">-</span><span class="n">transformers</span><span class="o">==</span><span class="mf">3.0.1</span> \
             <span class="n">python</span><span class="o">-</span><span class="n">dotenv</span><span class="o">==</span><span class="mf">1.0.1</span> \
             <span class="n">lark</span><span class="o">==</span><span class="mf">1.1.9</span> \
             <span class="n">llama</span><span class="o">-</span><span class="n">index</span><span class="o">-</span><span class="n">core</span> \
             <span class="n">llama</span><span class="o">-</span><span class="n">parse</span><span class="o">==</span><span class="mf">0.5.11</span> \
             <span class="n">llama</span><span class="o">-</span><span class="n">index</span><span class="o">-</span><span class="n">readers</span><span class="o">-</span><span class="n">file</span> \
             <span class="n">llama</span><span class="o">-</span><span class="n">index</span><span class="o">-</span><span class="n">llms</span><span class="o">-</span><span class="n">langchain</span> \
             <span class="n">langgraph</span> \
             <span class="n">groq</span> \
             <span class="n">mem0ai</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Collecting openai==1.55.3
  Downloading openai-1.55.3-py3-none-any.whl.metadata (24 kB)
Collecting langchain==0.2.7
  Downloading langchain-0.2.7-py3-none-any.whl.metadata (6.9 kB)
Collecting langchain-community==0.2.7
  Downloading langchain_community-0.2.7-py3-none-any.whl.metadata (2.5 kB)
Collecting langchain-huggingface==0.0.3
  Downloading langchain_huggingface-0.0.3-py3-none-any.whl.metadata (1.2 kB)
Collecting langchain-experimental==0.0.62
  Downloading langchain_experimental-0.0.62-py3-none-any.whl.metadata (1.5 kB)
Collecting langchain-openai==0.1.14
  Downloading langchain_openai-0.1.14-py3-none-any.whl.metadata (2.5 kB)
Collecting chromadb==0.5.3
  Downloading chromadb-0.5.3-py3-none-any.whl.metadata (6.8 kB)
Collecting sentence-transformers==3.0.1
  Downloading sentence_transformers-3.0.1-py3-none-any.whl.metadata (10 kB)
Collecting python-dotenv==1.0.1
  Downloading python_dotenv-1.0.1-py3-none-any.whl.metadata (23 kB)
Collecting lark==1.1.9
  Downloading lark-1.1.9-py3-none-any.whl.metadata (1.9 kB)
Collecting llama-index-core
  Downloading llama_index_core-0.12.38-py3-none-any.whl.metadata (2.4 kB)
Collecting llama-parse==0.5.11
  Downloading llama_parse-0.5.11-py3-none-any.whl.metadata (6.9 kB)
Collecting llama-index-readers-file
  Downloading llama_index_readers_file-0.4.8-py3-none-any.whl.metadata (5.2 kB)
Collecting llama-index-llms-langchain
  Downloading llama_index_llms_langchain-0.6.1-py3-none-any.whl.metadata (1.4 kB)
Collecting langgraph
  Downloading langgraph-0.4.7-py3-none-any.whl.metadata (6.8 kB)
Collecting groq
  Downloading groq-0.26.0-py3-none-any.whl.metadata (15 kB)
Collecting mem0ai
  Downloading mem0ai-0.1.102-py3-none-any.whl.metadata (7.4 kB)
Requirement already satisfied: anyio&lt;5,&gt;=3.5.0 in /usr/local/lib/python3.11/dist-packages (from openai==1.55.3) (4.9.0)
Requirement already satisfied: distro&lt;2,&gt;=1.7.0 in /usr/local/lib/python3.11/dist-packages (from openai==1.55.3) (1.9.0)
Requirement already satisfied: httpx&lt;1,&gt;=0.23.0 in /usr/local/lib/python3.11/dist-packages (from openai==1.55.3) (0.28.1)
Requirement already satisfied: jiter&lt;1,&gt;=0.4.0 in /usr/local/lib/python3.11/dist-packages (from openai==1.55.3) (0.10.0)
Requirement already satisfied: pydantic&lt;3,&gt;=1.9.0 in /usr/local/lib/python3.11/dist-packages (from openai==1.55.3) (2.11.4)
Requirement already satisfied: sniffio in /usr/local/lib/python3.11/dist-packages (from openai==1.55.3) (1.3.1)
Requirement already satisfied: tqdm&gt;4 in /usr/local/lib/python3.11/dist-packages (from openai==1.55.3) (4.67.1)
Requirement already satisfied: typing-extensions&lt;5,&gt;=4.11 in /usr/local/lib/python3.11/dist-packages (from openai==1.55.3) (4.13.2)
Requirement already satisfied: PyYAML&gt;=5.3 in /usr/local/lib/python3.11/dist-packages (from langchain==0.2.7) (6.0.2)
Requirement already satisfied: SQLAlchemy&lt;3,&gt;=1.4 in /usr/local/lib/python3.11/dist-packages (from langchain==0.2.7) (2.0.41)
Requirement already satisfied: aiohttp&lt;4.0.0,&gt;=3.8.3 in /usr/local/lib/python3.11/dist-packages (from langchain==0.2.7) (3.11.15)
Collecting langchain-core&lt;0.3.0,&gt;=0.2.12 (from langchain==0.2.7)
  Downloading langchain_core-0.2.43-py3-none-any.whl.metadata (6.2 kB)
Collecting langchain-text-splitters&lt;0.3.0,&gt;=0.2.0 (from langchain==0.2.7)
  Downloading langchain_text_splitters-0.2.4-py3-none-any.whl.metadata (2.3 kB)
Collecting langsmith&lt;0.2.0,&gt;=0.1.17 (from langchain==0.2.7)
  Downloading langsmith-0.1.147-py3-none-any.whl.metadata (14 kB)
Collecting numpy&lt;2,&gt;=1 (from langchain==0.2.7)
  Downloading numpy-1.26.4-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (61 kB)
     <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">61.0/61.0 kB</span> <span class="ansi-red-fg">3.2 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Requirement already satisfied: requests&lt;3,&gt;=2 in /usr/local/lib/python3.11/dist-packages (from langchain==0.2.7) (2.32.3)
Collecting tenacity!=8.4.0,&lt;9.0.0,&gt;=8.1.0 (from langchain==0.2.7)
  Downloading tenacity-8.5.0-py3-none-any.whl.metadata (1.2 kB)
Collecting dataclasses-json&lt;0.7,&gt;=0.5.7 (from langchain-community==0.2.7)
  Downloading dataclasses_json-0.6.7-py3-none-any.whl.metadata (25 kB)
Requirement already satisfied: huggingface-hub&gt;=0.23.0 in /usr/local/lib/python3.11/dist-packages (from langchain-huggingface==0.0.3) (0.31.4)
Requirement already satisfied: tokenizers&gt;=0.19.1 in /usr/local/lib/python3.11/dist-packages (from langchain-huggingface==0.0.3) (0.21.1)
Requirement already satisfied: transformers&gt;=4.39.0 in /usr/local/lib/python3.11/dist-packages (from langchain-huggingface==0.0.3) (4.52.2)
Requirement already satisfied: tiktoken&lt;1,&gt;=0.7 in /usr/local/lib/python3.11/dist-packages (from langchain-openai==0.1.14) (0.9.0)
Requirement already satisfied: build&gt;=1.0.3 in /usr/local/lib/python3.11/dist-packages (from chromadb==0.5.3) (1.2.2.post1)
Collecting chroma-hnswlib==0.7.3 (from chromadb==0.5.3)
  Downloading chroma_hnswlib-0.7.3-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (252 bytes)
Collecting fastapi&gt;=0.95.2 (from chromadb==0.5.3)
  Downloading fastapi-0.115.12-py3-none-any.whl.metadata (27 kB)
Collecting uvicorn&gt;=0.18.3 (from uvicorn[standard]&gt;=0.18.3-&gt;chromadb==0.5.3)
  Downloading uvicorn-0.34.2-py3-none-any.whl.metadata (6.5 kB)
Collecting posthog&gt;=2.4.0 (from chromadb==0.5.3)
  Downloading posthog-4.2.0-py2.py3-none-any.whl.metadata (3.0 kB)
Collecting onnxruntime&gt;=1.14.1 (from chromadb==0.5.3)
  Downloading onnxruntime-1.22.0-cp311-cp311-manylinux_2_27_x86_64.manylinux_2_28_x86_64.whl.metadata (4.5 kB)
Collecting opentelemetry-api&gt;=1.2.0 (from chromadb==0.5.3)
  Downloading opentelemetry_api-1.33.1-py3-none-any.whl.metadata (1.6 kB)
Collecting opentelemetry-exporter-otlp-proto-grpc&gt;=1.2.0 (from chromadb==0.5.3)
  Downloading opentelemetry_exporter_otlp_proto_grpc-1.33.1-py3-none-any.whl.metadata (2.5 kB)
Collecting opentelemetry-instrumentation-fastapi&gt;=0.41b0 (from chromadb==0.5.3)
  Downloading opentelemetry_instrumentation_fastapi-0.54b1-py3-none-any.whl.metadata (2.2 kB)
Collecting opentelemetry-sdk&gt;=1.2.0 (from chromadb==0.5.3)
  Downloading opentelemetry_sdk-1.33.1-py3-none-any.whl.metadata (1.6 kB)
Collecting pypika&gt;=0.48.9 (from chromadb==0.5.3)
  Downloading PyPika-0.48.9.tar.gz (67 kB)
     <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">67.3/67.3 kB</span> <span class="ansi-red-fg">5.5 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
  Installing build dependencies ... done
  Getting requirements to build wheel ... done
  Preparing metadata (pyproject.toml) ... done
Collecting overrides&gt;=7.3.1 (from chromadb==0.5.3)
  Downloading overrides-7.7.0-py3-none-any.whl.metadata (5.8 kB)
Requirement already satisfied: importlib-resources in /usr/local/lib/python3.11/dist-packages (from chromadb==0.5.3) (6.5.2)
Requirement already satisfied: grpcio&gt;=1.58.0 in /usr/local/lib/python3.11/dist-packages (from chromadb==0.5.3) (1.71.0)
Collecting bcrypt&gt;=4.0.1 (from chromadb==0.5.3)
  Downloading bcrypt-4.3.0-cp39-abi3-manylinux_2_34_x86_64.whl.metadata (10 kB)
Requirement already satisfied: typer&gt;=0.9.0 in /usr/local/lib/python3.11/dist-packages (from chromadb==0.5.3) (0.15.3)
Collecting kubernetes&gt;=28.1.0 (from chromadb==0.5.3)
  Downloading kubernetes-32.0.1-py2.py3-none-any.whl.metadata (1.7 kB)
Collecting mmh3&gt;=4.0.1 (from chromadb==0.5.3)
  Downloading mmh3-5.1.0-cp311-cp311-manylinux_2_5_x86_64.manylinux1_x86_64.manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (16 kB)
Requirement already satisfied: orjson&gt;=3.9.12 in /usr/local/lib/python3.11/dist-packages (from chromadb==0.5.3) (3.10.18)
Requirement already satisfied: torch&gt;=1.11.0 in /usr/local/lib/python3.11/dist-packages (from sentence-transformers==3.0.1) (2.6.0+cu124)
Requirement already satisfied: scikit-learn in /usr/local/lib/python3.11/dist-packages (from sentence-transformers==3.0.1) (1.6.1)
Requirement already satisfied: scipy in /usr/local/lib/python3.11/dist-packages (from sentence-transformers==3.0.1) (1.15.3)
Requirement already satisfied: Pillow in /usr/local/lib/python3.11/dist-packages (from sentence-transformers==3.0.1) (11.2.1)
Requirement already satisfied: click&lt;9.0.0,&gt;=8.1.7 in /usr/local/lib/python3.11/dist-packages (from llama-parse==0.5.11) (8.2.1)
Collecting aiosqlite (from llama-index-core)
  Downloading aiosqlite-0.21.0-py3-none-any.whl.metadata (4.3 kB)
Collecting banks&lt;3,&gt;=2.0.0 (from llama-index-core)
  Downloading banks-2.1.2-py3-none-any.whl.metadata (12 kB)
Collecting deprecated&gt;=1.2.9.3 (from llama-index-core)
  Downloading Deprecated-1.2.18-py2.py3-none-any.whl.metadata (5.7 kB)
Collecting dirtyjson&lt;2,&gt;=1.0.8 (from llama-index-core)
  Downloading dirtyjson-1.0.8-py3-none-any.whl.metadata (11 kB)
Collecting filetype&lt;2,&gt;=1.2.0 (from llama-index-core)
  Downloading filetype-1.2.0-py2.py3-none-any.whl.metadata (6.5 kB)
Requirement already satisfied: fsspec&gt;=2023.5.0 in /usr/local/lib/python3.11/dist-packages (from llama-index-core) (2025.3.2)
Requirement already satisfied: nest-asyncio&lt;2,&gt;=1.5.8 in /usr/local/lib/python3.11/dist-packages (from llama-index-core) (1.6.0)
Requirement already satisfied: networkx&gt;=3.0 in /usr/local/lib/python3.11/dist-packages (from llama-index-core) (3.4.2)
Requirement already satisfied: nltk&gt;3.8.1 in /usr/local/lib/python3.11/dist-packages (from llama-index-core) (3.9.1)
Collecting typing-inspect&gt;=0.8.0 (from llama-index-core)
  Downloading typing_inspect-0.9.0-py3-none-any.whl.metadata (1.5 kB)
Requirement already satisfied: wrapt in /usr/local/lib/python3.11/dist-packages (from llama-index-core) (1.17.2)
Requirement already satisfied: beautifulsoup4&lt;5,&gt;=4.12.3 in /usr/local/lib/python3.11/dist-packages (from llama-index-readers-file) (4.13.4)
Requirement already satisfied: pandas in /usr/local/lib/python3.11/dist-packages (from llama-index-readers-file) (2.2.2)
Collecting pypdf&lt;6,&gt;=5.1.0 (from llama-index-readers-file)
  Downloading pypdf-5.5.0-py3-none-any.whl.metadata (7.2 kB)
Collecting striprtf&lt;0.0.27,&gt;=0.0.26 (from llama-index-readers-file)
  Downloading striprtf-0.0.26-py3-none-any.whl.metadata (2.1 kB)
Collecting langgraph-checkpoint&gt;=2.0.26 (from langgraph)
  Downloading langgraph_checkpoint-2.0.26-py3-none-any.whl.metadata (4.6 kB)
Collecting langgraph-prebuilt&gt;=0.2.0 (from langgraph)
  Downloading langgraph_prebuilt-0.2.2-py3-none-any.whl.metadata (4.5 kB)
Collecting langgraph-sdk&gt;=0.1.42 (from langgraph)
  Downloading langgraph_sdk-0.1.70-py3-none-any.whl.metadata (1.5 kB)
Requirement already satisfied: xxhash&gt;=3.5.0 in /usr/local/lib/python3.11/dist-packages (from langgraph) (3.5.0)
Requirement already satisfied: pytz&gt;=2024.1 in /usr/local/lib/python3.11/dist-packages (from mem0ai) (2025.2)
Collecting qdrant-client&gt;=1.9.1 (from mem0ai)
  Downloading qdrant_client-1.14.2-py3-none-any.whl.metadata (10 kB)
Requirement already satisfied: aiohappyeyeballs&gt;=2.3.0 in /usr/local/lib/python3.11/dist-packages (from aiohttp&lt;4.0.0,&gt;=3.8.3-&gt;langchain==0.2.7) (2.6.1)
Requirement already satisfied: aiosignal&gt;=1.1.2 in /usr/local/lib/python3.11/dist-packages (from aiohttp&lt;4.0.0,&gt;=3.8.3-&gt;langchain==0.2.7) (1.3.2)
Requirement already satisfied: attrs&gt;=17.3.0 in /usr/local/lib/python3.11/dist-packages (from aiohttp&lt;4.0.0,&gt;=3.8.3-&gt;langchain==0.2.7) (25.3.0)
Requirement already satisfied: frozenlist&gt;=1.1.1 in /usr/local/lib/python3.11/dist-packages (from aiohttp&lt;4.0.0,&gt;=3.8.3-&gt;langchain==0.2.7) (1.6.0)
Requirement already satisfied: multidict&lt;7.0,&gt;=4.5 in /usr/local/lib/python3.11/dist-packages (from aiohttp&lt;4.0.0,&gt;=3.8.3-&gt;langchain==0.2.7) (6.4.4)
Requirement already satisfied: propcache&gt;=0.2.0 in /usr/local/lib/python3.11/dist-packages (from aiohttp&lt;4.0.0,&gt;=3.8.3-&gt;langchain==0.2.7) (0.3.1)
Requirement already satisfied: yarl&lt;2.0,&gt;=1.17.0 in /usr/local/lib/python3.11/dist-packages (from aiohttp&lt;4.0.0,&gt;=3.8.3-&gt;langchain==0.2.7) (1.20.0)
Requirement already satisfied: idna&gt;=2.8 in /usr/local/lib/python3.11/dist-packages (from anyio&lt;5,&gt;=3.5.0-&gt;openai==1.55.3) (3.10)
Collecting griffe (from banks&lt;3,&gt;=2.0.0-&gt;llama-index-core)
  Downloading griffe-1.7.3-py3-none-any.whl.metadata (5.0 kB)
Requirement already satisfied: jinja2 in /usr/local/lib/python3.11/dist-packages (from banks&lt;3,&gt;=2.0.0-&gt;llama-index-core) (3.1.6)
Requirement already satisfied: platformdirs in /usr/local/lib/python3.11/dist-packages (from banks&lt;3,&gt;=2.0.0-&gt;llama-index-core) (4.3.8)
Requirement already satisfied: soupsieve&gt;1.2 in /usr/local/lib/python3.11/dist-packages (from beautifulsoup4&lt;5,&gt;=4.12.3-&gt;llama-index-readers-file) (2.7)
Requirement already satisfied: packaging&gt;=19.1 in /usr/local/lib/python3.11/dist-packages (from build&gt;=1.0.3-&gt;chromadb==0.5.3) (24.2)
Requirement already satisfied: pyproject_hooks in /usr/local/lib/python3.11/dist-packages (from build&gt;=1.0.3-&gt;chromadb==0.5.3) (1.2.0)
Collecting marshmallow&lt;4.0.0,&gt;=3.18.0 (from dataclasses-json&lt;0.7,&gt;=0.5.7-&gt;langchain-community==0.2.7)
  Downloading marshmallow-3.26.1-py3-none-any.whl.metadata (7.3 kB)
Collecting starlette&lt;0.47.0,&gt;=0.40.0 (from fastapi&gt;=0.95.2-&gt;chromadb==0.5.3)
  Downloading starlette-0.46.2-py3-none-any.whl.metadata (6.2 kB)
Requirement already satisfied: certifi in /usr/local/lib/python3.11/dist-packages (from httpx&lt;1,&gt;=0.23.0-&gt;openai==1.55.3) (2025.4.26)
Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.11/dist-packages (from httpx&lt;1,&gt;=0.23.0-&gt;openai==1.55.3) (1.0.9)
Requirement already satisfied: h11&gt;=0.16 in /usr/local/lib/python3.11/dist-packages (from httpcore==1.*-&gt;httpx&lt;1,&gt;=0.23.0-&gt;openai==1.55.3) (0.16.0)
Requirement already satisfied: filelock in /usr/local/lib/python3.11/dist-packages (from huggingface-hub&gt;=0.23.0-&gt;langchain-huggingface==0.0.3) (3.18.0)
Requirement already satisfied: six&gt;=1.9.0 in /usr/local/lib/python3.11/dist-packages (from kubernetes&gt;=28.1.0-&gt;chromadb==0.5.3) (1.17.0)
Requirement already satisfied: python-dateutil&gt;=2.5.3 in /usr/local/lib/python3.11/dist-packages (from kubernetes&gt;=28.1.0-&gt;chromadb==0.5.3) (2.9.0.post0)
Requirement already satisfied: google-auth&gt;=1.0.1 in /usr/local/lib/python3.11/dist-packages (from kubernetes&gt;=28.1.0-&gt;chromadb==0.5.3) (2.38.0)
Requirement already satisfied: websocket-client!=0.40.0,!=0.41.*,!=0.42.*,&gt;=0.32.0 in /usr/local/lib/python3.11/dist-packages (from kubernetes&gt;=28.1.0-&gt;chromadb==0.5.3) (1.8.0)
Requirement already satisfied: requests-oauthlib in /usr/local/lib/python3.11/dist-packages (from kubernetes&gt;=28.1.0-&gt;chromadb==0.5.3) (2.0.0)
Requirement already satisfied: oauthlib&gt;=3.2.2 in /usr/local/lib/python3.11/dist-packages (from kubernetes&gt;=28.1.0-&gt;chromadb==0.5.3) (3.2.2)
Requirement already satisfied: urllib3&gt;=1.24.2 in /usr/local/lib/python3.11/dist-packages (from kubernetes&gt;=28.1.0-&gt;chromadb==0.5.3) (2.4.0)
Collecting durationpy&gt;=0.7 (from kubernetes&gt;=28.1.0-&gt;chromadb==0.5.3)
  Downloading durationpy-0.10-py3-none-any.whl.metadata (340 bytes)
Requirement already satisfied: jsonpatch&lt;2.0,&gt;=1.33 in /usr/local/lib/python3.11/dist-packages (from langchain-core&lt;0.3.0,&gt;=0.2.12-&gt;langchain==0.2.7) (1.33)
Collecting ormsgpack&lt;2.0.0,&gt;=1.8.0 (from langgraph-checkpoint&gt;=2.0.26-&gt;langgraph)
  Downloading ormsgpack-1.10.0-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (43 kB)
     <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">43.7/43.7 kB</span> <span class="ansi-red-fg">2.7 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
INFO: pip is looking at multiple versions of langgraph-prebuilt to determine which version is compatible with other requirements. This could take a while.
Collecting langgraph-prebuilt&gt;=0.2.0 (from langgraph)
  Downloading langgraph_prebuilt-0.2.1-py3-none-any.whl.metadata (4.5 kB)
  Downloading langgraph_prebuilt-0.2.0-py3-none-any.whl.metadata (4.5 kB)
Collecting langchain-text-splitters&lt;0.3.0,&gt;=0.2.0 (from langchain==0.2.7)
  Downloading langchain_text_splitters-0.2.2-py3-none-any.whl.metadata (2.1 kB)
  Downloading langchain_text_splitters-0.2.1-py3-none-any.whl.metadata (2.2 kB)
INFO: pip is still looking at multiple versions of langgraph-prebuilt to determine which version is compatible with other requirements. This could take a while.
  Downloading langchain_text_splitters-0.2.0-py3-none-any.whl.metadata (2.2 kB)
Collecting langgraph
  Downloading langgraph-0.4.6-py3-none-any.whl.metadata (6.8 kB)
INFO: This is taking longer than usual. You might need to provide the dependency resolver with stricter constraints to reduce runtime. See https://pip.pypa.io/warnings/backtracking for guidance. If you want to abort this run, press Ctrl + C.
  Downloading langgraph-0.4.5-py3-none-any.whl.metadata (7.3 kB)
Collecting langgraph-prebuilt&gt;=0.1.8 (from langgraph)
  Downloading langgraph_prebuilt-0.1.8-py3-none-any.whl.metadata (5.0 kB)
Requirement already satisfied: requests-toolbelt&lt;2.0.0,&gt;=1.0.0 in /usr/local/lib/python3.11/dist-packages (from langsmith&lt;0.2.0,&gt;=0.1.17-&gt;langchain==0.2.7) (1.0.0)
Requirement already satisfied: joblib in /usr/local/lib/python3.11/dist-packages (from nltk&gt;3.8.1-&gt;llama-index-core) (1.5.0)
Requirement already satisfied: regex&gt;=2021.8.3 in /usr/local/lib/python3.11/dist-packages (from nltk&gt;3.8.1-&gt;llama-index-core) (2024.11.6)
Collecting coloredlogs (from onnxruntime&gt;=1.14.1-&gt;chromadb==0.5.3)
  Downloading coloredlogs-15.0.1-py2.py3-none-any.whl.metadata (12 kB)
Requirement already satisfied: flatbuffers in /usr/local/lib/python3.11/dist-packages (from onnxruntime&gt;=1.14.1-&gt;chromadb==0.5.3) (25.2.10)
Requirement already satisfied: protobuf in /usr/local/lib/python3.11/dist-packages (from onnxruntime&gt;=1.14.1-&gt;chromadb==0.5.3) (5.29.4)
Requirement already satisfied: sympy in /usr/local/lib/python3.11/dist-packages (from onnxruntime&gt;=1.14.1-&gt;chromadb==0.5.3) (1.13.1)
Collecting importlib-metadata&lt;8.7.0,&gt;=6.0 (from opentelemetry-api&gt;=1.2.0-&gt;chromadb==0.5.3)
  Downloading importlib_metadata-8.6.1-py3-none-any.whl.metadata (4.7 kB)
Requirement already satisfied: googleapis-common-protos~=1.52 in /usr/local/lib/python3.11/dist-packages (from opentelemetry-exporter-otlp-proto-grpc&gt;=1.2.0-&gt;chromadb==0.5.3) (1.70.0)
Collecting opentelemetry-exporter-otlp-proto-common==1.33.1 (from opentelemetry-exporter-otlp-proto-grpc&gt;=1.2.0-&gt;chromadb==0.5.3)
  Downloading opentelemetry_exporter_otlp_proto_common-1.33.1-py3-none-any.whl.metadata (1.9 kB)
Collecting opentelemetry-proto==1.33.1 (from opentelemetry-exporter-otlp-proto-grpc&gt;=1.2.0-&gt;chromadb==0.5.3)
  Downloading opentelemetry_proto-1.33.1-py3-none-any.whl.metadata (2.4 kB)
Collecting opentelemetry-instrumentation-asgi==0.54b1 (from opentelemetry-instrumentation-fastapi&gt;=0.41b0-&gt;chromadb==0.5.3)
  Downloading opentelemetry_instrumentation_asgi-0.54b1-py3-none-any.whl.metadata (2.1 kB)
Collecting opentelemetry-instrumentation==0.54b1 (from opentelemetry-instrumentation-fastapi&gt;=0.41b0-&gt;chromadb==0.5.3)
  Downloading opentelemetry_instrumentation-0.54b1-py3-none-any.whl.metadata (6.8 kB)
Collecting opentelemetry-semantic-conventions==0.54b1 (from opentelemetry-instrumentation-fastapi&gt;=0.41b0-&gt;chromadb==0.5.3)
  Downloading opentelemetry_semantic_conventions-0.54b1-py3-none-any.whl.metadata (2.5 kB)
Collecting opentelemetry-util-http==0.54b1 (from opentelemetry-instrumentation-fastapi&gt;=0.41b0-&gt;chromadb==0.5.3)
  Downloading opentelemetry_util_http-0.54b1-py3-none-any.whl.metadata (2.6 kB)
Collecting asgiref~=3.0 (from opentelemetry-instrumentation-asgi==0.54b1-&gt;opentelemetry-instrumentation-fastapi&gt;=0.41b0-&gt;chromadb==0.5.3)
  Downloading asgiref-3.8.1-py3-none-any.whl.metadata (9.3 kB)
Collecting backoff&gt;=1.10.0 (from posthog&gt;=2.4.0-&gt;chromadb==0.5.3)
  Downloading backoff-2.2.1-py3-none-any.whl.metadata (14 kB)
Requirement already satisfied: annotated-types&gt;=0.6.0 in /usr/local/lib/python3.11/dist-packages (from pydantic&lt;3,&gt;=1.9.0-&gt;openai==1.55.3) (0.7.0)
Requirement already satisfied: pydantic-core==2.33.2 in /usr/local/lib/python3.11/dist-packages (from pydantic&lt;3,&gt;=1.9.0-&gt;openai==1.55.3) (2.33.2)
Requirement already satisfied: typing-inspection&gt;=0.4.0 in /usr/local/lib/python3.11/dist-packages (from pydantic&lt;3,&gt;=1.9.0-&gt;openai==1.55.3) (0.4.1)
Collecting portalocker&lt;3.0.0,&gt;=2.7.0 (from qdrant-client&gt;=1.9.1-&gt;mem0ai)
  Downloading portalocker-2.10.1-py3-none-any.whl.metadata (8.5 kB)
Requirement already satisfied: charset-normalizer&lt;4,&gt;=2 in /usr/local/lib/python3.11/dist-packages (from requests&lt;3,&gt;=2-&gt;langchain==0.2.7) (3.4.2)
Requirement already satisfied: greenlet&gt;=1 in /usr/local/lib/python3.11/dist-packages (from SQLAlchemy&lt;3,&gt;=1.4-&gt;langchain==0.2.7) (3.2.2)
Collecting nvidia-cuda-nvrtc-cu12==12.4.127 (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1)
  Downloading nvidia_cuda_nvrtc_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl.metadata (1.5 kB)
Collecting nvidia-cuda-runtime-cu12==12.4.127 (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1)
  Downloading nvidia_cuda_runtime_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl.metadata (1.5 kB)
Collecting nvidia-cuda-cupti-cu12==12.4.127 (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1)
  Downloading nvidia_cuda_cupti_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl.metadata (1.6 kB)
Collecting nvidia-cudnn-cu12==9.1.0.70 (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1)
  Downloading nvidia_cudnn_cu12-9.1.0.70-py3-none-manylinux2014_x86_64.whl.metadata (1.6 kB)
Collecting nvidia-cublas-cu12==12.4.5.8 (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1)
  Downloading nvidia_cublas_cu12-12.4.5.8-py3-none-manylinux2014_x86_64.whl.metadata (1.5 kB)
Collecting nvidia-cufft-cu12==11.2.1.3 (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1)
  Downloading nvidia_cufft_cu12-11.2.1.3-py3-none-manylinux2014_x86_64.whl.metadata (1.5 kB)
Collecting nvidia-curand-cu12==10.3.5.147 (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1)
  Downloading nvidia_curand_cu12-10.3.5.147-py3-none-manylinux2014_x86_64.whl.metadata (1.5 kB)
Collecting nvidia-cusolver-cu12==11.6.1.9 (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1)
  Downloading nvidia_cusolver_cu12-11.6.1.9-py3-none-manylinux2014_x86_64.whl.metadata (1.6 kB)
Collecting nvidia-cusparse-cu12==12.3.1.170 (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1)
  Downloading nvidia_cusparse_cu12-12.3.1.170-py3-none-manylinux2014_x86_64.whl.metadata (1.6 kB)
Requirement already satisfied: nvidia-cusparselt-cu12==0.6.2 in /usr/local/lib/python3.11/dist-packages (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1) (0.6.2)
Requirement already satisfied: nvidia-nccl-cu12==2.21.5 in /usr/local/lib/python3.11/dist-packages (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1) (2.21.5)
Requirement already satisfied: nvidia-nvtx-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1) (12.4.127)
Collecting nvidia-nvjitlink-cu12==12.4.127 (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1)
  Downloading nvidia_nvjitlink_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl.metadata (1.5 kB)
Requirement already satisfied: triton==3.2.0 in /usr/local/lib/python3.11/dist-packages (from torch&gt;=1.11.0-&gt;sentence-transformers==3.0.1) (3.2.0)
Requirement already satisfied: mpmath&lt;1.4,&gt;=1.1.0 in /usr/local/lib/python3.11/dist-packages (from sympy-&gt;onnxruntime&gt;=1.14.1-&gt;chromadb==0.5.3) (1.3.0)
Requirement already satisfied: safetensors&gt;=0.4.3 in /usr/local/lib/python3.11/dist-packages (from transformers&gt;=4.39.0-&gt;langchain-huggingface==0.0.3) (0.5.3)
Requirement already satisfied: shellingham&gt;=1.3.0 in /usr/local/lib/python3.11/dist-packages (from typer&gt;=0.9.0-&gt;chromadb==0.5.3) (1.5.4)
Requirement already satisfied: rich&gt;=10.11.0 in /usr/local/lib/python3.11/dist-packages (from typer&gt;=0.9.0-&gt;chromadb==0.5.3) (13.9.4)
Collecting mypy-extensions&gt;=0.3.0 (from typing-inspect&gt;=0.8.0-&gt;llama-index-core)
  Downloading mypy_extensions-1.1.0-py3-none-any.whl.metadata (1.1 kB)
Collecting httptools&gt;=0.6.3 (from uvicorn[standard]&gt;=0.18.3-&gt;chromadb==0.5.3)
  Downloading httptools-0.6.4-cp311-cp311-manylinux_2_5_x86_64.manylinux1_x86_64.manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (3.6 kB)
Collecting uvloop!=0.15.0,!=0.15.1,&gt;=0.14.0 (from uvicorn[standard]&gt;=0.18.3-&gt;chromadb==0.5.3)
  Downloading uvloop-0.21.0-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (4.9 kB)
Collecting watchfiles&gt;=0.13 (from uvicorn[standard]&gt;=0.18.3-&gt;chromadb==0.5.3)
  Downloading watchfiles-1.0.5-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (4.9 kB)
Requirement already satisfied: websockets&gt;=10.4 in /usr/local/lib/python3.11/dist-packages (from uvicorn[standard]&gt;=0.18.3-&gt;chromadb==0.5.3) (15.0.1)
Requirement already satisfied: tzdata&gt;=2022.7 in /usr/local/lib/python3.11/dist-packages (from pandas-&gt;llama-index-readers-file) (2025.2)
Requirement already satisfied: threadpoolctl&gt;=3.1.0 in /usr/local/lib/python3.11/dist-packages (from scikit-learn-&gt;sentence-transformers==3.0.1) (3.6.0)
Requirement already satisfied: cachetools&lt;6.0,&gt;=2.0.0 in /usr/local/lib/python3.11/dist-packages (from google-auth&gt;=1.0.1-&gt;kubernetes&gt;=28.1.0-&gt;chromadb==0.5.3) (5.5.2)
Requirement already satisfied: pyasn1-modules&gt;=0.2.1 in /usr/local/lib/python3.11/dist-packages (from google-auth&gt;=1.0.1-&gt;kubernetes&gt;=28.1.0-&gt;chromadb==0.5.3) (0.4.2)
Requirement already satisfied: rsa&lt;5,&gt;=3.1.4 in /usr/local/lib/python3.11/dist-packages (from google-auth&gt;=1.0.1-&gt;kubernetes&gt;=28.1.0-&gt;chromadb==0.5.3) (4.9.1)
Requirement already satisfied: h2&lt;5,&gt;=3 in /usr/local/lib/python3.11/dist-packages (from httpx[http2]&gt;=0.20.0-&gt;qdrant-client&gt;=1.9.1-&gt;mem0ai) (4.2.0)
Requirement already satisfied: zipp&gt;=3.20 in /usr/local/lib/python3.11/dist-packages (from importlib-metadata&lt;8.7.0,&gt;=6.0-&gt;opentelemetry-api&gt;=1.2.0-&gt;chromadb==0.5.3) (3.21.0)
Requirement already satisfied: jsonpointer&gt;=1.9 in /usr/local/lib/python3.11/dist-packages (from jsonpatch&lt;2.0,&gt;=1.33-&gt;langchain-core&lt;0.3.0,&gt;=0.2.12-&gt;langchain==0.2.7) (3.0.0)
Requirement already satisfied: markdown-it-py&gt;=2.2.0 in /usr/local/lib/python3.11/dist-packages (from rich&gt;=10.11.0-&gt;typer&gt;=0.9.0-&gt;chromadb==0.5.3) (3.0.0)
Requirement already satisfied: pygments&lt;3.0.0,&gt;=2.13.0 in /usr/local/lib/python3.11/dist-packages (from rich&gt;=10.11.0-&gt;typer&gt;=0.9.0-&gt;chromadb==0.5.3) (2.19.1)
Collecting humanfriendly&gt;=9.1 (from coloredlogs-&gt;onnxruntime&gt;=1.14.1-&gt;chromadb==0.5.3)
  Downloading humanfriendly-10.0-py2.py3-none-any.whl.metadata (9.2 kB)
Collecting colorama&gt;=0.4 (from griffe-&gt;banks&lt;3,&gt;=2.0.0-&gt;llama-index-core)
  Downloading colorama-0.4.6-py2.py3-none-any.whl.metadata (17 kB)
Requirement already satisfied: MarkupSafe&gt;=2.0 in /usr/local/lib/python3.11/dist-packages (from jinja2-&gt;banks&lt;3,&gt;=2.0.0-&gt;llama-index-core) (3.0.2)
Requirement already satisfied: hyperframe&lt;7,&gt;=6.1 in /usr/local/lib/python3.11/dist-packages (from h2&lt;5,&gt;=3-&gt;httpx[http2]&gt;=0.20.0-&gt;qdrant-client&gt;=1.9.1-&gt;mem0ai) (6.1.0)
Requirement already satisfied: hpack&lt;5,&gt;=4.1 in /usr/local/lib/python3.11/dist-packages (from h2&lt;5,&gt;=3-&gt;httpx[http2]&gt;=0.20.0-&gt;qdrant-client&gt;=1.9.1-&gt;mem0ai) (4.1.0)
Requirement already satisfied: mdurl~=0.1 in /usr/local/lib/python3.11/dist-packages (from markdown-it-py&gt;=2.2.0-&gt;rich&gt;=10.11.0-&gt;typer&gt;=0.9.0-&gt;chromadb==0.5.3) (0.1.2)
Requirement already satisfied: pyasn1&lt;0.7.0,&gt;=0.6.1 in /usr/local/lib/python3.11/dist-packages (from pyasn1-modules&gt;=0.2.1-&gt;google-auth&gt;=1.0.1-&gt;kubernetes&gt;=28.1.0-&gt;chromadb==0.5.3) (0.6.1)
Downloading openai-1.55.3-py3-none-any.whl (389 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">389.6/389.6 kB</span> <span class="ansi-red-fg">13.5 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading langchain-0.2.7-py3-none-any.whl (983 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">983.6/983.6 kB</span> <span class="ansi-red-fg">34.0 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading langchain_community-0.2.7-py3-none-any.whl (2.2 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">2.2/2.2 MB</span> <span class="ansi-red-fg">32.4 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading langchain_huggingface-0.0.3-py3-none-any.whl (17 kB)
Downloading langchain_experimental-0.0.62-py3-none-any.whl (202 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">202.7/202.7 kB</span> <span class="ansi-red-fg">14.6 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading langchain_openai-0.1.14-py3-none-any.whl (45 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">45.9/45.9 kB</span> <span class="ansi-red-fg">2.9 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading chromadb-0.5.3-py3-none-any.whl (559 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">559.5/559.5 kB</span> <span class="ansi-red-fg">27.5 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading sentence_transformers-3.0.1-py3-none-any.whl (227 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">227.1/227.1 kB</span> <span class="ansi-red-fg">15.0 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading python_dotenv-1.0.1-py3-none-any.whl (19 kB)
Downloading lark-1.1.9-py3-none-any.whl (111 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">111.7/111.7 kB</span> <span class="ansi-red-fg">8.3 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading llama_parse-0.5.11-py3-none-any.whl (13 kB)
Downloading chroma_hnswlib-0.7.3-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (2.4 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">2.4/2.4 MB</span> <span class="ansi-red-fg">71.8 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading llama_index_core-0.12.38-py3-none-any.whl (7.7 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">7.7/7.7 MB</span> <span class="ansi-red-fg">69.4 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading llama_index_readers_file-0.4.8-py3-none-any.whl (40 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">41.0/41.0 kB</span> <span class="ansi-red-fg">2.4 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading llama_index_llms_langchain-0.6.1-py3-none-any.whl (6.1 kB)
Downloading langgraph-0.4.5-py3-none-any.whl (155 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">155.3/155.3 kB</span> <span class="ansi-red-fg">10.1 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading langchain_core-0.2.43-py3-none-any.whl (397 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">397.1/397.1 kB</span> <span class="ansi-red-fg">27.2 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading langchain_text_splitters-0.2.4-py3-none-any.whl (25 kB)
Downloading langgraph_checkpoint-2.0.26-py3-none-any.whl (44 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">44.2/44.2 kB</span> <span class="ansi-red-fg">3.1 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading langgraph_prebuilt-0.1.8-py3-none-any.whl (25 kB)
Downloading groq-0.26.0-py3-none-any.whl (129 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">129.6/129.6 kB</span> <span class="ansi-red-fg">9.2 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading mem0ai-0.1.102-py3-none-any.whl (156 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">156.0/156.0 kB</span> <span class="ansi-red-fg">11.8 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading banks-2.1.2-py3-none-any.whl (28 kB)
Downloading bcrypt-4.3.0-cp39-abi3-manylinux_2_34_x86_64.whl (284 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">284.2/284.2 kB</span> <span class="ansi-red-fg">19.7 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading dataclasses_json-0.6.7-py3-none-any.whl (28 kB)
Downloading Deprecated-1.2.18-py2.py3-none-any.whl (10.0 kB)
Downloading dirtyjson-1.0.8-py3-none-any.whl (25 kB)
Downloading fastapi-0.115.12-py3-none-any.whl (95 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">95.2/95.2 kB</span> <span class="ansi-red-fg">6.4 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading filetype-1.2.0-py2.py3-none-any.whl (19 kB)
Downloading kubernetes-32.0.1-py2.py3-none-any.whl (2.0 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">2.0/2.0 MB</span> <span class="ansi-red-fg">50.9 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading langgraph_sdk-0.1.70-py3-none-any.whl (49 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">50.0/50.0 kB</span> <span class="ansi-red-fg">3.1 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading langsmith-0.1.147-py3-none-any.whl (311 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">311.8/311.8 kB</span> <span class="ansi-red-fg">18.7 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading mmh3-5.1.0-cp311-cp311-manylinux_2_5_x86_64.manylinux1_x86_64.manylinux_2_17_x86_64.manylinux2014_x86_64.whl (101 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">101.6/101.6 kB</span> <span class="ansi-red-fg">6.6 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading numpy-1.26.4-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (18.3 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">18.3/18.3 MB</span> <span class="ansi-red-fg">85.0 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading onnxruntime-1.22.0-cp311-cp311-manylinux_2_27_x86_64.manylinux_2_28_x86_64.whl (16.4 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">16.4/16.4 MB</span> <span class="ansi-red-fg">62.4 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading opentelemetry_api-1.33.1-py3-none-any.whl (65 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">65.8/65.8 kB</span> <span class="ansi-red-fg">4.2 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading opentelemetry_exporter_otlp_proto_grpc-1.33.1-py3-none-any.whl (18 kB)
Downloading opentelemetry_exporter_otlp_proto_common-1.33.1-py3-none-any.whl (18 kB)
Downloading opentelemetry_proto-1.33.1-py3-none-any.whl (55 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">55.9/55.9 kB</span> <span class="ansi-red-fg">3.7 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading opentelemetry_instrumentation_fastapi-0.54b1-py3-none-any.whl (12 kB)
Downloading opentelemetry_instrumentation-0.54b1-py3-none-any.whl (31 kB)
Downloading opentelemetry_instrumentation_asgi-0.54b1-py3-none-any.whl (16 kB)
Downloading opentelemetry_semantic_conventions-0.54b1-py3-none-any.whl (194 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">194.9/194.9 kB</span> <span class="ansi-red-fg">13.2 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading opentelemetry_util_http-0.54b1-py3-none-any.whl (7.3 kB)
Downloading opentelemetry_sdk-1.33.1-py3-none-any.whl (118 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">119.0/119.0 kB</span> <span class="ansi-red-fg">8.4 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading overrides-7.7.0-py3-none-any.whl (17 kB)
Downloading posthog-4.2.0-py2.py3-none-any.whl (96 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">96.7/96.7 kB</span> <span class="ansi-red-fg">6.8 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading pypdf-5.5.0-py3-none-any.whl (303 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">303.4/303.4 kB</span> <span class="ansi-red-fg">17.7 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading qdrant_client-1.14.2-py3-none-any.whl (327 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">327.7/327.7 kB</span> <span class="ansi-red-fg">21.5 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading striprtf-0.0.26-py3-none-any.whl (6.9 kB)
Downloading tenacity-8.5.0-py3-none-any.whl (28 kB)
Downloading nvidia_cublas_cu12-12.4.5.8-py3-none-manylinux2014_x86_64.whl (363.4 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">363.4/363.4 MB</span> <span class="ansi-red-fg">4.2 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading nvidia_cuda_cupti_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl (13.8 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">13.8/13.8 MB</span> <span class="ansi-red-fg">52.7 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading nvidia_cuda_nvrtc_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl (24.6 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">24.6/24.6 MB</span> <span class="ansi-red-fg">26.0 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading nvidia_cuda_runtime_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl (883 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">883.7/883.7 kB</span> <span class="ansi-red-fg">38.2 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading nvidia_cudnn_cu12-9.1.0.70-py3-none-manylinux2014_x86_64.whl (664.8 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">664.8/664.8 MB</span> <span class="ansi-red-fg">2.8 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading nvidia_cufft_cu12-11.2.1.3-py3-none-manylinux2014_x86_64.whl (211.5 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">211.5/211.5 MB</span> <span class="ansi-red-fg">5.5 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading nvidia_curand_cu12-10.3.5.147-py3-none-manylinux2014_x86_64.whl (56.3 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">56.3/56.3 MB</span> <span class="ansi-red-fg">12.0 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading nvidia_cusolver_cu12-11.6.1.9-py3-none-manylinux2014_x86_64.whl (127.9 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">127.9/127.9 MB</span> <span class="ansi-red-fg">7.4 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading nvidia_cusparse_cu12-12.3.1.170-py3-none-manylinux2014_x86_64.whl (207.5 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">207.5/207.5 MB</span> <span class="ansi-red-fg">6.2 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading nvidia_nvjitlink_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl (21.1 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">21.1/21.1 MB</span> <span class="ansi-red-fg">67.6 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading typing_inspect-0.9.0-py3-none-any.whl (8.8 kB)
Downloading uvicorn-0.34.2-py3-none-any.whl (62 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">62.5/62.5 kB</span> <span class="ansi-red-fg">4.0 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading aiosqlite-0.21.0-py3-none-any.whl (15 kB)
Downloading backoff-2.2.1-py3-none-any.whl (15 kB)
Downloading durationpy-0.10-py3-none-any.whl (3.9 kB)
Downloading httptools-0.6.4-cp311-cp311-manylinux_2_5_x86_64.manylinux1_x86_64.manylinux_2_17_x86_64.manylinux2014_x86_64.whl (459 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">459.8/459.8 kB</span> <span class="ansi-red-fg">30.2 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading importlib_metadata-8.6.1-py3-none-any.whl (26 kB)
Downloading marshmallow-3.26.1-py3-none-any.whl (50 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">50.9/50.9 kB</span> <span class="ansi-red-fg">3.7 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading mypy_extensions-1.1.0-py3-none-any.whl (5.0 kB)
Downloading ormsgpack-1.10.0-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (216 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">216.5/216.5 kB</span> <span class="ansi-red-fg">14.7 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading portalocker-2.10.1-py3-none-any.whl (18 kB)
Downloading starlette-0.46.2-py3-none-any.whl (72 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">72.0/72.0 kB</span> <span class="ansi-red-fg">5.1 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading uvloop-0.21.0-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (4.0 MB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">4.0/4.0 MB</span> <span class="ansi-red-fg">60.9 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading watchfiles-1.0.5-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (454 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">454.8/454.8 kB</span> <span class="ansi-red-fg">18.1 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading coloredlogs-15.0.1-py2.py3-none-any.whl (46 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">46.0/46.0 kB</span> <span class="ansi-red-fg">3.2 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading griffe-1.7.3-py3-none-any.whl (129 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">129.3/129.3 kB</span> <span class="ansi-red-fg">9.8 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Downloading asgiref-3.8.1-py3-none-any.whl (23 kB)
Downloading colorama-0.4.6-py2.py3-none-any.whl (25 kB)
Downloading humanfriendly-10.0-py2.py3-none-any.whl (86 kB)
   <span class="ansi-black-intense-fg"></span> <span class="ansi-green-fg">86.8/86.8 kB</span> <span class="ansi-red-fg">6.4 MB/s</span> eta <span class="ansi-cyan-fg">0:00:00</span>
Building wheels for collected packages: pypika
  Building wheel for pypika (pyproject.toml) ... done
  Created wheel for pypika: filename=pypika-0.48.9-py2.py3-none-any.whl size=53803 sha256=3d074b8143d3219a48a081de164fe3ee3ffe93a35407963bf740eab769fab2fc
  Stored in directory: /root/.cache/pip/wheels/a3/01/bd/4c40ceb9d5354160cb186dcc153360f4ab7eb23e2b24daf96d
Successfully built pypika
Installing collected packages: striprtf, pypika, filetype, durationpy, dirtyjson, uvloop, uvicorn, tenacity, python-dotenv, pypdf, portalocker, overrides, ormsgpack, opentelemetry-util-http, opentelemetry-proto, nvidia-nvjitlink-cu12, nvidia-curand-cu12, nvidia-cufft-cu12, nvidia-cuda-runtime-cu12, nvidia-cuda-nvrtc-cu12, nvidia-cuda-cupti-cu12, nvidia-cublas-cu12, numpy, mypy-extensions, mmh3, marshmallow, lark, importlib-metadata, humanfriendly, httptools, deprecated, colorama, bcrypt, backoff, asgiref, aiosqlite, watchfiles, typing-inspect, starlette, posthog, opentelemetry-exporter-otlp-proto-common, opentelemetry-api, nvidia-cusparse-cu12, nvidia-cudnn-cu12, griffe, coloredlogs, chroma-hnswlib, opentelemetry-semantic-conventions, openai, onnxruntime, nvidia-cusolver-cu12, langsmith, langgraph-sdk, kubernetes, groq, fastapi, dataclasses-json, banks, qdrant-client, opentelemetry-sdk, opentelemetry-instrumentation, llama-index-core, langchain-core, sentence-transformers, opentelemetry-instrumentation-asgi, opentelemetry-exporter-otlp-proto-grpc, mem0ai, llama-parse, llama-index-readers-file, langgraph-checkpoint, langchain-text-splitters, langchain-openai, opentelemetry-instrumentation-fastapi, langgraph-prebuilt, langchain-huggingface, langchain, llama-index-llms-langchain, langgraph, langchain-community, chromadb, langchain-experimental
  Attempting uninstall: tenacity
    Found existing installation: tenacity 9.1.2
    Uninstalling tenacity-9.1.2:
      Successfully uninstalled tenacity-9.1.2
  Attempting uninstall: nvidia-nvjitlink-cu12
    Found existing installation: nvidia-nvjitlink-cu12 12.5.82
    Uninstalling nvidia-nvjitlink-cu12-12.5.82:
      Successfully uninstalled nvidia-nvjitlink-cu12-12.5.82
  Attempting uninstall: nvidia-curand-cu12
    Found existing installation: nvidia-curand-cu12 10.3.6.82
    Uninstalling nvidia-curand-cu12-10.3.6.82:
      Successfully uninstalled nvidia-curand-cu12-10.3.6.82
  Attempting uninstall: nvidia-cufft-cu12
    Found existing installation: nvidia-cufft-cu12 11.2.3.61
    Uninstalling nvidia-cufft-cu12-11.2.3.61:
      Successfully uninstalled nvidia-cufft-cu12-11.2.3.61
  Attempting uninstall: nvidia-cuda-runtime-cu12
    Found existing installation: nvidia-cuda-runtime-cu12 12.5.82
    Uninstalling nvidia-cuda-runtime-cu12-12.5.82:
      Successfully uninstalled nvidia-cuda-runtime-cu12-12.5.82
  Attempting uninstall: nvidia-cuda-nvrtc-cu12
    Found existing installation: nvidia-cuda-nvrtc-cu12 12.5.82
    Uninstalling nvidia-cuda-nvrtc-cu12-12.5.82:
      Successfully uninstalled nvidia-cuda-nvrtc-cu12-12.5.82
  Attempting uninstall: nvidia-cuda-cupti-cu12
    Found existing installation: nvidia-cuda-cupti-cu12 12.5.82
    Uninstalling nvidia-cuda-cupti-cu12-12.5.82:
      Successfully uninstalled nvidia-cuda-cupti-cu12-12.5.82
  Attempting uninstall: nvidia-cublas-cu12
    Found existing installation: nvidia-cublas-cu12 12.5.3.2
    Uninstalling nvidia-cublas-cu12-12.5.3.2:
      Successfully uninstalled nvidia-cublas-cu12-12.5.3.2
  Attempting uninstall: numpy
    Found existing installation: numpy 2.0.2
    Uninstalling numpy-2.0.2:
      Successfully uninstalled numpy-2.0.2
  Attempting uninstall: importlib-metadata
    Found existing installation: importlib_metadata 8.7.0
    Uninstalling importlib_metadata-8.7.0:
      Successfully uninstalled importlib_metadata-8.7.0
  Attempting uninstall: nvidia-cusparse-cu12
    Found existing installation: nvidia-cusparse-cu12 12.5.1.3
    Uninstalling nvidia-cusparse-cu12-12.5.1.3:
      Successfully uninstalled nvidia-cusparse-cu12-12.5.1.3
  Attempting uninstall: nvidia-cudnn-cu12
    Found existing installation: nvidia-cudnn-cu12 9.3.0.75
    Uninstalling nvidia-cudnn-cu12-9.3.0.75:
      Successfully uninstalled nvidia-cudnn-cu12-9.3.0.75
  Attempting uninstall: openai
    Found existing installation: openai 1.81.0
    Uninstalling openai-1.81.0:
      Successfully uninstalled openai-1.81.0
  Attempting uninstall: nvidia-cusolver-cu12
    Found existing installation: nvidia-cusolver-cu12 11.6.3.83
    Uninstalling nvidia-cusolver-cu12-11.6.3.83:
      Successfully uninstalled nvidia-cusolver-cu12-11.6.3.83
  Attempting uninstall: langsmith
    Found existing installation: langsmith 0.3.42
    Uninstalling langsmith-0.3.42:
      Successfully uninstalled langsmith-0.3.42
  Attempting uninstall: langchain-core
    Found existing installation: langchain-core 0.3.60
    Uninstalling langchain-core-0.3.60:
      Successfully uninstalled langchain-core-0.3.60
  Attempting uninstall: sentence-transformers
    Found existing installation: sentence-transformers 4.1.0
    Uninstalling sentence-transformers-4.1.0:
      Successfully uninstalled sentence-transformers-4.1.0
  Attempting uninstall: langchain-text-splitters
    Found existing installation: langchain-text-splitters 0.3.8
    Uninstalling langchain-text-splitters-0.3.8:
      Successfully uninstalled langchain-text-splitters-0.3.8
  Attempting uninstall: langchain
    Found existing installation: langchain 0.3.25
    Uninstalling langchain-0.3.25:
      Successfully uninstalled langchain-0.3.25
<span class="ansi-red-fg">ERROR: pip's dependency resolver does not currently take into account all the packages that are installed. This behaviour is the source of the following dependency conflicts.
thinc 8.3.6 requires numpy&lt;3.0.0,&gt;=2.0.0, but you have numpy 1.26.4 which is incompatible.</span><span class="ansi-red-fg">
</span>Successfully installed aiosqlite-0.21.0 asgiref-3.8.1 backoff-2.2.1 banks-2.1.2 bcrypt-4.3.0 chroma-hnswlib-0.7.3 chromadb-0.5.3 colorama-0.4.6 coloredlogs-15.0.1 dataclasses-json-0.6.7 deprecated-1.2.18 dirtyjson-1.0.8 durationpy-0.10 fastapi-0.115.12 filetype-1.2.0 griffe-1.7.3 groq-0.26.0 httptools-0.6.4 humanfriendly-10.0 importlib-metadata-8.6.1 kubernetes-32.0.1 langchain-0.2.7 langchain-community-0.2.7 langchain-core-0.2.43 langchain-experimental-0.0.62 langchain-huggingface-0.0.3 langchain-openai-0.1.14 langchain-text-splitters-0.2.4 langgraph-0.4.5 langgraph-checkpoint-2.0.26 langgraph-prebuilt-0.1.8 langgraph-sdk-0.1.70 langsmith-0.1.147 lark-1.1.9 llama-index-core-0.12.38 llama-index-llms-langchain-0.6.1 llama-index-readers-file-0.4.8 llama-parse-0.5.11 marshmallow-3.26.1 mem0ai-0.1.102 mmh3-5.1.0 mypy-extensions-1.1.0 numpy-1.26.4 nvidia-cublas-cu12-12.4.5.8 nvidia-cuda-cupti-cu12-12.4.127 nvidia-cuda-nvrtc-cu12-12.4.127 nvidia-cuda-runtime-cu12-12.4.127 nvidia-cudnn-cu12-9.1.0.70 nvidia-cufft-cu12-11.2.1.3 nvidia-curand-cu12-10.3.5.147 nvidia-cusolver-cu12-11.6.1.9 nvidia-cusparse-cu12-12.3.1.170 nvidia-nvjitlink-cu12-12.4.127 onnxruntime-1.22.0 openai-1.55.3 opentelemetry-api-1.33.1 opentelemetry-exporter-otlp-proto-common-1.33.1 opentelemetry-exporter-otlp-proto-grpc-1.33.1 opentelemetry-instrumentation-0.54b1 opentelemetry-instrumentation-asgi-0.54b1 opentelemetry-instrumentation-fastapi-0.54b1 opentelemetry-proto-1.33.1 opentelemetry-sdk-1.33.1 opentelemetry-semantic-conventions-0.54b1 opentelemetry-util-http-0.54b1 ormsgpack-1.10.0 overrides-7.7.0 portalocker-2.10.1 posthog-4.2.0 pypdf-5.5.0 pypika-0.48.9 python-dotenv-1.0.1 qdrant-client-1.14.2 sentence-transformers-3.0.1 starlette-0.46.2 striprtf-0.0.26 tenacity-8.5.0 typing-inspect-0.9.0 uvicorn-0.34.2 uvloop-0.21.0 watchfiles-1.0.5
</pre>
</div>
</div>
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[7]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="kn">import</span><span class="w"> </span><span class="nn">os</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">chromadb</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">numpy</span><span class="w"> </span><span class="k">as</span><span class="w"> </span><span class="nn">np</span>
<span class="n">np</span><span class="o">.</span><span class="n">float_</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">float64</span>

<span class="kn">from</span><span class="w"> </span><span class="nn">dotenv</span><span class="w"> </span><span class="kn">import</span> <span class="n">load_dotenv</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">json</span>

<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_core.documents</span><span class="w"> </span><span class="kn">import</span> <span class="n">Document</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_community.vectorstores</span><span class="w"> </span><span class="kn">import</span> <span class="n">Chroma</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_openai</span><span class="w"> </span><span class="kn">import</span> <span class="n">OpenAIEmbeddings</span><span class="p">,</span> <span class="n">ChatOpenAI</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_openai</span><span class="w"> </span><span class="kn">import</span> <span class="n">ChatOpenAI</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.embeddings</span><span class="w"> </span><span class="kn">import</span> <span class="n">OpenAIEmbeddings</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_openai</span><span class="w"> </span><span class="kn">import</span> <span class="n">OpenAIEmbeddings</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_community.document_loaders</span><span class="w"> </span><span class="kn">import</span> <span class="n">PyPDFDirectoryLoader</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_experimental.text_splitter</span><span class="w"> </span><span class="kn">import</span> <span class="n">SemanticChunker</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.chains.query_constructor.base</span><span class="w"> </span><span class="kn">import</span> <span class="n">AttributeInfo</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.retrievers.self_query.base</span><span class="w"> </span><span class="kn">import</span> <span class="n">SelfQueryRetriever</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.retrievers.document_compressors</span><span class="w"> </span><span class="kn">import</span> <span class="n">LLMChainExtractor</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.retrievers</span><span class="w"> </span><span class="kn">import</span> <span class="n">ContextualCompressionRetriever</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.retrievers.document_compressors</span><span class="w"> </span><span class="kn">import</span> <span class="n">CrossEncoderReranker</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_community.cross_encoders</span><span class="w"> </span><span class="kn">import</span> <span class="n">HuggingFaceCrossEncoder</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.text_splitter</span><span class="w"> </span><span class="kn">import</span> <span class="p">(</span>
    <span class="n">CharacterTextSplitter</span><span class="p">,</span>  <span class="c1"># Splitting text by characters</span>
    <span class="n">RecursiveCharacterTextSplitter</span>  <span class="c1"># Recursive splitting of text by characters</span>
<span class="p">)</span>

<span class="kn">from</span><span class="w"> </span><span class="nn">llama_parse</span><span class="w"> </span><span class="kn">import</span> <span class="n">LlamaParse</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">llama_index.core</span><span class="w"> </span><span class="kn">import</span> <span class="n">Settings</span><span class="p">,</span> <span class="n">SimpleDirectoryReader</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h2 id="1.2-Setting-Up-Data-and-LLM-Configuration"><strong>1.2 Setting Up Data and LLM Configuration</strong><a class="anchor-link" href="#1.2-Setting-Up-Data-and-LLM-Configuration"></a></h2>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="Unzipping-the-Documents"><strong>Unzipping the Documents</strong><a class="anchor-link" href="#Unzipping-the-Documents"></a></h3>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[10]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Unzipping the insurance documents into the insurance_docs folder</span>
<span class="err">!</span><span class="n">unzip</span> <span class="n">Nutritional_Medical_Reference</span><span class="o">.</span><span class="n">zip</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Archive:  Nutritional_Medical_Reference.zip
replace Nutritional Medical Reference/Nutritional Disorders.pdf? [y]es, [n]o, [A]ll, [N]one, [r]ename: y
  inflating: Nutritional Medical Reference/Nutritional Disorders.pdf  
</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="Configuration-Setup"><strong>Configuration Setup</strong><a class="anchor-link" href="#Configuration-Setup"></a></h3>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[11]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Define a function to read a JSON config file and return its contents as a dictionary.</span>
<span class="k">def</span><span class="w"> </span><span class="nf">read_config</span><span class="p">(</span><span class="n">config_file</span><span class="p">):</span>
<span class="w">  </span><span class="sd">"""Reads a JSON config file and returns a dictionary."""</span>
  <span class="k">with</span> <span class="nb">open</span><span class="p">(</span><span class="n">config_file</span><span class="p">,</span> <span class="s1">'r'</span><span class="p">)</span> <span class="k">as</span> <span class="n">f</span><span class="p">:</span>
    <span class="k">return</span> <span class="n">json</span><span class="o">.</span><span class="n">load</span><span class="p">(</span><span class="n">f</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[12]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="n">config</span> <span class="o">=</span> <span class="n">read_config</span><span class="p">(</span><span class="s2">"config_GANLP.json"</span><span class="p">)</span>  <span class="c1">#Copy and paste the path of the config file uploaded in Colab</span>
<span class="n">config2</span> <span class="o">=</span> <span class="n">read_config</span><span class="p">(</span><span class="s2">"config2_emb_tested.json"</span><span class="p">)</span>
<span class="n">api_key</span> <span class="o">=</span> <span class="n">config</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"API_KEY"</span><span class="p">)</span>
<span class="n">endpoint</span> <span class="o">=</span> <span class="n">config</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"OPENAI_API_BASE"</span><span class="p">)</span>
<span class="n">llamaparse_api_key</span> <span class="o">=</span> <span class="n">config2</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"LLAMA_KEY"</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[13]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Initialize the OpenAI embedding function for Chroma</span>
<span class="n">embedding_function</span> <span class="o">=</span> <span class="n">chromadb</span><span class="o">.</span><span class="n">utils</span><span class="o">.</span><span class="n">embedding_functions</span><span class="o">.</span><span class="n">OpenAIEmbeddingFunction</span><span class="p">(</span>
    <span class="n">api_base</span><span class="o">=</span><span class="n">endpoint</span><span class="p">,</span>
    <span class="n">api_key</span><span class="o">=</span><span class="n">api_key</span><span class="p">,</span>
    <span class="n">model_name</span><span class="o">=</span><span class="s1">'text-embedding-ada-002'</span>
<span class="p">)</span>
<span class="c1"># This initializes the OpenAI embedding function for the Chroma vectorstore, using the provided endpoint and API key.</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[14]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Initialize the OpenAI Embeddings</span>
<span class="n">embedding_model</span> <span class="o">=</span> <span class="n">OpenAIEmbeddings</span><span class="p">(</span>
    <span class="n">openai_api_base</span><span class="o">=</span><span class="n">endpoint</span><span class="p">,</span>
    <span class="n">openai_api_key</span><span class="o">=</span><span class="n">api_key</span><span class="p">,</span>
    <span class="n">model</span><span class="o">=</span><span class="s1">'text-embedding-ada-002'</span>
<span class="p">)</span>
<span class="c1"># This initializes the OpenAI embeddings model using the specified endpoint, API key, and model name.</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[15]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Initialize the Chat OpenAI model</span>
<span class="n">llm</span> <span class="o">=</span> <span class="n">ChatOpenAI</span><span class="p">(</span>
    <span class="n">openai_api_base</span><span class="o">=</span><span class="n">endpoint</span><span class="p">,</span>
    <span class="n">openai_api_key</span><span class="o">=</span><span class="n">api_key</span><span class="p">,</span>
    <span class="n">model</span><span class="o">=</span><span class="s2">"gpt-4o-mini"</span><span class="p">,</span>
    <span class="n">streaming</span><span class="o">=</span><span class="kc">False</span>
<span class="p">)</span>
<span class="c1"># This initializes the Chat OpenAI model using the provided endpoint, API key, deployment name.</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[16]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># set the LLM and embedding model in the LlamaIndex settings.</span>
<span class="n">Settings</span><span class="o">.</span><span class="n">llm</span> <span class="o">=</span> <span class="n">llm</span>
<span class="n">Settings</span><span class="o">.</span><span class="n">embedding</span> <span class="o">=</span> <span class="n">embedding_model</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h2 id="1.3-Parsing-and-Extracting-Tables-from-the-Documents"><strong>1.3 Parsing and Extracting Tables from the Documents</strong><a class="anchor-link" href="#1.3-Parsing-and-Extracting-Tables-from-the-Documents"></a></h2>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Setting Up Async Environment for LlamaParse</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[17]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Import necessary library for async operations in notebooks</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">nest_asyncio</span>

<span class="c1"># Apply the nested async loop to allow async code execution in the notebook</span>
<span class="n">nest_asyncio</span><span class="o">.</span><span class="n">apply</span><span class="p">()</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Initializing LlamaParse for PDF Parsing</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[18]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Import LlamaParse for parsing documents</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">llama_parse</span><span class="w"> </span><span class="kn">import</span> <span class="n">LlamaParse</span>

<span class="c1"># Initialize LlamaParse with desired settings</span>
<span class="n">parser</span> <span class="o">=</span> <span class="n">LlamaParse</span><span class="p">(</span>
    <span class="n">result_type</span><span class="o">=</span><span class="s2">"markdown"</span><span class="p">,</span>  <span class="c1"># Specify the result format</span>
    <span class="n">skip_diagonal_text</span><span class="o">=</span><span class="kc">True</span><span class="p">,</span>  <span class="c1"># Skip diagonal text in the PDFs</span>
    <span class="n">fast_mode</span><span class="o">=</span><span class="kc">False</span><span class="p">,</span>  <span class="c1"># Use normal mode for parsing</span>
    <span class="n">num_workers</span><span class="o">=</span><span class="mi">9</span><span class="p">,</span>  <span class="c1"># Number of workers for parallel processing</span>
    <span class="n">check_interval</span><span class="o">=</span><span class="mi">10</span><span class="p">,</span>  <span class="c1"># Check interval for processing</span>
    <span class="n">api_key</span><span class="o">=</span><span class="n">llamaparse_api_key</span>  <span class="c1"># API key for LlamaParse</span>
<span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Parsing Content from PDFs</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[19]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="kn">import</span><span class="w"> </span><span class="nn">os</span>

<span class="c1"># List to store parsed JSON objects</span>
<span class="n">json_objs</span> <span class="o">=</span> <span class="p">[]</span>

<span class="c1"># Define the folder containing the documents</span>
<span class="n">folder_path</span> <span class="o">=</span> <span class="s2">"Nutritional Medical Reference"</span>

<span class="c1"># Iterate through PDFs in the folder and parse content</span>
<span class="k">for</span> <span class="n">pdf</span> <span class="ow">in</span> <span class="n">os</span><span class="o">.</span><span class="n">listdir</span><span class="p">(</span><span class="n">folder_path</span><span class="p">):</span>
    <span class="k">if</span> <span class="n">pdf</span><span class="o">.</span><span class="n">endswith</span><span class="p">(</span><span class="s2">".pdf"</span><span class="p">):</span>
        <span class="n">pdf_path</span> <span class="o">=</span> <span class="n">os</span><span class="o">.</span><span class="n">path</span><span class="o">.</span><span class="n">join</span><span class="p">(</span><span class="n">folder_path</span><span class="p">,</span> <span class="n">pdf</span><span class="p">)</span>
        <span class="n">json_objs</span><span class="o">.</span><span class="n">extend</span><span class="p">(</span><span class="n">parser</span><span class="o">.</span><span class="n">get_json_result</span><span class="p">(</span><span class="n">pdf_path</span><span class="p">))</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Started parsing the file under job_id 3727e792-2ec8-4cdc-9be4-6dc5dd920a62
</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Inspecting Parsed JSON Object</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[20]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Pretty print JSON object for inspection</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">json</span>

<span class="nb">print</span><span class="p">(</span><span class="n">json</span><span class="o">.</span><span class="n">dumps</span><span class="p">(</span><span class="n">json_objs</span><span class="p">[</span><span class="mi">0</span><span class="p">],</span> <span class="n">indent</span><span class="o">=</span><span class="mi">4</span><span class="p">))</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>{
    "pages": [
        {
            "page": 1,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition          Chapter 1. Nutrition: General Considerations\n 1 - Nutritional Disorders\n Chapter 1. Nutrition: General Considerations\n Introduction\n Nutrition is the science of food and its relationship to health. Nutrients are chemicals in foods that are\n used by the body for growth, maintenance, and energy. Nutrients that cannot be synthesized by the body\n and thus must be derived from the diet are considered essential. They include vitamins, minerals, some\n amino acids, and some fatty acids. Nutrients that the body can synthesize from other compounds,\n although they may also be derived from the diet, are considered nonessential. Macronutrients are\n required by the body in relatively large amounts; micronutrients are needed in minute amounts.\n Lack of nutrients can result in deficiency syndromes (eg, kwashiorkor, pellagra) or other disorders (see p.\n 9). Excess intake of macronutrients can lead to obesity (see p. 56) and related disorders; excess intake of\n micro-nutrients can be toxic. Also, the balance of various types of nutrients, such as how much\n usaturated vs saturated fat is consumed, can influence the development of disorders.\n Macronutrients\n Macronutrients constitute the bulk of the diet and supply energy and many essential nutrients.\n Carbohydrates, proteins (including essential amino acids), fats (including essential fatty acids),\n macrominerals, and water are macronutrients. Carbohydrates, fats, and proteins are interchangeable as\n sources of energy; fats yield 9 kcal/g (37.8 kJ/g); proteins and carbohydrates yield 4 kcal/g (16.8 kJ/g).\n Carbohydrates: Dietary carbohydrates are broken down into glucose and other monosaccharides.\n Carbohydrates increase blood glucose levels, supplying energy. Simple carbohydrates are composed of\n small molecules, generally monosaccharides or disaccharides, which increase blood glucose levels\n rapidly. Complex carbohydrates are composed of larger molecules, which are broken down into\n monosaccharides. Complex carbohydrates increase blood glucose levels more slowly but for a longer\n time. Glucose and sucrose are simple carbohydrates; starches and fiber are complex carbohydrates.\n The glycemic index measures how rapidly consumption of a carbohydrate increases plasma glucose\n levels. Values range from 1 (the slowest increase) to 100 (the fastest increase, equivalent to pure glucose\n \u2014see\n Table 1-1). However, the actual rate of increase also depends on what foods are consumed with the\n carbohydrate.\n Carbohydrates with a high glycemic index may increase plasma glucose to high levels rapidly. It is\n hypothesized that, as a result, insulin levels increase, inducing hypoglycemia and hunger, which tends to\n lead to consumption of excess calories and weight gain. Carbohydrates with a low glycemic index\n increase plasma glucose levels slowly, resulting in lower postprandial insulin levels and less hunger,\n which probably makes consumption of excess calories less likely. These effects are predicted to result in\n a more favorable lipid profile and a decreased risk of obesity, diabetes mellitus, and complications of\n diabetes if present.\n Proteins: Dietary proteins are broken down into peptides and amino acids. Proteins are required for\n tissue maintenance, replacement, function, and growth. However, if the body is not getting enough\n calories from dietary sources or tissue stores (particularly of fat), protein may be used for energy.\n As the body uses dietary protein for tissue production, there is a net gain of protein (positive nitrogen\n balance). During catabolic\n [Table 1-1. Glycemic Index of Some Foods]\n states (eg, starvation, infections, burns), more protein may be used (because body tissues are broken\n down) than is absorbed, resulting in a net loss of protein (negative nitrogen balance). Nitrogen balance is\n best determined by subtracting the amount of nitrogen excreted in urine and feces from the amount of\n                                                                                                        53",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 1. Nutrition: General Considerations\n\n# 1 - Nutritional Disorders\n\n# Introduction\n\nNutrition is the science of food and its relationship to health. Nutrients are chemicals in foods that are used by the body for growth, maintenance, and energy. Nutrients that cannot be synthesized by the body and thus must be derived from the diet are considered essential. They include vitamins, minerals, some amino acids, and some fatty acids. Nutrients that the body can synthesize from other compounds, although they may also be derived from the diet, are considered nonessential. Macronutrients are required by the body in relatively large amounts; micronutrients are needed in minute amounts.\n\nLack of nutrients can result in deficiency syndromes (eg, kwashiorkor, pellagra) or other disorders (see p. 9). Excess intake of macronutrients can lead to obesity (see p. 56) and related disorders; excess intake of micronutrients can be toxic. Also, the balance of various types of nutrients, such as how much unsaturated vs saturated fat is consumed, can influence the development of disorders.\n\n# Macronutrients\n\nMacronutrients constitute the bulk of the diet and supply energy and many essential nutrients. Carbohydrates, proteins (including essential amino acids), fats (including essential fatty acids), macrominerals, and water are macronutrients. Carbohydrates, fats, and proteins are interchangeable as sources of energy; fats yield 9 kcal/g (37.8 kJ/g); proteins and carbohydrates yield 4 kcal/g (16.8 kJ/g).\n\n# Carbohydrates\n\nDietary carbohydrates are broken down into glucose and other monosaccharides. Carbohydrates increase blood glucose levels, supplying energy. Simple carbohydrates are composed of small molecules, generally monosaccharides or disaccharides, which increase blood glucose levels rapidly. Complex carbohydrates are composed of larger molecules, which are broken down into monosaccharides. Complex carbohydrates increase blood glucose levels more slowly but for a longer time. Glucose and sucrose are simple carbohydrates; starches and fiber are complex carbohydrates.\n\nThe glycemic index measures how rapidly consumption of a carbohydrate increases plasma glucose levels. Values range from 1 (the slowest increase) to 100 (the fastest increase, equivalent to pure glucose \u2014see Table 1-1). However, the actual rate of increase also depends on what foods are consumed with the carbohydrate.\n\nCarbohydrates with a high glycemic index may increase plasma glucose to high levels rapidly. It is hypothesized that, as a result, insulin levels increase, inducing hypoglycemia and hunger, which tends to lead to consumption of excess calories and weight gain. Carbohydrates with a low glycemic index increase plasma glucose levels slowly, resulting in lower postprandial insulin levels and less hunger, which probably makes consumption of excess calories less likely. These effects are predicted to result in a more favorable lipid profile and a decreased risk of obesity, diabetes mellitus, and complications of diabetes if present.\n\n# Proteins\n\nDietary proteins are broken down into peptides and amino acids. Proteins are required for tissue maintenance, replacement, function, and growth. However, if the body is not getting enough calories from dietary sources or tissue stores (particularly of fat), protein may be used for energy. As the body uses dietary protein for tissue production, there is a net gain of protein (positive nitrogen balance). During catabolic states (eg, starvation, infections, burns), more protein may be used (because body tissues are broken down) than is absorbed, resulting in a net loss of protein (negative nitrogen balance). Nitrogen balance is best determined by subtracting the amount of nitrogen excreted in urine and feces from the amount of nitrogen ingested.\n\n# Table 1-1. Glycemic Index of Some Foods\n\n| Food     | Glycemic Index |\n| -------- | -------------- |\n| Glucose  | 100            |\n| Sucrose  | 65             |\n| Starches | Variable       |\n| Fiber    | 0              |\n",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 1. Nutrition: General Considerations",
                    "md": "# Chapter 1. Nutrition: General Considerations",
                    "bBox": {
                        "x": 55,
                        "y": 30.72,
                        "w": 488,
                        "h": 61.18
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "1 - Nutritional Disorders",
                    "md": "# 1 - Nutritional Disorders",
                    "bBox": {
                        "x": 55,
                        "y": 54.9,
                        "w": 119,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Introduction",
                    "md": "# Introduction",
                    "bBox": {
                        "x": 55,
                        "y": 104.9,
                        "w": 61,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Nutrition is the science of food and its relationship to health. Nutrients are chemicals in foods that are used by the body for growth, maintenance, and energy. Nutrients that cannot be synthesized by the body and thus must be derived from the diet are considered essential. They include vitamins, minerals, some amino acids, and some fatty acids. Nutrients that the body can synthesize from other compounds, although they may also be derived from the diet, are considered nonessential. Macronutrients are required by the body in relatively large amounts; micronutrients are needed in minute amounts.\n\nLack of nutrients can result in deficiency syndromes (eg, kwashiorkor, pellagra) or other disorders (see p. 9). Excess intake of macronutrients can lead to obesity (see p. 56) and related disorders; excess intake of micronutrients can be toxic. Also, the balance of various types of nutrients, such as how much unsaturated vs saturated fat is consumed, can influence the development of disorders.",
                    "md": "Nutrition is the science of food and its relationship to health. Nutrients are chemicals in foods that are used by the body for growth, maintenance, and energy. Nutrients that cannot be synthesized by the body and thus must be derived from the diet are considered essential. They include vitamins, minerals, some amino acids, and some fatty acids. Nutrients that the body can synthesize from other compounds, although they may also be derived from the diet, are considered nonessential. Macronutrients are required by the body in relatively large amounts; micronutrients are needed in minute amounts.\n\nLack of nutrients can result in deficiency syndromes (eg, kwashiorkor, pellagra) or other disorders (see p. 9). Excess intake of macronutrients can lead to obesity (see p. 56) and related disorders; excess intake of micronutrients can be toxic. Also, the balance of various types of nutrients, such as how much unsaturated vs saturated fat is consumed, can influence the development of disorders.",
                    "bBox": {
                        "x": 55,
                        "y": 130.9,
                        "w": 483,
                        "h": 164
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Macronutrients",
                    "md": "# Macronutrients",
                    "bBox": {
                        "x": 55,
                        "y": 282.9,
                        "w": 76,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Macronutrients constitute the bulk of the diet and supply energy and many essential nutrients. Carbohydrates, proteins (including essential amino acids), fats (including essential fatty acids), macrominerals, and water are macronutrients. Carbohydrates, fats, and proteins are interchangeable as sources of energy; fats yield 9 kcal/g (37.8 kJ/g); proteins and carbohydrates yield 4 kcal/g (16.8 kJ/g).",
                    "md": "Macronutrients constitute the bulk of the diet and supply energy and many essential nutrients. Carbohydrates, proteins (including essential amino acids), fats (including essential fatty acids), macrominerals, and water are macronutrients. Carbohydrates, fats, and proteins are interchangeable as sources of energy; fats yield 9 kcal/g (37.8 kJ/g); proteins and carbohydrates yield 4 kcal/g (16.8 kJ/g).",
                    "bBox": {
                        "x": 55,
                        "y": 282.9,
                        "w": 474,
                        "h": 75
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Carbohydrates",
                    "md": "# Carbohydrates",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Dietary carbohydrates are broken down into glucose and other monosaccharides. Carbohydrates increase blood glucose levels, supplying energy. Simple carbohydrates are composed of small molecules, generally monosaccharides or disaccharides, which increase blood glucose levels rapidly. Complex carbohydrates are composed of larger molecules, which are broken down into monosaccharides. Complex carbohydrates increase blood glucose levels more slowly but for a longer time. Glucose and sucrose are simple carbohydrates; starches and fiber are complex carbohydrates.\n\nThe glycemic index measures how rapidly consumption of a carbohydrate increases plasma glucose levels. Values range from 1 (the slowest increase) to 100 (the fastest increase, equivalent to pure glucose \u2014see Table 1-1). However, the actual rate of increase also depends on what foods are consumed with the carbohydrate.\n\nCarbohydrates with a high glycemic index may increase plasma glucose to high levels rapidly. It is hypothesized that, as a result, insulin levels increase, inducing hypoglycemia and hunger, which tends to lead to consumption of excess calories and weight gain. Carbohydrates with a low glycemic index increase plasma glucose levels slowly, resulting in lower postprandial insulin levels and less hunger, which probably makes consumption of excess calories less likely. These effects are predicted to result in a more favorable lipid profile and a decreased risk of obesity, diabetes mellitus, and complications of diabetes if present.",
                    "md": "Dietary carbohydrates are broken down into glucose and other monosaccharides. Carbohydrates increase blood glucose levels, supplying energy. Simple carbohydrates are composed of small molecules, generally monosaccharides or disaccharides, which increase blood glucose levels rapidly. Complex carbohydrates are composed of larger molecules, which are broken down into monosaccharides. Complex carbohydrates increase blood glucose levels more slowly but for a longer time. Glucose and sucrose are simple carbohydrates; starches and fiber are complex carbohydrates.\n\nThe glycemic index measures how rapidly consumption of a carbohydrate increases plasma glucose levels. Values range from 1 (the slowest increase) to 100 (the fastest increase, equivalent to pure glucose \u2014see Table 1-1). However, the actual rate of increase also depends on what foods are consumed with the carbohydrate.\n\nCarbohydrates with a high glycemic index may increase plasma glucose to high levels rapidly. It is hypothesized that, as a result, insulin levels increase, inducing hypoglycemia and hunger, which tends to lead to consumption of excess calories and weight gain. Carbohydrates with a low glycemic index increase plasma glucose levels slowly, resulting in lower postprandial insulin levels and less hunger, which probably makes consumption of excess calories less likely. These effects are predicted to result in a more favorable lipid profile and a decreased risk of obesity, diabetes mellitus, and complications of diabetes if present.",
                    "bBox": {
                        "x": 55,
                        "y": 383.9,
                        "w": 482,
                        "h": 240
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Proteins",
                    "md": "# Proteins",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Dietary proteins are broken down into peptides and amino acids. Proteins are required for tissue maintenance, replacement, function, and growth. However, if the body is not getting enough calories from dietary sources or tissue stores (particularly of fat), protein may be used for energy. As the body uses dietary protein for tissue production, there is a net gain of protein (positive nitrogen balance). During catabolic states (eg, starvation, infections, burns), more protein may be used (because body tissues are broken down) than is absorbed, resulting in a net loss of protein (negative nitrogen balance). Nitrogen balance is best determined by subtracting the amount of nitrogen excreted in urine and feces from the amount of nitrogen ingested.",
                    "md": "Dietary proteins are broken down into peptides and amino acids. Proteins are required for tissue maintenance, replacement, function, and growth. However, if the body is not getting enough calories from dietary sources or tissue stores (particularly of fat), protein may be used for energy. As the body uses dietary protein for tissue production, there is a net gain of protein (positive nitrogen balance). During catabolic states (eg, starvation, infections, burns), more protein may be used (because body tissues are broken down) than is absorbed, resulting in a net loss of protein (negative nitrogen balance). Nitrogen balance is best determined by subtracting the amount of nitrogen excreted in urine and feces from the amount of nitrogen ingested.",
                    "bBox": {
                        "x": 55,
                        "y": 649.9,
                        "w": 480,
                        "h": 139
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Table 1-1. Glycemic Index of Some Foods",
                    "md": "# Table 1-1. Glycemic Index of Some Foods",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "table",
                    "rows": [
                        [
                            "Food",
                            "Glycemic Index"
                        ],
                        [
                            "Glucose",
                            "100"
                        ],
                        [
                            "Sucrose",
                            "65"
                        ],
                        [
                            "Starches",
                            "Variable"
                        ],
                        [
                            "Fiber",
                            "0"
                        ]
                    ],
                    "md": "| Food     | Glycemic Index |\n| -------- | -------------- |\n| Glucose  | 100            |\n| Sucrose  | 65             |\n| Starches | Variable       |\n| Fiber    | 0              |",
                    "isPerfectTable": true,
                    "csv": "\"Food\",\"Glycemic Index\"\n\"Glucose\",\"100\"\n\"Sucrose\",\"65\"\n\"Starches\",\"Variable\"\n\"Fiber\",\"0\"",
                    "bBox": {
                        "x": 55,
                        "y": 130.9,
                        "w": 482,
                        "h": 607
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.977
        },
        {
            "page": 2,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition           Chapter 1. Nutrition: General Considerations\n nitrogen consumed.\n Of the 20 amino acids, 9 are essential amino acids (EAAs); they cannot be synthesized and must be\n obtained from the diet. All people require 8 EAAs; infants also require histidine.\n The weight-adjusted requirement for dietary protein correlates with growth rate, which decreases from\n infancy until adulthood. The daily dietary protein requirement decreases from 2.2 g/kg in 3-mo-old infants\n to 1.2 g/kg in 5-yr-old children and to 0.8 g/kg in adults. Protein requirements correspond to EAA\n requirements (see\n Table 1-2). Adults trying to increase muscle mass need very little extra protein beyond the requirements in\n the table.\n The amino acid composition of protein varies widely. Biological value (BV) reflects the similarity in amino\n acid composition of protein to that of animal tissues; thus, BV indicates what percentage of a dietary\n protein provides EAAs for the body. A perfect match is egg protein, with a value of 100. Animal proteins in\n milk and meat have a high BV (~90); proteins in cereal and vegetables have a lower BV (~40), and some\n derived proteins (eg, gelatin) have a BV of 0. The extent to which dietary proteins supply each other's\n missing amino acids (complementarity) determines the overall BV of the diet. The recommended daily\n allowances (RDA) for protein assumes that the average mixed diet has a BV of 70.\n Fats: Fats are broken down into fatty acids and glycerol. Fats are required for tissue growth and hormone\n production. Saturated fatty acids, common in animal fats, tend to be solid at room temperature. Except for\n palm and coconut oils, fats derived from plants tend to be liquid at room temperature; these fats contain\n high levels of monounsaturated fatty acids or polyunsaturated fatty acids (PUFAs).\n Partial hydrogenation of unsaturated fatty acids (as occurs during food manufacturing) produces trans\n fatty acids, which are solid or semisolid at room temperature. In the US, the main dietary source of trans\n fatty acids is partially hydrogenated vegetable oils, used in manufacturing certain foods (eg, cookies,\n crackers, chips) to prolong shelf-life. Trans fatty acids may elevate LDL cholesterol and lower HDL; they\n may also independently increase the risk of coronary artery disease.\n Essential fatty acids (EFAs) are linoleic acid, an \u03c9-6 (n-6) fatty acid, and linolenic acid, an \u03c9-3 (n-3) fatty\n acid. Other \u03c9-6 acids (eg, arachidonic acid) and other \u03c9-3 fatty acids (eg, eicosapentaenoic acid,\n docosahexaenoic acid) are required by the body but can be synthesized from EFAs.\n EFAs (see also p. 19) are needed for the formation of various eicosanoids (biologically active lipids),\n including prostaglandins, thromboxanes, prostacyclins, and leukotrienes. Consumption of \u03c9-3 fatty acids\n may decrease the risk of coronary artery disease.\n [Table 1-2. Essential Amino Acid Requirements in mg/kg Body Weight]\n Requirements for EFAs vary by age. Adults require amounts of linoleic acid equal to at least 2% of total\n caloric needs and linolenic acid equal to at least 0.5%. Vegetable oils provide linoleic acid and linolenic\n acid. Oils made from safflower, sunflower, corn, soya, primrose, pumpkin, and wheat germ provide large\n amounts of linoleic acid. Marine fish oils and oils made from flax-seeds, pumpkin, soy, and canola provide\n large amounts of linolenic acid. Marine fish oils also provide some other \u03c9-3 fatty acids in large amounts.\n Macrominerals: Na, Cl, K, Ca, P, and Mg are required in relatively large amounts per day (see\n Tables 1-3,\n 1-4, and\n 5-2).\n Water: Water is considered a macronutrient because it is required in amounts of 1 mL/kcal (0.24 mL/kJ)\n of energy expended, or about 2500 mL/day. Needs vary with fever, physical activity, and changes in\n climate and humidity.\n [Table 1-3. Macrominerals]\n                                                                                                         54",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 1. Nutrition: General Considerations\n\nNitrogen consumed. Of the 20 amino acids, 9 are essential amino acids (EAAs); they cannot be synthesized and must be obtained from the diet. All people require 8 EAAs; infants also require histidine.\n\nThe weight-adjusted requirement for dietary protein correlates with growth rate, which decreases from infancy until adulthood. The daily dietary protein requirement decreases from 2.2 g/kg in 3-mo-old infants to 1.2 g/kg in 5-yr-old children and to 0.8 g/kg in adults. Protein requirements correspond to EAA requirements (see Table 1-2). Adults trying to increase muscle mass need very little extra protein beyond the requirements in the table.\n\nThe amino acid composition of protein varies widely. Biological value (BV) reflects the similarity in amino acid composition of protein to that of animal tissues; thus, BV indicates what percentage of a dietary protein provides EAAs for the body. A perfect match is egg protein, with a value of 100. Animal proteins in milk and meat have a high BV (~90); proteins in cereal and vegetables have a lower BV (~40), and some derived proteins (eg, gelatin) have a BV of 0. The extent to which dietary proteins supply each other's missing amino acids (complementarity) determines the overall BV of the diet. The recommended daily allowances (RDA) for protein assumes that the average mixed diet has a BV of 70.\n\n# Fats\n\nFats are broken down into fatty acids and glycerol. Fats are required for tissue growth and hormone production. Saturated fatty acids, common in animal fats, tend to be solid at room temperature. Except for palm and coconut oils, fats derived from plants tend to be liquid at room temperature; these fats contain high levels of monounsaturated fatty acids or polyunsaturated fatty acids (PUFAs).\n\nPartial hydrogenation of unsaturated fatty acids (as occurs during food manufacturing) produces trans fatty acids, which are solid or semisolid at room temperature. In the US, the main dietary source of trans fatty acids is partially hydrogenated vegetable oils, used in manufacturing certain foods (eg, cookies, crackers, chips) to prolong shelf-life. Trans fatty acids may elevate LDL cholesterol and lower HDL; they may also independently increase the risk of coronary artery disease.\n\nEssential fatty acids (EFAs) are linoleic acid, an \u03c9-6 (n-6) fatty acid, and linolenic acid, an \u03c9-3 (n-3) fatty acid. Other \u03c9-6 acids (eg, arachidonic acid) and other \u03c9-3 fatty acids (eg, eicosapentaenoic acid, docosahexaenoic acid) are required by the body but can be synthesized from EFAs.\n\nEFAs (see also p. 19) are needed for the formation of various eicosanoids (biologically active lipids), including prostaglandins, thromboxanes, prostacyclins, and leukotrienes. Consumption of \u03c9-3 fatty acids may decrease the risk of coronary artery disease.\n\n# Essential Amino Acid Requirements in mg/kg Body Weight\n\nRequirements for EFAs vary by age. Adults require amounts of linoleic acid equal to at least 2% of total caloric needs and linolenic acid equal to at least 0.5%. Vegetable oils provide linoleic acid and linolenic acid. Oils made from safflower, sunflower, corn, soya, primrose, pumpkin, and wheat germ provide large amounts of linoleic acid. Marine fish oils and oils made from flax-seeds, pumpkin, soy, and canola provide large amounts of linolenic acid. Marine fish oils also provide some other \u03c9-3 fatty acids in large amounts.\n# Macrominerals\n\nNa, Cl, K, Ca, P, and Mg are required in relatively large amounts per day (see Tables 1-3, 1-4, and 5-2).\n\n# Water\n\nWater is considered a macronutrient because it is required in amounts of 1 mL/kcal (0.24 mL/kJ) of energy expended, or about 2500 mL/day. Needs vary with fever, physical activity, and changes in climate and humidity.\n\n# Macrominerals\n\nTable 1-3. Macrominerals",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 1. Nutrition: General Considerations",
                    "md": "# Chapter 1. Nutrition: General Considerations",
                    "bBox": {
                        "x": 345,
                        "y": 30.72,
                        "w": 198,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "Nitrogen consumed. Of the 20 amino acids, 9 are essential amino acids (EAAs); they cannot be synthesized and must be obtained from the diet. All people require 8 EAAs; infants also require histidine.\n\nThe weight-adjusted requirement for dietary protein correlates with growth rate, which decreases from infancy until adulthood. The daily dietary protein requirement decreases from 2.2 g/kg in 3-mo-old infants to 1.2 g/kg in 5-yr-old children and to 0.8 g/kg in adults. Protein requirements correspond to EAA requirements (see Table 1-2). Adults trying to increase muscle mass need very little extra protein beyond the requirements in the table.\n\nThe amino acid composition of protein varies widely. Biological value (BV) reflects the similarity in amino acid composition of protein to that of animal tissues; thus, BV indicates what percentage of a dietary protein provides EAAs for the body. A perfect match is egg protein, with a value of 100. Animal proteins in milk and meat have a high BV (~90); proteins in cereal and vegetables have a lower BV (~40), and some derived proteins (eg, gelatin) have a BV of 0. The extent to which dietary proteins supply each other's missing amino acids (complementarity) determines the overall BV of the diet. The recommended daily allowances (RDA) for protein assumes that the average mixed diet has a BV of 70.",
                    "md": "Nitrogen consumed. Of the 20 amino acids, 9 are essential amino acids (EAAs); they cannot be synthesized and must be obtained from the diet. All people require 8 EAAs; infants also require histidine.\n\nThe weight-adjusted requirement for dietary protein correlates with growth rate, which decreases from infancy until adulthood. The daily dietary protein requirement decreases from 2.2 g/kg in 3-mo-old infants to 1.2 g/kg in 5-yr-old children and to 0.8 g/kg in adults. Protein requirements correspond to EAA requirements (see Table 1-2). Adults trying to increase muscle mass need very little extra protein beyond the requirements in the table.\n\nThe amino acid composition of protein varies widely. Biological value (BV) reflects the similarity in amino acid composition of protein to that of animal tissues; thus, BV indicates what percentage of a dietary protein provides EAAs for the body. A perfect match is egg protein, with a value of 100. Animal proteins in milk and meat have a high BV (~90); proteins in cereal and vegetables have a lower BV (~40), and some derived proteins (eg, gelatin) have a BV of 0. The extent to which dietary proteins supply each other's missing amino acids (complementarity) determines the overall BV of the diet. The recommended daily allowances (RDA) for protein assumes that the average mixed diet has a BV of 70.",
                    "bBox": {
                        "x": 55,
                        "y": 50.9,
                        "w": 482,
                        "h": 240
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Fats",
                    "md": "# Fats",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Fats are broken down into fatty acids and glycerol. Fats are required for tissue growth and hormone production. Saturated fatty acids, common in animal fats, tend to be solid at room temperature. Except for palm and coconut oils, fats derived from plants tend to be liquid at room temperature; these fats contain high levels of monounsaturated fatty acids or polyunsaturated fatty acids (PUFAs).\n\nPartial hydrogenation of unsaturated fatty acids (as occurs during food manufacturing) produces trans fatty acids, which are solid or semisolid at room temperature. In the US, the main dietary source of trans fatty acids is partially hydrogenated vegetable oils, used in manufacturing certain foods (eg, cookies, crackers, chips) to prolong shelf-life. Trans fatty acids may elevate LDL cholesterol and lower HDL; they may also independently increase the risk of coronary artery disease.\n\nEssential fatty acids (EFAs) are linoleic acid, an \u03c9-6 (n-6) fatty acid, and linolenic acid, an \u03c9-3 (n-3) fatty acid. Other \u03c9-6 acids (eg, arachidonic acid) and other \u03c9-3 fatty acids (eg, eicosapentaenoic acid, docosahexaenoic acid) are required by the body but can be synthesized from EFAs.\n\nEFAs (see also p. 19) are needed for the formation of various eicosanoids (biologically active lipids), including prostaglandins, thromboxanes, prostacyclins, and leukotrienes. Consumption of \u03c9-3 fatty acids may decrease the risk of coronary artery disease.",
                    "md": "Fats are broken down into fatty acids and glycerol. Fats are required for tissue growth and hormone production. Saturated fatty acids, common in animal fats, tend to be solid at room temperature. Except for palm and coconut oils, fats derived from plants tend to be liquid at room temperature; these fats contain high levels of monounsaturated fatty acids or polyunsaturated fatty acids (PUFAs).\n\nPartial hydrogenation of unsaturated fatty acids (as occurs during food manufacturing) produces trans fatty acids, which are solid or semisolid at room temperature. In the US, the main dietary source of trans fatty acids is partially hydrogenated vegetable oils, used in manufacturing certain foods (eg, cookies, crackers, chips) to prolong shelf-life. Trans fatty acids may elevate LDL cholesterol and lower HDL; they may also independently increase the risk of coronary artery disease.\n\nEssential fatty acids (EFAs) are linoleic acid, an \u03c9-6 (n-6) fatty acid, and linolenic acid, an \u03c9-3 (n-3) fatty acid. Other \u03c9-6 acids (eg, arachidonic acid) and other \u03c9-3 fatty acids (eg, eicosapentaenoic acid, docosahexaenoic acid) are required by the body but can be synthesized from EFAs.\n\nEFAs (see also p. 19) are needed for the formation of various eicosanoids (biologically active lipids), including prostaglandins, thromboxanes, prostacyclins, and leukotrienes. Consumption of \u03c9-3 fatty acids may decrease the risk of coronary artery disease.",
                    "bBox": {
                        "x": 55,
                        "y": 316.9,
                        "w": 480,
                        "h": 214
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Essential Amino Acid Requirements in mg/kg Body Weight",
                    "md": "# Essential Amino Acid Requirements in mg/kg Body Weight",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Requirements for EFAs vary by age. Adults require amounts of linoleic acid equal to at least 2% of total caloric needs and linolenic acid equal to at least 0.5%. Vegetable oils provide linoleic acid and linolenic acid. Oils made from safflower, sunflower, corn, soya, primrose, pumpkin, and wheat germ provide large amounts of linoleic acid. Marine fish oils and oils made from flax-seeds, pumpkin, soy, and canola provide large amounts of linolenic acid. Marine fish oils also provide some other \u03c9-3 fatty acids in large amounts.",
                    "md": "Requirements for EFAs vary by age. Adults require amounts of linoleic acid equal to at least 2% of total caloric needs and linolenic acid equal to at least 0.5%. Vegetable oils provide linoleic acid and linolenic acid. Oils made from safflower, sunflower, corn, soya, primrose, pumpkin, and wheat germ provide large amounts of linoleic acid. Marine fish oils and oils made from flax-seeds, pumpkin, soy, and canola provide large amounts of linolenic acid. Marine fish oils also provide some other \u03c9-3 fatty acids in large amounts.",
                    "bBox": {
                        "x": 55,
                        "y": 569.9,
                        "w": 480,
                        "h": 63
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Macrominerals",
                    "md": "# Macrominerals",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Na, Cl, K, Ca, P, and Mg are required in relatively large amounts per day (see Tables 1-3, 1-4, and 5-2).",
                    "md": "Na, Cl, K, Ca, P, and Mg are required in relatively large amounts per day (see Tables 1-3, 1-4, and 5-2).",
                    "bBox": {
                        "x": 55,
                        "y": 658.9,
                        "w": 52,
                        "h": 37
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Water",
                    "md": "# Water",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Water is considered a macronutrient because it is required in amounts of 1 mL/kcal (0.24 mL/kJ) of energy expended, or about 2500 mL/day. Needs vary with fever, physical activity, and changes in climate and humidity.",
                    "md": "Water is considered a macronutrient because it is required in amounts of 1 mL/kcal (0.24 mL/kJ) of energy expended, or about 2500 mL/day. Needs vary with fever, physical activity, and changes in climate and humidity.",
                    "bBox": {
                        "x": 55,
                        "y": 721.9,
                        "w": 454,
                        "h": 25
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Macrominerals",
                    "md": "# Macrominerals",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Table 1-3. Macrominerals",
                    "md": "Table 1-3. Macrominerals",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.994
        },
        {
            "page": 3,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition          Chapter 1. Nutrition: General Considerations\n [Table 1-4. Recommended Dietary Reference Intakes* for Some Macronutrients, Food and Nutrition\n Board, Institute of Medicine of the National Academies]\n Micronutrients\n Vitamins and minerals required in minute amounts (trace minerals) are micronutrients (see Chs. 4 and 5).\n Water-soluble vitamins are vitamin C (ascorbic acid) and 8 members of the vitamin B complex: biotin,\n folate, niacin, pantothenic acid, riboflavin (vitamin B2), thiamin (vitamin B1), vitamin B6 (pyridoxine), and\n vitamin B12 (cobalamin).\n Fat-soluble vitamins are vitamins A (retinol), D (cholecalciferol and ergocalciferol), E (\u03b1-tocopherol), and\n K (phylloquinone and menaquinone).\n Only vitamins A, E, and B12 are stored to any significant extent in the body; the other vitamins must be\n consumed regularly to maintain tissue health.\n Essential trace minerals include chromium, copper, iodine, iron, manganese, molybdenum, selenium,\n and zinc. Except for chromium, each of these is incorporated into enzymes or hormones required in\n metabolism. Except for deficiencies of iron and zinc, micromineral deficiencies are uncommon in\n developed countries (see Ch. 5).\n Other minerals (eg, aluminum, arsenic, boron, cobalt, fluoride, nickel, silicon, vanadium) have not been\n proved essential for people. Fluoride, although not essential, helps prevent tooth decay by forming a\n compound with Ca (CaF2), which stabilizes the mineral matrix in teeth.\n All trace minerals are toxic at high levels, and some (arsenic, nickel, and chromium) may cause cancer.\n Other Dietary Substances\n The daily human diet typically contains as many as 100,000 chemicals (eg, coffee contains 1000). Of\n these, only 300 are nutrients, only some of which are essential. However, many nonnutrients in foods are\n useful. For example, food additives (eg, preservatives, emulsifiers, antioxidants, stabilizers) improve the\n production and stability of foods. Trace components (eg, spices, flavors, odors, colors, phytochemicals,\n many other natural products) improve appearance and taste.\n Fiber: Fiber occurs in various forms (eg, cellulose, hemicellulose, pectin, gums). It increases GI motility,\n prevents constipation, and helps control diverticular disease. Fiber is thought to accelerate the elimination\n of cancer-causing substances produced by bacteria in the large intestine. Epidemiologic evidence\n suggests an association between colon cancer and low fiber intake and a beneficial effect of fiber in\n patients with functional bowel disorders, Crohn's disease, obesity, and hemorrhoids. Soluble fiber\n (present in fruits, vegetables, oats, barley, and legumes) reduces the postprandial increase in blood\n glucose and insulin and can reduce cholesterol levels.\n The typical Western diet is low in fiber (about 12 g/day) because of a high intake of highly refined wheat\n flour and a low intake of fruits and vegetables. Increasing fiber intake to about 30 g/day by consuming\n more vegetables, fruits, and high-fiber cereals and grains is generally recommended. However, very high\n fiber intake may reduce absorption of certain minerals.\n Nutritional Requirements\n Good nutrition aims to achieve and maintain a desirable body composition and high potential for physical\n and mental work. Balancing energy intake with energy expenditure is necessary for a desirable body\n weight. Energy expenditure depends on age, sex, weight (see Table 1-4), and metabolic and physical\n activity. If energy intake exceeds expenditure, weight is gained. Taking in about 100 calories/day more\n than needed results in a weight gain of about 4 to 5 kg in a year. If energy intake is less than expenditure,\n weight is lost.\n                                                                                                        55",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 1. Nutrition: General Considerations\n\n# [Table 1-4. Recommended Dietary Reference Intakes* for Some Macronutrients, Food and Nutrition Board, Institute of Medicine of the National Academies]\n\n# Micronutrients\n\nVitamins and minerals required in minute amounts (trace minerals) are micronutrients (see Chs. 4 and 5).\n\nWater-soluble vitamins are vitamin C (ascorbic acid) and 8 members of the vitamin B complex: biotin, folate, niacin, pantothenic acid, riboflavin (vitamin B2), thiamin (vitamin B1), vitamin B6 (pyridoxine), and vitamin B12 (cobalamin).\n\nFat-soluble vitamins are vitamins A (retinol), D (cholecalciferol and ergocalciferol), E (\u03b1-tocopherol), and K (phylloquinone and menaquinone).\n\nOnly vitamins A, E, and B12 are stored to any significant extent in the body; the other vitamins must be consumed regularly to maintain tissue health.\n\nEssential trace minerals include chromium, copper, iodine, iron, manganese, molybdenum, selenium, and zinc. Except for chromium, each of these is incorporated into enzymes or hormones required in metabolism. Except for deficiencies of iron and zinc, micromineral deficiencies are uncommon in developed countries (see Ch. 5).\n\nOther minerals (eg, aluminum, arsenic, boron, cobalt, fluoride, nickel, silicon, vanadium) have not been proved essential for people. Fluoride, although not essential, helps prevent tooth decay by forming a compound with Ca (CaF2), which stabilizes the mineral matrix in teeth.\n\nAll trace minerals are toxic at high levels, and some (arsenic, nickel, and chromium) may cause cancer.\n\n# Other Dietary Substances\n\nThe daily human diet typically contains as many as 100,000 chemicals (eg, coffee contains 1000). Of these, only 300 are nutrients, only some of which are essential. However, many nonnutrients in foods are useful. For example, food additives (eg, preservatives, emulsifiers, antioxidants, stabilizers) improve the production and stability of foods. Trace components (eg, spices, flavors, odors, colors, phytochemicals, many other natural products) improve appearance and taste.\n\n# Fiber\n\nFiber occurs in various forms (eg, cellulose, hemicellulose, pectin, gums). It increases GI motility, prevents constipation, and helps control diverticular disease. Fiber is thought to accelerate the elimination of cancer-causing substances produced by bacteria in the large intestine. Epidemiologic evidence suggests an association between colon cancer and low fiber intake and a beneficial effect of fiber in patients with functional bowel disorders, Crohn's disease, obesity, and hemorrhoids. Soluble fiber (present in fruits, vegetables, oats, barley, and legumes) reduces the postprandial increase in blood glucose and insulin and can reduce cholesterol levels.\n\nThe typical Western diet is low in fiber (about 12 g/day) because of a high intake of highly refined wheat flour and a low intake of fruits and vegetables. Increasing fiber intake to about 30 g/day by consuming more vegetables, fruits, and high-fiber cereals and grains is generally recommended. However, very high fiber intake may reduce absorption of certain minerals.\n\n# Nutritional Requirements\n\nGood nutrition aims to achieve and maintain a desirable body composition and high potential for physical and mental work. Balancing energy intake with energy expenditure is necessary for a desirable body weight. Energy expenditure depends on age, sex, weight (see Table 1-4), and metabolic and physical activity. If energy intake exceeds expenditure, weight is gained. Taking in about 100 calories/day more than needed results in a weight gain of about 4 to 5 kg in a year. If energy intake is less than expenditure, weight is lost.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 1. Nutrition: General Considerations",
                    "md": "# Chapter 1. Nutrition: General Considerations",
                    "bBox": {
                        "x": 345,
                        "y": 30.72,
                        "w": 198,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "[Table 1-4. Recommended Dietary Reference Intakes* for Some Macronutrients, Food and Nutrition Board, Institute of Medicine of the National Academies]",
                    "md": "# [Table 1-4. Recommended Dietary Reference Intakes* for Some Macronutrients, Food and Nutrition Board, Institute of Medicine of the National Academies]",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 455,
                        "h": 25
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Micronutrients",
                    "md": "# Micronutrients",
                    "bBox": {
                        "x": 55,
                        "y": 86.9,
                        "w": 73,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamins and minerals required in minute amounts (trace minerals) are micronutrients (see Chs. 4 and 5).\n\nWater-soluble vitamins are vitamin C (ascorbic acid) and 8 members of the vitamin B complex: biotin, folate, niacin, pantothenic acid, riboflavin (vitamin B2), thiamin (vitamin B1), vitamin B6 (pyridoxine), and vitamin B12 (cobalamin).\n\nFat-soluble vitamins are vitamins A (retinol), D (cholecalciferol and ergocalciferol), E (\u03b1-tocopherol), and K (phylloquinone and menaquinone).\n\nOnly vitamins A, E, and B12 are stored to any significant extent in the body; the other vitamins must be consumed regularly to maintain tissue health.\n\nEssential trace minerals include chromium, copper, iodine, iron, manganese, molybdenum, selenium, and zinc. Except for chromium, each of these is incorporated into enzymes or hormones required in metabolism. Except for deficiencies of iron and zinc, micromineral deficiencies are uncommon in developed countries (see Ch. 5).\n\nOther minerals (eg, aluminum, arsenic, boron, cobalt, fluoride, nickel, silicon, vanadium) have not been proved essential for people. Fluoride, although not essential, helps prevent tooth decay by forming a compound with Ca (CaF2), which stabilizes the mineral matrix in teeth.\n\nAll trace minerals are toxic at high levels, and some (arsenic, nickel, and chromium) may cause cancer.",
                    "md": "Vitamins and minerals required in minute amounts (trace minerals) are micronutrients (see Chs. 4 and 5).\n\nWater-soluble vitamins are vitamin C (ascorbic acid) and 8 members of the vitamin B complex: biotin, folate, niacin, pantothenic acid, riboflavin (vitamin B2), thiamin (vitamin B1), vitamin B6 (pyridoxine), and vitamin B12 (cobalamin).\n\nFat-soluble vitamins are vitamins A (retinol), D (cholecalciferol and ergocalciferol), E (\u03b1-tocopherol), and K (phylloquinone and menaquinone).\n\nOnly vitamins A, E, and B12 are stored to any significant extent in the body; the other vitamins must be consumed regularly to maintain tissue health.\n\nEssential trace minerals include chromium, copper, iodine, iron, manganese, molybdenum, selenium, and zinc. Except for chromium, each of these is incorporated into enzymes or hormones required in metabolism. Except for deficiencies of iron and zinc, micromineral deficiencies are uncommon in developed countries (see Ch. 5).\n\nOther minerals (eg, aluminum, arsenic, boron, cobalt, fluoride, nickel, silicon, vanadium) have not been proved essential for people. Fluoride, although not essential, helps prevent tooth decay by forming a compound with Ca (CaF2), which stabilizes the mineral matrix in teeth.\n\nAll trace minerals are toxic at high levels, and some (arsenic, nickel, and chromium) may cause cancer.",
                    "bBox": {
                        "x": 55,
                        "y": 86.9,
                        "w": 484,
                        "h": 313
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Other Dietary Substances",
                    "md": "# Other Dietary Substances",
                    "bBox": {
                        "x": 55,
                        "y": 412.9,
                        "w": 129,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "The daily human diet typically contains as many as 100,000 chemicals (eg, coffee contains 1000). Of these, only 300 are nutrients, only some of which are essential. However, many nonnutrients in foods are useful. For example, food additives (eg, preservatives, emulsifiers, antioxidants, stabilizers) improve the production and stability of foods. Trace components (eg, spices, flavors, odors, colors, phytochemicals, many other natural products) improve appearance and taste.",
                    "md": "The daily human diet typically contains as many as 100,000 chemicals (eg, coffee contains 1000). Of these, only 300 are nutrients, only some of which are essential. However, many nonnutrients in foods are useful. For example, food additives (eg, preservatives, emulsifiers, antioxidants, stabilizers) improve the production and stability of foods. Trace components (eg, spices, flavors, odors, colors, phytochemicals, many other natural products) improve appearance and taste.",
                    "bBox": {
                        "x": 55,
                        "y": 438.9,
                        "w": 479,
                        "h": 62
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Fiber",
                    "md": "# Fiber",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Fiber occurs in various forms (eg, cellulose, hemicellulose, pectin, gums). It increases GI motility, prevents constipation, and helps control diverticular disease. Fiber is thought to accelerate the elimination of cancer-causing substances produced by bacteria in the large intestine. Epidemiologic evidence suggests an association between colon cancer and low fiber intake and a beneficial effect of fiber in patients with functional bowel disorders, Crohn's disease, obesity, and hemorrhoids. Soluble fiber (present in fruits, vegetables, oats, barley, and legumes) reduces the postprandial increase in blood glucose and insulin and can reduce cholesterol levels.\n\nThe typical Western diet is low in fiber (about 12 g/day) because of a high intake of highly refined wheat flour and a low intake of fruits and vegetables. Increasing fiber intake to about 30 g/day by consuming more vegetables, fruits, and high-fiber cereals and grains is generally recommended. However, very high fiber intake may reduce absorption of certain minerals.",
                    "md": "Fiber occurs in various forms (eg, cellulose, hemicellulose, pectin, gums). It increases GI motility, prevents constipation, and helps control diverticular disease. Fiber is thought to accelerate the elimination of cancer-causing substances produced by bacteria in the large intestine. Epidemiologic evidence suggests an association between colon cancer and low fiber intake and a beneficial effect of fiber in patients with functional bowel disorders, Crohn's disease, obesity, and hemorrhoids. Soluble fiber (present in fruits, vegetables, oats, barley, and legumes) reduces the postprandial increase in blood glucose and insulin and can reduce cholesterol levels.\n\nThe typical Western diet is low in fiber (about 12 g/day) because of a high intake of highly refined wheat flour and a low intake of fruits and vegetables. Increasing fiber intake to about 30 g/day by consuming more vegetables, fruits, and high-fiber cereals and grains is generally recommended. However, very high fiber intake may reduce absorption of certain minerals.",
                    "bBox": {
                        "x": 55,
                        "y": 526.9,
                        "w": 483,
                        "h": 139
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Nutritional Requirements",
                    "md": "# Nutritional Requirements",
                    "bBox": {
                        "x": 55,
                        "y": 679.9,
                        "w": 126,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Good nutrition aims to achieve and maintain a desirable body composition and high potential for physical and mental work. Balancing energy intake with energy expenditure is necessary for a desirable body weight. Energy expenditure depends on age, sex, weight (see Table 1-4), and metabolic and physical activity. If energy intake exceeds expenditure, weight is gained. Taking in about 100 calories/day more than needed results in a weight gain of about 4 to 5 kg in a year. If energy intake is less than expenditure, weight is lost.",
                    "md": "Good nutrition aims to achieve and maintain a desirable body composition and high potential for physical and mental work. Balancing energy intake with energy expenditure is necessary for a desirable body weight. Energy expenditure depends on age, sex, weight (see Table 1-4), and metabolic and physical activity. If energy intake exceeds expenditure, weight is gained. Taking in about 100 calories/day more than needed results in a weight gain of about 4 to 5 kg in a year. If energy intake is less than expenditure, weight is lost.",
                    "bBox": {
                        "x": 55,
                        "y": 704.9,
                        "w": 481,
                        "h": 75
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 4,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition           Chapter 1. Nutrition: General Considerations\n Daily dietary requirements for essential nutrients also depend on age, sex, weight, and metabolic and\n physical activity. Every 5 yr, the Food and Nutrition Board of the National Academy of Sciences/National\n Research Council and the US Department of Agriculture (USDA) issues the dietary reference intakes\n (DRIs) for protein, energy, and some vitamins and minerals (see Tables 1-4,\n 4-1, and 5-2). For vitamins and minerals about which less is known, safe and adequate daily dietary\n intakes are estimated.\n Pregnant women (see p. 2608) and infants (see p. 2703) have special nutritional needs.\n The USDA publishes the Food Guide Pyramid, which specifies the number of recommended daily\n servings of various food groups. The recommendations are individualized based on age, sex, and\n physical activity (see\n Table 1-5). Generally, the recommended intake decreases with aging because physical activity tends to\n decrease, resulting in less energy expended. The new Food Guide Pyramid emphasizes the following:\n \u2022 Increasing consumption of whole grains\n \u2022 Increasing consumption of vegetables and fruits\n \u2022 Substituting fat-free or low-fat milk products (or equivalents) for whole-fat milk products\n \u2022 Reducing consumption of saturated fats and trans fatty acids\n \u2022 Exercising regularly\n Adequate fluid intake is also important.\n Fats should constitute \u2264 30% of total calories, and saturated and trans fatty acids should constitute &lt;\n 10%. Excess intake of saturated fats contributes to atherosclerosis. Substituting polyunsaturated fatty\n acids for saturated fats can decrease the risk of atherosclerosis. Routine use of nutritional supplements is\n not necessary or beneficial; some supplements can be harmful. For example, excess vitamin A can lead to\n hypervitaminosis A, with headaches, osteoporosis, and rash.\n Nutrition in Clinical Medicine\n Nutritional deficiencies can often worsen health outcomes (whether a disorder is present or not), and\n some disorders (eg, malabsorption) can cause nutritional deficiencies. Also, many patients (eg, elderly\n patients during acute hospitalization) have unsuspected nutritional deficiencies that require treatment.\n Many medical centers have multi-disciplinary nutrition support teams of physicians, nurses, dietitians, and\n pharmacists to help the clinician prevent, diagnose, and treat occult nutritional deficiencies.\n Overnutrition may contribute to chronic disorders, such as cancer, hypertension, obesity, diabetes\n mellitus, and coronary artery disease. Dietary restrictions are necessary in many hereditary metabolic\n disorders (eg, galactosemia, phenylketonuria).\n Evaluation of Nutritional Status\n Indications for nutritional evaluation include undesirable body weight or body composition, suspicion of\n specific deficiencies or toxicities\n [Table 1-5. Recommended Dietary Intake for 40-yr-Olds with Moderate Physical Activity*]\n of essential nutrients, and, in infants and children, insufficient growth or development. Nutritional status\n should be evaluated routinely as part of the clinical examination for infants and children, the elderly,\n people taking several drugs, people with psychiatric disorders, and people with systemic disorders that\n last longer than several days.\n                                                                                                         56",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 1. Nutrition: General Considerations\n\nDaily dietary requirements for essential nutrients also depend on age, sex, weight, and metabolic and physical activity. Every 5 yr, the Food and Nutrition Board of the National Academy of Sciences/National Research Council and the US Department of Agriculture (USDA) issues the dietary reference intakes (DRIs) for protein, energy, and some vitamins and minerals (see Tables 1-4, 4-1, and 5-2). For vitamins and minerals about which less is known, safe and adequate daily dietary intakes are estimated.\n\nPregnant women (see p. 2608) and infants (see p. 2703) have special nutritional needs. The USDA publishes the Food Guide Pyramid, which specifies the number of recommended daily servings of various food groups. The recommendations are individualized based on age, sex, and physical activity (see Table 1-5). Generally, the recommended intake decreases with aging because physical activity tends to decrease, resulting in less energy expended. The new Food Guide Pyramid emphasizes the following:\n\n- Increasing consumption of whole grains\n- Increasing consumption of vegetables and fruits\n- Substituting fat-free or low-fat milk products (or equivalents) for whole-fat milk products\n- Reducing consumption of saturated fats and trans fatty acids\n- Exercising regularly\n\nAdequate fluid intake is also important. Fats should constitute \u2264 30% of total calories, and saturated and trans fatty acids should constitute &lt; 10%. Excess intake of saturated fats contributes to atherosclerosis. Substituting polyunsaturated fatty acids for saturated fats can decrease the risk of atherosclerosis. Routine use of nutritional supplements is not necessary or beneficial; some supplements can be harmful. For example, excess vitamin A can lead to hypervitaminosis A, with headaches, osteoporosis, and rash.\n\n# Nutrition in Clinical Medicine\n\nNutritional deficiencies can often worsen health outcomes (whether a disorder is present or not), and some disorders (eg, malabsorption) can cause nutritional deficiencies. Also, many patients (eg, elderly patients during acute hospitalization) have unsuspected nutritional deficiencies that require treatment. Many medical centers have multi-disciplinary nutrition support teams of physicians, nurses, dietitians, and pharmacists to help the clinician prevent, diagnose, and treat occult nutritional deficiencies.\n\nOvernutrition may contribute to chronic disorders, such as cancer, hypertension, obesity, diabetes mellitus, and coronary artery disease. Dietary restrictions are necessary in many hereditary metabolic disorders (eg, galactosemia, phenylketonuria).\n\n# Evaluation of Nutritional Status\n\nIndications for nutritional evaluation include undesirable body weight or body composition, suspicion of specific deficiencies or toxicities of essential nutrients, and, in infants and children, insufficient growth or development. Nutritional status should be evaluated routinely as part of the clinical examination for infants and children, the elderly, people taking several drugs, people with psychiatric disorders, and people with systemic disorders that last longer than several days.\n\n|   |   |   |\n| - | - | - |\n",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 1. Nutrition: General Considerations",
                    "md": "# Chapter 1. Nutrition: General Considerations",
                    "bBox": {
                        "x": 345,
                        "y": 30.72,
                        "w": 198,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "Daily dietary requirements for essential nutrients also depend on age, sex, weight, and metabolic and physical activity. Every 5 yr, the Food and Nutrition Board of the National Academy of Sciences/National Research Council and the US Department of Agriculture (USDA) issues the dietary reference intakes (DRIs) for protein, energy, and some vitamins and minerals (see Tables 1-4, 4-1, and 5-2). For vitamins and minerals about which less is known, safe and adequate daily dietary intakes are estimated.\n\nPregnant women (see p. 2608) and infants (see p. 2703) have special nutritional needs. The USDA publishes the Food Guide Pyramid, which specifies the number of recommended daily servings of various food groups. The recommendations are individualized based on age, sex, and physical activity (see Table 1-5). Generally, the recommended intake decreases with aging because physical activity tends to decrease, resulting in less energy expended. The new Food Guide Pyramid emphasizes the following:\n\n- Increasing consumption of whole grains\n- Increasing consumption of vegetables and fruits\n- Substituting fat-free or low-fat milk products (or equivalents) for whole-fat milk products\n- Reducing consumption of saturated fats and trans fatty acids\n- Exercising regularly\n\nAdequate fluid intake is also important. Fats should constitute \u2264 30% of total calories, and saturated and trans fatty acids should constitute &lt; 10%. Excess intake of saturated fats contributes to atherosclerosis. Substituting polyunsaturated fatty acids for saturated fats can decrease the risk of atherosclerosis. Routine use of nutritional supplements is not necessary or beneficial; some supplements can be harmful. For example, excess vitamin A can lead to hypervitaminosis A, with headaches, osteoporosis, and rash.",
                    "md": "Daily dietary requirements for essential nutrients also depend on age, sex, weight, and metabolic and physical activity. Every 5 yr, the Food and Nutrition Board of the National Academy of Sciences/National Research Council and the US Department of Agriculture (USDA) issues the dietary reference intakes (DRIs) for protein, energy, and some vitamins and minerals (see Tables 1-4, 4-1, and 5-2). For vitamins and minerals about which less is known, safe and adequate daily dietary intakes are estimated.\n\nPregnant women (see p. 2608) and infants (see p. 2703) have special nutritional needs. The USDA publishes the Food Guide Pyramid, which specifies the number of recommended daily servings of various food groups. The recommendations are individualized based on age, sex, and physical activity (see Table 1-5). Generally, the recommended intake decreases with aging because physical activity tends to decrease, resulting in less energy expended. The new Food Guide Pyramid emphasizes the following:\n\n- Increasing consumption of whole grains\n- Increasing consumption of vegetables and fruits\n- Substituting fat-free or low-fat milk products (or equivalents) for whole-fat milk products\n- Reducing consumption of saturated fats and trans fatty acids\n- Exercising regularly\n\nAdequate fluid intake is also important. Fats should constitute \u2264 30% of total calories, and saturated and trans fatty acids should constitute &lt; 10%. Excess intake of saturated fats contributes to atherosclerosis. Substituting polyunsaturated fatty acids for saturated fats can decrease the risk of atherosclerosis. Routine use of nutritional supplements is not necessary or beneficial; some supplements can be harmful. For example, excess vitamin A can lead to hypervitaminosis A, with headaches, osteoporosis, and rash.",
                    "bBox": {
                        "x": 55,
                        "y": 61.9,
                        "w": 482,
                        "h": 405
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Nutrition in Clinical Medicine",
                    "md": "# Nutrition in Clinical Medicine",
                    "bBox": {
                        "x": 55,
                        "y": 479.9,
                        "w": 143,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Nutritional deficiencies can often worsen health outcomes (whether a disorder is present or not), and some disorders (eg, malabsorption) can cause nutritional deficiencies. Also, many patients (eg, elderly patients during acute hospitalization) have unsuspected nutritional deficiencies that require treatment. Many medical centers have multi-disciplinary nutrition support teams of physicians, nurses, dietitians, and pharmacists to help the clinician prevent, diagnose, and treat occult nutritional deficiencies.\n\nOvernutrition may contribute to chronic disorders, such as cancer, hypertension, obesity, diabetes mellitus, and coronary artery disease. Dietary restrictions are necessary in many hereditary metabolic disorders (eg, galactosemia, phenylketonuria).",
                    "md": "Nutritional deficiencies can often worsen health outcomes (whether a disorder is present or not), and some disorders (eg, malabsorption) can cause nutritional deficiencies. Also, many patients (eg, elderly patients during acute hospitalization) have unsuspected nutritional deficiencies that require treatment. Many medical centers have multi-disciplinary nutrition support teams of physicians, nurses, dietitians, and pharmacists to help the clinician prevent, diagnose, and treat occult nutritional deficiencies.\n\nOvernutrition may contribute to chronic disorders, such as cancer, hypertension, obesity, diabetes mellitus, and coronary artery disease. Dietary restrictions are necessary in many hereditary metabolic disorders (eg, galactosemia, phenylketonuria).",
                    "bBox": {
                        "x": 55,
                        "y": 505.9,
                        "w": 482,
                        "h": 113
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Evaluation of Nutritional Status",
                    "md": "# Evaluation of Nutritional Status",
                    "bBox": {
                        "x": 55,
                        "y": 631.9,
                        "w": 155,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Indications for nutritional evaluation include undesirable body weight or body composition, suspicion of specific deficiencies or toxicities of essential nutrients, and, in infants and children, insufficient growth or development. Nutritional status should be evaluated routinely as part of the clinical examination for infants and children, the elderly, people taking several drugs, people with psychiatric disorders, and people with systemic disorders that last longer than several days.",
                    "md": "Indications for nutritional evaluation include undesirable body weight or body composition, suspicion of specific deficiencies or toxicities of essential nutrients, and, in infants and children, insufficient growth or development. Nutritional status should be evaluated routinely as part of the clinical examination for infants and children, the elderly, people taking several drugs, people with psychiatric disorders, and people with systemic disorders that last longer than several days.",
                    "bBox": {
                        "x": 55,
                        "y": 657.9,
                        "w": 470,
                        "h": 113
                    }
                },
                {
                    "type": "table",
                    "rows": [],
                    "md": "|   |   |   |\n| - | - | - |",
                    "isPerfectTable": true,
                    "csv": "",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.97
        },
        {
            "page": 5,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition           Chapter 1. Nutrition: General Considerations\n Evaluating general nutritional status includes history, physical examination, and sometimes tests. If\n undernutrition is suspected, laboratory tests (eg, albumin levels) and skin tests for delayed\n hypersensitivity may be done (see p.\n 13). Body composition analysis (eg, skinfold measurements, bioelectrical impedance analysis) is used to\n estimate percentage of body fat and to evaluate obesity (see p. 58).\n History includes questions about dietary intake, weight change, and risk factors for nutritional deficiencies\n and a focused review of systems (see\n Table 2-1 on p. 11). A dietitian can obtain a more detailed dietary history. It usually includes a list of foods\n eaten within the previous 24 h and a food questionnaire. A food diary may be used to record all foods\n eaten. The weighed ad libitum diet, in which the patient weighs and writes down all foods consumed, is\n the most accurate record.\n A complete physical examination, including measurement of height and weight and distribution of body\n fat, should be done. Body mass index (BMI)\u2014weight(kg)/height(m)2, which adjusts weight for height (see\n Table 6-2 on p. 59), is more accurate than height and weight tables. There are standards for growth and\n weight gain in infants, children, and adolescents (see p. 2756).\n Distribution of body fat is important. Disproportionate truncal obesity (ie, waist/hip ratio &gt; 0.8) is\n associated with cardiovascular and cerebrovascular disorders, hypertension, and diabetes mellitus more\n often than fat located elsewhere. Measuring waist circumference in patients with a BMI of &lt; 35 helps\n determine whether they have truncal obesity and helps predict risk of diabetes, hypertension,\n hypercholesterolemia, and cardiovascular disorders. Risk is increased if waist circumference is &gt; 102 cm\n (&gt; 40 in) in men or &gt; 88 cm (&gt; 35 in) in women.\n Nutrient-Drug Interactions\n Nutrition can affect the body's response to drugs; conversely, drugs can affect the body's nutrition.\n Foods can enhance, delay, or decrease drug absorption. Foods impair absorption of many antibiotics.\n They can alter metabolism of drugs; eg, high-protein diets can accelerate metabolism of certain drugs by\n stimulating cytochrome P-450. Eating grapefruit can inhibit cytochrome P-450 34A, slowing metabolism of\n some drugs (eg, amiodarone, carbamazepine, cyclosporine, certain Ca channel blockers). Diets that alter\n the bacterial flora may markedly affect the overall metabolism of certain drugs. Some foods affect the\n body's response to drugs. For example, tyramine, a component of cheese and a potent vasoconstrictor,\n can cause hypertensive crisis in some patients who take monoamine oxidase inhibitors and eat cheese.\n Nutritional deficiencies can affect drug absorption and metabolism. Severe energy and protein\n deficiencies reduce enzyme tissue concentrations and may impair the response to drugs by reducing\n absorption or protein binding and causing liver dysfunction. Changes in the GI tract can impair absorption\n and affect the response to a drug. Deficiency of Ca, Mg, or zinc may impair drug metabolism. Vitamin C\n deficiency decreases activity of drug-metabolizing enzymes, especially in the elderly.\n Many drugs affect appetite, food absorption, and tissue metabolism (see\n Table 1-6). Some drugs (eg, metoclopramide) increase GI motility, decreasing food absorption. Other\n drugs (eg, opioids, anticholinergics) decrease GI motility. Some drugs are better tolerated if taken with\n food.\n Certain drugs affect mineral metabolism. For example, diuretics, especially thiazides, and corticosteroids\n can deplete body K, increasing susceptibility to digoxin-induced cardiac arrhythmias. Repeated use of\n laxatives may deplete K. Cortisol, desoxycorticosterone, and aldosterone cause marked Na and water\n retention, at least temporarily; retention is much less with prednisone, prednisolone, and some other\n corticosteroid analogs. Sulfonylureas and lithium can impair the uptake or release of iodine by the thyroid.\n Oral contraceptives can lower blood zinc levels and increase copper levels. Certain antibiotics (eg,\n tetracyclines) reduce iron absorption, as can certain foods (eg, vegetables, tea, bran).\n Certain drugs affect vitamin absorption or metabolism. Ethanol impairs thiamin utilization, and isoniazid\n interferes with niacin and pyridoxine metabolism. Ethanol and oral contraceptives inhibit folate (folic acid)\n                                                                                                         57",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 1. Nutrition: General Considerations\n\nEvaluating general nutritional status includes history, physical examination, and sometimes tests. If undernutrition is suspected, laboratory tests (eg, albumin levels) and skin tests for delayed hypersensitivity may be done (see p. 13). Body composition analysis (eg, skinfold measurements, bioelectrical impedance analysis) is used to estimate percentage of body fat and to evaluate obesity (see p. 58).\n\nHistory includes questions about dietary intake, weight change, and risk factors for nutritional deficiencies and a focused review of systems (see Table 2-1 on p. 11). A dietitian can obtain a more detailed dietary history. It usually includes a list of foods eaten within the previous 24 h and a food questionnaire. A food diary may be used to record all foods eaten. The weighed ad libitum diet, in which the patient weighs and writes down all foods consumed, is the most accurate record.\n\nA complete physical examination, including measurement of height and weight and distribution of body fat, should be done. Body mass index (BMI)\u2014weight(kg)/height(m)2, which adjusts weight for height (see Table 6-2 on p. 59), is more accurate than height and weight tables. There are standards for growth and weight gain in infants, children, and adolescents (see p. 2756).\n\nDistribution of body fat is important. Disproportionate truncal obesity (ie, waist/hip ratio &gt; 0.8) is associated with cardiovascular and cerebrovascular disorders, hypertension, and diabetes mellitus more often than fat located elsewhere. Measuring waist circumference in patients with a BMI of &lt; 35 helps determine whether they have truncal obesity and helps predict risk of diabetes, hypertension, hypercholesterolemia, and cardiovascular disorders. Risk is increased if waist circumference is &gt; 102 cm (&gt; 40 in) in men or &gt; 88 cm (&gt; 35 in) in women.\n\n# Nutrient-Drug Interactions\n\nNutrition can affect the body's response to drugs; conversely, drugs can affect the body's nutrition. Foods can enhance, delay, or decrease drug absorption. Foods impair absorption of many antibiotics. They can alter metabolism of drugs; eg, high-protein diets can accelerate metabolism of certain drugs by stimulating cytochrome P-450. Eating grapefruit can inhibit cytochrome P-450 34A, slowing metabolism of some drugs (eg, amiodarone, carbamazepine, cyclosporine, certain Ca channel blockers). Diets that alter the bacterial flora may markedly affect the overall metabolism of certain drugs. Some foods affect the body's response to drugs. For example, tyramine, a component of cheese and a potent vasoconstrictor, can cause hypertensive crisis in some patients who take monoamine oxidase inhibitors and eat cheese.\n\nNutritional deficiencies can affect drug absorption and metabolism. Severe energy and protein deficiencies reduce enzyme tissue concentrations and may impair the response to drugs by reducing absorption or protein binding and causing liver dysfunction. Changes in the GI tract can impair absorption and affect the response to a drug. Deficiency of Ca, Mg, or zinc may impair drug metabolism. Vitamin C deficiency decreases activity of drug-metabolizing enzymes, especially in the elderly.\n\nMany drugs affect appetite, food absorption, and tissue metabolism (see Table 1-6). Some drugs (eg, metoclopramide) increase GI motility, decreasing food absorption. Other drugs (eg, opioids, anticholinergics) decrease GI motility. Some drugs are better tolerated if taken with food.\n\nCertain drugs affect mineral metabolism. For example, diuretics, especially thiazides, and corticosteroids can deplete body K, increasing susceptibility to digoxin-induced cardiac arrhythmias. Repeated use of laxatives may deplete K. Cortisol, desoxycorticosterone, and aldosterone cause marked Na and water retention, at least temporarily; retention is much less with prednisone, prednisolone, and some other corticosteroid analogs. Sulfonylureas and lithium can impair the uptake or release of iodine by the thyroid. Oral contraceptives can lower blood zinc levels and increase copper levels. Certain antibiotics (eg, tetracyclines) reduce iron absorption, as can certain foods (eg, vegetables, tea, bran).\n\nCertain drugs affect vitamin absorption or metabolism. Ethanol impairs thiamin utilization, and isoniazid interferes with niacin and pyridoxine metabolism. Ethanol and oral contraceptives inhibit folate (folic acid).",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 1. Nutrition: General Considerations",
                    "md": "# Chapter 1. Nutrition: General Considerations",
                    "bBox": {
                        "x": 345,
                        "y": 30.72,
                        "w": 198,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "Evaluating general nutritional status includes history, physical examination, and sometimes tests. If undernutrition is suspected, laboratory tests (eg, albumin levels) and skin tests for delayed hypersensitivity may be done (see p. 13). Body composition analysis (eg, skinfold measurements, bioelectrical impedance analysis) is used to estimate percentage of body fat and to evaluate obesity (see p. 58).\n\nHistory includes questions about dietary intake, weight change, and risk factors for nutritional deficiencies and a focused review of systems (see Table 2-1 on p. 11). A dietitian can obtain a more detailed dietary history. It usually includes a list of foods eaten within the previous 24 h and a food questionnaire. A food diary may be used to record all foods eaten. The weighed ad libitum diet, in which the patient weighs and writes down all foods consumed, is the most accurate record.\n\nA complete physical examination, including measurement of height and weight and distribution of body fat, should be done. Body mass index (BMI)\u2014weight(kg)/height(m)2, which adjusts weight for height (see Table 6-2 on p. 59), is more accurate than height and weight tables. There are standards for growth and weight gain in infants, children, and adolescents (see p. 2756).\n\nDistribution of body fat is important. Disproportionate truncal obesity (ie, waist/hip ratio &gt; 0.8) is associated with cardiovascular and cerebrovascular disorders, hypertension, and diabetes mellitus more often than fat located elsewhere. Measuring waist circumference in patients with a BMI of &lt; 35 helps determine whether they have truncal obesity and helps predict risk of diabetes, hypertension, hypercholesterolemia, and cardiovascular disorders. Risk is increased if waist circumference is &gt; 102 cm (&gt; 40 in) in men or &gt; 88 cm (&gt; 35 in) in women.",
                    "md": "Evaluating general nutritional status includes history, physical examination, and sometimes tests. If undernutrition is suspected, laboratory tests (eg, albumin levels) and skin tests for delayed hypersensitivity may be done (see p. 13). Body composition analysis (eg, skinfold measurements, bioelectrical impedance analysis) is used to estimate percentage of body fat and to evaluate obesity (see p. 58).\n\nHistory includes questions about dietary intake, weight change, and risk factors for nutritional deficiencies and a focused review of systems (see Table 2-1 on p. 11). A dietitian can obtain a more detailed dietary history. It usually includes a list of foods eaten within the previous 24 h and a food questionnaire. A food diary may be used to record all foods eaten. The weighed ad libitum diet, in which the patient weighs and writes down all foods consumed, is the most accurate record.\n\nA complete physical examination, including measurement of height and weight and distribution of body fat, should be done. Body mass index (BMI)\u2014weight(kg)/height(m)2, which adjusts weight for height (see Table 6-2 on p. 59), is more accurate than height and weight tables. There are standards for growth and weight gain in infants, children, and adolescents (see p. 2756).\n\nDistribution of body fat is important. Disproportionate truncal obesity (ie, waist/hip ratio &gt; 0.8) is associated with cardiovascular and cerebrovascular disorders, hypertension, and diabetes mellitus more often than fat located elsewhere. Measuring waist circumference in patients with a BMI of &lt; 35 helps determine whether they have truncal obesity and helps predict risk of diabetes, hypertension, hypercholesterolemia, and cardiovascular disorders. Risk is increased if waist circumference is &gt; 102 cm (&gt; 40 in) in men or &gt; 88 cm (&gt; 35 in) in women.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 482,
                        "h": 308
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Nutrient-Drug Interactions",
                    "md": "# Nutrient-Drug Interactions",
                    "bBox": {
                        "x": 55,
                        "y": 369.9,
                        "w": 130,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Nutrition can affect the body's response to drugs; conversely, drugs can affect the body's nutrition. Foods can enhance, delay, or decrease drug absorption. Foods impair absorption of many antibiotics. They can alter metabolism of drugs; eg, high-protein diets can accelerate metabolism of certain drugs by stimulating cytochrome P-450. Eating grapefruit can inhibit cytochrome P-450 34A, slowing metabolism of some drugs (eg, amiodarone, carbamazepine, cyclosporine, certain Ca channel blockers). Diets that alter the bacterial flora may markedly affect the overall metabolism of certain drugs. Some foods affect the body's response to drugs. For example, tyramine, a component of cheese and a potent vasoconstrictor, can cause hypertensive crisis in some patients who take monoamine oxidase inhibitors and eat cheese.\n\nNutritional deficiencies can affect drug absorption and metabolism. Severe energy and protein deficiencies reduce enzyme tissue concentrations and may impair the response to drugs by reducing absorption or protein binding and causing liver dysfunction. Changes in the GI tract can impair absorption and affect the response to a drug. Deficiency of Ca, Mg, or zinc may impair drug metabolism. Vitamin C deficiency decreases activity of drug-metabolizing enzymes, especially in the elderly.\n\nMany drugs affect appetite, food absorption, and tissue metabolism (see Table 1-6). Some drugs (eg, metoclopramide) increase GI motility, decreasing food absorption. Other drugs (eg, opioids, anticholinergics) decrease GI motility. Some drugs are better tolerated if taken with food.\n\nCertain drugs affect mineral metabolism. For example, diuretics, especially thiazides, and corticosteroids can deplete body K, increasing susceptibility to digoxin-induced cardiac arrhythmias. Repeated use of laxatives may deplete K. Cortisol, desoxycorticosterone, and aldosterone cause marked Na and water retention, at least temporarily; retention is much less with prednisone, prednisolone, and some other corticosteroid analogs. Sulfonylureas and lithium can impair the uptake or release of iodine by the thyroid. Oral contraceptives can lower blood zinc levels and increase copper levels. Certain antibiotics (eg, tetracyclines) reduce iron absorption, as can certain foods (eg, vegetables, tea, bran).\n\nCertain drugs affect vitamin absorption or metabolism. Ethanol impairs thiamin utilization, and isoniazid interferes with niacin and pyridoxine metabolism. Ethanol and oral contraceptives inhibit folate (folic acid).",
                    "md": "Nutrition can affect the body's response to drugs; conversely, drugs can affect the body's nutrition. Foods can enhance, delay, or decrease drug absorption. Foods impair absorption of many antibiotics. They can alter metabolism of drugs; eg, high-protein diets can accelerate metabolism of certain drugs by stimulating cytochrome P-450. Eating grapefruit can inhibit cytochrome P-450 34A, slowing metabolism of some drugs (eg, amiodarone, carbamazepine, cyclosporine, certain Ca channel blockers). Diets that alter the bacterial flora may markedly affect the overall metabolism of certain drugs. Some foods affect the body's response to drugs. For example, tyramine, a component of cheese and a potent vasoconstrictor, can cause hypertensive crisis in some patients who take monoamine oxidase inhibitors and eat cheese.\n\nNutritional deficiencies can affect drug absorption and metabolism. Severe energy and protein deficiencies reduce enzyme tissue concentrations and may impair the response to drugs by reducing absorption or protein binding and causing liver dysfunction. Changes in the GI tract can impair absorption and affect the response to a drug. Deficiency of Ca, Mg, or zinc may impair drug metabolism. Vitamin C deficiency decreases activity of drug-metabolizing enzymes, especially in the elderly.\n\nMany drugs affect appetite, food absorption, and tissue metabolism (see Table 1-6). Some drugs (eg, metoclopramide) increase GI motility, decreasing food absorption. Other drugs (eg, opioids, anticholinergics) decrease GI motility. Some drugs are better tolerated if taken with food.\n\nCertain drugs affect mineral metabolism. For example, diuretics, especially thiazides, and corticosteroids can deplete body K, increasing susceptibility to digoxin-induced cardiac arrhythmias. Repeated use of laxatives may deplete K. Cortisol, desoxycorticosterone, and aldosterone cause marked Na and water retention, at least temporarily; retention is much less with prednisone, prednisolone, and some other corticosteroid analogs. Sulfonylureas and lithium can impair the uptake or release of iodine by the thyroid. Oral contraceptives can lower blood zinc levels and increase copper levels. Certain antibiotics (eg, tetracyclines) reduce iron absorption, as can certain foods (eg, vegetables, tea, bran).\n\nCertain drugs affect vitamin absorption or metabolism. Ethanol impairs thiamin utilization, and isoniazid interferes with niacin and pyridoxine metabolism. Ethanol and oral contraceptives inhibit folate (folic acid).",
                    "bBox": {
                        "x": 55,
                        "y": 395.9,
                        "w": 482,
                        "h": 392
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 6,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition           Chapter 1. Nutrition: General Considerations\n absorption. Most patients receiving phenytoin, phenobarbital, primidone, or phenothiazines develop folate\n deficiency, probably because hepatic microsomal drug-metabolizing enzymes are affected. Folate\n supplements may\n [Table 1-6. Effects of Some Drugs on Nutrition]\n make phenytoin less effective. Anticonvulsants can cause vitamin D deficiency. Malabsorption of vitamin\n B12 can occur with use of aminosalicylic acid, slow-release K iodide, colchicine, trifluoperazine, ethanol,\n and oral contraceptives. Oral contraceptives with a high progestin dose can cause depression, probably\n because of metabolically induced tryptophan deficiency.\n Food Additives and Contaminants\n Additives: Chemicals are often combined with foods to facilitate their processing and preservation or to\n enhance their desirability. Only amounts of additives shown to be safe by laboratory tests are permitted in\n commercially prepared foods.\n Weighing the benefits of additives (eg, reduced waste, increased variety of available foods, protection\n against food-borne illness) against the risks is often complex. For example, nitrite, which is used in cured\n meats, inhibits the growth of Clostridium botulinum and improves flavor. However, nitrite converts to\n nitrosamines, which are carcinogens in animals. On the other hand, the amount of nitrite added to cured\n meat is small compared with the amount from naturally occurring food nitrates converted to nitrite by the\n salivary glands. Dietary vitamin C can reduce nitrite formation in the GI tract. Rarely, some additives (eg,\n sulfites) cause food hypersensitivity (allergy) reactions. Most of these reactions are caused by ordinary\n foods (see p. 1118).\n Contaminants: Sometimes limited amounts of contaminants are allowed in foods because the\n contaminants cannot be completely eliminated without damaging the foods. Common contaminants are\n pesticides, heavy metals (lead, cadmium, mercury), nitrates (in green leafy vegetables), aflatoxins (in nuts\n and milk), growth-promoting hormones (in dairy products and meat), animal hairs and feces, and insect\n parts.\n FDA-estimated safe levels are levels that have not caused illness or adverse effects in people. However,\n demonstrating a causal relationship between extremely low level exposures and adverse effects is\n difficult; long-term adverse effects, although unlikely, are still possible. Safe levels are often determined\n by consensus rather than by hard evidence.\n                                                                                                        58",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 1. Nutrition: General Considerations\n\nabsorption. Most patients receiving phenytoin, phenobarbital, primidone, or phenothiazines develop folate deficiency, probably because hepatic microsomal drug-metabolizing enzymes are affected. Folate supplements may make phenytoin less effective. Anticonvulsants can cause vitamin D deficiency. Malabsorption of vitamin B12 can occur with use of aminosalicylic acid, slow-release K iodide, colchicine, trifluoperazine, ethanol, and oral contraceptives. Oral contraceptives with a high progestin dose can cause depression, probably because of metabolically induced tryptophan deficiency.\n\n# Food Additives and Contaminants\n\n# Additives:\n\nChemicals are often combined with foods to facilitate their processing and preservation or to enhance their desirability. Only amounts of additives shown to be safe by laboratory tests are permitted in commercially prepared foods.\n\nWeighing the benefits of additives (eg, reduced waste, increased variety of available foods, protection against food-borne illness) against the risks is often complex. For example, nitrite, which is used in cured meats, inhibits the growth of *Clostridium botulinum* and improves flavor. However, nitrite converts to nitrosamines, which are carcinogens in animals. On the other hand, the amount of nitrite added to cured meat is small compared with the amount from naturally occurring food nitrates converted to nitrite by the salivary glands. Dietary vitamin C can reduce nitrite formation in the GI tract. Rarely, some additives (eg, sulfites) cause food hypersensitivity (allergy) reactions. Most of these reactions are caused by ordinary foods (see p. 1118).\n\n# Contaminants:\n\nSometimes limited amounts of contaminants are allowed in foods because the contaminants cannot be completely eliminated without damaging the foods. Common contaminants are pesticides, heavy metals (lead, cadmium, mercury), nitrates (in green leafy vegetables), aflatoxins (in nuts and milk), growth-promoting hormones (in dairy products and meat), animal hairs and feces, and insect parts.\n\nFDA-estimated safe levels are levels that have not caused illness or adverse effects in people. However, demonstrating a causal relationship between extremely low level exposures and adverse effects is difficult; long-term adverse effects, although unlikely, are still possible. Safe levels are often determined by consensus rather than by hard evidence.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 1. Nutrition: General Considerations",
                    "md": "# Chapter 1. Nutrition: General Considerations",
                    "bBox": {
                        "x": 345,
                        "y": 30.72,
                        "w": 198,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "absorption. Most patients receiving phenytoin, phenobarbital, primidone, or phenothiazines develop folate deficiency, probably because hepatic microsomal drug-metabolizing enzymes are affected. Folate supplements may make phenytoin less effective. Anticonvulsants can cause vitamin D deficiency. Malabsorption of vitamin B12 can occur with use of aminosalicylic acid, slow-release K iodide, colchicine, trifluoperazine, ethanol, and oral contraceptives. Oral contraceptives with a high progestin dose can cause depression, probably because of metabolically induced tryptophan deficiency.",
                    "md": "absorption. Most patients receiving phenytoin, phenobarbital, primidone, or phenothiazines develop folate deficiency, probably because hepatic microsomal drug-metabolizing enzymes are affected. Folate supplements may make phenytoin less effective. Anticonvulsants can cause vitamin D deficiency. Malabsorption of vitamin B12 can occur with use of aminosalicylic acid, slow-release K iodide, colchicine, trifluoperazine, ethanol, and oral contraceptives. Oral contraceptives with a high progestin dose can cause depression, probably because of metabolically induced tryptophan deficiency.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 482,
                        "h": 129
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Food Additives and Contaminants",
                    "md": "# Food Additives and Contaminants",
                    "bBox": {
                        "x": 55,
                        "y": 190.9,
                        "w": 170,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Additives:",
                    "md": "# Additives:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Chemicals are often combined with foods to facilitate their processing and preservation or to enhance their desirability. Only amounts of additives shown to be safe by laboratory tests are permitted in commercially prepared foods.\n\nWeighing the benefits of additives (eg, reduced waste, increased variety of available foods, protection against food-borne illness) against the risks is often complex. For example, nitrite, which is used in cured meats, inhibits the growth of *Clostridium botulinum* and improves flavor. However, nitrite converts to nitrosamines, which are carcinogens in animals. On the other hand, the amount of nitrite added to cured meat is small compared with the amount from naturally occurring food nitrates converted to nitrite by the salivary glands. Dietary vitamin C can reduce nitrite formation in the GI tract. Rarely, some additives (eg, sulfites) cause food hypersensitivity (allergy) reactions. Most of these reactions are caused by ordinary foods (see p. 1118).",
                    "md": "Chemicals are often combined with foods to facilitate their processing and preservation or to enhance their desirability. Only amounts of additives shown to be safe by laboratory tests are permitted in commercially prepared foods.\n\nWeighing the benefits of additives (eg, reduced waste, increased variety of available foods, protection against food-borne illness) against the risks is often complex. For example, nitrite, which is used in cured meats, inhibits the growth of *Clostridium botulinum* and improves flavor. However, nitrite converts to nitrosamines, which are carcinogens in animals. On the other hand, the amount of nitrite added to cured meat is small compared with the amount from naturally occurring food nitrates converted to nitrite by the salivary glands. Dietary vitamin C can reduce nitrite formation in the GI tract. Rarely, some additives (eg, sulfites) cause food hypersensitivity (allergy) reactions. Most of these reactions are caused by ordinary foods (see p. 1118).",
                    "bBox": {
                        "x": 55,
                        "y": 228.9,
                        "w": 481,
                        "h": 139
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Contaminants:",
                    "md": "# Contaminants:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Sometimes limited amounts of contaminants are allowed in foods because the contaminants cannot be completely eliminated without damaging the foods. Common contaminants are pesticides, heavy metals (lead, cadmium, mercury), nitrates (in green leafy vegetables), aflatoxins (in nuts and milk), growth-promoting hormones (in dairy products and meat), animal hairs and feces, and insect parts.\n\nFDA-estimated safe levels are levels that have not caused illness or adverse effects in people. However, demonstrating a causal relationship between extremely low level exposures and adverse effects is difficult; long-term adverse effects, although unlikely, are still possible. Safe levels are often determined by consensus rather than by hard evidence.",
                    "md": "Sometimes limited amounts of contaminants are allowed in foods because the contaminants cannot be completely eliminated without damaging the foods. Common contaminants are pesticides, heavy metals (lead, cadmium, mercury), nitrates (in green leafy vegetables), aflatoxins (in nuts and milk), growth-promoting hormones (in dairy products and meat), animal hairs and feces, and insect parts.\n\nFDA-estimated safe levels are levels that have not caused illness or adverse effects in people. However, demonstrating a causal relationship between extremely low level exposures and adverse effects is difficult; long-term adverse effects, although unlikely, are still possible. Safe levels are often determined by consensus rather than by hard evidence.",
                    "bBox": {
                        "x": 55,
                        "y": 393.9,
                        "w": 482,
                        "h": 114
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.977
        },
        {
            "page": 7,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                           Chapter 2. Undernutrition\n Chapter 2. Undernutrition\n Introduction\n Undernutrition is a form of malnutrition. (Malnutrition also includes overnutrition\u2014see Ch. 6).\n Undernutrition can result from inadequate ingestion of nutrients, malabsorption, impaired\n metabolism, loss of nutrients due to diarrhea, or increased nutritional requirements (as occurs\n in cancer or infection). Undernutrition progresses in stages; each stage usually takes\n considerable time to develop. First, nutrient levels in blood and tissues change, followed by\n intracellular changes in biochemical functions and structure. Ultimately, symptoms and signs\n appear.\n Risk Factors\n Undernutrition is associated with many disorders and circumstances, including poverty and social\n deprivation. Risk is also greater at certain times (ie, during infancy, early childhood, adolescence,\n pregnancy, breastfeeding, and old age).\n Infancy and childhood: Infants and children are particularly susceptible to undernutrition because of\n their high demand for energy and essential nutrients. Because vitamin K does not readily cross the\n placenta, neonates may be deficient, so all are given a single injection of vitamin K within 1 h of birth to\n prevent hemorrhagic disease of the newborn, a life-threatening disorder (see pp. 46 and\n 2783). Infants fed only breast milk, which is typically low in vitamin D, are given supplemental vitamin D;\n they can develop vitamin B12 deficiency if the mother is a vegan. Inadequately fed infants and children\n are at risk of protein-energy undernutrition (PEU\u2014previously called protein-energy malnutrition) and\n deficiencies of iron, folate (folic acid), vitamins A and C, copper, and zinc. During adolescence, nutritional\n requirements increase because the growth rate accelerates. Anorexia nervosa (see p. 1535) may affect\n adolescent girls in particular.\n Pregnancy and breastfeeding: Requirements for nutrients increase during pregnancy and\n breastfeeding. Aberrations of diet, including pica (consumption of nonnutritive substances, such as clay\n and charcoal), may occur during pregnancy. Anemia due to iron deficiency is common, as is anemia due\n to folate deficiency, especially among women who have taken oral contraceptives. Vitamin D deficiency is\n common during late pregnancy, predisposing the child to decreased bone mass.\n Old age: Aging\u2014even when disease or dietary deficiency is absent\u2014leads to sarcopenia (progressive\n loss of lean body mass), starting after age 40 and eventually amounting to a muscle loss of about 10 kg\n (22 lb) in men and 5 kg (11 lb) in women. Undernutrition contributes to sarcopenia, and sarcopenia\n accounts for many of the complications of undernutrition (eg, decreased nitrogen balance, increased\n susceptibility to infections). Causes of sarcopenia include the following:\n \u2022 Decreased physical activity\n \u2022 Decreased food intake\n \u2022 Increased levels of cytokines (particularly interleukin-6)\n \u2022 Decreased levels of growth hormone and mechano growth factor (insulin-like growth factor-3)\n \u2022 In men, decreasing androgen levels\n Aging decreases basal metabolic rate (due mainly to decreased fat-free mass), total body weight, height,\n and skeletal mass; aging increases mean body fat (as a percentage of body weight) to about 30% (from\n 20%) in men and to 40% (from 27%) in women.\n From age 20 to 80, food intake decreases, especially in men. Anorexia due to aging itself has many\n causes, including reduced adaptive relaxation of the stomach's fundus, increased release and activity of\n                                                                                                      59",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 2. Undernutrition\n\n# Introduction\n\nUndernutrition is a form of malnutrition. (Malnutrition also includes overnutrition\u2014see Ch. 6). Undernutrition can result from inadequate ingestion of nutrients, malabsorption, impaired metabolism, loss of nutrients due to diarrhea, or increased nutritional requirements (as occurs in cancer or infection). Undernutrition progresses in stages; each stage usually takes considerable time to develop. First, nutrient levels in blood and tissues change, followed by intracellular changes in biochemical functions and structure. Ultimately, symptoms and signs appear.\n\n# Risk Factors\n\nUndernutrition is associated with many disorders and circumstances, including poverty and social deprivation. Risk is also greater at certain times (ie, during infancy, early childhood, adolescence, pregnancy, breastfeeding, and old age).\n\n# Infancy and childhood:\n\nInfants and children are particularly susceptible to undernutrition because of their high demand for energy and essential nutrients. Because vitamin K does not readily cross the placenta, neonates may be deficient, so all are given a single injection of vitamin K within 1 h of birth to prevent hemorrhagic disease of the newborn, a life-threatening disorder (see pp. 46 and 2783). Infants fed only breast milk, which is typically low in vitamin D, are given supplemental vitamin D; they can develop vitamin B12 deficiency if the mother is a vegan. Inadequately fed infants and children are at risk of protein-energy undernutrition (PEU\u2014previously called protein-energy malnutrition) and deficiencies of iron, folate (folic acid), vitamins A and C, copper, and zinc. During adolescence, nutritional requirements increase because the growth rate accelerates. Anorexia nervosa (see p. 1535) may affect adolescent girls in particular.\n\n# Pregnancy and breastfeeding:\n\nRequirements for nutrients increase during pregnancy and breastfeeding. Aberrations of diet, including pica (consumption of nonnutritive substances, such as clay and charcoal), may occur during pregnancy. Anemia due to iron deficiency is common, as is anemia due to folate deficiency, especially among women who have taken oral contraceptives. Vitamin D deficiency is common during late pregnancy, predisposing the child to decreased bone mass.\n\n# Old age:\n\nAging\u2014even when disease or dietary deficiency is absent\u2014leads to sarcopenia (progressive loss of lean body mass), starting after age 40 and eventually amounting to a muscle loss of about 10 kg (22 lb) in men and 5 kg (11 lb) in women. Undernutrition contributes to sarcopenia, and sarcopenia accounts for many of the complications of undernutrition (eg, decreased nitrogen balance, increased susceptibility to infections). Causes of sarcopenia include the following:\n\n- Decreased physical activity\n- Decreased food intake\n- Increased levels of cytokines (particularly interleukin-6)\n- Decreased levels of growth hormone and mechano growth factor (insulin-like growth factor-3)\n- In men, decreasing androgen levels\n\nAging decreases basal metabolic rate (due mainly to decreased fat-free mass), total body weight, height, and skeletal mass; aging increases mean body fat (as a percentage of body weight) to about 30% (from 20%) in men and to 40% (from 27%) in women.\n\nFrom age 20 to 80, food intake decreases, especially in men. Anorexia due to aging itself has many causes, including reduced adaptive relaxation of the stomach's fundus, increased release and activity of",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 2. Undernutrition",
                    "md": "# Chapter 2. Undernutrition",
                    "bBox": {
                        "x": 55,
                        "y": 30.72,
                        "w": 489,
                        "h": 36.18
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Introduction",
                    "md": "# Introduction",
                    "bBox": {
                        "x": 55,
                        "y": 79.9,
                        "w": 61,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Undernutrition is a form of malnutrition. (Malnutrition also includes overnutrition\u2014see Ch. 6). Undernutrition can result from inadequate ingestion of nutrients, malabsorption, impaired metabolism, loss of nutrients due to diarrhea, or increased nutritional requirements (as occurs in cancer or infection). Undernutrition progresses in stages; each stage usually takes considerable time to develop. First, nutrient levels in blood and tissues change, followed by intracellular changes in biochemical functions and structure. Ultimately, symptoms and signs appear.",
                    "md": "Undernutrition is a form of malnutrition. (Malnutrition also includes overnutrition\u2014see Ch. 6). Undernutrition can result from inadequate ingestion of nutrients, malabsorption, impaired metabolism, loss of nutrients due to diarrhea, or increased nutritional requirements (as occurs in cancer or infection). Undernutrition progresses in stages; each stage usually takes considerable time to develop. First, nutrient levels in blood and tissues change, followed by intracellular changes in biochemical functions and structure. Ultimately, symptoms and signs appear.",
                    "bBox": {
                        "x": 55,
                        "y": 104.9,
                        "w": 473,
                        "h": 88
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Risk Factors",
                    "md": "# Risk Factors",
                    "bBox": {
                        "x": 55,
                        "y": 206.9,
                        "w": 62,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Undernutrition is associated with many disorders and circumstances, including poverty and social deprivation. Risk is also greater at certain times (ie, during infancy, early childhood, adolescence, pregnancy, breastfeeding, and old age).",
                    "md": "Undernutrition is associated with many disorders and circumstances, including poverty and social deprivation. Risk is also greater at certain times (ie, during infancy, early childhood, adolescence, pregnancy, breastfeeding, and old age).",
                    "bBox": {
                        "x": 55,
                        "y": 231.9,
                        "w": 444,
                        "h": 37
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Infancy and childhood:",
                    "md": "# Infancy and childhood:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Infants and children are particularly susceptible to undernutrition because of their high demand for energy and essential nutrients. Because vitamin K does not readily cross the placenta, neonates may be deficient, so all are given a single injection of vitamin K within 1 h of birth to prevent hemorrhagic disease of the newborn, a life-threatening disorder (see pp. 46 and 2783). Infants fed only breast milk, which is typically low in vitamin D, are given supplemental vitamin D; they can develop vitamin B12 deficiency if the mother is a vegan. Inadequately fed infants and children are at risk of protein-energy undernutrition (PEU\u2014previously called protein-energy malnutrition) and deficiencies of iron, folate (folic acid), vitamins A and C, copper, and zinc. During adolescence, nutritional requirements increase because the growth rate accelerates. Anorexia nervosa (see p. 1535) may affect adolescent girls in particular.",
                    "md": "Infants and children are particularly susceptible to undernutrition because of their high demand for energy and essential nutrients. Because vitamin K does not readily cross the placenta, neonates may be deficient, so all are given a single injection of vitamin K within 1 h of birth to prevent hemorrhagic disease of the newborn, a life-threatening disorder (see pp. 46 and 2783). Infants fed only breast milk, which is typically low in vitamin D, are given supplemental vitamin D; they can develop vitamin B12 deficiency if the mother is a vegan. Inadequately fed infants and children are at risk of protein-energy undernutrition (PEU\u2014previously called protein-energy malnutrition) and deficiencies of iron, folate (folic acid), vitamins A and C, copper, and zinc. During adolescence, nutritional requirements increase because the growth rate accelerates. Anorexia nervosa (see p. 1535) may affect adolescent girls in particular.",
                    "bBox": {
                        "x": 55,
                        "y": 294.9,
                        "w": 478,
                        "h": 116
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Pregnancy and breastfeeding:",
                    "md": "# Pregnancy and breastfeeding:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Requirements for nutrients increase during pregnancy and breastfeeding. Aberrations of diet, including pica (consumption of nonnutritive substances, such as clay and charcoal), may occur during pregnancy. Anemia due to iron deficiency is common, as is anemia due to folate deficiency, especially among women who have taken oral contraceptives. Vitamin D deficiency is common during late pregnancy, predisposing the child to decreased bone mass.",
                    "md": "Requirements for nutrients increase during pregnancy and breastfeeding. Aberrations of diet, including pica (consumption of nonnutritive substances, such as clay and charcoal), may occur during pregnancy. Anemia due to iron deficiency is common, as is anemia due to folate deficiency, especially among women who have taken oral contraceptives. Vitamin D deficiency is common during late pregnancy, predisposing the child to decreased bone mass.",
                    "bBox": {
                        "x": 55,
                        "y": 436.9,
                        "w": 480,
                        "h": 50
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Old age:",
                    "md": "# Old age:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Aging\u2014even when disease or dietary deficiency is absent\u2014leads to sarcopenia (progressive loss of lean body mass), starting after age 40 and eventually amounting to a muscle loss of about 10 kg (22 lb) in men and 5 kg (11 lb) in women. Undernutrition contributes to sarcopenia, and sarcopenia accounts for many of the complications of undernutrition (eg, decreased nitrogen balance, increased susceptibility to infections). Causes of sarcopenia include the following:\n\n- Decreased physical activity\n- Decreased food intake\n- Increased levels of cytokines (particularly interleukin-6)\n- Decreased levels of growth hormone and mechano growth factor (insulin-like growth factor-3)\n- In men, decreasing androgen levels\n\nAging decreases basal metabolic rate (due mainly to decreased fat-free mass), total body weight, height, and skeletal mass; aging increases mean body fat (as a percentage of body weight) to about 30% (from 20%) in men and to 40% (from 27%) in women.\n\nFrom age 20 to 80, food intake decreases, especially in men. Anorexia due to aging itself has many causes, including reduced adaptive relaxation of the stomach's fundus, increased release and activity of",
                    "md": "Aging\u2014even when disease or dietary deficiency is absent\u2014leads to sarcopenia (progressive loss of lean body mass), starting after age 40 and eventually amounting to a muscle loss of about 10 kg (22 lb) in men and 5 kg (11 lb) in women. Undernutrition contributes to sarcopenia, and sarcopenia accounts for many of the complications of undernutrition (eg, decreased nitrogen balance, increased susceptibility to infections). Causes of sarcopenia include the following:\n\n- Decreased physical activity\n- Decreased food intake\n- Increased levels of cytokines (particularly interleukin-6)\n- Decreased levels of growth hormone and mechano growth factor (insulin-like growth factor-3)\n- In men, decreasing androgen levels\n\nAging decreases basal metabolic rate (due mainly to decreased fat-free mass), total body weight, height, and skeletal mass; aging increases mean body fat (as a percentage of body weight) to about 30% (from 20%) in men and to 40% (from 27%) in women.\n\nFrom age 20 to 80, food intake decreases, especially in men. Anorexia due to aging itself has many causes, including reduced adaptive relaxation of the stomach's fundus, increased release and activity of",
                    "bBox": {
                        "x": 55,
                        "y": 512.9,
                        "w": 477,
                        "h": 266
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.991
        },
        {
            "page": 8,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                             Chapter 2. Undernutrition\n cholecystokinin (which produces satiation), and increased leptin (an anorectic hormone produced by fat\n cells). Diminished taste and smell can decrease eating pleasure but usually decrease food intake only\n slightly. Anorexia may have other causes (eg, loneliness, inability to shop or prepare meals, dementia,\n some chronic disorders, use of certain drugs). Depression is a common cause. Occasionally, anorexia\n nervosa (sometimes called anorexia tardive in the elderly), paranoia, or mania interferes with eating.\n Dental problems limit the ability to chew and subsequently to digest foods. Swallowing difficulties (eg, due\n to strokes, other neurologic disorders, esophageal candidiasis, or xerostomia) are common. Poverty or\n functional impairment limits access to nutrients.\n The institutionalized elderly are at particular risk of PEU. They are often confused and may be unable to\n express hunger or preferences for foods. They may be physically unable to feed themselves. Chewing or\n swallowing may be very slow, making it tedious for another person to feed them enough food.\n In the elderly, particularly the institutionalized elderly, inadequate intake and often decreased absorption\n or synthesis of vitamin D, increased demand for vitamin D, and inadequate exposure to sunshine\n contribute to osteomalacia (see p. 41).\n Disorders and medical procedures: Diabetes, some chronic disorders that affect the GI tract, intestinal\n resection, and certain other GI surgical procedures tend to impair absorption of fat-soluble vitamins,\n vitamin B12, Ca, and iron. Gluten enteropathy, pancreatic insufficiency, or other disorders can result in\n malabsorption. Decreased absorption possibly contributes to iron deficiency and osteoporosis. Liver\n disorders impair storage of vitamins A and B12 and interfere with metabolism of protein and energy\n sources. Renal insufficiency predisposes to protein, iron, and vitamin D deficiencies. Anorexia causes\n some patients with cancer or depression and many with AIDS to consume inadequate amounts of food.\n Infections, trauma, hyperthyroidism, extensive burns, and prolonged fever increase metabolic demands.\n Any condition that increases cytokines may be accompanied by muscle loss, lipolysis, low albumin levels,\n and anorexia.\n Vegetarian diets: Iron deficiency can occur in ovo-lacto vegetarians (although such a diet can be\n compatible with good health). Vegans may develop vitamin B12 deficiency unless they consume yeast\n extracts or Asian-style fermented foods. Their intake of Ca, iron, and zinc also tends to be low. A fruit-only\n diet is not recommended because it is deficient in protein, Na, and many micronutrients.\n Fad diets: Some fad diets result in vitamin, mineral, and protein deficiencies; cardiac, renal, and\n metabolic disorders; and sometimes death. Very low calorie diets (&lt; 400 kcal/day) cannot sustain health\n for long.\n Drugs and nutritional supplements: Many drugs (eg, appetite suppressants, digoxin) decrease\n appetite; others impair nutrient absorption or metabolism. Some drugs (eg, stimulants) have catabolic\n effects. Certain drugs can impair absorption of many nutrients; eg, anticonvulsants can impair absorption\n of vitamins.\n Alcohol or drug dependency: Patients with alcohol or drug dependency may neglect their nutritional\n needs. Absorption and metabolism of nutrients may also be impaired. IV drug addicts typically become\n undernourished, as do\n [\n Table 2-1. Symptoms and Signs of Nutritional Deficiency]\n alcoholics who consume \u2265 1 quart of hard liquor/day. Alcoholism can cause deficiencies of Mg, zinc, and\n certain vitamins, including thiamin.\n Symptoms and Signs\n Symptoms vary depending on the cause and type of undernutrition (see p. 15 and Chs. 4 and 5).\n Evaluation\n                                                                                                        60",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 2. Undernutrition\n\nCholecystokinin (which produces satiation), and increased leptin (an anorectic hormone produced by fat cells). Diminished taste and smell can decrease eating pleasure but usually decrease food intake only slightly. Anorexia may have other causes (eg, loneliness, inability to shop or prepare meals, dementia, some chronic disorders, use of certain drugs). Depression is a common cause. Occasionally, anorexia nervosa (sometimes called anorexia tardive in the elderly), paranoia, or mania interferes with eating. Dental problems limit the ability to chew and subsequently to digest foods. Swallowing difficulties (eg, due to strokes, other neurologic disorders, esophageal candidiasis, or xerostomia) are common. Poverty or functional impairment limits access to nutrients.\n\nThe institutionalized elderly are at particular risk of PEU. They are often confused and may be unable to express hunger or preferences for foods. They may be physically unable to feed themselves. Chewing or swallowing may be very slow, making it tedious for another person to feed them enough food.\n\nIn the elderly, particularly the institutionalized elderly, inadequate intake and often decreased absorption or synthesis of vitamin D, increased demand for vitamin D, and inadequate exposure to sunshine contribute to osteomalacia (see p. 41).\n\nDisorders and medical procedures: Diabetes, some chronic disorders that affect the GI tract, intestinal resection, and certain other GI surgical procedures tend to impair absorption of fat-soluble vitamins, vitamin B12, Ca, and iron. Gluten enteropathy, pancreatic insufficiency, or other disorders can result in malabsorption. Decreased absorption possibly contributes to iron deficiency and osteoporosis. Liver disorders impair storage of vitamins A and B12 and interfere with metabolism of protein and energy sources. Renal insufficiency predisposes to protein, iron, and vitamin D deficiencies. Anorexia causes some patients with cancer or depression and many with AIDS to consume inadequate amounts of food. Infections, trauma, hyperthyroidism, extensive burns, and prolonged fever increase metabolic demands. Any condition that increases cytokines may be accompanied by muscle loss, lipolysis, low albumin levels, and anorexia.\n\nVegetarian diets: Iron deficiency can occur in ovo-lacto vegetarians (although such a diet can be compatible with good health). Vegans may develop vitamin B12 deficiency unless they consume yeast extracts or Asian-style fermented foods. Their intake of Ca, iron, and zinc also tends to be low. A fruit-only diet is not recommended because it is deficient in protein, Na, and many micronutrients.\n\nFad diets: Some fad diets result in vitamin, mineral, and protein deficiencies; cardiac, renal, and metabolic disorders; and sometimes death. Very low calorie diets (&amp;lt; 400 kcal/day) cannot sustain health for long.\n\nDrugs and nutritional supplements: Many drugs (eg, appetite suppressants, digoxin) decrease appetite; others impair nutrient absorption or metabolism. Some drugs (eg, stimulants) have catabolic effects. Certain drugs can impair absorption of many nutrients; eg, anticonvulsants can impair absorption of vitamins.\n\nAlcohol or drug dependency: Patients with alcohol or drug dependency may neglect their nutritional needs. Absorption and metabolism of nutrients may also be impaired. IV drug addicts typically become undernourished, as do alcoholics who consume \u2265 1 quart of hard liquor/day. Alcoholism can cause deficiencies of Mg, zinc, and certain vitamins, including thiamin.\n\n# Symptoms and Signs\n\nSymptoms vary depending on the cause and type of undernutrition (see p. 15 and Chs. 4 and 5).\n\n# Evaluation\n\nSymptoms and Signs",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 2. Undernutrition",
                    "md": "# Chapter 2. Undernutrition",
                    "bBox": {
                        "x": 431,
                        "y": 30.72,
                        "w": 113,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "Cholecystokinin (which produces satiation), and increased leptin (an anorectic hormone produced by fat cells). Diminished taste and smell can decrease eating pleasure but usually decrease food intake only slightly. Anorexia may have other causes (eg, loneliness, inability to shop or prepare meals, dementia, some chronic disorders, use of certain drugs). Depression is a common cause. Occasionally, anorexia nervosa (sometimes called anorexia tardive in the elderly), paranoia, or mania interferes with eating. Dental problems limit the ability to chew and subsequently to digest foods. Swallowing difficulties (eg, due to strokes, other neurologic disorders, esophageal candidiasis, or xerostomia) are common. Poverty or functional impairment limits access to nutrients.\n\nThe institutionalized elderly are at particular risk of PEU. They are often confused and may be unable to express hunger or preferences for foods. They may be physically unable to feed themselves. Chewing or swallowing may be very slow, making it tedious for another person to feed them enough food.\n\nIn the elderly, particularly the institutionalized elderly, inadequate intake and often decreased absorption or synthesis of vitamin D, increased demand for vitamin D, and inadequate exposure to sunshine contribute to osteomalacia (see p. 41).\n\nDisorders and medical procedures: Diabetes, some chronic disorders that affect the GI tract, intestinal resection, and certain other GI surgical procedures tend to impair absorption of fat-soluble vitamins, vitamin B12, Ca, and iron. Gluten enteropathy, pancreatic insufficiency, or other disorders can result in malabsorption. Decreased absorption possibly contributes to iron deficiency and osteoporosis. Liver disorders impair storage of vitamins A and B12 and interfere with metabolism of protein and energy sources. Renal insufficiency predisposes to protein, iron, and vitamin D deficiencies. Anorexia causes some patients with cancer or depression and many with AIDS to consume inadequate amounts of food. Infections, trauma, hyperthyroidism, extensive burns, and prolonged fever increase metabolic demands. Any condition that increases cytokines may be accompanied by muscle loss, lipolysis, low albumin levels, and anorexia.\n\nVegetarian diets: Iron deficiency can occur in ovo-lacto vegetarians (although such a diet can be compatible with good health). Vegans may develop vitamin B12 deficiency unless they consume yeast extracts or Asian-style fermented foods. Their intake of Ca, iron, and zinc also tends to be low. A fruit-only diet is not recommended because it is deficient in protein, Na, and many micronutrients.\n\nFad diets: Some fad diets result in vitamin, mineral, and protein deficiencies; cardiac, renal, and metabolic disorders; and sometimes death. Very low calorie diets (&amp;lt; 400 kcal/day) cannot sustain health for long.\n\nDrugs and nutritional supplements: Many drugs (eg, appetite suppressants, digoxin) decrease appetite; others impair nutrient absorption or metabolism. Some drugs (eg, stimulants) have catabolic effects. Certain drugs can impair absorption of many nutrients; eg, anticonvulsants can impair absorption of vitamins.\n\nAlcohol or drug dependency: Patients with alcohol or drug dependency may neglect their nutritional needs. Absorption and metabolism of nutrients may also be impaired. IV drug addicts typically become undernourished, as do alcoholics who consume \u2265 1 quart of hard liquor/day. Alcoholism can cause deficiencies of Mg, zinc, and certain vitamins, including thiamin.",
                    "md": "Cholecystokinin (which produces satiation), and increased leptin (an anorectic hormone produced by fat cells). Diminished taste and smell can decrease eating pleasure but usually decrease food intake only slightly. Anorexia may have other causes (eg, loneliness, inability to shop or prepare meals, dementia, some chronic disorders, use of certain drugs). Depression is a common cause. Occasionally, anorexia nervosa (sometimes called anorexia tardive in the elderly), paranoia, or mania interferes with eating. Dental problems limit the ability to chew and subsequently to digest foods. Swallowing difficulties (eg, due to strokes, other neurologic disorders, esophageal candidiasis, or xerostomia) are common. Poverty or functional impairment limits access to nutrients.\n\nThe institutionalized elderly are at particular risk of PEU. They are often confused and may be unable to express hunger or preferences for foods. They may be physically unable to feed themselves. Chewing or swallowing may be very slow, making it tedious for another person to feed them enough food.\n\nIn the elderly, particularly the institutionalized elderly, inadequate intake and often decreased absorption or synthesis of vitamin D, increased demand for vitamin D, and inadequate exposure to sunshine contribute to osteomalacia (see p. 41).\n\nDisorders and medical procedures: Diabetes, some chronic disorders that affect the GI tract, intestinal resection, and certain other GI surgical procedures tend to impair absorption of fat-soluble vitamins, vitamin B12, Ca, and iron. Gluten enteropathy, pancreatic insufficiency, or other disorders can result in malabsorption. Decreased absorption possibly contributes to iron deficiency and osteoporosis. Liver disorders impair storage of vitamins A and B12 and interfere with metabolism of protein and energy sources. Renal insufficiency predisposes to protein, iron, and vitamin D deficiencies. Anorexia causes some patients with cancer or depression and many with AIDS to consume inadequate amounts of food. Infections, trauma, hyperthyroidism, extensive burns, and prolonged fever increase metabolic demands. Any condition that increases cytokines may be accompanied by muscle loss, lipolysis, low albumin levels, and anorexia.\n\nVegetarian diets: Iron deficiency can occur in ovo-lacto vegetarians (although such a diet can be compatible with good health). Vegans may develop vitamin B12 deficiency unless they consume yeast extracts or Asian-style fermented foods. Their intake of Ca, iron, and zinc also tends to be low. A fruit-only diet is not recommended because it is deficient in protein, Na, and many micronutrients.\n\nFad diets: Some fad diets result in vitamin, mineral, and protein deficiencies; cardiac, renal, and metabolic disorders; and sometimes death. Very low calorie diets (&amp;lt; 400 kcal/day) cannot sustain health for long.\n\nDrugs and nutritional supplements: Many drugs (eg, appetite suppressants, digoxin) decrease appetite; others impair nutrient absorption or metabolism. Some drugs (eg, stimulants) have catabolic effects. Certain drugs can impair absorption of many nutrients; eg, anticonvulsants can impair absorption of vitamins.\n\nAlcohol or drug dependency: Patients with alcohol or drug dependency may neglect their nutritional needs. Absorption and metabolism of nutrients may also be impaired. IV drug addicts typically become undernourished, as do alcoholics who consume \u2265 1 quart of hard liquor/day. Alcoholism can cause deficiencies of Mg, zinc, and certain vitamins, including thiamin.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 483,
                        "h": 653
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 714.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Symptoms vary depending on the cause and type of undernutrition (see p. 15 and Chs. 4 and 5).",
                    "md": "Symptoms vary depending on the cause and type of undernutrition (see p. 15 and Chs. 4 and 5).",
                    "bBox": {
                        "x": 55,
                        "y": 740.9,
                        "w": 441,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Evaluation",
                    "md": "# Evaluation",
                    "bBox": {
                        "x": 55,
                        "y": 765.9,
                        "w": 53,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Symptoms and Signs",
                    "md": "Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 714.9,
                        "w": 107,
                        "h": 12
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.987
        },
        {
            "page": 9,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                              Chapter 2. Undernutrition\n Diagnosis is based on results of medical and diet histories, physical examination, body composition\n analysis (see p. 58), and selected laboratory tests.\n History: History should include questions about dietary intake (see\n Fig. 2-1), recent changes in weight, and risk factors for undernutrition, including drug and alcohol use.\n Unintentional loss of \u2265 10% of usual body weight during a 3-mo period indicates a high probability of\n undernutrition. Social history should include questions about whether money is available for food and\n whether the patient can shop and cook.\n Review of systems should focus on symptoms of nutritional deficiencies (see Table 2-1). For example,\n impaired night vision may indicate vitamin A deficiency.\n Physical examination: Physical examination should include measurement of height and weight,\n inspection of body fat distribution, and anthropometric measurements of lean body mass. Body mass\n index (BMI = weight(kg)/height(m)2) adjusts weight for height (see\n Table 6-2 on p. 59). If weight is &lt; 80% of what is predicted for the patient's height or if BMI is \u2264 18,\n undernutrition should be suspected. Although these findings are useful in diagnosing undernutrition and\n are acceptably sensitive, they lack specificity.\n [Fig. 2-1. Mini nutritional assessment.]\n The mid upper arm muscle area estimates lean body mass. This area is derived from the triceps skinfold\n thickness (TSF) and mid upper arm circumference. Both are measured at the same site, with the patient's\n right arm in a relaxed position. The average mid upper arm circumference is about 32 \u00b1 5 cm for men and\n 28 \u00b1 6 cm for women. The formula for calculating the mid upper arm muscle area in cm2 is as follows:\n (midarm circumference (cm) (3.14X TSF cm)]\"  10 (males) or  6.5 (temales)\n This formula corrects the upper arm area for fat and bone. Average values for the mid upper arm muscle\n area are 54 \u00b1 11 cm2 for men and 30 \u00b1 7 cm2 for women. A value &lt; 75% of this standard (depending on\n age) indicates depletion of lean body mass (see\n Table 2-2). This measurement may be affected by physical activity, genetic factors, and age-related\n muscle loss.\n Physical examination should focus on signs of specific nutritional deficiencies. Signs of PEU (eg, edema,\n muscle wasting, skin changes) should be sought. Examination should also focus on signs of conditions\n that could predispose to nutritional deficiencies, such as dental problems. Mental status should be\n assessed, because depression and cognitive impairment can lead to weight loss.\n The widely used Subjective Global Assessment (SGA) uses information from the patient history (eg,\n weight loss, change in intake, GI symptoms), physical examination findings (eg, loss of muscle and\n subcutaneous fat, edema, ascites), and the clinician's judgment of the patient's nutritional status. The\n Mini Nutritional Assessment (MNA) has been validated and is widely used, especially for elderly patients\n (see Fig. 2-1). The Simplified Nutrition Assessment Questionnaire (SNAQ), a simple, validated method of\n predicting future weight loss, may be used (see\n Fig. 2-2).\n Testing: The extent of laboratory testing needed is unclear and may depend on the patient's\n circumstances. If the cause is obvious and correctable (eg, a wilderness survival situation), testing is\n probably of little benefit. Other patients may require more detailed evaluation.\n Serum albumin measurement is the laboratory test most often used. Decreases in albumin and other\n proteins (eg, prealbumin [transthyretin], transferrin, retinol-binding protein) may indicate protein deficiency\n or PEU. As undernutrition progresses, albumin decreases slowly; prealbumin, transferrin, and retinol-\n binding protein decrease rapidly. Albumin measurement is inexpensive and predicts morbidity and\n                                                                                                         61",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 2. Undernutrition\n\nDiagnosis is based on results of medical and diet histories, physical examination, body composition analysis (see p. 58), and selected laboratory tests.\n\n# History\n\nHistory should include questions about dietary intake (see Fig. 2-1), recent changes in weight, and risk factors for undernutrition, including drug and alcohol use. Unintentional loss of \u2265 10% of usual body weight during a 3-mo period indicates a high probability of undernutrition. Social history should include questions about whether money is available for food and whether the patient can shop and cook.\n\n# Review of Systems\n\nReview of systems should focus on symptoms of nutritional deficiencies (see Table 2-1). For example, impaired night vision may indicate vitamin A deficiency.\n\n# Physical Examination\n\nPhysical examination should include measurement of height and weight, inspection of body fat distribution, and anthropometric measurements of lean body mass. Body mass index (BMI = weight(kg)/height(m)2) adjusts weight for height (see Table 6-2 on p. 59). If weight is &lt; 80% of what is predicted for the patient's height or if BMI is \u2264 18, undernutrition should be suspected. Although these findings are useful in diagnosing undernutrition and are acceptably sensitive, they lack specificity.\n\n[Fig. 2-1. Mini nutritional assessment.]\n\nThe mid upper arm muscle area estimates lean body mass. This area is derived from the triceps skinfold thickness (TSF) and mid upper arm circumference. Both are measured at the same site, with the patient's right arm in a relaxed position. The average mid upper arm circumference is about 32 \u00b1 5 cm for men and 28 \u00b1 6 cm for women. The formula for calculating the mid upper arm muscle area in cm2 is as follows:\n\n(midarm circumference (cm) (3.14 X TSF cm)) / 10 (males) or 6.5 (females)\n\nThis formula corrects the upper arm area for fat and bone. Average values for the mid upper arm muscle area are 54 \u00b1 11 cm2 for men and 30 \u00b1 7 cm2 for women. A value &lt; 75% of this standard (depending on age) indicates depletion of lean body mass (see Table 2-2). This measurement may be affected by physical activity, genetic factors, and age-related muscle loss.\n\nPhysical examination should focus on signs of specific nutritional deficiencies. Signs of PEU (eg, edema, muscle wasting, skin changes) should be sought. Examination should also focus on signs of conditions that could predispose to nutritional deficiencies, such as dental problems. Mental status should be assessed, because depression and cognitive impairment can lead to weight loss.\n\nThe widely used Subjective Global Assessment (SGA) uses information from the patient history (eg, weight loss, change in intake, GI symptoms), physical examination findings (eg, loss of muscle and subcutaneous fat, edema, ascites), and the clinician's judgment of the patient's nutritional status. The Mini Nutritional Assessment (MNA) has been validated and is widely used, especially for elderly patients (see Fig. 2-1). The Simplified Nutrition Assessment Questionnaire (SNAQ), a simple, validated method of predicting future weight loss, may be used (see Fig. 2-2).\n\n# Testing\n\nThe extent of laboratory testing needed is unclear and may depend on the patient's circumstances. If the cause is obvious and correctable (eg, a wilderness survival situation), testing is probably of little benefit. Other patients may require more detailed evaluation.\n\nSerum albumin measurement is the laboratory test most often used. Decreases in albumin and other proteins (eg, prealbumin [transthyretin], transferrin, retinol-binding protein) may indicate protein deficiency or PEU. As undernutrition progresses, albumin decreases slowly; prealbumin, transferrin, and retinol-binding protein decrease rapidly. Albumin measurement is inexpensive and predicts morbidity and",
            "images": [
                {
                    "name": "img_p8_1.png",
                    "height": 35,
                    "width": 463,
                    "x": 55.727999957600005,
                    "y": 400.75200200799986,
                    "original_width": 463,
                    "original_height": 35,
                    "ocr": [
                        {
                            "x": 0,
                            "y": 5,
                            "w": 161,
                            "h": 14,
                            "confidence": 0.8291095890473399,
                            "text": "(midarm circumference (cm)"
                        },
                        {
                            "x": 171,
                            "y": 3,
                            "w": 106,
                            "h": 18,
                            "confidence": 0.7491981272797772,
                            "text": "(3.14X TSF cm)]\""
                        },
                        {
                            "x": 295,
                            "y": 15,
                            "w": 78,
                            "h": 16,
                            "confidence": 0.8831350699334549,
                            "text": "10 (males) or"
                        },
                        {
                            "x": 389,
                            "y": 17,
                            "w": 74,
                            "h": 14,
                            "confidence": 0.4913671938391091,
                            "text": "6.5 (temales)"
                        }
                    ]
                }
            ],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 2. Undernutrition",
                    "md": "# Chapter 2. Undernutrition",
                    "bBox": {
                        "x": 431,
                        "y": 30.72,
                        "w": 113,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "Diagnosis is based on results of medical and diet histories, physical examination, body composition analysis (see p. 58), and selected laboratory tests.",
                    "md": "Diagnosis is based on results of medical and diet histories, physical examination, body composition analysis (see p. 58), and selected laboratory tests.",
                    "bBox": {
                        "x": 55,
                        "y": 61.9,
                        "w": 452,
                        "h": 25
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "History",
                    "md": "# History",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "History should include questions about dietary intake (see Fig. 2-1), recent changes in weight, and risk factors for undernutrition, including drug and alcohol use. Unintentional loss of \u2265 10% of usual body weight during a 3-mo period indicates a high probability of undernutrition. Social history should include questions about whether money is available for food and whether the patient can shop and cook.",
                    "md": "History should include questions about dietary intake (see Fig. 2-1), recent changes in weight, and risk factors for undernutrition, including drug and alcohol use. Unintentional loss of \u2265 10% of usual body weight during a 3-mo period indicates a high probability of undernutrition. Social history should include questions about whether money is available for food and whether the patient can shop and cook.",
                    "bBox": {
                        "x": 55,
                        "y": 112.9,
                        "w": 465,
                        "h": 50
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Review of Systems",
                    "md": "# Review of Systems",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Review of systems should focus on symptoms of nutritional deficiencies (see Table 2-1). For example, impaired night vision may indicate vitamin A deficiency.",
                    "md": "Review of systems should focus on symptoms of nutritional deficiencies (see Table 2-1). For example, impaired night vision may indicate vitamin A deficiency.",
                    "bBox": {
                        "x": 55,
                        "y": 175.9,
                        "w": 465,
                        "h": 25
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Physical Examination",
                    "md": "# Physical Examination",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Physical examination should include measurement of height and weight, inspection of body fat distribution, and anthropometric measurements of lean body mass. Body mass index (BMI = weight(kg)/height(m)2) adjusts weight for height (see Table 6-2 on p. 59). If weight is &lt; 80% of what is predicted for the patient's height or if BMI is \u2264 18, undernutrition should be suspected. Although these findings are useful in diagnosing undernutrition and are acceptably sensitive, they lack specificity.\n\n[Fig. 2-1. Mini nutritional assessment.]\n\nThe mid upper arm muscle area estimates lean body mass. This area is derived from the triceps skinfold thickness (TSF) and mid upper arm circumference. Both are measured at the same site, with the patient's right arm in a relaxed position. The average mid upper arm circumference is about 32 \u00b1 5 cm for men and 28 \u00b1 6 cm for women. The formula for calculating the mid upper arm muscle area in cm2 is as follows:\n\n(midarm circumference (cm) (3.14 X TSF cm)) / 10 (males) or 6.5 (females)\n\nThis formula corrects the upper arm area for fat and bone. Average values for the mid upper arm muscle area are 54 \u00b1 11 cm2 for men and 30 \u00b1 7 cm2 for women. A value &lt; 75% of this standard (depending on age) indicates depletion of lean body mass (see Table 2-2). This measurement may be affected by physical activity, genetic factors, and age-related muscle loss.\n\nPhysical examination should focus on signs of specific nutritional deficiencies. Signs of PEU (eg, edema, muscle wasting, skin changes) should be sought. Examination should also focus on signs of conditions that could predispose to nutritional deficiencies, such as dental problems. Mental status should be assessed, because depression and cognitive impairment can lead to weight loss.\n\nThe widely used Subjective Global Assessment (SGA) uses information from the patient history (eg, weight loss, change in intake, GI symptoms), physical examination findings (eg, loss of muscle and subcutaneous fat, edema, ascites), and the clinician's judgment of the patient's nutritional status. The Mini Nutritional Assessment (MNA) has been validated and is widely used, especially for elderly patients (see Fig. 2-1). The Simplified Nutrition Assessment Questionnaire (SNAQ), a simple, validated method of predicting future weight loss, may be used (see Fig. 2-2).",
                    "md": "Physical examination should include measurement of height and weight, inspection of body fat distribution, and anthropometric measurements of lean body mass. Body mass index (BMI = weight(kg)/height(m)2) adjusts weight for height (see Table 6-2 on p. 59). If weight is &lt; 80% of what is predicted for the patient's height or if BMI is \u2264 18, undernutrition should be suspected. Although these findings are useful in diagnosing undernutrition and are acceptably sensitive, they lack specificity.\n\n[Fig. 2-1. Mini nutritional assessment.]\n\nThe mid upper arm muscle area estimates lean body mass. This area is derived from the triceps skinfold thickness (TSF) and mid upper arm circumference. Both are measured at the same site, with the patient's right arm in a relaxed position. The average mid upper arm circumference is about 32 \u00b1 5 cm for men and 28 \u00b1 6 cm for women. The formula for calculating the mid upper arm muscle area in cm2 is as follows:\n\n(midarm circumference (cm) (3.14 X TSF cm)) / 10 (males) or 6.5 (females)\n\nThis formula corrects the upper arm area for fat and bone. Average values for the mid upper arm muscle area are 54 \u00b1 11 cm2 for men and 30 \u00b1 7 cm2 for women. A value &lt; 75% of this standard (depending on age) indicates depletion of lean body mass (see Table 2-2). This measurement may be affected by physical activity, genetic factors, and age-related muscle loss.\n\nPhysical examination should focus on signs of specific nutritional deficiencies. Signs of PEU (eg, edema, muscle wasting, skin changes) should be sought. Examination should also focus on signs of conditions that could predispose to nutritional deficiencies, such as dental problems. Mental status should be assessed, because depression and cognitive impairment can lead to weight loss.\n\nThe widely used Subjective Global Assessment (SGA) uses information from the patient history (eg, weight loss, change in intake, GI symptoms), physical examination findings (eg, loss of muscle and subcutaneous fat, edema, ascites), and the clinician's judgment of the patient's nutritional status. The Mini Nutritional Assessment (MNA) has been validated and is widely used, especially for elderly patients (see Fig. 2-1). The Simplified Nutrition Assessment Questionnaire (SNAQ), a simple, validated method of predicting future weight loss, may be used (see Fig. 2-2).",
                    "bBox": {
                        "x": 55,
                        "y": 226.9,
                        "w": 481,
                        "h": 439
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Testing",
                    "md": "# Testing",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "The extent of laboratory testing needed is unclear and may depend on the patient's circumstances. If the cause is obvious and correctable (eg, a wilderness survival situation), testing is probably of little benefit. Other patients may require more detailed evaluation.\n\nSerum albumin measurement is the laboratory test most often used. Decreases in albumin and other proteins (eg, prealbumin [transthyretin], transferrin, retinol-binding protein) may indicate protein deficiency or PEU. As undernutrition progresses, albumin decreases slowly; prealbumin, transferrin, and retinol-binding protein decrease rapidly. Albumin measurement is inexpensive and predicts morbidity and",
                    "md": "The extent of laboratory testing needed is unclear and may depend on the patient's circumstances. If the cause is obvious and correctable (eg, a wilderness survival situation), testing is probably of little benefit. Other patients may require more detailed evaluation.\n\nSerum albumin measurement is the laboratory test most often used. Decreases in albumin and other proteins (eg, prealbumin [transthyretin], transferrin, retinol-binding protein) may indicate protein deficiency or PEU. As undernutrition progresses, albumin decreases slowly; prealbumin, transferrin, and retinol-binding protein decrease rapidly. Albumin measurement is inexpensive and predicts morbidity and",
                    "bBox": {
                        "x": 55,
                        "y": 691.9,
                        "w": 482,
                        "h": 88
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.99
        },
        {
            "page": 10,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                           Chapter 2. Undernutrition\n mortality better than measurement of the other proteins. However, the correlation of albumin with\n morbidity and mortality may be related to nonnutritional as well as nutritional factors. Inflammation\n produces cytokines that cause albumin and other nutritional protein markers to extravasate, decreasing\n serum levels. Because prealbumin, transferrin, and retinol-binding protein decrease more rapidly during\n starvation than does albumin, their measurements are sometimes used to diagnose or assess the severity\n of acute starvation. However, whether they are more sensitive or specific than albumin is unclear.\n Total lymphocyte count, which often decreases as undernutrition progresses, may be determined.\n Undernutrition causes a marked decline in CD4+ T lymphocytes, so this count may not be useful in\n patients who have AIDS.\n Skin tests using antigens can detect impaired cell-mediated immunity in PEU and in some other disorders\n of undernutrition (see p.\n 1098).\n Other laboratory tests, such as measuring vitamin and mineral levels, are used selectively to diagnose\n specific deficiencies.\n [Table 2-2. Mid Upper Arm Muscle Area in Adults]\n [Figure 2-2. Simplified Nutrition Assessment Questionnaire (SNAQ).]\n Protein-Energy Undernutrition\n Protein-energy undernutrition (PEU), previously called protein-energy malnutrition, is an energy\n deficit due to chronic deficiency of all macronutrients. It commonly includes deficiencies of\n many micronutrients. PEU can be sudden and total (starvation) or gradual. Severity ranges from\n subclinical deficiencies to obvious wasting (with edema, hair loss, and skin atrophy) to\n starvation. Multiple organ systems are often impaired. Diagnosis usually involves laboratory\n testing, including serum albumin. Treatment consists of correcting fluid and electrolyte deficits\n with IV solutions, then gradually replenishing nutrients, orally if possible.\n In developed countries, PEU is common among the institutionalized elderly (although often not suspected)\n and among patients with disorders that decrease appetite or impair nutrient digestion, absorption, or\n metabolism. In developing countries, PEU affects children who do not consume enough calories or\n protein.\n Classification and Etiology\n PEU is graded as mild, moderate, or severe. Grade is determined by calculating weight as a percentage\n of expected weight for length or height using international standards (normal, 90 to 110%; mild PEU, 85 to\n 90%; moderate, 75 to 85%; severe, &lt;75%).\n PEU may be primary or secondary. Primary PEU is caused by inadequate nutrient intake. Secondary PEU\n results from disorders or drugs that interfere with nutrient use.\n Primary PEU: Worldwide, primary PEU occurs mostly in children and the elderly who lack access to\n nutrients, although a common cause in the elderly is depression. PEU can also result from fasting or\n anorexia nervosa. Child or elder abuse may be a cause.\n In children, chronic primary PEU has 2 common forms: marasmus and kwashiorkor. The form depends on\n the balance of nonprotein and protein sources of energy. Starvation is an acute severe form of primary\n PEU.\n Marasmus (also called the dry form of PEU) causes weight loss and depletion of fat and muscle. In\n developing countries, marasmus is the most common form of PEU in children.\n Kwashiorkor (also called the wet, swollen, or edematous form) is associated with premature abandonment\n                                                                                                      62",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 2. Undernutrition\n\nMortality better than measurement of the other proteins. However, the correlation of albumin with morbidity and mortality may be related to nonnutritional as well as nutritional factors. Inflammation produces cytokines that cause albumin and other nutritional protein markers to extravasate, decreasing serum levels. Because prealbumin, transferrin, and retinol-binding protein decrease more rapidly during starvation than does albumin, their measurements are sometimes used to diagnose or assess the severity of acute starvation. However, whether they are more sensitive or specific than albumin is unclear. Total lymphocyte count, which often decreases as undernutrition progresses, may be determined. Undernutrition causes a marked decline in CD4+ T lymphocytes, so this count may not be useful in patients who have AIDS.\n\nSkin tests using antigens can detect impaired cell-mediated immunity in PEU and in some other disorders of undernutrition (see p. 1098). Other laboratory tests, such as measuring vitamin and mineral levels, are used selectively to diagnose specific deficiencies.\n\n[Figure 2-2. Simplified Nutrition Assessment Questionnaire (SNAQ).]\n\n# Protein-Energy Undernutrition\n\nProtein-energy undernutrition (PEU), previously called protein-energy malnutrition, is an energy deficit due to chronic deficiency of all macronutrients. It commonly includes deficiencies of many micronutrients. PEU can be sudden and total (starvation) or gradual. Severity ranges from subclinical deficiencies to obvious wasting (with edema, hair loss, and skin atrophy) to starvation. Multiple organ systems are often impaired. Diagnosis usually involves laboratory testing, including serum albumin. Treatment consists of correcting fluid and electrolyte deficits with IV solutions, then gradually replenishing nutrients, orally if possible.\n\nIn developed countries, PEU is common among the institutionalized elderly (although often not suspected) and among patients with disorders that decrease appetite or impair nutrient digestion, absorption, or metabolism. In developing countries, PEU affects children who do not consume enough calories or protein.\n\n# Classification and Etiology\n\nPEU is graded as mild, moderate, or severe. Grade is determined by calculating weight as a percentage of expected weight for length or height using international standards (normal, 90 to 110%; mild PEU, 85 to 90%; moderate, 75 to 85%; severe, &amp;lt;75%).\n\nPEU may be primary or secondary. Primary PEU is caused by inadequate nutrient intake. Secondary PEU results from disorders or drugs that interfere with nutrient use.\n\n# Primary PEU:\n\nWorldwide, primary PEU occurs mostly in children and the elderly who lack access to nutrients, although a common cause in the elderly is depression. PEU can also result from fasting or anorexia nervosa. Child or elder abuse may be a cause.\n\nIn children, chronic primary PEU has 2 common forms: marasmus and kwashiorkor. The form depends on the balance of nonprotein and protein sources of energy. Starvation is an acute severe form of primary PEU.\n\n# Marasmus\n\n(also called the dry form of PEU) causes weight loss and depletion of fat and muscle. In developing countries, marasmus is the most common form of PEU in children.\n\n# Kwashiorkor\n\n(also called the wet, swollen, or edematous form) is associated with premature abandonment.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 2. Undernutrition",
                    "md": "# Chapter 2. Undernutrition",
                    "bBox": {
                        "x": 431,
                        "y": 30.72,
                        "w": 113,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "Mortality better than measurement of the other proteins. However, the correlation of albumin with morbidity and mortality may be related to nonnutritional as well as nutritional factors. Inflammation produces cytokines that cause albumin and other nutritional protein markers to extravasate, decreasing serum levels. Because prealbumin, transferrin, and retinol-binding protein decrease more rapidly during starvation than does albumin, their measurements are sometimes used to diagnose or assess the severity of acute starvation. However, whether they are more sensitive or specific than albumin is unclear. Total lymphocyte count, which often decreases as undernutrition progresses, may be determined. Undernutrition causes a marked decline in CD4+ T lymphocytes, so this count may not be useful in patients who have AIDS.\n\nSkin tests using antigens can detect impaired cell-mediated immunity in PEU and in some other disorders of undernutrition (see p. 1098). Other laboratory tests, such as measuring vitamin and mineral levels, are used selectively to diagnose specific deficiencies.\n\n[Figure 2-2. Simplified Nutrition Assessment Questionnaire (SNAQ).]",
                    "md": "Mortality better than measurement of the other proteins. However, the correlation of albumin with morbidity and mortality may be related to nonnutritional as well as nutritional factors. Inflammation produces cytokines that cause albumin and other nutritional protein markers to extravasate, decreasing serum levels. Because prealbumin, transferrin, and retinol-binding protein decrease more rapidly during starvation than does albumin, their measurements are sometimes used to diagnose or assess the severity of acute starvation. However, whether they are more sensitive or specific than albumin is unclear. Total lymphocyte count, which often decreases as undernutrition progresses, may be determined. Undernutrition causes a marked decline in CD4+ T lymphocytes, so this count may not be useful in patients who have AIDS.\n\nSkin tests using antigens can detect impaired cell-mediated immunity in PEU and in some other disorders of undernutrition (see p. 1098). Other laboratory tests, such as measuring vitamin and mineral levels, are used selectively to diagnose specific deficiencies.\n\n[Figure 2-2. Simplified Nutrition Assessment Questionnaire (SNAQ).]",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 483,
                        "h": 266
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Protein-Energy Undernutrition",
                    "md": "# Protein-Energy Undernutrition",
                    "bBox": {
                        "x": 55,
                        "y": 327.9,
                        "w": 152,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Protein-energy undernutrition (PEU), previously called protein-energy malnutrition, is an energy deficit due to chronic deficiency of all macronutrients. It commonly includes deficiencies of many micronutrients. PEU can be sudden and total (starvation) or gradual. Severity ranges from subclinical deficiencies to obvious wasting (with edema, hair loss, and skin atrophy) to starvation. Multiple organ systems are often impaired. Diagnosis usually involves laboratory testing, including serum albumin. Treatment consists of correcting fluid and electrolyte deficits with IV solutions, then gradually replenishing nutrients, orally if possible.\n\nIn developed countries, PEU is common among the institutionalized elderly (although often not suspected) and among patients with disorders that decrease appetite or impair nutrient digestion, absorption, or metabolism. In developing countries, PEU affects children who do not consume enough calories or protein.",
                    "md": "Protein-energy undernutrition (PEU), previously called protein-energy malnutrition, is an energy deficit due to chronic deficiency of all macronutrients. It commonly includes deficiencies of many micronutrients. PEU can be sudden and total (starvation) or gradual. Severity ranges from subclinical deficiencies to obvious wasting (with edema, hair loss, and skin atrophy) to starvation. Multiple organ systems are often impaired. Diagnosis usually involves laboratory testing, including serum albumin. Treatment consists of correcting fluid and electrolyte deficits with IV solutions, then gradually replenishing nutrients, orally if possible.\n\nIn developed countries, PEU is common among the institutionalized elderly (although often not suspected) and among patients with disorders that decrease appetite or impair nutrient digestion, absorption, or metabolism. In developing countries, PEU affects children who do not consume enough calories or protein.",
                    "bBox": {
                        "x": 55,
                        "y": 327.9,
                        "w": 483,
                        "h": 177
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Classification and Etiology",
                    "md": "# Classification and Etiology",
                    "bBox": {
                        "x": 55,
                        "y": 517.9,
                        "w": 133,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "PEU is graded as mild, moderate, or severe. Grade is determined by calculating weight as a percentage of expected weight for length or height using international standards (normal, 90 to 110%; mild PEU, 85 to 90%; moderate, 75 to 85%; severe, &amp;lt;75%).\n\nPEU may be primary or secondary. Primary PEU is caused by inadequate nutrient intake. Secondary PEU results from disorders or drugs that interfere with nutrient use.",
                    "md": "PEU is graded as mild, moderate, or severe. Grade is determined by calculating weight as a percentage of expected weight for length or height using international standards (normal, 90 to 110%; mild PEU, 85 to 90%; moderate, 75 to 85%; severe, &amp;lt;75%).\n\nPEU may be primary or secondary. Primary PEU is caused by inadequate nutrient intake. Secondary PEU results from disorders or drugs that interfere with nutrient use.",
                    "bBox": {
                        "x": 55,
                        "y": 543.9,
                        "w": 484,
                        "h": 75
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Primary PEU:",
                    "md": "# Primary PEU:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Worldwide, primary PEU occurs mostly in children and the elderly who lack access to nutrients, although a common cause in the elderly is depression. PEU can also result from fasting or anorexia nervosa. Child or elder abuse may be a cause.\n\nIn children, chronic primary PEU has 2 common forms: marasmus and kwashiorkor. The form depends on the balance of nonprotein and protein sources of energy. Starvation is an acute severe form of primary PEU.",
                    "md": "Worldwide, primary PEU occurs mostly in children and the elderly who lack access to nutrients, although a common cause in the elderly is depression. PEU can also result from fasting or anorexia nervosa. Child or elder abuse may be a cause.\n\nIn children, chronic primary PEU has 2 common forms: marasmus and kwashiorkor. The form depends on the balance of nonprotein and protein sources of energy. Starvation is an acute severe form of primary PEU.",
                    "bBox": {
                        "x": 55,
                        "y": 644.9,
                        "w": 481,
                        "h": 75
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Marasmus",
                    "md": "# Marasmus",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "(also called the dry form of PEU) causes weight loss and depletion of fat and muscle. In developing countries, marasmus is the most common form of PEU in children.",
                    "md": "(also called the dry form of PEU) causes weight loss and depletion of fat and muscle. In developing countries, marasmus is the most common form of PEU in children.",
                    "bBox": {
                        "x": 55,
                        "y": 745.9,
                        "w": 354,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Kwashiorkor",
                    "md": "# Kwashiorkor",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "(also called the wet, swollen, or edematous form) is associated with premature abandonment.",
                    "md": "(also called the wet, swollen, or edematous form) is associated with premature abandonment.",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.981
        },
        {
            "page": 11,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                              Chapter 2. Undernutrition\n of breastfeeding, which typically occurs when a younger sibling is born, displacing the older child from the\n breast. So children with kwashiorkor tend to be older than those with marasmus. Kwashiorkor may also\n result from an acute illness, often gastroenteritis or another infection (probably secondary to cytokine\n release), in a child who already has PEU. A diet that is more deficient in protein than energy may be more\n likely to cause kwashiorkor than marasmus. Less common than marasmus, kwashiorkor tends to be\n confined to specific parts of the world, such as rural Africa, the Caribbean, and the Pacific islands. In\n these areas, staple foods (eg, yams, cassavas, sweet potatoes, green bananas) are low in protein and\n high in carbohydrates. In kwashiorkor, cell membranes leak, causing extravasation of intravascular fluid\n and protein, resulting in peripheral edema.\n Starvation is a complete lack of nutrients. It occasionally occurs when food is available (as in fasting or\n anorexia nervosa) but usually occurs because food is unavailable (eg, during famine or wilderness\n exposure).\n Secondary PEU: This type most commonly results from the following:\n \u2022 Disorders that affect GI function: These disorders can interfere with digestion (eg, pancreatic\n   insufficiency), absorption (eg, enteritis, enteropathy), or lymphatic transport of nutrients (eg,\n   retroperitoneal fibrosis, Milroy's disease).\n \u2022 Wasting disorders: In wasting disorders (eg, AIDS, cancer) and renal failure, catabolism causes cytokine\n   excess, resulting in undernutrition via anorexia and cachexia (wasting of muscle and fat). End-stage\n   heart failure can cause cardiac cachexia, a severe form of undernutrition; mortality rate is particularly\n   high. Factors contributing to cardiac cachexia may include passive hepatic congestion (causing\n   anorexia), edema of the intestinal tract (impairing absorption), and, in advanced disease, increased O2\n   requirement due to anaerobic metabolism. Wasting disorders can decrease appetite or impair\n   metabolism of nutrients.\n \u2022 Conditions that increase metabolic demands: These conditions include infections, hyperthyroidism,\n   pheochromocytoma, other endocrine disorders, burns, trauma, surgery, and other critical illnesses.\n Pathophysiology\n The initial metabolic response is decreased metabolic rate. To supply energy, the body first breaks down\n adipose tissue. However, later when these tissues are depleted, the body may use protein for energy,\n resulting in a negative nitrogen balance. Visceral organs and muscle are broken down and decrease in\n weight. Loss of organ weight is greatest in the liver and intestine, intermediate in the heart and kidneys,\n and least in the nervous system.\n Symptoms and Signs\n Symptoms of moderate PEU can be constitutional or involve specific organ systems. Apathy and irritability\n are common. The patient is weak, and work capacity decreases. Cognition and sometimes\n consciousness are impaired. Temporary lactose deficiency and achlorhydria develop. Diarrhea is common\n and can be aggravated by deficiency of intestinal disaccharidases, especially lactase (see p. 157).\n Gonadal tissues atrophy. PEU can cause amenorrhea in women and loss of libido in men and women.\n Wasting of fat and muscle is common in all forms of PEU. In adult volunteers who fasted for 30 to 40\n days, weight loss was marked (25% of initial weight). If starvation is more prolonged, weight loss may\n reach 50% in adults and possibly more in children.\n In adults, cachexia is most obvious in areas where prominent fat depots normally exist. Muscles shrink\n and bones protrude. The skin becomes thin, dry, inelastic, pale, and cold. The hair is dry and falls out\n easily, becoming sparse. Wound healing is impaired. In elderly patients, risk of hip fractures and pressure\n (decubitus) ulcers increases.\n With acute or chronic severe PEU, heart size and cardiac output decrease; pulse slows\n                                                                                                         63",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 2. Undernutrition\n\nof breastfeeding, which typically occurs when a younger sibling is born, displacing the older child from the breast. So children with kwashiorkor tend to be older than those with marasmus. Kwashiorkor may also result from an acute illness, often gastroenteritis or another infection (probably secondary to cytokine release), in a child who already has PEU. A diet that is more deficient in protein than energy may be more likely to cause kwashiorkor than marasmus. Less common than marasmus, kwashiorkor tends to be confined to specific parts of the world, such as rural Africa, the Caribbean, and the Pacific islands. In these areas, staple foods (eg, yams, cassavas, sweet potatoes, green bananas) are low in protein and high in carbohydrates. In kwashiorkor, cell membranes leak, causing extravasation of intravascular fluid and protein, resulting in peripheral edema.\n\nStarvation is a complete lack of nutrients. It occasionally occurs when food is available (as in fasting or anorexia nervosa) but usually occurs because food is unavailable (eg, during famine or wilderness exposure).\n\n# Secondary PEU\n\nThis type most commonly results from the following:\n\n- Disorders that affect GI function: These disorders can interfere with digestion (eg, pancreatic insufficiency), absorption (eg, enteritis, enteropathy), or lymphatic transport of nutrients (eg, retroperitoneal fibrosis, Milroy's disease).\n- Wasting disorders: In wasting disorders (eg, AIDS, cancer) and renal failure, catabolism causes cytokine excess, resulting in undernutrition via anorexia and cachexia (wasting of muscle and fat). End-stage heart failure can cause cardiac cachexia, a severe form of undernutrition; mortality rate is particularly high. Factors contributing to cardiac cachexia may include passive hepatic congestion (causing anorexia), edema of the intestinal tract (impairing absorption), and, in advanced disease, increased O2 requirement due to anaerobic metabolism. Wasting disorders can decrease appetite or impair metabolism of nutrients.\n- Conditions that increase metabolic demands: These conditions include infections, hyperthyroidism, pheochromocytoma, other endocrine disorders, burns, trauma, surgery, and other critical illnesses.\n\n# Pathophysiology\n\nThe initial metabolic response is decreased metabolic rate. To supply energy, the body first breaks down adipose tissue. However, later when these tissues are depleted, the body may use protein for energy, resulting in a negative nitrogen balance. Visceral organs and muscle are broken down and decrease in weight. Loss of organ weight is greatest in the liver and intestine, intermediate in the heart and kidneys, and least in the nervous system.\n\n# Symptoms and Signs\n\nSymptoms of moderate PEU can be constitutional or involve specific organ systems. Apathy and irritability are common. The patient is weak, and work capacity decreases. Cognition and sometimes consciousness are impaired. Temporary lactose deficiency and achlorhydria develop. Diarrhea is common and can be aggravated by deficiency of intestinal disaccharidases, especially lactase (see p. 157). Gonadal tissues atrophy. PEU can cause amenorrhea in women and loss of libido in men and women. Wasting of fat and muscle is common in all forms of PEU. In adult volunteers who fasted for 30 to 40 days, weight loss was marked (25% of initial weight). If starvation is more prolonged, weight loss may reach 50% in adults and possibly more in children.\n\nIn adults, cachexia is most obvious in areas where prominent fat depots normally exist. Muscles shrink and bones protrude. The skin becomes thin, dry, inelastic, pale, and cold. The hair is dry and falls out easily, becoming sparse. Wound healing is impaired. In elderly patients, risk of hip fractures and pressure (decubitus) ulcers increases.\n\nWith acute or chronic severe PEU, heart size and cardiac output decrease; pulse slows.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 2. Undernutrition",
                    "md": "# Chapter 2. Undernutrition",
                    "bBox": {
                        "x": 431,
                        "y": 30.72,
                        "w": 113,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "of breastfeeding, which typically occurs when a younger sibling is born, displacing the older child from the breast. So children with kwashiorkor tend to be older than those with marasmus. Kwashiorkor may also result from an acute illness, often gastroenteritis or another infection (probably secondary to cytokine release), in a child who already has PEU. A diet that is more deficient in protein than energy may be more likely to cause kwashiorkor than marasmus. Less common than marasmus, kwashiorkor tends to be confined to specific parts of the world, such as rural Africa, the Caribbean, and the Pacific islands. In these areas, staple foods (eg, yams, cassavas, sweet potatoes, green bananas) are low in protein and high in carbohydrates. In kwashiorkor, cell membranes leak, causing extravasation of intravascular fluid and protein, resulting in peripheral edema.\n\nStarvation is a complete lack of nutrients. It occasionally occurs when food is available (as in fasting or anorexia nervosa) but usually occurs because food is unavailable (eg, during famine or wilderness exposure).",
                    "md": "of breastfeeding, which typically occurs when a younger sibling is born, displacing the older child from the breast. So children with kwashiorkor tend to be older than those with marasmus. Kwashiorkor may also result from an acute illness, often gastroenteritis or another infection (probably secondary to cytokine release), in a child who already has PEU. A diet that is more deficient in protein than energy may be more likely to cause kwashiorkor than marasmus. Less common than marasmus, kwashiorkor tends to be confined to specific parts of the world, such as rural Africa, the Caribbean, and the Pacific islands. In these areas, staple foods (eg, yams, cassavas, sweet potatoes, green bananas) are low in protein and high in carbohydrates. In kwashiorkor, cell membranes leak, causing extravasation of intravascular fluid and protein, resulting in peripheral edema.\n\nStarvation is a complete lack of nutrients. It occasionally occurs when food is available (as in fasting or anorexia nervosa) but usually occurs because food is unavailable (eg, during famine or wilderness exposure).",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 482,
                        "h": 164
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Secondary PEU",
                    "md": "# Secondary PEU",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "This type most commonly results from the following:\n\n- Disorders that affect GI function: These disorders can interfere with digestion (eg, pancreatic insufficiency), absorption (eg, enteritis, enteropathy), or lymphatic transport of nutrients (eg, retroperitoneal fibrosis, Milroy's disease).\n- Wasting disorders: In wasting disorders (eg, AIDS, cancer) and renal failure, catabolism causes cytokine excess, resulting in undernutrition via anorexia and cachexia (wasting of muscle and fat). End-stage heart failure can cause cardiac cachexia, a severe form of undernutrition; mortality rate is particularly high. Factors contributing to cardiac cachexia may include passive hepatic congestion (causing anorexia), edema of the intestinal tract (impairing absorption), and, in advanced disease, increased O2 requirement due to anaerobic metabolism. Wasting disorders can decrease appetite or impair metabolism of nutrients.\n- Conditions that increase metabolic demands: These conditions include infections, hyperthyroidism, pheochromocytoma, other endocrine disorders, burns, trauma, surgery, and other critical illnesses.",
                    "md": "This type most commonly results from the following:\n\n- Disorders that affect GI function: These disorders can interfere with digestion (eg, pancreatic insufficiency), absorption (eg, enteritis, enteropathy), or lymphatic transport of nutrients (eg, retroperitoneal fibrosis, Milroy's disease).\n- Wasting disorders: In wasting disorders (eg, AIDS, cancer) and renal failure, catabolism causes cytokine excess, resulting in undernutrition via anorexia and cachexia (wasting of muscle and fat). End-stage heart failure can cause cardiac cachexia, a severe form of undernutrition; mortality rate is particularly high. Factors contributing to cardiac cachexia may include passive hepatic congestion (causing anorexia), edema of the intestinal tract (impairing absorption), and, in advanced disease, increased O2 requirement due to anaerobic metabolism. Wasting disorders can decrease appetite or impair metabolism of nutrients.\n- Conditions that increase metabolic demands: These conditions include infections, hyperthyroidism, pheochromocytoma, other endocrine disorders, burns, trauma, surgery, and other critical illnesses.",
                    "bBox": {
                        "x": 64,
                        "y": 264.9,
                        "w": 469,
                        "h": 166
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Pathophysiology",
                    "md": "# Pathophysiology",
                    "bBox": {
                        "x": 55,
                        "y": 444.9,
                        "w": 84,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "The initial metabolic response is decreased metabolic rate. To supply energy, the body first breaks down adipose tissue. However, later when these tissues are depleted, the body may use protein for energy, resulting in a negative nitrogen balance. Visceral organs and muscle are broken down and decrease in weight. Loss of organ weight is greatest in the liver and intestine, intermediate in the heart and kidneys, and least in the nervous system.",
                    "md": "The initial metabolic response is decreased metabolic rate. To supply energy, the body first breaks down adipose tissue. However, later when these tissues are depleted, the body may use protein for energy, resulting in a negative nitrogen balance. Visceral organs and muscle are broken down and decrease in weight. Loss of organ weight is greatest in the liver and intestine, intermediate in the heart and kidneys, and least in the nervous system.",
                    "bBox": {
                        "x": 55,
                        "y": 469.9,
                        "w": 477,
                        "h": 63
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 545.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Symptoms of moderate PEU can be constitutional or involve specific organ systems. Apathy and irritability are common. The patient is weak, and work capacity decreases. Cognition and sometimes consciousness are impaired. Temporary lactose deficiency and achlorhydria develop. Diarrhea is common and can be aggravated by deficiency of intestinal disaccharidases, especially lactase (see p. 157). Gonadal tissues atrophy. PEU can cause amenorrhea in women and loss of libido in men and women. Wasting of fat and muscle is common in all forms of PEU. In adult volunteers who fasted for 30 to 40 days, weight loss was marked (25% of initial weight). If starvation is more prolonged, weight loss may reach 50% in adults and possibly more in children.\n\nIn adults, cachexia is most obvious in areas where prominent fat depots normally exist. Muscles shrink and bones protrude. The skin becomes thin, dry, inelastic, pale, and cold. The hair is dry and falls out easily, becoming sparse. Wound healing is impaired. In elderly patients, risk of hip fractures and pressure (decubitus) ulcers increases.\n\nWith acute or chronic severe PEU, heart size and cardiac output decrease; pulse slows.",
                    "md": "Symptoms of moderate PEU can be constitutional or involve specific organ systems. Apathy and irritability are common. The patient is weak, and work capacity decreases. Cognition and sometimes consciousness are impaired. Temporary lactose deficiency and achlorhydria develop. Diarrhea is common and can be aggravated by deficiency of intestinal disaccharidases, especially lactase (see p. 157). Gonadal tissues atrophy. PEU can cause amenorrhea in women and loss of libido in men and women. Wasting of fat and muscle is common in all forms of PEU. In adult volunteers who fasted for 30 to 40 days, weight loss was marked (25% of initial weight). If starvation is more prolonged, weight loss may reach 50% in adults and possibly more in children.\n\nIn adults, cachexia is most obvious in areas where prominent fat depots normally exist. Muscles shrink and bones protrude. The skin becomes thin, dry, inelastic, pale, and cold. The hair is dry and falls out easily, becoming sparse. Wound healing is impaired. In elderly patients, risk of hip fractures and pressure (decubitus) ulcers increases.\n\nWith acute or chronic severe PEU, heart size and cardiac output decrease; pulse slows.",
                    "bBox": {
                        "x": 55,
                        "y": 570.9,
                        "w": 483,
                        "h": 202
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 12,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                             Chapter 2. Undernutrition\n [\n Table 2-3. Values Commonly Used to Grade the Severity of Protein-Energy Undernutrition]\n and BP falls. Respiratory rate and vital capacity decrease. Body temperature falls, sometimes contributing\n to death. Edema, anemia, jaundice, and petechiae can develop. Liver, kidney, or heart failure may occur.\n Cell-mediated immunity is impaired, increasing susceptibility to infections. Bacterial infections (eg,\n pneumonia, gastroenteritis, otitis media, UTIs, sepsis) are common in both forms of PEU. Infections result\n in release of cytokines, which cause anorexia, worsen muscle wasting, and cause a marked decrease in\n serum albumin levels.\n Marasmus in infants causes hunger, weight loss, growth retardation, and wasting of subcutaneous fat\n and muscle. Ribs and facial bones appear prominent. Loose, thin skin hangs in folds.\n Kwashiorkor is characterized by peripheral and periorbital edema. The abdomen protrudes because\n abdominal muscles are weakened, the intestine is distended, the liver enlarges, and ascites is present.\n The skin is dry, thin, and wrinkled; it can become hyperpigmented and fissured and later hypopigmented,\n friable, and atrophic. Skin in different areas of the body may be affected at different times. The hair can\n become thin, reddish brown, or gray. Scalp hair falls out easily, eventually becoming sparse, but eyelash\n hair may grow excessively. Alternating episodes of undernutrition and adequate nutrition may cause the\n hair to have a dramatic \"striped flag\" appearance. Affected children may be apathetic but become irritable\n when held.\n Total starvation is fatal in 8 to 12 wk. Thus, certain symptoms of PEU do not have time to develop.\n Diagnosis\n \u2022 Diagnosis usually based on history\n \u2022 To determine severity: BMI, serum albumin, total lymphocyte count, CD4+ count, serum transferrin\n \u2022 To diagnose complications and consequences: CBC, electrolytes, BUN, glucose, Ca, Mg, phosphate\n Diagnosis can be based on history when dietary intake is markedly inadequate. The cause of inadequate\n intake, particularly in children, needs to be identified. In children and adolescents, child abuse and\n anorexia nervosa should be considered.\n Physical examination findings can usually confirm the diagnosis. Laboratory tests are required if dietary\n history does not clearly indicate inadequate caloric intake. Measurement of serum albumin, total\n lymphocyte count, CD4+ T lymphocytes, transferrin, and response to skin antigens may help determine\n the severity of PEU (see Table 2-3) or confirm the diagnosis in borderline cases. Many other test results\n may be abnormal: eg, decreased levels of hormones, vitamins, lipids, cholesterol, prealbumin, insulin\n growth factor-1, fibronectin, and retinol-binding protein. Urinary creatine and methylhistidine levels can be\n used to gauge the degree of muscle wasting. Because protein catabolism slows, urinary urea level also\n decreases. These findings rarely affect treatment.\n Laboratory tests are required to identify causes of suspected secondary PEU. C-reactive protein or\n soluble interleukin-2 receptor should be measured when the cause of undernutrition is unclear; these\n measurements can help determine whether there is cytokine excess. Thyroid function tests may also be\n done.\n Other laboratory tests can detect associated abnormalities that may require treatment. Serum\n electrolytes, BUN, glucose, and possibly levels of Ca, Mg, and phosphate should be measured. Levels of\n serum glucose, electrolytes (especially K, occasionally Na), phosphate, Ca, and Mg are usually low. BUN\n is often low unless renal failure is present. Metabolic acidosis may be present. CBC is usually obtained;\n normocytic anemia (usually due to protein deficiency) or microcytic anemia (due to simultaneous iron\n deficiency) is usually present.\n                                                                                                        64",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 2. Undernutrition\n\n# Table 2-3. Values Commonly Used to Grade the Severity of Protein-Energy Undernutrition\n\nand BP falls. Respiratory rate and vital capacity decrease. Body temperature falls, sometimes contributing to death. Edema, anemia, jaundice, and petechiae can develop. Liver, kidney, or heart failure may occur. Cell-mediated immunity is impaired, increasing susceptibility to infections. Bacterial infections (eg, pneumonia, gastroenteritis, otitis media, UTIs, sepsis) are common in both forms of PEU. Infections result in release of cytokines, which cause anorexia, worsen muscle wasting, and cause a marked decrease in serum albumin levels.\n\nMarasmus in infants causes hunger, weight loss, growth retardation, and wasting of subcutaneous fat and muscle. Ribs and facial bones appear prominent. Loose, thin skin hangs in folds.\n\nKwashiorkor is characterized by peripheral and periorbital edema. The abdomen protrudes because abdominal muscles are weakened, the intestine is distended, the liver enlarges, and ascites is present. The skin is dry, thin, and wrinkled; it can become hyperpigmented and fissured and later hypopigmented, friable, and atrophic. Skin in different areas of the body may be affected at different times. The hair can become thin, reddish brown, or gray. Scalp hair falls out easily, eventually becoming sparse, but eyelash hair may grow excessively. Alternating episodes of undernutrition and adequate nutrition may cause the hair to have a dramatic \"striped flag\" appearance. Affected children may be apathetic but become irritable when held.\n\nTotal starvation is fatal in 8 to 12 wk. Thus, certain symptoms of PEU do not have time to develop.\n\n# Diagnosis\n\n- Diagnosis usually based on history\n- To determine severity: BMI, serum albumin, total lymphocyte count, CD4+ count, serum transferrin\n- To diagnose complications and consequences: CBC, electrolytes, BUN, glucose, Ca, Mg, phosphate\n\nDiagnosis can be based on history when dietary intake is markedly inadequate. The cause of inadequate intake, particularly in children, needs to be identified. In children and adolescents, child abuse and anorexia nervosa should be considered.\n\nPhysical examination findings can usually confirm the diagnosis. Laboratory tests are required if dietary history does not clearly indicate inadequate caloric intake. Measurement of serum albumin, total lymphocyte count, CD4+ T lymphocytes, transferrin, and response to skin antigens may help determine the severity of PEU (see Table 2-3) or confirm the diagnosis in borderline cases. Many other test results may be abnormal: eg, decreased levels of hormones, vitamins, lipids, cholesterol, prealbumin, insulin growth factor-1, fibronectin, and retinol-binding protein. Urinary creatine and methylhistidine levels can be used to gauge the degree of muscle wasting. Because protein catabolism slows, urinary urea level also decreases. These findings rarely affect treatment.\n\nLaboratory tests are required to identify causes of suspected secondary PEU. C-reactive protein or soluble interleukin-2 receptor should be measured when the cause of undernutrition is unclear; these measurements can help determine whether there is cytokine excess. Thyroid function tests may also be done.\n\nOther laboratory tests can detect associated abnormalities that may require treatment. Serum electrolytes, BUN, glucose, and possibly levels of Ca, Mg, and phosphate should be measured. Levels of serum glucose, electrolytes (especially K, occasionally Na), phosphate, Ca, and Mg are usually low. BUN is often low unless renal failure is present. Metabolic acidosis may be present. CBC is usually obtained; normocytic anemia (usually due to protein deficiency) or microcytic anemia (due to simultaneous iron deficiency) is usually present.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 347.18
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 2. Undernutrition",
                    "md": "# Chapter 2. Undernutrition",
                    "bBox": {
                        "x": 431,
                        "y": 30.72,
                        "w": 113,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Table 2-3. Values Commonly Used to Grade the Severity of Protein-Energy Undernutrition",
                    "md": "# Table 2-3. Values Commonly Used to Grade the Severity of Protein-Energy Undernutrition",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "and BP falls. Respiratory rate and vital capacity decrease. Body temperature falls, sometimes contributing to death. Edema, anemia, jaundice, and petechiae can develop. Liver, kidney, or heart failure may occur. Cell-mediated immunity is impaired, increasing susceptibility to infections. Bacterial infections (eg, pneumonia, gastroenteritis, otitis media, UTIs, sepsis) are common in both forms of PEU. Infections result in release of cytokines, which cause anorexia, worsen muscle wasting, and cause a marked decrease in serum albumin levels.\n\nMarasmus in infants causes hunger, weight loss, growth retardation, and wasting of subcutaneous fat and muscle. Ribs and facial bones appear prominent. Loose, thin skin hangs in folds.\n\nKwashiorkor is characterized by peripheral and periorbital edema. The abdomen protrudes because abdominal muscles are weakened, the intestine is distended, the liver enlarges, and ascites is present. The skin is dry, thin, and wrinkled; it can become hyperpigmented and fissured and later hypopigmented, friable, and atrophic. Skin in different areas of the body may be affected at different times. The hair can become thin, reddish brown, or gray. Scalp hair falls out easily, eventually becoming sparse, but eyelash hair may grow excessively. Alternating episodes of undernutrition and adequate nutrition may cause the hair to have a dramatic \"striped flag\" appearance. Affected children may be apathetic but become irritable when held.\n\nTotal starvation is fatal in 8 to 12 wk. Thus, certain symptoms of PEU do not have time to develop.",
                    "md": "and BP falls. Respiratory rate and vital capacity decrease. Body temperature falls, sometimes contributing to death. Edema, anemia, jaundice, and petechiae can develop. Liver, kidney, or heart failure may occur. Cell-mediated immunity is impaired, increasing susceptibility to infections. Bacterial infections (eg, pneumonia, gastroenteritis, otitis media, UTIs, sepsis) are common in both forms of PEU. Infections result in release of cytokines, which cause anorexia, worsen muscle wasting, and cause a marked decrease in serum albumin levels.\n\nMarasmus in infants causes hunger, weight loss, growth retardation, and wasting of subcutaneous fat and muscle. Ribs and facial bones appear prominent. Loose, thin skin hangs in folds.\n\nKwashiorkor is characterized by peripheral and periorbital edema. The abdomen protrudes because abdominal muscles are weakened, the intestine is distended, the liver enlarges, and ascites is present. The skin is dry, thin, and wrinkled; it can become hyperpigmented and fissured and later hypopigmented, friable, and atrophic. Skin in different areas of the body may be affected at different times. The hair can become thin, reddish brown, or gray. Scalp hair falls out easily, eventually becoming sparse, but eyelash hair may grow excessively. Alternating episodes of undernutrition and adequate nutrition may cause the hair to have a dramatic \"striped flag\" appearance. Affected children may be apathetic but become irritable when held.\n\nTotal starvation is fatal in 8 to 12 wk. Thus, certain symptoms of PEU do not have time to develop.",
                    "bBox": {
                        "x": 55,
                        "y": 86.9,
                        "w": 483,
                        "h": 266
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 365.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Diagnosis usually based on history\n- To determine severity: BMI, serum albumin, total lymphocyte count, CD4+ count, serum transferrin\n- To diagnose complications and consequences: CBC, electrolytes, BUN, glucose, Ca, Mg, phosphate\n\nDiagnosis can be based on history when dietary intake is markedly inadequate. The cause of inadequate intake, particularly in children, needs to be identified. In children and adolescents, child abuse and anorexia nervosa should be considered.\n\nPhysical examination findings can usually confirm the diagnosis. Laboratory tests are required if dietary history does not clearly indicate inadequate caloric intake. Measurement of serum albumin, total lymphocyte count, CD4+ T lymphocytes, transferrin, and response to skin antigens may help determine the severity of PEU (see Table 2-3) or confirm the diagnosis in borderline cases. Many other test results may be abnormal: eg, decreased levels of hormones, vitamins, lipids, cholesterol, prealbumin, insulin growth factor-1, fibronectin, and retinol-binding protein. Urinary creatine and methylhistidine levels can be used to gauge the degree of muscle wasting. Because protein catabolism slows, urinary urea level also decreases. These findings rarely affect treatment.\n\nLaboratory tests are required to identify causes of suspected secondary PEU. C-reactive protein or soluble interleukin-2 receptor should be measured when the cause of undernutrition is unclear; these measurements can help determine whether there is cytokine excess. Thyroid function tests may also be done.\n\nOther laboratory tests can detect associated abnormalities that may require treatment. Serum electrolytes, BUN, glucose, and possibly levels of Ca, Mg, and phosphate should be measured. Levels of serum glucose, electrolytes (especially K, occasionally Na), phosphate, Ca, and Mg are usually low. BUN is often low unless renal failure is present. Metabolic acidosis may be present. CBC is usually obtained; normocytic anemia (usually due to protein deficiency) or microcytic anemia (due to simultaneous iron deficiency) is usually present.",
                    "md": "- Diagnosis usually based on history\n- To determine severity: BMI, serum albumin, total lymphocyte count, CD4+ count, serum transferrin\n- To diagnose complications and consequences: CBC, electrolytes, BUN, glucose, Ca, Mg, phosphate\n\nDiagnosis can be based on history when dietary intake is markedly inadequate. The cause of inadequate intake, particularly in children, needs to be identified. In children and adolescents, child abuse and anorexia nervosa should be considered.\n\nPhysical examination findings can usually confirm the diagnosis. Laboratory tests are required if dietary history does not clearly indicate inadequate caloric intake. Measurement of serum albumin, total lymphocyte count, CD4+ T lymphocytes, transferrin, and response to skin antigens may help determine the severity of PEU (see Table 2-3) or confirm the diagnosis in borderline cases. Many other test results may be abnormal: eg, decreased levels of hormones, vitamins, lipids, cholesterol, prealbumin, insulin growth factor-1, fibronectin, and retinol-binding protein. Urinary creatine and methylhistidine levels can be used to gauge the degree of muscle wasting. Because protein catabolism slows, urinary urea level also decreases. These findings rarely affect treatment.\n\nLaboratory tests are required to identify causes of suspected secondary PEU. C-reactive protein or soluble interleukin-2 receptor should be measured when the cause of undernutrition is unclear; these measurements can help determine whether there is cytokine excess. Thyroid function tests may also be done.\n\nOther laboratory tests can detect associated abnormalities that may require treatment. Serum electrolytes, BUN, glucose, and possibly levels of Ca, Mg, and phosphate should be measured. Levels of serum glucose, electrolytes (especially K, occasionally Na), phosphate, Ca, and Mg are usually low. BUN is often low unless renal failure is present. Metabolic acidosis may be present. CBC is usually obtained; normocytic anemia (usually due to protein deficiency) or microcytic anemia (due to simultaneous iron deficiency) is usually present.",
                    "bBox": {
                        "x": 55,
                        "y": 365.9,
                        "w": 482,
                        "h": 405
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 13,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                              Chapter 2. Undernutrition\n Stool cultures should be obtained and checked for ova and parasites if diarrhea is severe or does not\n resolve with treatment. Sometimes urinalysis, urine culture, blood cultures, tuberculin testing, and a chest\n x-ray are used to diagnose occult infections because people with PEU may have a muted response to\n infections.\n Prognosis\n Children: In children, mortality varies from 5 to 40%. Mortality rates are lower in children with mild PEU\n and those given intensive care. Death in the first days of treatment is usually due to electrolyte deficits,\n sepsis, hypothermia, or heart failure. Impaired consciousness, jaundice, petechiae, hyponatremia, and\n persistent diarrhea are ominous signs. Resolution of apathy, edema, and anorexia is a favorable sign.\n Recovery is more rapid in kwashiorkor than in marasmus.\n Long-term effects of PEU in children are not fully documented. Some children develop chronic\n malabsorption and pancreatic insufficiency. In very young children, mild intellectual disability may develop\n and persist until at least school age. Permanent cognitive impairment may occur, depending on the\n duration, severity, and age at onset of PEU.\n Adults: In adults, PEU can result in morbidity and mortality (eg, progressive weight loss increases\n mortality rate for elderly patients in nursing homes). In elderly patients, PEU increases the risk of\n morbidity and mortality due to surgery, infections, or other disorders. Except when organ failure occurs,\n treatment is uniformly successful.\n Treatment\n \u2022 Usually, oral feeding\n \u2022 Possibly avoidance of lactose (eg, if persistent diarrhea suggests lactose intolerance)\n \u2022 Supportive care (eg, environmental changes, assistance with feeding, orexigenic drugs)\n \u2022 For children, feeding delayed 24 to 48 h\n Worldwide, the most important preventive strategy is to reduce poverty and improve nutritional education\n and public health measures.\n Mild or moderate PEU, including brief starvation, can be treated by providing a balanced diet, preferably\n orally. Liquid oral food supplements (usually lactose-free) can be used when solid food cannot be\n adequately ingested. Diarrhea often complicates oral feeding because starvation makes the GI tract more\n likely to move bacteria into Peyer's patches, facilitating infectious diarrhea. If diarrhea persists\n (suggesting lactose intolerance), yogurt-based rather than milk-based formulas are given because people\n with lactose intolerance can tolerate yogurt. Patients should also be given a multivitamin supplement.\n Severe PEU or prolonged starvation requires treatment in a hospital with a controlled diet. The first\n priority is to correct fluid and electrolyte abnormalities (see Ch. 97) and treat infections. Next is to supply\n macronutrients orally or, if necessary (eg, when swallowing is difficult), through a feeding tube, a\n nasogastric tube (usually), or a gastrostomy tube. Parenteral nutrition is indicated if malabsorption is\n severe (see p. 23).\n Other treatments may be needed to correct specific deficiencies, which may become evident as weight\n increases. To avoid deficiencies, patients should take micronutrients at about twice the recommended\n daily allowance (RDA) until recovery is complete.\n Children: Underlying disorders should be treated. For children with diarrhea, feeding may be delayed 24\n to 48 h to avoid making the diarrhea worse; during this interval, children require oral or IV rehydration.\n Feedings are given often (6 to 12 times/day) but, to avoid overwhelming the limited intestinal absorptive\n capacity, are limited to small amounts (&lt; 100 mL). During the first week, milk-based formulas with\n supplements added are usually given in progressively increasing amounts; after a week, the full amounts\n                                                                                                         65",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 2. Undernutrition\n\nStool cultures should be obtained and checked for ova and parasites if diarrhea is severe or does not resolve with treatment. Sometimes urinalysis, urine culture, blood cultures, tuberculin testing, and a chest x-ray are used to diagnose occult infections because people with PEU may have a muted response to infections.\n\n# Prognosis\n\n# Children:\n\nIn children, mortality varies from 5 to 40%. Mortality rates are lower in children with mild PEU and those given intensive care. Death in the first days of treatment is usually due to electrolyte deficits, sepsis, hypothermia, or heart failure. Impaired consciousness, jaundice, petechiae, hyponatremia, and persistent diarrhea are ominous signs. Resolution of apathy, edema, and anorexia is a favorable sign. Recovery is more rapid in kwashiorkor than in marasmus.\n\nLong-term effects of PEU in children are not fully documented. Some children develop chronic malabsorption and pancreatic insufficiency. In very young children, mild intellectual disability may develop and persist until at least school age. Permanent cognitive impairment may occur, depending on the duration, severity, and age at onset of PEU.\n\n# Adults:\n\nIn adults, PEU can result in morbidity and mortality (eg, progressive weight loss increases mortality rate for elderly patients in nursing homes). In elderly patients, PEU increases the risk of morbidity and mortality due to surgery, infections, or other disorders. Except when organ failure occurs, treatment is uniformly successful.\n\n# Treatment\n\n- Usually, oral feeding\n- Possibly avoidance of lactose (eg, if persistent diarrhea suggests lactose intolerance)\n- Supportive care (eg, environmental changes, assistance with feeding, orexigenic drugs)\n- For children, feeding delayed 24 to 48 h\n\nWorldwide, the most important preventive strategy is to reduce poverty and improve nutritional education and public health measures.\n\nMild or moderate PEU, including brief starvation, can be treated by providing a balanced diet, preferably orally. Liquid oral food supplements (usually lactose-free) can be used when solid food cannot be adequately ingested. Diarrhea often complicates oral feeding because starvation makes the GI tract more likely to move bacteria into Peyer's patches, facilitating infectious diarrhea. If diarrhea persists (suggesting lactose intolerance), yogurt-based rather than milk-based formulas are given because people with lactose intolerance can tolerate yogurt. Patients should also be given a multivitamin supplement.\n\nSevere PEU or prolonged starvation requires treatment in a hospital with a controlled diet. The first priority is to correct fluid and electrolyte abnormalities (see Ch. 97) and treat infections. Next is to supply macronutrients orally or, if necessary (eg, when swallowing is difficult), through a feeding tube, a nasogastric tube (usually), or a gastrostomy tube. Parenteral nutrition is indicated if malabsorption is severe (see p. 23).\n\nOther treatments may be needed to correct specific deficiencies, which may become evident as weight increases. To avoid deficiencies, patients should take micronutrients at about twice the recommended daily allowance (RDA) until recovery is complete.\n\n# Children:\n\nUnderlying disorders should be treated. For children with diarrhea, feeding may be delayed 24 to 48 h to avoid making the diarrhea worse; during this interval, children require oral or IV rehydration. Feedings are given often (6 to 12 times/day) but, to avoid overwhelming the limited intestinal absorptive capacity, are limited to small amounts (&amp;lt; 100 mL). During the first week, milk-based formulas with supplements added are usually given in progressively increasing amounts; after a week, the full amounts.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 2. Undernutrition",
                    "md": "# Chapter 2. Undernutrition",
                    "bBox": {
                        "x": 431,
                        "y": 30.72,
                        "w": 113,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "Stool cultures should be obtained and checked for ova and parasites if diarrhea is severe or does not resolve with treatment. Sometimes urinalysis, urine culture, blood cultures, tuberculin testing, and a chest x-ray are used to diagnose occult infections because people with PEU may have a muted response to infections.",
                    "md": "Stool cultures should be obtained and checked for ova and parasites if diarrhea is severe or does not resolve with treatment. Sometimes urinalysis, urine culture, blood cultures, tuberculin testing, and a chest x-ray are used to diagnose occult infections because people with PEU may have a muted response to infections.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 480,
                        "h": 304
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Prognosis",
                    "md": "# Prognosis",
                    "bBox": {
                        "x": 55,
                        "y": 112.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Children:",
                    "md": "# Children:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "In children, mortality varies from 5 to 40%. Mortality rates are lower in children with mild PEU and those given intensive care. Death in the first days of treatment is usually due to electrolyte deficits, sepsis, hypothermia, or heart failure. Impaired consciousness, jaundice, petechiae, hyponatremia, and persistent diarrhea are ominous signs. Resolution of apathy, edema, and anorexia is a favorable sign. Recovery is more rapid in kwashiorkor than in marasmus.\n\nLong-term effects of PEU in children are not fully documented. Some children develop chronic malabsorption and pancreatic insufficiency. In very young children, mild intellectual disability may develop and persist until at least school age. Permanent cognitive impairment may occur, depending on the duration, severity, and age at onset of PEU.",
                    "md": "In children, mortality varies from 5 to 40%. Mortality rates are lower in children with mild PEU and those given intensive care. Death in the first days of treatment is usually due to electrolyte deficits, sepsis, hypothermia, or heart failure. Impaired consciousness, jaundice, petechiae, hyponatremia, and persistent diarrhea are ominous signs. Resolution of apathy, edema, and anorexia is a favorable sign. Recovery is more rapid in kwashiorkor than in marasmus.\n\nLong-term effects of PEU in children are not fully documented. Some children develop chronic malabsorption and pancreatic insufficiency. In very young children, mild intellectual disability may develop and persist until at least school age. Permanent cognitive impairment may occur, depending on the duration, severity, and age at onset of PEU.",
                    "bBox": {
                        "x": 55,
                        "y": 150.9,
                        "w": 480,
                        "h": 202
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Adults:",
                    "md": "# Adults:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "In adults, PEU can result in morbidity and mortality (eg, progressive weight loss increases mortality rate for elderly patients in nursing homes). In elderly patients, PEU increases the risk of morbidity and mortality due to surgery, infections, or other disorders. Except when organ failure occurs, treatment is uniformly successful.",
                    "md": "In adults, PEU can result in morbidity and mortality (eg, progressive weight loss increases mortality rate for elderly patients in nursing homes). In elderly patients, PEU increases the risk of morbidity and mortality due to surgery, infections, or other disorders. Except when organ failure occurs, treatment is uniformly successful.",
                    "bBox": {
                        "x": 55,
                        "y": 289.9,
                        "w": 469,
                        "h": 63
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 340.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Usually, oral feeding\n- Possibly avoidance of lactose (eg, if persistent diarrhea suggests lactose intolerance)\n- Supportive care (eg, environmental changes, assistance with feeding, orexigenic drugs)\n- For children, feeding delayed 24 to 48 h\n\nWorldwide, the most important preventive strategy is to reduce poverty and improve nutritional education and public health measures.\n\nMild or moderate PEU, including brief starvation, can be treated by providing a balanced diet, preferably orally. Liquid oral food supplements (usually lactose-free) can be used when solid food cannot be adequately ingested. Diarrhea often complicates oral feeding because starvation makes the GI tract more likely to move bacteria into Peyer's patches, facilitating infectious diarrhea. If diarrhea persists (suggesting lactose intolerance), yogurt-based rather than milk-based formulas are given because people with lactose intolerance can tolerate yogurt. Patients should also be given a multivitamin supplement.\n\nSevere PEU or prolonged starvation requires treatment in a hospital with a controlled diet. The first priority is to correct fluid and electrolyte abnormalities (see Ch. 97) and treat infections. Next is to supply macronutrients orally or, if necessary (eg, when swallowing is difficult), through a feeding tube, a nasogastric tube (usually), or a gastrostomy tube. Parenteral nutrition is indicated if malabsorption is severe (see p. 23).\n\nOther treatments may be needed to correct specific deficiencies, which may become evident as weight increases. To avoid deficiencies, patients should take micronutrients at about twice the recommended daily allowance (RDA) until recovery is complete.",
                    "md": "- Usually, oral feeding\n- Possibly avoidance of lactose (eg, if persistent diarrhea suggests lactose intolerance)\n- Supportive care (eg, environmental changes, assistance with feeding, orexigenic drugs)\n- For children, feeding delayed 24 to 48 h\n\nWorldwide, the most important preventive strategy is to reduce poverty and improve nutritional education and public health measures.\n\nMild or moderate PEU, including brief starvation, can be treated by providing a balanced diet, preferably orally. Liquid oral food supplements (usually lactose-free) can be used when solid food cannot be adequately ingested. Diarrhea often complicates oral feeding because starvation makes the GI tract more likely to move bacteria into Peyer's patches, facilitating infectious diarrhea. If diarrhea persists (suggesting lactose intolerance), yogurt-based rather than milk-based formulas are given because people with lactose intolerance can tolerate yogurt. Patients should also be given a multivitamin supplement.\n\nSevere PEU or prolonged starvation requires treatment in a hospital with a controlled diet. The first priority is to correct fluid and electrolyte abnormalities (see Ch. 97) and treat infections. Next is to supply macronutrients orally or, if necessary (eg, when swallowing is difficult), through a feeding tube, a nasogastric tube (usually), or a gastrostomy tube. Parenteral nutrition is indicated if malabsorption is severe (see p. 23).\n\nOther treatments may be needed to correct specific deficiencies, which may become evident as weight increases. To avoid deficiencies, patients should take micronutrients at about twice the recommended daily allowance (RDA) until recovery is complete.",
                    "bBox": {
                        "x": 55,
                        "y": 86.9,
                        "w": 482,
                        "h": 621
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Children:",
                    "md": "# Children:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Underlying disorders should be treated. For children with diarrhea, feeding may be delayed 24 to 48 h to avoid making the diarrhea worse; during this interval, children require oral or IV rehydration. Feedings are given often (6 to 12 times/day) but, to avoid overwhelming the limited intestinal absorptive capacity, are limited to small amounts (&amp;lt; 100 mL). During the first week, milk-based formulas with supplements added are usually given in progressively increasing amounts; after a week, the full amounts.",
                    "md": "Underlying disorders should be treated. For children with diarrhea, feeding may be delayed 24 to 48 h to avoid making the diarrhea worse; during this interval, children require oral or IV rehydration. Feedings are given often (6 to 12 times/day) but, to avoid overwhelming the limited intestinal absorptive capacity, are limited to small amounts (&amp;lt; 100 mL). During the first week, milk-based formulas with supplements added are usually given in progressively increasing amounts; after a week, the full amounts.",
                    "bBox": {
                        "x": 55,
                        "y": 733.9,
                        "w": 478,
                        "h": 50
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 14,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                              Chapter 2. Undernutrition\n of 175 kcal/kg and 4 g of protein/kg can be given. Twice the RDA of micronutrients should be given,\n using commercial multivitamin supplements. After 4 wk, the formula can be replaced with whole milk plus\n cod liver oil and solid foods, including eggs, fruit, meats, and yeast.\n Energy distribution among macronutrients should be about 16% protein, 50% fat, and 34% carbohydrate.\n An example is a combination of powdered cow's skimmed milk (110 g), sucrose (100 g), vegetable oil (70\n g), and water (900 mL). Many other formulas (eg, whole [full-fat] fresh milk plus corn oil and maltodextrin)\n can be used. Milk powders used in formulas are diluted with water.\n Usually, supplements should be added to formulas:\n \u2022 Mg 0.4 mEq/kg/day IM is given for 7 days.\n \u2022 B-complex vitamins at twice the RDA are given parenterally for the first 3 days, usually with vitamin A,\n   phosphorus, zinc, manganese, copper, iodine, fluoride, molybdenum, and selenium.\n \u2022 Because absorption of oral iron is poor in children with PEU, oral or IM iron supplementation may be\n   necessary.\n Parents are taught about nutritional requirements.\n Adults: Underlying disorders should be treated. For example, if AIDS or cancer results in excess cytokine\n production, megestrol acetate or medroxyprogesterone may improve food intake. However, because\n these drugs dramatically decrease testosterone in men (possibly causing muscle loss), testosterone\n should be replaced. Because these drugs can cause adrenal insufficiency, they should be used only\n short-term (&lt; 3 mo).\n In patients with functional limitations, home delivery of meals and feeding assistance are key.\n An orexigenic drug, such as the cannabis extract dronabinol, should be given to patients with anorexia\n when no cause is obvious or to patients at the end of life when anorexia impairs quality of life. An\n anabolic steroid (eg, enanthate, nandrolone, testosterone) or growth hormone can benefit patients with\n cachexia due to renal failure and possibly elderly patients (eg, by increasing lean body mass or possibly\n by improving function).\n Correction of PEU in adults generally resembles that in children; feedings are often limited to small\n amounts. However, for most adults, feeding does not need to be delayed. A commercial formula for oral\n feeding can be used. Daily nutrient supply should be given at a rate of 60 kcal/kg and 1.2 to 2 g of\n protein/kg. If liquid oral supplements are used with solid food, they should be given at least 1 h before\n meals so that the amount of food eaten at the meal is not reduced.\n Treatment of institutionalized elderly patients with PEU requires multiple interventions:\n \u2022 Environmental measures (eg, making the dining area more attractive)\n \u2022 Feeding assistance\n \u2022 Changes in diet (eg, use of food enhancers and caloric supplements between meals)\n \u2022 Treatment of depression and other underlying disorders\n \u2022 Use of orexigenics, anabolic steroids, or both\n The long-term use of gastrostomy tube feeding is essential for patients with severe dysphagia; its use in\n patients with dementia is controversial. Increasing evidence supports the avoidance of unpalatable\n therapeutic diets (eg, low salt, diabetic, low cholesterol) in institutionalized patients because these diets\n decrease food intake and may cause severe PEU.\n                                                                                                         66",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 2. Undernutrition\n\nof 175 kcal/kg and 4 g of protein/kg can be given. Twice the RDA of micronutrients should be given, using commercial multivitamin supplements. After 4 wk, the formula can be replaced with whole milk plus cod liver oil and solid foods, including eggs, fruit, meats, and yeast.\n\nEnergy distribution among macronutrients should be about 16% protein, 50% fat, and 34% carbohydrate. An example is a combination of powdered cow's skimmed milk (110 g), sucrose (100 g), vegetable oil (70 g), and water (900 mL). Many other formulas (eg, whole [full-fat] fresh milk plus corn oil and maltodextrin) can be used. Milk powders used in formulas are diluted with water.\n\nUsually, supplements should be added to formulas:\n\n- Mg 0.4 mEq/kg/day IM is given for 7 days.\n- B-complex vitamins at twice the RDA are given parenterally for the first 3 days, usually with vitamin A, phosphorus, zinc, manganese, copper, iodine, fluoride, molybdenum, and selenium.\n- Because absorption of oral iron is poor in children with PEU, oral or IM iron supplementation may be necessary.\n\nParents are taught about nutritional requirements.\n\nAdults: Underlying disorders should be treated. For example, if AIDS or cancer results in excess cytokine production, megestrol acetate or medroxyprogesterone may improve food intake. However, because these drugs dramatically decrease testosterone in men (possibly causing muscle loss), testosterone should be replaced. Because these drugs can cause adrenal insufficiency, they should be used only short-term (&amp;lt; 3 mo).\n\nIn patients with functional limitations, home delivery of meals and feeding assistance are key. An orexigenic drug, such as the cannabis extract dronabinol, should be given to patients with anorexia when no cause is obvious or to patients at the end of life when anorexia impairs quality of life. An anabolic steroid (eg, enanthate, nandrolone, testosterone) or growth hormone can benefit patients with cachexia due to renal failure and possibly elderly patients (eg, by increasing lean body mass or possibly by improving function).\n\nCorrection of PEU in adults generally resembles that in children; feedings are often limited to small amounts. However, for most adults, feeding does not need to be delayed. A commercial formula for oral feeding can be used. Daily nutrient supply should be given at a rate of 60 kcal/kg and 1.2 to 2 g of protein/kg. If liquid oral supplements are used with solid food, they should be given at least 1 h before meals so that the amount of food eaten at the meal is not reduced.\n\nTreatment of institutionalized elderly patients with PEU requires multiple interventions:\n\n- Environmental measures (eg, making the dining area more attractive)\n- Feeding assistance\n- Changes in diet (eg, use of food enhancers and caloric supplements between meals)\n- Treatment of depression and other underlying disorders\n- Use of orexigenics, anabolic steroids, or both\n\nThe long-term use of gastrostomy tube feeding is essential for patients with severe dysphagia; its use in patients with dementia is controversial. Increasing evidence supports the avoidance of unpalatable therapeutic diets (eg, low salt, diabetic, low cholesterol) in institutionalized patients because these diets decrease food intake and may cause severe PEU.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 2. Undernutrition",
                    "md": "# Chapter 2. Undernutrition",
                    "bBox": {
                        "x": 431,
                        "y": 30.72,
                        "w": 113,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "of 175 kcal/kg and 4 g of protein/kg can be given. Twice the RDA of micronutrients should be given, using commercial multivitamin supplements. After 4 wk, the formula can be replaced with whole milk plus cod liver oil and solid foods, including eggs, fruit, meats, and yeast.\n\nEnergy distribution among macronutrients should be about 16% protein, 50% fat, and 34% carbohydrate. An example is a combination of powdered cow's skimmed milk (110 g), sucrose (100 g), vegetable oil (70 g), and water (900 mL). Many other formulas (eg, whole [full-fat] fresh milk plus corn oil and maltodextrin) can be used. Milk powders used in formulas are diluted with water.\n\nUsually, supplements should be added to formulas:\n\n- Mg 0.4 mEq/kg/day IM is given for 7 days.\n- B-complex vitamins at twice the RDA are given parenterally for the first 3 days, usually with vitamin A, phosphorus, zinc, manganese, copper, iodine, fluoride, molybdenum, and selenium.\n- Because absorption of oral iron is poor in children with PEU, oral or IM iron supplementation may be necessary.\n\nParents are taught about nutritional requirements.\n\nAdults: Underlying disorders should be treated. For example, if AIDS or cancer results in excess cytokine production, megestrol acetate or medroxyprogesterone may improve food intake. However, because these drugs dramatically decrease testosterone in men (possibly causing muscle loss), testosterone should be replaced. Because these drugs can cause adrenal insufficiency, they should be used only short-term (&amp;lt; 3 mo).\n\nIn patients with functional limitations, home delivery of meals and feeding assistance are key. An orexigenic drug, such as the cannabis extract dronabinol, should be given to patients with anorexia when no cause is obvious or to patients at the end of life when anorexia impairs quality of life. An anabolic steroid (eg, enanthate, nandrolone, testosterone) or growth hormone can benefit patients with cachexia due to renal failure and possibly elderly patients (eg, by increasing lean body mass or possibly by improving function).\n\nCorrection of PEU in adults generally resembles that in children; feedings are often limited to small amounts. However, for most adults, feeding does not need to be delayed. A commercial formula for oral feeding can be used. Daily nutrient supply should be given at a rate of 60 kcal/kg and 1.2 to 2 g of protein/kg. If liquid oral supplements are used with solid food, they should be given at least 1 h before meals so that the amount of food eaten at the meal is not reduced.\n\nTreatment of institutionalized elderly patients with PEU requires multiple interventions:\n\n- Environmental measures (eg, making the dining area more attractive)\n- Feeding assistance\n- Changes in diet (eg, use of food enhancers and caloric supplements between meals)\n- Treatment of depression and other underlying disorders\n- Use of orexigenics, anabolic steroids, or both\n\nThe long-term use of gastrostomy tube feeding is essential for patients with severe dysphagia; its use in patients with dementia is controversial. Increasing evidence supports the avoidance of unpalatable therapeutic diets (eg, low salt, diabetic, low cholesterol) in institutionalized patients because these diets decrease food intake and may cause severe PEU.",
                    "md": "of 175 kcal/kg and 4 g of protein/kg can be given. Twice the RDA of micronutrients should be given, using commercial multivitamin supplements. After 4 wk, the formula can be replaced with whole milk plus cod liver oil and solid foods, including eggs, fruit, meats, and yeast.\n\nEnergy distribution among macronutrients should be about 16% protein, 50% fat, and 34% carbohydrate. An example is a combination of powdered cow's skimmed milk (110 g), sucrose (100 g), vegetable oil (70 g), and water (900 mL). Many other formulas (eg, whole [full-fat] fresh milk plus corn oil and maltodextrin) can be used. Milk powders used in formulas are diluted with water.\n\nUsually, supplements should be added to formulas:\n\n- Mg 0.4 mEq/kg/day IM is given for 7 days.\n- B-complex vitamins at twice the RDA are given parenterally for the first 3 days, usually with vitamin A, phosphorus, zinc, manganese, copper, iodine, fluoride, molybdenum, and selenium.\n- Because absorption of oral iron is poor in children with PEU, oral or IM iron supplementation may be necessary.\n\nParents are taught about nutritional requirements.\n\nAdults: Underlying disorders should be treated. For example, if AIDS or cancer results in excess cytokine production, megestrol acetate or medroxyprogesterone may improve food intake. However, because these drugs dramatically decrease testosterone in men (possibly causing muscle loss), testosterone should be replaced. Because these drugs can cause adrenal insufficiency, they should be used only short-term (&amp;lt; 3 mo).\n\nIn patients with functional limitations, home delivery of meals and feeding assistance are key. An orexigenic drug, such as the cannabis extract dronabinol, should be given to patients with anorexia when no cause is obvious or to patients at the end of life when anorexia impairs quality of life. An anabolic steroid (eg, enanthate, nandrolone, testosterone) or growth hormone can benefit patients with cachexia due to renal failure and possibly elderly patients (eg, by increasing lean body mass or possibly by improving function).\n\nCorrection of PEU in adults generally resembles that in children; feedings are often limited to small amounts. However, for most adults, feeding does not need to be delayed. A commercial formula for oral feeding can be used. Daily nutrient supply should be given at a rate of 60 kcal/kg and 1.2 to 2 g of protein/kg. If liquid oral supplements are used with solid food, they should be given at least 1 h before meals so that the amount of food eaten at the meal is not reduced.\n\nTreatment of institutionalized elderly patients with PEU requires multiple interventions:\n\n- Environmental measures (eg, making the dining area more attractive)\n- Feeding assistance\n- Changes in diet (eg, use of food enhancers and caloric supplements between meals)\n- Treatment of depression and other underlying disorders\n- Use of orexigenics, anabolic steroids, or both\n\nThe long-term use of gastrostomy tube feeding is essential for patients with severe dysphagia; its use in patients with dementia is controversial. Increasing evidence supports the avoidance of unpalatable therapeutic diets (eg, low salt, diabetic, low cholesterol) in institutionalized patients because these diets decrease food intake and may cause severe PEU.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 482,
                        "h": 722
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 15,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                            Chapter 2. Undernutrition\n Complications of treatment: Treatment of PEU can cause complications (refeeding syndrome),\n including fluid overload, electrolyte deficits, hyperglycemia, cardiac arrhythmias, and diarrhea. Diarrhea is\n usually mild and resolves; however, diarrhea in patients with severe PEU occasionally causes severe\n dehydration or death. Causes of diarrhea (eg, sorbitol used in elixir tube feedings, Clostridium difficile if\n the patient has received an antibiotic) may be correctable. Osmotic diarrhea due to excess calories is rare\n in adults and should be considered only when other causes have been excluded.\n Because PEU can impair cardiac and renal function, hydration can cause intravascular volume overload.\n Treatment decreases extra-cellular K and Mg. Depletion of K or Mg may cause arrhythmias.\n Carbohydrate metabolism that occurs during treatment stimulates insulin release, which drives phosphate\n into cells. Hypophosphatemia can cause muscle weakness, paresthesias, seizures, coma, and\n arrhythmias. Because phosphate levels can change rapidly during parenteral feeding, levels should be\n measured regularly.\n During treatment, endogenous insulin may become ineffective, leading to hyperglycemia. Dehydration\n and hyperosmolarity can result. Fatal ventricular arrhythmias can develop, possibly caused by a\n prolonged QT interval.\n Carnitine Deficiency\n Carnitine deficiency results from inadequate intake of or inability to metabolize the amino acid\n carnitine. It can cause a heterogeneous group of disorders. Muscle metabolism is impaired,\n causing myopathy, hypoglycemia, or cardiomyopathy. Infants typically present with\n hypoglycemic, hypoketotic encephalopathy. Most often, treatment consists of dietary L-\n carnitine.\n The amino acid carnitine is required for the transport of long-chain fatty acyl coenzyme A (CoA) esters\n into myocyte mitochondria, where they are oxidized for energy. Carnitine is obtained from foods,\n particularly animal-based foods, and via endogenous synthesis.\n Causes of carnitine deficiency include the following:\n \u2022 Inadequate intake (eg, due to fad diets, lack of access, or long-term TPN)\n \u2022 Inability to metabolize carnitine due to enzyme deficiencies (eg, carnitine palmitoyltransferase deficiency,\n   methylmalonicaciduria, propionicacidemia, isovalericacidemia)\n \u2022 Decreased endogenous synthesis of carnitine due to a severe liver disorder\n \u2022 Excess loss of carnitine due to diarrhea, diuresis, or hemodialysis\n \u2022 A hereditary disorder in which carnitine leaks from renal tubules\n \u2022 Increased requirements for carnitine when ketosis is present or demand for fat oxidation is high (eg,\n   during a critical illness such as sepsis or major burns; after major surgery of the GI tract)\n \u2022 Decreased muscle carnitine levels due to mitochondrial impairment (eg, due to use of zidovudine)\n \u2022 Use of valproate\n The deficiency may be generalized (systemic) or may affect mainly muscle (myopathic).\n Symptoms and Signs\n Symptoms and the age at which symptoms appear depend on the cause. Carnitine deficiency may cause\n muscle necrosis, myoglobinuria, lipid-storage myopathy, hypoglycemia, fatty liver, and hyperammonemia\n with muscle aches, fatigue, confusion, and cardiomyopathy.\n                                                                                                       67",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 2. Undernutrition\n\n# Complications of treatment\n\nTreatment of PEU can cause complications (refeeding syndrome), including fluid overload, electrolyte deficits, hyperglycemia, cardiac arrhythmias, and diarrhea. Diarrhea is usually mild and resolves; however, diarrhea in patients with severe PEU occasionally causes severe dehydration or death. Causes of diarrhea (eg, sorbitol used in elixir tube feedings, Clostridium difficile if the patient has received an antibiotic) may be correctable. Osmotic diarrhea due to excess calories is rare in adults and should be considered only when other causes have been excluded.\n\nBecause PEU can impair cardiac and renal function, hydration can cause intravascular volume overload. Treatment decreases extra-cellular K and Mg. Depletion of K or Mg may cause arrhythmias. Carbohydrate metabolism that occurs during treatment stimulates insulin release, which drives phosphate into cells. Hypophosphatemia can cause muscle weakness, paresthesias, seizures, coma, and arrhythmias. Because phosphate levels can change rapidly during parenteral feeding, levels should be measured regularly.\n\nDuring treatment, endogenous insulin may become ineffective, leading to hyperglycemia. Dehydration and hyperosmolarity can result. Fatal ventricular arrhythmias can develop, possibly caused by a prolonged QT interval.\n\n# Carnitine Deficiency\n\nCarnitine deficiency results from inadequate intake of or inability to metabolize the amino acid carnitine. It can cause a heterogeneous group of disorders. Muscle metabolism is impaired, causing myopathy, hypoglycemia, or cardiomyopathy. Infants typically present with hypoglycemic, hypoketotic encephalopathy. Most often, treatment consists of dietary L-carnitine.\n\nThe amino acid carnitine is required for the transport of long-chain fatty acyl coenzyme A (CoA) esters into myocyte mitochondria, where they are oxidized for energy. Carnitine is obtained from foods, particularly animal-based foods, and via endogenous synthesis.\n\n# Causes of carnitine deficiency include the following:\n\n- Inadequate intake (eg, due to fad diets, lack of access, or long-term TPN)\n- Inability to metabolize carnitine due to enzyme deficiencies (eg, carnitine palmitoyltransferase deficiency, methylmalonic aciduria, propionic acidemia, isovaleric acidemia)\n- Decreased endogenous synthesis of carnitine due to a severe liver disorder\n- Excess loss of carnitine due to diarrhea, diuresis, or hemodialysis\n- A hereditary disorder in which carnitine leaks from renal tubules\n- Increased requirements for carnitine when ketosis is present or demand for fat oxidation is high (eg, during a critical illness such as sepsis or major burns; after major surgery of the GI tract)\n- Decreased muscle carnitine levels due to mitochondrial impairment (eg, due to use of zidovudine)\n- Use of valproate\n\nThe deficiency may be generalized (systemic) or may affect mainly muscle (myopathic).\n\n# Symptoms and Signs\n\nSymptoms and the age at which symptoms appear depend on the cause. Carnitine deficiency may cause muscle necrosis, myoglobinuria, lipid-storage myopathy, hypoglycemia, fatty liver, and hyperammonemia with muscle aches, fatigue, confusion, and cardiomyopathy.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 2. Undernutrition",
                    "md": "# Chapter 2. Undernutrition",
                    "bBox": {
                        "x": 431,
                        "y": 30.72,
                        "w": 113,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Complications of treatment",
                    "md": "# Complications of treatment",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Treatment of PEU can cause complications (refeeding syndrome), including fluid overload, electrolyte deficits, hyperglycemia, cardiac arrhythmias, and diarrhea. Diarrhea is usually mild and resolves; however, diarrhea in patients with severe PEU occasionally causes severe dehydration or death. Causes of diarrhea (eg, sorbitol used in elixir tube feedings, Clostridium difficile if the patient has received an antibiotic) may be correctable. Osmotic diarrhea due to excess calories is rare in adults and should be considered only when other causes have been excluded.\n\nBecause PEU can impair cardiac and renal function, hydration can cause intravascular volume overload. Treatment decreases extra-cellular K and Mg. Depletion of K or Mg may cause arrhythmias. Carbohydrate metabolism that occurs during treatment stimulates insulin release, which drives phosphate into cells. Hypophosphatemia can cause muscle weakness, paresthesias, seizures, coma, and arrhythmias. Because phosphate levels can change rapidly during parenteral feeding, levels should be measured regularly.\n\nDuring treatment, endogenous insulin may become ineffective, leading to hyperglycemia. Dehydration and hyperosmolarity can result. Fatal ventricular arrhythmias can develop, possibly caused by a prolonged QT interval.",
                    "md": "Treatment of PEU can cause complications (refeeding syndrome), including fluid overload, electrolyte deficits, hyperglycemia, cardiac arrhythmias, and diarrhea. Diarrhea is usually mild and resolves; however, diarrhea in patients with severe PEU occasionally causes severe dehydration or death. Causes of diarrhea (eg, sorbitol used in elixir tube feedings, Clostridium difficile if the patient has received an antibiotic) may be correctable. Osmotic diarrhea due to excess calories is rare in adults and should be considered only when other causes have been excluded.\n\nBecause PEU can impair cardiac and renal function, hydration can cause intravascular volume overload. Treatment decreases extra-cellular K and Mg. Depletion of K or Mg may cause arrhythmias. Carbohydrate metabolism that occurs during treatment stimulates insulin release, which drives phosphate into cells. Hypophosphatemia can cause muscle weakness, paresthesias, seizures, coma, and arrhythmias. Because phosphate levels can change rapidly during parenteral feeding, levels should be measured regularly.\n\nDuring treatment, endogenous insulin may become ineffective, leading to hyperglycemia. Dehydration and hyperosmolarity can result. Fatal ventricular arrhythmias can develop, possibly caused by a prolonged QT interval.",
                    "bBox": {
                        "x": 55,
                        "y": 61.9,
                        "w": 483,
                        "h": 203
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Carnitine Deficiency",
                    "md": "# Carnitine Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 277.9,
                        "w": 102,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Carnitine deficiency results from inadequate intake of or inability to metabolize the amino acid carnitine. It can cause a heterogeneous group of disorders. Muscle metabolism is impaired, causing myopathy, hypoglycemia, or cardiomyopathy. Infants typically present with hypoglycemic, hypoketotic encephalopathy. Most often, treatment consists of dietary L-carnitine.\n\nThe amino acid carnitine is required for the transport of long-chain fatty acyl coenzyme A (CoA) esters into myocyte mitochondria, where they are oxidized for energy. Carnitine is obtained from foods, particularly animal-based foods, and via endogenous synthesis.",
                    "md": "Carnitine deficiency results from inadequate intake of or inability to metabolize the amino acid carnitine. It can cause a heterogeneous group of disorders. Muscle metabolism is impaired, causing myopathy, hypoglycemia, or cardiomyopathy. Infants typically present with hypoglycemic, hypoketotic encephalopathy. Most often, treatment consists of dietary L-carnitine.\n\nThe amino acid carnitine is required for the transport of long-chain fatty acyl coenzyme A (CoA) esters into myocyte mitochondria, where they are oxidized for energy. Carnitine is obtained from foods, particularly animal-based foods, and via endogenous synthesis.",
                    "bBox": {
                        "x": 55,
                        "y": 277.9,
                        "w": 473,
                        "h": 139
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Causes of carnitine deficiency include the following:",
                    "md": "# Causes of carnitine deficiency include the following:",
                    "bBox": {
                        "x": 55,
                        "y": 277.9,
                        "w": 237,
                        "h": 164
                    }
                },
                {
                    "type": "text",
                    "value": "- Inadequate intake (eg, due to fad diets, lack of access, or long-term TPN)\n- Inability to metabolize carnitine due to enzyme deficiencies (eg, carnitine palmitoyltransferase deficiency, methylmalonic aciduria, propionic acidemia, isovaleric acidemia)\n- Decreased endogenous synthesis of carnitine due to a severe liver disorder\n- Excess loss of carnitine due to diarrhea, diuresis, or hemodialysis\n- A hereditary disorder in which carnitine leaks from renal tubules\n- Increased requirements for carnitine when ketosis is present or demand for fat oxidation is high (eg, during a critical illness such as sepsis or major burns; after major surgery of the GI tract)\n- Decreased muscle carnitine levels due to mitochondrial impairment (eg, due to use of zidovudine)\n- Use of valproate\n\nThe deficiency may be generalized (systemic) or may affect mainly muscle (myopathic).",
                    "md": "- Inadequate intake (eg, due to fad diets, lack of access, or long-term TPN)\n- Inability to metabolize carnitine due to enzyme deficiencies (eg, carnitine palmitoyltransferase deficiency, methylmalonic aciduria, propionic acidemia, isovaleric acidemia)\n- Decreased endogenous synthesis of carnitine due to a severe liver disorder\n- Excess loss of carnitine due to diarrhea, diuresis, or hemodialysis\n- A hereditary disorder in which carnitine leaks from renal tubules\n- Increased requirements for carnitine when ketosis is present or demand for fat oxidation is high (eg, during a critical illness such as sepsis or major burns; after major surgery of the GI tract)\n- Decreased muscle carnitine levels due to mitochondrial impairment (eg, due to use of zidovudine)\n- Use of valproate\n\nThe deficiency may be generalized (systemic) or may affect mainly muscle (myopathic).",
                    "bBox": {
                        "x": 55,
                        "y": 493.9,
                        "w": 411,
                        "h": 202
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 708.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Symptoms and the age at which symptoms appear depend on the cause. Carnitine deficiency may cause muscle necrosis, myoglobinuria, lipid-storage myopathy, hypoglycemia, fatty liver, and hyperammonemia with muscle aches, fatigue, confusion, and cardiomyopathy.",
                    "md": "Symptoms and the age at which symptoms appear depend on the cause. Carnitine deficiency may cause muscle necrosis, myoglobinuria, lipid-storage myopathy, hypoglycemia, fatty liver, and hyperammonemia with muscle aches, fatigue, confusion, and cardiomyopathy.",
                    "bBox": {
                        "x": 55,
                        "y": 277.9,
                        "w": 479,
                        "h": 494
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.991
        },
        {
            "page": 16,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                              Chapter 2. Undernutrition\n Diagnosis\n In neonates, carnitine palmitoyltransferase deficiency is diagnosed using mass spectrometry to screen\n blood. Prenatal diagnosis may be possible using amniotic villous cells. In adults, the definitive diagnosis is\n based on acylcarnitine levels in serum, urine, and tissues (muscle and liver for systemic deficiency;\n muscle only for myopathic deficiency).\n Treatment\n \u2022 Avoidance of fasting and strenuous exercise\n \u2022 Dietary interventions, based on cause\n Carnitine deficiency due to inadequate dietary intake, increased requirements, excess losses, decreased\n synthesis, or (sometimes) enzyme deficiencies can be treated by giving L-carnitine 25 mg/kg po q 6 h.\n All patients must avoid fasting and strenuous exercise. Consuming uncooked cornstarch at bedtime\n prevents early morning hypoglycemia. Some patients require supplementation with medium-chain\n triglycerides and essential fatty acids (eg, linoleic acid, linolenic acid). Patients with a fatty acid oxidation\n disorder require a high-carbohydrate, low-fat diet.\n Essential Fatty Acid Deficiency\n Essential fatty acid (EFA) deficiency is rare, occurring most often in infants fed diets deficient in\n EFAs. Signs include scaly dermatitis, alopecia, thrombocytopenia, and, in children, growth\n retardation. Diagnosis is clinical. Dietary replenishment of EFAs reverses the deficiency.\n The EFAs linoleic and linolenic acid are substrates for the endogenous synthesis of other fatty acids that\n are needed for many physiologic processes, including maintaining the integrity of skin and cell\n membranes and synthesizing prostaglandins and leukotrienes. For example, eicosapentaenoic acid and\n docosahexaenoic acid, synthesized from EFAs, are important components of the brain and retina.\n For EFA deficiency to develop, dietary intake must be very low. Even small amounts of EFAs can prevent\n EFA deficiency. Cow's milk has only about 25% of the linoleic acid in human milk, but when ingested in\n normal amounts, it has enough linoleic acid to prevent EFA deficiency. Total fat intake of people in many\n developing countries may be very low, but the fat is often vegetable based, with large amounts of linoleic\n acid and enough linolenic acid to prevent EFA deficiency.\n Babies fed a formula low in linoleic acid, such as a skim-milk formula, can develop EFA deficiency. EFA\n deficiency used to result from long-term TPN if fat was not included. But now, most TPN solutions include\n fat emulsions to prevent EFA deficiency. In patients with fat malabsorption or increased metabolic needs\n (eg, because of surgery, multiple trauma, or burns), laboratory evidence of EFA deficiency may be\n present without clinical signs.\n Dermatitis due to EFA deficiency is generalized and scaly; in infants, it can resemble congenital\n ichthyosis. The dermatitis increases water loss from the skin.\n Diagnosis is usually clinical; however, laboratory assays are now available in large research centers.\n Treatment consists of dietary EFAs, reversing the deficiency.\n                                                                                                         68",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 2. Undernutrition\n\n# Diagnosis\n\nIn neonates, carnitine palmitoyltransferase deficiency is diagnosed using mass spectrometry to screen blood. Prenatal diagnosis may be possible using amniotic villous cells. In adults, the definitive diagnosis is based on acylcarnitine levels in serum, urine, and tissues (muscle and liver for systemic deficiency; muscle only for myopathic deficiency).\n\n# Treatment\n\n- Avoidance of fasting and strenuous exercise\n- Dietary interventions, based on cause\n\nCarnitine deficiency due to inadequate dietary intake, increased requirements, excess losses, decreased synthesis, or (sometimes) enzyme deficiencies can be treated by giving L-carnitine 25 mg/kg po q 6 h. All patients must avoid fasting and strenuous exercise. Consuming uncooked cornstarch at bedtime prevents early morning hypoglycemia. Some patients require supplementation with medium-chain triglycerides and essential fatty acids (eg, linoleic acid, linolenic acid). Patients with a fatty acid oxidation disorder require a high-carbohydrate, low-fat diet.\n\n# Essential Fatty Acid Deficiency\n\nEssential fatty acid (EFA) deficiency is rare, occurring most often in infants fed diets deficient in EFAs. Signs include scaly dermatitis, alopecia, thrombocytopenia, and, in children, growth retardation. Diagnosis is clinical. Dietary replenishment of EFAs reverses the deficiency.\n\nThe EFAs linoleic and linolenic acid are substrates for the endogenous synthesis of other fatty acids that are needed for many physiologic processes, including maintaining the integrity of skin and cell membranes and synthesizing prostaglandins and leukotrienes. For example, eicosapentaenoic acid and docosahexaenoic acid, synthesized from EFAs, are important components of the brain and retina.\n\nFor EFA deficiency to develop, dietary intake must be very low. Even small amounts of EFAs can prevent EFA deficiency. Cow's milk has only about 25% of the linoleic acid in human milk, but when ingested in normal amounts, it has enough linoleic acid to prevent EFA deficiency. Total fat intake of people in many developing countries may be very low, but the fat is often vegetable based, with large amounts of linoleic acid and enough linolenic acid to prevent EFA deficiency.\n\nBabies fed a formula low in linoleic acid, such as a skim-milk formula, can develop EFA deficiency. EFA deficiency used to result from long-term TPN if fat was not included. But now, most TPN solutions include fat emulsions to prevent EFA deficiency. In patients with fat malabsorption or increased metabolic needs (eg, because of surgery, multiple trauma, or burns), laboratory evidence of EFA deficiency may be present without clinical signs.\n\nDermatitis due to EFA deficiency is generalized and scaly; in infants, it can resemble congenital ichthyosis. The dermatitis increases water loss from the skin.\n\nDiagnosis is usually clinical; however, laboratory assays are now available in large research centers. Treatment consists of dietary EFAs, reversing the deficiency.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 30.18
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 2. Undernutrition",
                    "md": "# Chapter 2. Undernutrition",
                    "bBox": {
                        "x": 431,
                        "y": 30.72,
                        "w": 113,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "In neonates, carnitine palmitoyltransferase deficiency is diagnosed using mass spectrometry to screen blood. Prenatal diagnosis may be possible using amniotic villous cells. In adults, the definitive diagnosis is based on acylcarnitine levels in serum, urine, and tissues (muscle and liver for systemic deficiency; muscle only for myopathic deficiency).",
                    "md": "In neonates, carnitine palmitoyltransferase deficiency is diagnosed using mass spectrometry to screen blood. Prenatal diagnosis may be possible using amniotic villous cells. In adults, the definitive diagnosis is based on acylcarnitine levels in serum, urine, and tissues (muscle and liver for systemic deficiency; muscle only for myopathic deficiency).",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 483,
                        "h": 76
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 137.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Avoidance of fasting and strenuous exercise\n- Dietary interventions, based on cause\n\nCarnitine deficiency due to inadequate dietary intake, increased requirements, excess losses, decreased synthesis, or (sometimes) enzyme deficiencies can be treated by giving L-carnitine 25 mg/kg po q 6 h. All patients must avoid fasting and strenuous exercise. Consuming uncooked cornstarch at bedtime prevents early morning hypoglycemia. Some patients require supplementation with medium-chain triglycerides and essential fatty acids (eg, linoleic acid, linolenic acid). Patients with a fatty acid oxidation disorder require a high-carbohydrate, low-fat diet.",
                    "md": "- Avoidance of fasting and strenuous exercise\n- Dietary interventions, based on cause\n\nCarnitine deficiency due to inadequate dietary intake, increased requirements, excess losses, decreased synthesis, or (sometimes) enzyme deficiencies can be treated by giving L-carnitine 25 mg/kg po q 6 h. All patients must avoid fasting and strenuous exercise. Consuming uncooked cornstarch at bedtime prevents early morning hypoglycemia. Some patients require supplementation with medium-chain triglycerides and essential fatty acids (eg, linoleic acid, linolenic acid). Patients with a fatty acid oxidation disorder require a high-carbohydrate, low-fat diet.",
                    "bBox": {
                        "x": 55,
                        "y": 213.9,
                        "w": 478,
                        "h": 88
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Essential Fatty Acid Deficiency",
                    "md": "# Essential Fatty Acid Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 315.9,
                        "w": 155,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Essential fatty acid (EFA) deficiency is rare, occurring most often in infants fed diets deficient in EFAs. Signs include scaly dermatitis, alopecia, thrombocytopenia, and, in children, growth retardation. Diagnosis is clinical. Dietary replenishment of EFAs reverses the deficiency.\n\nThe EFAs linoleic and linolenic acid are substrates for the endogenous synthesis of other fatty acids that are needed for many physiologic processes, including maintaining the integrity of skin and cell membranes and synthesizing prostaglandins and leukotrienes. For example, eicosapentaenoic acid and docosahexaenoic acid, synthesized from EFAs, are important components of the brain and retina.\n\nFor EFA deficiency to develop, dietary intake must be very low. Even small amounts of EFAs can prevent EFA deficiency. Cow's milk has only about 25% of the linoleic acid in human milk, but when ingested in normal amounts, it has enough linoleic acid to prevent EFA deficiency. Total fat intake of people in many developing countries may be very low, but the fat is often vegetable based, with large amounts of linoleic acid and enough linolenic acid to prevent EFA deficiency.\n\nBabies fed a formula low in linoleic acid, such as a skim-milk formula, can develop EFA deficiency. EFA deficiency used to result from long-term TPN if fat was not included. But now, most TPN solutions include fat emulsions to prevent EFA deficiency. In patients with fat malabsorption or increased metabolic needs (eg, because of surgery, multiple trauma, or burns), laboratory evidence of EFA deficiency may be present without clinical signs.\n\nDermatitis due to EFA deficiency is generalized and scaly; in infants, it can resemble congenital ichthyosis. The dermatitis increases water loss from the skin.\n\nDiagnosis is usually clinical; however, laboratory assays are now available in large research centers. Treatment consists of dietary EFAs, reversing the deficiency.",
                    "md": "Essential fatty acid (EFA) deficiency is rare, occurring most often in infants fed diets deficient in EFAs. Signs include scaly dermatitis, alopecia, thrombocytopenia, and, in children, growth retardation. Diagnosis is clinical. Dietary replenishment of EFAs reverses the deficiency.\n\nThe EFAs linoleic and linolenic acid are substrates for the endogenous synthesis of other fatty acids that are needed for many physiologic processes, including maintaining the integrity of skin and cell membranes and synthesizing prostaglandins and leukotrienes. For example, eicosapentaenoic acid and docosahexaenoic acid, synthesized from EFAs, are important components of the brain and retina.\n\nFor EFA deficiency to develop, dietary intake must be very low. Even small amounts of EFAs can prevent EFA deficiency. Cow's milk has only about 25% of the linoleic acid in human milk, but when ingested in normal amounts, it has enough linoleic acid to prevent EFA deficiency. Total fat intake of people in many developing countries may be very low, but the fat is often vegetable based, with large amounts of linoleic acid and enough linolenic acid to prevent EFA deficiency.\n\nBabies fed a formula low in linoleic acid, such as a skim-milk formula, can develop EFA deficiency. EFA deficiency used to result from long-term TPN if fat was not included. But now, most TPN solutions include fat emulsions to prevent EFA deficiency. In patients with fat malabsorption or increased metabolic needs (eg, because of surgery, multiple trauma, or burns), laboratory evidence of EFA deficiency may be present without clinical signs.\n\nDermatitis due to EFA deficiency is generalized and scaly; in infants, it can resemble congenital ichthyosis. The dermatitis increases water loss from the skin.\n\nDiagnosis is usually clinical; however, laboratory assays are now available in large research centers. Treatment consists of dietary EFAs, reversing the deficiency.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 481,
                        "h": 633
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.997
        },
        {
            "page": 17,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                        Chapter 3. Nutritional Support\n Chapter 3. Nutritional Support\n Introduction\n Many undernourished patients need nutritional support, which aims to increase lean body mass. Oral\n feeding can be difficult for some patients with anorexia or with eating or absorption problems. Behavioral\n measures that sometimes enhance oral intake include the following:\n \u2022 Encouraging patients to eat\n \u2022 Heating or seasoning foods\n \u2022 Providing favorite or strongly flavored foods\n \u2022 Encouraging patients to eat small portions\n \u2022 Scheduling around meals\n \u2022 Assisting patients with feeding\n If behavioral measures are ineffective, nutritional support\u2014oral, enteral tube, or parenteral nutrition\u2014is\n indicated, except sometimes for dying or severely demented patients (see p. 25).\n Predicting Nutritional Requirements\n Nutritional requirements are predicted so that interventions can be planned. Requirements can be\n estimated by formulas or measured by indirect calorimetry. Indirect calorimetry requires use of a metabolic\n cart (a closed rebreathing system that determines energy expenditure based on total CO2 production),\n which requires special expertise and is not always available. Thus, total energy expenditure (TEE) and\n protein requirements usually are estimated.\n Energy expenditure: TEE varies based on the patient's weight, activity level, and degree of metabolic\n stress (metabolic demands); TEE ranges from 25 kcal/kg/day for people who are sedentary and not under\n stress to about 40 kcal/kg/day for people who are critically ill. TEE equals the sum of\n \u2022 Resting metabolic rate (RMR, or resting energy expenditure rate), which is normally about 70% of TEE\n \u2022 Energy dissipated by metabolism of food (10% of TEE)\n \u2022 Energy expended during physical activity (20% of TEE)\n Undernutrition can decrease RMR up to 20%. Conditions that increase metabolic stress (eg, critical\n illness, infection, inflammation, trauma, surgery) can increase RMR but rarely by &gt; 50%.\n The Mifflin-St. Jeor equation estimates RMR more precisely and with fewer errors than the commonly\n used Harris-Benedict equation, usually providing results that are within 20% of those measured by\n indirect calorimetry. The Mifflin-St. Jeor equation estimates RMR as follows:\n   Men: kcal / day = 66 + (13.7 \u00d7 wt[kg]) + (5 \u00d7 height[cm]) - (6.8 \u00d7 age)\n Women: kcal / day = 665 + (9.6 \u00d7 wt[kg]) + (1.8 \u00d7 height[cm]) - (4.7 \u00d7 age)\n TEE can be estimated by adding about 10% (for sedentary people) to about 40% (for people who are\n critically ill) to RMR.\n Protein requirements: For healthy people, protein requirements are estimated at 0.8 g/kg/day.\n However, for patients with metabolic stress or kidney failure and for elderly patients, requirements may be\n higher (see\n                                                                                                        69",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 3. Nutritional Support\n\n# Introduction\n\nMany undernourished patients need nutritional support, which aims to increase lean body mass. Oral feeding can be difficult for some patients with anorexia or with eating or absorption problems. Behavioral measures that sometimes enhance oral intake include the following:\n\n- Encouraging patients to eat\n- Heating or seasoning foods\n- Providing favorite or strongly flavored foods\n- Encouraging patients to eat small portions\n- Scheduling around meals\n- Assisting patients with feeding\n\nIf behavioral measures are ineffective, nutritional support\u2014oral, enteral tube, or parenteral nutrition\u2014is indicated, except sometimes for dying or severely demented patients (see p. 25).\n\n# Predicting Nutritional Requirements\n\nNutritional requirements are predicted so that interventions can be planned. Requirements can be estimated by formulas or measured by indirect calorimetry. Indirect calorimetry requires use of a metabolic cart (a closed rebreathing system that determines energy expenditure based on total CO2 production), which requires special expertise and is not always available. Thus, total energy expenditure (TEE) and protein requirements usually are estimated.\n\n# Energy expenditure:\n\nTEE varies based on the patient's weight, activity level, and degree of metabolic stress (metabolic demands); TEE ranges from 25 kcal/kg/day for people who are sedentary and not under stress to about 40 kcal/kg/day for people who are critically ill. TEE equals the sum of:\n\n- Resting metabolic rate (RMR, or resting energy expenditure rate), which is normally about 70% of TEE\n- Energy dissipated by metabolism of food (10% of TEE)\n- Energy expended during physical activity (20% of TEE)\n\nUndernutrition can decrease RMR up to 20%. Conditions that increase metabolic stress (eg, critical illness, infection, inflammation, trauma, surgery) can increase RMR but rarely by &gt; 50%.\n\n# The Mifflin-St. Jeor equation\n\nestimates RMR more precisely and with fewer errors than the commonly used Harris-Benedict equation, usually providing results that are within 20% of those measured by indirect calorimetry. The Mifflin-St. Jeor equation estimates RMR as follows:\n\n| Men:   | kcal / day = 66 + (13.7 \u00d7 wt\\[kg]) + (5 \u00d7 height\\[cm]) - (6.8 \u00d7 age)   |\n| ------ | ---------------------------------------------------------------------- |\n| Women: | kcal / day = 665 + (9.6 \u00d7 wt\\[kg]) + (1.8 \u00d7 height\\[cm]) - (4.7 \u00d7 age) |\n\nTEE can be estimated by adding about 10% (for sedentary people) to about 40% (for people who are critically ill) to RMR.\n\n# Protein requirements:\n\nFor healthy people, protein requirements are estimated at 0.8 g/kg/day. However, for patients with metabolic stress or kidney failure and for elderly patients, requirements may be higher (see 69).",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 3. Nutritional Support",
                    "md": "# Chapter 3. Nutritional Support",
                    "bBox": {
                        "x": 55,
                        "y": 30.72,
                        "w": 488,
                        "h": 36.18
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Introduction",
                    "md": "# Introduction",
                    "bBox": {
                        "x": 55,
                        "y": 79.9,
                        "w": 61,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Many undernourished patients need nutritional support, which aims to increase lean body mass. Oral feeding can be difficult for some patients with anorexia or with eating or absorption problems. Behavioral measures that sometimes enhance oral intake include the following:\n\n- Encouraging patients to eat\n- Heating or seasoning foods\n- Providing favorite or strongly flavored foods\n- Encouraging patients to eat small portions\n- Scheduling around meals\n- Assisting patients with feeding\n\nIf behavioral measures are ineffective, nutritional support\u2014oral, enteral tube, or parenteral nutrition\u2014is indicated, except sometimes for dying or severely demented patients (see p. 25).",
                    "md": "Many undernourished patients need nutritional support, which aims to increase lean body mass. Oral feeding can be difficult for some patients with anorexia or with eating or absorption problems. Behavioral measures that sometimes enhance oral intake include the following:\n\n- Encouraging patients to eat\n- Heating or seasoning foods\n- Providing favorite or strongly flavored foods\n- Encouraging patients to eat small portions\n- Scheduling around meals\n- Assisting patients with feeding\n\nIf behavioral measures are ineffective, nutritional support\u2014oral, enteral tube, or parenteral nutrition\u2014is indicated, except sometimes for dying or severely demented patients (see p. 25).",
                    "bBox": {
                        "x": 55,
                        "y": 104.9,
                        "w": 476,
                        "h": 228
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Predicting Nutritional Requirements",
                    "md": "# Predicting Nutritional Requirements",
                    "bBox": {
                        "x": 55,
                        "y": 345.9,
                        "w": 181,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Nutritional requirements are predicted so that interventions can be planned. Requirements can be estimated by formulas or measured by indirect calorimetry. Indirect calorimetry requires use of a metabolic cart (a closed rebreathing system that determines energy expenditure based on total CO2 production), which requires special expertise and is not always available. Thus, total energy expenditure (TEE) and protein requirements usually are estimated.",
                    "md": "Nutritional requirements are predicted so that interventions can be planned. Requirements can be estimated by formulas or measured by indirect calorimetry. Indirect calorimetry requires use of a metabolic cart (a closed rebreathing system that determines energy expenditure based on total CO2 production), which requires special expertise and is not always available. Thus, total energy expenditure (TEE) and protein requirements usually are estimated.",
                    "bBox": {
                        "x": 55,
                        "y": 370.9,
                        "w": 482,
                        "h": 65
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Energy expenditure:",
                    "md": "# Energy expenditure:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "TEE varies based on the patient's weight, activity level, and degree of metabolic stress (metabolic demands); TEE ranges from 25 kcal/kg/day for people who are sedentary and not under stress to about 40 kcal/kg/day for people who are critically ill. TEE equals the sum of:\n\n- Resting metabolic rate (RMR, or resting energy expenditure rate), which is normally about 70% of TEE\n- Energy dissipated by metabolism of food (10% of TEE)\n- Energy expended during physical activity (20% of TEE)\n\nUndernutrition can decrease RMR up to 20%. Conditions that increase metabolic stress (eg, critical illness, infection, inflammation, trauma, surgery) can increase RMR but rarely by &gt; 50%.",
                    "md": "TEE varies based on the patient's weight, activity level, and degree of metabolic stress (metabolic demands); TEE ranges from 25 kcal/kg/day for people who are sedentary and not under stress to about 40 kcal/kg/day for people who are critically ill. TEE equals the sum of:\n\n- Resting metabolic rate (RMR, or resting energy expenditure rate), which is normally about 70% of TEE\n- Energy dissipated by metabolism of food (10% of TEE)\n- Energy expended during physical activity (20% of TEE)\n\nUndernutrition can decrease RMR up to 20%. Conditions that increase metabolic stress (eg, critical illness, infection, inflammation, trauma, surgery) can increase RMR but rarely by &gt; 50%.",
                    "bBox": {
                        "x": 55,
                        "y": 461.9,
                        "w": 483,
                        "h": 139
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Mifflin-St. Jeor equation",
                    "md": "# The Mifflin-St. Jeor equation",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "estimates RMR more precisely and with fewer errors than the commonly used Harris-Benedict equation, usually providing results that are within 20% of those measured by indirect calorimetry. The Mifflin-St. Jeor equation estimates RMR as follows:",
                    "md": "estimates RMR more precisely and with fewer errors than the commonly used Harris-Benedict equation, usually providing results that are within 20% of those measured by indirect calorimetry. The Mifflin-St. Jeor equation estimates RMR as follows:",
                    "bBox": {
                        "x": 55,
                        "y": 626.9,
                        "w": 449,
                        "h": 25
                    }
                },
                {
                    "type": "table",
                    "rows": [
                        [
                            "Men:",
                            "kcal / day = 66 + (13.7 \u00d7 wt[kg]) + (5 \u00d7 height[cm]) - (6.8 \u00d7 age)"
                        ],
                        [
                            "Women:",
                            "kcal / day = 665 + (9.6 \u00d7 wt[kg]) + (1.8 \u00d7 height[cm]) - (4.7 \u00d7 age)"
                        ]
                    ],
                    "md": "| Men:   | kcal / day = 66 + (13.7 \u00d7 wt\\[kg]) + (5 \u00d7 height\\[cm]) - (6.8 \u00d7 age)   |\n| ------ | ---------------------------------------------------------------------- |\n| Women: | kcal / day = 665 + (9.6 \u00d7 wt\\[kg]) + (1.8 \u00d7 height\\[cm]) - (4.7 \u00d7 age) |",
                    "isPerfectTable": true,
                    "csv": "\"Men:\",\"kcal / day = 66 + (13.7 \u00d7 wt[kg]) + (5 \u00d7 height[cm]) - (6.8 \u00d7 age)\"\n\"Women:\",\"kcal / day = 665 + (9.6 \u00d7 wt[kg]) + (1.8 \u00d7 height[cm]) - (4.7 \u00d7 age)\"",
                    "bBox": {
                        "x": 57,
                        "y": 666.9,
                        "w": 343,
                        "h": 27
                    }
                },
                {
                    "type": "text",
                    "value": "TEE can be estimated by adding about 10% (for sedentary people) to about 40% (for people who are critically ill) to RMR.",
                    "md": "TEE can be estimated by adding about 10% (for sedentary people) to about 40% (for people who are critically ill) to RMR.",
                    "bBox": {
                        "x": 55,
                        "y": 708.9,
                        "w": 463,
                        "h": 25
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Protein requirements:",
                    "md": "# Protein requirements:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "For healthy people, protein requirements are estimated at 0.8 g/kg/day. However, for patients with metabolic stress or kidney failure and for elderly patients, requirements may be higher (see 69).",
                    "md": "For healthy people, protein requirements are estimated at 0.8 g/kg/day. However, for patients with metabolic stress or kidney failure and for elderly patients, requirements may be higher (see 69).",
                    "bBox": {
                        "x": 55,
                        "y": 759.9,
                        "w": 488,
                        "h": 47.82
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.987
        },
        {
            "page": 18,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                         Chapter 3. Nutritional Support\n Table 3-1).\n Assessing Response to Nutritional Support\n There is no gold standard to assess response. Clinicians commonly use indicators of lean body mass\n such as the following:\n \u2022 Body mass index (BMI)\n \u2022 Body composition analysis\n \u2022 Body fat distribution (see pp.\n 11 and 58)\n Nitrogen balance, response to skin antigens, muscle strength measurement, and indirect calorimetry can\n also be used.\n [Table 3-1. Estimated Adult Daily Protein Requirement]\n Nitrogen balance, which reflects the balance between protein needs and supplies, is the difference\n between amount of nitrogen ingested and amount lost. A positive balance (ie, more ingested than lost)\n implies adequate intake. Precise measurement is impractical, but estimates help assess response to\n nutritional support. Nitrogen intake is estimated from protein intake: nitrogen (g) equals protein (g)/6.25.\n Estimated nitrogen losses consist of urinary nitrogen losses (estimated by measuring urea nitrogen\n content of an accurately obtained 24-h urine collection) plus stool losses (estimated at 1 g/day if stool is\n produced; negligible if stool is not produced) plus insensible and other unmeasured losses (estimated at\n 3 g).\n Response to skin antigens, a measure of delayed hypersensitivity, often increases to normal as\n undernourished patients respond to nutritional support. However, other factors can affect response to\n skin antigens.\n Muscle strength indirectly reflects increases in lean body mass. It can be measured quantitatively, by\n hand-grip dynamometry, or electrophysiologically (typically by stimulating the ulnar nerve with an\n electrode).\n Levels of acute-phase reactant serum proteins (particularly short-lived proteins such as prealbumin\n [transthyretin], retinol-binding protein, and transferrin) sometimes correlate with improved nutritional\n status, but these levels correlate better with inflammatory conditions.\n Enteral Tube Nutrition\n Enteral tube nutrition is indicated for patients who have a functioning GI tract but cannot ingest enough\n nutrients orally because they are unable or unwilling to take oral feedings. Compared with parenteral\n nutrition, enteral nutrition has the following advantages:\n \u2022 Better preservation of the structure and function of the GI tract\n \u2022 Lower cost\n \u2022 Probably fewer complications, particularly infections\n Specific indications for enteral nutrition include the following:\n \u2022 Prolonged anorexia\n \u2022 Severe protein-energy undernutrition\n                                                                                                         70",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 3. Nutritional Support\n\n# Assessing Response to Nutritional Support\n\nThere is no gold standard to assess response. Clinicians commonly use indicators of lean body mass such as the following:\n\n- Body mass index (BMI)\n- Body composition analysis\n- Body fat distribution (see pp. 11 and 58)\n\nNitrogen balance, response to skin antigens, muscle strength measurement, and indirect calorimetry can also be used.\n\n# Table 3-1. Estimated Adult Daily Protein Requirement\n\nNitrogen balance, which reflects the balance between protein needs and supplies, is the difference between amount of nitrogen ingested and amount lost. A positive balance (ie, more ingested than lost) implies adequate intake. Precise measurement is impractical, but estimates help assess response to nutritional support. Nitrogen intake is estimated from protein intake: nitrogen (g) equals protein (g)/6.25. Estimated nitrogen losses consist of urinary nitrogen losses (estimated by measuring urea nitrogen content of an accurately obtained 24-h urine collection) plus stool losses (estimated at 1 g/day if stool is produced; negligible if stool is not produced) plus insensible and other unmeasured losses (estimated at 3 g).\n\nResponse to skin antigens, a measure of delayed hypersensitivity, often increases to normal as undernourished patients respond to nutritional support. However, other factors can affect response to skin antigens.\n\nMuscle strength indirectly reflects increases in lean body mass. It can be measured quantitatively, by hand-grip dynamometry, or electrophysiologically (typically by stimulating the ulnar nerve with an electrode).\n\nLevels of acute-phase reactant serum proteins (particularly short-lived proteins such as prealbumin [transthyretin], retinol-binding protein, and transferrin) sometimes correlate with improved nutritional status, but these levels correlate better with inflammatory conditions.\n\n# Enteral Tube Nutrition\n\nEnteral tube nutrition is indicated for patients who have a functioning GI tract but cannot ingest enough nutrients orally because they are unable or unwilling to take oral feedings. Compared with parenteral nutrition, enteral nutrition has the following advantages:\n\n- Better preservation of the structure and function of the GI tract\n- Lower cost\n- Probably fewer complications, particularly infections\n\nSpecific indications for enteral nutrition include the following:\n\n- Prolonged anorexia\n- Severe protein-energy undernutrition",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 3. Nutritional Support",
                    "md": "# Chapter 3. Nutritional Support",
                    "bBox": {
                        "x": 410,
                        "y": 30.72,
                        "w": 133,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Assessing Response to Nutritional Support",
                    "md": "# Assessing Response to Nutritional Support",
                    "bBox": {
                        "x": 55,
                        "y": 74.9,
                        "w": 216,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "There is no gold standard to assess response. Clinicians commonly use indicators of lean body mass such as the following:\n\n- Body mass index (BMI)\n- Body composition analysis\n- Body fat distribution (see pp. 11 and 58)\n\nNitrogen balance, response to skin antigens, muscle strength measurement, and indirect calorimetry can also be used.",
                    "md": "There is no gold standard to assess response. Clinicians commonly use indicators of lean body mass such as the following:\n\n- Body mass index (BMI)\n- Body composition analysis\n- Body fat distribution (see pp. 11 and 58)\n\nNitrogen balance, response to skin antigens, muscle strength measurement, and indirect calorimetry can also be used.",
                    "bBox": {
                        "x": 55,
                        "y": 99.9,
                        "w": 477,
                        "h": 151
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Table 3-1. Estimated Adult Daily Protein Requirement",
                    "md": "# Table 3-1. Estimated Adult Daily Protein Requirement",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Nitrogen balance, which reflects the balance between protein needs and supplies, is the difference between amount of nitrogen ingested and amount lost. A positive balance (ie, more ingested than lost) implies adequate intake. Precise measurement is impractical, but estimates help assess response to nutritional support. Nitrogen intake is estimated from protein intake: nitrogen (g) equals protein (g)/6.25. Estimated nitrogen losses consist of urinary nitrogen losses (estimated by measuring urea nitrogen content of an accurately obtained 24-h urine collection) plus stool losses (estimated at 1 g/day if stool is produced; negligible if stool is not produced) plus insensible and other unmeasured losses (estimated at 3 g).\n\nResponse to skin antigens, a measure of delayed hypersensitivity, often increases to normal as undernourished patients respond to nutritional support. However, other factors can affect response to skin antigens.\n\nMuscle strength indirectly reflects increases in lean body mass. It can be measured quantitatively, by hand-grip dynamometry, or electrophysiologically (typically by stimulating the ulnar nerve with an electrode).\n\nLevels of acute-phase reactant serum proteins (particularly short-lived proteins such as prealbumin [transthyretin], retinol-binding protein, and transferrin) sometimes correlate with improved nutritional status, but these levels correlate better with inflammatory conditions.",
                    "md": "Nitrogen balance, which reflects the balance between protein needs and supplies, is the difference between amount of nitrogen ingested and amount lost. A positive balance (ie, more ingested than lost) implies adequate intake. Precise measurement is impractical, but estimates help assess response to nutritional support. Nitrogen intake is estimated from protein intake: nitrogen (g) equals protein (g)/6.25. Estimated nitrogen losses consist of urinary nitrogen losses (estimated by measuring urea nitrogen content of an accurately obtained 24-h urine collection) plus stool losses (estimated at 1 g/day if stool is produced; negligible if stool is not produced) plus insensible and other unmeasured losses (estimated at 3 g).\n\nResponse to skin antigens, a measure of delayed hypersensitivity, often increases to normal as undernourished patients respond to nutritional support. However, other factors can affect response to skin antigens.\n\nMuscle strength indirectly reflects increases in lean body mass. It can be measured quantitatively, by hand-grip dynamometry, or electrophysiologically (typically by stimulating the ulnar nerve with an electrode).\n\nLevels of acute-phase reactant serum proteins (particularly short-lived proteins such as prealbumin [transthyretin], retinol-binding protein, and transferrin) sometimes correlate with improved nutritional status, but these levels correlate better with inflammatory conditions.",
                    "bBox": {
                        "x": 55,
                        "y": 289.9,
                        "w": 475,
                        "h": 253
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Enteral Tube Nutrition",
                    "md": "# Enteral Tube Nutrition",
                    "bBox": {
                        "x": 55,
                        "y": 555.9,
                        "w": 109,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Enteral tube nutrition is indicated for patients who have a functioning GI tract but cannot ingest enough nutrients orally because they are unable or unwilling to take oral feedings. Compared with parenteral nutrition, enteral nutrition has the following advantages:\n\n- Better preservation of the structure and function of the GI tract\n- Lower cost\n- Probably fewer complications, particularly infections\n\nSpecific indications for enteral nutrition include the following:\n\n- Prolonged anorexia\n- Severe protein-energy undernutrition",
                    "md": "Enteral tube nutrition is indicated for patients who have a functioning GI tract but cannot ingest enough nutrients orally because they are unable or unwilling to take oral feedings. Compared with parenteral nutrition, enteral nutrition has the following advantages:\n\n- Better preservation of the structure and function of the GI tract\n- Lower cost\n- Probably fewer complications, particularly infections\n\nSpecific indications for enteral nutrition include the following:\n\n- Prolonged anorexia\n- Severe protein-energy undernutrition",
                    "bBox": {
                        "x": 55,
                        "y": 555.9,
                        "w": 469,
                        "h": 164
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.992
        },
        {
            "page": 19,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                         Chapter 3. Nutritional Support\n \u2022 Coma or depressed sensorium\n \u2022 Liver failure\n \u2022 Inability to take oral feedings due to head or neck trauma or neurologic disorders\n \u2022 Critical illnesses (eg, burns) causing metabolic stress\n Other indications may include bowel preparation for surgery in seriously ill or undernourished patients,\n closure of enterocutaneous fistulas, and small-bowel adaptation after massive intestinal resection or in\n disorders that may cause malabsorption (eg, Crohn's disease).\n Procedure: If tube feeding is needed for \u2264 4 to 6 wk, a small-caliber, soft nasogastric or nasoenteric (eg,\n nasoduodenal) tube made of silicone or polyurethane is usually used. If a nasal injury or deformity makes\n nasal placement difficult, an orogastric or other oroenteric tube can be placed.\n Tube feeding for &gt; 4 to 6 wk usually requires a gastrostomy or jejunostomy tube, placed endoscopically,\n surgically, or radiologically. Choice depends on physician capabilities and patient preference.\n Jejunostomy tubes are useful for patients with contraindications to gastrostomy (eg, gastrectomy, bowel\n obstruction proximal to the jejunum). However, these tubes do not pose less risk of tracheobronchial\n aspiration than gastrostomy tubes, as is often thought. Jejunostomy tubes are easily dislodged and are\n usually used only for inpatients.\n Feeding tubes are surgically placed if endoscopic and radiologic placement is unavailable, technically\n impossible, or unsafe (eg, because of overlying bowel). Open or laparoscopic techniques can be used.\n Formulas: Liquid formulas commonly used include feeding modules and polymeric or other specialized\n formulas.\n Feeding modules are commercially available products that contain a single nutrient, such as proteins,\n fats, or carbohydrates. Feeding modules may be used individually to treat a specific deficiency or\n combined with other formulas to completely satisfy nutritional requirements.\n Polymeric formulas (including blenderized food and milk-based or lactose-free commercial formulas)\n are commercially available and generally provide a complete, balanced diet. For oral or tube feedings,\n they are usually preferred to feeding modules. In hospitalized patients, lactose-free formulas are the most\n commonly used polymeric formulas. However, milk-based formulas tend to taste better than lactose-free\n formulas. Patients with lactose intolerance may be able to tolerate milk-based formulas given slowly by\n continuous infusion.\n Specialized formulas include hydrolyzed protein or sometimes amino acid formulas, which are used for\n patients who have difficulty digesting complex proteins. However, these formulas are expensive and\n usually unnecessary. Most patients with pancreatic insufficiency, if given enzymes, and most patients with\n malabsorption can digest complex proteins. Other specialized formulas (eg, calorie- and protein-dense\n formulas for patients whose fluids are restricted, fiber-enriched formulas for constipated patients) may be\n helpful.\n Administration: Patients should be sitting upright at 30 to 45\u00b0 during tube feeding and for 1 to 2 h\n afterward to minimize incidence of nosocomial aspiration pneumonia and to allow gravity to help propel\n the food. Tube feedings are given in boluses several times a day or by continuous infusion. Bolus feeding\n is more physiologic and may be preferred for patients with diabetes. Continuous infusion is necessary if\n boluses cause nausea.\n [\n Table 3-2. Complications of Enteral Tube Nutrition]\n For bolus feeding, total daily volume is divided into 4 to 6 separate feedings, which are injected through\n                                                                                                         71",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 3. Nutritional Support\n\n- Coma or depressed sensorium\n- Liver failure\n- Inability to take oral feedings due to head or neck trauma or neurologic disorders\n- Critical illnesses (eg, burns) causing metabolic stress\n\nOther indications may include bowel preparation for surgery in seriously ill or undernourished patients, closure of enterocutaneous fistulas, and small-bowel adaptation after massive intestinal resection or in disorders that may cause malabsorption (eg, Crohn's disease).\n\n# Procedure\n\nIf tube feeding is needed for \u2264 4 to 6 wk, a small-caliber, soft nasogastric or nasoenteric (eg, nasoduodenal) tube made of silicone or polyurethane is usually used. If a nasal injury or deformity makes nasal placement difficult, an orogastric or other oroenteric tube can be placed.\n\nTube feeding for &gt; 4 to 6 wk usually requires a gastrostomy or jejunostomy tube, placed endoscopically, surgically, or radiologically. Choice depends on physician capabilities and patient preference.\n\nJejunostomy tubes are useful for patients with contraindications to gastrostomy (eg, gastrectomy, bowel obstruction proximal to the jejunum). However, these tubes do not pose less risk of tracheobronchial aspiration than gastrostomy tubes, as is often thought. Jejunostomy tubes are easily dislodged and are usually used only for inpatients.\n\nFeeding tubes are surgically placed if endoscopic and radiologic placement is unavailable, technically impossible, or unsafe (eg, because of overlying bowel). Open or laparoscopic techniques can be used.\n\n# Formulas\n\nLiquid formulas commonly used include feeding modules and polymeric or other specialized formulas.\n\nFeeding modules are commercially available products that contain a single nutrient, such as proteins, fats, or carbohydrates. Feeding modules may be used individually to treat a specific deficiency or combined with other formulas to completely satisfy nutritional requirements.\n\nPolymeric formulas (including blenderized food and milk-based or lactose-free commercial formulas) are commercially available and generally provide a complete, balanced diet. For oral or tube feedings, they are usually preferred to feeding modules. In hospitalized patients, lactose-free formulas are the most commonly used polymeric formulas. However, milk-based formulas tend to taste better than lactose-free formulas. Patients with lactose intolerance may be able to tolerate milk-based formulas given slowly by continuous infusion.\n\nSpecialized formulas include hydrolyzed protein or sometimes amino acid formulas, which are used for patients who have difficulty digesting complex proteins. However, these formulas are expensive and usually unnecessary. Most patients with pancreatic insufficiency, if given enzymes, and most patients with malabsorption can digest complex proteins. Other specialized formulas (eg, calorie- and protein-dense formulas for patients whose fluids are restricted, fiber-enriched formulas for constipated patients) may be helpful.\n\n# Administration\n\nPatients should be sitting upright at 30 to 45\u00b0 during tube feeding and for 1 to 2 h afterward to minimize incidence of nosocomial aspiration pneumonia and to allow gravity to help propel the food. Tube feedings are given in boluses several times a day or by continuous infusion. Bolus feeding is more physiologic and may be preferred for patients with diabetes. Continuous infusion is necessary if boluses cause nausea.\n\n# Table 3-2. Complications of Enteral Tube Nutrition\n\nFor bolus feeding, total daily volume is divided into 4 to 6 separate feedings, which are injected through",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 3. Nutritional Support",
                    "md": "# Chapter 3. Nutritional Support",
                    "bBox": {
                        "x": 410,
                        "y": 30.72,
                        "w": 133,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "- Coma or depressed sensorium\n- Liver failure\n- Inability to take oral feedings due to head or neck trauma or neurologic disorders\n- Critical illnesses (eg, burns) causing metabolic stress\n\nOther indications may include bowel preparation for surgery in seriously ill or undernourished patients, closure of enterocutaneous fistulas, and small-bowel adaptation after massive intestinal resection or in disorders that may cause malabsorption (eg, Crohn's disease).",
                    "md": "- Coma or depressed sensorium\n- Liver failure\n- Inability to take oral feedings due to head or neck trauma or neurologic disorders\n- Critical illnesses (eg, burns) causing metabolic stress\n\nOther indications may include bowel preparation for surgery in seriously ill or undernourished patients, closure of enterocutaneous fistulas, and small-bowel adaptation after massive intestinal resection or in disorders that may cause malabsorption (eg, Crohn's disease).",
                    "bBox": {
                        "x": 55,
                        "y": 150.9,
                        "w": 467,
                        "h": 37
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Procedure",
                    "md": "# Procedure",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "If tube feeding is needed for \u2264 4 to 6 wk, a small-caliber, soft nasogastric or nasoenteric (eg, nasoduodenal) tube made of silicone or polyurethane is usually used. If a nasal injury or deformity makes nasal placement difficult, an orogastric or other oroenteric tube can be placed.\n\nTube feeding for &gt; 4 to 6 wk usually requires a gastrostomy or jejunostomy tube, placed endoscopically, surgically, or radiologically. Choice depends on physician capabilities and patient preference.\n\nJejunostomy tubes are useful for patients with contraindications to gastrostomy (eg, gastrectomy, bowel obstruction proximal to the jejunum). However, these tubes do not pose less risk of tracheobronchial aspiration than gastrostomy tubes, as is often thought. Jejunostomy tubes are easily dislodged and are usually used only for inpatients.\n\nFeeding tubes are surgically placed if endoscopic and radiologic placement is unavailable, technically impossible, or unsafe (eg, because of overlying bowel). Open or laparoscopic techniques can be used.",
                    "md": "If tube feeding is needed for \u2264 4 to 6 wk, a small-caliber, soft nasogastric or nasoenteric (eg, nasoduodenal) tube made of silicone or polyurethane is usually used. If a nasal injury or deformity makes nasal placement difficult, an orogastric or other oroenteric tube can be placed.\n\nTube feeding for &gt; 4 to 6 wk usually requires a gastrostomy or jejunostomy tube, placed endoscopically, surgically, or radiologically. Choice depends on physician capabilities and patient preference.\n\nJejunostomy tubes are useful for patients with contraindications to gastrostomy (eg, gastrectomy, bowel obstruction proximal to the jejunum). However, these tubes do not pose less risk of tracheobronchial aspiration than gastrostomy tubes, as is often thought. Jejunostomy tubes are easily dislodged and are usually used only for inpatients.\n\nFeeding tubes are surgically placed if endoscopic and radiologic placement is unavailable, technically impossible, or unsafe (eg, because of overlying bowel). Open or laparoscopic techniques can be used.",
                    "bBox": {
                        "x": 55,
                        "y": 213.9,
                        "w": 479,
                        "h": 164
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Formulas",
                    "md": "# Formulas",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Liquid formulas commonly used include feeding modules and polymeric or other specialized formulas.\n\nFeeding modules are commercially available products that contain a single nutrient, such as proteins, fats, or carbohydrates. Feeding modules may be used individually to treat a specific deficiency or combined with other formulas to completely satisfy nutritional requirements.\n\nPolymeric formulas (including blenderized food and milk-based or lactose-free commercial formulas) are commercially available and generally provide a complete, balanced diet. For oral or tube feedings, they are usually preferred to feeding modules. In hospitalized patients, lactose-free formulas are the most commonly used polymeric formulas. However, milk-based formulas tend to taste better than lactose-free formulas. Patients with lactose intolerance may be able to tolerate milk-based formulas given slowly by continuous infusion.\n\nSpecialized formulas include hydrolyzed protein or sometimes amino acid formulas, which are used for patients who have difficulty digesting complex proteins. However, these formulas are expensive and usually unnecessary. Most patients with pancreatic insufficiency, if given enzymes, and most patients with malabsorption can digest complex proteins. Other specialized formulas (eg, calorie- and protein-dense formulas for patients whose fluids are restricted, fiber-enriched formulas for constipated patients) may be helpful.",
                    "md": "Liquid formulas commonly used include feeding modules and polymeric or other specialized formulas.\n\nFeeding modules are commercially available products that contain a single nutrient, such as proteins, fats, or carbohydrates. Feeding modules may be used individually to treat a specific deficiency or combined with other formulas to completely satisfy nutritional requirements.\n\nPolymeric formulas (including blenderized food and milk-based or lactose-free commercial formulas) are commercially available and generally provide a complete, balanced diet. For oral or tube feedings, they are usually preferred to feeding modules. In hospitalized patients, lactose-free formulas are the most commonly used polymeric formulas. However, milk-based formulas tend to taste better than lactose-free formulas. Patients with lactose intolerance may be able to tolerate milk-based formulas given slowly by continuous infusion.\n\nSpecialized formulas include hydrolyzed protein or sometimes amino acid formulas, which are used for patients who have difficulty digesting complex proteins. However, these formulas are expensive and usually unnecessary. Most patients with pancreatic insufficiency, if given enzymes, and most patients with malabsorption can digest complex proteins. Other specialized formulas (eg, calorie- and protein-dense formulas for patients whose fluids are restricted, fiber-enriched formulas for constipated patients) may be helpful.",
                    "bBox": {
                        "x": 55,
                        "y": 403.9,
                        "w": 480,
                        "h": 240
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Administration",
                    "md": "# Administration",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Patients should be sitting upright at 30 to 45\u00b0 during tube feeding and for 1 to 2 h afterward to minimize incidence of nosocomial aspiration pneumonia and to allow gravity to help propel the food. Tube feedings are given in boluses several times a day or by continuous infusion. Bolus feeding is more physiologic and may be preferred for patients with diabetes. Continuous infusion is necessary if boluses cause nausea.",
                    "md": "Patients should be sitting upright at 30 to 45\u00b0 during tube feeding and for 1 to 2 h afterward to minimize incidence of nosocomial aspiration pneumonia and to allow gravity to help propel the food. Tube feedings are given in boluses several times a day or by continuous infusion. Bolus feeding is more physiologic and may be preferred for patients with diabetes. Continuous infusion is necessary if boluses cause nausea.",
                    "bBox": {
                        "x": 55,
                        "y": 543.9,
                        "w": 482,
                        "h": 176
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Table 3-2. Complications of Enteral Tube Nutrition",
                    "md": "# Table 3-2. Complications of Enteral Tube Nutrition",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "For bolus feeding, total daily volume is divided into 4 to 6 separate feedings, which are injected through",
                    "md": "For bolus feeding, total daily volume is divided into 4 to 6 separate feedings, which are injected through",
                    "bBox": {
                        "x": 55,
                        "y": 771.9,
                        "w": 472,
                        "h": 12
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 20,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                         Chapter 3. Nutritional Support\n the tube with a syringe or infused by gravity from an elevated bag. After feedings, the tube is flushed with\n water to prevent clogging.\n Nasogastric or nasoduodenal tube feeding often causes diarrhea initially; thus, feedings are usually\n started with small amounts of dilute preparations and increased as tolerated. Most formulas contain 0.5,\n 1, or 2 kcal/mL. Formulas with higher caloric concentration (less water per calorie) may cause decreased\n gastric emptying and thus higher gastric residuals than when more dilute formulas with the same number\n of calories are used. Initially, a 1-kcal/mL commercially prepared solution may be given undiluted at 50\n mL/h or, if patients have not been fed for a while, at 25 mL/h. Usually, these solutions do not supply\n enough water, particularly if vomiting, diarrhea, sweating, or fever has increased water loss. Extra water\n is supplied as boluses via the feeding tube or IV. After a few days, the rate or concentration can be\n increased as needed to meet caloric and water needs.\n Jejunostomy tube feeding requires greater dilution and smaller volumes. Feeding usually begins at a\n concentration of \u2264 0.5 kcal/mL and a rate of 25 mL/h. After a few days, concentrations and volumes can\n be increased to eventually meet caloric and water needs. Usually, the maximum that can be tolerated is\n 0.8 kcal/mL at 125 mL/h, providing 2400 kcal/day.\n Complications: Complications are common and can be serious (see Table 3-2).\n Total Parenteral Nutrition\n Parenteral nutrition is by definition given IV.\n Partial parenteral nutrition supplies only part of daily nutritional requirements, supplementing oral\n intake. Many hospitalized patients are given dextrose or amino acid solutions by this method.\n Total parenteral nutrition (TPN) supplies all daily nutritional requirements. TPN can be used in the\n hospital or at home. Because TPN solutions are concentrated and can cause thrombosis of peripheral\n veins, a central venous catheter is usually required.\n Parenteral nutrition should not be used routinely in patients with an intact GI tract. Compared with enteral\n nutrition, it causes more complications, does not preserve GI tract structure and function as well, and is\n more expensive.\n Indications: TPN may be the only feasible option for patients who do not have a functioning GI tract or\n who have disorders requiring complete bowel rest, such as the following:\n \u2022 Some stages of Crohn's disease or ulcerative colitis\n \u2022 Bowel obstruction\n \u2022 Certain pediatric GI disorders (eg, congenital GI anomalies, prolonged diarrhea regardless of its cause)\n \u2022 Short bowel syndrome due to surgery\n Nutritional content: TPN requires water (30 to 40 mL/kg/day), energy (30 to 60 kcal/kg/day, depending\n on energy expenditure), amino acids (1 to 2.0 g/kg/day, depending on the degree of catabolism), essential\n fatty acids, vitamins, and minerals (see\n Table 3-3). Children who need TPN may have different fluid requirements and need more energy (up to\n 120 kcal/kg/day) and amino acids (up to 2.5 or 3.5 g/kg/day).\n Basic TPN solutions are prepared using sterile techniques, usually in liter batches according to standard\n formulas. Normally, 2 L/day of the standard solution is needed. Solutions may be modified based on\n laboratory results, underlying disorders, hypermetabolism, or other factors.\n Most calories are supplied as carbohydrate. Typically, about 4 to 5 mg/kg/day of dextrose is given.\n Standard solutions contain up to about 25% dextrose, but the amount and concentration depend on other\n                                                                                                         72",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 3. Nutritional Support\n\nThe tube with a syringe or infused by gravity from an elevated bag. After feedings, the tube is flushed with water to prevent clogging.\n\nNasogastric or nasoduodenal tube feeding often causes diarrhea initially; thus, feedings are usually started with small amounts of dilute preparations and increased as tolerated. Most formulas contain 0.5, 1, or 2 kcal/mL. Formulas with higher caloric concentration (less water per calorie) may cause decreased gastric emptying and thus higher gastric residuals than when more dilute formulas with the same number of calories are used. Initially, a 1-kcal/mL commercially prepared solution may be given undiluted at 50 mL/h or, if patients have not been fed for a while, at 25 mL/h. Usually, these solutions do not supply enough water, particularly if vomiting, diarrhea, sweating, or fever has increased water loss. Extra water is supplied as boluses via the feeding tube or IV. After a few days, the rate or concentration can be increased as needed to meet caloric and water needs.\n\nJejunostomy tube feeding requires greater dilution and smaller volumes. Feeding usually begins at a concentration of \u2264 0.5 kcal/mL and a rate of 25 mL/h. After a few days, concentrations and volumes can be increased to eventually meet caloric and water needs. Usually, the maximum that can be tolerated is 0.8 kcal/mL at 125 mL/h, providing 2400 kcal/day.\n\n# Complications:\n\nComplications are common and can be serious (see Table 3-2).\n\n# Total Parenteral Nutrition\n\nParenteral nutrition is by definition given IV.\n\nPartial parenteral nutrition supplies only part of daily nutritional requirements, supplementing oral intake. Many hospitalized patients are given dextrose or amino acid solutions by this method.\n\nTotal parenteral nutrition (TPN) supplies all daily nutritional requirements. TPN can be used in the hospital or at home. Because TPN solutions are concentrated and can cause thrombosis of peripheral veins, a central venous catheter is usually required.\n\nParenteral nutrition should not be used routinely in patients with an intact GI tract. Compared with enteral nutrition, it causes more complications, does not preserve GI tract structure and function as well, and is more expensive.\n\n# Indications:\n\nTPN may be the only feasible option for patients who do not have a functioning GI tract or who have disorders requiring complete bowel rest, such as the following:\n\n- Some stages of Crohn's disease or ulcerative colitis\n- Bowel obstruction\n- Certain pediatric GI disorders (eg, congenital GI anomalies, prolonged diarrhea regardless of its cause)\n- Short bowel syndrome due to surgery\n\n# Nutritional content:\n\nTPN requires water (30 to 40 mL/kg/day), energy (30 to 60 kcal/kg/day, depending on energy expenditure), amino acids (1 to 2.0 g/kg/day, depending on the degree of catabolism), essential fatty acids, vitamins, and minerals (see Table 3-3). Children who need TPN may have different fluid requirements and need more energy (up to 120 kcal/kg/day) and amino acids (up to 2.5 or 3.5 g/kg/day).\n\nBasic TPN solutions are prepared using sterile techniques, usually in liter batches according to standard formulas. Normally, 2 L/day of the standard solution is needed. Solutions may be modified based on laboratory results, underlying disorders, hypermetabolism, or other factors.\n\nMost calories are supplied as carbohydrate. Typically, about 4 to 5 mg/kg/day of dextrose is given. Standard solutions contain up to about 25% dextrose, but the amount and concentration depend on other factors.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 3. Nutritional Support",
                    "md": "# Chapter 3. Nutritional Support",
                    "bBox": {
                        "x": 410,
                        "y": 30.72,
                        "w": 133,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "The tube with a syringe or infused by gravity from an elevated bag. After feedings, the tube is flushed with water to prevent clogging.\n\nNasogastric or nasoduodenal tube feeding often causes diarrhea initially; thus, feedings are usually started with small amounts of dilute preparations and increased as tolerated. Most formulas contain 0.5, 1, or 2 kcal/mL. Formulas with higher caloric concentration (less water per calorie) may cause decreased gastric emptying and thus higher gastric residuals than when more dilute formulas with the same number of calories are used. Initially, a 1-kcal/mL commercially prepared solution may be given undiluted at 50 mL/h or, if patients have not been fed for a while, at 25 mL/h. Usually, these solutions do not supply enough water, particularly if vomiting, diarrhea, sweating, or fever has increased water loss. Extra water is supplied as boluses via the feeding tube or IV. After a few days, the rate or concentration can be increased as needed to meet caloric and water needs.\n\nJejunostomy tube feeding requires greater dilution and smaller volumes. Feeding usually begins at a concentration of \u2264 0.5 kcal/mL and a rate of 25 mL/h. After a few days, concentrations and volumes can be increased to eventually meet caloric and water needs. Usually, the maximum that can be tolerated is 0.8 kcal/mL at 125 mL/h, providing 2400 kcal/day.",
                    "md": "The tube with a syringe or infused by gravity from an elevated bag. After feedings, the tube is flushed with water to prevent clogging.\n\nNasogastric or nasoduodenal tube feeding often causes diarrhea initially; thus, feedings are usually started with small amounts of dilute preparations and increased as tolerated. Most formulas contain 0.5, 1, or 2 kcal/mL. Formulas with higher caloric concentration (less water per calorie) may cause decreased gastric emptying and thus higher gastric residuals than when more dilute formulas with the same number of calories are used. Initially, a 1-kcal/mL commercially prepared solution may be given undiluted at 50 mL/h or, if patients have not been fed for a while, at 25 mL/h. Usually, these solutions do not supply enough water, particularly if vomiting, diarrhea, sweating, or fever has increased water loss. Extra water is supplied as boluses via the feeding tube or IV. After a few days, the rate or concentration can be increased as needed to meet caloric and water needs.\n\nJejunostomy tube feeding requires greater dilution and smaller volumes. Feeding usually begins at a concentration of \u2264 0.5 kcal/mL and a rate of 25 mL/h. After a few days, concentrations and volumes can be increased to eventually meet caloric and water needs. Usually, the maximum that can be tolerated is 0.8 kcal/mL at 125 mL/h, providing 2400 kcal/day.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 479,
                        "h": 215
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Complications:",
                    "md": "# Complications:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Complications are common and can be serious (see Table 3-2).",
                    "md": "Complications are common and can be serious (see Table 3-2).",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Total Parenteral Nutrition",
                    "md": "# Total Parenteral Nutrition",
                    "bBox": {
                        "x": 55,
                        "y": 302.9,
                        "w": 125,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Parenteral nutrition is by definition given IV.\n\nPartial parenteral nutrition supplies only part of daily nutritional requirements, supplementing oral intake. Many hospitalized patients are given dextrose or amino acid solutions by this method.\n\nTotal parenteral nutrition (TPN) supplies all daily nutritional requirements. TPN can be used in the hospital or at home. Because TPN solutions are concentrated and can cause thrombosis of peripheral veins, a central venous catheter is usually required.\n\nParenteral nutrition should not be used routinely in patients with an intact GI tract. Compared with enteral nutrition, it causes more complications, does not preserve GI tract structure and function as well, and is more expensive.",
                    "md": "Parenteral nutrition is by definition given IV.\n\nPartial parenteral nutrition supplies only part of daily nutritional requirements, supplementing oral intake. Many hospitalized patients are given dextrose or amino acid solutions by this method.\n\nTotal parenteral nutrition (TPN) supplies all daily nutritional requirements. TPN can be used in the hospital or at home. Because TPN solutions are concentrated and can cause thrombosis of peripheral veins, a central venous catheter is usually required.\n\nParenteral nutrition should not be used routinely in patients with an intact GI tract. Compared with enteral nutrition, it causes more complications, does not preserve GI tract structure and function as well, and is more expensive.",
                    "bBox": {
                        "x": 55,
                        "y": 302.9,
                        "w": 479,
                        "h": 177
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Indications:",
                    "md": "# Indications:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "TPN may be the only feasible option for patients who do not have a functioning GI tract or who have disorders requiring complete bowel rest, such as the following:\n\n- Some stages of Crohn's disease or ulcerative colitis\n- Bowel obstruction\n- Certain pediatric GI disorders (eg, congenital GI anomalies, prolonged diarrhea regardless of its cause)\n- Short bowel syndrome due to surgery",
                    "md": "TPN may be the only feasible option for patients who do not have a functioning GI tract or who have disorders requiring complete bowel rest, such as the following:\n\n- Some stages of Crohn's disease or ulcerative colitis\n- Bowel obstruction\n- Certain pediatric GI disorders (eg, congenital GI anomalies, prolonged diarrhea regardless of its cause)\n- Short bowel syndrome due to surgery",
                    "bBox": {
                        "x": 55,
                        "y": 505.9,
                        "w": 332,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Nutritional content:",
                    "md": "# Nutritional content:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "TPN requires water (30 to 40 mL/kg/day), energy (30 to 60 kcal/kg/day, depending on energy expenditure), amino acids (1 to 2.0 g/kg/day, depending on the degree of catabolism), essential fatty acids, vitamins, and minerals (see Table 3-3). Children who need TPN may have different fluid requirements and need more energy (up to 120 kcal/kg/day) and amino acids (up to 2.5 or 3.5 g/kg/day).\n\nBasic TPN solutions are prepared using sterile techniques, usually in liter batches according to standard formulas. Normally, 2 L/day of the standard solution is needed. Solutions may be modified based on laboratory results, underlying disorders, hypermetabolism, or other factors.\n\nMost calories are supplied as carbohydrate. Typically, about 4 to 5 mg/kg/day of dextrose is given. Standard solutions contain up to about 25% dextrose, but the amount and concentration depend on other factors.",
                    "md": "TPN requires water (30 to 40 mL/kg/day), energy (30 to 60 kcal/kg/day, depending on energy expenditure), amino acids (1 to 2.0 g/kg/day, depending on the degree of catabolism), essential fatty acids, vitamins, and minerals (see Table 3-3). Children who need TPN may have different fluid requirements and need more energy (up to 120 kcal/kg/day) and amino acids (up to 2.5 or 3.5 g/kg/day).\n\nBasic TPN solutions are prepared using sterile techniques, usually in liter batches according to standard formulas. Normally, 2 L/day of the standard solution is needed. Solutions may be modified based on laboratory results, underlying disorders, hypermetabolism, or other factors.\n\nMost calories are supplied as carbohydrate. Typically, about 4 to 5 mg/kg/day of dextrose is given. Standard solutions contain up to about 25% dextrose, but the amount and concentration depend on other factors.",
                    "bBox": {
                        "x": 55,
                        "y": 644.9,
                        "w": 483,
                        "h": 139
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.995
        },
        {
            "page": 21,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                        Chapter 3. Nutritional Support\n factors, such as metabolic needs and the proportion of caloric needs that are supplied by lipids.\n Commercially available lipid emulsions are often added to supply essential fatty acids and triglycerides;\n 20 to 30% of total calories are usually supplied as lipids. However, withholding lipids and their calories\n may help obese patients mobilize endogenous fat stores, increasing insulin sensitivity.\n Solutions: Many solutions are commonly used. Electrolytes can be added to meet the patient's needs.\n Solutions vary depending on other disorders present and patient age, as for the following:\n \u2022 For renal insufficiency not being treated with dialysis or for liver failure: Reduced protein content and a\n   high percentage of essential amino acids\n \u2022 For heart or kidney failure: Limited volume (liquid) intake\n \u2022 For respiratory failure: A lipid emulsion that provides most of nonprotein calories to minimize CO2\n   production by carbohydrate metabolism\n \u2022 For neonates: Lower dextrose concentrations (17 to 18%)\n Beginning TPN administration: Because the central venous catheter needs to remain in place for a\n long time, strict sterile technique must be used during insertion and maintenance. The TPN line should\n not be used for any other purpose. External tubing should be changed every 24 h with the first bag of the\n day. In-line filters have not been shown to decrease complications. Dressings should be kept sterile and\n are usually changed every 48 h using strict sterile techniques. If TPN is given outside the hospital,\n patients must be taught to recognize symptoms of infection, and qualified home nursing must be\n arranged.\n The solution is started slowly at 50% of the calculated requirements, using 5% dextrose to make up the\n balance of fluid requirements. Energy and nitrogen should be given simultaneously. The amount of\n regular insulin given (added directly to the TPN solution) depends on the plasma glucose level; if the\n level is normal and the final solution contains 25% dextrose, the usual starting dose is 5 to 10 units of\n regular insulin/L of TPN fluid.\n Monitoring: Progress should be followed on a flowchart. An interdisciplinary nutrition team, if available,\n should monitor patients. Weight, CBC, electrolytes, and BUN should be monitored often (eg, daily for\n inpatients). Plasma glucose should be monitored every 6 h until patients and glucose levels become\n stable. Fluid intake and output should be monitored continuously. When patients become stable, blood\n tests can be done much less often.\n Liver function tests should be done. Plasma proteins (eg, serum albumin, possibly transthyretin or retinol-\n binding protein), PT, plasma and urine osmolality, and Ca, Mg, and phosphate should be measured\n twice/wk. Changes in transthyretin and retinol-binding protein reflect overall clinical status rather than\n nutritional status alone. If possible, blood tests should not be done during glucose infusion. Full nutritional\n assessment (including BMI calculation and anthropometric measurements\u2014see pp. 11 and 58) should be\n repeated at 2-wk intervals.\n Complications: About 5 to 10% of patients have complications related to central venous access.\n [Table 3-3. Basic Adult Daily Requirements for Total Parenteral Nutrition]\n Catheter-related sepsis occurs in about \u2265 50% of patients. Glucose abnormalities (hyperglycemia or\n hypoglycemia) or liver dysfunction occurs in &gt; 90% of patients.\n Glucose abnormalities are common. Hyperglycemia can be avoided by monitoring plasma glucose\n often, adjusting the insulin dose in the TPN solution and giving subcutaneous insulin as needed.\n Hypoglycemia can be precipitated by suddenly stopping constant concentrated dextrose infusions.\n Treatment depends on the degree of hypoglycemia. Short-term hypoglycemia may be reversed with 50%\n dextrose IV; more prolonged hypoglycemia may require infusion of 5 or 10% dextrose for 24 h before\n                                                                                                       73",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 3. Nutritional Support\n\nFactors, such as metabolic needs and the proportion of caloric needs that are supplied by lipids. Commercially available lipid emulsions are often added to supply essential fatty acids and triglycerides; 20 to 30% of total calories are usually supplied as lipids. However, withholding lipids and their calories may help obese patients mobilize endogenous fat stores, increasing insulin sensitivity.\n\n# Solutions:\n\nMany solutions are commonly used. Electrolytes can be added to meet the patient's needs. Solutions vary depending on other disorders present and patient age, as for the following:\n\n- For renal insufficiency not being treated with dialysis or for liver failure: Reduced protein content and a high percentage of essential amino acids\n- For heart or kidney failure: Limited volume (liquid) intake\n- For respiratory failure: A lipid emulsion that provides most of nonprotein calories to minimize CO2 production by carbohydrate metabolism\n- For neonates: Lower dextrose concentrations (17 to 18%)\n\n# Beginning TPN administration:\n\nBecause the central venous catheter needs to remain in place for a long time, strict sterile technique must be used during insertion and maintenance. The TPN line should not be used for any other purpose. External tubing should be changed every 24 h with the first bag of the day. In-line filters have not been shown to decrease complications. Dressings should be kept sterile and are usually changed every 48 h using strict sterile techniques. If TPN is given outside the hospital, patients must be taught to recognize symptoms of infection, and qualified home nursing must be arranged.\n\nThe solution is started slowly at 50% of the calculated requirements, using 5% dextrose to make up the balance of fluid requirements. Energy and nitrogen should be given simultaneously. The amount of regular insulin given (added directly to the TPN solution) depends on the plasma glucose level; if the level is normal and the final solution contains 25% dextrose, the usual starting dose is 5 to 10 units of regular insulin/L of TPN fluid.\n\n# Monitoring:\n\nProgress should be followed on a flowchart. An interdisciplinary nutrition team, if available, should monitor patients. Weight, CBC, electrolytes, and BUN should be monitored often (eg, daily for inpatients). Plasma glucose should be monitored every 6 h until patients and glucose levels become stable. Fluid intake and output should be monitored continuously. When patients become stable, blood tests can be done much less often.\n\nLiver function tests should be done. Plasma proteins (eg, serum albumin, possibly transthyretin or retinol-binding protein), PT, plasma and urine osmolality, and Ca, Mg, and phosphate should be measured twice/wk. Changes in transthyretin and retinol-binding protein reflect overall clinical status rather than nutritional status alone. If possible, blood tests should not be done during glucose infusion. Full nutritional assessment (including BMI calculation and anthropometric measurements\u2014see pp. 11 and 58) should be repeated at 2-wk intervals.\n\n# Complications:\n\nAbout 5 to 10% of patients have complications related to central venous access. Catheter-related sepsis occurs in about \u2265 50% of patients. Glucose abnormalities (hyperglycemia or hypoglycemia) or liver dysfunction occurs in &gt; 90% of patients.\n\nGlucose abnormalities are common. Hyperglycemia can be avoided by monitoring plasma glucose often, adjusting the insulin dose in the TPN solution and giving subcutaneous insulin as needed. Hypoglycemia can be precipitated by suddenly stopping constant concentrated dextrose infusions. Treatment depends on the degree of hypoglycemia. Short-term hypoglycemia may be reversed with 50% dextrose IV; more prolonged hypoglycemia may require infusion of 5 or 10% dextrose for 24 h before.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 3. Nutritional Support",
                    "md": "# Chapter 3. Nutritional Support",
                    "bBox": {
                        "x": 410,
                        "y": 30.72,
                        "w": 133,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "Factors, such as metabolic needs and the proportion of caloric needs that are supplied by lipids. Commercially available lipid emulsions are often added to supply essential fatty acids and triglycerides; 20 to 30% of total calories are usually supplied as lipids. However, withholding lipids and their calories may help obese patients mobilize endogenous fat stores, increasing insulin sensitivity.",
                    "md": "Factors, such as metabolic needs and the proportion of caloric needs that are supplied by lipids. Commercially available lipid emulsions are often added to supply essential fatty acids and triglycerides; 20 to 30% of total calories are usually supplied as lipids. However, withholding lipids and their calories may help obese patients mobilize endogenous fat stores, increasing insulin sensitivity.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 470,
                        "h": 50
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Solutions:",
                    "md": "# Solutions:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Many solutions are commonly used. Electrolytes can be added to meet the patient's needs. Solutions vary depending on other disorders present and patient age, as for the following:\n\n- For renal insufficiency not being treated with dialysis or for liver failure: Reduced protein content and a high percentage of essential amino acids\n- For heart or kidney failure: Limited volume (liquid) intake\n- For respiratory failure: A lipid emulsion that provides most of nonprotein calories to minimize CO2 production by carbohydrate metabolism\n- For neonates: Lower dextrose concentrations (17 to 18%)",
                    "md": "Many solutions are commonly used. Electrolytes can be added to meet the patient's needs. Solutions vary depending on other disorders present and patient age, as for the following:\n\n- For renal insufficiency not being treated with dialysis or for liver failure: Reduced protein content and a high percentage of essential amino acids\n- For heart or kidney failure: Limited volume (liquid) intake\n- For respiratory failure: A lipid emulsion that provides most of nonprotein calories to minimize CO2 production by carbohydrate metabolism\n- For neonates: Lower dextrose concentrations (17 to 18%)",
                    "bBox": {
                        "x": 55,
                        "y": 137.9,
                        "w": 410,
                        "h": 116
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Beginning TPN administration:",
                    "md": "# Beginning TPN administration:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Because the central venous catheter needs to remain in place for a long time, strict sterile technique must be used during insertion and maintenance. The TPN line should not be used for any other purpose. External tubing should be changed every 24 h with the first bag of the day. In-line filters have not been shown to decrease complications. Dressings should be kept sterile and are usually changed every 48 h using strict sterile techniques. If TPN is given outside the hospital, patients must be taught to recognize symptoms of infection, and qualified home nursing must be arranged.\n\nThe solution is started slowly at 50% of the calculated requirements, using 5% dextrose to make up the balance of fluid requirements. Energy and nitrogen should be given simultaneously. The amount of regular insulin given (added directly to the TPN solution) depends on the plasma glucose level; if the level is normal and the final solution contains 25% dextrose, the usual starting dose is 5 to 10 units of regular insulin/L of TPN fluid.",
                    "md": "Because the central venous catheter needs to remain in place for a long time, strict sterile technique must be used during insertion and maintenance. The TPN line should not be used for any other purpose. External tubing should be changed every 24 h with the first bag of the day. In-line filters have not been shown to decrease complications. Dressings should be kept sterile and are usually changed every 48 h using strict sterile techniques. If TPN is given outside the hospital, patients must be taught to recognize symptoms of infection, and qualified home nursing must be arranged.\n\nThe solution is started slowly at 50% of the calculated requirements, using 5% dextrose to make up the balance of fluid requirements. Energy and nitrogen should be given simultaneously. The amount of regular insulin given (added directly to the TPN solution) depends on the plasma glucose level; if the level is normal and the final solution contains 25% dextrose, the usual starting dose is 5 to 10 units of regular insulin/L of TPN fluid.",
                    "bBox": {
                        "x": 55,
                        "y": 304.9,
                        "w": 479,
                        "h": 152
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Monitoring:",
                    "md": "# Monitoring:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Progress should be followed on a flowchart. An interdisciplinary nutrition team, if available, should monitor patients. Weight, CBC, electrolytes, and BUN should be monitored often (eg, daily for inpatients). Plasma glucose should be monitored every 6 h until patients and glucose levels become stable. Fluid intake and output should be monitored continuously. When patients become stable, blood tests can be done much less often.\n\nLiver function tests should be done. Plasma proteins (eg, serum albumin, possibly transthyretin or retinol-binding protein), PT, plasma and urine osmolality, and Ca, Mg, and phosphate should be measured twice/wk. Changes in transthyretin and retinol-binding protein reflect overall clinical status rather than nutritional status alone. If possible, blood tests should not be done during glucose infusion. Full nutritional assessment (including BMI calculation and anthropometric measurements\u2014see pp. 11 and 58) should be repeated at 2-wk intervals.",
                    "md": "Progress should be followed on a flowchart. An interdisciplinary nutrition team, if available, should monitor patients. Weight, CBC, electrolytes, and BUN should be monitored often (eg, daily for inpatients). Plasma glucose should be monitored every 6 h until patients and glucose levels become stable. Fluid intake and output should be monitored continuously. When patients become stable, blood tests can be done much less often.\n\nLiver function tests should be done. Plasma proteins (eg, serum albumin, possibly transthyretin or retinol-binding protein), PT, plasma and urine osmolality, and Ca, Mg, and phosphate should be measured twice/wk. Changes in transthyretin and retinol-binding protein reflect overall clinical status rather than nutritional status alone. If possible, blood tests should not be done during glucose infusion. Full nutritional assessment (including BMI calculation and anthropometric measurements\u2014see pp. 11 and 58) should be repeated at 2-wk intervals.",
                    "bBox": {
                        "x": 55,
                        "y": 482.9,
                        "w": 482,
                        "h": 138
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Complications:",
                    "md": "# Complications:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "About 5 to 10% of patients have complications related to central venous access. Catheter-related sepsis occurs in about \u2265 50% of patients. Glucose abnormalities (hyperglycemia or hypoglycemia) or liver dysfunction occurs in &gt; 90% of patients.\n\nGlucose abnormalities are common. Hyperglycemia can be avoided by monitoring plasma glucose often, adjusting the insulin dose in the TPN solution and giving subcutaneous insulin as needed. Hypoglycemia can be precipitated by suddenly stopping constant concentrated dextrose infusions. Treatment depends on the degree of hypoglycemia. Short-term hypoglycemia may be reversed with 50% dextrose IV; more prolonged hypoglycemia may require infusion of 5 or 10% dextrose for 24 h before.",
                    "md": "About 5 to 10% of patients have complications related to central venous access. Catheter-related sepsis occurs in about \u2265 50% of patients. Glucose abnormalities (hyperglycemia or hypoglycemia) or liver dysfunction occurs in &gt; 90% of patients.\n\nGlucose abnormalities are common. Hyperglycemia can be avoided by monitoring plasma glucose often, adjusting the insulin dose in the TPN solution and giving subcutaneous insulin as needed. Hypoglycemia can be precipitated by suddenly stopping constant concentrated dextrose infusions. Treatment depends on the degree of hypoglycemia. Short-term hypoglycemia may be reversed with 50% dextrose IV; more prolonged hypoglycemia may require infusion of 5 or 10% dextrose for 24 h before.",
                    "bBox": {
                        "x": 55,
                        "y": 684.9,
                        "w": 478,
                        "h": 101
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.978
        },
        {
            "page": 22,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                        Chapter 3. Nutritional Support\n resuming TPN via the central venous catheter.\n Hepatic complications include liver dysfunction, painful hepatomegaly, and hyperammonemia. They can\n develop at any age but are most common among infants, particularly premature ones (whose liver is\n immature).\n \u2022 Liver dysfunction may be transient, evidenced by increased transaminases, bilirubin, and alkaline\n   phosphatase; it commonly occurs when TPN is started. Delayed or persistent elevations may result\n   from excess amino acids. Pathogenesis is unknown, but cholestasis and inflammation may contribute.\n   Progressive fibrosis occasionally develops. Reducing protein delivery may help.\n \u2022 Painful hepatomegaly suggests fat accumulation; carbohydrate delivery should be reduced.\n \u2022 Hyperammonemia can develop in infants, causing lethargy, twitching, and generalized seizures. Arginine\n   supplementation at 0.5 to 1.0 mmol/kg/day can correct it.\n If infants develop any hepatic complication, limiting amino acids to 1.0 g/kg/day may be necessary.\n Abnormalities of serum electrolytes and minerals should be corrected by modifying subsequent\n infusions or, if correction is urgently required, by beginning appropriate peripheral vein infusions. Vitamin\n and mineral deficiencies are rare when solutions are given correctly. Elevated BUN may reflect\n dehydration, which can be corrected by giving free water as 5% dextrose via a peripheral vein.\n Volume overload (suggested by &gt; 1 kg/day weight gain) may occur when patients have high daily\n energy requirements and thus require large fluid volumes.\n Metabolic bone disease, or bone demineralization (osteoporosis or osteomalacia), develops in some\n patients given TPN for &gt; 3 mo. The mechanism is unknown. Advanced disease can cause severe\n periarticular, lower-extremity, and back pain. Temporarily or permanently stopping TPN is the only known\n treatment.\n Adverse reactions to lipid emulsions (eg, dyspnea, cutaneous allergic reactions, nausea, headache,\n back pain, sweating, dizziness) are uncommon but may occur early, particularly if lipids are given at &gt; 1.0\n kcal/kg/h. Temporary hyperlipidemia may occur, particularly in patients with kidney or liver failure;\n treatment is usually not required. Delayed adverse reactions to lipid emulsions include hepatomegaly, mild\n elevation of liver enzymes, splenomegaly, thrombocytopenia, leukopenia, and, especially in premature\n infants with respiratory distress syndrome, pulmonary function abnormalities. Temporarily or permanently\n slowing or stopping lipid emulsion infusion may prevent or minimize these adverse reactions.\n Gallbladder complications include cholelithiasis, gallbladder sludge, and cholecystitis. These\n complications can be caused or worsened by prolonged gallbladder stasis. Stimulating contraction by\n providing about 20 to 30% of calories as fat and stopping glucose infusion several hours a day is helpful.\n Oral or enteral intake also helps. Treatment with metronidazole, ursodeoxycholic acid, phenobarbital, or\n cholecystokinin helps some patients with cholestasis.\n Nutritional Support for Dying or Severely Demented Patients\n Anorexia or loss of appetite is common among dying patients (see p. 3485). Behavioral measures (eg,\n using flexible feeding schedules, feeding slowly, giving small portions or favorite or strongly flavored\n foods) can often increase oral intake. A small amount of a favorite alcoholic drink, given 30 min before\n meals, may also help. Certain antidepressants, megestrol acetate, and dronabinol may stimulate appetite.\n Metoclopramide enhances gastric emptying, but it may take 1 to 2 wk to reach peak effectiveness.\n Advanced dementia eventually leads to inability to eat; sometimes affected patients are given tube\n feedings. However, there is no convincing evidence that tube feedings prolong life, provide comfort,\n improve function, or prevent complications (eg, aspiration, pressure ulcers).\n Tube feedings and parenteral nutrition cause discomfort and are usually not indicated for patients who\n                                                                                                        74",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 3. Nutritional Support\n\nresuming TPN via the central venous catheter.\n\n# Hepatic Complications\n\nHepatic complications include liver dysfunction, painful hepatomegaly, and hyperammonemia. They can develop at any age but are most common among infants, particularly premature ones (whose liver is immature).\n\n- Liver dysfunction may be transient, evidenced by increased transaminases, bilirubin, and alkaline phosphatase; it commonly occurs when TPN is started. Delayed or persistent elevations may result from excess amino acids. Pathogenesis is unknown, but cholestasis and inflammation may contribute. Progressive fibrosis occasionally develops. Reducing protein delivery may help.\n- Painful hepatomegaly suggests fat accumulation; carbohydrate delivery should be reduced.\n- Hyperammonemia can develop in infants, causing lethargy, twitching, and generalized seizures. Arginine supplementation at 0.5 to 1.0 mmol/kg/day can correct it.\n\nIf infants develop any hepatic complication, limiting amino acids to 1.0 g/kg/day may be necessary. Abnormalities of serum electrolytes and minerals should be corrected by modifying subsequent infusions or, if correction is urgently required, by beginning appropriate peripheral vein infusions. Vitamin and mineral deficiencies are rare when solutions are given correctly. Elevated BUN may reflect dehydration, which can be corrected by giving free water as 5% dextrose via a peripheral vein. Volume overload (suggested by &gt; 1 kg/day weight gain) may occur when patients have high daily energy requirements and thus require large fluid volumes.\n\n# Metabolic Bone Disease\n\nMetabolic bone disease, or bone demineralization (osteoporosis or osteomalacia), develops in some patients given TPN for &gt; 3 mo. The mechanism is unknown. Advanced disease can cause severe periarticular, lower-extremity, and back pain. Temporarily or permanently stopping TPN is the only known treatment.\n\n# Adverse Reactions to Lipid Emulsions\n\nAdverse reactions to lipid emulsions (eg, dyspnea, cutaneous allergic reactions, nausea, headache, back pain, sweating, dizziness) are uncommon but may occur early, particularly if lipids are given at &gt; 1.0 kcal/kg/h. Temporary hyperlipidemia may occur, particularly in patients with kidney or liver failure; treatment is usually not required. Delayed adverse reactions to lipid emulsions include hepatomegaly, mild elevation of liver enzymes, splenomegaly, thrombocytopenia, leukopenia, and, especially in premature infants with respiratory distress syndrome, pulmonary function abnormalities. Temporarily or permanently slowing or stopping lipid emulsion infusion may prevent or minimize these adverse reactions.\n\n# Gallbladder Complications\n\nGallbladder complications include cholelithiasis, gallbladder sludge, and cholecystitis. These complications can be caused or worsened by prolonged gallbladder stasis. Stimulating contraction by providing about 20 to 30% of calories as fat and stopping glucose infusion several hours a day is helpful. Oral or enteral intake also helps. Treatment with metronidazole, ursodeoxycholic acid, phenobarbital, or cholecystokinin helps some patients with cholestasis.\n\n# Nutritional Support for Dying or Severely Demented Patients\n\nAnorexia or loss of appetite is common among dying patients (see p. 3485). Behavioral measures (eg, using flexible feeding schedules, feeding slowly, giving small portions or favorite or strongly flavored foods) can often increase oral intake. A small amount of a favorite alcoholic drink, given 30 min before meals, may also help. Certain antidepressants, megestrol acetate, and dronabinol may stimulate appetite. Metoclopramide enhances gastric emptying, but it may take 1 to 2 wk to reach peak effectiveness.\n\nAdvanced dementia eventually leads to inability to eat; sometimes affected patients are given tube feedings. However, there is no convincing evidence that tube feedings prolong life, provide comfort, improve function, or prevent complications (eg, aspiration, pressure ulcers). Tube feedings and parenteral nutrition cause discomfort and are usually not indicated for patients who",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 3. Nutritional Support",
                    "md": "# Chapter 3. Nutritional Support",
                    "bBox": {
                        "x": 410,
                        "y": 30.72,
                        "w": 133,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "resuming TPN via the central venous catheter.",
                    "md": "resuming TPN via the central venous catheter.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 213,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Hepatic Complications",
                    "md": "# Hepatic Complications",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Hepatic complications include liver dysfunction, painful hepatomegaly, and hyperammonemia. They can develop at any age but are most common among infants, particularly premature ones (whose liver is immature).\n\n- Liver dysfunction may be transient, evidenced by increased transaminases, bilirubin, and alkaline phosphatase; it commonly occurs when TPN is started. Delayed or persistent elevations may result from excess amino acids. Pathogenesis is unknown, but cholestasis and inflammation may contribute. Progressive fibrosis occasionally develops. Reducing protein delivery may help.\n- Painful hepatomegaly suggests fat accumulation; carbohydrate delivery should be reduced.\n- Hyperammonemia can develop in infants, causing lethargy, twitching, and generalized seizures. Arginine supplementation at 0.5 to 1.0 mmol/kg/day can correct it.\n\nIf infants develop any hepatic complication, limiting amino acids to 1.0 g/kg/day may be necessary. Abnormalities of serum electrolytes and minerals should be corrected by modifying subsequent infusions or, if correction is urgently required, by beginning appropriate peripheral vein infusions. Vitamin and mineral deficiencies are rare when solutions are given correctly. Elevated BUN may reflect dehydration, which can be corrected by giving free water as 5% dextrose via a peripheral vein. Volume overload (suggested by &gt; 1 kg/day weight gain) may occur when patients have high daily energy requirements and thus require large fluid volumes.",
                    "md": "Hepatic complications include liver dysfunction, painful hepatomegaly, and hyperammonemia. They can develop at any age but are most common among infants, particularly premature ones (whose liver is immature).\n\n- Liver dysfunction may be transient, evidenced by increased transaminases, bilirubin, and alkaline phosphatase; it commonly occurs when TPN is started. Delayed or persistent elevations may result from excess amino acids. Pathogenesis is unknown, but cholestasis and inflammation may contribute. Progressive fibrosis occasionally develops. Reducing protein delivery may help.\n- Painful hepatomegaly suggests fat accumulation; carbohydrate delivery should be reduced.\n- Hyperammonemia can develop in infants, causing lethargy, twitching, and generalized seizures. Arginine supplementation at 0.5 to 1.0 mmol/kg/day can correct it.\n\nIf infants develop any hepatic complication, limiting amino acids to 1.0 g/kg/day may be necessary. Abnormalities of serum electrolytes and minerals should be corrected by modifying subsequent infusions or, if correction is urgently required, by beginning appropriate peripheral vein infusions. Vitamin and mineral deficiencies are rare when solutions are given correctly. Elevated BUN may reflect dehydration, which can be corrected by giving free water as 5% dextrose via a peripheral vein. Volume overload (suggested by &gt; 1 kg/day weight gain) may occur when patients have high daily energy requirements and thus require large fluid volumes.",
                    "bBox": {
                        "x": 55,
                        "y": 74.9,
                        "w": 483,
                        "h": 291
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Metabolic Bone Disease",
                    "md": "# Metabolic Bone Disease",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Metabolic bone disease, or bone demineralization (osteoporosis or osteomalacia), develops in some patients given TPN for &gt; 3 mo. The mechanism is unknown. Advanced disease can cause severe periarticular, lower-extremity, and back pain. Temporarily or permanently stopping TPN is the only known treatment.",
                    "md": "Metabolic bone disease, or bone demineralization (osteoporosis or osteomalacia), develops in some patients given TPN for &gt; 3 mo. The mechanism is unknown. Advanced disease can cause severe periarticular, lower-extremity, and back pain. Temporarily or permanently stopping TPN is the only known treatment.",
                    "bBox": {
                        "x": 55,
                        "y": 378.9,
                        "w": 477,
                        "h": 50
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Adverse Reactions to Lipid Emulsions",
                    "md": "# Adverse Reactions to Lipid Emulsions",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Adverse reactions to lipid emulsions (eg, dyspnea, cutaneous allergic reactions, nausea, headache, back pain, sweating, dizziness) are uncommon but may occur early, particularly if lipids are given at &gt; 1.0 kcal/kg/h. Temporary hyperlipidemia may occur, particularly in patients with kidney or liver failure; treatment is usually not required. Delayed adverse reactions to lipid emulsions include hepatomegaly, mild elevation of liver enzymes, splenomegaly, thrombocytopenia, leukopenia, and, especially in premature infants with respiratory distress syndrome, pulmonary function abnormalities. Temporarily or permanently slowing or stopping lipid emulsion infusion may prevent or minimize these adverse reactions.",
                    "md": "Adverse reactions to lipid emulsions (eg, dyspnea, cutaneous allergic reactions, nausea, headache, back pain, sweating, dizziness) are uncommon but may occur early, particularly if lipids are given at &gt; 1.0 kcal/kg/h. Temporary hyperlipidemia may occur, particularly in patients with kidney or liver failure; treatment is usually not required. Delayed adverse reactions to lipid emulsions include hepatomegaly, mild elevation of liver enzymes, splenomegaly, thrombocytopenia, leukopenia, and, especially in premature infants with respiratory distress syndrome, pulmonary function abnormalities. Temporarily or permanently slowing or stopping lipid emulsion infusion may prevent or minimize these adverse reactions.",
                    "bBox": {
                        "x": 55,
                        "y": 441.9,
                        "w": 483,
                        "h": 88
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Gallbladder Complications",
                    "md": "# Gallbladder Complications",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Gallbladder complications include cholelithiasis, gallbladder sludge, and cholecystitis. These complications can be caused or worsened by prolonged gallbladder stasis. Stimulating contraction by providing about 20 to 30% of calories as fat and stopping glucose infusion several hours a day is helpful. Oral or enteral intake also helps. Treatment with metronidazole, ursodeoxycholic acid, phenobarbital, or cholecystokinin helps some patients with cholestasis.",
                    "md": "Gallbladder complications include cholelithiasis, gallbladder sludge, and cholecystitis. These complications can be caused or worsened by prolonged gallbladder stasis. Stimulating contraction by providing about 20 to 30% of calories as fat and stopping glucose infusion several hours a day is helpful. Oral or enteral intake also helps. Treatment with metronidazole, ursodeoxycholic acid, phenobarbital, or cholecystokinin helps some patients with cholestasis.",
                    "bBox": {
                        "x": 55,
                        "y": 543.9,
                        "w": 478,
                        "h": 62
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Nutritional Support for Dying or Severely Demented Patients",
                    "md": "# Nutritional Support for Dying or Severely Demented Patients",
                    "bBox": {
                        "x": 55,
                        "y": 619.9,
                        "w": 304,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Anorexia or loss of appetite is common among dying patients (see p. 3485). Behavioral measures (eg, using flexible feeding schedules, feeding slowly, giving small portions or favorite or strongly flavored foods) can often increase oral intake. A small amount of a favorite alcoholic drink, given 30 min before meals, may also help. Certain antidepressants, megestrol acetate, and dronabinol may stimulate appetite. Metoclopramide enhances gastric emptying, but it may take 1 to 2 wk to reach peak effectiveness.\n\nAdvanced dementia eventually leads to inability to eat; sometimes affected patients are given tube feedings. However, there is no convincing evidence that tube feedings prolong life, provide comfort, improve function, or prevent complications (eg, aspiration, pressure ulcers). Tube feedings and parenteral nutrition cause discomfort and are usually not indicated for patients who",
                    "md": "Anorexia or loss of appetite is common among dying patients (see p. 3485). Behavioral measures (eg, using flexible feeding schedules, feeding slowly, giving small portions or favorite or strongly flavored foods) can often increase oral intake. A small amount of a favorite alcoholic drink, given 30 min before meals, may also help. Certain antidepressants, megestrol acetate, and dronabinol may stimulate appetite. Metoclopramide enhances gastric emptying, but it may take 1 to 2 wk to reach peak effectiveness.\n\nAdvanced dementia eventually leads to inability to eat; sometimes affected patients are given tube feedings. However, there is no convincing evidence that tube feedings prolong life, provide comfort, improve function, or prevent complications (eg, aspiration, pressure ulcers). Tube feedings and parenteral nutrition cause discomfort and are usually not indicated for patients who",
                    "bBox": {
                        "x": 55,
                        "y": 644.9,
                        "w": 482,
                        "h": 139
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.973
        },
        {
            "page": 23,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                         Chapter 3. Nutritional Support\n are dying or too demented to eat. Forgoing nutritional support may be difficult for family members to\n accept, but they should understand that patients are usually more comfortable eating and drinking as they\n choose. Sips of water and easy-to-swallow foods may be useful. Supportive care, including good oral\n hygiene (eg, brushing the teeth, moistening the oral cavity with swabs and ice chips as needed, applying\n lip salve), can physically and psychologically comfort the patients and the family members who provide\n the care.\n Counseling may help family members who are dealing with anxieties about whether to use invasive\n nutritional support.\n                                                                                                         75",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 3. Nutritional Support\n\nare dying or too demented to eat. Forgoing nutritional support may be difficult for family members to accept, but they should understand that patients are usually more comfortable eating and drinking as they choose. Sips of water and easy-to-swallow foods may be useful. Supportive care, including good oral hygiene (eg, brushing the teeth, moistening the oral cavity with swabs and ice chips as needed, applying lip salve), can physically and psychologically comfort the patients and the family members who provide the care.\n\nCounseling may help family members who are dealing with anxieties about whether to use invasive nutritional support.\n\n75",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 3. Nutritional Support",
                    "md": "# Chapter 3. Nutritional Support",
                    "bBox": {
                        "x": 410,
                        "y": 30.72,
                        "w": 133,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "are dying or too demented to eat. Forgoing nutritional support may be difficult for family members to accept, but they should understand that patients are usually more comfortable eating and drinking as they choose. Sips of water and easy-to-swallow foods may be useful. Supportive care, including good oral hygiene (eg, brushing the teeth, moistening the oral cavity with swabs and ice chips as needed, applying lip salve), can physically and psychologically comfort the patients and the family members who provide the care.\n\nCounseling may help family members who are dealing with anxieties about whether to use invasive nutritional support.\n\n75",
                    "md": "are dying or too demented to eat. Forgoing nutritional support may be difficult for family members to accept, but they should understand that patients are usually more comfortable eating and drinking as they choose. Sips of water and easy-to-swallow foods may be useful. Supportive care, including good oral hygiene (eg, brushing the teeth, moistening the oral cavity with swabs and ice chips as needed, applying lip salve), can physically and psychologically comfort the patients and the family members who provide the care.\n\nCounseling may help family members who are dealing with anxieties about whether to use invasive nutritional support.\n\n75",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 488,
                        "h": 758.82
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.997
        },
        {
            "page": 24,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n Chapter 4. Vitamin Deficiency, Dependency, and Toxicity\n Introduction\n Vitamins may be fat soluble (vitamins A, D, E, and K) or water soluble (B vitamins and vitamin C). The B\n vitamins include biotin, folate, niacin, pantothenic acid, riboflavin (B2), thiamin (B1), B6 (eg, pyridoxine),\n and B12 (cobalamins). For dietary requirements, sources, functions, effects of deficiencies and toxicities,\n blood levels, and usual therapeutic dosages for vitamins, see\n Tables 4-1 and\n 4-2.\n Dietary requirements for vitamins (and other nutrients) are expressed as daily recommended intake (DRI).\n There are 3 types of DRI:\n \u2022 Recommended daily allowance (RDA): RDAs are set to meet the needs of 97 to 98% of healthy\n   people.\n \u2022 Adequate intake (AI): When data to calculate an RDA are insufficient, AIs are based on observed or\n   experimentally determined estimates of nutrient intake by healthy people.\n \u2022 Tolerable upper intake level (UL): ULs are the largest amount of a nutrient that most adults can\n   ingest daily without risk of adverse health effects.\n In developed countries, vitamin deficiencies result mainly from poverty, food faddism, drugs (see p. 7 and\n Table 4-3), alcoholism, or prolonged and inadequately supplemented parenteral feeding. Mild vitamin\n deficiency is common among frail and institutionalized elderly people who have protein-energy\n undernutrition. In developing countries, deficiencies can result from lack of access to nutrients.\n Deficiencies of water-soluble vitamins (except vitamin B12) may develop after weeks to months of\n undernutrition. Deficiencies of fat-soluble vitamins and of vitamin B12 take &gt; 1 yr to develop because the\n body stores them in relatively large amounts. Intake of vitamins sufficient to prevent classic vitamin\n deficiencies (like scurvy or beriberi) may not be adequate for optimum health. This area remains one of\n controversy and active research.\n Vitamin dependency results from a genetic defect involving metabolism of a vitamin. In some cases,\n vitamin doses as high as 1000 times the DRI improve function of the altered metabolic pathway. Vitamin\n toxicity (hypervitaminosis) usually results from taking megadoses of vitamin A, D, C, B6, or niacin.\n Because many people eat irregularly, foods alone may provide suboptimal amounts of some vitamins. In\n these cases, the risk of certain cancers or other disorders may be increased. Because of this risk, routine\n daily multivitamin supplements are sometimes recommended.\n Biotin and Pantothenic Acid\n Biotin acts as a coenzyme for carboxylation reactions essential to fat and carbohydrate metabolism.\n Adequate intake for adults is 30 \u03bcg/day. Pantothenic acid is widely distributed in foods; it is an essential\n component of coenzyme A. Adults probably require about 5 mg/day. A beneficial role for pantothenic acid\n supplementation in lipid metabolism, RA, or athletic performance remains unproved. Isolated deficiency of\n biotin or pantothenic acid virtually never occurs.\n Folate\n Folate (folic acid) is now added to enriched grain foods in the US. Folate is also plentiful in various plant\n foods and meats, but its bioavailability is greater when it is in supplements\n [Table 4-1. Recommended Daily Intakes for Vitamins]\n or enriched foods than when it occurs naturally in food.\n                                                                                                        76",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency, and Toxicity\n\n# Introduction\n\nVitamins may be fat soluble (vitamins A, D, E, and K) or water soluble (B vitamins and vitamin C). The B vitamins include biotin, folate, niacin, pantothenic acid, riboflavin (B2), thiamin (B1), B6 (eg, pyridoxine), and B12 (cobalamins). For dietary requirements, sources, functions, effects of deficiencies and toxicities, blood levels, and usual therapeutic dosages for vitamins, see Tables 4-1 and 4-2.\n\nDietary requirements for vitamins (and other nutrients) are expressed as daily recommended intake (DRI). There are 3 types of DRI:\n\n- Recommended daily allowance (RDA): RDAs are set to meet the needs of 97 to 98% of healthy people.\n- Adequate intake (AI): When data to calculate an RDA are insufficient, AIs are based on observed or experimentally determined estimates of nutrient intake by healthy people.\n- Tolerable upper intake level (UL): ULs are the largest amount of a nutrient that most adults can ingest daily without risk of adverse health effects.\n\nIn developed countries, vitamin deficiencies result mainly from poverty, food faddism, drugs (see p. 7 and Table 4-3), alcoholism, or prolonged and inadequately supplemented parenteral feeding. Mild vitamin deficiency is common among frail and institutionalized elderly people who have protein-energy undernutrition. In developing countries, deficiencies can result from lack of access to nutrients.\n\nDeficiencies of water-soluble vitamins (except vitamin B12) may develop after weeks to months of undernutrition. Deficiencies of fat-soluble vitamins and of vitamin B12 take &amp;gt; 1 yr to develop because the body stores them in relatively large amounts. Intake of vitamins sufficient to prevent classic vitamin deficiencies (like scurvy or beriberi) may not be adequate for optimum health. This area remains one of controversy and active research.\n\nVitamin dependency results from a genetic defect involving metabolism of a vitamin. In some cases, vitamin doses as high as 1000 times the DRI improve function of the altered metabolic pathway. Vitamin toxicity (hypervitaminosis) usually results from taking megadoses of vitamin A, D, C, B6, or niacin. Because many people eat irregularly, foods alone may provide suboptimal amounts of some vitamins. In these cases, the risk of certain cancers or other disorders may be increased. Because of this risk, routine daily multivitamin supplements are sometimes recommended.\n\n# Biotin and Pantothenic Acid\n\nBiotin acts as a coenzyme for carboxylation reactions essential to fat and carbohydrate metabolism. Adequate intake for adults is 30 \u03bcg/day. Pantothenic acid is widely distributed in foods; it is an essential component of coenzyme A. Adults probably require about 5 mg/day. A beneficial role for pantothenic acid supplementation in lipid metabolism, RA, or athletic performance remains unproved. Isolated deficiency of biotin or pantothenic acid virtually never occurs.\n\n# Folate\n\nFolate (folic acid) is now added to enriched grain foods in the US. Folate is also plentiful in various plant foods and meats, but its bioavailability is greater when it is in supplements or enriched foods than when it occurs naturally in food.\n\n|   |   |\n| - | - |\n",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency, and Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency, and Toxicity",
                    "bBox": {
                        "x": 55,
                        "y": 54.9,
                        "w": 282,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Introduction",
                    "md": "# Introduction",
                    "bBox": {
                        "x": 55,
                        "y": 79.9,
                        "w": 61,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamins may be fat soluble (vitamins A, D, E, and K) or water soluble (B vitamins and vitamin C). The B vitamins include biotin, folate, niacin, pantothenic acid, riboflavin (B2), thiamin (B1), B6 (eg, pyridoxine), and B12 (cobalamins). For dietary requirements, sources, functions, effects of deficiencies and toxicities, blood levels, and usual therapeutic dosages for vitamins, see Tables 4-1 and 4-2.\n\nDietary requirements for vitamins (and other nutrients) are expressed as daily recommended intake (DRI). There are 3 types of DRI:\n\n- Recommended daily allowance (RDA): RDAs are set to meet the needs of 97 to 98% of healthy people.\n- Adequate intake (AI): When data to calculate an RDA are insufficient, AIs are based on observed or experimentally determined estimates of nutrient intake by healthy people.\n- Tolerable upper intake level (UL): ULs are the largest amount of a nutrient that most adults can ingest daily without risk of adverse health effects.\n\nIn developed countries, vitamin deficiencies result mainly from poverty, food faddism, drugs (see p. 7 and Table 4-3), alcoholism, or prolonged and inadequately supplemented parenteral feeding. Mild vitamin deficiency is common among frail and institutionalized elderly people who have protein-energy undernutrition. In developing countries, deficiencies can result from lack of access to nutrients.\n\nDeficiencies of water-soluble vitamins (except vitamin B12) may develop after weeks to months of undernutrition. Deficiencies of fat-soluble vitamins and of vitamin B12 take &amp;gt; 1 yr to develop because the body stores them in relatively large amounts. Intake of vitamins sufficient to prevent classic vitamin deficiencies (like scurvy or beriberi) may not be adequate for optimum health. This area remains one of controversy and active research.\n\nVitamin dependency results from a genetic defect involving metabolism of a vitamin. In some cases, vitamin doses as high as 1000 times the DRI improve function of the altered metabolic pathway. Vitamin toxicity (hypervitaminosis) usually results from taking megadoses of vitamin A, D, C, B6, or niacin. Because many people eat irregularly, foods alone may provide suboptimal amounts of some vitamins. In these cases, the risk of certain cancers or other disorders may be increased. Because of this risk, routine daily multivitamin supplements are sometimes recommended.",
                    "md": "Vitamins may be fat soluble (vitamins A, D, E, and K) or water soluble (B vitamins and vitamin C). The B vitamins include biotin, folate, niacin, pantothenic acid, riboflavin (B2), thiamin (B1), B6 (eg, pyridoxine), and B12 (cobalamins). For dietary requirements, sources, functions, effects of deficiencies and toxicities, blood levels, and usual therapeutic dosages for vitamins, see Tables 4-1 and 4-2.\n\nDietary requirements for vitamins (and other nutrients) are expressed as daily recommended intake (DRI). There are 3 types of DRI:\n\n- Recommended daily allowance (RDA): RDAs are set to meet the needs of 97 to 98% of healthy people.\n- Adequate intake (AI): When data to calculate an RDA are insufficient, AIs are based on observed or experimentally determined estimates of nutrient intake by healthy people.\n- Tolerable upper intake level (UL): ULs are the largest amount of a nutrient that most adults can ingest daily without risk of adverse health effects.\n\nIn developed countries, vitamin deficiencies result mainly from poverty, food faddism, drugs (see p. 7 and Table 4-3), alcoholism, or prolonged and inadequately supplemented parenteral feeding. Mild vitamin deficiency is common among frail and institutionalized elderly people who have protein-energy undernutrition. In developing countries, deficiencies can result from lack of access to nutrients.\n\nDeficiencies of water-soluble vitamins (except vitamin B12) may develop after weeks to months of undernutrition. Deficiencies of fat-soluble vitamins and of vitamin B12 take &amp;gt; 1 yr to develop because the body stores them in relatively large amounts. Intake of vitamins sufficient to prevent classic vitamin deficiencies (like scurvy or beriberi) may not be adequate for optimum health. This area remains one of controversy and active research.\n\nVitamin dependency results from a genetic defect involving metabolism of a vitamin. In some cases, vitamin doses as high as 1000 times the DRI improve function of the altered metabolic pathway. Vitamin toxicity (hypervitaminosis) usually results from taking megadoses of vitamin A, D, C, B6, or niacin. Because many people eat irregularly, foods alone may provide suboptimal amounts of some vitamins. In these cases, the risk of certain cancers or other disorders may be increased. Because of this risk, routine daily multivitamin supplements are sometimes recommended.",
                    "bBox": {
                        "x": 55,
                        "y": 104.9,
                        "w": 482,
                        "h": 594
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Biotin and Pantothenic Acid",
                    "md": "# Biotin and Pantothenic Acid",
                    "bBox": {
                        "x": 55,
                        "y": 585.9,
                        "w": 138,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Biotin acts as a coenzyme for carboxylation reactions essential to fat and carbohydrate metabolism. Adequate intake for adults is 30 \u03bcg/day. Pantothenic acid is widely distributed in foods; it is an essential component of coenzyme A. Adults probably require about 5 mg/day. A beneficial role for pantothenic acid supplementation in lipid metabolism, RA, or athletic performance remains unproved. Isolated deficiency of biotin or pantothenic acid virtually never occurs.",
                    "md": "Biotin acts as a coenzyme for carboxylation reactions essential to fat and carbohydrate metabolism. Adequate intake for adults is 30 \u03bcg/day. Pantothenic acid is widely distributed in foods; it is an essential component of coenzyme A. Adults probably require about 5 mg/day. A beneficial role for pantothenic acid supplementation in lipid metabolism, RA, or athletic performance remains unproved. Isolated deficiency of biotin or pantothenic acid virtually never occurs.",
                    "bBox": {
                        "x": 55,
                        "y": 610.9,
                        "w": 480,
                        "h": 63
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Folate",
                    "md": "# Folate",
                    "bBox": {
                        "x": 55,
                        "y": 686.9,
                        "w": 31,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Folate (folic acid) is now added to enriched grain foods in the US. Folate is also plentiful in various plant foods and meats, but its bioavailability is greater when it is in supplements or enriched foods than when it occurs naturally in food.",
                    "md": "Folate (folic acid) is now added to enriched grain foods in the US. Folate is also plentiful in various plant foods and meats, but its bioavailability is greater when it is in supplements or enriched foods than when it occurs naturally in food.",
                    "bBox": {
                        "x": 55,
                        "y": 686.9,
                        "w": 475,
                        "h": 101
                    }
                },
                {
                    "type": "table",
                    "rows": [],
                    "md": "|   |   |\n| - | - |",
                    "isPerfectTable": true,
                    "csv": "",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.968
        },
        {
            "page": 25,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n Folates are involved in RBC maturation and synthesis of purines and pyrimidines. They are required for\n development of the fetal nervous system. Absorption occurs in the duodenum and upper jejunum.\n Enterohepatic circulation of folate occurs. Folate supplements\n [Table 4-2. Sources, Functions, and Effects of Vitamins]\n do not protect against coronary artery disease or stroke (by lowering homocysteine levels); their role in\n reducing the risk of various cancers is unclear. The upper limit for folate intake is 1000 \u03bcg; higher doses\n (up to 5 mg) are recommended for women who have had a baby with a neural tube defect. Folate is\n essentially nontoxic.\n Folate Deficiency\n Folate deficiency is common. It may result from inadequate intake, malabsorption, or use of various drugs.\n Deficiency causes megaloblastic anemia (indistinguishable from that due to vitamin B12 deficiency).\n Maternal deficiency increases the risk of neural tube birth defects. Diagnosis requires laboratory testing\n to confirm. Measurement of neutrophil hypersegmentation is sensitive and readily available. Treatment\n with oral folate is usually successful.\n Etiology and Pathophysiology\n The most common causes are inadequate intake (usually in patients with undernutrition or alcoholism),\n increased demand (eg, due to pregnancy or breastfeeding), and impaired absorption (eg, in tropical\n sprue, due to certain drugs). Deficiency can also result from inadequate bioavailability and increased\n excretion (see\n Table 4-4).\n Prolonged cooking destroys folate, predisposing to inadequate intake. Intake is sometimes barely\n adequate (eg, in alcoholics). Liver stores provide only a several-month supply.\n Alcohol interferes with folate absorption, metabolism, renal excretion, and enterohepatic reabsorption, as\n well as intake. 5-Fluorouracil, metformin, methotrexate, phenobarbital, phenytoin, sulfasalazine,\n triamterene, and trimethoprim impair folate metabolism.\n In the US, many dietary staples (eg, cereals, grain products) are routinely enriched with folate, tending to\n reduce risk of deficiency.\n [Table 4-3. Potential Vitamin-Drug Interactions]\n Symptoms and Signs\n Folate deficiency may cause glossitis, diarrhea, depression, and confusion. Anemia may develop\n insidiously and, because of compensatory mechanisms, be more severe than symptoms suggest.\n Folate deficiency during pregnancy increases the risk of fetal neural tube defects and perhaps other brain\n defects (see p. 2992).\n Diagnosis\n \u2022 CBC and serum vitamin B12 and folate levels\n CBC may indicate megaloblastic anemia indistinguishable from that of vitamin B12 deficiency. If serum\n folate is &lt; 3 \u03bcg/L or ng/mL (&lt; 7 nmol/L), deficiency is likely. Serum folate reflects folate status unless\n intake has recently increased or decreased. If intake has changed, erythrocyte (RBC) folate level better\n reflects tissue stores. A level of &lt; 140 \u03bcg/L or ng/mL (&lt; 305 nmol/L) indicates inadequate status. Also, an\n increase in the homocysteine level suggests tissue folate deficiency (but the level is also affected by\n                                                                                                        77",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nFolates are involved in RBC maturation and synthesis of purines and pyrimidines. They are required for development of the fetal nervous system. Absorption occurs in the duodenum and upper jejunum. Enterohepatic circulation of folate occurs. Folate supplements do not protect against coronary artery disease or stroke (by lowering homocysteine levels); their role in reducing the risk of various cancers is unclear. The upper limit for folate intake is 1000 \u03bcg; higher doses (up to 5 mg) are recommended for women who have had a baby with a neural tube defect. Folate is essentially nontoxic.\n\n# Folate Deficiency\n\nFolate deficiency is common. It may result from inadequate intake, malabsorption, or use of various drugs. Deficiency causes megaloblastic anemia (indistinguishable from that due to vitamin B12 deficiency). Maternal deficiency increases the risk of neural tube birth defects. Diagnosis requires laboratory testing to confirm. Measurement of neutrophil hypersegmentation is sensitive and readily available. Treatment with oral folate is usually successful.\n\n# Etiology and Pathophysiology\n\nThe most common causes are inadequate intake (usually in patients with undernutrition or alcoholism), increased demand (eg, due to pregnancy or breastfeeding), and impaired absorption (eg, in tropical sprue, due to certain drugs). Deficiency can also result from inadequate bioavailability and increased excretion (see Table 4-4). Prolonged cooking destroys folate, predisposing to inadequate intake. Intake is sometimes barely adequate (eg, in alcoholics). Liver stores provide only a several-month supply. Alcohol interferes with folate absorption, metabolism, renal excretion, and enterohepatic reabsorption, as well as intake. 5-Fluorouracil, metformin, methotrexate, phenobarbital, phenytoin, sulfasalazine, triamterene, and trimethoprim impair folate metabolism. In the US, many dietary staples (eg, cereals, grain products) are routinely enriched with folate, tending to reduce risk of deficiency.\n\n# Symptoms and Signs\n\nFolate deficiency may cause glossitis, diarrhea, depression, and confusion. Anemia may develop insidiously and, because of compensatory mechanisms, be more severe than symptoms suggest. Folate deficiency during pregnancy increases the risk of fetal neural tube defects and perhaps other brain defects (see p. 2992).\n\n# Diagnosis\n\n- CBC and serum vitamin B12 and folate levels\n\nCBC may indicate megaloblastic anemia indistinguishable from that of vitamin B12 deficiency. If serum folate is &lt; 3 \u03bcg/L or ng/mL (&lt; 7 nmol/L), deficiency is likely. Serum folate reflects folate status unless intake has recently increased or decreased. If intake has changed, erythrocyte (RBC) folate level better reflects tissue stores. A level of &lt; 140 \u03bcg/L or ng/mL (&lt; 305 nmol/L) indicates inadequate status. Also, an increase in the homocysteine level suggests tissue folate deficiency (but the level is also affected by).",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 659.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Folates are involved in RBC maturation and synthesis of purines and pyrimidines. They are required for development of the fetal nervous system. Absorption occurs in the duodenum and upper jejunum. Enterohepatic circulation of folate occurs. Folate supplements do not protect against coronary artery disease or stroke (by lowering homocysteine levels); their role in reducing the risk of various cancers is unclear. The upper limit for folate intake is 1000 \u03bcg; higher doses (up to 5 mg) are recommended for women who have had a baby with a neural tube defect. Folate is essentially nontoxic.",
                    "md": "Folates are involved in RBC maturation and synthesis of purines and pyrimidines. They are required for development of the fetal nervous system. Absorption occurs in the duodenum and upper jejunum. Enterohepatic circulation of folate occurs. Folate supplements do not protect against coronary artery disease or stroke (by lowering homocysteine levels); their role in reducing the risk of various cancers is unclear. The upper limit for folate intake is 1000 \u03bcg; higher doses (up to 5 mg) are recommended for women who have had a baby with a neural tube defect. Folate is essentially nontoxic.",
                    "bBox": {
                        "x": 55,
                        "y": 61.9,
                        "w": 474,
                        "h": 126
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Folate Deficiency",
                    "md": "# Folate Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 200.9,
                        "w": 87,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Folate deficiency is common. It may result from inadequate intake, malabsorption, or use of various drugs. Deficiency causes megaloblastic anemia (indistinguishable from that due to vitamin B12 deficiency). Maternal deficiency increases the risk of neural tube birth defects. Diagnosis requires laboratory testing to confirm. Measurement of neutrophil hypersegmentation is sensitive and readily available. Treatment with oral folate is usually successful.",
                    "md": "Folate deficiency is common. It may result from inadequate intake, malabsorption, or use of various drugs. Deficiency causes megaloblastic anemia (indistinguishable from that due to vitamin B12 deficiency). Maternal deficiency increases the risk of neural tube birth defects. Diagnosis requires laboratory testing to confirm. Measurement of neutrophil hypersegmentation is sensitive and readily available. Treatment with oral folate is usually successful.",
                    "bBox": {
                        "x": 55,
                        "y": 200.9,
                        "w": 483,
                        "h": 471
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Etiology and Pathophysiology",
                    "md": "# Etiology and Pathophysiology",
                    "bBox": {
                        "x": 55,
                        "y": 304.9,
                        "w": 150,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "The most common causes are inadequate intake (usually in patients with undernutrition or alcoholism), increased demand (eg, due to pregnancy or breastfeeding), and impaired absorption (eg, in tropical sprue, due to certain drugs). Deficiency can also result from inadequate bioavailability and increased excretion (see Table 4-4). Prolonged cooking destroys folate, predisposing to inadequate intake. Intake is sometimes barely adequate (eg, in alcoholics). Liver stores provide only a several-month supply. Alcohol interferes with folate absorption, metabolism, renal excretion, and enterohepatic reabsorption, as well as intake. 5-Fluorouracil, metformin, methotrexate, phenobarbital, phenytoin, sulfasalazine, triamterene, and trimethoprim impair folate metabolism. In the US, many dietary staples (eg, cereals, grain products) are routinely enriched with folate, tending to reduce risk of deficiency.",
                    "md": "The most common causes are inadequate intake (usually in patients with undernutrition or alcoholism), increased demand (eg, due to pregnancy or breastfeeding), and impaired absorption (eg, in tropical sprue, due to certain drugs). Deficiency can also result from inadequate bioavailability and increased excretion (see Table 4-4). Prolonged cooking destroys folate, predisposing to inadequate intake. Intake is sometimes barely adequate (eg, in alcoholics). Liver stores provide only a several-month supply. Alcohol interferes with folate absorption, metabolism, renal excretion, and enterohepatic reabsorption, as well as intake. 5-Fluorouracil, metformin, methotrexate, phenobarbital, phenytoin, sulfasalazine, triamterene, and trimethoprim impair folate metabolism. In the US, many dietary staples (eg, cereals, grain products) are routinely enriched with folate, tending to reduce risk of deficiency.",
                    "bBox": {
                        "x": 55,
                        "y": 330.9,
                        "w": 478,
                        "h": 189
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 558.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Folate deficiency may cause glossitis, diarrhea, depression, and confusion. Anemia may develop insidiously and, because of compensatory mechanisms, be more severe than symptoms suggest. Folate deficiency during pregnancy increases the risk of fetal neural tube defects and perhaps other brain defects (see p. 2992).",
                    "md": "Folate deficiency may cause glossitis, diarrhea, depression, and confusion. Anemia may develop insidiously and, because of compensatory mechanisms, be more severe than symptoms suggest. Folate deficiency during pregnancy increases the risk of fetal neural tube defects and perhaps other brain defects (see p. 2992).",
                    "bBox": {
                        "x": 55,
                        "y": 200.9,
                        "w": 482,
                        "h": 446
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 659.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- CBC and serum vitamin B12 and folate levels\n\nCBC may indicate megaloblastic anemia indistinguishable from that of vitamin B12 deficiency. If serum folate is &lt; 3 \u03bcg/L or ng/mL (&lt; 7 nmol/L), deficiency is likely. Serum folate reflects folate status unless intake has recently increased or decreased. If intake has changed, erythrocyte (RBC) folate level better reflects tissue stores. A level of &lt; 140 \u03bcg/L or ng/mL (&lt; 305 nmol/L) indicates inadequate status. Also, an increase in the homocysteine level suggests tissue folate deficiency (but the level is also affected by).",
                    "md": "- CBC and serum vitamin B12 and folate levels\n\nCBC may indicate megaloblastic anemia indistinguishable from that of vitamin B12 deficiency. If serum folate is &lt; 3 \u03bcg/L or ng/mL (&lt; 7 nmol/L), deficiency is likely. Serum folate reflects folate status unless intake has recently increased or decreased. If intake has changed, erythrocyte (RBC) folate level better reflects tissue stores. A level of &lt; 140 \u03bcg/L or ng/mL (&lt; 305 nmol/L) indicates inadequate status. Also, an increase in the homocysteine level suggests tissue folate deficiency (but the level is also affected by).",
                    "bBox": {
                        "x": 55,
                        "y": 200.9,
                        "w": 476,
                        "h": 577
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.964
        },
        {
            "page": 26,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n vitamin B12 and vitamin B6 levels, renal insufficiency, and genetic factors). A normal methylmalonic acid\n (MMA) level may differentiate folate deficiency from vitamin B12 deficiency because MMA levels rise in\n vitamin B12 deficiency but not in folate deficiency.\n Treatment\n \u2022 Supplemental oral folate\n Folate 400 to 1000 \u03bcg po once/day replenishes tissues and is usually successful even if deficiency has\n resulted from malabsorption. The normal requirement is 400 \u03bcg/day.\n [Table 4-4. Causes of Folate Deficiency]\n (CAUTION: In patients with megaloblastic anemia, vitamin B12 deficiency must be ruled out before\n treating with folate. If vitamin B12 deficiency is present, folate supplementation can alleviate the\n anemia but does not reverse and may even worsen neurologic deficits.) For pregnant women, the\n recommended daily allowance (RDA) is 600 \u03bcg/day. For women who have had a fetus or infant with a\n neural tube defect, the recommended dose is 1000 to 5000 \u03bcg/day.\n Niacin\n Niacin (nicotinic acid, nicotinamide) derivatives include nicotinamide adenine dinucleotide (NAD) and\n nicotinamide adenine dinucleotide phosphate (NADP), which are coenzymes in oxidation-reduction\n reactions. They are vital in cell metabolism. Because dietary tryptophan can be metabolized to niacin,\n foods rich in tryptophan (eg, dairy products) can compensate for inadequate dietary niacin.\n Niacin Deficiency\n Dietary niacin deficiency (causing pellagra) is uncommon in developed countries. Clinical\n manifestations include the \"three Ds\": localized pigmented rash (dermatitis); gastroenteritis\n (diarrhea); and widespread neurologic deficits, including cognitive decline (dementia).\n Diagnosis is usually clinical, and dietary supplementation (oral or, if needed, IM) is usually\n successful.\n Etiology\n Primary deficiency results from extremely inadequate intake of both niacin and tryptophan, which usually\n occurs in areas where maize (Indian corn) constitutes a substantial part of the diet. Bound niacin, found in\n maize, is not assimilated in the GI tract unless it has been previously treated with alkali, as when tortillas\n are prepared. Corn protein is also deficient in tryptophan. The high incidence of pellagra in India among\n people who eat millet with a high leucine content has led to the hypothesis that amino acid imbalance may\n contribute to deficiency. Deficiencies of protein and many B vitamins commonly accompany primary niacin\n deficiency.\n Secondary deficiency may be due to diarrhea, cirrhosis, or alcoholism. Pellagra also may occur in\n carcinoid syndrome (tryptophan is diverted to form 5-hydroxytryptophan and serotonin) and in Hartnup\n disease (absorption of tryptophan by the intestine and kidneys is defective).\n Symptoms and Signs\n Pellagra is characterized by skin, mucous membrane, CNS, and GI symptoms. Advanced pellagra can\n cause a symmetric photosensitive rash, stomatitis, glossitis, diarrhea, and mental aberrations. Symptoms\n may appear alone or in combination.\n Skin symptoms include several types of lesions, which are usually bilaterally symmetric. The distribution\n of lesions\u2014at pressure points or sun-exposed skin\u2014is more pathognomonic than the form of the lesions.\n Lesions can develop in a glovelike distribution on the hands (pellagrous glove) or in a boot-shaped\n                                                                                                      78",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nVitamin B12 and vitamin B6 levels, renal insufficiency, and genetic factors. A normal methylmalonic acid (MMA) level may differentiate folate deficiency from vitamin B12 deficiency because MMA levels rise in vitamin B12 deficiency but not in folate deficiency.\n\n# Treatment\n\n- Supplemental oral folate\n\nFolate 400 to 1000 \u03bcg po once/day replenishes tissues and is usually successful even if deficiency has resulted from malabsorption. The normal requirement is 400 \u03bcg/day.\n\nCAUTION: In patients with megaloblastic anemia, vitamin B12 deficiency must be ruled out before treating with folate. If vitamin B12 deficiency is present, folate supplementation can alleviate the anemia but does not reverse and may even worsen neurologic deficits. For pregnant women, the recommended daily allowance (RDA) is 600 \u03bcg/day. For women who have had a fetus or infant with a neural tube defect, the recommended dose is 1000 to 5000 \u03bcg/day.\n\n# Niacin\n\nNiacin (nicotinic acid, nicotinamide) derivatives include nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are coenzymes in oxidation-reduction reactions. They are vital in cell metabolism. Because dietary tryptophan can be metabolized to niacin, foods rich in tryptophan (eg, dairy products) can compensate for inadequate dietary niacin.\n\n# Niacin Deficiency\n\nDietary niacin deficiency (causing pellagra) is uncommon in developed countries. Clinical manifestations include the \"three Ds\": localized pigmented rash (dermatitis); gastroenteritis (diarrhea); and widespread neurologic deficits, including cognitive decline (dementia). Diagnosis is usually clinical, and dietary supplementation (oral or, if needed, IM) is usually successful.\n\n# Etiology\n\nPrimary deficiency results from extremely inadequate intake of both niacin and tryptophan, which usually occurs in areas where maize (Indian corn) constitutes a substantial part of the diet. Bound niacin, found in maize, is not assimilated in the GI tract unless it has been previously treated with alkali, as when tortillas are prepared. Corn protein is also deficient in tryptophan. The high incidence of pellagra in India among people who eat millet with a high leucine content has led to the hypothesis that amino acid imbalance may contribute to deficiency. Deficiencies of protein and many B vitamins commonly accompany primary niacin deficiency.\n\nSecondary deficiency may be due to diarrhea, cirrhosis, or alcoholism. Pellagra also may occur in carcinoid syndrome (tryptophan is diverted to form 5-hydroxytryptophan and serotonin) and in Hartnup disease (absorption of tryptophan by the intestine and kidneys is defective).\n\n# Symptoms and Signs\n\nPellagra is characterized by skin, mucous membrane, CNS, and GI symptoms. Advanced pellagra can cause a symmetric photosensitive rash, stomatitis, glossitis, diarrhea, and mental aberrations. Symptoms may appear alone or in combination.\n\nSkin symptoms include several types of lesions, which are usually bilaterally symmetric. The distribution of lesions\u2014at pressure points or sun-exposed skin\u2014is more pathognomonic than the form of the lesions. Lesions can develop in a glovelike distribution on the hands (pellagrous glove) or in a boot-shaped.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin B12 and vitamin B6 levels, renal insufficiency, and genetic factors. A normal methylmalonic acid (MMA) level may differentiate folate deficiency from vitamin B12 deficiency because MMA levels rise in vitamin B12 deficiency but not in folate deficiency.",
                    "md": "Vitamin B12 and vitamin B6 levels, renal insufficiency, and genetic factors. A normal methylmalonic acid (MMA) level may differentiate folate deficiency from vitamin B12 deficiency because MMA levels rise in vitamin B12 deficiency but not in folate deficiency.",
                    "bBox": {
                        "x": 55,
                        "y": 63.9,
                        "w": 467,
                        "h": 543
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 106.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Supplemental oral folate\n\nFolate 400 to 1000 \u03bcg po once/day replenishes tissues and is usually successful even if deficiency has resulted from malabsorption. The normal requirement is 400 \u03bcg/day.\n\nCAUTION: In patients with megaloblastic anemia, vitamin B12 deficiency must be ruled out before treating with folate. If vitamin B12 deficiency is present, folate supplementation can alleviate the anemia but does not reverse and may even worsen neurologic deficits. For pregnant women, the recommended daily allowance (RDA) is 600 \u03bcg/day. For women who have had a fetus or infant with a neural tube defect, the recommended dose is 1000 to 5000 \u03bcg/day.",
                    "md": "- Supplemental oral folate\n\nFolate 400 to 1000 \u03bcg po once/day replenishes tissues and is usually successful even if deficiency has resulted from malabsorption. The normal requirement is 400 \u03bcg/day.\n\nCAUTION: In patients with megaloblastic anemia, vitamin B12 deficiency must be ruled out before treating with folate. If vitamin B12 deficiency is present, folate supplementation can alleviate the anemia but does not reverse and may even worsen neurologic deficits. For pregnant women, the recommended daily allowance (RDA) is 600 \u03bcg/day. For women who have had a fetus or infant with a neural tube defect, the recommended dose is 1000 to 5000 \u03bcg/day.",
                    "bBox": {
                        "x": 55,
                        "y": 157.9,
                        "w": 470,
                        "h": 132
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Niacin",
                    "md": "# Niacin",
                    "bBox": {
                        "x": 55,
                        "y": 302.9,
                        "w": 31,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Niacin (nicotinic acid, nicotinamide) derivatives include nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are coenzymes in oxidation-reduction reactions. They are vital in cell metabolism. Because dietary tryptophan can be metabolized to niacin, foods rich in tryptophan (eg, dairy products) can compensate for inadequate dietary niacin.",
                    "md": "Niacin (nicotinic acid, nicotinamide) derivatives include nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are coenzymes in oxidation-reduction reactions. They are vital in cell metabolism. Because dietary tryptophan can be metabolized to niacin, foods rich in tryptophan (eg, dairy products) can compensate for inadequate dietary niacin.",
                    "bBox": {
                        "x": 55,
                        "y": 302.9,
                        "w": 463,
                        "h": 76
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Niacin Deficiency",
                    "md": "# Niacin Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 302.9,
                        "w": 87,
                        "h": 101
                    }
                },
                {
                    "type": "text",
                    "value": "Dietary niacin deficiency (causing pellagra) is uncommon in developed countries. Clinical manifestations include the \"three Ds\": localized pigmented rash (dermatitis); gastroenteritis (diarrhea); and widespread neurologic deficits, including cognitive decline (dementia). Diagnosis is usually clinical, and dietary supplementation (oral or, if needed, IM) is usually successful.",
                    "md": "Dietary niacin deficiency (causing pellagra) is uncommon in developed countries. Clinical manifestations include the \"three Ds\": localized pigmented rash (dermatitis); gastroenteritis (diarrhea); and widespread neurologic deficits, including cognitive decline (dementia). Diagnosis is usually clinical, and dietary supplementation (oral or, if needed, IM) is usually successful.",
                    "bBox": {
                        "x": 55,
                        "y": 302.9,
                        "w": 463,
                        "h": 177
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Etiology",
                    "md": "# Etiology",
                    "bBox": {
                        "x": 55,
                        "y": 493.9,
                        "w": 41,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Primary deficiency results from extremely inadequate intake of both niacin and tryptophan, which usually occurs in areas where maize (Indian corn) constitutes a substantial part of the diet. Bound niacin, found in maize, is not assimilated in the GI tract unless it has been previously treated with alkali, as when tortillas are prepared. Corn protein is also deficient in tryptophan. The high incidence of pellagra in India among people who eat millet with a high leucine content has led to the hypothesis that amino acid imbalance may contribute to deficiency. Deficiencies of protein and many B vitamins commonly accompany primary niacin deficiency.\n\nSecondary deficiency may be due to diarrhea, cirrhosis, or alcoholism. Pellagra also may occur in carcinoid syndrome (tryptophan is diverted to form 5-hydroxytryptophan and serotonin) and in Hartnup disease (absorption of tryptophan by the intestine and kidneys is defective).",
                    "md": "Primary deficiency results from extremely inadequate intake of both niacin and tryptophan, which usually occurs in areas where maize (Indian corn) constitutes a substantial part of the diet. Bound niacin, found in maize, is not assimilated in the GI tract unless it has been previously treated with alkali, as when tortillas are prepared. Corn protein is also deficient in tryptophan. The high incidence of pellagra in India among people who eat millet with a high leucine content has led to the hypothesis that amino acid imbalance may contribute to deficiency. Deficiencies of protein and many B vitamins commonly accompany primary niacin deficiency.\n\nSecondary deficiency may be due to diarrhea, cirrhosis, or alcoholism. Pellagra also may occur in carcinoid syndrome (tryptophan is diverted to form 5-hydroxytryptophan and serotonin) and in Hartnup disease (absorption of tryptophan by the intestine and kidneys is defective).",
                    "bBox": {
                        "x": 55,
                        "y": 302.9,
                        "w": 483,
                        "h": 355
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 670.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Pellagra is characterized by skin, mucous membrane, CNS, and GI symptoms. Advanced pellagra can cause a symmetric photosensitive rash, stomatitis, glossitis, diarrhea, and mental aberrations. Symptoms may appear alone or in combination.\n\nSkin symptoms include several types of lesions, which are usually bilaterally symmetric. The distribution of lesions\u2014at pressure points or sun-exposed skin\u2014is more pathognomonic than the form of the lesions. Lesions can develop in a glovelike distribution on the hands (pellagrous glove) or in a boot-shaped.",
                    "md": "Pellagra is characterized by skin, mucous membrane, CNS, and GI symptoms. Advanced pellagra can cause a symmetric photosensitive rash, stomatitis, glossitis, diarrhea, and mental aberrations. Symptoms may appear alone or in combination.\n\nSkin symptoms include several types of lesions, which are usually bilaterally symmetric. The distribution of lesions\u2014at pressure points or sun-exposed skin\u2014is more pathognomonic than the form of the lesions. Lesions can develop in a glovelike distribution on the hands (pellagrous glove) or in a boot-shaped.",
                    "bBox": {
                        "x": 55,
                        "y": 695.9,
                        "w": 483,
                        "h": 88
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.984
        },
        {
            "page": 27,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n distribution on the feet and legs (pellagrous boot). Sunlight causes Casal's necklace and butterfly-shaped\n lesions on the face.\n Mucous membrane symptoms affect primarily the mouth but may also affect the vagina and urethra.\n Glossitis and stomatitis characterize acute deficiency. As the deficiency progresses, the tongue and oral\n mucous membranes become reddened, followed by pain in the mouth, increased salivation, and edema of\n the tongue. Ulcerations may appear, especially under the tongue, on the mucosa of the lower lip, and\n opposite the molar teeth.\n GI symptoms early in the deficiency include burning in the pharynx and esophagus and abdominal\n discomfort and distention. Constipation is common. Later, nausea, vomiting, and diarrhea may occur.\n Diarrhea is often bloody because of bowel hyperemia and ulceration.\n CNS symptoms include psychosis, encephalopathy (characterized by impaired consciousness), and\n cognitive decline (dementia). Psychosis is characterized by memory impairment, disorientation, confusion,\n and confabulation; the predominant symptom may be excitement, depression, mania, delirium, or\n paranoia.\n Diagnosis\n \u2022 Clinical evaluation\n Diagnosis is clinical and may be straightforward when skin and mouth lesions, diarrhea, delirium, and\n dementia occur simultaneously. More often, the presentation is not so specific. Differentiating the CNS\n changes from those in thiamin deficiency is difficult. A history of a diet lacking niacin and tryptophan may\n help establish the diagnosis. A favorable response to treatment with niacin can usually confirm it. If\n available, laboratory testing can help confirm the diagnosis, particularly when the diagnosis is otherwise\n unclear. Urinary excretion of N1-methylnicotinamide (NMN) is decreased; &lt; 0.8 mg/day (&lt; 5.8 \u03bcmol/day)\n suggests a niacin deficiency.\n Treatment\n \u2022 Nicotinamide and other nutrients\n Because multiple deficiencies are common, a balanced diet, including other B vitamins (particularly\n riboflavin and pyridoxine), is needed. Nicotinamide is usually used to treat deficiency, because\n nicotinamide, unlike nicotinic acid (the most common form of niacin), does not cause flushing, itching,\n burning, or tingling sensations. Nicotinamide is given in doses ranging from 40 to 250 mg/day po in\n divided doses 3 to 4 times a day.\n Niacin Toxicity\n Niacin (nicotinic acid) in large amounts is sometimes used to lower low-density lipoprotein\n (LDL) cholesterol and triglyceride levels and to increase high-density lipoprotein (HDL)\n cholesterol levels. Symptoms may include flushing and, rarely, hepatotoxicity.\n Immediate- and sustained-release preparations of niacin (but not nicotinamide) may improve lipid levels.\n Flushing, which is prostaglandin-mediated, is more common with immediate-release preparations. It may\n be more intense after alcohol ingestion, aerobic activity, sun exposure, and consumption of spicy foods.\n Flushing is minimized if niacin is taken after meals or if aspirin (325 mg) is taken 30 to 45 min before\n niacin. The chance of severe flushing can be reduced by starting immediate-release niacin at a low dose\n (eg, 50 mg tid) and increasing it very slowly. At intermediate doses (1000 mg/day), triglyceride levels\n decrease 15 to 20%, and HDL cholesterol levels increase 15 to 30%. Reductions in LDL cholesterol are\n modest (&lt; 10%). Higher doses of niacin (3000 mg/day) reduce LDL cholesterol 15 to 20% but may cause\n jaundice, abdominal discomfort, blurred vision, worsening of hyperglycemia, and precipitation of\n preexisting gout. People with a liver disorder probably should not take high-dose niacin.\n Hepatotoxicity may be more common with some sustained-release preparations. Some authorities\n                                                                                                        79",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nDistribution on the feet and legs (pellagrous boot). Sunlight causes Casal's necklace and butterfly-shaped lesions on the face.\n\nMucous membrane symptoms affect primarily the mouth but may also affect the vagina and urethra. Glossitis and stomatitis characterize acute deficiency. As the deficiency progresses, the tongue and oral mucous membranes become reddened, followed by pain in the mouth, increased salivation, and edema of the tongue. Ulcerations may appear, especially under the tongue, on the mucosa of the lower lip, and opposite the molar teeth.\n\nGI symptoms early in the deficiency include burning in the pharynx and esophagus and abdominal discomfort and distention. Constipation is common. Later, nausea, vomiting, and diarrhea may occur. Diarrhea is often bloody because of bowel hyperemia and ulceration.\n\nCNS symptoms include psychosis, encephalopathy (characterized by impaired consciousness), and cognitive decline (dementia). Psychosis is characterized by memory impairment, disorientation, confusion, and confabulation; the predominant symptom may be excitement, depression, mania, delirium, or paranoia.\n\n# Diagnosis\n\n- Clinical evaluation\n\nDiagnosis is clinical and may be straightforward when skin and mouth lesions, diarrhea, delirium, and dementia occur simultaneously. More often, the presentation is not so specific. Differentiating the CNS changes from those in thiamin deficiency is difficult. A history of a diet lacking niacin and tryptophan may help establish the diagnosis. A favorable response to treatment with niacin can usually confirm it. If available, laboratory testing can help confirm the diagnosis, particularly when the diagnosis is otherwise unclear. Urinary excretion of N1-methylnicotinamide (NMN) is decreased; &amp;lt; 0.8 mg/day (&amp;lt; 5.8 \u03bcmol/day) suggests a niacin deficiency.\n\n# Treatment\n\n- Nicotinamide and other nutrients\n\nBecause multiple deficiencies are common, a balanced diet, including other B vitamins (particularly riboflavin and pyridoxine), is needed. Nicotinamide is usually used to treat deficiency, because nicotinamide, unlike nicotinic acid (the most common form of niacin), does not cause flushing, itching, burning, or tingling sensations. Nicotinamide is given in doses ranging from 40 to 250 mg/day po in divided doses 3 to 4 times a day.\n\n# Niacin Toxicity\n\nNiacin (nicotinic acid) in large amounts is sometimes used to lower low-density lipoprotein (LDL) cholesterol and triglyceride levels and to increase high-density lipoprotein (HDL) cholesterol levels. Symptoms may include flushing and, rarely, hepatotoxicity.\n\nImmediate- and sustained-release preparations of niacin (but not nicotinamide) may improve lipid levels. Flushing, which is prostaglandin-mediated, is more common with immediate-release preparations. It may be more intense after alcohol ingestion, aerobic activity, sun exposure, and consumption of spicy foods. Flushing is minimized if niacin is taken after meals or if aspirin (325 mg) is taken 30 to 45 min before niacin. The chance of severe flushing can be reduced by starting immediate-release niacin at a low dose (eg, 50 mg tid) and increasing it very slowly. At intermediate doses (1000 mg/day), triglyceride levels decrease 15 to 20%, and HDL cholesterol levels increase 15 to 30%. Reductions in LDL cholesterol are modest (&amp;lt; 10%). Higher doses of niacin (3000 mg/day) reduce LDL cholesterol 15 to 20% but may cause jaundice, abdominal discomfort, blurred vision, worsening of hyperglycemia, and precipitation of preexisting gout. People with a liver disorder probably should not take high-dose niacin. Hepatotoxicity may be more common with some sustained-release preparations.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 277.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Distribution on the feet and legs (pellagrous boot). Sunlight causes Casal's necklace and butterfly-shaped lesions on the face.\n\nMucous membrane symptoms affect primarily the mouth but may also affect the vagina and urethra. Glossitis and stomatitis characterize acute deficiency. As the deficiency progresses, the tongue and oral mucous membranes become reddened, followed by pain in the mouth, increased salivation, and edema of the tongue. Ulcerations may appear, especially under the tongue, on the mucosa of the lower lip, and opposite the molar teeth.\n\nGI symptoms early in the deficiency include burning in the pharynx and esophagus and abdominal discomfort and distention. Constipation is common. Later, nausea, vomiting, and diarrhea may occur. Diarrhea is often bloody because of bowel hyperemia and ulceration.\n\nCNS symptoms include psychosis, encephalopathy (characterized by impaired consciousness), and cognitive decline (dementia). Psychosis is characterized by memory impairment, disorientation, confusion, and confabulation; the predominant symptom may be excitement, depression, mania, delirium, or paranoia.",
                    "md": "Distribution on the feet and legs (pellagrous boot). Sunlight causes Casal's necklace and butterfly-shaped lesions on the face.\n\nMucous membrane symptoms affect primarily the mouth but may also affect the vagina and urethra. Glossitis and stomatitis characterize acute deficiency. As the deficiency progresses, the tongue and oral mucous membranes become reddened, followed by pain in the mouth, increased salivation, and edema of the tongue. Ulcerations may appear, especially under the tongue, on the mucosa of the lower lip, and opposite the molar teeth.\n\nGI symptoms early in the deficiency include burning in the pharynx and esophagus and abdominal discomfort and distention. Constipation is common. Later, nausea, vomiting, and diarrhea may occur. Diarrhea is often bloody because of bowel hyperemia and ulceration.\n\nCNS symptoms include psychosis, encephalopathy (characterized by impaired consciousness), and cognitive decline (dementia). Psychosis is characterized by memory impairment, disorientation, confusion, and confabulation; the predominant symptom may be excitement, depression, mania, delirium, or paranoia.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 483,
                        "h": 215
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 277.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Clinical evaluation\n\nDiagnosis is clinical and may be straightforward when skin and mouth lesions, diarrhea, delirium, and dementia occur simultaneously. More often, the presentation is not so specific. Differentiating the CNS changes from those in thiamin deficiency is difficult. A history of a diet lacking niacin and tryptophan may help establish the diagnosis. A favorable response to treatment with niacin can usually confirm it. If available, laboratory testing can help confirm the diagnosis, particularly when the diagnosis is otherwise unclear. Urinary excretion of N1-methylnicotinamide (NMN) is decreased; &amp;lt; 0.8 mg/day (&amp;lt; 5.8 \u03bcmol/day) suggests a niacin deficiency.",
                    "md": "- Clinical evaluation\n\nDiagnosis is clinical and may be straightforward when skin and mouth lesions, diarrhea, delirium, and dementia occur simultaneously. More often, the presentation is not so specific. Differentiating the CNS changes from those in thiamin deficiency is difficult. A history of a diet lacking niacin and tryptophan may help establish the diagnosis. A favorable response to treatment with niacin can usually confirm it. If available, laboratory testing can help confirm the diagnosis, particularly when the diagnosis is otherwise unclear. Urinary excretion of N1-methylnicotinamide (NMN) is decreased; &amp;lt; 0.8 mg/day (&amp;lt; 5.8 \u03bcmol/day) suggests a niacin deficiency.",
                    "bBox": {
                        "x": 55,
                        "y": 277.9,
                        "w": 475,
                        "h": 168
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 433.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Nicotinamide and other nutrients\n\nBecause multiple deficiencies are common, a balanced diet, including other B vitamins (particularly riboflavin and pyridoxine), is needed. Nicotinamide is usually used to treat deficiency, because nicotinamide, unlike nicotinic acid (the most common form of niacin), does not cause flushing, itching, burning, or tingling sensations. Nicotinamide is given in doses ranging from 40 to 250 mg/day po in divided doses 3 to 4 times a day.",
                    "md": "- Nicotinamide and other nutrients\n\nBecause multiple deficiencies are common, a balanced diet, including other B vitamins (particularly riboflavin and pyridoxine), is needed. Nicotinamide is usually used to treat deficiency, because nicotinamide, unlike nicotinic acid (the most common form of niacin), does not cause flushing, itching, burning, or tingling sensations. Nicotinamide is given in doses ranging from 40 to 250 mg/day po in divided doses 3 to 4 times a day.",
                    "bBox": {
                        "x": 55,
                        "y": 483.9,
                        "w": 461,
                        "h": 63
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Niacin Toxicity",
                    "md": "# Niacin Toxicity",
                    "bBox": {
                        "x": 55,
                        "y": 559.9,
                        "w": 73,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Niacin (nicotinic acid) in large amounts is sometimes used to lower low-density lipoprotein (LDL) cholesterol and triglyceride levels and to increase high-density lipoprotein (HDL) cholesterol levels. Symptoms may include flushing and, rarely, hepatotoxicity.\n\nImmediate- and sustained-release preparations of niacin (but not nicotinamide) may improve lipid levels. Flushing, which is prostaglandin-mediated, is more common with immediate-release preparations. It may be more intense after alcohol ingestion, aerobic activity, sun exposure, and consumption of spicy foods. Flushing is minimized if niacin is taken after meals or if aspirin (325 mg) is taken 30 to 45 min before niacin. The chance of severe flushing can be reduced by starting immediate-release niacin at a low dose (eg, 50 mg tid) and increasing it very slowly. At intermediate doses (1000 mg/day), triglyceride levels decrease 15 to 20%, and HDL cholesterol levels increase 15 to 30%. Reductions in LDL cholesterol are modest (&amp;lt; 10%). Higher doses of niacin (3000 mg/day) reduce LDL cholesterol 15 to 20% but may cause jaundice, abdominal discomfort, blurred vision, worsening of hyperglycemia, and precipitation of preexisting gout. People with a liver disorder probably should not take high-dose niacin. Hepatotoxicity may be more common with some sustained-release preparations.",
                    "md": "Niacin (nicotinic acid) in large amounts is sometimes used to lower low-density lipoprotein (LDL) cholesterol and triglyceride levels and to increase high-density lipoprotein (HDL) cholesterol levels. Symptoms may include flushing and, rarely, hepatotoxicity.\n\nImmediate- and sustained-release preparations of niacin (but not nicotinamide) may improve lipid levels. Flushing, which is prostaglandin-mediated, is more common with immediate-release preparations. It may be more intense after alcohol ingestion, aerobic activity, sun exposure, and consumption of spicy foods. Flushing is minimized if niacin is taken after meals or if aspirin (325 mg) is taken 30 to 45 min before niacin. The chance of severe flushing can be reduced by starting immediate-release niacin at a low dose (eg, 50 mg tid) and increasing it very slowly. At intermediate doses (1000 mg/day), triglyceride levels decrease 15 to 20%, and HDL cholesterol levels increase 15 to 30%. Reductions in LDL cholesterol are modest (&amp;lt; 10%). Higher doses of niacin (3000 mg/day) reduce LDL cholesterol 15 to 20% but may cause jaundice, abdominal discomfort, blurred vision, worsening of hyperglycemia, and precipitation of preexisting gout. People with a liver disorder probably should not take high-dose niacin. Hepatotoxicity may be more common with some sustained-release preparations.",
                    "bBox": {
                        "x": 55,
                        "y": 585.9,
                        "w": 478,
                        "h": 176
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.992
        },
        {
            "page": 28,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n recommend checking levels of uric acid, serum glucose, and plasma transaminases every 6 to 8 wk until\n the dose of niacin has been stabilized.\n Riboflavin\n Riboflavin (vitamin B2) is involved in carbohydrate metabolism as an essential coenzyme in many\n oxidation-reduction reactions. Riboflavin is essentially nontoxic.\n Riboflavin Deficiency\n Riboflavin deficiency usually occurs with other B-vitamin deficiencies. Symptoms and signs\n include sore throat, lesions of the lips and mucosa of the mouth, glossitis, conjunctivitis,\n seborrheic dermatitis, and normochromicnormocytic anemia. Diagnosis is usually clinical.\n Treatment consists of oral or, if needed, IM riboflavin.\n Primary riboflavin deficiency results from inadequate intake of fortified cereals, milk, and other animal\n products. The most common causes of secondary deficiency are chronic diarrhea, malabsorption\n syndromes, liver disorders, hemodialysis, peritoneal dialysis, long-term use of barbiturates, and chronic\n alcoholism.\n Symptoms and Signs\n The most common signs are pallor and maceration of the mucosa at the angles of the mouth (angular\n stomatitis) and vermilion surfaces of the lips (cheilosis), eventually replaced by superficial linear fissures.\n The fissures can become infected with Candida albicans, causing grayish white lesions (perleche). The\n tongue may appear magenta. Seborrheic dermatitis develops, usually affecting the nasolabial folds, ears,\n eyelids, and scrotum or labia majora. These areas become red, scaly, and greasy.\n Rarely, neovascularization and keratitis of the cornea occur, causing lacrimation and photophobia.\n Diagnosis\n The lesions characteristic of riboflavin deficiency are nonspecific. Riboflavin deficiency should be\n suspected if characteristic signs develop in a patient with other B vitamin deficiencies. Diagnosis can be\n confirmed by a therapeutic trial or laboratory testing, usually by measuring urinary excretion of riboflavin.\n Treatment\n Riboflavin 5 to 10 mg/day po is given until recovery. Other water-soluble vitamins should also be given.\n Thiamin\n Thiamin (vitamin B1) is widely available in the diet. Thiamin is involved in carbohydrate, fat, amino acid,\n glucose, and alcohol metabolism. Thiamin is essentially nontoxic.\n Thiamin Deficiency\n Thiamin deficiency (causing beriberi) is most common among people subsisting on white rice\n or highly refined carbohydrates in developing countries and among alcoholics. Symptoms\n include diffuse polyneuropathy, high-output heart failure, and Wernicke-Korsakoff syndrome.\n Thiamin is given to help diagnose and treat the deficiency.\n Etiology\n Primary thiamin deficiency is caused by inadequate intake of thiamin. It is commonly due to a diet of\n highly refined carbohydrates (eg, polished rice, white flour, white sugar). It also develops when intake of\n other nutrients is inadequate; it often occurs with other B vitamin deficiencies.\n                                                                                                      80",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nRecommend checking levels of uric acid, serum glucose, and plasma transaminases every 6 to 8 wk until the dose of niacin has been stabilized.\n\n# Riboflavin\n\nRiboflavin (vitamin B2) is involved in carbohydrate metabolism as an essential coenzyme in many oxidation-reduction reactions. Riboflavin is essentially nontoxic.\n\n# Riboflavin Deficiency\n\nRiboflavin deficiency usually occurs with other B-vitamin deficiencies. Symptoms and signs include sore throat, lesions of the lips and mucosa of the mouth, glossitis, conjunctivitis, seborrheic dermatitis, and normochromic normocytic anemia. Diagnosis is usually clinical. Treatment consists of oral or, if needed, IM riboflavin.\n\nPrimary riboflavin deficiency results from inadequate intake of fortified cereals, milk, and other animal products. The most common causes of secondary deficiency are chronic diarrhea, malabsorption syndromes, liver disorders, hemodialysis, peritoneal dialysis, long-term use of barbiturates, and chronic alcoholism.\n\n# Symptoms and Signs\n\nThe most common signs are pallor and maceration of the mucosa at the angles of the mouth (angular stomatitis) and vermilion surfaces of the lips (cheilosis), eventually replaced by superficial linear fissures. The fissures can become infected with *Candida albicans*, causing grayish white lesions (perleche). The tongue may appear magenta. Seborrheic dermatitis develops, usually affecting the nasolabial folds, ears, eyelids, and scrotum or labia majora. These areas become red, scaly, and greasy.\n\nRarely, neovascularization and keratitis of the cornea occur, causing lacrimation and photophobia.\n\n# Diagnosis\n\nThe lesions characteristic of riboflavin deficiency are nonspecific. Riboflavin deficiency should be suspected if characteristic signs develop in a patient with other B vitamin deficiencies. Diagnosis can be confirmed by a therapeutic trial or laboratory testing, usually by measuring urinary excretion of riboflavin.\n\n# Treatment\n\nRiboflavin 5 to 10 mg/day po is given until recovery. Other water-soluble vitamins should also be given.\n\n# Thiamin\n\nThiamin (vitamin B1) is widely available in the diet. Thiamin is involved in carbohydrate, fat, amino acid, glucose, and alcohol metabolism. Thiamin is essentially nontoxic.\n\n# Thiamin Deficiency\n\nThiamin deficiency (causing beriberi) is most common among people subsisting on white rice or highly refined carbohydrates in developing countries and among alcoholics. Symptoms include diffuse polyneuropathy, high-output heart failure, and Wernicke-Korsakoff syndrome. Thiamin is given to help diagnose and treat the deficiency.\n\n# Etiology\n\nPrimary thiamin deficiency is caused by inadequate intake of thiamin. It is commonly due to a diet of highly refined carbohydrates (eg, polished rice, white flour, white sugar). It also develops when intake of other nutrients is inadequate; it often occurs with other B vitamin deficiencies.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 431.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Recommend checking levels of uric acid, serum glucose, and plasma transaminases every 6 to 8 wk until the dose of niacin has been stabilized.",
                    "md": "Recommend checking levels of uric acid, serum glucose, and plasma transaminases every 6 to 8 wk until the dose of niacin has been stabilized.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 475,
                        "h": 25
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Riboflavin",
                    "md": "# Riboflavin",
                    "bBox": {
                        "x": 55,
                        "y": 86.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Riboflavin (vitamin B2) is involved in carbohydrate metabolism as an essential coenzyme in many oxidation-reduction reactions. Riboflavin is essentially nontoxic.",
                    "md": "Riboflavin (vitamin B2) is involved in carbohydrate metabolism as an essential coenzyme in many oxidation-reduction reactions. Riboflavin is essentially nontoxic.",
                    "bBox": {
                        "x": 55,
                        "y": 86.9,
                        "w": 443,
                        "h": 53
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Riboflavin Deficiency",
                    "md": "# Riboflavin Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 86.9,
                        "w": 107,
                        "h": 78
                    }
                },
                {
                    "type": "text",
                    "value": "Riboflavin deficiency usually occurs with other B-vitamin deficiencies. Symptoms and signs include sore throat, lesions of the lips and mucosa of the mouth, glossitis, conjunctivitis, seborrheic dermatitis, and normochromic normocytic anemia. Diagnosis is usually clinical. Treatment consists of oral or, if needed, IM riboflavin.\n\nPrimary riboflavin deficiency results from inadequate intake of fortified cereals, milk, and other animal products. The most common causes of secondary deficiency are chronic diarrhea, malabsorption syndromes, liver disorders, hemodialysis, peritoneal dialysis, long-term use of barbiturates, and chronic alcoholism.",
                    "md": "Riboflavin deficiency usually occurs with other B-vitamin deficiencies. Symptoms and signs include sore throat, lesions of the lips and mucosa of the mouth, glossitis, conjunctivitis, seborrheic dermatitis, and normochromic normocytic anemia. Diagnosis is usually clinical. Treatment consists of oral or, if needed, IM riboflavin.\n\nPrimary riboflavin deficiency results from inadequate intake of fortified cereals, milk, and other animal products. The most common causes of secondary deficiency are chronic diarrhea, malabsorption syndromes, liver disorders, hemodialysis, peritoneal dialysis, long-term use of barbiturates, and chronic alcoholism.",
                    "bBox": {
                        "x": 55,
                        "y": 86.9,
                        "w": 471,
                        "h": 433
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 304.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "The most common signs are pallor and maceration of the mucosa at the angles of the mouth (angular stomatitis) and vermilion surfaces of the lips (cheilosis), eventually replaced by superficial linear fissures. The fissures can become infected with *Candida albicans*, causing grayish white lesions (perleche). The tongue may appear magenta. Seborrheic dermatitis develops, usually affecting the nasolabial folds, ears, eyelids, and scrotum or labia majora. These areas become red, scaly, and greasy.\n\nRarely, neovascularization and keratitis of the cornea occur, causing lacrimation and photophobia.",
                    "md": "The most common signs are pallor and maceration of the mucosa at the angles of the mouth (angular stomatitis) and vermilion surfaces of the lips (cheilosis), eventually replaced by superficial linear fissures. The fissures can become infected with *Candida albicans*, causing grayish white lesions (perleche). The tongue may appear magenta. Seborrheic dermatitis develops, usually affecting the nasolabial folds, ears, eyelids, and scrotum or labia majora. These areas become red, scaly, and greasy.\n\nRarely, neovascularization and keratitis of the cornea occur, causing lacrimation and photophobia.",
                    "bBox": {
                        "x": 55,
                        "y": 330.9,
                        "w": 479,
                        "h": 88
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 431.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "The lesions characteristic of riboflavin deficiency are nonspecific. Riboflavin deficiency should be suspected if characteristic signs develop in a patient with other B vitamin deficiencies. Diagnosis can be confirmed by a therapeutic trial or laboratory testing, usually by measuring urinary excretion of riboflavin.",
                    "md": "The lesions characteristic of riboflavin deficiency are nonspecific. Riboflavin deficiency should be suspected if characteristic signs develop in a patient with other B vitamin deficiencies. Diagnosis can be confirmed by a therapeutic trial or laboratory testing, usually by measuring urinary excretion of riboflavin.",
                    "bBox": {
                        "x": 55,
                        "y": 86.9,
                        "w": 476,
                        "h": 408
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 507.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Riboflavin 5 to 10 mg/day po is given until recovery. Other water-soluble vitamins should also be given.",
                    "md": "Riboflavin 5 to 10 mg/day po is given until recovery. Other water-soluble vitamins should also be given.",
                    "bBox": {
                        "x": 55,
                        "y": 86.9,
                        "w": 469,
                        "h": 459
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Thiamin",
                    "md": "# Thiamin",
                    "bBox": {
                        "x": 55,
                        "y": 558.9,
                        "w": 41,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Thiamin (vitamin B1) is widely available in the diet. Thiamin is involved in carbohydrate, fat, amino acid, glucose, and alcohol metabolism. Thiamin is essentially nontoxic.",
                    "md": "Thiamin (vitamin B1) is widely available in the diet. Thiamin is involved in carbohydrate, fat, amino acid, glucose, and alcohol metabolism. Thiamin is essentially nontoxic.",
                    "bBox": {
                        "x": 55,
                        "y": 558.9,
                        "w": 472,
                        "h": 52
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Thiamin Deficiency",
                    "md": "# Thiamin Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 558.9,
                        "w": 96,
                        "h": 78
                    }
                },
                {
                    "type": "text",
                    "value": "Thiamin deficiency (causing beriberi) is most common among people subsisting on white rice or highly refined carbohydrates in developing countries and among alcoholics. Symptoms include diffuse polyneuropathy, high-output heart failure, and Wernicke-Korsakoff syndrome. Thiamin is given to help diagnose and treat the deficiency.",
                    "md": "Thiamin deficiency (causing beriberi) is most common among people subsisting on white rice or highly refined carbohydrates in developing countries and among alcoholics. Symptoms include diffuse polyneuropathy, high-output heart failure, and Wernicke-Korsakoff syndrome. Thiamin is given to help diagnose and treat the deficiency.",
                    "bBox": {
                        "x": 55,
                        "y": 558.9,
                        "w": 471,
                        "h": 141
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Etiology",
                    "md": "# Etiology",
                    "bBox": {
                        "x": 55,
                        "y": 713.9,
                        "w": 41,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Primary thiamin deficiency is caused by inadequate intake of thiamin. It is commonly due to a diet of highly refined carbohydrates (eg, polished rice, white flour, white sugar). It also develops when intake of other nutrients is inadequate; it often occurs with other B vitamin deficiencies.",
                    "md": "Primary thiamin deficiency is caused by inadequate intake of thiamin. It is commonly due to a diet of highly refined carbohydrates (eg, polished rice, white flour, white sugar). It also develops when intake of other nutrients is inadequate; it often occurs with other B vitamin deficiencies.",
                    "bBox": {
                        "x": 55,
                        "y": 558.9,
                        "w": 474,
                        "h": 217
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.993
        },
        {
            "page": 29,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n Secondary thiamin deficiency is caused by increased demand (eg, due to hyperthyroidism, pregnancy,\n breastfeeding, strenuous exercise, or fever), impaired absorption (eg, due to prolonged diarrhea), or\n impaired metabolism (eg, due to hepatic insufficiency). In alcoholics, many mechanisms contribute to\n thiamin deficiency; they include decreased intake, impaired absorption and use, increased demand, and\n possibly an apoenzyme defect.\n Pathophysiology\n Deficiency causes degeneration of peripheral nerves, thalamus, mammillary bodies, and cerebellum.\n Cerebral blood flow is markedly reduced, and vascular resistance is increased.\n The heart may become dilated; muscle fibers become swollen, fragmented, and vacuolized, with\n interstitial spaces dilated by fluid. Vasodilation occurs and can result in edema in the feet and legs.\n Arteriovenous shunting of blood increases. Eventually, high-output heart failure may occur.\n Symptoms and Signs\n Early symptoms are nonspecific: fatigue, irritability, poor memory, sleep disturbances, precordial pain,\n anorexia, and abdominal discomfort.\n Dry beriberi refers to peripheral neurologic deficits due to thiamin deficiency. These deficits are bilateral\n and roughly symmetric, occurring in a stocking-glove distribution. They affect predominantly the lower\n extremities, beginning with paresthesias in the toes, burning in the feet (particularly severe at night),\n muscle cramps in the calves, pains in the legs, and plantar dysesthesias. Calf muscle tenderness,\n difficulty rising from a squatting position, and decreased vibratory sensation in the toes are early signs.\n Muscle wasting occurs. Continued deficiency worsens polyneuropathy, which can eventually affect the\n arms.\n Wernicke-Korsakoff syndrome, which combines Wernicke's encephalopathy (see p. 1522) and\n Korsakoff's psychosis (see p. 1523), occurs in some alcoholics who do not consume foods fortified with\n thiamin. Wernicke's encephalopathy consists of psychomotor slowing or apathy, nystagmus, ataxia,\n ophthalmoplegia, impaired consciousness, and, if untreated, coma and death. It probably results from\n severe acute deficiency superimposed on chronic deficiency. Korsakoff's psychosis consists of mental\n confusion, dysphonia, and confabulation with impaired memory of recent events. It probably results from\n chronic deficiency and may develop after repeated episodes of Wernicke's encephalopathy.\n Cardiovascular (wet) beriberi is myocardial disease due to thiamin deficiency. The first effects are\n vasodilation, tachycardia, a wide pulse pressure, sweating, warm skin, and lactic acidosis. Later, heart\n failure develops, causing orthopnea and pulmonary and peripheral edema. Vasodilation can continue,\n sometimes resulting in shock.\n Infantile beriberi occurs in infants (usually by age 3 to 4 wk) who are breastfed by thiamin-deficient\n mothers. Heart failure (which may occur suddenly), aphonia, and absent deep tendon reflexes are\n characteristic.\n Because thiamin is necessary for glucose metabolism, glucose infusions may precipitate or worsen\n symptoms of deficiency in thiamin-deficient people.\n Diagnosis\n \u2022 Favorable response to thiamin\n Diagnosis is usually based on a favorable response to treatment with thiamin in a patient with symptoms\n or signs of deficiency. Similar bilateral lower-extremity polyneuropathies due to other disorders (eg,\n diabetes, alcoholism, vitamin B12 deficiency, heavy metal poisoning) do not respond to thiamin. Single-\n nerve neuritides (mononeuropathies\u2014eg, sciatica) and multiple mononeuropathies (mononeuritis\n multiplex) are unlikely to result from thiamin deficiency.\n                                                                                                       81",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\n# Secondary thiamin deficiency\n\nSecondary thiamin deficiency is caused by increased demand (eg, due to hyperthyroidism, pregnancy, breastfeeding, strenuous exercise, or fever), impaired absorption (eg, due to prolonged diarrhea), or impaired metabolism (eg, due to hepatic insufficiency). In alcoholics, many mechanisms contribute to thiamin deficiency; they include decreased intake, impaired absorption and use, increased demand, and possibly an apoenzyme defect.\n\n# Pathophysiology\n\nDeficiency causes degeneration of peripheral nerves, thalamus, mammillary bodies, and cerebellum. Cerebral blood flow is markedly reduced, and vascular resistance is increased. The heart may become dilated; muscle fibers become swollen, fragmented, and vacuolized, with interstitial spaces dilated by fluid. Vasodilation occurs and can result in edema in the feet and legs. Arteriovenous shunting of blood increases. Eventually, high-output heart failure may occur.\n\n# Symptoms and Signs\n\nEarly symptoms are nonspecific: fatigue, irritability, poor memory, sleep disturbances, precordial pain, anorexia, and abdominal discomfort.\n\nDry beriberi refers to peripheral neurologic deficits due to thiamin deficiency. These deficits are bilateral and roughly symmetric, occurring in a stocking-glove distribution. They affect predominantly the lower extremities, beginning with paresthesias in the toes, burning in the feet (particularly severe at night), muscle cramps in the calves, pains in the legs, and plantar dysesthesias. Calf muscle tenderness, difficulty rising from a squatting position, and decreased vibratory sensation in the toes are early signs. Muscle wasting occurs. Continued deficiency worsens polyneuropathy, which can eventually affect the arms.\n\nWernicke-Korsakoff syndrome, which combines Wernicke's encephalopathy (see p. 1522) and Korsakoff's psychosis (see p. 1523), occurs in some alcoholics who do not consume foods fortified with thiamin. Wernicke's encephalopathy consists of psychomotor slowing or apathy, nystagmus, ataxia, ophthalmoplegia, impaired consciousness, and, if untreated, coma and death. It probably results from severe acute deficiency superimposed on chronic deficiency. Korsakoff's psychosis consists of mental confusion, dysphonia, and confabulation with impaired memory of recent events. It probably results from chronic deficiency and may develop after repeated episodes of Wernicke's encephalopathy.\n\nCardiovascular (wet) beriberi is myocardial disease due to thiamin deficiency. The first effects are vasodilation, tachycardia, a wide pulse pressure, sweating, warm skin, and lactic acidosis. Later, heart failure develops, causing orthopnea and pulmonary and peripheral edema. Vasodilation can continue, sometimes resulting in shock.\n\nInfantile beriberi occurs in infants (usually by age 3 to 4 wk) who are breastfed by thiamin-deficient mothers. Heart failure (which may occur suddenly), aphonia, and absent deep tendon reflexes are characteristic.\n\nBecause thiamin is necessary for glucose metabolism, glucose infusions may precipitate or worsen symptoms of deficiency in thiamin-deficient people.\n\n# Diagnosis\n\n- Favorable response to thiamin\n\nDiagnosis is usually based on a favorable response to treatment with thiamin in a patient with symptoms or signs of deficiency. Similar bilateral lower-extremity polyneuropathies due to other disorders (eg, diabetes, alcoholism, vitamin B12 deficiency, heavy metal poisoning) do not respond to thiamin. Single-nerve neuritides (mononeuropathies\u2014eg, sciatica) and multiple mononeuropathies (mononeuritis multiplex) are unlikely to result from thiamin deficiency.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 657.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Secondary thiamin deficiency",
                    "md": "# Secondary thiamin deficiency",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Secondary thiamin deficiency is caused by increased demand (eg, due to hyperthyroidism, pregnancy, breastfeeding, strenuous exercise, or fever), impaired absorption (eg, due to prolonged diarrhea), or impaired metabolism (eg, due to hepatic insufficiency). In alcoholics, many mechanisms contribute to thiamin deficiency; they include decreased intake, impaired absorption and use, increased demand, and possibly an apoenzyme defect.",
                    "md": "Secondary thiamin deficiency is caused by increased demand (eg, due to hyperthyroidism, pregnancy, breastfeeding, strenuous exercise, or fever), impaired absorption (eg, due to prolonged diarrhea), or impaired metabolism (eg, due to hepatic insufficiency). In alcoholics, many mechanisms contribute to thiamin deficiency; they include decreased intake, impaired absorption and use, increased demand, and possibly an apoenzyme defect.",
                    "bBox": {
                        "x": 55,
                        "y": 49.9,
                        "w": 474,
                        "h": 63
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Pathophysiology",
                    "md": "# Pathophysiology",
                    "bBox": {
                        "x": 55,
                        "y": 125.9,
                        "w": 84,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Deficiency causes degeneration of peripheral nerves, thalamus, mammillary bodies, and cerebellum. Cerebral blood flow is markedly reduced, and vascular resistance is increased. The heart may become dilated; muscle fibers become swollen, fragmented, and vacuolized, with interstitial spaces dilated by fluid. Vasodilation occurs and can result in edema in the feet and legs. Arteriovenous shunting of blood increases. Eventually, high-output heart failure may occur.",
                    "md": "Deficiency causes degeneration of peripheral nerves, thalamus, mammillary bodies, and cerebellum. Cerebral blood flow is markedly reduced, and vascular resistance is increased. The heart may become dilated; muscle fibers become swollen, fragmented, and vacuolized, with interstitial spaces dilated by fluid. Vasodilation occurs and can result in edema in the feet and legs. Arteriovenous shunting of blood increases. Eventually, high-output heart failure may occur.",
                    "bBox": {
                        "x": 55,
                        "y": 150.9,
                        "w": 458,
                        "h": 76
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 239.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Early symptoms are nonspecific: fatigue, irritability, poor memory, sleep disturbances, precordial pain, anorexia, and abdominal discomfort.\n\nDry beriberi refers to peripheral neurologic deficits due to thiamin deficiency. These deficits are bilateral and roughly symmetric, occurring in a stocking-glove distribution. They affect predominantly the lower extremities, beginning with paresthesias in the toes, burning in the feet (particularly severe at night), muscle cramps in the calves, pains in the legs, and plantar dysesthesias. Calf muscle tenderness, difficulty rising from a squatting position, and decreased vibratory sensation in the toes are early signs. Muscle wasting occurs. Continued deficiency worsens polyneuropathy, which can eventually affect the arms.\n\nWernicke-Korsakoff syndrome, which combines Wernicke's encephalopathy (see p. 1522) and Korsakoff's psychosis (see p. 1523), occurs in some alcoholics who do not consume foods fortified with thiamin. Wernicke's encephalopathy consists of psychomotor slowing or apathy, nystagmus, ataxia, ophthalmoplegia, impaired consciousness, and, if untreated, coma and death. It probably results from severe acute deficiency superimposed on chronic deficiency. Korsakoff's psychosis consists of mental confusion, dysphonia, and confabulation with impaired memory of recent events. It probably results from chronic deficiency and may develop after repeated episodes of Wernicke's encephalopathy.\n\nCardiovascular (wet) beriberi is myocardial disease due to thiamin deficiency. The first effects are vasodilation, tachycardia, a wide pulse pressure, sweating, warm skin, and lactic acidosis. Later, heart failure develops, causing orthopnea and pulmonary and peripheral edema. Vasodilation can continue, sometimes resulting in shock.\n\nInfantile beriberi occurs in infants (usually by age 3 to 4 wk) who are breastfed by thiamin-deficient mothers. Heart failure (which may occur suddenly), aphonia, and absent deep tendon reflexes are characteristic.\n\nBecause thiamin is necessary for glucose metabolism, glucose infusions may precipitate or worsen symptoms of deficiency in thiamin-deficient people.",
                    "md": "Early symptoms are nonspecific: fatigue, irritability, poor memory, sleep disturbances, precordial pain, anorexia, and abdominal discomfort.\n\nDry beriberi refers to peripheral neurologic deficits due to thiamin deficiency. These deficits are bilateral and roughly symmetric, occurring in a stocking-glove distribution. They affect predominantly the lower extremities, beginning with paresthesias in the toes, burning in the feet (particularly severe at night), muscle cramps in the calves, pains in the legs, and plantar dysesthesias. Calf muscle tenderness, difficulty rising from a squatting position, and decreased vibratory sensation in the toes are early signs. Muscle wasting occurs. Continued deficiency worsens polyneuropathy, which can eventually affect the arms.\n\nWernicke-Korsakoff syndrome, which combines Wernicke's encephalopathy (see p. 1522) and Korsakoff's psychosis (see p. 1523), occurs in some alcoholics who do not consume foods fortified with thiamin. Wernicke's encephalopathy consists of psychomotor slowing or apathy, nystagmus, ataxia, ophthalmoplegia, impaired consciousness, and, if untreated, coma and death. It probably results from severe acute deficiency superimposed on chronic deficiency. Korsakoff's psychosis consists of mental confusion, dysphonia, and confabulation with impaired memory of recent events. It probably results from chronic deficiency and may develop after repeated episodes of Wernicke's encephalopathy.\n\nCardiovascular (wet) beriberi is myocardial disease due to thiamin deficiency. The first effects are vasodilation, tachycardia, a wide pulse pressure, sweating, warm skin, and lactic acidosis. Later, heart failure develops, causing orthopnea and pulmonary and peripheral edema. Vasodilation can continue, sometimes resulting in shock.\n\nInfantile beriberi occurs in infants (usually by age 3 to 4 wk) who are breastfed by thiamin-deficient mothers. Heart failure (which may occur suddenly), aphonia, and absent deep tendon reflexes are characteristic.\n\nBecause thiamin is necessary for glucose metabolism, glucose infusions may precipitate or worsen symptoms of deficiency in thiamin-deficient people.",
                    "bBox": {
                        "x": 55,
                        "y": 264.9,
                        "w": 478,
                        "h": 380
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 657.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Favorable response to thiamin\n\nDiagnosis is usually based on a favorable response to treatment with thiamin in a patient with symptoms or signs of deficiency. Similar bilateral lower-extremity polyneuropathies due to other disorders (eg, diabetes, alcoholism, vitamin B12 deficiency, heavy metal poisoning) do not respond to thiamin. Single-nerve neuritides (mononeuropathies\u2014eg, sciatica) and multiple mononeuropathies (mononeuritis multiplex) are unlikely to result from thiamin deficiency.",
                    "md": "- Favorable response to thiamin\n\nDiagnosis is usually based on a favorable response to treatment with thiamin in a patient with symptoms or signs of deficiency. Similar bilateral lower-extremity polyneuropathies due to other disorders (eg, diabetes, alcoholism, vitamin B12 deficiency, heavy metal poisoning) do not respond to thiamin. Single-nerve neuritides (mononeuropathies\u2014eg, sciatica) and multiple mononeuropathies (mononeuritis multiplex) are unlikely to result from thiamin deficiency.",
                    "bBox": {
                        "x": 55,
                        "y": 657.9,
                        "w": 475,
                        "h": 116
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.99
        },
        {
            "page": 30,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n Electrolytes, including Mg, should be measured to exclude other causes. For confirmation in equivocal\n cases, erythrocyte transketolase activity and 24-h urinary thiamin excretion may be measured.\n Diagnosis of cardiovascular beriberi can be difficult if other disorders that cause heart failure are present.\n A therapeutic trial of thiamin can help.\n Treatment\n \u2022 Supplemental thiamin, with dose based on clinical manifestations\n Ensuring that dietary supplies of thiamin are adequate is important regardless of symptoms. Because IV\n glucose can worsen thiamin deficiency, alcoholics and others at risk of thiamin deficiency should receive\n IV thiamin 100 mg before receiving IV glucose solutions.\n For mild polyneuropathy, thiamin 10 to 20 mg po once/day is given for 2 wk. For moderate or advanced\n neuropathy, the dose is 20 to 30 mg/day; it should be continued for several weeks after symptoms\n disappear. For edema and congestion due to cardiovascular beriberi, thiamin 100 mg IV once/day is given\n for several days. Heart failure is also treated.\n For Wernicke-Korsakoff syndrome, thiamin 50 to 100 mg IM or IV bid must usually be given for several\n days, followed by 10 to 20 mg once/day until a therapeutic response is obtained. Anaphylactic reactions\n to IV thiamin are rare. Symptoms of ophthalmoplegia may resolve in a day; improvement in patients with\n Korsakoff psychosis may take 1 to 3 mo. Recovery from neurologic deficits is often incomplete in\n Wernicke-Korsakoff syndrome and in other forms of thiamin deficiency.\n Because thiamin deficiency often occurs with other B vitamin deficiencies, multiple water-soluble vitamins\n are usually given for several weeks. Patients should continue to consume a nutritious diet, supplying 1 to\n 2 times the daily recommended intake of vitamins; all alcohol intake should stop.\n Vitamin A\n Vitamin A (retinol) is required for the formation of rhodopsin, a photoreceptor pigment in the retina. Vitamin\n A helps maintain epithelial tissues. Normally, the liver stores 80 to 90% of the body's vitamin A. To use\n vitamin A, the body releases it into the circulation bound to prealbumin (transthyretin) and retinol-binding\n protein. \u03b2-Carotene and other provitamin carotenoids, contained in green leafy and yellow vegetables\n and deep- or bright-colored fruits, are converted to vitamin A. Carotenoids are absorbed better from\n vegetables when they are cooked or homogenized and served with some fats or oils.\n Retinol activity equivalents (RAE) were developed because provitamin A carotenoids have less vitamin A\n activity than preformed vitamin A; 1 \u03bcg retinol = 3.33 IU.\n Synthetic vitamin analogs (retinoids) are being used increasingly in dermatology. The possible protective\n role of \u03b2-carotene, retinol, and retinoids against some epithelial cancers is under study. However, risk of\n certain cancers may be increased after \u03b2-carotene supplementation.\n Vitamin A Deficiency\n Vitamin A deficiency can result from inadequate intake, fat malabsorption, or liver disorders.\n Deficiency impairs immunity and hematopoiesis and causes rashes and typical ocular effects\n (eg, xerophthalmia, night blindness). Diagnosis is based on typical ocular findings and low\n vitamin A levels. Treatment consists of vitamin A given orally or, if symptoms are severe or\n malabsorption is the cause, parenterally.\n Etiology\n Primary vitamin A deficiency is usually caused by prolonged dietary deprivation. It is endemic in areas\n such as southern and eastern Asia, where rice, devoid of \u03b2-carotene, is the staple food. Xerophthalmia\n due to primary deficiency is a common cause of blindness among young children in developing countries.\n                                                                                                        82",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\n# Thiamin Deficiency\n\nElectrolytes, including Mg, should be measured to exclude other causes. For confirmation in equivocal cases, erythrocyte transketolase activity and 24-h urinary thiamin excretion may be measured. Diagnosis of cardiovascular beriberi can be difficult if other disorders that cause heart failure are present. A therapeutic trial of thiamin can help.\n\n# Treatment\n\n- Supplemental thiamin, with dose based on clinical manifestations\n\nEnsuring that dietary supplies of thiamin are adequate is important regardless of symptoms. Because IV glucose can worsen thiamin deficiency, alcoholics and others at risk of thiamin deficiency should receive IV thiamin 100 mg before receiving IV glucose solutions.\n\nFor mild polyneuropathy, thiamin 10 to 20 mg po once/day is given for 2 wk. For moderate or advanced neuropathy, the dose is 20 to 30 mg/day; it should be continued for several weeks after symptoms disappear. For edema and congestion due to cardiovascular beriberi, thiamin 100 mg IV once/day is given for several days. Heart failure is also treated.\n\nFor Wernicke-Korsakoff syndrome, thiamin 50 to 100 mg IM or IV bid must usually be given for several days, followed by 10 to 20 mg once/day until a therapeutic response is obtained. Anaphylactic reactions to IV thiamin are rare. Symptoms of ophthalmoplegia may resolve in a day; improvement in patients with Korsakoff psychosis may take 1 to 3 mo. Recovery from neurologic deficits is often incomplete in Wernicke-Korsakoff syndrome and in other forms of thiamin deficiency.\n\nBecause thiamin deficiency often occurs with other B vitamin deficiencies, multiple water-soluble vitamins are usually given for several weeks. Patients should continue to consume a nutritious diet, supplying 1 to 2 times the daily recommended intake of vitamins; all alcohol intake should stop.\n\n# Vitamin A\n\nVitamin A (retinol) is required for the formation of rhodopsin, a photoreceptor pigment in the retina. Vitamin A helps maintain epithelial tissues. Normally, the liver stores 80 to 90% of the body's vitamin A. To use vitamin A, the body releases it into the circulation bound to prealbumin (transthyretin) and retinol-binding protein. \u03b2-Carotene and other provitamin carotenoids, contained in green leafy and yellow vegetables and deep- or bright-colored fruits, are converted to vitamin A. Carotenoids are absorbed better from vegetables when they are cooked or homogenized and served with some fats or oils.\n\nRetinol activity equivalents (RAE) were developed because provitamin A carotenoids have less vitamin A activity than preformed vitamin A; 1 \u03bcg retinol = 3.33 IU. Synthetic vitamin analogs (retinoids) are being used increasingly in dermatology. The possible protective role of \u03b2-carotene, retinol, and retinoids against some epithelial cancers is under study. However, risk of certain cancers may be increased after \u03b2-carotene supplementation.\n\n# Vitamin A Deficiency\n\nVitamin A deficiency can result from inadequate intake, fat malabsorption, or liver disorders. Deficiency impairs immunity and hematopoiesis and causes rashes and typical ocular effects (eg, xerophthalmia, night blindness). Diagnosis is based on typical ocular findings and low vitamin A levels. Treatment consists of vitamin A given orally or, if symptoms are severe or malabsorption is the cause, parenterally.\n\n# Etiology\n\nPrimary vitamin A deficiency is usually caused by prolonged dietary deprivation. It is endemic in areas such as southern and eastern Asia, where rice, devoid of \u03b2-carotene, is the staple food. Xerophthalmia due to primary deficiency is a common cause of blindness among young children in developing countries.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Thiamin Deficiency",
                    "md": "# Thiamin Deficiency",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Electrolytes, including Mg, should be measured to exclude other causes. For confirmation in equivocal cases, erythrocyte transketolase activity and 24-h urinary thiamin excretion may be measured. Diagnosis of cardiovascular beriberi can be difficult if other disorders that cause heart failure are present. A therapeutic trial of thiamin can help.",
                    "md": "Electrolytes, including Mg, should be measured to exclude other causes. For confirmation in equivocal cases, erythrocyte transketolase activity and 24-h urinary thiamin excretion may be measured. Diagnosis of cardiovascular beriberi can be difficult if other disorders that cause heart failure are present. A therapeutic trial of thiamin can help.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 480,
                        "h": 63
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 124.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Supplemental thiamin, with dose based on clinical manifestations\n\nEnsuring that dietary supplies of thiamin are adequate is important regardless of symptoms. Because IV glucose can worsen thiamin deficiency, alcoholics and others at risk of thiamin deficiency should receive IV thiamin 100 mg before receiving IV glucose solutions.\n\nFor mild polyneuropathy, thiamin 10 to 20 mg po once/day is given for 2 wk. For moderate or advanced neuropathy, the dose is 20 to 30 mg/day; it should be continued for several weeks after symptoms disappear. For edema and congestion due to cardiovascular beriberi, thiamin 100 mg IV once/day is given for several days. Heart failure is also treated.\n\nFor Wernicke-Korsakoff syndrome, thiamin 50 to 100 mg IM or IV bid must usually be given for several days, followed by 10 to 20 mg once/day until a therapeutic response is obtained. Anaphylactic reactions to IV thiamin are rare. Symptoms of ophthalmoplegia may resolve in a day; improvement in patients with Korsakoff psychosis may take 1 to 3 mo. Recovery from neurologic deficits is often incomplete in Wernicke-Korsakoff syndrome and in other forms of thiamin deficiency.\n\nBecause thiamin deficiency often occurs with other B vitamin deficiencies, multiple water-soluble vitamins are usually given for several weeks. Patients should continue to consume a nutritious diet, supplying 1 to 2 times the daily recommended intake of vitamins; all alcohol intake should stop.",
                    "md": "- Supplemental thiamin, with dose based on clinical manifestations\n\nEnsuring that dietary supplies of thiamin are adequate is important regardless of symptoms. Because IV glucose can worsen thiamin deficiency, alcoholics and others at risk of thiamin deficiency should receive IV thiamin 100 mg before receiving IV glucose solutions.\n\nFor mild polyneuropathy, thiamin 10 to 20 mg po once/day is given for 2 wk. For moderate or advanced neuropathy, the dose is 20 to 30 mg/day; it should be continued for several weeks after symptoms disappear. For edema and congestion due to cardiovascular beriberi, thiamin 100 mg IV once/day is given for several days. Heart failure is also treated.\n\nFor Wernicke-Korsakoff syndrome, thiamin 50 to 100 mg IM or IV bid must usually be given for several days, followed by 10 to 20 mg once/day until a therapeutic response is obtained. Anaphylactic reactions to IV thiamin are rare. Symptoms of ophthalmoplegia may resolve in a day; improvement in patients with Korsakoff psychosis may take 1 to 3 mo. Recovery from neurologic deficits is often incomplete in Wernicke-Korsakoff syndrome and in other forms of thiamin deficiency.\n\nBecause thiamin deficiency often occurs with other B vitamin deficiencies, multiple water-soluble vitamins are usually given for several weeks. Patients should continue to consume a nutritious diet, supplying 1 to 2 times the daily recommended intake of vitamins; all alcohol intake should stop.",
                    "bBox": {
                        "x": 55,
                        "y": 175.9,
                        "w": 482,
                        "h": 228
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin A",
                    "md": "# Vitamin A",
                    "bBox": {
                        "x": 55,
                        "y": 416.9,
                        "w": 49,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin A (retinol) is required for the formation of rhodopsin, a photoreceptor pigment in the retina. Vitamin A helps maintain epithelial tissues. Normally, the liver stores 80 to 90% of the body's vitamin A. To use vitamin A, the body releases it into the circulation bound to prealbumin (transthyretin) and retinol-binding protein. \u03b2-Carotene and other provitamin carotenoids, contained in green leafy and yellow vegetables and deep- or bright-colored fruits, are converted to vitamin A. Carotenoids are absorbed better from vegetables when they are cooked or homogenized and served with some fats or oils.\n\nRetinol activity equivalents (RAE) were developed because provitamin A carotenoids have less vitamin A activity than preformed vitamin A; 1 \u03bcg retinol = 3.33 IU. Synthetic vitamin analogs (retinoids) are being used increasingly in dermatology. The possible protective role of \u03b2-carotene, retinol, and retinoids against some epithelial cancers is under study. However, risk of certain cancers may be increased after \u03b2-carotene supplementation.",
                    "md": "Vitamin A (retinol) is required for the formation of rhodopsin, a photoreceptor pigment in the retina. Vitamin A helps maintain epithelial tissues. Normally, the liver stores 80 to 90% of the body's vitamin A. To use vitamin A, the body releases it into the circulation bound to prealbumin (transthyretin) and retinol-binding protein. \u03b2-Carotene and other provitamin carotenoids, contained in green leafy and yellow vegetables and deep- or bright-colored fruits, are converted to vitamin A. Carotenoids are absorbed better from vegetables when they are cooked or homogenized and served with some fats or oils.\n\nRetinol activity equivalents (RAE) were developed because provitamin A carotenoids have less vitamin A activity than preformed vitamin A; 1 \u03bcg retinol = 3.33 IU. Synthetic vitamin analogs (retinoids) are being used increasingly in dermatology. The possible protective role of \u03b2-carotene, retinol, and retinoids against some epithelial cancers is under study. However, risk of certain cancers may be increased after \u03b2-carotene supplementation.",
                    "bBox": {
                        "x": 55,
                        "y": 416.9,
                        "w": 482,
                        "h": 189
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin A Deficiency",
                    "md": "# Vitamin A Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 416.9,
                        "w": 104,
                        "h": 215
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin A deficiency can result from inadequate intake, fat malabsorption, or liver disorders. Deficiency impairs immunity and hematopoiesis and causes rashes and typical ocular effects (eg, xerophthalmia, night blindness). Diagnosis is based on typical ocular findings and low vitamin A levels. Treatment consists of vitamin A given orally or, if symptoms are severe or malabsorption is the cause, parenterally.",
                    "md": "Vitamin A deficiency can result from inadequate intake, fat malabsorption, or liver disorders. Deficiency impairs immunity and hematopoiesis and causes rashes and typical ocular effects (eg, xerophthalmia, night blindness). Diagnosis is based on typical ocular findings and low vitamin A levels. Treatment consists of vitamin A given orally or, if symptoms are severe or malabsorption is the cause, parenterally.",
                    "bBox": {
                        "x": 55,
                        "y": 124.9,
                        "w": 469,
                        "h": 583
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Etiology",
                    "md": "# Etiology",
                    "bBox": {
                        "x": 55,
                        "y": 720.9,
                        "w": 41,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Primary vitamin A deficiency is usually caused by prolonged dietary deprivation. It is endemic in areas such as southern and eastern Asia, where rice, devoid of \u03b2-carotene, is the staple food. Xerophthalmia due to primary deficiency is a common cause of blindness among young children in developing countries.",
                    "md": "Primary vitamin A deficiency is usually caused by prolonged dietary deprivation. It is endemic in areas such as southern and eastern Asia, where rice, devoid of \u03b2-carotene, is the staple food. Xerophthalmia due to primary deficiency is a common cause of blindness among young children in developing countries.",
                    "bBox": {
                        "x": 55,
                        "y": 416.9,
                        "w": 480,
                        "h": 367
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.993
        },
        {
            "page": 31,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n Secondary vitamin A deficiency may be due to decreased bioavailability of provitamin A carotenoids or to\n interference with absorption, storage, or transport of vitamin A. Interference with absorption or storage is\n likely in sprue, cystic fibrosis, pancreatic insufficiency, duodenal bypass, chronic diarrhea, bile duct\n obstruction, giardiasis, and cirrhosis. Vitamin A deficiency is common in prolonged protein-energy\n undernutrition not only because the diet is deficient but also because vitamin A storage and transport is\n defective. In children with complicated measles, vitamin A can shorten the duration of the disorder and\n reduce the severity of symptoms and risk of death.\n Symptoms and Signs\n Impaired dark adaptation of the eyes, which can lead to night blindness, is an early symptom.\n Xerophthalmia (which is nearly pathognomonic) results from keratinization of the eyes. It involves drying\n (xerosis) and thickening of the conjunctivae and corneas. Superficial foamy patches composed of\n epithelial debris and secretions on the exposed bulbar conjunctiva (Bitot's spots) develop. In advanced\n deficiency, the cornea becomes hazy and can develop erosions, which can lead to its destruction\n (keratomalacia).\n Keratinization of the skin and of the mucous membranes in the respiratory, GI, and urinary tracts can\n occur. Drying, scaling, and follicular thickening of the skin and respiratory infections can result. Immunity\n is generally impaired.\n The younger the patient, the more severe are the effects of vitamin A deficiency. Growth retardation and\n infections are common among children. Mortality rate can exceed 50% in children with severe vitamin A\n deficiency.\n Diagnosis\n \u2022 Serum retinol levels, clinical evaluation, and response to vitamin A\n Ocular findings suggest the diagnosis. Dark adaptation can be impaired in other disorders (eg, zinc\n deficiency, retinitis pigmentosa, severe refractive errors, cataracts, diabetic retinopathy). If dark\n adaptation is impaired, rod scotometry and electroretinography are done to determine whether vitamin A\n deficiency is the cause.\n Serum levels of retinol are measured. Normal range is 28 to 86 \u03bcg/dL (1 to 3 \u03bcmol/L). However, levels\n decrease only after the deficiency is advanced because the liver contains large stores of vitamin A. Also,\n decreased levels may result from acute infection, which causes retinol-binding protein and transthyretin\n (also called prealbumin) levels to decrease transiently. A therapeutic trial of vitamin A may help confirm\n the diagnosis.\n Prevention\n The diet should include dark green leafy vegetables, deep- or bright-colored fruits (eg, papayas,\n oranges), carrots, and yellow vegetables (eg, squash, pumpkin). Vitamin A-fortified milk and cereals, liver,\n egg yolks, and fish liver oils are helpful. Carotenoids are absorbed better when consumed with some\n dietary fat. If milk allergy is suspected in infants, they should be given adequate vitamin A in formula\n feedings. In developing countries, prophylactic supplements of vitamin A palmitate in oil 60,000 RAE\n (200,000 IU) po every 6 mo are advised for all children between 1 and 5 yr of age; infants &lt; 6 mo can be\n given a one-time dose of 15,000 RAE (50,000 IU), and those aged 6 to 12 mo can be given a one-time\n dose of 30,000 RAE (100,000 IU).\n Treatment\n \u2022 Vitamin A palmitate\n Dietary deficiency is traditionally treated with vitamin A palmitate in oil 60,000 IU po once/day for 2 days,\n followed by 4500 IU po once/day. If vomiting or malabsorption is present or xerophthalmia is probable, a\n                                                                                                          83",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nSecondary vitamin A deficiency may be due to decreased bioavailability of provitamin A carotenoids or to interference with absorption, storage, or transport of vitamin A. Interference with absorption or storage is likely in sprue, cystic fibrosis, pancreatic insufficiency, duodenal bypass, chronic diarrhea, bile duct obstruction, giardiasis, and cirrhosis. Vitamin A deficiency is common in prolonged protein-energy undernutrition not only because the diet is deficient but also because vitamin A storage and transport is defective. In children with complicated measles, vitamin A can shorten the duration of the disorder and reduce the severity of symptoms and risk of death.\n\n# Symptoms and Signs\n\nImpaired dark adaptation of the eyes, which can lead to night blindness, is an early symptom. Xerophthalmia (which is nearly pathognomonic) results from keratinization of the eyes. It involves drying (xerosis) and thickening of the conjunctivae and corneas. Superficial foamy patches composed of epithelial debris and secretions on the exposed bulbar conjunctiva (Bitot's spots) develop. In advanced deficiency, the cornea becomes hazy and can develop erosions, which can lead to its destruction (keratomalacia).\n\nKeratinization of the skin and of the mucous membranes in the respiratory, GI, and urinary tracts can occur. Drying, scaling, and follicular thickening of the skin and respiratory infections can result. Immunity is generally impaired.\n\nThe younger the patient, the more severe are the effects of vitamin A deficiency. Growth retardation and infections are common among children. Mortality rate can exceed 50% in children with severe vitamin A deficiency.\n\n# Diagnosis\n\n- Serum retinol levels, clinical evaluation, and response to vitamin A\n\nOcular findings suggest the diagnosis. Dark adaptation can be impaired in other disorders (eg, zinc deficiency, retinitis pigmentosa, severe refractive errors, cataracts, diabetic retinopathy). If dark adaptation is impaired, rod scotometry and electroretinography are done to determine whether vitamin A deficiency is the cause.\n\nSerum levels of retinol are measured. Normal range is 28 to 86 \u03bcg/dL (1 to 3 \u03bcmol/L). However, levels decrease only after the deficiency is advanced because the liver contains large stores of vitamin A. Also, decreased levels may result from acute infection, which causes retinol-binding protein and transthyretin (also called prealbumin) levels to decrease transiently. A therapeutic trial of vitamin A may help confirm the diagnosis.\n\n# Prevention\n\nThe diet should include dark green leafy vegetables, deep- or bright-colored fruits (eg, papayas, oranges), carrots, and yellow vegetables (eg, squash, pumpkin). Vitamin A-fortified milk and cereals, liver, egg yolks, and fish liver oils are helpful. Carotenoids are absorbed better when consumed with some dietary fat. If milk allergy is suspected in infants, they should be given adequate vitamin A in formula feedings. In developing countries, prophylactic supplements of vitamin A palmitate in oil 60,000 RAE (200,000 IU) po every 6 mo are advised for all children between 1 and 5 yr of age; infants &lt; 6 mo can be given a one-time dose of 15,000 RAE (50,000 IU), and those aged 6 to 12 mo can be given a one-time dose of 30,000 RAE (100,000 IU).\n\n# Treatment\n\n- Vitamin A palmitate\n\nDietary deficiency is traditionally treated with vitamin A palmitate in oil 60,000 IU po once/day for 2 days, followed by 4500 IU po once/day. If vomiting or malabsorption is present or xerophthalmia is probable, a",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 378.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Secondary vitamin A deficiency may be due to decreased bioavailability of provitamin A carotenoids or to interference with absorption, storage, or transport of vitamin A. Interference with absorption or storage is likely in sprue, cystic fibrosis, pancreatic insufficiency, duodenal bypass, chronic diarrhea, bile duct obstruction, giardiasis, and cirrhosis. Vitamin A deficiency is common in prolonged protein-energy undernutrition not only because the diet is deficient but also because vitamin A storage and transport is defective. In children with complicated measles, vitamin A can shorten the duration of the disorder and reduce the severity of symptoms and risk of death.",
                    "md": "Secondary vitamin A deficiency may be due to decreased bioavailability of provitamin A carotenoids or to interference with absorption, storage, or transport of vitamin A. Interference with absorption or storage is likely in sprue, cystic fibrosis, pancreatic insufficiency, duodenal bypass, chronic diarrhea, bile duct obstruction, giardiasis, and cirrhosis. Vitamin A deficiency is common in prolonged protein-energy undernutrition not only because the diet is deficient but also because vitamin A storage and transport is defective. In children with complicated measles, vitamin A can shorten the duration of the disorder and reduce the severity of symptoms and risk of death.",
                    "bBox": {
                        "x": 55,
                        "y": 61.9,
                        "w": 475,
                        "h": 88
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 162.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Impaired dark adaptation of the eyes, which can lead to night blindness, is an early symptom. Xerophthalmia (which is nearly pathognomonic) results from keratinization of the eyes. It involves drying (xerosis) and thickening of the conjunctivae and corneas. Superficial foamy patches composed of epithelial debris and secretions on the exposed bulbar conjunctiva (Bitot's spots) develop. In advanced deficiency, the cornea becomes hazy and can develop erosions, which can lead to its destruction (keratomalacia).\n\nKeratinization of the skin and of the mucous membranes in the respiratory, GI, and urinary tracts can occur. Drying, scaling, and follicular thickening of the skin and respiratory infections can result. Immunity is generally impaired.\n\nThe younger the patient, the more severe are the effects of vitamin A deficiency. Growth retardation and infections are common among children. Mortality rate can exceed 50% in children with severe vitamin A deficiency.",
                    "md": "Impaired dark adaptation of the eyes, which can lead to night blindness, is an early symptom. Xerophthalmia (which is nearly pathognomonic) results from keratinization of the eyes. It involves drying (xerosis) and thickening of the conjunctivae and corneas. Superficial foamy patches composed of epithelial debris and secretions on the exposed bulbar conjunctiva (Bitot's spots) develop. In advanced deficiency, the cornea becomes hazy and can develop erosions, which can lead to its destruction (keratomalacia).\n\nKeratinization of the skin and of the mucous membranes in the respiratory, GI, and urinary tracts can occur. Drying, scaling, and follicular thickening of the skin and respiratory infections can result. Immunity is generally impaired.\n\nThe younger the patient, the more severe are the effects of vitamin A deficiency. Growth retardation and infections are common among children. Mortality rate can exceed 50% in children with severe vitamin A deficiency.",
                    "bBox": {
                        "x": 55,
                        "y": 188.9,
                        "w": 475,
                        "h": 177
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 378.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Serum retinol levels, clinical evaluation, and response to vitamin A\n\nOcular findings suggest the diagnosis. Dark adaptation can be impaired in other disorders (eg, zinc deficiency, retinitis pigmentosa, severe refractive errors, cataracts, diabetic retinopathy). If dark adaptation is impaired, rod scotometry and electroretinography are done to determine whether vitamin A deficiency is the cause.\n\nSerum levels of retinol are measured. Normal range is 28 to 86 \u03bcg/dL (1 to 3 \u03bcmol/L). However, levels decrease only after the deficiency is advanced because the liver contains large stores of vitamin A. Also, decreased levels may result from acute infection, which causes retinol-binding protein and transthyretin (also called prealbumin) levels to decrease transiently. A therapeutic trial of vitamin A may help confirm the diagnosis.",
                    "md": "- Serum retinol levels, clinical evaluation, and response to vitamin A\n\nOcular findings suggest the diagnosis. Dark adaptation can be impaired in other disorders (eg, zinc deficiency, retinitis pigmentosa, severe refractive errors, cataracts, diabetic retinopathy). If dark adaptation is impaired, rod scotometry and electroretinography are done to determine whether vitamin A deficiency is the cause.\n\nSerum levels of retinol are measured. Normal range is 28 to 86 \u03bcg/dL (1 to 3 \u03bcmol/L). However, levels decrease only after the deficiency is advanced because the liver contains large stores of vitamin A. Also, decreased levels may result from acute infection, which causes retinol-binding protein and transthyretin (also called prealbumin) levels to decrease transiently. A therapeutic trial of vitamin A may help confirm the diagnosis.",
                    "bBox": {
                        "x": 55,
                        "y": 378.9,
                        "w": 475,
                        "h": 177
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Prevention",
                    "md": "# Prevention",
                    "bBox": {
                        "x": 55,
                        "y": 568.9,
                        "w": 56,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "The diet should include dark green leafy vegetables, deep- or bright-colored fruits (eg, papayas, oranges), carrots, and yellow vegetables (eg, squash, pumpkin). Vitamin A-fortified milk and cereals, liver, egg yolks, and fish liver oils are helpful. Carotenoids are absorbed better when consumed with some dietary fat. If milk allergy is suspected in infants, they should be given adequate vitamin A in formula feedings. In developing countries, prophylactic supplements of vitamin A palmitate in oil 60,000 RAE (200,000 IU) po every 6 mo are advised for all children between 1 and 5 yr of age; infants &lt; 6 mo can be given a one-time dose of 15,000 RAE (50,000 IU), and those aged 6 to 12 mo can be given a one-time dose of 30,000 RAE (100,000 IU).",
                    "md": "The diet should include dark green leafy vegetables, deep- or bright-colored fruits (eg, papayas, oranges), carrots, and yellow vegetables (eg, squash, pumpkin). Vitamin A-fortified milk and cereals, liver, egg yolks, and fish liver oils are helpful. Carotenoids are absorbed better when consumed with some dietary fat. If milk allergy is suspected in infants, they should be given adequate vitamin A in formula feedings. In developing countries, prophylactic supplements of vitamin A palmitate in oil 60,000 RAE (200,000 IU) po every 6 mo are advised for all children between 1 and 5 yr of age; infants &lt; 6 mo can be given a one-time dose of 15,000 RAE (50,000 IU), and those aged 6 to 12 mo can be given a one-time dose of 30,000 RAE (100,000 IU).",
                    "bBox": {
                        "x": 55,
                        "y": 593.9,
                        "w": 480,
                        "h": 101
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 707.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Vitamin A palmitate\n\nDietary deficiency is traditionally treated with vitamin A palmitate in oil 60,000 IU po once/day for 2 days, followed by 4500 IU po once/day. If vomiting or malabsorption is present or xerophthalmia is probable, a",
                    "md": "- Vitamin A palmitate\n\nDietary deficiency is traditionally treated with vitamin A palmitate in oil 60,000 IU po once/day for 2 days, followed by 4500 IU po once/day. If vomiting or malabsorption is present or xerophthalmia is probable, a",
                    "bBox": {
                        "x": 55,
                        "y": 758.9,
                        "w": 474,
                        "h": 25
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 32,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n dose of 50,000 IU for infants &lt; 6 mo, 100,000 IU for infants 6 to 12 mo, or 200,000 IU for children &gt; 12 mo\n and adults should be given for 2 days, with a third dose at least 2 wk later. The same doses are\n recommended for infants and children with complicated measles. Infants born of HIV-positive mothers\n should receive 50,000 IU (15,000 RAE) within 48 h of birth. Prolonged daily administration of large doses,\n especially to infants, must be avoided because toxicity may result.\n For pregnant or breastfeeding women, prophylactic or therapeutic doses should not exceed 10,000 IU\n (3000 RAE)/day to avoid possible damage to the fetus or infant.\n Vitamin A Toxicity\n Vitamin A toxicity can be acute (usually due to accidental ingestion by children) or chronic. Both\n types usually cause headache and increased intracranial pressure. Acute toxicity also causes\n nausea and vomiting. Chronic toxicity also causes changes in skin, hair, and nails; abnormal\n liver test results; and, in a fetus, birth defects. Diagnosis is usually clinical. Unless birth defects\n are present, adjusting the dose almost always leads to complete recovery.\n Acute vitamin A toxicity in children may result from taking large doses (&gt; 100,000 RAE [&gt; 300,000 IU]),\n usually accidentally. In adults, acute toxicity has occurred when arctic explorers ingested polar bear or\n seal livers, which contain several million units of vitamin A.\n Chronic toxicity in older children and adults usually develops after doses of &gt; 30,000 RAE (&gt; 100,000\n IU)/day have been taken for months. Megavitamin therapy is a possible cause, as are massive daily\n doses (50,000 to 120,000 RAE [150,000 to 350,000 IU]) of vitamin A or its metabolites, which are\n sometimes given for nodular acne or other skin disorders. Adults who consume &gt; 1500 RAE (&gt; 4500\n IU)/day of vitamin A may develop osteoporosis. Infants who are given excessive doses (6,000 to 20,000\n RAE [18,000 to 60,000 IU]/day) of water-miscible vitamin A may develop toxicity within a few weeks. Birth\n defects occur in children of women receiving isotretinoin (which is related to vitamin A) for acne treatment\n during pregnancy.\n Although carotene is converted to vitamin A in the body, excessive ingestion of carotene causes\n carotenemia, not vitamin A toxicity. Carotenemia is usually asymptomatic but may lead to carotenodermia,\n in which the skin becomes yellow. When taken as a supplement, \u03b2-carotene has been associated with\n increased cancer risk; risk does not seem to increase when carotenoids are consumed in fruits and\n vegetables.\n Symptoms and Signs\n Although symptoms may vary, headache and rash usually develop during acute or chronic toxicity. Acute\n toxicity causes increased intracranial pressure. Drowsiness, irritability, abdominal pain, nausea, and\n vomiting are common. Sometimes the skin subsequently peels.\n Early symptoms of chronic toxicity are sparsely distributed, coarse hair; alopecia of the eyebrows; dry,\n rough skin; dry eyes; and cracked lips. Later, severe headache, pseudotumor cerebri, and generalized\n weakness develop. Cortical hyperostosis of bone and arthralgia may occur, especially in children.\n Fractures may occur easily, especially in the elderly. In children, toxicity can cause pruritus, anorexia, and\n failure to thrive. Hepatomegaly and splenomegaly may occur.\n In carotenodermia, the skin (but not the sclera) becomes deep yellow, especially on the palms and soles.\n Diagnosis\n \u2022 Clinical evaluation\n Diagnosis is clinical. Blood vitamin levels correlate poorly with toxicity. However, if clinical diagnosis is\n equivocal, laboratory testing may help. In vitamin A toxicity, fasting serum retinol levels may increase from\n normal (28 to 86 \u03bcg/dL [1 to 3 \u03bcmol/L]) to &gt; 100 \u03bcg/dL (&gt; 3.49 \u03bcmol/L), sometimes to &gt; 2000 \u03bcg/dL (&gt; 69.8\n \u03bcmol/L). Hypercalcemia is common.\n                                                                                                       84",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nDose of 50,000 IU for infants &amp;lt; 6 mo, 100,000 IU for infants 6 to 12 mo, or 200,000 IU for children &amp;gt; 12 mo and adults should be given for 2 days, with a third dose at least 2 wk later. The same doses are recommended for infants and children with complicated measles. Infants born of HIV-positive mothers should receive 50,000 IU (15,000 RAE) within 48 h of birth. Prolonged daily administration of large doses, especially to infants, must be avoided because toxicity may result.\n\nFor pregnant or breastfeeding women, prophylactic or therapeutic doses should not exceed 10,000 IU (3000 RAE)/day to avoid possible damage to the fetus or infant.\n\n# Vitamin A Toxicity\n\nVitamin A toxicity can be acute (usually due to accidental ingestion by children) or chronic. Both types usually cause headache and increased intracranial pressure. Acute toxicity also causes nausea and vomiting. Chronic toxicity also causes changes in skin, hair, and nails; abnormal liver test results; and, in a fetus, birth defects. Diagnosis is usually clinical. Unless birth defects are present, adjusting the dose almost always leads to complete recovery.\n\nAcute vitamin A toxicity in children may result from taking large doses (&amp;gt; 100,000 RAE [&amp;gt; 300,000 IU]), usually accidentally. In adults, acute toxicity has occurred when arctic explorers ingested polar bear or seal livers, which contain several million units of vitamin A.\n\nChronic toxicity in older children and adults usually develops after doses of &amp;gt; 30,000 RAE (&amp;gt; 100,000 IU)/day have been taken for months. Megavitamin therapy is a possible cause, as are massive daily doses (50,000 to 120,000 RAE [150,000 to 350,000 IU]) of vitamin A or its metabolites, which are sometimes given for nodular acne or other skin disorders. Adults who consume &amp;gt; 1500 RAE (&amp;gt; 4500 IU)/day of vitamin A may develop osteoporosis. Infants who are given excessive doses (6,000 to 20,000 RAE [18,000 to 60,000 IU]/day) of water-miscible vitamin A may develop toxicity within a few weeks. Birth defects occur in children of women receiving isotretinoin (which is related to vitamin A) for acne treatment during pregnancy.\n\nAlthough carotene is converted to vitamin A in the body, excessive ingestion of carotene causes carotenemia, not vitamin A toxicity. Carotenemia is usually asymptomatic but may lead to carotenodermia, in which the skin becomes yellow. When taken as a supplement, \u03b2-carotene has been associated with increased cancer risk; risk does not seem to increase when carotenoids are consumed in fruits and vegetables.\n\n# Symptoms and Signs\n\nAlthough symptoms may vary, headache and rash usually develop during acute or chronic toxicity. Acute toxicity causes increased intracranial pressure. Drowsiness, irritability, abdominal pain, nausea, and vomiting are common. Sometimes the skin subsequently peels.\n\nEarly symptoms of chronic toxicity are sparsely distributed, coarse hair; alopecia of the eyebrows; dry, rough skin; dry eyes; and cracked lips. Later, severe headache, pseudotumor cerebri, and generalized weakness develop. Cortical hyperostosis of bone and arthralgia may occur, especially in children. Fractures may occur easily, especially in the elderly. In children, toxicity can cause pruritus, anorexia, and failure to thrive. Hepatomegaly and splenomegaly may occur.\n\nIn carotenodermia, the skin (but not the sclera) becomes deep yellow, especially on the palms and soles.\n\n# Diagnosis\n\n- Clinical evaluation\n\nDiagnosis is clinical. Blood vitamin levels correlate poorly with toxicity. However, if clinical diagnosis is equivocal, laboratory testing may help. In vitamin A toxicity, fasting serum retinol levels may increase from normal (28 to 86 \u03bcg/dL [1 to 3 \u03bcmol/L]) to &amp;gt; 100 \u03bcg/dL (&amp;gt; 3.49 \u03bcmol/L), sometimes to &amp;gt; 2000 \u03bcg/dL (&amp;gt; 69.8 \u03bcmol/L). Hypercalcemia is common.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 682.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Dose of 50,000 IU for infants &amp;lt; 6 mo, 100,000 IU for infants 6 to 12 mo, or 200,000 IU for children &amp;gt; 12 mo and adults should be given for 2 days, with a third dose at least 2 wk later. The same doses are recommended for infants and children with complicated measles. Infants born of HIV-positive mothers should receive 50,000 IU (15,000 RAE) within 48 h of birth. Prolonged daily administration of large doses, especially to infants, must be avoided because toxicity may result.\n\nFor pregnant or breastfeeding women, prophylactic or therapeutic doses should not exceed 10,000 IU (3000 RAE)/day to avoid possible damage to the fetus or infant.",
                    "md": "Dose of 50,000 IU for infants &amp;lt; 6 mo, 100,000 IU for infants 6 to 12 mo, or 200,000 IU for children &amp;gt; 12 mo and adults should be given for 2 days, with a third dose at least 2 wk later. The same doses are recommended for infants and children with complicated measles. Infants born of HIV-positive mothers should receive 50,000 IU (15,000 RAE) within 48 h of birth. Prolonged daily administration of large doses, especially to infants, must be avoided because toxicity may result.\n\nFor pregnant or breastfeeding women, prophylactic or therapeutic doses should not exceed 10,000 IU (3000 RAE)/day to avoid possible damage to the fetus or infant.",
                    "bBox": {
                        "x": 55,
                        "y": 61.9,
                        "w": 481,
                        "h": 88
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin A Toxicity",
                    "md": "# Vitamin A Toxicity",
                    "bBox": {
                        "x": 55,
                        "y": 162.9,
                        "w": 89,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin A toxicity can be acute (usually due to accidental ingestion by children) or chronic. Both types usually cause headache and increased intracranial pressure. Acute toxicity also causes nausea and vomiting. Chronic toxicity also causes changes in skin, hair, and nails; abnormal liver test results; and, in a fetus, birth defects. Diagnosis is usually clinical. Unless birth defects are present, adjusting the dose almost always leads to complete recovery.\n\nAcute vitamin A toxicity in children may result from taking large doses (&amp;gt; 100,000 RAE [&amp;gt; 300,000 IU]), usually accidentally. In adults, acute toxicity has occurred when arctic explorers ingested polar bear or seal livers, which contain several million units of vitamin A.\n\nChronic toxicity in older children and adults usually develops after doses of &amp;gt; 30,000 RAE (&amp;gt; 100,000 IU)/day have been taken for months. Megavitamin therapy is a possible cause, as are massive daily doses (50,000 to 120,000 RAE [150,000 to 350,000 IU]) of vitamin A or its metabolites, which are sometimes given for nodular acne or other skin disorders. Adults who consume &amp;gt; 1500 RAE (&amp;gt; 4500 IU)/day of vitamin A may develop osteoporosis. Infants who are given excessive doses (6,000 to 20,000 RAE [18,000 to 60,000 IU]/day) of water-miscible vitamin A may develop toxicity within a few weeks. Birth defects occur in children of women receiving isotretinoin (which is related to vitamin A) for acne treatment during pregnancy.\n\nAlthough carotene is converted to vitamin A in the body, excessive ingestion of carotene causes carotenemia, not vitamin A toxicity. Carotenemia is usually asymptomatic but may lead to carotenodermia, in which the skin becomes yellow. When taken as a supplement, \u03b2-carotene has been associated with increased cancer risk; risk does not seem to increase when carotenoids are consumed in fruits and vegetables.",
                    "md": "Vitamin A toxicity can be acute (usually due to accidental ingestion by children) or chronic. Both types usually cause headache and increased intracranial pressure. Acute toxicity also causes nausea and vomiting. Chronic toxicity also causes changes in skin, hair, and nails; abnormal liver test results; and, in a fetus, birth defects. Diagnosis is usually clinical. Unless birth defects are present, adjusting the dose almost always leads to complete recovery.\n\nAcute vitamin A toxicity in children may result from taking large doses (&amp;gt; 100,000 RAE [&amp;gt; 300,000 IU]), usually accidentally. In adults, acute toxicity has occurred when arctic explorers ingested polar bear or seal livers, which contain several million units of vitamin A.\n\nChronic toxicity in older children and adults usually develops after doses of &amp;gt; 30,000 RAE (&amp;gt; 100,000 IU)/day have been taken for months. Megavitamin therapy is a possible cause, as are massive daily doses (50,000 to 120,000 RAE [150,000 to 350,000 IU]) of vitamin A or its metabolites, which are sometimes given for nodular acne or other skin disorders. Adults who consume &amp;gt; 1500 RAE (&amp;gt; 4500 IU)/day of vitamin A may develop osteoporosis. Infants who are given excessive doses (6,000 to 20,000 RAE [18,000 to 60,000 IU]/day) of water-miscible vitamin A may develop toxicity within a few weeks. Birth defects occur in children of women receiving isotretinoin (which is related to vitamin A) for acne treatment during pregnancy.\n\nAlthough carotene is converted to vitamin A in the body, excessive ingestion of carotene causes carotenemia, not vitamin A toxicity. Carotenemia is usually asymptomatic but may lead to carotenodermia, in which the skin becomes yellow. When taken as a supplement, \u03b2-carotene has been associated with increased cancer risk; risk does not seem to increase when carotenoids are consumed in fruits and vegetables.",
                    "bBox": {
                        "x": 55,
                        "y": 162.9,
                        "w": 482,
                        "h": 532
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 505.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Although symptoms may vary, headache and rash usually develop during acute or chronic toxicity. Acute toxicity causes increased intracranial pressure. Drowsiness, irritability, abdominal pain, nausea, and vomiting are common. Sometimes the skin subsequently peels.\n\nEarly symptoms of chronic toxicity are sparsely distributed, coarse hair; alopecia of the eyebrows; dry, rough skin; dry eyes; and cracked lips. Later, severe headache, pseudotumor cerebri, and generalized weakness develop. Cortical hyperostosis of bone and arthralgia may occur, especially in children. Fractures may occur easily, especially in the elderly. In children, toxicity can cause pruritus, anorexia, and failure to thrive. Hepatomegaly and splenomegaly may occur.\n\nIn carotenodermia, the skin (but not the sclera) becomes deep yellow, especially on the palms and soles.",
                    "md": "Although symptoms may vary, headache and rash usually develop during acute or chronic toxicity. Acute toxicity causes increased intracranial pressure. Drowsiness, irritability, abdominal pain, nausea, and vomiting are common. Sometimes the skin subsequently peels.\n\nEarly symptoms of chronic toxicity are sparsely distributed, coarse hair; alopecia of the eyebrows; dry, rough skin; dry eyes; and cracked lips. Later, severe headache, pseudotumor cerebri, and generalized weakness develop. Cortical hyperostosis of bone and arthralgia may occur, especially in children. Fractures may occur easily, especially in the elderly. In children, toxicity can cause pruritus, anorexia, and failure to thrive. Hepatomegaly and splenomegaly may occur.\n\nIn carotenodermia, the skin (but not the sclera) becomes deep yellow, especially on the palms and soles.",
                    "bBox": {
                        "x": 55,
                        "y": 530.9,
                        "w": 479,
                        "h": 139
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 682.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Clinical evaluation\n\nDiagnosis is clinical. Blood vitamin levels correlate poorly with toxicity. However, if clinical diagnosis is equivocal, laboratory testing may help. In vitamin A toxicity, fasting serum retinol levels may increase from normal (28 to 86 \u03bcg/dL [1 to 3 \u03bcmol/L]) to &amp;gt; 100 \u03bcg/dL (&amp;gt; 3.49 \u03bcmol/L), sometimes to &amp;gt; 2000 \u03bcg/dL (&amp;gt; 69.8 \u03bcmol/L). Hypercalcemia is common.",
                    "md": "- Clinical evaluation\n\nDiagnosis is clinical. Blood vitamin levels correlate poorly with toxicity. However, if clinical diagnosis is equivocal, laboratory testing may help. In vitamin A toxicity, fasting serum retinol levels may increase from normal (28 to 86 \u03bcg/dL [1 to 3 \u03bcmol/L]) to &amp;gt; 100 \u03bcg/dL (&amp;gt; 3.49 \u03bcmol/L), sometimes to &amp;gt; 2000 \u03bcg/dL (&amp;gt; 69.8 \u03bcmol/L). Hypercalcemia is common.",
                    "bBox": {
                        "x": 55,
                        "y": 162.9,
                        "w": 479,
                        "h": 621
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.997
        },
        {
            "page": 33,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n Differentiating vitamin A toxicity from other disorders may be difficult. Carotenodermia may also occur in\n severe hypothyroidism and anorexia nervosa, possibly because carotene is converted to vitamin A more\n slowly.\n Prognosis\n Complete recovery usually occurs if vitamin A ingestion stops. Symptoms and signs of chronic toxicity\n usually disappear within 1 to 4 wk. However, birth defects in the fetus of a mother who has taken\n megadoses of vitamin A are not reversible.\n Treatment\n Vitamin A is stopped.\n Vitamin B6\n Vitamin B6 includes a group of closely related compounds: pyridoxine, pyridoxal, and pyridoxamine. They\n are metabolized in the body to pyridoxal phosphate, which acts as a coenzyme in many important\n reactions in blood, CNS, and skin metabolism. Vitamin B6 is important in heme and nucleic acid\n biosynthesis and in lipid, carbohydrate, and amino acid metabolism.\n Vitamin B6 Deficiency and Dependency\n Because vitamin B6 is present in most foods, dietary deficiency is rare. Secondary deficiency\n may result from various conditions. Symptoms can include peripheral neuropathy, a pellagra-\n like syndrome, anemia, and seizures, which, particularly in infants, may not resolve when\n treated with anticonvulsants. Impaired metabolism (dependency) is rare; it causes various\n symptoms, including seizures, intellectual disability, and anemia. Diagnosis is usually clinical;\n no laboratory test readily assesses vitamin B6 status. Treatment consists of giving oral vitamin\n B6 and, when possible, treating the cause.\n Dietary deficiency, though rare, can develop because extensive processing can deplete foods of vitamin\n B6. Secondary deficiency most often results from protein-energy undernutrition, malabsorption,\n alcoholism, use of pyridoxine-inactivating drugs (eg, anticonvulsants, isoniazid, cycloserine, hydralazine,\n corticosteroids, penicillamine), or excessive loss. Rarely, it results from increased metabolic demand (eg,\n in hyperthyroidism).\n Rare inborn errors of metabolism can affect pyridoxine metabolism.\n The role of vitamin B6 deficiency in increasing plasma homocysteine levels and in contributing to vascular\n disorders is under study.\n Symptoms and Signs\n Deficiency causes a pellagra-like syndrome, with seborrheic dermatitis, glossitis, and cheilosis, and, in\n adults, can cause depression, confusion, EEG abnormalities, and seizures. Rarely, deficiency or\n dependency causes seizures in infants. Seizures, particularly in infants, may be refractory to treatment\n with anticonvulsants. Normocytic, microcytic, or sideroblastic anemia can also develop.\n Diagnosis\n \u2022 Clinical evaluation\n Vitamin B6 deficiency should be considered in any infant who has seizures, any patient who has seizures\n refractory to treatment with anticonvulsants, and any patient with deficiencies of other B vitamins,\n                                                                                                    85",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\n# Vitamin A Toxicity\n\nDifferentiating vitamin A toxicity from other disorders may be difficult. Carotenodermia may also occur in severe hypothyroidism and anorexia nervosa, possibly because carotene is converted to vitamin A more slowly.\n\n# Prognosis\n\nComplete recovery usually occurs if vitamin A ingestion stops. Symptoms and signs of chronic toxicity usually disappear within 1 to 4 weeks. However, birth defects in the fetus of a mother who has taken megadoses of vitamin A are not reversible.\n\n# Treatment\n\nVitamin A is stopped.\n\n# Vitamin B6\n\nVitamin B6 includes a group of closely related compounds: pyridoxine, pyridoxal, and pyridoxamine. They are metabolized in the body to pyridoxal phosphate, which acts as a coenzyme in many important reactions in blood, CNS, and skin metabolism. Vitamin B6 is important in heme and nucleic acid biosynthesis and in lipid, carbohydrate, and amino acid metabolism.\n\n# Vitamin B6 Deficiency and Dependency\n\nBecause vitamin B6 is present in most foods, dietary deficiency is rare. Secondary deficiency may result from various conditions. Symptoms can include peripheral neuropathy, a pellagra-like syndrome, anemia, and seizures, which, particularly in infants, may not resolve when treated with anticonvulsants. Impaired metabolism (dependency) is rare; it causes various symptoms, including seizures, intellectual disability, and anemia. Diagnosis is usually clinical; no laboratory test readily assesses vitamin B6 status. Treatment consists of giving oral vitamin B6 and, when possible, treating the cause.\n\nDietary deficiency, though rare, can develop because extensive processing can deplete foods of vitamin B6. Secondary deficiency most often results from protein-energy undernutrition, malabsorption, alcoholism, use of pyridoxine-inactivating drugs (e.g., anticonvulsants, isoniazid, cycloserine, hydralazine, corticosteroids, penicillamine), or excessive loss. Rarely, it results from increased metabolic demand (e.g., in hyperthyroidism).\n\nRare inborn errors of metabolism can affect pyridoxine metabolism. The role of vitamin B6 deficiency in increasing plasma homocysteine levels and in contributing to vascular disorders is under study.\n\n# Symptoms and Signs\n\nDeficiency causes a pellagra-like syndrome, with seborrheic dermatitis, glossitis, and cheilosis, and, in adults, can cause depression, confusion, EEG abnormalities, and seizures. Rarely, deficiency or dependency causes seizures in infants. Seizures, particularly in infants, may be refractory to treatment with anticonvulsants. Normocytic, microcytic, or sideroblastic anemia can also develop.\n\n# Diagnosis\n\n- Clinical evaluation\n\nVitamin B6 deficiency should be considered in any infant who has seizures, any patient who has seizures refractory to treatment with anticonvulsants, and any patient with deficiencies of other B vitamins.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 703.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin A Toxicity",
                    "md": "# Vitamin A Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Differentiating vitamin A toxicity from other disorders may be difficult. Carotenodermia may also occur in severe hypothyroidism and anorexia nervosa, possibly because carotene is converted to vitamin A more slowly.",
                    "md": "Differentiating vitamin A toxicity from other disorders may be difficult. Carotenodermia may also occur in severe hypothyroidism and anorexia nervosa, possibly because carotene is converted to vitamin A more slowly.",
                    "bBox": {
                        "x": 55,
                        "y": 61.9,
                        "w": 473,
                        "h": 37
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Prognosis",
                    "md": "# Prognosis",
                    "bBox": {
                        "x": 55,
                        "y": 112.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Complete recovery usually occurs if vitamin A ingestion stops. Symptoms and signs of chronic toxicity usually disappear within 1 to 4 weeks. However, birth defects in the fetus of a mother who has taken megadoses of vitamin A are not reversible.",
                    "md": "Complete recovery usually occurs if vitamin A ingestion stops. Symptoms and signs of chronic toxicity usually disappear within 1 to 4 weeks. However, birth defects in the fetus of a mother who has taken megadoses of vitamin A are not reversible.",
                    "bBox": {
                        "x": 55,
                        "y": 137.9,
                        "w": 461,
                        "h": 489
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 188.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin A is stopped.",
                    "md": "Vitamin A is stopped.",
                    "bBox": {
                        "x": 55,
                        "y": 213.9,
                        "w": 95,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin B6",
                    "md": "# Vitamin B6",
                    "bBox": {
                        "x": 55,
                        "y": 238.9,
                        "w": 55,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin B6 includes a group of closely related compounds: pyridoxine, pyridoxal, and pyridoxamine. They are metabolized in the body to pyridoxal phosphate, which acts as a coenzyme in many important reactions in blood, CNS, and skin metabolism. Vitamin B6 is important in heme and nucleic acid biosynthesis and in lipid, carbohydrate, and amino acid metabolism.",
                    "md": "Vitamin B6 includes a group of closely related compounds: pyridoxine, pyridoxal, and pyridoxamine. They are metabolized in the body to pyridoxal phosphate, which acts as a coenzyme in many important reactions in blood, CNS, and skin metabolism. Vitamin B6 is important in heme and nucleic acid biosynthesis and in lipid, carbohydrate, and amino acid metabolism.",
                    "bBox": {
                        "x": 55,
                        "y": 238.9,
                        "w": 480,
                        "h": 83
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin B6 Deficiency and Dependency",
                    "md": "# Vitamin B6 Deficiency and Dependency",
                    "bBox": {
                        "x": 55,
                        "y": 238.9,
                        "w": 199,
                        "h": 108
                    }
                },
                {
                    "type": "text",
                    "value": "Because vitamin B6 is present in most foods, dietary deficiency is rare. Secondary deficiency may result from various conditions. Symptoms can include peripheral neuropathy, a pellagra-like syndrome, anemia, and seizures, which, particularly in infants, may not resolve when treated with anticonvulsants. Impaired metabolism (dependency) is rare; it causes various symptoms, including seizures, intellectual disability, and anemia. Diagnosis is usually clinical; no laboratory test readily assesses vitamin B6 status. Treatment consists of giving oral vitamin B6 and, when possible, treating the cause.\n\nDietary deficiency, though rare, can develop because extensive processing can deplete foods of vitamin B6. Secondary deficiency most often results from protein-energy undernutrition, malabsorption, alcoholism, use of pyridoxine-inactivating drugs (e.g., anticonvulsants, isoniazid, cycloserine, hydralazine, corticosteroids, penicillamine), or excessive loss. Rarely, it results from increased metabolic demand (e.g., in hyperthyroidism).\n\nRare inborn errors of metabolism can affect pyridoxine metabolism. The role of vitamin B6 deficiency in increasing plasma homocysteine levels and in contributing to vascular disorders is under study.",
                    "md": "Because vitamin B6 is present in most foods, dietary deficiency is rare. Secondary deficiency may result from various conditions. Symptoms can include peripheral neuropathy, a pellagra-like syndrome, anemia, and seizures, which, particularly in infants, may not resolve when treated with anticonvulsants. Impaired metabolism (dependency) is rare; it causes various symptoms, including seizures, intellectual disability, and anemia. Diagnosis is usually clinical; no laboratory test readily assesses vitamin B6 status. Treatment consists of giving oral vitamin B6 and, when possible, treating the cause.\n\nDietary deficiency, though rare, can develop because extensive processing can deplete foods of vitamin B6. Secondary deficiency most often results from protein-energy undernutrition, malabsorption, alcoholism, use of pyridoxine-inactivating drugs (e.g., anticonvulsants, isoniazid, cycloserine, hydralazine, corticosteroids, penicillamine), or excessive loss. Rarely, it results from increased metabolic demand (e.g., in hyperthyroidism).\n\nRare inborn errors of metabolism can affect pyridoxine metabolism. The role of vitamin B6 deficiency in increasing plasma homocysteine levels and in contributing to vascular disorders is under study.",
                    "bBox": {
                        "x": 55,
                        "y": 188.9,
                        "w": 483,
                        "h": 527
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 614.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Deficiency causes a pellagra-like syndrome, with seborrheic dermatitis, glossitis, and cheilosis, and, in adults, can cause depression, confusion, EEG abnormalities, and seizures. Rarely, deficiency or dependency causes seizures in infants. Seizures, particularly in infants, may be refractory to treatment with anticonvulsants. Normocytic, microcytic, or sideroblastic anemia can also develop.",
                    "md": "Deficiency causes a pellagra-like syndrome, with seborrheic dermatitis, glossitis, and cheilosis, and, in adults, can cause depression, confusion, EEG abnormalities, and seizures. Rarely, deficiency or dependency causes seizures in infants. Seizures, particularly in infants, may be refractory to treatment with anticonvulsants. Normocytic, microcytic, or sideroblastic anemia can also develop.",
                    "bBox": {
                        "x": 55,
                        "y": 188.9,
                        "w": 467,
                        "h": 501
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 703.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Clinical evaluation\n\nVitamin B6 deficiency should be considered in any infant who has seizures, any patient who has seizures refractory to treatment with anticonvulsants, and any patient with deficiencies of other B vitamins.",
                    "md": "- Clinical evaluation\n\nVitamin B6 deficiency should be considered in any infant who has seizures, any patient who has seizures refractory to treatment with anticonvulsants, and any patient with deficiencies of other B vitamins.",
                    "bBox": {
                        "x": 55,
                        "y": 188.9,
                        "w": 480,
                        "h": 577
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.983
        },
        {
            "page": 34,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\nparticularly in patients with alcoholism or protein-energy undernutrition. Diagnosis is usually clinical.\nThere is no single accepted laboratory test of vitamin B6 status; measurement of serum pyridoxal\nphosphate is most common.\nTreatment\n\u2022 Pyridoxine\n\u2022 Elimination of risk factors when possible\nFor secondary deficiency, causes (eg, use of pyridoxine-inactivating drugs, malabsorption) should be\ncorrected if possible. Usually, pyridoxine 50 to 100 mg po once/day corrects the deficiency in adults. Most\npeople taking isoniazid should also be given pyridoxine 30 to 50 mg/day. For deficiency due to increased\nmetabolic demand, amounts larger than the daily recommended intake may be required. For most cases\nof inborn errors of metabolism, high doses of pyridoxine may be effective.\nVitamin B6 Toxicity\nThe ingestion of megadoses (&gt; 500 mg/day) of pyridoxine (eg, taken to treat carpal tunnel syndrome or\npremenstrual syndrome although efficacy is unproved) may cause peripheral neuropathy with deficits in a\nstocking-glove distribution, including progressive sensory ataxia and severe impairment of position and\nvibration senses. Senses of touch, temperature, and pain are less affected. Motor and central nervous\nsystems are usually intact.\nDiagnosis is clinical. Treatment is to stop taking vitamin B6. Recovery is slow and, for some patients,\nincomplete.\nVitamin B12\nCobalamin is a general term for compounds with biologic vitamin B12 activity. These compounds are\ninvolved in nucleic acid metabolism, methyl transfer, and myelin synthesis and repair. They are necessary\nfor the formation of normal RBCs.\nFood-bound vitamin B12 is released in the stomach's acid environment and is bound to R protein\n(haptocorrin). Pancreatic enzymes cleave this B12 complex (B12-R protein) in the small intestine. After\ncleavage, intrinsic factor, secreted by parietal cells in the gastric mucosa, binds with vitamin B12. Intrinsic\nfactor is required for absorption of vitamin B12, which takes place in the terminal ileum.\nVitamin B12 in plasma is bound to transcobalamins I and II. Transcobalamin II is responsible for delivering\nvitamin B12 to tissues. The liver stores large amounts of vitamin B12. Enterohepatic reabsorption helps\nretain vitamin B12. Liver vitamin B12 stores can normally sustain physiologic needs for 3 to 5 yr if B12\nintake stops (eg, in people who become vegans) and for months to 1 yr if enterohepatic reabsorption\ncapacity is absent.\nLarge amounts of vitamin B12 seem to be nontoxic but are not recommended for regular use (ie, as a\ngeneral tonic).\nVitamin B12 Deficiency\nDietary vitamin B12 deficiency usually results from inadequate absorption, but deficiency can\ndevelop in vegans who do not take vitamin supplements. Deficiency causes megaloblastic\nanemia, damage to the white matter of the spinal cord and brain, and peripheral neuropathy.\nDiagnosis is usually made by measuring serum vitamin B12 levels. The Schilling test helps\ndetermine etiology. Treatment consists of oral or parenteral vitamin B12. Folate (folic acid)\nshould not be used instead of vitamin B12 because folate may alleviate the anemia but allow\n                                                                                                   86",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nparticularly in patients with alcoholism or protein-energy undernutrition. Diagnosis is usually clinical.\n\nThere is no single accepted laboratory test of vitamin B6 status; measurement of serum pyridoxal phosphate is most common.\n\n# Treatment\n\n- Pyridoxine\n- Elimination of risk factors when possible\n\nFor secondary deficiency, causes (eg, use of pyridoxine-inactivating drugs, malabsorption) should be corrected if possible. Usually, pyridoxine 50 to 100 mg po once/day corrects the deficiency in adults. Most people taking isoniazid should also be given pyridoxine 30 to 50 mg/day. For deficiency due to increased metabolic demand, amounts larger than the daily recommended intake may be required. For most cases of inborn errors of metabolism, high doses of pyridoxine may be effective.\n\n# Vitamin B6 Toxicity\n\nThe ingestion of megadoses (&amp;gt; 500 mg/day) of pyridoxine (eg, taken to treat carpal tunnel syndrome or premenstrual syndrome although efficacy is unproved) may cause peripheral neuropathy with deficits in a stocking-glove distribution, including progressive sensory ataxia and severe impairment of position and vibration senses. Senses of touch, temperature, and pain are less affected. Motor and central nervous systems are usually intact.\n\nDiagnosis is clinical. Treatment is to stop taking vitamin B6. Recovery is slow and, for some patients, incomplete.\n\n# Vitamin B12\n\nCobalamin is a general term for compounds with biologic vitamin B12 activity. These compounds are involved in nucleic acid metabolism, methyl transfer, and myelin synthesis and repair. They are necessary for the formation of normal RBCs.\n\nFood-bound vitamin B12 is released in the stomach's acid environment and is bound to R protein (haptocorrin). Pancreatic enzymes cleave this B12 complex (B12-R protein) in the small intestine. After cleavage, intrinsic factor, secreted by parietal cells in the gastric mucosa, binds with vitamin B12. Intrinsic factor is required for absorption of vitamin B12, which takes place in the terminal ileum.\n\nVitamin B12 in plasma is bound to transcobalamins I and II. Transcobalamin II is responsible for delivering vitamin B12 to tissues. The liver stores large amounts of vitamin B12. Enterohepatic reabsorption helps retain vitamin B12. Liver vitamin B12 stores can normally sustain physiologic needs for 3 to 5 yr if B12 intake stops (eg, in people who become vegans) and for months to 1 yr if enterohepatic reabsorption capacity is absent.\n\nLarge amounts of vitamin B12 seem to be nontoxic but are not recommended for regular use (ie, as a general tonic).\n\n# Vitamin B12 Deficiency\n\nDietary vitamin B12 deficiency usually results from inadequate absorption, but deficiency can develop in vegans who do not take vitamin supplements. Deficiency causes megaloblastic anemia, damage to the white matter of the spinal cord and brain, and peripheral neuropathy.\n\nDiagnosis is usually made by measuring serum vitamin B12 levels. The Schilling test helps determine etiology. Treatment consists of oral or parenteral vitamin B12. Folate (folic acid) should not be used instead of vitamin B12 because folate may alleviate the anemia but allow",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "particularly in patients with alcoholism or protein-energy undernutrition. Diagnosis is usually clinical.\n\nThere is no single accepted laboratory test of vitamin B6 status; measurement of serum pyridoxal phosphate is most common.",
                    "md": "particularly in patients with alcoholism or protein-energy undernutrition. Diagnosis is usually clinical.\n\nThere is no single accepted laboratory test of vitamin B6 status; measurement of serum pyridoxal phosphate is most common.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 455,
                        "h": 40
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 101.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Pyridoxine\n- Elimination of risk factors when possible\n\nFor secondary deficiency, causes (eg, use of pyridoxine-inactivating drugs, malabsorption) should be corrected if possible. Usually, pyridoxine 50 to 100 mg po once/day corrects the deficiency in adults. Most people taking isoniazid should also be given pyridoxine 30 to 50 mg/day. For deficiency due to increased metabolic demand, amounts larger than the daily recommended intake may be required. For most cases of inborn errors of metabolism, high doses of pyridoxine may be effective.",
                    "md": "- Pyridoxine\n- Elimination of risk factors when possible\n\nFor secondary deficiency, causes (eg, use of pyridoxine-inactivating drugs, malabsorption) should be corrected if possible. Usually, pyridoxine 50 to 100 mg po once/day corrects the deficiency in adults. Most people taking isoniazid should also be given pyridoxine 30 to 50 mg/day. For deficiency due to increased metabolic demand, amounts larger than the daily recommended intake may be required. For most cases of inborn errors of metabolism, high doses of pyridoxine may be effective.",
                    "bBox": {
                        "x": 55,
                        "y": 177.9,
                        "w": 481,
                        "h": 63
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin B6 Toxicity",
                    "md": "# Vitamin B6 Toxicity",
                    "bBox": {
                        "x": 55,
                        "y": 253.9,
                        "w": 97,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "The ingestion of megadoses (&amp;gt; 500 mg/day) of pyridoxine (eg, taken to treat carpal tunnel syndrome or premenstrual syndrome although efficacy is unproved) may cause peripheral neuropathy with deficits in a stocking-glove distribution, including progressive sensory ataxia and severe impairment of position and vibration senses. Senses of touch, temperature, and pain are less affected. Motor and central nervous systems are usually intact.\n\nDiagnosis is clinical. Treatment is to stop taking vitamin B6. Recovery is slow and, for some patients, incomplete.",
                    "md": "The ingestion of megadoses (&amp;gt; 500 mg/day) of pyridoxine (eg, taken to treat carpal tunnel syndrome or premenstrual syndrome although efficacy is unproved) may cause peripheral neuropathy with deficits in a stocking-glove distribution, including progressive sensory ataxia and severe impairment of position and vibration senses. Senses of touch, temperature, and pain are less affected. Motor and central nervous systems are usually intact.\n\nDiagnosis is clinical. Treatment is to stop taking vitamin B6. Recovery is slow and, for some patients, incomplete.",
                    "bBox": {
                        "x": 55,
                        "y": 101.9,
                        "w": 481,
                        "h": 283
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin B12",
                    "md": "# Vitamin B12",
                    "bBox": {
                        "x": 55,
                        "y": 397.9,
                        "w": 61,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Cobalamin is a general term for compounds with biologic vitamin B12 activity. These compounds are involved in nucleic acid metabolism, methyl transfer, and myelin synthesis and repair. They are necessary for the formation of normal RBCs.\n\nFood-bound vitamin B12 is released in the stomach's acid environment and is bound to R protein (haptocorrin). Pancreatic enzymes cleave this B12 complex (B12-R protein) in the small intestine. After cleavage, intrinsic factor, secreted by parietal cells in the gastric mucosa, binds with vitamin B12. Intrinsic factor is required for absorption of vitamin B12, which takes place in the terminal ileum.\n\nVitamin B12 in plasma is bound to transcobalamins I and II. Transcobalamin II is responsible for delivering vitamin B12 to tissues. The liver stores large amounts of vitamin B12. Enterohepatic reabsorption helps retain vitamin B12. Liver vitamin B12 stores can normally sustain physiologic needs for 3 to 5 yr if B12 intake stops (eg, in people who become vegans) and for months to 1 yr if enterohepatic reabsorption capacity is absent.\n\nLarge amounts of vitamin B12 seem to be nontoxic but are not recommended for regular use (ie, as a general tonic).",
                    "md": "Cobalamin is a general term for compounds with biologic vitamin B12 activity. These compounds are involved in nucleic acid metabolism, methyl transfer, and myelin synthesis and repair. They are necessary for the formation of normal RBCs.\n\nFood-bound vitamin B12 is released in the stomach's acid environment and is bound to R protein (haptocorrin). Pancreatic enzymes cleave this B12 complex (B12-R protein) in the small intestine. After cleavage, intrinsic factor, secreted by parietal cells in the gastric mucosa, binds with vitamin B12. Intrinsic factor is required for absorption of vitamin B12, which takes place in the terminal ileum.\n\nVitamin B12 in plasma is bound to transcobalamins I and II. Transcobalamin II is responsible for delivering vitamin B12 to tissues. The liver stores large amounts of vitamin B12. Enterohepatic reabsorption helps retain vitamin B12. Liver vitamin B12 stores can normally sustain physiologic needs for 3 to 5 yr if B12 intake stops (eg, in people who become vegans) and for months to 1 yr if enterohepatic reabsorption capacity is absent.\n\nLarge amounts of vitamin B12 seem to be nontoxic but are not recommended for regular use (ie, as a general tonic).",
                    "bBox": {
                        "x": 55,
                        "y": 397.9,
                        "w": 482,
                        "h": 264
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin B12 Deficiency",
                    "md": "# Vitamin B12 Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 397.9,
                        "w": 117,
                        "h": 289
                    }
                },
                {
                    "type": "text",
                    "value": "Dietary vitamin B12 deficiency usually results from inadequate absorption, but deficiency can develop in vegans who do not take vitamin supplements. Deficiency causes megaloblastic anemia, damage to the white matter of the spinal cord and brain, and peripheral neuropathy.\n\nDiagnosis is usually made by measuring serum vitamin B12 levels. The Schilling test helps determine etiology. Treatment consists of oral or parenteral vitamin B12. Folate (folic acid) should not be used instead of vitamin B12 because folate may alleviate the anemia but allow",
                    "md": "Dietary vitamin B12 deficiency usually results from inadequate absorption, but deficiency can develop in vegans who do not take vitamin supplements. Deficiency causes megaloblastic anemia, damage to the white matter of the spinal cord and brain, and peripheral neuropathy.\n\nDiagnosis is usually made by measuring serum vitamin B12 levels. The Schilling test helps determine etiology. Treatment consists of oral or parenteral vitamin B12. Folate (folic acid) should not be used instead of vitamin B12 because folate may alleviate the anemia but allow",
                    "bBox": {
                        "x": 55,
                        "y": 101.9,
                        "w": 471,
                        "h": 683
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 35,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n neurologic deficits to progress.\n Etiology\n Inadequate vitamin B12 intake is possible in vegans but is otherwise unlikely. Breastfed babies of vegan\n mothers may develop vitamin B12 deficiency by age 4 to 6 mo because their\n [\n Table 4-5. Causes of Vitamin B12 Deficiency]\n liver stores (which are normally extensive) are limited and their rapid growth rate results in high demand.\n Vitamin B12 deficiency usually results from inadequate absorption (see Table 4-5 and p. 153), which, in\n the elderly, most commonly results from decreased acid secretion. In such cases, crystalline vitamin B12\n (such as that available in vitamin supplements) can be absorbed, but food-bound vitamin B12 is not\n liberated and absorbed normally. Inadequate absorption may occur in blind loop syndrome (with\n overgrowth of bacteria) or fish tapeworm infestation; in these cases, bacteria or parasites use ingested\n vitamin B12 so that less is available for absorption. Vitamin B12 absorption may be inadequate if ileal\n absorptive sites are destroyed by inflammatory bowel disease or are surgically removed. Less common\n causes of inadequate vitamin B12 absorption include chronic pancreatitis, gastric surgery, malabsorption\n syndromes, AIDS, use of certain drugs (eg, antacids, metformin), repeated exposure to nitrous oxide, and\n a genetic disorder causing malabsorption in the ileum (Imerslund-Graesbeck syndrome).\n Pernicious anemia is often used synonymously with vitamin B12 deficiency. However, pernicious\n anemia specifically refers to anemia resulting from vitamin B12 deficiency caused by an autoimmune\n metaplastic atrophic gastritis with loss of intrinsic factor (see p. 133). Patients with classic pernicious\n anemia, most commonly younger adults, are at increased risk of stomach and other GI cancers.\n Subacute combined degeneration refers to degenerative changes in the nervous system due to\n vitamin B12 deficiency; they affect mostly brain and spinal cord white matter. Demyelinating or axonal\n peripheral neuropathies can occur.\n Symptoms and Signs\n Anemia usually develops insidiously. It is often more severe than its symptoms indicate because its slow\n evolution allows physiologic adaptation. Occasionally, splenomegaly and hepatomegaly occur. Various GI\n symptoms, including weight loss and poorly localized abdominal pain, may occur. Glossitis, usually\n described as burning of the tongue, is uncommon.\n Neurologic symptoms develop independently from and often without hematologic abnormalities. In early\n stages, decreased position and vibratory sensation in the extremities is accompanied by mild to moderate\n weakness and hyporeflexia. In later stages, spasticity, extensor plantar responses, greater loss of position\n and vibratory sensation in the lower extremities, and ataxia emerge. These deficits may develop in a\n stocking-glove distribution. Tactile, pain, and temperature sensations are usually spared but may be\n difficult to assess in the elderly.\n Some patients are also irritable and mildly depressed. Paranoia (megaloblastic madness), delirium,\n confusion, spastic ataxia, and, at times, postural hypotension may occur in advanced cases. The\n confusion may be difficult to differentiate from age-related dementias, such as Alzheimer's disease.\n Diagnosis\n \u2022 CBC and vitamin B12 and folate levels\n \u2022 Sometimes methylmalonic acid levels or Schilling test\n                                                                                                      87",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\n# Etiology\n\nInadequate vitamin B12 intake is possible in vegans but is otherwise unlikely. Breastfed babies of vegan mothers may develop vitamin B12 deficiency by age 4 to 6 mo because their liver stores (which are normally extensive) are limited and their rapid growth rate results in high demand.\n\n| Inadequate absorption              | Decreased acid secretion (elderly)              |\n| ---------------------------------- | ----------------------------------------------- |\n| Blind loop syndrome                | Fish tapeworm infestation                       |\n| Inflammatory bowel disease         | Surgical removal of ileal absorptive sites      |\n| Chronic pancreatitis               | Gastric surgery                                 |\n| Malabsorption syndromes            | AIDS                                            |\n| Use of certain drugs               | (e.g., antacids, metformin)                     |\n| Repeated exposure to nitrous oxide | Genetic disorder (Imerslund-Graesbeck syndrome) |\n\nPernicious anemia is often used synonymously with vitamin B12 deficiency. However, pernicious anemia specifically refers to anemia resulting from vitamin B12 deficiency caused by an autoimmune metaplastic atrophic gastritis with loss of intrinsic factor. Patients with classic pernicious anemia, most commonly younger adults, are at increased risk of stomach and other GI cancers.\n\nSubacute combined degeneration refers to degenerative changes in the nervous system due to vitamin B12 deficiency; they affect mostly brain and spinal cord white matter. Demyelinating or axonal peripheral neuropathies can occur.\n\n# Symptoms and Signs\n\nAnemia usually develops insidiously. It is often more severe than its symptoms indicate because its slow evolution allows physiologic adaptation. Occasionally, splenomegaly and hepatomegaly occur. Various GI symptoms, including weight loss and poorly localized abdominal pain, may occur. Glossitis, usually described as burning of the tongue, is uncommon.\n\nNeurologic symptoms develop independently from and often without hematologic abnormalities. In early stages, decreased position and vibratory sensation in the extremities is accompanied by mild to moderate weakness and hyporeflexia. In later stages, spasticity, extensor plantar responses, greater loss of position and vibratory sensation in the lower extremities, and ataxia emerge. These deficits may develop in a stocking-glove distribution. Tactile, pain, and temperature sensations are usually spared but may be difficult to assess in the elderly.\n\nSome patients are also irritable and mildly depressed. Paranoia (megaloblastic madness), delirium, confusion, spastic ataxia, and, at times, postural hypotension may occur in advanced cases. The confusion may be difficult to differentiate from age-related dementias, such as Alzheimer's disease.\n\n# Diagnosis\n\n- CBC and vitamin B12 and folate levels\n- Sometimes methylmalonic acid levels or Schilling test",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 707.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Etiology",
                    "md": "# Etiology",
                    "bBox": {
                        "x": 55,
                        "y": 74.9,
                        "w": 41,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Inadequate vitamin B12 intake is possible in vegans but is otherwise unlikely. Breastfed babies of vegan mothers may develop vitamin B12 deficiency by age 4 to 6 mo because their liver stores (which are normally extensive) are limited and their rapid growth rate results in high demand.",
                    "md": "Inadequate vitamin B12 intake is possible in vegans but is otherwise unlikely. Breastfed babies of vegan mothers may develop vitamin B12 deficiency by age 4 to 6 mo because their liver stores (which are normally extensive) are limited and their rapid growth rate results in high demand.",
                    "bBox": {
                        "x": 55,
                        "y": 99.9,
                        "w": 475,
                        "h": 95
                    }
                },
                {
                    "type": "table",
                    "rows": [
                        [
                            "Inadequate absorption",
                            "Decreased acid secretion (elderly)"
                        ],
                        [
                            "Blind loop syndrome",
                            "Fish tapeworm infestation"
                        ],
                        [
                            "Inflammatory bowel disease",
                            "Surgical removal of ileal absorptive sites"
                        ],
                        [
                            "Chronic pancreatitis",
                            "Gastric surgery"
                        ],
                        [
                            "Malabsorption syndromes",
                            "AIDS"
                        ],
                        [
                            "Use of certain drugs",
                            "(e.g., antacids, metformin)"
                        ],
                        [
                            "Repeated exposure to nitrous oxide",
                            "Genetic disorder (Imerslund-Graesbeck syndrome)"
                        ]
                    ],
                    "md": "| Inadequate absorption              | Decreased acid secretion (elderly)              |\n| ---------------------------------- | ----------------------------------------------- |\n| Blind loop syndrome                | Fish tapeworm infestation                       |\n| Inflammatory bowel disease         | Surgical removal of ileal absorptive sites      |\n| Chronic pancreatitis               | Gastric surgery                                 |\n| Malabsorption syndromes            | AIDS                                            |\n| Use of certain drugs               | (e.g., antacids, metformin)                     |\n| Repeated exposure to nitrous oxide | Genetic disorder (Imerslund-Graesbeck syndrome) |",
                    "isPerfectTable": true,
                    "csv": "\"Inadequate absorption\",\"Decreased acid secretion (elderly)\"\n\"Blind loop syndrome\",\"Fish tapeworm infestation\"\n\"Inflammatory bowel disease\",\"Surgical removal of ileal absorptive sites\"\n\"Chronic pancreatitis\",\"Gastric surgery\"\n\"Malabsorption syndromes\",\"AIDS\"\n\"Use of certain drugs\",\"(e.g., antacids, metformin)\"\n\"Repeated exposure to nitrous oxide\",\"Genetic disorder (Imerslund-Graesbeck syndrome)\"",
                    "bBox": {
                        "x": 55,
                        "y": 207.9,
                        "w": 479,
                        "h": 125
                    }
                },
                {
                    "type": "text",
                    "value": "Pernicious anemia is often used synonymously with vitamin B12 deficiency. However, pernicious anemia specifically refers to anemia resulting from vitamin B12 deficiency caused by an autoimmune metaplastic atrophic gastritis with loss of intrinsic factor. Patients with classic pernicious anemia, most commonly younger adults, are at increased risk of stomach and other GI cancers.\n\nSubacute combined degeneration refers to degenerative changes in the nervous system due to vitamin B12 deficiency; they affect mostly brain and spinal cord white matter. Demyelinating or axonal peripheral neuropathies can occur.",
                    "md": "Pernicious anemia is often used synonymously with vitamin B12 deficiency. However, pernicious anemia specifically refers to anemia resulting from vitamin B12 deficiency caused by an autoimmune metaplastic atrophic gastritis with loss of intrinsic factor. Patients with classic pernicious anemia, most commonly younger adults, are at increased risk of stomach and other GI cancers.\n\nSubacute combined degeneration refers to degenerative changes in the nervous system due to vitamin B12 deficiency; they affect mostly brain and spinal cord white matter. Demyelinating or axonal peripheral neuropathies can occur.",
                    "bBox": {
                        "x": 55,
                        "y": 358.9,
                        "w": 462,
                        "h": 108
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 479.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Anemia usually develops insidiously. It is often more severe than its symptoms indicate because its slow evolution allows physiologic adaptation. Occasionally, splenomegaly and hepatomegaly occur. Various GI symptoms, including weight loss and poorly localized abdominal pain, may occur. Glossitis, usually described as burning of the tongue, is uncommon.\n\nNeurologic symptoms develop independently from and often without hematologic abnormalities. In early stages, decreased position and vibratory sensation in the extremities is accompanied by mild to moderate weakness and hyporeflexia. In later stages, spasticity, extensor plantar responses, greater loss of position and vibratory sensation in the lower extremities, and ataxia emerge. These deficits may develop in a stocking-glove distribution. Tactile, pain, and temperature sensations are usually spared but may be difficult to assess in the elderly.\n\nSome patients are also irritable and mildly depressed. Paranoia (megaloblastic madness), delirium, confusion, spastic ataxia, and, at times, postural hypotension may occur in advanced cases. The confusion may be difficult to differentiate from age-related dementias, such as Alzheimer's disease.",
                    "md": "Anemia usually develops insidiously. It is often more severe than its symptoms indicate because its slow evolution allows physiologic adaptation. Occasionally, splenomegaly and hepatomegaly occur. Various GI symptoms, including weight loss and poorly localized abdominal pain, may occur. Glossitis, usually described as burning of the tongue, is uncommon.\n\nNeurologic symptoms develop independently from and often without hematologic abnormalities. In early stages, decreased position and vibratory sensation in the extremities is accompanied by mild to moderate weakness and hyporeflexia. In later stages, spasticity, extensor plantar responses, greater loss of position and vibratory sensation in the lower extremities, and ataxia emerge. These deficits may develop in a stocking-glove distribution. Tactile, pain, and temperature sensations are usually spared but may be difficult to assess in the elderly.\n\nSome patients are also irritable and mildly depressed. Paranoia (megaloblastic madness), delirium, confusion, spastic ataxia, and, at times, postural hypotension may occur in advanced cases. The confusion may be difficult to differentiate from age-related dementias, such as Alzheimer's disease.",
                    "bBox": {
                        "x": 55,
                        "y": 505.9,
                        "w": 482,
                        "h": 189
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 707.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- CBC and vitamin B12 and folate levels\n- Sometimes methylmalonic acid levels or Schilling test",
                    "md": "- CBC and vitamin B12 and folate levels\n- Sometimes methylmalonic acid levels or Schilling test",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.767
        },
        {
            "page": 36,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n Diagnosis is based on CBC and vitamin B12 and folate levels. It is important to remember that severe\n neurologic disease may occur without anemia or macrocytosis.\n CBC detects megaloblastic anemia. Tissue deficiency and macrocytic indexes may precede the\n development of anemia. A vitamin B12 level &lt; 200 pg/mL (&lt; 145 pmol/L) indicates vitamin B12 deficiency.\n The folate level is measured because vitamin B12 deficiency must be differentiated from folate deficiency\n as a cause of megaloblastic anemia; folate supplementation can mask vitamin B12 deficiency and may\n alleviate megaloblastic anemia but allow the neurologic deficits to progress or even accelerate.\n When clinical judgment suggests vitamin B12 deficiency but the vitamin B12 level is low-normal (200 to\n 350 pg/mL [145 to 260 pmol/L]) or hematologic indexes are normal, other tests can be done. Measuring\n serum methylmalonic acid (MMA) levels may be useful. An elevated MMA level supports vitamin B12\n deficiency but may be due to renal failure. MMA levels can also be used to monitor the response to\n treatment. MMA levels remain normal in folate deficiency; homocysteine levels may be elevated with\n either vitamin B12 or folate deficiency. Less commonly, holotranscobalamin II (transcobalamin II-B12\n complex) content is measured; when holotranscobalamin II is &lt; 40 pg/mL (&lt; 30 pmol/L), vitamin B12 is\n deficient.\n After deficiency is diagnosed, additional tests may be indicated for younger adults but usually not for the\n elderly. Unless dietary vitamin B12 is obviously inadequate, measurement of serum gastrin levels or\n autoantibodies to intrinsic factor may be done; sensitivity and specificity of these tests may be poor.\n Schilling test: The Schilling test is useful only if diagnosing intrinsic factor deficiency is important, as in\n classic pernicious anemia. This test is not necessary for most elderly patients. The Schilling test\n measures absorption of free radiolabeled vitamin B12. Radiolabeled vitamin B12 is given orally, followed\n in 1 to 6 h by 1000 \u03bcg (1 mg) of parenteral vitamin B12, which reduces uptake of radiolabeled vitamin\n B12 by the liver. Absorbed radiolabeled vitamin B12 is excreted in urine, which is collected for 24 h. The\n amount excreted is measured, and the percentage of total radiolabeled vitamin B12 is determined. If\n absorption is normal, \u2265 9% of the dose given appears in the urine. Reduced urinary excretion (&lt; 5% if\n kidney function is normal) indicates inadequate vitamin B12 absorption. Improved absorption with the\n subsequent addition of intrinsic factor to radiolabeled vitamin B12 confirms the diagnosis of pernicious\n anemia. The test is often difficult to do or interpret because of incomplete urine collection or renal\n insufficiency. In addition, because the Schilling test does not measure absorption of protein-bound vitamin\n B12, the test does not detect defective liberation of vitamin B12 from foods, which is common among the\n elderly. The Schilling test repletes vitamin B12 and can mask deficiency, so it should be done only after all\n other diagnostic tests and therapeutic trials.\n If malabsorption is identified, the Schilling test can be repeated after a 2-wk trial of an oral antibiotic. If\n antibiotic therapy corrects malabsorption, the likely cause is intestinal overgrowth of bacteria (eg, blind-\n loop syndrome).\n Treatment\n \u2022 Supplemental vitamin B12\n Vitamin B12 1000 to 2000 \u03bcg po can be given once/day to patients who do not have severe deficiency or\n neurologic symptoms or signs. A nasal gel preparation of vitamin B12 is available at a higher price. Large\n oral doses can be absorbed by mass action, even when intrinsic factor is absent. If the MMA level\n (sometimes used to monitor treatment) does not decrease, patients may not be taking vitamin B12. For\n more severe deficiency, vitamin B12 1 mg IM is usually given 1 to 4 times/wk for several weeks until\n hematologic abnormalities are corrected; then it is given once/mo.\n Although hematologic abnormalities are usually corrected within 6 wk (reticulocyte count should improve\n within 1 wk), resolution of neurologic symptoms may take much longer. Neurologic symptoms that persist\n                                                                                                       88",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nDiagnosis is based on CBC and vitamin B12 and folate levels. It is important to remember that severe neurologic disease may occur without anemia or macrocytosis.\n\nCBC detects megaloblastic anemia. Tissue deficiency and macrocytic indexes may precede the development of anemia. A vitamin B12 level &amp;lt; 200 pg/mL (&amp;lt; 145 pmol/L) indicates vitamin B12 deficiency.\n\nThe folate level is measured because vitamin B12 deficiency must be differentiated from folate deficiency as a cause of megaloblastic anemia; folate supplementation can mask vitamin B12 deficiency and may alleviate megaloblastic anemia but allow the neurologic deficits to progress or even accelerate.\n\nWhen clinical judgment suggests vitamin B12 deficiency but the vitamin B12 level is low-normal (200 to 350 pg/mL [145 to 260 pmol/L]) or hematologic indexes are normal, other tests can be done. Measuring serum methylmalonic acid (MMA) levels may be useful. An elevated MMA level supports vitamin B12 deficiency but may be due to renal failure. MMA levels can also be used to monitor the response to treatment. MMA levels remain normal in folate deficiency; homocysteine levels may be elevated with either vitamin B12 or folate deficiency. Less commonly, holotranscobalamin II (transcobalamin II-B12 complex) content is measured; when holotranscobalamin II is &amp;lt; 40 pg/mL (&amp;lt; 30 pmol/L), vitamin B12 is deficient.\n\nAfter deficiency is diagnosed, additional tests may be indicated for younger adults but usually not for the elderly. Unless dietary vitamin B12 is obviously inadequate, measurement of serum gastrin levels or autoantibodies to intrinsic factor may be done; sensitivity and specificity of these tests may be poor.\n\n# Schilling test:\n\nThe Schilling test is useful only if diagnosing intrinsic factor deficiency is important, as in classic pernicious anemia. This test is not necessary for most elderly patients. The Schilling test measures absorption of free radiolabeled vitamin B12. Radiolabeled vitamin B12 is given orally, followed in 1 to 6 h by 1000 \u03bcg (1 mg) of parenteral vitamin B12, which reduces uptake of radiolabeled vitamin B12 by the liver. Absorbed radiolabeled vitamin B12 is excreted in urine, which is collected for 24 h. The amount excreted is measured, and the percentage of total radiolabeled vitamin B12 is determined. If absorption is normal, \u2265 9% of the dose given appears in the urine. Reduced urinary excretion (&amp;lt; 5% if kidney function is normal) indicates inadequate vitamin B12 absorption. Improved absorption with the subsequent addition of intrinsic factor to radiolabeled vitamin B12 confirms the diagnosis of pernicious anemia. The test is often difficult to do or interpret because of incomplete urine collection or renal insufficiency. In addition, because the Schilling test does not measure absorption of protein-bound vitamin B12, the test does not detect defective liberation of vitamin B12 from foods, which is common among the elderly. The Schilling test repletes vitamin B12 and can mask deficiency, so it should be done only after all other diagnostic tests and therapeutic trials.\n\nIf malabsorption is identified, the Schilling test can be repeated after a 2-wk trial of an oral antibiotic. If antibiotic therapy corrects malabsorption, the likely cause is intestinal overgrowth of bacteria (eg, blind-loop syndrome).\n\n# Treatment\n\n- Supplemental vitamin B12\n\nVitamin B12 1000 to 2000 \u03bcg po can be given once/day to patients who do not have severe deficiency or neurologic symptoms or signs. A nasal gel preparation of vitamin B12 is available at a higher price. Large oral doses can be absorbed by mass action, even when intrinsic factor is absent. If the MMA level (sometimes used to monitor treatment) does not decrease, patients may not be taking vitamin B12. For more severe deficiency, vitamin B12 1 mg IM is usually given 1 to 4 times/wk for several weeks until hematologic abnormalities are corrected; then it is given once/mo.\n\nAlthough hematologic abnormalities are usually corrected within 6 wk (reticulocyte count should improve within 1 wk), resolution of neurologic symptoms may take much longer. Neurologic symptoms that persist",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Diagnosis is based on CBC and vitamin B12 and folate levels. It is important to remember that severe neurologic disease may occur without anemia or macrocytosis.\n\nCBC detects megaloblastic anemia. Tissue deficiency and macrocytic indexes may precede the development of anemia. A vitamin B12 level &amp;lt; 200 pg/mL (&amp;lt; 145 pmol/L) indicates vitamin B12 deficiency.\n\nThe folate level is measured because vitamin B12 deficiency must be differentiated from folate deficiency as a cause of megaloblastic anemia; folate supplementation can mask vitamin B12 deficiency and may alleviate megaloblastic anemia but allow the neurologic deficits to progress or even accelerate.\n\nWhen clinical judgment suggests vitamin B12 deficiency but the vitamin B12 level is low-normal (200 to 350 pg/mL [145 to 260 pmol/L]) or hematologic indexes are normal, other tests can be done. Measuring serum methylmalonic acid (MMA) levels may be useful. An elevated MMA level supports vitamin B12 deficiency but may be due to renal failure. MMA levels can also be used to monitor the response to treatment. MMA levels remain normal in folate deficiency; homocysteine levels may be elevated with either vitamin B12 or folate deficiency. Less commonly, holotranscobalamin II (transcobalamin II-B12 complex) content is measured; when holotranscobalamin II is &amp;lt; 40 pg/mL (&amp;lt; 30 pmol/L), vitamin B12 is deficient.\n\nAfter deficiency is diagnosed, additional tests may be indicated for younger adults but usually not for the elderly. Unless dietary vitamin B12 is obviously inadequate, measurement of serum gastrin levels or autoantibodies to intrinsic factor may be done; sensitivity and specificity of these tests may be poor.",
                    "md": "Diagnosis is based on CBC and vitamin B12 and folate levels. It is important to remember that severe neurologic disease may occur without anemia or macrocytosis.\n\nCBC detects megaloblastic anemia. Tissue deficiency and macrocytic indexes may precede the development of anemia. A vitamin B12 level &amp;lt; 200 pg/mL (&amp;lt; 145 pmol/L) indicates vitamin B12 deficiency.\n\nThe folate level is measured because vitamin B12 deficiency must be differentiated from folate deficiency as a cause of megaloblastic anemia; folate supplementation can mask vitamin B12 deficiency and may alleviate megaloblastic anemia but allow the neurologic deficits to progress or even accelerate.\n\nWhen clinical judgment suggests vitamin B12 deficiency but the vitamin B12 level is low-normal (200 to 350 pg/mL [145 to 260 pmol/L]) or hematologic indexes are normal, other tests can be done. Measuring serum methylmalonic acid (MMA) levels may be useful. An elevated MMA level supports vitamin B12 deficiency but may be due to renal failure. MMA levels can also be used to monitor the response to treatment. MMA levels remain normal in folate deficiency; homocysteine levels may be elevated with either vitamin B12 or folate deficiency. Less commonly, holotranscobalamin II (transcobalamin II-B12 complex) content is measured; when holotranscobalamin II is &amp;lt; 40 pg/mL (&amp;lt; 30 pmol/L), vitamin B12 is deficient.\n\nAfter deficiency is diagnosed, additional tests may be indicated for younger adults but usually not for the elderly. Unless dietary vitamin B12 is obviously inadequate, measurement of serum gastrin levels or autoantibodies to intrinsic factor may be done; sensitivity and specificity of these tests may be poor.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 479,
                        "h": 571
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Schilling test:",
                    "md": "# Schilling test:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "The Schilling test is useful only if diagnosing intrinsic factor deficiency is important, as in classic pernicious anemia. This test is not necessary for most elderly patients. The Schilling test measures absorption of free radiolabeled vitamin B12. Radiolabeled vitamin B12 is given orally, followed in 1 to 6 h by 1000 \u03bcg (1 mg) of parenteral vitamin B12, which reduces uptake of radiolabeled vitamin B12 by the liver. Absorbed radiolabeled vitamin B12 is excreted in urine, which is collected for 24 h. The amount excreted is measured, and the percentage of total radiolabeled vitamin B12 is determined. If absorption is normal, \u2265 9% of the dose given appears in the urine. Reduced urinary excretion (&amp;lt; 5% if kidney function is normal) indicates inadequate vitamin B12 absorption. Improved absorption with the subsequent addition of intrinsic factor to radiolabeled vitamin B12 confirms the diagnosis of pernicious anemia. The test is often difficult to do or interpret because of incomplete urine collection or renal insufficiency. In addition, because the Schilling test does not measure absorption of protein-bound vitamin B12, the test does not detect defective liberation of vitamin B12 from foods, which is common among the elderly. The Schilling test repletes vitamin B12 and can mask deficiency, so it should be done only after all other diagnostic tests and therapeutic trials.\n\nIf malabsorption is identified, the Schilling test can be repeated after a 2-wk trial of an oral antibiotic. If antibiotic therapy corrects malabsorption, the likely cause is intestinal overgrowth of bacteria (eg, blind-loop syndrome).",
                    "md": "The Schilling test is useful only if diagnosing intrinsic factor deficiency is important, as in classic pernicious anemia. This test is not necessary for most elderly patients. The Schilling test measures absorption of free radiolabeled vitamin B12. Radiolabeled vitamin B12 is given orally, followed in 1 to 6 h by 1000 \u03bcg (1 mg) of parenteral vitamin B12, which reduces uptake of radiolabeled vitamin B12 by the liver. Absorbed radiolabeled vitamin B12 is excreted in urine, which is collected for 24 h. The amount excreted is measured, and the percentage of total radiolabeled vitamin B12 is determined. If absorption is normal, \u2265 9% of the dose given appears in the urine. Reduced urinary excretion (&amp;lt; 5% if kidney function is normal) indicates inadequate vitamin B12 absorption. Improved absorption with the subsequent addition of intrinsic factor to radiolabeled vitamin B12 confirms the diagnosis of pernicious anemia. The test is often difficult to do or interpret because of incomplete urine collection or renal insufficiency. In addition, because the Schilling test does not measure absorption of protein-bound vitamin B12, the test does not detect defective liberation of vitamin B12 from foods, which is common among the elderly. The Schilling test repletes vitamin B12 and can mask deficiency, so it should be done only after all other diagnostic tests and therapeutic trials.\n\nIf malabsorption is identified, the Schilling test can be repeated after a 2-wk trial of an oral antibiotic. If antibiotic therapy corrects malabsorption, the likely cause is intestinal overgrowth of bacteria (eg, blind-loop syndrome).",
                    "bBox": {
                        "x": 55,
                        "y": 361.9,
                        "w": 483,
                        "h": 233
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 607.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Supplemental vitamin B12\n\nVitamin B12 1000 to 2000 \u03bcg po can be given once/day to patients who do not have severe deficiency or neurologic symptoms or signs. A nasal gel preparation of vitamin B12 is available at a higher price. Large oral doses can be absorbed by mass action, even when intrinsic factor is absent. If the MMA level (sometimes used to monitor treatment) does not decrease, patients may not be taking vitamin B12. For more severe deficiency, vitamin B12 1 mg IM is usually given 1 to 4 times/wk for several weeks until hematologic abnormalities are corrected; then it is given once/mo.\n\nAlthough hematologic abnormalities are usually corrected within 6 wk (reticulocyte count should improve within 1 wk), resolution of neurologic symptoms may take much longer. Neurologic symptoms that persist",
                    "md": "- Supplemental vitamin B12\n\nVitamin B12 1000 to 2000 \u03bcg po can be given once/day to patients who do not have severe deficiency or neurologic symptoms or signs. A nasal gel preparation of vitamin B12 is available at a higher price. Large oral doses can be absorbed by mass action, even when intrinsic factor is absent. If the MMA level (sometimes used to monitor treatment) does not decrease, patients may not be taking vitamin B12. For more severe deficiency, vitamin B12 1 mg IM is usually given 1 to 4 times/wk for several weeks until hematologic abnormalities are corrected; then it is given once/mo.\n\nAlthough hematologic abnormalities are usually corrected within 6 wk (reticulocyte count should improve within 1 wk), resolution of neurologic symptoms may take much longer. Neurologic symptoms that persist",
                    "bBox": {
                        "x": 55,
                        "y": 607.9,
                        "w": 479,
                        "h": 176
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.999
        },
        {
            "page": 37,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n for months or years become irreversible. In most elderly people with vitamin B12 deficiency and dementia,\n cognition does not improve after treatment. Vitamin B12 treatment must be continued for life unless the\n pathophysiologic mechanism for the deficiency is corrected.\n Infants of vegan mothers should receive supplemental vitamin B12 from birth.\n Vitamin C\n Vitamin C (ascorbic acid) plays a role in collagen, carnitine, hormone, and amino acid formation. It is\n essential for wound healing and facilitates recovery from burns. Vitamin C is also an antioxidant, supports\n immune function, and facilitates the absorption of iron.\n Vitamin C Deficiency\n In developed countries, vitamin C deficiency can occur as part of general undernutrition, but\n severe deficiency (causing scurvy) is uncommon. Symptoms include fatigue, depression, and\n connective tissue defects (eg, gingivitis, petechiae, rash, internal bleeding, impaired wound\n healing). In infants and children, bone growth may be impaired. Diagnosis is usually clinical.\n Treatment consists of oral vitamin C.\n Severe deficiency results in scurvy, a disorder characterized by hemorrhagic manifestations and abnormal\n osteoid and dentin formation.\n Etiology\n In adults, primary deficiency is usually due to inadequate diet. The need for dietary vitamin C is increased\n by febrile illnesses, inflammatory disorders (particularly diarrheal disorders), achlorhydria, smoking,\n thyrotoxicosis, iron deficiency, cold or heat stress, surgery, burns, and protein deficiency. Heat (eg,\n sterilization of formulas, cooking) can destroy some of the vitamin C in food.\n Pathophysiology\n Formation of intercellular cement substances in connective tissues, bones, and dentin is defective,\n resulting in weakened capillaries with subsequent hemorrhage and defects in bone and related\n structures.\n Bone tissue formation becomes impaired, which, in children, causes bone lesions and poor bone growth.\n Fibrous tissue forms between the diaphysis and the epiphysis, and costochondral junctions enlarge.\n Densely calcified fragments of cartilage are embedded in the fibrous tissue. Subperiosteal hemorrhages,\n sometimes due to small fractures, may occur in children or adults.\n Symptoms and Signs\n In adults, symptoms develop after weeks to months of vitamin C depletion. Lassitude, weakness,\n irritability, weight loss, and vague myalgias and arthralgias may develop early.\n Later, symptoms related to defects in connective tissues develop. Follicular hyperkeratosis, coiled hair,\n and perifollicular hemorrhages may develop. Gums may become swollen, purple, spongy, and friable; they\n bleed easily in severe deficiency. Eventually, teeth become loose and avulsed. Secondary infections may\n develop. Wounds heal poorly and tear easily, and spontaneous hemorrhages may occur, especially as\n ecchymoses in the skin of the lower limbs or as bulbar conjunctival hemorrhage.\n Other symptoms and signs include femoral neuropathy due to hemorrhage into femoral sheaths (which\n may mimic deep venous thrombosis), lower-extremity edema, and painful bleeding or effusions within\n joints.\n Diagnosis\n                                                                                                       89",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nfor months or years become irreversible. In most elderly people with vitamin B12 deficiency and dementia, cognition does not improve after treatment. Vitamin B12 treatment must be continued for life unless the pathophysiologic mechanism for the deficiency is corrected.\n\nInfants of vegan mothers should receive supplemental vitamin B12 from birth.\n\n# Vitamin C\n\nVitamin C (ascorbic acid) plays a role in collagen, carnitine, hormone, and amino acid formation. It is essential for wound healing and facilitates recovery from burns. Vitamin C is also an antioxidant, supports immune function, and facilitates the absorption of iron.\n\n# Vitamin C Deficiency\n\nIn developed countries, vitamin C deficiency can occur as part of general undernutrition, but severe deficiency (causing scurvy) is uncommon. Symptoms include fatigue, depression, and connective tissue defects (eg, gingivitis, petechiae, rash, internal bleeding, impaired wound healing). In infants and children, bone growth may be impaired. Diagnosis is usually clinical. Treatment consists of oral vitamin C.\n\nSevere deficiency results in scurvy, a disorder characterized by hemorrhagic manifestations and abnormal osteoid and dentin formation.\n\n# Etiology\n\nIn adults, primary deficiency is usually due to inadequate diet. The need for dietary vitamin C is increased by febrile illnesses, inflammatory disorders (particularly diarrheal disorders), achlorhydria, smoking, thyrotoxicosis, iron deficiency, cold or heat stress, surgery, burns, and protein deficiency. Heat (eg, sterilization of formulas, cooking) can destroy some of the vitamin C in food.\n\n# Pathophysiology\n\nFormation of intercellular cement substances in connective tissues, bones, and dentin is defective, resulting in weakened capillaries with subsequent hemorrhage and defects in bone and related structures.\n\nBone tissue formation becomes impaired, which, in children, causes bone lesions and poor bone growth. Fibrous tissue forms between the diaphysis and the epiphysis, and costochondral junctions enlarge. Densely calcified fragments of cartilage are embedded in the fibrous tissue. Subperiosteal hemorrhages, sometimes due to small fractures, may occur in children or adults.\n\n# Symptoms and Signs\n\nIn adults, symptoms develop after weeks to months of vitamin C depletion. Lassitude, weakness, irritability, weight loss, and vague myalgias and arthralgias may develop early.\n\nLater, symptoms related to defects in connective tissues develop. Follicular hyperkeratosis, coiled hair, and perifollicular hemorrhages may develop. Gums may become swollen, purple, spongy, and friable; they bleed easily in severe deficiency. Eventually, teeth become loose and avulsed. Secondary infections may develop. Wounds heal poorly and tear easily, and spontaneous hemorrhages may occur, especially as ecchymoses in the skin of the lower limbs or as bulbar conjunctival hemorrhage.\n\nOther symptoms and signs include femoral neuropathy due to hemorrhage into femoral sheaths (which may mimic deep venous thrombosis), lower-extremity edema, and painful bleeding or effusions within joints.\n\n# Diagnosis",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 765.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "for months or years become irreversible. In most elderly people with vitamin B12 deficiency and dementia, cognition does not improve after treatment. Vitamin B12 treatment must be continued for life unless the pathophysiologic mechanism for the deficiency is corrected.\n\nInfants of vegan mothers should receive supplemental vitamin B12 from birth.",
                    "md": "for months or years become irreversible. In most elderly people with vitamin B12 deficiency and dementia, cognition does not improve after treatment. Vitamin B12 treatment must be continued for life unless the pathophysiologic mechanism for the deficiency is corrected.\n\nInfants of vegan mothers should receive supplemental vitamin B12 from birth.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 482,
                        "h": 68
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin C",
                    "md": "# Vitamin C",
                    "bBox": {
                        "x": 55,
                        "y": 131.9,
                        "w": 49,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin C (ascorbic acid) plays a role in collagen, carnitine, hormone, and amino acid formation. It is essential for wound healing and facilitates recovery from burns. Vitamin C is also an antioxidant, supports immune function, and facilitates the absorption of iron.",
                    "md": "Vitamin C (ascorbic acid) plays a role in collagen, carnitine, hormone, and amino acid formation. It is essential for wound healing and facilitates recovery from burns. Vitamin C is also an antioxidant, supports immune function, and facilitates the absorption of iron.",
                    "bBox": {
                        "x": 55,
                        "y": 131.9,
                        "w": 481,
                        "h": 63
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin C Deficiency",
                    "md": "# Vitamin C Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 131.9,
                        "w": 105,
                        "h": 88
                    }
                },
                {
                    "type": "text",
                    "value": "In developed countries, vitamin C deficiency can occur as part of general undernutrition, but severe deficiency (causing scurvy) is uncommon. Symptoms include fatigue, depression, and connective tissue defects (eg, gingivitis, petechiae, rash, internal bleeding, impaired wound healing). In infants and children, bone growth may be impaired. Diagnosis is usually clinical. Treatment consists of oral vitamin C.\n\nSevere deficiency results in scurvy, a disorder characterized by hemorrhagic manifestations and abnormal osteoid and dentin formation.",
                    "md": "In developed countries, vitamin C deficiency can occur as part of general undernutrition, but severe deficiency (causing scurvy) is uncommon. Symptoms include fatigue, depression, and connective tissue defects (eg, gingivitis, petechiae, rash, internal bleeding, impaired wound healing). In infants and children, bone growth may be impaired. Diagnosis is usually clinical. Treatment consists of oral vitamin C.\n\nSevere deficiency results in scurvy, a disorder characterized by hemorrhagic manifestations and abnormal osteoid and dentin formation.",
                    "bBox": {
                        "x": 55,
                        "y": 131.9,
                        "w": 483,
                        "h": 646
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Etiology",
                    "md": "# Etiology",
                    "bBox": {
                        "x": 55,
                        "y": 347.9,
                        "w": 41,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "In adults, primary deficiency is usually due to inadequate diet. The need for dietary vitamin C is increased by febrile illnesses, inflammatory disorders (particularly diarrheal disorders), achlorhydria, smoking, thyrotoxicosis, iron deficiency, cold or heat stress, surgery, burns, and protein deficiency. Heat (eg, sterilization of formulas, cooking) can destroy some of the vitamin C in food.",
                    "md": "In adults, primary deficiency is usually due to inadequate diet. The need for dietary vitamin C is increased by febrile illnesses, inflammatory disorders (particularly diarrheal disorders), achlorhydria, smoking, thyrotoxicosis, iron deficiency, cold or heat stress, surgery, burns, and protein deficiency. Heat (eg, sterilization of formulas, cooking) can destroy some of the vitamin C in food.",
                    "bBox": {
                        "x": 55,
                        "y": 131.9,
                        "w": 481,
                        "h": 291
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Pathophysiology",
                    "md": "# Pathophysiology",
                    "bBox": {
                        "x": 55,
                        "y": 435.9,
                        "w": 84,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Formation of intercellular cement substances in connective tissues, bones, and dentin is defective, resulting in weakened capillaries with subsequent hemorrhage and defects in bone and related structures.\n\nBone tissue formation becomes impaired, which, in children, causes bone lesions and poor bone growth. Fibrous tissue forms between the diaphysis and the epiphysis, and costochondral junctions enlarge. Densely calcified fragments of cartilage are embedded in the fibrous tissue. Subperiosteal hemorrhages, sometimes due to small fractures, may occur in children or adults.",
                    "md": "Formation of intercellular cement substances in connective tissues, bones, and dentin is defective, resulting in weakened capillaries with subsequent hemorrhage and defects in bone and related structures.\n\nBone tissue formation becomes impaired, which, in children, causes bone lesions and poor bone growth. Fibrous tissue forms between the diaphysis and the epiphysis, and costochondral junctions enlarge. Densely calcified fragments of cartilage are embedded in the fibrous tissue. Subperiosteal hemorrhages, sometimes due to small fractures, may occur in children or adults.",
                    "bBox": {
                        "x": 55,
                        "y": 461.9,
                        "w": 478,
                        "h": 101
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 575.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "In adults, symptoms develop after weeks to months of vitamin C depletion. Lassitude, weakness, irritability, weight loss, and vague myalgias and arthralgias may develop early.\n\nLater, symptoms related to defects in connective tissues develop. Follicular hyperkeratosis, coiled hair, and perifollicular hemorrhages may develop. Gums may become swollen, purple, spongy, and friable; they bleed easily in severe deficiency. Eventually, teeth become loose and avulsed. Secondary infections may develop. Wounds heal poorly and tear easily, and spontaneous hemorrhages may occur, especially as ecchymoses in the skin of the lower limbs or as bulbar conjunctival hemorrhage.\n\nOther symptoms and signs include femoral neuropathy due to hemorrhage into femoral sheaths (which may mimic deep venous thrombosis), lower-extremity edema, and painful bleeding or effusions within joints.",
                    "md": "In adults, symptoms develop after weeks to months of vitamin C depletion. Lassitude, weakness, irritability, weight loss, and vague myalgias and arthralgias may develop early.\n\nLater, symptoms related to defects in connective tissues develop. Follicular hyperkeratosis, coiled hair, and perifollicular hemorrhages may develop. Gums may become swollen, purple, spongy, and friable; they bleed easily in severe deficiency. Eventually, teeth become loose and avulsed. Secondary infections may develop. Wounds heal poorly and tear easily, and spontaneous hemorrhages may occur, especially as ecchymoses in the skin of the lower limbs or as bulbar conjunctival hemorrhage.\n\nOther symptoms and signs include femoral neuropathy due to hemorrhage into femoral sheaths (which may mimic deep venous thrombosis), lower-extremity edema, and painful bleeding or effusions within joints.",
                    "bBox": {
                        "x": 55,
                        "y": 131.9,
                        "w": 483,
                        "h": 621
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 765.9,
                        "w": 50,
                        "h": 12
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 38,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n \u2022 Usually, skin or gingival findings and risk factors\n Diagnosis is usually made clinically in a patient who has skin or gingival signs and is at risk of vitamin C\n deficiency. Laboratory confirmation may be available. Anemia is common. Bleeding, coagulation, and PT\n are normal.\n Skeletal x-rays can help diagnose childhood (but not adult) scurvy. Changes are most evident at the ends\n of long bones, particularly at the knee. Early changes resemble atrophy. Loss of trabeculae results in a\n ground-glass appearance. The cortex thins. A line of calcified, irregular cartilage (white line of Fraenkel)\n may be visible at the metaphysis. A zone of rarefaction or a linear fracture proximal and parallel to the\n white line may be visible as only a triangular defect at the bone's lateral margin but is specific. The\n epiphysis may be compressed. Healing subperiosteal hemorrhages may elevate and calcify the\n periosteum.\n Laboratory diagnosis, which requires measuring blood ascorbic acid, is sometimes done at academic\n centers. Levels of &lt; 0.6 mg/dL (&lt; 34 \u03bcmol/L) are considered marginal; levels of &lt; 0.2 mg/dL (&lt; 11 \u03bcmol/L)\n indicate vitamin C deficiency. Measurement of ascorbic acid levels in the WBC-platelet layer of\n centrifuged blood is not widely available or standardized.\n In adults, scurvy must be differentiated from arthritis, hemorrhagic disorders, gingivitis, and protein-energy\n undernutrition. Hyperkeratotic hair follicles with surrounding hyperemia or hemorrhage are almost\n pathognomonic. Bleeding gums, conjunctival hemorrhages, most petechiae, and ecchymoses are\n nonspecific.\n Treatment\n \u2022 Nutritious diet with supplemental ascorbic acid\n For scurvy in adults, ascorbic acid 100 to 500 mg po tid is given for 1 to 2 wk, until signs disappear, and\n followed by a nutritious diet supplying 1 to 2 times the daily recommended intake. In scurvy, therapeutic\n doses of ascorbic acid restore the functions of vitamin C in a few days. The symptoms and signs usually\n disappear over 1 to 2 wk. Chronic gingivitis with extensive subcutaneous hemorrhage persists longer.\n Prevention\n Vitamin C 75 mg po once/day for women and 90 mg po once/day for men prevents deficiency. Smokers\n should consume an additional 35 mg/day. Five servings of most fruits and vegetables (recommended\n daily) provide &gt; 200 mg of vitamin C.\n Vitamin C Toxicity\n The upper limit for vitamin C intake is 2000 mg/day. Up to 10 g/day of vitamin C are sometimes taken for\n unproven health benefits, such as preventing or shortening the duration of viral infections or slowing or\n reversing the progression of cancer or atherosclerosis. Such doses may acidify the urine, cause nausea\n and diarrhea, interfere with the healthy antioxidant-prooxidant balance in the body, and, in patients with\n thalassemia or hemochromatosis, promote iron overload. Intake below the upper limit does not have toxic\n effects in healthy adults.\n Vitamin D\n Vitamin D has 2 main forms: D2 (ergocalciferol) and D3 (cholecalciferol); the latter is the naturally\n occurring form and the form used for low-dose supplementation. Vitamin D3 is synthesized in skin by\n exposure to direct sunlight (ultraviolet B radiation) and obtained in the diet chiefly in fish liver oils and salt\n water fish. In some developed countries, milk and other foods are fortified with vitamin D. Human breast\n milk is low in vitamin D, containing an average of only 10% of the amount in fortified cow's milk.\n Requirements for vitamin D increase with age because skin synthesis declines. Sunscreen use and dark\n skin pigmentation also reduce skin synthesis of vitamin D.\n                                                                                                        90",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\n\u2022 Usually, skin or gingival findings and risk factors\n\nDiagnosis is usually made clinically in a patient who has skin or gingival signs and is at risk of vitamin C deficiency. Laboratory confirmation may be available. Anemia is common. Bleeding, coagulation, and PT are normal.\n\nSkeletal x-rays can help diagnose childhood (but not adult) scurvy. Changes are most evident at the ends of long bones, particularly at the knee. Early changes resemble atrophy. Loss of trabeculae results in a ground-glass appearance. The cortex thins. A line of calcified, irregular cartilage (white line of Fraenkel) may be visible at the metaphysis. A zone of rarefaction or a linear fracture proximal and parallel to the white line may be visible as only a triangular defect at the bone's lateral margin but is specific. The epiphysis may be compressed. Healing subperiosteal hemorrhages may elevate and calcify the periosteum.\n\nLaboratory diagnosis, which requires measuring blood ascorbic acid, is sometimes done at academic centers. Levels of &lt; 0.6 mg/dL (&lt; 34 \u03bcmol/L) are considered marginal; levels of &lt; 0.2 mg/dL (&lt; 11 \u03bcmol/L) indicate vitamin C deficiency. Measurement of ascorbic acid levels in the WBC-platelet layer of centrifuged blood is not widely available or standardized.\n\nIn adults, scurvy must be differentiated from arthritis, hemorrhagic disorders, gingivitis, and protein-energy undernutrition. Hyperkeratotic hair follicles with surrounding hyperemia or hemorrhage are almost pathognomonic. Bleeding gums, conjunctival hemorrhages, most petechiae, and ecchymoses are nonspecific.\n\n# Treatment\n\n\u2022 Nutritious diet with supplemental ascorbic acid\n\nFor scurvy in adults, ascorbic acid 100 to 500 mg po tid is given for 1 to 2 wk, until signs disappear, and followed by a nutritious diet supplying 1 to 2 times the daily recommended intake. In scurvy, therapeutic doses of ascorbic acid restore the functions of vitamin C in a few days. The symptoms and signs usually disappear over 1 to 2 wk. Chronic gingivitis with extensive subcutaneous hemorrhage persists longer.\n\n# Prevention\n\nVitamin C 75 mg po once/day for women and 90 mg po once/day for men prevents deficiency. Smokers should consume an additional 35 mg/day. Five servings of most fruits and vegetables (recommended daily) provide &gt; 200 mg of vitamin C.\n\n# Vitamin C Toxicity\n\nThe upper limit for vitamin C intake is 2000 mg/day. Up to 10 g/day of vitamin C are sometimes taken for unproven health benefits, such as preventing or shortening the duration of viral infections or slowing or reversing the progression of cancer or atherosclerosis. Such doses may acidify the urine, cause nausea and diarrhea, interfere with the healthy antioxidant-prooxidant balance in the body, and, in patients with thalassemia or hemochromatosis, promote iron overload. Intake below the upper limit does not have toxic effects in healthy adults.\n\n# Vitamin D\n\nVitamin D has 2 main forms: D2 (ergocalciferol) and D3 (cholecalciferol); the latter is the naturally occurring form and the form used for low-dose supplementation. Vitamin D3 is synthesized in skin by exposure to direct sunlight (ultraviolet B radiation) and obtained in the diet chiefly in fish liver oils and salt water fish. In some developed countries, milk and other foods are fortified with vitamin D. Human breast milk is low in vitamin D, containing an average of only 10% of the amount in fortified cow's milk. Requirements for vitamin D increase with age because skin synthesis declines. Sunscreen use and dark skin pigmentation also reduce skin synthesis of vitamin D.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 55,
                        "y": 669.9,
                        "w": 49,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "\u2022 Usually, skin or gingival findings and risk factors\n\nDiagnosis is usually made clinically in a patient who has skin or gingival signs and is at risk of vitamin C deficiency. Laboratory confirmation may be available. Anemia is common. Bleeding, coagulation, and PT are normal.\n\nSkeletal x-rays can help diagnose childhood (but not adult) scurvy. Changes are most evident at the ends of long bones, particularly at the knee. Early changes resemble atrophy. Loss of trabeculae results in a ground-glass appearance. The cortex thins. A line of calcified, irregular cartilage (white line of Fraenkel) may be visible at the metaphysis. A zone of rarefaction or a linear fracture proximal and parallel to the white line may be visible as only a triangular defect at the bone's lateral margin but is specific. The epiphysis may be compressed. Healing subperiosteal hemorrhages may elevate and calcify the periosteum.\n\nLaboratory diagnosis, which requires measuring blood ascorbic acid, is sometimes done at academic centers. Levels of &lt; 0.6 mg/dL (&lt; 34 \u03bcmol/L) are considered marginal; levels of &lt; 0.2 mg/dL (&lt; 11 \u03bcmol/L) indicate vitamin C deficiency. Measurement of ascorbic acid levels in the WBC-platelet layer of centrifuged blood is not widely available or standardized.\n\nIn adults, scurvy must be differentiated from arthritis, hemorrhagic disorders, gingivitis, and protein-energy undernutrition. Hyperkeratotic hair follicles with surrounding hyperemia or hemorrhage are almost pathognomonic. Bleeding gums, conjunctival hemorrhages, most petechiae, and ecchymoses are nonspecific.",
                    "md": "\u2022 Usually, skin or gingival findings and risk factors\n\nDiagnosis is usually made clinically in a patient who has skin or gingival signs and is at risk of vitamin C deficiency. Laboratory confirmation may be available. Anemia is common. Bleeding, coagulation, and PT are normal.\n\nSkeletal x-rays can help diagnose childhood (but not adult) scurvy. Changes are most evident at the ends of long bones, particularly at the knee. Early changes resemble atrophy. Loss of trabeculae results in a ground-glass appearance. The cortex thins. A line of calcified, irregular cartilage (white line of Fraenkel) may be visible at the metaphysis. A zone of rarefaction or a linear fracture proximal and parallel to the white line may be visible as only a triangular defect at the bone's lateral margin but is specific. The epiphysis may be compressed. Healing subperiosteal hemorrhages may elevate and calcify the periosteum.\n\nLaboratory diagnosis, which requires measuring blood ascorbic acid, is sometimes done at academic centers. Levels of &lt; 0.6 mg/dL (&lt; 34 \u03bcmol/L) are considered marginal; levels of &lt; 0.2 mg/dL (&lt; 11 \u03bcmol/L) indicate vitamin C deficiency. Measurement of ascorbic acid levels in the WBC-platelet layer of centrifuged blood is not widely available or standardized.\n\nIn adults, scurvy must be differentiated from arthritis, hemorrhagic disorders, gingivitis, and protein-energy undernutrition. Hyperkeratotic hair follicles with surrounding hyperemia or hemorrhage are almost pathognomonic. Bleeding gums, conjunctival hemorrhages, most petechiae, and ecchymoses are nonspecific.",
                    "bBox": {
                        "x": 55,
                        "y": 61.9,
                        "w": 483,
                        "h": 291
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 365.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "\u2022 Nutritious diet with supplemental ascorbic acid\n\nFor scurvy in adults, ascorbic acid 100 to 500 mg po tid is given for 1 to 2 wk, until signs disappear, and followed by a nutritious diet supplying 1 to 2 times the daily recommended intake. In scurvy, therapeutic doses of ascorbic acid restore the functions of vitamin C in a few days. The symptoms and signs usually disappear over 1 to 2 wk. Chronic gingivitis with extensive subcutaneous hemorrhage persists longer.",
                    "md": "\u2022 Nutritious diet with supplemental ascorbic acid\n\nFor scurvy in adults, ascorbic acid 100 to 500 mg po tid is given for 1 to 2 wk, until signs disappear, and followed by a nutritious diet supplying 1 to 2 times the daily recommended intake. In scurvy, therapeutic doses of ascorbic acid restore the functions of vitamin C in a few days. The symptoms and signs usually disappear over 1 to 2 wk. Chronic gingivitis with extensive subcutaneous hemorrhage persists longer.",
                    "bBox": {
                        "x": 55,
                        "y": 391.9,
                        "w": 476,
                        "h": 75
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Prevention",
                    "md": "# Prevention",
                    "bBox": {
                        "x": 55,
                        "y": 479.9,
                        "w": 56,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin C 75 mg po once/day for women and 90 mg po once/day for men prevents deficiency. Smokers should consume an additional 35 mg/day. Five servings of most fruits and vegetables (recommended daily) provide &gt; 200 mg of vitamin C.",
                    "md": "Vitamin C 75 mg po once/day for women and 90 mg po once/day for men prevents deficiency. Smokers should consume an additional 35 mg/day. Five servings of most fruits and vegetables (recommended daily) provide &gt; 200 mg of vitamin C.",
                    "bBox": {
                        "x": 55,
                        "y": 505.9,
                        "w": 488,
                        "h": 301.82
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin C Toxicity",
                    "md": "# Vitamin C Toxicity",
                    "bBox": {
                        "x": 55,
                        "y": 555.9,
                        "w": 91,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "The upper limit for vitamin C intake is 2000 mg/day. Up to 10 g/day of vitamin C are sometimes taken for unproven health benefits, such as preventing or shortening the duration of viral infections or slowing or reversing the progression of cancer or atherosclerosis. Such doses may acidify the urine, cause nausea and diarrhea, interfere with the healthy antioxidant-prooxidant balance in the body, and, in patients with thalassemia or hemochromatosis, promote iron overload. Intake below the upper limit does not have toxic effects in healthy adults.",
                    "md": "The upper limit for vitamin C intake is 2000 mg/day. Up to 10 g/day of vitamin C are sometimes taken for unproven health benefits, such as preventing or shortening the duration of viral infections or slowing or reversing the progression of cancer or atherosclerosis. Such doses may acidify the urine, cause nausea and diarrhea, interfere with the healthy antioxidant-prooxidant balance in the body, and, in patients with thalassemia or hemochromatosis, promote iron overload. Intake below the upper limit does not have toxic effects in healthy adults.",
                    "bBox": {
                        "x": 55,
                        "y": 581.9,
                        "w": 479,
                        "h": 75
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin D",
                    "md": "# Vitamin D",
                    "bBox": {
                        "x": 55,
                        "y": 669.9,
                        "w": 49,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin D has 2 main forms: D2 (ergocalciferol) and D3 (cholecalciferol); the latter is the naturally occurring form and the form used for low-dose supplementation. Vitamin D3 is synthesized in skin by exposure to direct sunlight (ultraviolet B radiation) and obtained in the diet chiefly in fish liver oils and salt water fish. In some developed countries, milk and other foods are fortified with vitamin D. Human breast milk is low in vitamin D, containing an average of only 10% of the amount in fortified cow's milk. Requirements for vitamin D increase with age because skin synthesis declines. Sunscreen use and dark skin pigmentation also reduce skin synthesis of vitamin D.",
                    "md": "Vitamin D has 2 main forms: D2 (ergocalciferol) and D3 (cholecalciferol); the latter is the naturally occurring form and the form used for low-dose supplementation. Vitamin D3 is synthesized in skin by exposure to direct sunlight (ultraviolet B radiation) and obtained in the diet chiefly in fish liver oils and salt water fish. In some developed countries, milk and other foods are fortified with vitamin D. Human breast milk is low in vitamin D, containing an average of only 10% of the amount in fortified cow's milk. Requirements for vitamin D increase with age because skin synthesis declines. Sunscreen use and dark skin pigmentation also reduce skin synthesis of vitamin D.",
                    "bBox": {
                        "x": 55,
                        "y": 669.9,
                        "w": 479,
                        "h": 118
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 39,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n Vitamin D is a prohormone with several active metabolites that act as hormones. Vitamin D is metabolized\n by the liver to 25(OH)D, which is then converted by the kidneys to 1,25(OH)2D (1,25-\n dihydroxycholecalciferol, calcitriol, or active vitamin D hormone). 25(OH)D, the major circulating form, has\n some metabolic activity, but 1,25(OH)2D is the most metabolically active. The conversion to 1,25(OH)2D\n is regulated by its own concentration, parathyroid hormone (PTH), and serum concentrations of Ca and\n phosphate.\n [\n Table 4-6. Actions of Vitamin D and its Metabolites]\n Vitamin D affects many organ systems (see Table 4-6), but mainly it increases Ca and phosphate\n absorption from the intestine and promotes normal bone formation and mineralization. Vitamin D and\n related analogs may be used to treat psoriasis, hypoparathyroidism, renal osteodystrophy, and possibly\n leukemia and breast, prostate, and colon cancers; they may also be used for immunosuppression.\n Vitamin D Deficiency and Dependency\n Inadequate exposure to sunlight predisposes to vitamin D deficiency. Deficiency impairs bone\n mineralization, causing rickets in children and osteomalacia in adults and possibly contributing\n to osteoporosis. Treatment usually consists of oral vitamin D; Ca and phosphate are\n supplemented as needed. Prevention is often possible. Rarely, hereditary disorders cause\n impaired metabolism of vitamin D (dependency).\n Vitamin D deficiency is a common cause of rickets and osteomalacia, but these disorders may also result\n from other conditions, such as various renal tubular disorders, familial hypophosphatemic (vitamin D-\n resistant) rickets (see p. 2991), chronic metabolic acidosis, hypoparathyroidism (which reduces vitamin D\n absorption), inadequate dietary Ca, and disorders or drugs that impair the mineralization of bone matrix.\n Vitamin D deficiency causes hypocalcemia, which stimulates production of PTH, causing\n hyperparathyroidism. Hyperparathyroidism increases absorption, bone mobilization, and renal\n conservation of Ca but increases excretion of phosphate. As a result, the serum level of Ca may be\n normal, but because of hypophosphatemia, bone mineralization is impaired.\n Etiology\n Vitamin D deficiency may result from the following.\n Inadequate exposure or intake: Inadequate direct sunlight exposure (or sunscreen use) and\n inadequate intake usually occur simultaneously to result in clinical deficiency. Susceptible people include\n the elderly (who are often undernourished and are not exposed to enough sunlight), and certain\n communities (eg, women and children who are confined to the home or who wear clothing that covers the\n entire body and face). Inadequate vitamin D stores are common among the elderly, particularly those who\n are house-bound, institutionalized, or hospitalized or who have had a hip fracture. Recommended direct\n sunlight exposure is 5 to 15 min (suberythemal dose) to arms and legs, or face, arms and hands, at least\n 3 times a week.\n Reduced absorption: Malabsorption can deprive the body of dietary vitamin D; only a small amount of\n 25(OH)D is recirculated enterohepatically.\n Abnormal metabolism: Vitamin D deficiency may result from defects in the production of 25(OH)D or\n 1,25(OH)2D. People with a chronic renal disorder commonly develop rickets or osteomalacia because\n renal production of 1,25 (OH)2D is decreased and phosphate levels are elevated. Hepatic dysfunction\n can also interfere with production of active vitamin D metabolites.\n Type I hereditary vitamin D-dependent rickets is an autosomal recessive disorder characterized by absent\n or defective conversion of 25(OH)D to 1,25(OH)2D in the kidneys. X-linked familial hypophosphatemia\n                                                                                                      91",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nVitamin D is a prohormone with several active metabolites that act as hormones. Vitamin D is metabolized by the liver to 25(OH)D, which is then converted by the kidneys to 1,25(OH)2D (1,25-dihydroxycholecalciferol, calcitriol, or active vitamin D hormone). 25(OH)D, the major circulating form, has some metabolic activity, but 1,25(OH)2D is the most metabolically active. The conversion to 1,25(OH)2D is regulated by its own concentration, parathyroid hormone (PTH), and serum concentrations of Ca and phosphate.\n\n# Table 4-6. Actions of Vitamin D and its Metabolites\n\nVitamin D affects many organ systems (see Table 4-6), but mainly it increases Ca and phosphate absorption from the intestine and promotes normal bone formation and mineralization. Vitamin D and related analogs may be used to treat psoriasis, hypoparathyroidism, renal osteodystrophy, and possibly leukemia and breast, prostate, and colon cancers; they may also be used for immunosuppression.\n\n# Vitamin D Deficiency and Dependency\n\nInadequate exposure to sunlight predisposes to vitamin D deficiency. Deficiency impairs bone mineralization, causing rickets in children and osteomalacia in adults and possibly contributing to osteoporosis. Treatment usually consists of oral vitamin D; Ca and phosphate are supplemented as needed. Prevention is often possible. Rarely, hereditary disorders cause impaired metabolism of vitamin D (dependency).\n\nVitamin D deficiency is a common cause of rickets and osteomalacia, but these disorders may also result from other conditions, such as various renal tubular disorders, familial hypophosphatemic (vitamin D-resistant) rickets (see p. 2991), chronic metabolic acidosis, hypoparathyroidism (which reduces vitamin D absorption), inadequate dietary Ca, and disorders or drugs that impair the mineralization of bone matrix.\n\nVitamin D deficiency causes hypocalcemia, which stimulates production of PTH, causing hyperparathyroidism. Hyperparathyroidism increases absorption, bone mobilization, and renal conservation of Ca but increases excretion of phosphate. As a result, the serum level of Ca may be normal, but because of hypophosphatemia, bone mineralization is impaired.\n\n# Etiology\n\nVitamin D deficiency may result from the following:\n\n- Inadequate exposure or intake: Inadequate direct sunlight exposure (or sunscreen use) and inadequate intake usually occur simultaneously to result in clinical deficiency. Susceptible people include the elderly (who are often undernourished and are not exposed to enough sunlight), and certain communities (eg, women and children who are confined to the home or who wear clothing that covers the entire body and face). Inadequate vitamin D stores are common among the elderly, particularly those who are house-bound, institutionalized, or hospitalized or who have had a hip fracture. Recommended direct sunlight exposure is 5 to 15 min (suberythemal dose) to arms and legs, or face, arms and hands, at least 3 times a week.\n- Reduced absorption: Malabsorption can deprive the body of dietary vitamin D; only a small amount of 25(OH)D is recirculated enterohepatically.\n- Abnormal metabolism: Vitamin D deficiency may result from defects in the production of 25(OH)D or 1,25(OH)2D. People with a chronic renal disorder commonly develop rickets or osteomalacia because renal production of 1,25(OH)2D is decreased and phosphate levels are elevated. Hepatic dysfunction can also interfere with production of active vitamin D metabolites.\n- Type I hereditary vitamin D-dependent rickets: is an autosomal recessive disorder characterized by absent or defective conversion of 25(OH)D to 1,25(OH)2D in the kidneys. X-linked familial hypophosphatemia.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin D is a prohormone with several active metabolites that act as hormones. Vitamin D is metabolized by the liver to 25(OH)D, which is then converted by the kidneys to 1,25(OH)2D (1,25-dihydroxycholecalciferol, calcitriol, or active vitamin D hormone). 25(OH)D, the major circulating form, has some metabolic activity, but 1,25(OH)2D is the most metabolically active. The conversion to 1,25(OH)2D is regulated by its own concentration, parathyroid hormone (PTH), and serum concentrations of Ca and phosphate.",
                    "md": "Vitamin D is a prohormone with several active metabolites that act as hormones. Vitamin D is metabolized by the liver to 25(OH)D, which is then converted by the kidneys to 1,25(OH)2D (1,25-dihydroxycholecalciferol, calcitriol, or active vitamin D hormone). 25(OH)D, the major circulating form, has some metabolic activity, but 1,25(OH)2D is the most metabolically active. The conversion to 1,25(OH)2D is regulated by its own concentration, parathyroid hormone (PTH), and serum concentrations of Ca and phosphate.",
                    "bBox": {
                        "x": 55,
                        "y": 62.9,
                        "w": 481,
                        "h": 80
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Table 4-6. Actions of Vitamin D and its Metabolites",
                    "md": "# Table 4-6. Actions of Vitamin D and its Metabolites",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin D affects many organ systems (see Table 4-6), but mainly it increases Ca and phosphate absorption from the intestine and promotes normal bone formation and mineralization. Vitamin D and related analogs may be used to treat psoriasis, hypoparathyroidism, renal osteodystrophy, and possibly leukemia and breast, prostate, and colon cancers; they may also be used for immunosuppression.",
                    "md": "Vitamin D affects many organ systems (see Table 4-6), but mainly it increases Ca and phosphate absorption from the intestine and promotes normal bone formation and mineralization. Vitamin D and related analogs may be used to treat psoriasis, hypoparathyroidism, renal osteodystrophy, and possibly leukemia and breast, prostate, and colon cancers; they may also be used for immunosuppression.",
                    "bBox": {
                        "x": 55,
                        "y": 193.9,
                        "w": 471,
                        "h": 50
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin D Deficiency and Dependency",
                    "md": "# Vitamin D Deficiency and Dependency",
                    "bBox": {
                        "x": 55,
                        "y": 256.9,
                        "w": 193,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Inadequate exposure to sunlight predisposes to vitamin D deficiency. Deficiency impairs bone mineralization, causing rickets in children and osteomalacia in adults and possibly contributing to osteoporosis. Treatment usually consists of oral vitamin D; Ca and phosphate are supplemented as needed. Prevention is often possible. Rarely, hereditary disorders cause impaired metabolism of vitamin D (dependency).\n\nVitamin D deficiency is a common cause of rickets and osteomalacia, but these disorders may also result from other conditions, such as various renal tubular disorders, familial hypophosphatemic (vitamin D-resistant) rickets (see p. 2991), chronic metabolic acidosis, hypoparathyroidism (which reduces vitamin D absorption), inadequate dietary Ca, and disorders or drugs that impair the mineralization of bone matrix.\n\nVitamin D deficiency causes hypocalcemia, which stimulates production of PTH, causing hyperparathyroidism. Hyperparathyroidism increases absorption, bone mobilization, and renal conservation of Ca but increases excretion of phosphate. As a result, the serum level of Ca may be normal, but because of hypophosphatemia, bone mineralization is impaired.",
                    "md": "Inadequate exposure to sunlight predisposes to vitamin D deficiency. Deficiency impairs bone mineralization, causing rickets in children and osteomalacia in adults and possibly contributing to osteoporosis. Treatment usually consists of oral vitamin D; Ca and phosphate are supplemented as needed. Prevention is often possible. Rarely, hereditary disorders cause impaired metabolism of vitamin D (dependency).\n\nVitamin D deficiency is a common cause of rickets and osteomalacia, but these disorders may also result from other conditions, such as various renal tubular disorders, familial hypophosphatemic (vitamin D-resistant) rickets (see p. 2991), chronic metabolic acidosis, hypoparathyroidism (which reduces vitamin D absorption), inadequate dietary Ca, and disorders or drugs that impair the mineralization of bone matrix.\n\nVitamin D deficiency causes hypocalcemia, which stimulates production of PTH, causing hyperparathyroidism. Hyperparathyroidism increases absorption, bone mobilization, and renal conservation of Ca but increases excretion of phosphate. As a result, the serum level of Ca may be normal, but because of hypophosphatemia, bone mineralization is impaired.",
                    "bBox": {
                        "x": 55,
                        "y": 130.9,
                        "w": 488,
                        "h": 676.82
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Etiology",
                    "md": "# Etiology",
                    "bBox": {
                        "x": 55,
                        "y": 484.9,
                        "w": 41,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin D deficiency may result from the following:\n\n- Inadequate exposure or intake: Inadequate direct sunlight exposure (or sunscreen use) and inadequate intake usually occur simultaneously to result in clinical deficiency. Susceptible people include the elderly (who are often undernourished and are not exposed to enough sunlight), and certain communities (eg, women and children who are confined to the home or who wear clothing that covers the entire body and face). Inadequate vitamin D stores are common among the elderly, particularly those who are house-bound, institutionalized, or hospitalized or who have had a hip fracture. Recommended direct sunlight exposure is 5 to 15 min (suberythemal dose) to arms and legs, or face, arms and hands, at least 3 times a week.\n- Reduced absorption: Malabsorption can deprive the body of dietary vitamin D; only a small amount of 25(OH)D is recirculated enterohepatically.\n- Abnormal metabolism: Vitamin D deficiency may result from defects in the production of 25(OH)D or 1,25(OH)2D. People with a chronic renal disorder commonly develop rickets or osteomalacia because renal production of 1,25(OH)2D is decreased and phosphate levels are elevated. Hepatic dysfunction can also interfere with production of active vitamin D metabolites.\n- Type I hereditary vitamin D-dependent rickets: is an autosomal recessive disorder characterized by absent or defective conversion of 25(OH)D to 1,25(OH)2D in the kidneys. X-linked familial hypophosphatemia.",
                    "md": "Vitamin D deficiency may result from the following:\n\n- Inadequate exposure or intake: Inadequate direct sunlight exposure (or sunscreen use) and inadequate intake usually occur simultaneously to result in clinical deficiency. Susceptible people include the elderly (who are often undernourished and are not exposed to enough sunlight), and certain communities (eg, women and children who are confined to the home or who wear clothing that covers the entire body and face). Inadequate vitamin D stores are common among the elderly, particularly those who are house-bound, institutionalized, or hospitalized or who have had a hip fracture. Recommended direct sunlight exposure is 5 to 15 min (suberythemal dose) to arms and legs, or face, arms and hands, at least 3 times a week.\n- Reduced absorption: Malabsorption can deprive the body of dietary vitamin D; only a small amount of 25(OH)D is recirculated enterohepatically.\n- Abnormal metabolism: Vitamin D deficiency may result from defects in the production of 25(OH)D or 1,25(OH)2D. People with a chronic renal disorder commonly develop rickets or osteomalacia because renal production of 1,25(OH)2D is decreased and phosphate levels are elevated. Hepatic dysfunction can also interfere with production of active vitamin D metabolites.\n- Type I hereditary vitamin D-dependent rickets: is an autosomal recessive disorder characterized by absent or defective conversion of 25(OH)D to 1,25(OH)2D in the kidneys. X-linked familial hypophosphatemia.",
                    "bBox": {
                        "x": 55,
                        "y": 535.9,
                        "w": 481,
                        "h": 245
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 40,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n reduces vitamin D synthesis in the kidneys. Many anticonvulsants and glucocorticoid use increase the\n need for vitamin D supplementation.\n Resistance to effects of vitamin D: Type II hereditary vitamin D-dependent rickets has several forms\n and is due to mutations in the 1,25(OH)2D receptor. This receptor affects the metabolism of gut, kidney,\n bone, and other cells. In this disorder, 1,25(OH)2D is abundant but ineffective because the receptor is not\n functional.\n Symptoms and Signs\n Vitamin D deficiency can cause muscle aches, muscle weakness, and bone pain at any age.\n Vitamin D deficiency in a pregnant woman causes deficiency in the fetus. Occasionally, deficiency severe\n enough to cause maternal osteomalacia results in rickets with metaphyseal lesions in neonates. In young\n infants, rickets causes softening of the entire skull (craniotabes). When palpated, the occiput and\n posterior parietal bones feel like a ping pong ball. In older infants with rickets, sitting and crawling are\n delayed, as is fontanelle closure; there is bossing of the skull and costochondral thickening.\n Costochondral thickening can look like beadlike prominences along the lateral chest wall (rachitic rosary).\n In children 1 to 4 yr, epiphyseal cartilage at the lower ends of the radius, ulna, tibia, and fibula enlarges;\n kyphoscoliosis develops, and walking is delayed. In older children and adolescents, walking is painful; in\n extreme cases, deformities such as bowlegs and knock-knees develop.\n Tetany is caused by hypocalcemia and may accompany infantile or adult vitamin D deficiency. Tetany may\n cause paresthesias of the lips, tongue, and fingers; carpopedal and facial spasm; and, if very severe,\n seizures. Maternal deficiency can cause tetany in neonates.\n Osteomalacia predisposes to fractures. In the elderly, hip fractures may result from only minimal trauma.\n Diagnosis\n \u2022 Levels of 25(OH)D (D2+D3)\n Diagnosis may be suspected based on any of the following:\n \u2022 A history of inadequate sunlight exposure or dietary intake\n \u2022 Symptoms and signs of rickets, osteomalacia, or neonatal tetany\n \u2022 Characteristic bone changes seen on x-ray\n X-rays of the radius and ulna plus serum levels of Ca, phosphate, alkaline phosphatase, PTH, and\n 25(OH)D are needed to differentiate vitamin D deficiency from other causes of bone demineralization.\n Assessment of vitamin D status and serologic tests for syphilis can be considered for infants with\n craniotabes based on the history and physical, but most cases of craniotabes resolve spontaneously.\n Rickets can be distinguished from chondrodystrophy because the latter is characterized by a large head,\n short extremities, thick bones, and normal serum Ca, phosphate, and alkaline phosphatase levels.\n Tetany due to infantile rickets may be clinically indistinguishable from seizures due to other causes. Blood\n tests and clinical history may help distinguish them.\n Bone changes, seen on x-rays, precede clinical signs. In rickets, changes are most evident at the lower\n ends of the radius and ulna. The diaphyseal ends lose their sharp, clear outline; they are cup-shaped and\n show a spotty or fringy rarefaction. Later, because the ends of the radius and ulna have become\n noncalcified and radiolucent, the distance between them and the metacarpal bones appears increased.\n The bone matrix elsewhere also becomes more radiolucent. Characteristic deformities result from the\n bones bending at the cartilage-shaft junction because the shaft is weak. As healing begins, a thin white\n                                                                                                        92",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nReduces vitamin D synthesis in the kidneys. Many anticonvulsants and glucocorticoid use increase the need for vitamin D supplementation.\n\n# Resistance to effects of vitamin D\n\nType II hereditary vitamin D-dependent rickets has several forms and is due to mutations in the 1,25(OH)2D receptor. This receptor affects the metabolism of gut, kidney, bone, and other cells. In this disorder, 1,25(OH)2D is abundant but ineffective because the receptor is not functional.\n\n# Symptoms and Signs\n\nVitamin D deficiency can cause muscle aches, muscle weakness, and bone pain at any age. Vitamin D deficiency in a pregnant woman causes deficiency in the fetus. Occasionally, deficiency severe enough to cause maternal osteomalacia results in rickets with metaphyseal lesions in neonates. In young infants, rickets causes softening of the entire skull (craniotabes). When palpated, the occiput and posterior parietal bones feel like a ping pong ball. In older infants with rickets, sitting and crawling are delayed, as is fontanelle closure; there is bossing of the skull and costochondral thickening. Costochondral thickening can look like beadlike prominences along the lateral chest wall (rachitic rosary).\n\nIn children 1 to 4 yr, epiphyseal cartilage at the lower ends of the radius, ulna, tibia, and fibula enlarges; kyphoscoliosis develops, and walking is delayed. In older children and adolescents, walking is painful; in extreme cases, deformities such as bowlegs and knock-knees develop.\n\nTetany is caused by hypocalcemia and may accompany infantile or adult vitamin D deficiency. Tetany may cause paresthesias of the lips, tongue, and fingers; carpopedal and facial spasm; and, if very severe, seizures. Maternal deficiency can cause tetany in neonates. Osteomalacia predisposes to fractures. In the elderly, hip fractures may result from only minimal trauma.\n\n# Diagnosis\n\n\u2022 Levels of 25(OH)D (D2+D3)\n\nDiagnosis may be suspected based on any of the following:\n\n- A history of inadequate sunlight exposure or dietary intake\n- Symptoms and signs of rickets, osteomalacia, or neonatal tetany\n- Characteristic bone changes seen on x-ray\n\nX-rays of the radius and ulna plus serum levels of Ca, phosphate, alkaline phosphatase, PTH, and 25(OH)D are needed to differentiate vitamin D deficiency from other causes of bone demineralization. Assessment of vitamin D status and serologic tests for syphilis can be considered for infants with craniotabes based on the history and physical, but most cases of craniotabes resolve spontaneously.\n\nRickets can be distinguished from chondrodystrophy because the latter is characterized by a large head, short extremities, thick bones, and normal serum Ca, phosphate, and alkaline phosphatase levels. Tetany due to infantile rickets may be clinically indistinguishable from seizures due to other causes. Blood tests and clinical history may help distinguish them.\n\nBone changes, seen on x-rays, precede clinical signs. In rickets, changes are most evident at the lower ends of the radius and ulna. The diaphyseal ends lose their sharp, clear outline; they are cup-shaped and show a spotty or fringy rarefaction. Later, because the ends of the radius and ulna have become noncalcified and radiolucent, the distance between them and the metacarpal bones appears increased. The bone matrix elsewhere also becomes more radiolucent. Characteristic deformities result from the bones bending at the cartilage-shaft junction because the shaft is weak. As healing begins, a thin white.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 408.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Reduces vitamin D synthesis in the kidneys. Many anticonvulsants and glucocorticoid use increase the need for vitamin D supplementation.",
                    "md": "Reduces vitamin D synthesis in the kidneys. Many anticonvulsants and glucocorticoid use increase the need for vitamin D supplementation.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 466,
                        "h": 25
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Resistance to effects of vitamin D",
                    "md": "# Resistance to effects of vitamin D",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Type II hereditary vitamin D-dependent rickets has several forms and is due to mutations in the 1,25(OH)2D receptor. This receptor affects the metabolism of gut, kidney, bone, and other cells. In this disorder, 1,25(OH)2D is abundant but ineffective because the receptor is not functional.",
                    "md": "Type II hereditary vitamin D-dependent rickets has several forms and is due to mutations in the 1,25(OH)2D receptor. This receptor affects the metabolism of gut, kidney, bone, and other cells. In this disorder, 1,25(OH)2D is abundant but ineffective because the receptor is not functional.",
                    "bBox": {
                        "x": 55,
                        "y": 99.9,
                        "w": 482,
                        "h": 42
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 154.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin D deficiency can cause muscle aches, muscle weakness, and bone pain at any age. Vitamin D deficiency in a pregnant woman causes deficiency in the fetus. Occasionally, deficiency severe enough to cause maternal osteomalacia results in rickets with metaphyseal lesions in neonates. In young infants, rickets causes softening of the entire skull (craniotabes). When palpated, the occiput and posterior parietal bones feel like a ping pong ball. In older infants with rickets, sitting and crawling are delayed, as is fontanelle closure; there is bossing of the skull and costochondral thickening. Costochondral thickening can look like beadlike prominences along the lateral chest wall (rachitic rosary).\n\nIn children 1 to 4 yr, epiphyseal cartilage at the lower ends of the radius, ulna, tibia, and fibula enlarges; kyphoscoliosis develops, and walking is delayed. In older children and adolescents, walking is painful; in extreme cases, deformities such as bowlegs and knock-knees develop.\n\nTetany is caused by hypocalcemia and may accompany infantile or adult vitamin D deficiency. Tetany may cause paresthesias of the lips, tongue, and fingers; carpopedal and facial spasm; and, if very severe, seizures. Maternal deficiency can cause tetany in neonates. Osteomalacia predisposes to fractures. In the elderly, hip fractures may result from only minimal trauma.",
                    "md": "Vitamin D deficiency can cause muscle aches, muscle weakness, and bone pain at any age. Vitamin D deficiency in a pregnant woman causes deficiency in the fetus. Occasionally, deficiency severe enough to cause maternal osteomalacia results in rickets with metaphyseal lesions in neonates. In young infants, rickets causes softening of the entire skull (craniotabes). When palpated, the occiput and posterior parietal bones feel like a ping pong ball. In older infants with rickets, sitting and crawling are delayed, as is fontanelle closure; there is bossing of the skull and costochondral thickening. Costochondral thickening can look like beadlike prominences along the lateral chest wall (rachitic rosary).\n\nIn children 1 to 4 yr, epiphyseal cartilage at the lower ends of the radius, ulna, tibia, and fibula enlarges; kyphoscoliosis develops, and walking is delayed. In older children and adolescents, walking is painful; in extreme cases, deformities such as bowlegs and knock-knees develop.\n\nTetany is caused by hypocalcemia and may accompany infantile or adult vitamin D deficiency. Tetany may cause paresthesias of the lips, tongue, and fingers; carpopedal and facial spasm; and, if very severe, seizures. Maternal deficiency can cause tetany in neonates. Osteomalacia predisposes to fractures. In the elderly, hip fractures may result from only minimal trauma.",
                    "bBox": {
                        "x": 55,
                        "y": 180.9,
                        "w": 483,
                        "h": 214
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 408.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "\u2022 Levels of 25(OH)D (D2+D3)\n\nDiagnosis may be suspected based on any of the following:\n\n- A history of inadequate sunlight exposure or dietary intake\n- Symptoms and signs of rickets, osteomalacia, or neonatal tetany\n- Characteristic bone changes seen on x-ray\n\nX-rays of the radius and ulna plus serum levels of Ca, phosphate, alkaline phosphatase, PTH, and 25(OH)D are needed to differentiate vitamin D deficiency from other causes of bone demineralization. Assessment of vitamin D status and serologic tests for syphilis can be considered for infants with craniotabes based on the history and physical, but most cases of craniotabes resolve spontaneously.\n\nRickets can be distinguished from chondrodystrophy because the latter is characterized by a large head, short extremities, thick bones, and normal serum Ca, phosphate, and alkaline phosphatase levels. Tetany due to infantile rickets may be clinically indistinguishable from seizures due to other causes. Blood tests and clinical history may help distinguish them.\n\nBone changes, seen on x-rays, precede clinical signs. In rickets, changes are most evident at the lower ends of the radius and ulna. The diaphyseal ends lose their sharp, clear outline; they are cup-shaped and show a spotty or fringy rarefaction. Later, because the ends of the radius and ulna have become noncalcified and radiolucent, the distance between them and the metacarpal bones appears increased. The bone matrix elsewhere also becomes more radiolucent. Characteristic deformities result from the bones bending at the cartilage-shaft junction because the shaft is weak. As healing begins, a thin white.",
                    "md": "\u2022 Levels of 25(OH)D (D2+D3)\n\nDiagnosis may be suspected based on any of the following:\n\n- A history of inadequate sunlight exposure or dietary intake\n- Symptoms and signs of rickets, osteomalacia, or neonatal tetany\n- Characteristic bone changes seen on x-ray\n\nX-rays of the radius and ulna plus serum levels of Ca, phosphate, alkaline phosphatase, PTH, and 25(OH)D are needed to differentiate vitamin D deficiency from other causes of bone demineralization. Assessment of vitamin D status and serologic tests for syphilis can be considered for infants with craniotabes based on the history and physical, but most cases of craniotabes resolve spontaneously.\n\nRickets can be distinguished from chondrodystrophy because the latter is characterized by a large head, short extremities, thick bones, and normal serum Ca, phosphate, and alkaline phosphatase levels. Tetany due to infantile rickets may be clinically indistinguishable from seizures due to other causes. Blood tests and clinical history may help distinguish them.\n\nBone changes, seen on x-rays, precede clinical signs. In rickets, changes are most evident at the lower ends of the radius and ulna. The diaphyseal ends lose their sharp, clear outline; they are cup-shaped and show a spotty or fringy rarefaction. Later, because the ends of the radius and ulna have become noncalcified and radiolucent, the distance between them and the metacarpal bones appears increased. The bone matrix elsewhere also becomes more radiolucent. Characteristic deformities result from the bones bending at the cartilage-shaft junction because the shaft is weak. As healing begins, a thin white.",
                    "bBox": {
                        "x": 55,
                        "y": 154.9,
                        "w": 483,
                        "h": 623
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.996
        },
        {
            "page": 41,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n line of calcification appears at the epiphysis, becoming denser and thicker as calcification proceeds.\n Later, the bone matrix becomes calcified and opacified at the subperiosteal level.\n In adults, bone demineralization, particularly in the spine, pelvis, and lower extremities, can be seen on x-\n rays; the fibrous lamellae can also be seen, and incomplete ribbonlike areas of demineralization\n (pseudofractures, Looser's lines, Milkman's syndrome) appear in the cortex.\n Because levels of serum 25(OH)D reflect body stores of vitamin D and correlate with symptoms and signs\n of vitamin D deficiency better than levels of other vitamin D metabolites, 25(OH)D (D2+D3) measurement\n is generally considered the best way to diagnose deficiency. Goal 25(OH)D levels are 30 to 40 ng/mL\n (about 75 to 100 nmol/L); whether higher levels may be beneficial remains uncertain.\n If the diagnosis is unclear, serum levels of 1,25(OH)2D and urinary Ca concentration can be measured. In\n severe deficiency, serum 1,25(OH)2D is abnormally low, usually undetectable. Urinary Ca is low in all\n forms of the deficiency except those associated with acidosis.\n In vitamin D deficiency, serum Ca may be low or, because of secondary hyperparathyroidism, may be\n normal. Serum phosphate usually decreases, and serum alkaline phosphatase usually increases. Serum\n PTH is elevated.\n Type I hereditary vitamin D-dependent rickets results in normal serum 25(OH)D, low serum 1,25(OH)2D\n and Ca, and normal or low serum phosphate.\n Treatment\n \u2022 Correction of Ca and phosphate deficiencies\n \u2022 Supplemental vitamin D\n Ca deficiency (which is common) and phosphate deficiency should be corrected. As long as Ca and\n phosphate intake is adequate, adults with osteomalacia and children with uncomplicated rickets can be\n cured by giving vitamin D 40 \u03bcg (1600 IU) po once/day. Serum 25(OH)D and 1,25(OH)2D begin to\n increase within 1 or 2 days. Serum Ca and phosphate increase and serum alkaline phosphatase\n decreases within about 10 days. During the 3rd wk, enough Ca and phosphate are deposited in bones to\n be visible on x-rays. After about 1 mo, the dose can usually be reduced gradually to the usual\n maintenance level of 10 to 15 \u03bcg (400 to 600 IU) once/day. If tetany is present, vitamin D should be\n supplemented with IV Ca salts for up to 1 wk (see p. 841). Elderly patients may need 25 to \u2265 50 \u03bcg (1000\n to \u2265 2000 IU) daily to maintain a 25(OH)D level &gt; 30 ng/mL (&gt; 75 nmol/L); this dose is higher than the\n recommended daily allowance (RDA) for people &gt; 70 yr (600 IU) and may exceed the current upper limit\n of 2000 IU/day.\n Because rickets and osteomalacia due to defective production of vitamin D metabolites are vitamin D-\n resistant, they do not respond to the doses usually effective for rickets due to inadequate intake.\n Endocrinologic evaluation is required because treatment depends on the specific defect. When 25(OH)D\n production is defective, vitamin D 50 \u03bcg (2000 IU) once/day increases serum levels and results in clinical\n improvement. Patients with kidney disorders often need 1,25(OH)2D supplementation.\n Type I hereditary vitamin D-dependent rickets responds to 1,25(OH)2D 1 to 2 \u03bcg po once/day. Some\n patients with type II hereditary vitamin D-dependent rickets respond to very high doses (eg, 10 to 24\n \u03bcg/day) of 1,25(OH)2D; others require long-term infusions of Ca.\n Prevention\n Dietary counseling is particularly important in communities whose members are at risk of vitamin D\n deficiency. Fortifying unleavened chapati flour with vitamin D (125 \u03bcg/kg) has been effective among Indian\n immigrants in Britain. The benefits of sunlight exposure for vitamin D status must be weighed against the\n increased skin damage and skin cancer risks.\n                                                                                                     93",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nA line of calcification appears at the epiphysis, becoming denser and thicker as calcification proceeds. Later, the bone matrix becomes calcified and opacified at the subperiosteal level. In adults, bone demineralization, particularly in the spine, pelvis, and lower extremities, can be seen on x-rays; the fibrous lamellae can also be seen, and incomplete ribbonlike areas of demineralization (pseudofractures, Looser's lines, Milkman's syndrome) appear in the cortex.\n\nBecause levels of serum 25(OH)D reflect body stores of vitamin D and correlate with symptoms and signs of vitamin D deficiency better than levels of other vitamin D metabolites, 25(OH)D (D2+D3) measurement is generally considered the best way to diagnose deficiency. Goal 25(OH)D levels are 30 to 40 ng/mL (about 75 to 100 nmol/L); whether higher levels may be beneficial remains uncertain.\n\nIf the diagnosis is unclear, serum levels of 1,25(OH)2D and urinary Ca concentration can be measured. In severe deficiency, serum 1,25(OH)2D is abnormally low, usually undetectable. Urinary Ca is low in all forms of the deficiency except those associated with acidosis.\n\nIn vitamin D deficiency, serum Ca may be low or, because of secondary hyperparathyroidism, may be normal. Serum phosphate usually decreases, and serum alkaline phosphatase usually increases. Serum PTH is elevated.\n\n# Treatment\n\n- Correction of Ca and phosphate deficiencies\n- Supplemental vitamin D\n\nCa deficiency (which is common) and phosphate deficiency should be corrected. As long as Ca and phosphate intake is adequate, adults with osteomalacia and children with uncomplicated rickets can be cured by giving vitamin D 40 \u03bcg (1600 IU) po once/day. Serum 25(OH)D and 1,25(OH)2D begin to increase within 1 or 2 days. Serum Ca and phosphate increase and serum alkaline phosphatase decreases within about 10 days. During the 3rd wk, enough Ca and phosphate are deposited in bones to be visible on x-rays. After about 1 mo, the dose can usually be reduced gradually to the usual maintenance level of 10 to 15 \u03bcg (400 to 600 IU) once/day. If tetany is present, vitamin D should be supplemented with IV Ca salts for up to 1 wk (see p. 841). Elderly patients may need 25 to \u2265 50 \u03bcg (1000 to \u2265 2000 IU) daily to maintain a 25(OH)D level &gt; 30 ng/mL (&gt; 75 nmol/L); this dose is higher than the recommended daily allowance (RDA) for people &gt; 70 yr (600 IU) and may exceed the current upper limit of 2000 IU/day.\n\nBecause rickets and osteomalacia due to defective production of vitamin D metabolites are vitamin D-resistant, they do not respond to the doses usually effective for rickets due to inadequate intake. Endocrinologic evaluation is required because treatment depends on the specific defect. When 25(OH)D production is defective, vitamin D 50 \u03bcg (2000 IU) once/day increases serum levels and results in clinical improvement. Patients with kidney disorders often need 1,25(OH)2D supplementation.\n\nType I hereditary vitamin D-dependent rickets responds to 1,25(OH)2D 1 to 2 \u03bcg po once/day. Some patients with type II hereditary vitamin D-dependent rickets respond to very high doses (eg, 10 to 24 \u03bcg/day) of 1,25(OH)2D; others require long-term infusions of Ca.\n\n# Prevention\n\nDietary counseling is particularly important in communities whose members are at risk of vitamin D deficiency. Fortifying unleavened chapati flour with vitamin D (125 \u03bcg/kg) has been effective among Indian immigrants in Britain. The benefits of sunlight exposure for vitamin D status must be weighed against the increased skin damage and skin cancer risks.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "A line of calcification appears at the epiphysis, becoming denser and thicker as calcification proceeds. Later, the bone matrix becomes calcified and opacified at the subperiosteal level. In adults, bone demineralization, particularly in the spine, pelvis, and lower extremities, can be seen on x-rays; the fibrous lamellae can also be seen, and incomplete ribbonlike areas of demineralization (pseudofractures, Looser's lines, Milkman's syndrome) appear in the cortex.\n\nBecause levels of serum 25(OH)D reflect body stores of vitamin D and correlate with symptoms and signs of vitamin D deficiency better than levels of other vitamin D metabolites, 25(OH)D (D2+D3) measurement is generally considered the best way to diagnose deficiency. Goal 25(OH)D levels are 30 to 40 ng/mL (about 75 to 100 nmol/L); whether higher levels may be beneficial remains uncertain.\n\nIf the diagnosis is unclear, serum levels of 1,25(OH)2D and urinary Ca concentration can be measured. In severe deficiency, serum 1,25(OH)2D is abnormally low, usually undetectable. Urinary Ca is low in all forms of the deficiency except those associated with acidosis.\n\nIn vitamin D deficiency, serum Ca may be low or, because of secondary hyperparathyroidism, may be normal. Serum phosphate usually decreases, and serum alkaline phosphatase usually increases. Serum PTH is elevated.",
                    "md": "A line of calcification appears at the epiphysis, becoming denser and thicker as calcification proceeds. Later, the bone matrix becomes calcified and opacified at the subperiosteal level. In adults, bone demineralization, particularly in the spine, pelvis, and lower extremities, can be seen on x-rays; the fibrous lamellae can also be seen, and incomplete ribbonlike areas of demineralization (pseudofractures, Looser's lines, Milkman's syndrome) appear in the cortex.\n\nBecause levels of serum 25(OH)D reflect body stores of vitamin D and correlate with symptoms and signs of vitamin D deficiency better than levels of other vitamin D metabolites, 25(OH)D (D2+D3) measurement is generally considered the best way to diagnose deficiency. Goal 25(OH)D levels are 30 to 40 ng/mL (about 75 to 100 nmol/L); whether higher levels may be beneficial remains uncertain.\n\nIf the diagnosis is unclear, serum levels of 1,25(OH)2D and urinary Ca concentration can be measured. In severe deficiency, serum 1,25(OH)2D is abnormally low, usually undetectable. Urinary Ca is low in all forms of the deficiency except those associated with acidosis.\n\nIn vitamin D deficiency, serum Ca may be low or, because of secondary hyperparathyroidism, may be normal. Serum phosphate usually decreases, and serum alkaline phosphatase usually increases. Serum PTH is elevated.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 482,
                        "h": 247
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 349.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Correction of Ca and phosphate deficiencies\n- Supplemental vitamin D\n\nCa deficiency (which is common) and phosphate deficiency should be corrected. As long as Ca and phosphate intake is adequate, adults with osteomalacia and children with uncomplicated rickets can be cured by giving vitamin D 40 \u03bcg (1600 IU) po once/day. Serum 25(OH)D and 1,25(OH)2D begin to increase within 1 or 2 days. Serum Ca and phosphate increase and serum alkaline phosphatase decreases within about 10 days. During the 3rd wk, enough Ca and phosphate are deposited in bones to be visible on x-rays. After about 1 mo, the dose can usually be reduced gradually to the usual maintenance level of 10 to 15 \u03bcg (400 to 600 IU) once/day. If tetany is present, vitamin D should be supplemented with IV Ca salts for up to 1 wk (see p. 841). Elderly patients may need 25 to \u2265 50 \u03bcg (1000 to \u2265 2000 IU) daily to maintain a 25(OH)D level &gt; 30 ng/mL (&gt; 75 nmol/L); this dose is higher than the recommended daily allowance (RDA) for people &gt; 70 yr (600 IU) and may exceed the current upper limit of 2000 IU/day.\n\nBecause rickets and osteomalacia due to defective production of vitamin D metabolites are vitamin D-resistant, they do not respond to the doses usually effective for rickets due to inadequate intake. Endocrinologic evaluation is required because treatment depends on the specific defect. When 25(OH)D production is defective, vitamin D 50 \u03bcg (2000 IU) once/day increases serum levels and results in clinical improvement. Patients with kidney disorders often need 1,25(OH)2D supplementation.\n\nType I hereditary vitamin D-dependent rickets responds to 1,25(OH)2D 1 to 2 \u03bcg po once/day. Some patients with type II hereditary vitamin D-dependent rickets respond to very high doses (eg, 10 to 24 \u03bcg/day) of 1,25(OH)2D; others require long-term infusions of Ca.",
                    "md": "- Correction of Ca and phosphate deficiencies\n- Supplemental vitamin D\n\nCa deficiency (which is common) and phosphate deficiency should be corrected. As long as Ca and phosphate intake is adequate, adults with osteomalacia and children with uncomplicated rickets can be cured by giving vitamin D 40 \u03bcg (1600 IU) po once/day. Serum 25(OH)D and 1,25(OH)2D begin to increase within 1 or 2 days. Serum Ca and phosphate increase and serum alkaline phosphatase decreases within about 10 days. During the 3rd wk, enough Ca and phosphate are deposited in bones to be visible on x-rays. After about 1 mo, the dose can usually be reduced gradually to the usual maintenance level of 10 to 15 \u03bcg (400 to 600 IU) once/day. If tetany is present, vitamin D should be supplemented with IV Ca salts for up to 1 wk (see p. 841). Elderly patients may need 25 to \u2265 50 \u03bcg (1000 to \u2265 2000 IU) daily to maintain a 25(OH)D level &gt; 30 ng/mL (&gt; 75 nmol/L); this dose is higher than the recommended daily allowance (RDA) for people &gt; 70 yr (600 IU) and may exceed the current upper limit of 2000 IU/day.\n\nBecause rickets and osteomalacia due to defective production of vitamin D metabolites are vitamin D-resistant, they do not respond to the doses usually effective for rickets due to inadequate intake. Endocrinologic evaluation is required because treatment depends on the specific defect. When 25(OH)D production is defective, vitamin D 50 \u03bcg (2000 IU) once/day increases serum levels and results in clinical improvement. Patients with kidney disorders often need 1,25(OH)2D supplementation.\n\nType I hereditary vitamin D-dependent rickets responds to 1,25(OH)2D 1 to 2 \u03bcg po once/day. Some patients with type II hereditary vitamin D-dependent rickets respond to very high doses (eg, 10 to 24 \u03bcg/day) of 1,25(OH)2D; others require long-term infusions of Ca.",
                    "bBox": {
                        "x": 55,
                        "y": 349.9,
                        "w": 479,
                        "h": 348
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Prevention",
                    "md": "# Prevention",
                    "bBox": {
                        "x": 55,
                        "y": 713.9,
                        "w": 56,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Dietary counseling is particularly important in communities whose members are at risk of vitamin D deficiency. Fortifying unleavened chapati flour with vitamin D (125 \u03bcg/kg) has been effective among Indian immigrants in Britain. The benefits of sunlight exposure for vitamin D status must be weighed against the increased skin damage and skin cancer risks.",
                    "md": "Dietary counseling is particularly important in communities whose members are at risk of vitamin D deficiency. Fortifying unleavened chapati flour with vitamin D (125 \u03bcg/kg) has been effective among Indian immigrants in Britain. The benefits of sunlight exposure for vitamin D status must be weighed against the increased skin damage and skin cancer risks.",
                    "bBox": {
                        "x": 55,
                        "y": 738.9,
                        "w": 483,
                        "h": 50
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.959
        },
        {
            "page": 42,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n increased skin damage and skin cancer risks.\n All breastfed infants should be given supplemental vitamin D 5 \u03bcg (200 IU) once/day from birth to 6 mo; at\n 6 mo, a more diversified diet is available. For adolescents at risk, a single IM dose of ergocalciferol 2.5\n mg (100,000 IU) given in the fall can maintain adequate 25(OH)D levels throughout the winter. The\n recommended daily allowance (RDA) for vitamin D is 400 IU for people aged 51 to 70 and 600 IU for\n those &gt;70; many consider this intake too low, and the 2005 Dietary Guidelines for Americans\n recommends that healthy older adults consume 1000 IU/day.\n Vitamin D Toxicity\n Usually, vitamin D toxicity results from taking excessive amounts. Marked hypercalcemia\n commonly causes symptoms. Diagnosis is typically based on elevated blood levels of 25(OH)D.\n Treatment consists of stopping vitamin D, restricting dietary Ca, restoring intravascular volume\n deficits, and, if toxicity is severe, giving corticosteroids or bisphosphonates.\n Because synthesis of 1,25(OH)2D (the most active metabolite of vitamin D) is tightly regulated, vitamin D\n toxicity usually occurs only if excessive doses (prescription or megavitamin) are taken. Vitamin D 1000 \u03bcg\n (40,000 IU)/day causes toxicity within 1 to 4 mo in infants. In adults, taking 1250 \u03bcg (50,000 IU)/day for\n several months can cause toxicity. Vitamin D toxicity can occur iatrogenically when hypoparathyroidism is\n treated too aggressively (see p.\n 844).\n Symptoms and Signs\n The main symptoms result from hypercalcemia. Anorexia, nausea, and vomiting can develop, often\n followed by polyuria, polydipsia, weakness, nervousness, pruritus, and eventually renal failure.\n Proteinuria, urinary casts, azotemia, and metastatic calcifications (particularly in the kidneys) can develop.\n Diagnosis\n \u2022 Hypercalcemia plus risk factors or elevated serum 25(OH)D levels\n A history of excessive vitamin D intake may be the only clue differentiating vitamin D toxicity from other\n causes of hypercalcemia. Elevated serum Ca levels of 12 to 16 mg/dL (3 to 4 mmol/L) are a constant\n finding when toxic symptoms occur. Serum 25(OH)D levels are usually elevated &gt; 150 ng/mL (&gt; 375\n nmol/L). Levels of 1,25(OH)2D, which need not be measured to confirm the diagnosis, may be normal.\n Serum Ca should be measured often (weekly at first, then monthly) in all patients receiving large doses of\n vitamin D, particularly the potent 1,25(OH)2D.\n Treatment\n \u2022 IV hydration plus corticosteroids or bisphosphonates\n After stopping vitamin D intake, hydration with IV normal saline and corticosteroids or bisphosphonates\n (which inhibit bone resorption) are used to reduce blood Ca levels.\n Kidney damage or metastatic calcifications, if present, may be irreversible.\n Vitamin E\n Vitamin E is a group of compounds (including tocopherols and tocotrienols) that have similar biologic\n activities. The most biologically active is \u03b1-tocopherol, but \u03b2-, \u03b3-, and \u03b4-tocopherols, 4 tocotrienols, and\n several stereoisomers may also have important biologic activity. These compounds act as antioxidants,\n which prevent lipid peroxidation of polyunsaturated fatty acids in cellular membranes. Plasma tocopherol\n levels vary with total plasma lipid levels. Normally, the plasma \u03b1-tocopherol level is 5 to 20 \u03bcg/mL (11.6 to\n 46.4 \u03bcmol/L). High-dose vitamin E supplements do not protect against cardiovascular disorders;whether\n                                                                                                       94",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nincreased skin damage and skin cancer risks.\n\nAll breastfed infants should be given supplemental vitamin D 5 \u03bcg (200 IU) once/day from birth to 6 mo; at 6 mo, a more diversified diet is available. For adolescents at risk, a single IM dose of ergocalciferol 2.5 mg (100,000 IU) given in the fall can maintain adequate 25(OH)D levels throughout the winter. The recommended daily allowance (RDA) for vitamin D is 400 IU for people aged 51 to 70 and 600 IU for those &gt;70; many consider this intake too low, and the 2005 Dietary Guidelines for Americans recommends that healthy older adults consume 1000 IU/day.\n\n# Vitamin D Toxicity\n\nUsually, vitamin D toxicity results from taking excessive amounts. Marked hypercalcemia commonly causes symptoms. Diagnosis is typically based on elevated blood levels of 25(OH)D. Treatment consists of stopping vitamin D, restricting dietary Ca, restoring intravascular volume deficits, and, if toxicity is severe, giving corticosteroids or bisphosphonates.\n\nBecause synthesis of 1,25(OH)2D (the most active metabolite of vitamin D) is tightly regulated, vitamin D toxicity usually occurs only if excessive doses (prescription or megavitamin) are taken. Vitamin D 1000 \u03bcg (40,000 IU)/day causes toxicity within 1 to 4 mo in infants. In adults, taking 1250 \u03bcg (50,000 IU)/day for several months can cause toxicity. Vitamin D toxicity can occur iatrogenically when hypoparathyroidism is treated too aggressively (see p. 844).\n\n# Symptoms and Signs\n\nThe main symptoms result from hypercalcemia. Anorexia, nausea, and vomiting can develop, often followed by polyuria, polydipsia, weakness, nervousness, pruritus, and eventually renal failure. Proteinuria, urinary casts, azotemia, and metastatic calcifications (particularly in the kidneys) can develop.\n\n# Diagnosis\n\n- Hypercalcemia plus risk factors or elevated serum 25(OH)D levels\n\nA history of excessive vitamin D intake may be the only clue differentiating vitamin D toxicity from other causes of hypercalcemia. Elevated serum Ca levels of 12 to 16 mg/dL (3 to 4 mmol/L) are a constant finding when toxic symptoms occur. Serum 25(OH)D levels are usually elevated &gt; 150 ng/mL (&gt; 375 nmol/L). Levels of 1,25(OH)2D, which need not be measured to confirm the diagnosis, may be normal. Serum Ca should be measured often (weekly at first, then monthly) in all patients receiving large doses of vitamin D, particularly the potent 1,25(OH)2D.\n\n# Treatment\n\n- IV hydration plus corticosteroids or bisphosphonates\n\nAfter stopping vitamin D intake, hydration with IV normal saline and corticosteroids or bisphosphonates (which inhibit bone resorption) are used to reduce blood Ca levels. Kidney damage or metastatic calcifications, if present, may be irreversible.\n\n# Vitamin E\n\nVitamin E is a group of compounds (including tocopherols and tocotrienols) that have similar biologic activities. The most biologically active is \u03b1-tocopherol, but \u03b2-, \u03b3-, and \u03b4-tocopherols, 4 tocotrienols, and several stereoisomers may also have important biologic activity. These compounds act as antioxidants, which prevent lipid peroxidation of polyunsaturated fatty acids in cellular membranes. Plasma tocopherol levels vary with total plasma lipid levels. Normally, the plasma \u03b1-tocopherol level is 5 to 20 \u03bcg/mL (11.6 to 46.4 \u03bcmol/L). High-dose vitamin E supplements do not protect against cardiovascular disorders; whether",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 407.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "increased skin damage and skin cancer risks.\n\nAll breastfed infants should be given supplemental vitamin D 5 \u03bcg (200 IU) once/day from birth to 6 mo; at 6 mo, a more diversified diet is available. For adolescents at risk, a single IM dose of ergocalciferol 2.5 mg (100,000 IU) given in the fall can maintain adequate 25(OH)D levels throughout the winter. The recommended daily allowance (RDA) for vitamin D is 400 IU for people aged 51 to 70 and 600 IU for those &gt;70; many consider this intake too low, and the 2005 Dietary Guidelines for Americans recommends that healthy older adults consume 1000 IU/day.",
                    "md": "increased skin damage and skin cancer risks.\n\nAll breastfed infants should be given supplemental vitamin D 5 \u03bcg (200 IU) once/day from birth to 6 mo; at 6 mo, a more diversified diet is available. For adolescents at risk, a single IM dose of ergocalciferol 2.5 mg (100,000 IU) given in the fall can maintain adequate 25(OH)D levels throughout the winter. The recommended daily allowance (RDA) for vitamin D is 400 IU for people aged 51 to 70 and 600 IU for those &gt;70; many consider this intake too low, and the 2005 Dietary Guidelines for Americans recommends that healthy older adults consume 1000 IU/day.",
                    "bBox": {
                        "x": 55,
                        "y": 37.9,
                        "w": 481,
                        "h": 101
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin D Toxicity",
                    "md": "# Vitamin D Toxicity",
                    "bBox": {
                        "x": 55,
                        "y": 152.9,
                        "w": 91,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Usually, vitamin D toxicity results from taking excessive amounts. Marked hypercalcemia commonly causes symptoms. Diagnosis is typically based on elevated blood levels of 25(OH)D. Treatment consists of stopping vitamin D, restricting dietary Ca, restoring intravascular volume deficits, and, if toxicity is severe, giving corticosteroids or bisphosphonates.\n\nBecause synthesis of 1,25(OH)2D (the most active metabolite of vitamin D) is tightly regulated, vitamin D toxicity usually occurs only if excessive doses (prescription or megavitamin) are taken. Vitamin D 1000 \u03bcg (40,000 IU)/day causes toxicity within 1 to 4 mo in infants. In adults, taking 1250 \u03bcg (50,000 IU)/day for several months can cause toxicity. Vitamin D toxicity can occur iatrogenically when hypoparathyroidism is treated too aggressively (see p. 844).",
                    "md": "Usually, vitamin D toxicity results from taking excessive amounts. Marked hypercalcemia commonly causes symptoms. Diagnosis is typically based on elevated blood levels of 25(OH)D. Treatment consists of stopping vitamin D, restricting dietary Ca, restoring intravascular volume deficits, and, if toxicity is severe, giving corticosteroids or bisphosphonates.\n\nBecause synthesis of 1,25(OH)2D (the most active metabolite of vitamin D) is tightly regulated, vitamin D toxicity usually occurs only if excessive doses (prescription or megavitamin) are taken. Vitamin D 1000 \u03bcg (40,000 IU)/day causes toxicity within 1 to 4 mo in infants. In adults, taking 1250 \u03bcg (50,000 IU)/day for several months can cause toxicity. Vitamin D toxicity can occur iatrogenically when hypoparathyroidism is treated too aggressively (see p. 844).",
                    "bBox": {
                        "x": 55,
                        "y": 152.9,
                        "w": 481,
                        "h": 424
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 331.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "The main symptoms result from hypercalcemia. Anorexia, nausea, and vomiting can develop, often followed by polyuria, polydipsia, weakness, nervousness, pruritus, and eventually renal failure. Proteinuria, urinary casts, azotemia, and metastatic calcifications (particularly in the kidneys) can develop.",
                    "md": "The main symptoms result from hypercalcemia. Anorexia, nausea, and vomiting can develop, often followed by polyuria, polydipsia, weakness, nervousness, pruritus, and eventually renal failure. Proteinuria, urinary casts, azotemia, and metastatic calcifications (particularly in the kidneys) can develop.",
                    "bBox": {
                        "x": 55,
                        "y": 357.9,
                        "w": 483,
                        "h": 37
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 407.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Hypercalcemia plus risk factors or elevated serum 25(OH)D levels\n\nA history of excessive vitamin D intake may be the only clue differentiating vitamin D toxicity from other causes of hypercalcemia. Elevated serum Ca levels of 12 to 16 mg/dL (3 to 4 mmol/L) are a constant finding when toxic symptoms occur. Serum 25(OH)D levels are usually elevated &gt; 150 ng/mL (&gt; 375 nmol/L). Levels of 1,25(OH)2D, which need not be measured to confirm the diagnosis, may be normal. Serum Ca should be measured often (weekly at first, then monthly) in all patients receiving large doses of vitamin D, particularly the potent 1,25(OH)2D.",
                    "md": "- Hypercalcemia plus risk factors or elevated serum 25(OH)D levels\n\nA history of excessive vitamin D intake may be the only clue differentiating vitamin D toxicity from other causes of hypercalcemia. Elevated serum Ca levels of 12 to 16 mg/dL (3 to 4 mmol/L) are a constant finding when toxic symptoms occur. Serum 25(OH)D levels are usually elevated &gt; 150 ng/mL (&gt; 375 nmol/L). Levels of 1,25(OH)2D, which need not be measured to confirm the diagnosis, may be normal. Serum Ca should be measured often (weekly at first, then monthly) in all patients receiving large doses of vitamin D, particularly the potent 1,25(OH)2D.",
                    "bBox": {
                        "x": 55,
                        "y": 152.9,
                        "w": 481,
                        "h": 396
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 564.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- IV hydration plus corticosteroids or bisphosphonates\n\nAfter stopping vitamin D intake, hydration with IV normal saline and corticosteroids or bisphosphonates (which inhibit bone resorption) are used to reduce blood Ca levels. Kidney damage or metastatic calcifications, if present, may be irreversible.",
                    "md": "- IV hydration plus corticosteroids or bisphosphonates\n\nAfter stopping vitamin D intake, hydration with IV normal saline and corticosteroids or bisphosphonates (which inhibit bone resorption) are used to reduce blood Ca levels. Kidney damage or metastatic calcifications, if present, may be irreversible.",
                    "bBox": {
                        "x": 55,
                        "y": 615.9,
                        "w": 468,
                        "h": 50
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin E",
                    "md": "# Vitamin E",
                    "bBox": {
                        "x": 55,
                        "y": 678.9,
                        "w": 49,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin E is a group of compounds (including tocopherols and tocotrienols) that have similar biologic activities. The most biologically active is \u03b1-tocopherol, but \u03b2-, \u03b3-, and \u03b4-tocopherols, 4 tocotrienols, and several stereoisomers may also have important biologic activity. These compounds act as antioxidants, which prevent lipid peroxidation of polyunsaturated fatty acids in cellular membranes. Plasma tocopherol levels vary with total plasma lipid levels. Normally, the plasma \u03b1-tocopherol level is 5 to 20 \u03bcg/mL (11.6 to 46.4 \u03bcmol/L). High-dose vitamin E supplements do not protect against cardiovascular disorders; whether",
                    "md": "Vitamin E is a group of compounds (including tocopherols and tocotrienols) that have similar biologic activities. The most biologically active is \u03b1-tocopherol, but \u03b2-, \u03b3-, and \u03b4-tocopherols, 4 tocotrienols, and several stereoisomers may also have important biologic activity. These compounds act as antioxidants, which prevent lipid peroxidation of polyunsaturated fatty acids in cellular membranes. Plasma tocopherol levels vary with total plasma lipid levels. Normally, the plasma \u03b1-tocopherol level is 5 to 20 \u03bcg/mL (11.6 to 46.4 \u03bcmol/L). High-dose vitamin E supplements do not protect against cardiovascular disorders; whether",
                    "bBox": {
                        "x": 55,
                        "y": 678.9,
                        "w": 477,
                        "h": 101
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 43,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n supplements can protect against Alzheimer's disease, tardive dyskinesia, and prostate cancer among\n smokers is controversial.\n Although the amount of vitamin E in many fortified foods and supplements is given in IU, current\n recommendations are to use mg.\n Vitamin E Deficiency\n Dietary vitamin E deficiency is common in developing countries; deficiency among adults in\n developed countries is uncommon and usually due to fat malabsorption. The main symptoms\n are hemolytic anemia and neurologic deficits. Diagnosis is based on measuring the ratio of\n plasma \u03b1-tocopherol to total plasma lipids; a low ratio suggests vitamin E deficiency. Treatment\n consists of oral vitamin E, given in high doses if there are neurologic deficits or if deficiency\n results from malabsorption.\n Vitamin E deficiency causes fragility of RBCs and degeneration of neurons, particularly peripheral axons\n and posterior column neurons.\n Etiology\n In developing countries, the most common cause is inadequate intake of vitamin E. In developed\n countries, the most common causes are disorders that cause fat malabsorption, including\n abetalipoproteinemia (Bassen-Kornzweig syndrome, due to genetic absence of apolipoprotein B), chronic\n cholestatic hepatobiliary disease, pancreatitis, short bowel syndrome, and cystic fibrosis. A rare genetic\n form of vitamin E deficiency without fat malabsorption results from defective liver metabolism.\n Symptoms and Signs\n The main symptoms are mild hemolytic anemia and nonspecific neurologic deficits. Abetalipoproteinemia\n results in progressive neuropathy and retinopathy in the first 2 decades of life (see p. 904).\n Vitamin E deficiency may contribute to retinopathy of prematurity (also called retrolental fibroplasia) in\n premature infants and to some cases of intraventricular and subependymal hemorrhage in neonates.\n Affected premature neonates have muscle weakness.\n In children, chronic cholestatic hepatobiliary disease or cystic fibrosis causes neurologic deficits, including\n spinocerebellar ataxia with loss of deep tendon reflexes, truncal and limb ataxia, loss of vibration and\n position senses, ophthalmoplegia, muscle weakness, ptosis, and dysarthria.\n In adults with malabsorption, vitamin E deficiency very rarely causes spinocerebellar ataxia because\n adults have large vitamin E stores in adipose tissue.\n Diagnosis\n \u2022 Low \u03b1-tocopherol level or low ratio of serum \u03b1-tocopherol to serum lipids\n Without a history of inadequate intake or a predisposing condition, vitamin E deficiency is unlikely.\n Confirmation usually requires measuring the vitamin level. Measuring RBC hemolysis in response to\n peroxide can suggest the diagnosis but is nonspecific. Hemolysis increases as vitamin E deficiency\n impairs RBC stability.\n Measuring the serum \u03b1-tocopherol level is the most direct method of diagnosis. In adults, vitamin E\n deficiency is suggested if the \u03b1-tocopherol level is &lt; 5 \u03bcg/mL (&lt; 11.6 \u03bcmol/L). Because abnormal lipid\n levels can affect vitamin E status, a low ratio of serum \u03b1-tocopherol to lipids (&lt; 0.8 mg/g total lipid) is the\n most accurate indicator in adults with hyperlipidemia.\n In children and adults with abetalipoproteinemia, serum \u03b1-tocopherol levels are usually undetectable.\n                                                                                                      95",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nSupplements can protect against Alzheimer's disease, tardive dyskinesia, and prostate cancer among smokers is controversial.\n\nAlthough the amount of vitamin E in many fortified foods and supplements is given in IU, current recommendations are to use mg.\n\n# Vitamin E Deficiency\n\nDietary vitamin E deficiency is common in developing countries; deficiency among adults in developed countries is uncommon and usually due to fat malabsorption. The main symptoms are hemolytic anemia and neurologic deficits. Diagnosis is based on measuring the ratio of plasma \u03b1-tocopherol to total plasma lipids; a low ratio suggests vitamin E deficiency. Treatment consists of oral vitamin E, given in high doses if there are neurologic deficits or if deficiency results from malabsorption.\n\nVitamin E deficiency causes fragility of RBCs and degeneration of neurons, particularly peripheral axons and posterior column neurons.\n\n# Etiology\n\nIn developing countries, the most common cause is inadequate intake of vitamin E. In developed countries, the most common causes are disorders that cause fat malabsorption, including abetalipoproteinemia (Bassen-Kornzweig syndrome, due to genetic absence of apolipoprotein B), chronic cholestatic hepatobiliary disease, pancreatitis, short bowel syndrome, and cystic fibrosis. A rare genetic form of vitamin E deficiency without fat malabsorption results from defective liver metabolism.\n\n# Symptoms and Signs\n\nThe main symptoms are mild hemolytic anemia and nonspecific neurologic deficits. Abetalipoproteinemia results in progressive neuropathy and retinopathy in the first 2 decades of life (see p. 904). Vitamin E deficiency may contribute to retinopathy of prematurity (also called retrolental fibroplasia) in premature infants and to some cases of intraventricular and subependymal hemorrhage in neonates. Affected premature neonates have muscle weakness.\n\nIn children, chronic cholestatic hepatobiliary disease or cystic fibrosis causes neurologic deficits, including spinocerebellar ataxia with loss of deep tendon reflexes, truncal and limb ataxia, loss of vibration and position senses, ophthalmoplegia, muscle weakness, ptosis, and dysarthria.\n\nIn adults with malabsorption, vitamin E deficiency very rarely causes spinocerebellar ataxia because adults have large vitamin E stores in adipose tissue.\n\n# Diagnosis\n\n- Low \u03b1-tocopherol level or low ratio of serum \u03b1-tocopherol to serum lipids\n\nWithout a history of inadequate intake or a predisposing condition, vitamin E deficiency is unlikely. Confirmation usually requires measuring the vitamin level. Measuring RBC hemolysis in response to peroxide can suggest the diagnosis but is nonspecific. Hemolysis increases as vitamin E deficiency impairs RBC stability.\n\nMeasuring the serum \u03b1-tocopherol level is the most direct method of diagnosis. In adults, vitamin E deficiency is suggested if the \u03b1-tocopherol level is &lt; 5 \u03bcg/mL (&lt; 11.6 \u03bcmol/L). Because abnormal lipid levels can affect vitamin E status, a low ratio of serum \u03b1-tocopherol to lipids (&lt; 0.8 mg/g total lipid) is the most accurate indicator in adults with hyperlipidemia.\n\nIn children and adults with abetalipoproteinemia, serum \u03b1-tocopherol levels are usually undetectable.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 581.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Supplements can protect against Alzheimer's disease, tardive dyskinesia, and prostate cancer among smokers is controversial.\n\nAlthough the amount of vitamin E in many fortified foods and supplements is given in IU, current recommendations are to use mg.",
                    "md": "Supplements can protect against Alzheimer's disease, tardive dyskinesia, and prostate cancer among smokers is controversial.\n\nAlthough the amount of vitamin E in many fortified foods and supplements is given in IU, current recommendations are to use mg.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 460,
                        "h": 63
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin E Deficiency",
                    "md": "# Vitamin E Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 124.9,
                        "w": 104,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Dietary vitamin E deficiency is common in developing countries; deficiency among adults in developed countries is uncommon and usually due to fat malabsorption. The main symptoms are hemolytic anemia and neurologic deficits. Diagnosis is based on measuring the ratio of plasma \u03b1-tocopherol to total plasma lipids; a low ratio suggests vitamin E deficiency. Treatment consists of oral vitamin E, given in high doses if there are neurologic deficits or if deficiency results from malabsorption.\n\nVitamin E deficiency causes fragility of RBCs and degeneration of neurons, particularly peripheral axons and posterior column neurons.",
                    "md": "Dietary vitamin E deficiency is common in developing countries; deficiency among adults in developed countries is uncommon and usually due to fat malabsorption. The main symptoms are hemolytic anemia and neurologic deficits. Diagnosis is based on measuring the ratio of plasma \u03b1-tocopherol to total plasma lipids; a low ratio suggests vitamin E deficiency. Treatment consists of oral vitamin E, given in high doses if there are neurologic deficits or if deficiency results from malabsorption.\n\nVitamin E deficiency causes fragility of RBCs and degeneration of neurons, particularly peripheral axons and posterior column neurons.",
                    "bBox": {
                        "x": 55,
                        "y": 124.9,
                        "w": 479,
                        "h": 469
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Etiology",
                    "md": "# Etiology",
                    "bBox": {
                        "x": 55,
                        "y": 277.9,
                        "w": 41,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "In developing countries, the most common cause is inadequate intake of vitamin E. In developed countries, the most common causes are disorders that cause fat malabsorption, including abetalipoproteinemia (Bassen-Kornzweig syndrome, due to genetic absence of apolipoprotein B), chronic cholestatic hepatobiliary disease, pancreatitis, short bowel syndrome, and cystic fibrosis. A rare genetic form of vitamin E deficiency without fat malabsorption results from defective liver metabolism.",
                    "md": "In developing countries, the most common cause is inadequate intake of vitamin E. In developed countries, the most common causes are disorders that cause fat malabsorption, including abetalipoproteinemia (Bassen-Kornzweig syndrome, due to genetic absence of apolipoprotein B), chronic cholestatic hepatobiliary disease, pancreatitis, short bowel syndrome, and cystic fibrosis. A rare genetic form of vitamin E deficiency without fat malabsorption results from defective liver metabolism.",
                    "bBox": {
                        "x": 55,
                        "y": 124.9,
                        "w": 481,
                        "h": 241
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 378.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "The main symptoms are mild hemolytic anemia and nonspecific neurologic deficits. Abetalipoproteinemia results in progressive neuropathy and retinopathy in the first 2 decades of life (see p. 904). Vitamin E deficiency may contribute to retinopathy of prematurity (also called retrolental fibroplasia) in premature infants and to some cases of intraventricular and subependymal hemorrhage in neonates. Affected premature neonates have muscle weakness.\n\nIn children, chronic cholestatic hepatobiliary disease or cystic fibrosis causes neurologic deficits, including spinocerebellar ataxia with loss of deep tendon reflexes, truncal and limb ataxia, loss of vibration and position senses, ophthalmoplegia, muscle weakness, ptosis, and dysarthria.\n\nIn adults with malabsorption, vitamin E deficiency very rarely causes spinocerebellar ataxia because adults have large vitamin E stores in adipose tissue.",
                    "md": "The main symptoms are mild hemolytic anemia and nonspecific neurologic deficits. Abetalipoproteinemia results in progressive neuropathy and retinopathy in the first 2 decades of life (see p. 904). Vitamin E deficiency may contribute to retinopathy of prematurity (also called retrolental fibroplasia) in premature infants and to some cases of intraventricular and subependymal hemorrhage in neonates. Affected premature neonates have muscle weakness.\n\nIn children, chronic cholestatic hepatobiliary disease or cystic fibrosis causes neurologic deficits, including spinocerebellar ataxia with loss of deep tendon reflexes, truncal and limb ataxia, loss of vibration and position senses, ophthalmoplegia, muscle weakness, ptosis, and dysarthria.\n\nIn adults with malabsorption, vitamin E deficiency very rarely causes spinocerebellar ataxia because adults have large vitamin E stores in adipose tissue.",
                    "bBox": {
                        "x": 55,
                        "y": 124.9,
                        "w": 483,
                        "h": 443
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 581.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Low \u03b1-tocopherol level or low ratio of serum \u03b1-tocopherol to serum lipids\n\nWithout a history of inadequate intake or a predisposing condition, vitamin E deficiency is unlikely. Confirmation usually requires measuring the vitamin level. Measuring RBC hemolysis in response to peroxide can suggest the diagnosis but is nonspecific. Hemolysis increases as vitamin E deficiency impairs RBC stability.\n\nMeasuring the serum \u03b1-tocopherol level is the most direct method of diagnosis. In adults, vitamin E deficiency is suggested if the \u03b1-tocopherol level is &lt; 5 \u03bcg/mL (&lt; 11.6 \u03bcmol/L). Because abnormal lipid levels can affect vitamin E status, a low ratio of serum \u03b1-tocopherol to lipids (&lt; 0.8 mg/g total lipid) is the most accurate indicator in adults with hyperlipidemia.\n\nIn children and adults with abetalipoproteinemia, serum \u03b1-tocopherol levels are usually undetectable.",
                    "md": "- Low \u03b1-tocopherol level or low ratio of serum \u03b1-tocopherol to serum lipids\n\nWithout a history of inadequate intake or a predisposing condition, vitamin E deficiency is unlikely. Confirmation usually requires measuring the vitamin level. Measuring RBC hemolysis in response to peroxide can suggest the diagnosis but is nonspecific. Hemolysis increases as vitamin E deficiency impairs RBC stability.\n\nMeasuring the serum \u03b1-tocopherol level is the most direct method of diagnosis. In adults, vitamin E deficiency is suggested if the \u03b1-tocopherol level is &lt; 5 \u03bcg/mL (&lt; 11.6 \u03bcmol/L). Because abnormal lipid levels can affect vitamin E status, a low ratio of serum \u03b1-tocopherol to lipids (&lt; 0.8 mg/g total lipid) is the most accurate indicator in adults with hyperlipidemia.\n\nIn children and adults with abetalipoproteinemia, serum \u03b1-tocopherol levels are usually undetectable.",
                    "bBox": {
                        "x": 55,
                        "y": 124.9,
                        "w": 474,
                        "h": 646
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.996
        },
        {
            "page": 44,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n Treatment\n \u2022 Supplemental \u03b1-tocopherol\n If malabsorption causes clinically evident deficiency, \u03b1-tocopherol 15 to 25 mg/kg po once/day should be\n given. However, larger doses given by injection are required to treat neuropathy during its early stages or\n to overcome the defect of absorption and transport in abetalipoproteinemia.\n Prevention\n Although premature neonates may require supplementation, human milk and commercial formulas have\n enough vitamin E for full-term neonates.\n Vitamin E Toxicity\n Many adults take relatively large amounts of vitamin E (\u03b1-tocopherol 400 to 800 mg/day) for months to\n years without any apparent harm. Occasionally, muscle weakness, fatigue, nausea, and diarrhea occur.\n The most significant risk is bleeding. However, bleeding is uncommon unless the dose is &gt; 1000 mg/day\n or the patient takes oral coumarin or warfarin. Thus, the upper limit for adults aged \u226519 yr is 1000 mg for\n any form of \u03b1-tocopherol. Recent analyses of previous studies report that high vitamin E intakes may\n increase the risk of hemorrhagic stroke and premature death.\n Vitamin K\n Vitamin K1 (phylloquinone) is dietary vitamin K. Dietary fat enhances its absorption. Infant formulas\n contain supplemental vitamin K. Vitamin K2 refers to a group of compounds (menaquinones) synthesized\n by bacteria in the intestinal tract; the amount synthesized does not satisfy the vitamin K requirement.\n Vitamin K controls the formation of coagulation factors II (prothrombin), VII, IX, and X in the liver. Other\n coagulation factors dependent on vitamin K are protein C, protein S, and protein Z; proteins C and S are\n anticoagulants. Metabolic pathways conserve vitamin K. Once vitamin K has participated in formation of\n coagulation factors, the reaction product, vitamin K epoxide, is enzymatically converted to the active form,\n vitamin K hydroquinone.\n The actions of vitamin K-dependent proteins require Ca. The vitamin K-dependent proteins, osteocalcin\n and matrix \u03b3-carboxy-glutamyl (Gla) protein, may have important roles in bone and other tissues. Forms of\n vitamin K are common therapy for osteoporosis in Japan and other countries.\n Vitamin K Deficiency\n Vitamin K deficiency results from extremely inadequate intake, fat malabsorption, or use of\n coumarin anticoagulants. Deficiency is particularly common among breastfed infants. It impairs\n clotting. Diagnosis is suspected based on routine coagulation study findings and confirmed by\n response to vitamin K. Treatment consists of vitamin K given orally or, when fat malabsorption\n is the cause or risk of bleeding is high, parenterally.\n Vitamin K deficiency decreases levels of prothrombin and other vitamin K-dependent coagulation factors,\n causing defective coagulation and, potentially, bleeding.\n Etiology\n Worldwide, vitamin K deficiency causes infant morbidity and mortality. Vitamin K deficiency causes\n hemorrhagic disease of the newborn, which usually occurs 1 to 7 days postpartum. In affected neonates,\n birth trauma can cause intracranial hemorrhage. Neonates are prone to vitamin K deficiency because of\n the following:\n \u2022 The placenta transmits lipids and vitamin K relatively poorly.\n                                                                                                      96",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\n# Treatment\n\n\u2022 Supplemental \u03b1-tocopherol\n\nIf malabsorption causes clinically evident deficiency, \u03b1-tocopherol 15 to 25 mg/kg po once/day should be given. However, larger doses given by injection are required to treat neuropathy during its early stages or to overcome the defect of absorption and transport in abetalipoproteinemia.\n\n# Prevention\n\nAlthough premature neonates may require supplementation, human milk and commercial formulas have enough vitamin E for full-term neonates.\n\n# Vitamin E Toxicity\n\nMany adults take relatively large amounts of vitamin E (\u03b1-tocopherol 400 to 800 mg/day) for months to years without any apparent harm. Occasionally, muscle weakness, fatigue, nausea, and diarrhea occur. The most significant risk is bleeding. However, bleeding is uncommon unless the dose is &gt; 1000 mg/day or the patient takes oral coumarin or warfarin. Thus, the upper limit for adults aged \u226519 yr is 1000 mg for any form of \u03b1-tocopherol. Recent analyses of previous studies report that high vitamin E intakes may increase the risk of hemorrhagic stroke and premature death.\n\n# Vitamin K\n\nVitamin K1 (phylloquinone) is dietary vitamin K. Dietary fat enhances its absorption. Infant formulas contain supplemental vitamin K. Vitamin K2 refers to a group of compounds (menaquinones) synthesized by bacteria in the intestinal tract; the amount synthesized does not satisfy the vitamin K requirement. Vitamin K controls the formation of coagulation factors II (prothrombin), VII, IX, and X in the liver. Other coagulation factors dependent on vitamin K are protein C, protein S, and protein Z; proteins C and S are anticoagulants. Metabolic pathways conserve vitamin K. Once vitamin K has participated in formation of coagulation factors, the reaction product, vitamin K epoxide, is enzymatically converted to the active form, vitamin K hydroquinone.\n\nThe actions of vitamin K-dependent proteins require Ca. The vitamin K-dependent proteins, osteocalcin and matrix \u03b3-carboxy-glutamyl (Gla) protein, may have important roles in bone and other tissues. Forms of vitamin K are common therapy for osteoporosis in Japan and other countries.\n\n# Vitamin K Deficiency\n\nVitamin K deficiency results from extremely inadequate intake, fat malabsorption, or use of coumarin anticoagulants. Deficiency is particularly common among breastfed infants. It impairs clotting. Diagnosis is suspected based on routine coagulation study findings and confirmed by response to vitamin K. Treatment consists of vitamin K given orally or, when fat malabsorption is the cause or risk of bleeding is high, parenterally.\n\nVitamin K deficiency decreases levels of prothrombin and other vitamin K-dependent coagulation factors, causing defective coagulation and, potentially, bleeding.\n\n# Etiology\n\nWorldwide, vitamin K deficiency causes infant morbidity and mortality. Vitamin K deficiency causes hemorrhagic disease of the newborn, which usually occurs 1 to 7 days postpartum. In affected neonates, birth trauma can cause intracranial hemorrhage. Neonates are prone to vitamin K deficiency because of the following:\n\n- The placenta transmits lipids and vitamin K relatively poorly.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "\u2022 Supplemental \u03b1-tocopherol\n\nIf malabsorption causes clinically evident deficiency, \u03b1-tocopherol 15 to 25 mg/kg po once/day should be given. However, larger doses given by injection are required to treat neuropathy during its early stages or to overcome the defect of absorption and transport in abetalipoproteinemia.",
                    "md": "\u2022 Supplemental \u03b1-tocopherol\n\nIf malabsorption causes clinically evident deficiency, \u03b1-tocopherol 15 to 25 mg/kg po once/day should be given. However, larger doses given by injection are required to treat neuropathy during its early stages or to overcome the defect of absorption and transport in abetalipoproteinemia.",
                    "bBox": {
                        "x": 55,
                        "y": 74.9,
                        "w": 480,
                        "h": 62
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Prevention",
                    "md": "# Prevention",
                    "bBox": {
                        "x": 55,
                        "y": 150.9,
                        "w": 56,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Although premature neonates may require supplementation, human milk and commercial formulas have enough vitamin E for full-term neonates.",
                    "md": "Although premature neonates may require supplementation, human milk and commercial formulas have enough vitamin E for full-term neonates.",
                    "bBox": {
                        "x": 55,
                        "y": 175.9,
                        "w": 471,
                        "h": 25
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin E Toxicity",
                    "md": "# Vitamin E Toxicity",
                    "bBox": {
                        "x": 55,
                        "y": 213.9,
                        "w": 90,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Many adults take relatively large amounts of vitamin E (\u03b1-tocopherol 400 to 800 mg/day) for months to years without any apparent harm. Occasionally, muscle weakness, fatigue, nausea, and diarrhea occur. The most significant risk is bleeding. However, bleeding is uncommon unless the dose is &gt; 1000 mg/day or the patient takes oral coumarin or warfarin. Thus, the upper limit for adults aged \u226519 yr is 1000 mg for any form of \u03b1-tocopherol. Recent analyses of previous studies report that high vitamin E intakes may increase the risk of hemorrhagic stroke and premature death.",
                    "md": "Many adults take relatively large amounts of vitamin E (\u03b1-tocopherol 400 to 800 mg/day) for months to years without any apparent harm. Occasionally, muscle weakness, fatigue, nausea, and diarrhea occur. The most significant risk is bleeding. However, bleeding is uncommon unless the dose is &gt; 1000 mg/day or the patient takes oral coumarin or warfarin. Thus, the upper limit for adults aged \u226519 yr is 1000 mg for any form of \u03b1-tocopherol. Recent analyses of previous studies report that high vitamin E intakes may increase the risk of hemorrhagic stroke and premature death.",
                    "bBox": {
                        "x": 55,
                        "y": 238.9,
                        "w": 476,
                        "h": 76
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin K",
                    "md": "# Vitamin K",
                    "bBox": {
                        "x": 55,
                        "y": 327.9,
                        "w": 49,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin K1 (phylloquinone) is dietary vitamin K. Dietary fat enhances its absorption. Infant formulas contain supplemental vitamin K. Vitamin K2 refers to a group of compounds (menaquinones) synthesized by bacteria in the intestinal tract; the amount synthesized does not satisfy the vitamin K requirement. Vitamin K controls the formation of coagulation factors II (prothrombin), VII, IX, and X in the liver. Other coagulation factors dependent on vitamin K are protein C, protein S, and protein Z; proteins C and S are anticoagulants. Metabolic pathways conserve vitamin K. Once vitamin K has participated in formation of coagulation factors, the reaction product, vitamin K epoxide, is enzymatically converted to the active form, vitamin K hydroquinone.\n\nThe actions of vitamin K-dependent proteins require Ca. The vitamin K-dependent proteins, osteocalcin and matrix \u03b3-carboxy-glutamyl (Gla) protein, may have important roles in bone and other tissues. Forms of vitamin K are common therapy for osteoporosis in Japan and other countries.",
                    "md": "Vitamin K1 (phylloquinone) is dietary vitamin K. Dietary fat enhances its absorption. Infant formulas contain supplemental vitamin K. Vitamin K2 refers to a group of compounds (menaquinones) synthesized by bacteria in the intestinal tract; the amount synthesized does not satisfy the vitamin K requirement. Vitamin K controls the formation of coagulation factors II (prothrombin), VII, IX, and X in the liver. Other coagulation factors dependent on vitamin K are protein C, protein S, and protein Z; proteins C and S are anticoagulants. Metabolic pathways conserve vitamin K. Once vitamin K has participated in formation of coagulation factors, the reaction product, vitamin K epoxide, is enzymatically converted to the active form, vitamin K hydroquinone.\n\nThe actions of vitamin K-dependent proteins require Ca. The vitamin K-dependent proteins, osteocalcin and matrix \u03b3-carboxy-glutamyl (Gla) protein, may have important roles in bone and other tissues. Forms of vitamin K are common therapy for osteoporosis in Japan and other countries.",
                    "bBox": {
                        "x": 55,
                        "y": 327.9,
                        "w": 482,
                        "h": 194
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin K Deficiency",
                    "md": "# Vitamin K Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 327.9,
                        "w": 105,
                        "h": 220
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin K deficiency results from extremely inadequate intake, fat malabsorption, or use of coumarin anticoagulants. Deficiency is particularly common among breastfed infants. It impairs clotting. Diagnosis is suspected based on routine coagulation study findings and confirmed by response to vitamin K. Treatment consists of vitamin K given orally or, when fat malabsorption is the cause or risk of bleeding is high, parenterally.\n\nVitamin K deficiency decreases levels of prothrombin and other vitamin K-dependent coagulation factors, causing defective coagulation and, potentially, bleeding.",
                    "md": "Vitamin K deficiency results from extremely inadequate intake, fat malabsorption, or use of coumarin anticoagulants. Deficiency is particularly common among breastfed infants. It impairs clotting. Diagnosis is suspected based on routine coagulation study findings and confirmed by response to vitamin K. Treatment consists of vitamin K given orally or, when fat malabsorption is the cause or risk of bleeding is high, parenterally.\n\nVitamin K deficiency decreases levels of prothrombin and other vitamin K-dependent coagulation factors, causing defective coagulation and, potentially, bleeding.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 478,
                        "h": 613
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Etiology",
                    "md": "# Etiology",
                    "bBox": {
                        "x": 55,
                        "y": 674.9,
                        "w": 41,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Worldwide, vitamin K deficiency causes infant morbidity and mortality. Vitamin K deficiency causes hemorrhagic disease of the newborn, which usually occurs 1 to 7 days postpartum. In affected neonates, birth trauma can cause intracranial hemorrhage. Neonates are prone to vitamin K deficiency because of the following:\n\n- The placenta transmits lipids and vitamin K relatively poorly.",
                    "md": "Worldwide, vitamin K deficiency causes infant morbidity and mortality. Vitamin K deficiency causes hemorrhagic disease of the newborn, which usually occurs 1 to 7 days postpartum. In affected neonates, birth trauma can cause intracranial hemorrhage. Neonates are prone to vitamin K deficiency because of the following:\n\n- The placenta transmits lipids and vitamin K relatively poorly.",
                    "bBox": {
                        "x": 55,
                        "y": 327.9,
                        "w": 478,
                        "h": 422
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.997
        },
        {
            "page": 45,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n \u2022 The neonatal liver is immature with respect to prothrombin synthesis.\n \u2022 Breast milk is low in vitamin K, containing about 2.5 \u03bcg/L (cow's milk contains 5000 \u03bcg/L).\n \u2022 The neonatal gut is sterile during the first few days of life.\n Late hemorrhagic disease (occurring 3 to 8 wk postpartum) is usually associated with breastfeeding,\n malabsorption, or a liver disorder. If the mother has taken phenytoin anticonvulsants, coumarin\n anticoagulants, or cephalosporin antibiotics, the risk of both types of hemorrhagic disease is increased.\n In healthy adults, dietary vitamin K deficiency is uncommon because vitamin K is widely distributed in\n green vegetables and the bacteria of the normal gut synthesize menaquinones. However, biliary\n obstruction, malabsorption, cystic fibrosis, and resection of the small intestine can contribute to vitamin K\n deficiency.\n Coumarin anticoagulants interfere with the synthesis of vitamin K-dependent coagulation proteins (factors\n II, VII, IX, and X) in the liver. Certain antibiotics (particularly some cephalosporins and other broad-\n spectrum antibiotics), salicylates, megadoses of vitamin E, and hepatic insufficiency increase risk of\n bleeding in patients with vitamin K deficiency.\n Symptoms and Signs\n Bleeding is the usual manifestation. Easy bruisability and mucosal bleeding (especially epistaxis, GI\n hemorrhage, menorrhagia, and hematuria) can occur. Blood may ooze from puncture sites or incisions.\n Hemorrhagic disease of the newborn and late hemorrhagic disease in infants may cause cutaneous, GI,\n intrathoracic, or, in the worst cases, intracranial bleeding. If obstructive jaundice develops, bleeding\u2014if it\n occurs\u2014usually begins after the 4th or 5th day. It may begin as a slow ooze from a surgical incision, the\n gums, the nose, or GI mucosa, or it may begin as massive bleeding into the GI tract.\n Diagnosis\n \u2022 Usually, prolonged PT that decreases after phytonadione\n Vitamin K deficiency or antagonism (due to coumarin anticoagulants) is suspected when abnormal\n bleeding occurs in a patient at risk. Blood coagulation studies can preliminarily confirm the diagnosis. PT,\n usually reported as the INR, is prolonged, but PTT, thrombin time, platelet count, bleeding time, and\n levels of fibrinogen, fibrin-split products, and D-dimer are normal. If phytonadione (USP generic name for\n vitamin K1) 1 mg IV significantly decreases PT within 2 to 6 h, a liver disorder is not the likely cause, and\n the diagnosis of vitamin K deficiency is confirmed. Some centers can detect vitamin K deficiency more\n directly by measuring the serum vitamin level. The serum level of vitamin K1 ranges from 0.2 to 1.0 ng/mL\n in healthy people consuming adequate quantities of vitamin K1 (50 to 150 \u03bcg/day). Knowing vitamin K\n intake can help interpret serum levels; recent intake affects levels in serum but not in tissues.\n More sensitive indicators of vitamin K status, such as PIVKA (Protein Induced in Vitamin K Absence or\n Antagonism) and under-carboxylated osteocalcin, are under study.\n Treatment\n \u2022 Phytonadione\n Whenever possible, phytonadione should be given po or sc. The usual adult dose is 5 to 20 mg. (Rarely,\n even when phytonadione is correctly diluted and given slowly, IV replacement can result in anaphylaxis or\n anaphylactoid reactions.) INR usually decreases within 6 to 12 h. The dose may be repeated in 6 to 8 h if\n INR has not decreased satisfactorily. Phytonadione 2.5 to 10 mg po is indicated for nonemergency\n correction of a prolonged INR in patients taking anticoagulants. Correction usually occurs within 6 to 8 h.\n When only partial correction of INR is desirable (eg, when INR should remain slightly elevated because of\n                                                                                                        97",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\n- The neonatal liver is immature with respect to prothrombin synthesis.\n- Breast milk is low in vitamin K, containing about 2.5 \u03bcg/L (cow's milk contains 5000 \u03bcg/L).\n- The neonatal gut is sterile during the first few days of life.\n\nLate hemorrhagic disease (occurring 3 to 8 wk postpartum) is usually associated with breastfeeding, malabsorption, or a liver disorder. If the mother has taken phenytoin anticonvulsants, coumarin anticoagulants, or cephalosporin antibiotics, the risk of both types of hemorrhagic disease is increased.\n\nIn healthy adults, dietary vitamin K deficiency is uncommon because vitamin K is widely distributed in green vegetables and the bacteria of the normal gut synthesize menaquinones. However, biliary obstruction, malabsorption, cystic fibrosis, and resection of the small intestine can contribute to vitamin K deficiency.\n\nCoumarin anticoagulants interfere with the synthesis of vitamin K-dependent coagulation proteins (factors II, VII, IX, and X) in the liver. Certain antibiotics (particularly some cephalosporins and other broad-spectrum antibiotics), salicylates, megadoses of vitamin E, and hepatic insufficiency increase risk of bleeding in patients with vitamin K deficiency.\n\n# Symptoms and Signs\n\nBleeding is the usual manifestation. Easy bruisability and mucosal bleeding (especially epistaxis, GI hemorrhage, menorrhagia, and hematuria) can occur. Blood may ooze from puncture sites or incisions. Hemorrhagic disease of the newborn and late hemorrhagic disease in infants may cause cutaneous, GI, intrathoracic, or, in the worst cases, intracranial bleeding. If obstructive jaundice develops, bleeding\u2014if it occurs\u2014usually begins after the 4th or 5th day. It may begin as a slow ooze from a surgical incision, the gums, the nose, or GI mucosa, or it may begin as massive bleeding into the GI tract.\n\n# Diagnosis\n\n- Usually, prolonged PT that decreases after phytonadione\n\nVitamin K deficiency or antagonism (due to coumarin anticoagulants) is suspected when abnormal bleeding occurs in a patient at risk. Blood coagulation studies can preliminarily confirm the diagnosis. PT, usually reported as the INR, is prolonged, but PTT, thrombin time, platelet count, bleeding time, and levels of fibrinogen, fibrin-split products, and D-dimer are normal. If phytonadione (USP generic name for vitamin K1) 1 mg IV significantly decreases PT within 2 to 6 h, a liver disorder is not the likely cause, and the diagnosis of vitamin K deficiency is confirmed. Some centers can detect vitamin K deficiency more directly by measuring the serum vitamin level. The serum level of vitamin K1 ranges from 0.2 to 1.0 ng/mL in healthy people consuming adequate quantities of vitamin K1 (50 to 150 \u03bcg/day). Knowing vitamin K intake can help interpret serum levels; recent intake affects levels in serum but not in tissues. More sensitive indicators of vitamin K status, such as PIVKA (Protein Induced in Vitamin K Absence or Antagonism) and under-carboxylated osteocalcin, are under study.\n\n# Treatment\n\n- Phytonadione\n\nWhenever possible, phytonadione should be given po or sc. The usual adult dose is 5 to 20 mg. (Rarely, even when phytonadione is correctly diluted and given slowly, IV replacement can result in anaphylaxis or anaphylactoid reactions.) INR usually decreases within 6 to 12 h. The dose may be repeated in 6 to 8 h if INR has not decreased satisfactorily. Phytonadione 2.5 to 10 mg po is indicated for nonemergency correction of a prolonged INR in patients taking anticoagulants. Correction usually occurs within 6 to 8 h. When only partial correction of INR is desirable (eg, when INR should remain slightly elevated because of",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 55,
                        "y": 429.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "- The neonatal liver is immature with respect to prothrombin synthesis.\n- Breast milk is low in vitamin K, containing about 2.5 \u03bcg/L (cow's milk contains 5000 \u03bcg/L).\n- The neonatal gut is sterile during the first few days of life.\n\nLate hemorrhagic disease (occurring 3 to 8 wk postpartum) is usually associated with breastfeeding, malabsorption, or a liver disorder. If the mother has taken phenytoin anticonvulsants, coumarin anticoagulants, or cephalosporin antibiotics, the risk of both types of hemorrhagic disease is increased.\n\nIn healthy adults, dietary vitamin K deficiency is uncommon because vitamin K is widely distributed in green vegetables and the bacteria of the normal gut synthesize menaquinones. However, biliary obstruction, malabsorption, cystic fibrosis, and resection of the small intestine can contribute to vitamin K deficiency.\n\nCoumarin anticoagulants interfere with the synthesis of vitamin K-dependent coagulation proteins (factors II, VII, IX, and X) in the liver. Certain antibiotics (particularly some cephalosporins and other broad-spectrum antibiotics), salicylates, megadoses of vitamin E, and hepatic insufficiency increase risk of bleeding in patients with vitamin K deficiency.",
                    "md": "- The neonatal liver is immature with respect to prothrombin synthesis.\n- Breast milk is low in vitamin K, containing about 2.5 \u03bcg/L (cow's milk contains 5000 \u03bcg/L).\n- The neonatal gut is sterile during the first few days of life.\n\nLate hemorrhagic disease (occurring 3 to 8 wk postpartum) is usually associated with breastfeeding, malabsorption, or a liver disorder. If the mother has taken phenytoin anticonvulsants, coumarin anticoagulants, or cephalosporin antibiotics, the risk of both types of hemorrhagic disease is increased.\n\nIn healthy adults, dietary vitamin K deficiency is uncommon because vitamin K is widely distributed in green vegetables and the bacteria of the normal gut synthesize menaquinones. However, biliary obstruction, malabsorption, cystic fibrosis, and resection of the small intestine can contribute to vitamin K deficiency.\n\nCoumarin anticoagulants interfere with the synthesis of vitamin K-dependent coagulation proteins (factors II, VII, IX, and X) in the liver. Certain antibiotics (particularly some cephalosporins and other broad-spectrum antibiotics), salicylates, megadoses of vitamin E, and hepatic insufficiency increase risk of bleeding in patients with vitamin K deficiency.",
                    "bBox": {
                        "x": 55,
                        "y": 125.9,
                        "w": 482,
                        "h": 164
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 302.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Bleeding is the usual manifestation. Easy bruisability and mucosal bleeding (especially epistaxis, GI hemorrhage, menorrhagia, and hematuria) can occur. Blood may ooze from puncture sites or incisions. Hemorrhagic disease of the newborn and late hemorrhagic disease in infants may cause cutaneous, GI, intrathoracic, or, in the worst cases, intracranial bleeding. If obstructive jaundice develops, bleeding\u2014if it occurs\u2014usually begins after the 4th or 5th day. It may begin as a slow ooze from a surgical incision, the gums, the nose, or GI mucosa, or it may begin as massive bleeding into the GI tract.",
                    "md": "Bleeding is the usual manifestation. Easy bruisability and mucosal bleeding (especially epistaxis, GI hemorrhage, menorrhagia, and hematuria) can occur. Blood may ooze from puncture sites or incisions. Hemorrhagic disease of the newborn and late hemorrhagic disease in infants may cause cutaneous, GI, intrathoracic, or, in the worst cases, intracranial bleeding. If obstructive jaundice develops, bleeding\u2014if it occurs\u2014usually begins after the 4th or 5th day. It may begin as a slow ooze from a surgical incision, the gums, the nose, or GI mucosa, or it may begin as massive bleeding into the GI tract.",
                    "bBox": {
                        "x": 55,
                        "y": 328.9,
                        "w": 476,
                        "h": 88
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 429.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Usually, prolonged PT that decreases after phytonadione\n\nVitamin K deficiency or antagonism (due to coumarin anticoagulants) is suspected when abnormal bleeding occurs in a patient at risk. Blood coagulation studies can preliminarily confirm the diagnosis. PT, usually reported as the INR, is prolonged, but PTT, thrombin time, platelet count, bleeding time, and levels of fibrinogen, fibrin-split products, and D-dimer are normal. If phytonadione (USP generic name for vitamin K1) 1 mg IV significantly decreases PT within 2 to 6 h, a liver disorder is not the likely cause, and the diagnosis of vitamin K deficiency is confirmed. Some centers can detect vitamin K deficiency more directly by measuring the serum vitamin level. The serum level of vitamin K1 ranges from 0.2 to 1.0 ng/mL in healthy people consuming adequate quantities of vitamin K1 (50 to 150 \u03bcg/day). Knowing vitamin K intake can help interpret serum levels; recent intake affects levels in serum but not in tissues. More sensitive indicators of vitamin K status, such as PIVKA (Protein Induced in Vitamin K Absence or Antagonism) and under-carboxylated osteocalcin, are under study.",
                    "md": "- Usually, prolonged PT that decreases after phytonadione\n\nVitamin K deficiency or antagonism (due to coumarin anticoagulants) is suspected when abnormal bleeding occurs in a patient at risk. Blood coagulation studies can preliminarily confirm the diagnosis. PT, usually reported as the INR, is prolonged, but PTT, thrombin time, platelet count, bleeding time, and levels of fibrinogen, fibrin-split products, and D-dimer are normal. If phytonadione (USP generic name for vitamin K1) 1 mg IV significantly decreases PT within 2 to 6 h, a liver disorder is not the likely cause, and the diagnosis of vitamin K deficiency is confirmed. Some centers can detect vitamin K deficiency more directly by measuring the serum vitamin level. The serum level of vitamin K1 ranges from 0.2 to 1.0 ng/mL in healthy people consuming adequate quantities of vitamin K1 (50 to 150 \u03bcg/day). Knowing vitamin K intake can help interpret serum levels; recent intake affects levels in serum but not in tissues. More sensitive indicators of vitamin K status, such as PIVKA (Protein Induced in Vitamin K Absence or Antagonism) and under-carboxylated osteocalcin, are under study.",
                    "bBox": {
                        "x": 55,
                        "y": 429.9,
                        "w": 482,
                        "h": 210.42
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 653.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Phytonadione\n\nWhenever possible, phytonadione should be given po or sc. The usual adult dose is 5 to 20 mg. (Rarely, even when phytonadione is correctly diluted and given slowly, IV replacement can result in anaphylaxis or anaphylactoid reactions.) INR usually decreases within 6 to 12 h. The dose may be repeated in 6 to 8 h if INR has not decreased satisfactorily. Phytonadione 2.5 to 10 mg po is indicated for nonemergency correction of a prolonged INR in patients taking anticoagulants. Correction usually occurs within 6 to 8 h. When only partial correction of INR is desirable (eg, when INR should remain slightly elevated because of",
                    "md": "- Phytonadione\n\nWhenever possible, phytonadione should be given po or sc. The usual adult dose is 5 to 20 mg. (Rarely, even when phytonadione is correctly diluted and given slowly, IV replacement can result in anaphylaxis or anaphylactoid reactions.) INR usually decreases within 6 to 12 h. The dose may be repeated in 6 to 8 h if INR has not decreased satisfactorily. Phytonadione 2.5 to 10 mg po is indicated for nonemergency correction of a prolonged INR in patients taking anticoagulants. Correction usually occurs within 6 to 8 h. When only partial correction of INR is desirable (eg, when INR should remain slightly elevated because of",
                    "bBox": {
                        "x": 55,
                        "y": 703.9,
                        "w": 482,
                        "h": 76
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.998
        },
        {
            "page": 46,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n a prosthetic heart valve), lower doses (eg, 1 to 2.5 mg) of phytonadione can be given.\n In infants, bleeding due to deficiency can be corrected by giving phytonadione 1 mg sc or IM once. The\n dose is repeated if INR remains elevated. Higher doses may be necessary if the mother has been taking\n oral anticoagulants.\n Prevention\n Phytonadione 0.5 to 1 mg IM (or 0.3 mg/kg for preterm infants) is recommended for all neonates within 6 h\n of birth to reduce the incidence of intracranial hemorrhage due to birth trauma and of classic hemorrhagic\n disease of the newborn (increased bleeding risks 1 to 7 days after birth). It is also used prophylactically\n before surgery. Some clinicians recommend that pregnant women taking anticonvulsants receive\n phytonadione 10 mg po once/day for the 1 mo or 20 mg po once/day for the 2 wk before delivery. The low\n vitamin K1 content in breast milk can be increased by increasing maternal dietary intake of phylloquinone\n to 5 mg/day.\n Vitamin K Toxicity\n Vitamin K1 (phylloquinone) is not toxic when consumed orally, even in large amounts. However,\n menadione (a synthetic, water-soluble vitamin K precursor) can cause toxicity and should not be used to\n treat vitamin K deficiency.\n                                                                                                       98",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n\nA prosthetic heart valve), lower doses (eg, 1 to 2.5 mg) of phytonadione can be given.\n\nIn infants, bleeding due to deficiency can be corrected by giving phytonadione 1 mg sc or IM once. The dose is repeated if INR remains elevated. Higher doses may be necessary if the mother has been taking oral anticoagulants.\n\n# Prevention\n\nPhytonadione 0.5 to 1 mg IM (or 0.3 mg/kg for preterm infants) is recommended for all neonates within 6 h of birth to reduce the incidence of intracranial hemorrhage due to birth trauma and of classic hemorrhagic disease of the newborn (increased bleeding risks 1 to 7 days after birth). It is also used prophylactically before surgery. Some clinicians recommend that pregnant women taking anticonvulsants receive phytonadione 10 mg po once/day for the 1 mo or 20 mg po once/day for the 2 wk before delivery. The low vitamin K1 content in breast milk can be increased by increasing maternal dietary intake of phylloquinone to 5 mg/day.\n\n# Vitamin K Toxicity\n\nVitamin K1 (phylloquinone) is not toxic when consumed orally, even in large amounts. However, menadione (a synthetic, water-soluble vitamin K precursor) can cause toxicity and should not be used to treat vitamin K deficiency.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "md": "# Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "A prosthetic heart valve), lower doses (eg, 1 to 2.5 mg) of phytonadione can be given.\n\nIn infants, bleeding due to deficiency can be corrected by giving phytonadione 1 mg sc or IM once. The dose is repeated if INR remains elevated. Higher doses may be necessary if the mother has been taking oral anticoagulants.",
                    "md": "A prosthetic heart valve), lower doses (eg, 1 to 2.5 mg) of phytonadione can be given.\n\nIn infants, bleeding due to deficiency can be corrected by giving phytonadione 1 mg sc or IM once. The dose is repeated if INR remains elevated. Higher doses may be necessary if the mother has been taking oral anticoagulants.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 475,
                        "h": 63
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Prevention",
                    "md": "# Prevention",
                    "bBox": {
                        "x": 55,
                        "y": 124.9,
                        "w": 56,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Phytonadione 0.5 to 1 mg IM (or 0.3 mg/kg for preterm infants) is recommended for all neonates within 6 h of birth to reduce the incidence of intracranial hemorrhage due to birth trauma and of classic hemorrhagic disease of the newborn (increased bleeding risks 1 to 7 days after birth). It is also used prophylactically before surgery. Some clinicians recommend that pregnant women taking anticonvulsants receive phytonadione 10 mg po once/day for the 1 mo or 20 mg po once/day for the 2 wk before delivery. The low vitamin K1 content in breast milk can be increased by increasing maternal dietary intake of phylloquinone to 5 mg/day.",
                    "md": "Phytonadione 0.5 to 1 mg IM (or 0.3 mg/kg for preterm infants) is recommended for all neonates within 6 h of birth to reduce the incidence of intracranial hemorrhage due to birth trauma and of classic hemorrhagic disease of the newborn (increased bleeding risks 1 to 7 days after birth). It is also used prophylactically before surgery. Some clinicians recommend that pregnant women taking anticonvulsants receive phytonadione 10 mg po once/day for the 1 mo or 20 mg po once/day for the 2 wk before delivery. The low vitamin K1 content in breast milk can be increased by increasing maternal dietary intake of phylloquinone to 5 mg/day.",
                    "bBox": {
                        "x": 55,
                        "y": 150.9,
                        "w": 483,
                        "h": 90
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Vitamin K Toxicity",
                    "md": "# Vitamin K Toxicity",
                    "bBox": {
                        "x": 55,
                        "y": 253.9,
                        "w": 91,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Vitamin K1 (phylloquinone) is not toxic when consumed orally, even in large amounts. However, menadione (a synthetic, water-soluble vitamin K precursor) can cause toxicity and should not be used to treat vitamin K deficiency.",
                    "md": "Vitamin K1 (phylloquinone) is not toxic when consumed orally, even in large amounts. However, menadione (a synthetic, water-soluble vitamin K precursor) can cause toxicity and should not be used to treat vitamin K deficiency.",
                    "bBox": {
                        "x": 55,
                        "y": 279.9,
                        "w": 475,
                        "h": 39
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.991
        },
        {
            "page": 47,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition              Chapter 5. Mineral Deficiency &amp; Toxicity\n Chapter 5. Mineral Deficiency and Toxicity\n Introduction\n Six macrominerals are required by people in gram amounts. Four (Na, K, Ca, and Mg) are cations; two (Cl\n and P) are accompanying anions (see p. 820). Daily requirements range from 0.3 to 2.0 g. Bone, muscle,\n heart, and brain function depend on these minerals.\n Nine trace minerals (microminerals) are required by people in minute amounts: chromium, copper, iodine,\n iron, fluorine, manganese, molybdenum, selenium, and zinc. (For sources, functions, effects of deficiency\n and toxicity, and dietary requirements, see\n Tables 5-1 and\n 5-2.) All trace minerals are toxic at high levels; some minerals (arsenic, nickel, and chromium) may be\n carcinogens.\n Mineral deficiencies (except of iodine, iron, and zinc) do not often develop spontaneously in adults on\n ordinary diets; infants are more vulnerable because their growth is rapid and intake varies. Trace mineral\n imbalances can result from hereditary disorders (eg, hemochromatosis, Wilson's disease), kidney dialysis,\n parenteral nutrition, or restrictive diets prescribed for people with inborn errors of metabolism.\n Chromium\n Only 1 to 3% of biologically active trivalent chromium (Cr) is absorbed. Normal plasma levels are 0.05 to\n 0.50 \u03bcg/L (1.0 to 9.6 nmol/L). Chromium potentiates insulin activity and increases the growth rate in\n undernourished children. Supplements do not enhance muscle size or strength in men.\n Deficiency: Four patients receiving long-term TPN developed possible chromium deficiency, with\n glucose intolerance, weight loss, ataxia, and peripheral neuropathy. Symptoms resolved in 3 who were\n given trivalent chromium 150 to 250 mg.\n Toxicity: High doses of trivalent chromium given parenterally cause skin irritation, but lower doses given\n orally are not toxic. Exposure to hexavalent chromium (CrO3) in the workplace may irritate the skin, lungs,\n and GI tract and may cause perforation of the nasal septum and lung carcinoma.\n Copper\n Copper is a component of many body proteins; almost all of the body's copper is bound to copper\n proteins. Unbound (free) copper ions are toxic. Genetic mechanisms control the incorporation of copper\n into apoproteins and the processes that prevent toxic accumulation of copper in the body. Copper\n absorbed in excess of metabolic requirements is excreted through bile.\n [Table 5-1. Trace Minerals]\n Acquired Copper Deficiency\n If the genetic mechanisms controlling copper metabolism are normal, dietary deficiency rarely causes\n clinically significant copper deficiency. The only reported causes are kwashiorkor, persistent infantile\n diarrhea (usually associated with a diet limited to milk), severe malabsorption (as in sprue), and excessive\n zinc intake.\n Deficiency may cause neutropenia, impaired bone calcification, and hypochromic anemia not responsive\n to iron supplements.\n Diagnosis is based on low serum levels of copper and ceruloplasmin, although these tests are not always\n reliable. Treatment is directed at the cause, and copper 1.5 to 3 mg/day po (usually as copper sulfate) is\n given.\n                                                                                                       99",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 5. Mineral Deficiency and Toxicity\n\n# Introduction\n\nSix macrominerals are required by people in gram amounts. Four (Na, K, Ca, and Mg) are cations; two (Cl and P) are accompanying anions (see p. 820). Daily requirements range from 0.3 to 2.0 g. Bone, muscle, heart, and brain function depend on these minerals.\n\nNine trace minerals (microminerals) are required by people in minute amounts: chromium, copper, iodine, iron, fluorine, manganese, molybdenum, selenium, and zinc. (For sources, functions, effects of deficiency and toxicity, and dietary requirements, see Tables 5-1 and 5-2.) All trace minerals are toxic at high levels; some minerals (arsenic, nickel, and chromium) may be carcinogens.\n\nMineral deficiencies (except of iodine, iron, and zinc) do not often develop spontaneously in adults on ordinary diets; infants are more vulnerable because their growth is rapid and intake varies. Trace mineral imbalances can result from hereditary disorders (eg, hemochromatosis, Wilson's disease), kidney dialysis, parenteral nutrition, or restrictive diets prescribed for people with inborn errors of metabolism.\n\n# Chromium\n\nOnly 1 to 3% of biologically active trivalent chromium (Cr) is absorbed. Normal plasma levels are 0.05 to 0.50 \u03bcg/L (1.0 to 9.6 nmol/L). Chromium potentiates insulin activity and increases the growth rate in undernourished children. Supplements do not enhance muscle size or strength in men.\n\nDeficiency: Four patients receiving long-term TPN developed possible chromium deficiency, with glucose intolerance, weight loss, ataxia, and peripheral neuropathy. Symptoms resolved in 3 who were given trivalent chromium 150 to 250 mg.\n\nToxicity: High doses of trivalent chromium given parenterally cause skin irritation, but lower doses given orally are not toxic. Exposure to hexavalent chromium (CrO3) in the workplace may irritate the skin, lungs, and GI tract and may cause perforation of the nasal septum and lung carcinoma.\n\n# Copper\n\nCopper is a component of many body proteins; almost all of the body's copper is bound to copper proteins. Unbound (free) copper ions are toxic. Genetic mechanisms control the incorporation of copper into apoproteins and the processes that prevent toxic accumulation of copper in the body. Copper absorbed in excess of metabolic requirements is excreted through bile.\n\n# [Table 5-1. Trace Minerals]\n\n# Acquired Copper Deficiency\n\nIf the genetic mechanisms controlling copper metabolism are normal, dietary deficiency rarely causes clinically significant copper deficiency. The only reported causes are kwashiorkor, persistent infantile diarrhea (usually associated with a diet limited to milk), severe malabsorption (as in sprue), and excessive zinc intake.\n\nDeficiency may cause neutropenia, impaired bone calcification, and hypochromic anemia not responsive to iron supplements.\n\nDiagnosis is based on low serum levels of copper and ceruloplasmin, although these tests are not always reliable. Treatment is directed at the cause, and copper 1.5 to 3 mg/day po (usually as copper sulfate) is given.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 5. Mineral Deficiency and Toxicity",
                    "md": "# Chapter 5. Mineral Deficiency and Toxicity",
                    "bBox": {
                        "x": 55,
                        "y": 54.9,
                        "w": 210,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Introduction",
                    "md": "# Introduction",
                    "bBox": {
                        "x": 55,
                        "y": 79.9,
                        "w": 61,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Six macrominerals are required by people in gram amounts. Four (Na, K, Ca, and Mg) are cations; two (Cl and P) are accompanying anions (see p. 820). Daily requirements range from 0.3 to 2.0 g. Bone, muscle, heart, and brain function depend on these minerals.\n\nNine trace minerals (microminerals) are required by people in minute amounts: chromium, copper, iodine, iron, fluorine, manganese, molybdenum, selenium, and zinc. (For sources, functions, effects of deficiency and toxicity, and dietary requirements, see Tables 5-1 and 5-2.) All trace minerals are toxic at high levels; some minerals (arsenic, nickel, and chromium) may be carcinogens.\n\nMineral deficiencies (except of iodine, iron, and zinc) do not often develop spontaneously in adults on ordinary diets; infants are more vulnerable because their growth is rapid and intake varies. Trace mineral imbalances can result from hereditary disorders (eg, hemochromatosis, Wilson's disease), kidney dialysis, parenteral nutrition, or restrictive diets prescribed for people with inborn errors of metabolism.",
                    "md": "Six macrominerals are required by people in gram amounts. Four (Na, K, Ca, and Mg) are cations; two (Cl and P) are accompanying anions (see p. 820). Daily requirements range from 0.3 to 2.0 g. Bone, muscle, heart, and brain function depend on these minerals.\n\nNine trace minerals (microminerals) are required by people in minute amounts: chromium, copper, iodine, iron, fluorine, manganese, molybdenum, selenium, and zinc. (For sources, functions, effects of deficiency and toxicity, and dietary requirements, see Tables 5-1 and 5-2.) All trace minerals are toxic at high levels; some minerals (arsenic, nickel, and chromium) may be carcinogens.\n\nMineral deficiencies (except of iodine, iron, and zinc) do not often develop spontaneously in adults on ordinary diets; infants are more vulnerable because their growth is rapid and intake varies. Trace mineral imbalances can result from hereditary disorders (eg, hemochromatosis, Wilson's disease), kidney dialysis, parenteral nutrition, or restrictive diets prescribed for people with inborn errors of metabolism.",
                    "bBox": {
                        "x": 55,
                        "y": 104.9,
                        "w": 483,
                        "h": 395
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chromium",
                    "md": "# Chromium",
                    "bBox": {
                        "x": 55,
                        "y": 307.9,
                        "w": 53,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Only 1 to 3% of biologically active trivalent chromium (Cr) is absorbed. Normal plasma levels are 0.05 to 0.50 \u03bcg/L (1.0 to 9.6 nmol/L). Chromium potentiates insulin activity and increases the growth rate in undernourished children. Supplements do not enhance muscle size or strength in men.\n\nDeficiency: Four patients receiving long-term TPN developed possible chromium deficiency, with glucose intolerance, weight loss, ataxia, and peripheral neuropathy. Symptoms resolved in 3 who were given trivalent chromium 150 to 250 mg.\n\nToxicity: High doses of trivalent chromium given parenterally cause skin irritation, but lower doses given orally are not toxic. Exposure to hexavalent chromium (CrO3) in the workplace may irritate the skin, lungs, and GI tract and may cause perforation of the nasal septum and lung carcinoma.",
                    "md": "Only 1 to 3% of biologically active trivalent chromium (Cr) is absorbed. Normal plasma levels are 0.05 to 0.50 \u03bcg/L (1.0 to 9.6 nmol/L). Chromium potentiates insulin activity and increases the growth rate in undernourished children. Supplements do not enhance muscle size or strength in men.\n\nDeficiency: Four patients receiving long-term TPN developed possible chromium deficiency, with glucose intolerance, weight loss, ataxia, and peripheral neuropathy. Symptoms resolved in 3 who were given trivalent chromium 150 to 250 mg.\n\nToxicity: High doses of trivalent chromium given parenterally cause skin irritation, but lower doses given orally are not toxic. Exposure to hexavalent chromium (CrO3) in the workplace may irritate the skin, lungs, and GI tract and may cause perforation of the nasal septum and lung carcinoma.",
                    "bBox": {
                        "x": 55,
                        "y": 307.9,
                        "w": 482,
                        "h": 166
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Copper",
                    "md": "# Copper",
                    "bBox": {
                        "x": 55,
                        "y": 487.9,
                        "w": 37,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Copper is a component of many body proteins; almost all of the body's copper is bound to copper proteins. Unbound (free) copper ions are toxic. Genetic mechanisms control the incorporation of copper into apoproteins and the processes that prevent toxic accumulation of copper in the body. Copper absorbed in excess of metabolic requirements is excreted through bile.",
                    "md": "Copper is a component of many body proteins; almost all of the body's copper is bound to copper proteins. Unbound (free) copper ions are toxic. Genetic mechanisms control the incorporation of copper into apoproteins and the processes that prevent toxic accumulation of copper in the body. Copper absorbed in excess of metabolic requirements is excreted through bile.",
                    "bBox": {
                        "x": 55,
                        "y": 487.9,
                        "w": 472,
                        "h": 75
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "[Table 5-1. Trace Minerals]",
                    "md": "# [Table 5-1. Trace Minerals]",
                    "bBox": {
                        "x": 55,
                        "y": 575.9,
                        "w": 125,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Acquired Copper Deficiency",
                    "md": "# Acquired Copper Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 487.9,
                        "w": 141,
                        "h": 126
                    }
                },
                {
                    "type": "text",
                    "value": "If the genetic mechanisms controlling copper metabolism are normal, dietary deficiency rarely causes clinically significant copper deficiency. The only reported causes are kwashiorkor, persistent infantile diarrhea (usually associated with a diet limited to milk), severe malabsorption (as in sprue), and excessive zinc intake.\n\nDeficiency may cause neutropenia, impaired bone calcification, and hypochromic anemia not responsive to iron supplements.\n\nDiagnosis is based on low serum levels of copper and ceruloplasmin, although these tests are not always reliable. Treatment is directed at the cause, and copper 1.5 to 3 mg/day po (usually as copper sulfate) is given.",
                    "md": "If the genetic mechanisms controlling copper metabolism are normal, dietary deficiency rarely causes clinically significant copper deficiency. The only reported causes are kwashiorkor, persistent infantile diarrhea (usually associated with a diet limited to milk), severe malabsorption (as in sprue), and excessive zinc intake.\n\nDeficiency may cause neutropenia, impaired bone calcification, and hypochromic anemia not responsive to iron supplements.\n\nDiagnosis is based on low serum levels of copper and ceruloplasmin, although these tests are not always reliable. Treatment is directed at the cause, and copper 1.5 to 3 mg/day po (usually as copper sulfate) is given.",
                    "bBox": {
                        "x": 55,
                        "y": 487.9,
                        "w": 482,
                        "h": 278
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.985
        },
        {
            "page": 48,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition                Chapter 5. Mineral Deficiency &amp; Toxicity\n Inherited Copper Deficiency\n (Menkes Syndrome)\n Inherited copper deficiency occurs in male infants who inherit a mutant X-linked gene. Incidence is about\n 1 in 50,000 live births. Copper is deficient in the liver, serum, and essential copper proteins, including\n cytochrome-c oxidase, ceruloplasmin, and lysyl oxidase.\n Symptoms are severe intellectual disability, vomiting, diarrhea, protein-losing enteropathy,\n hypopigmentation, bone changes, and arterial rupture; the hair is sparse, steely, or kinky.\n Diagnosis\n \u2022 Serum copper and ceruloplasmin levels\n \u2022 Serum levels of dopamine, norepinephrine, dihydroxyphenylacetic acid, and dihydroxyphenylglycol in\n   infants at risk\n Diagnosis is based on low copper and ceruloplasmin levels in serum, although these tests are not always\n reliable. Because early diagnosis and treatment seem to result in a better prognosis, the disorder is\n ideally detected before age 2 wk. However, diagnostic accuracy of these tests is limited. Thus, infants at\n risk (eg, those with a family history) can be screened by measuring dopamine, norepinephrine,\n dihydroxyphenylacetic acid, and dihydroxyphenylglycol in serum. A dihydroxyphenylacetic\n acid:dihydroxyphenylglycol ratio of &gt; 4 seems to indicate deficiency, and a dopamine:norepinephrine ratio\n of &gt; 0.2 seems to confirm it.\n Treatment\n \u2022 Copper histidine\n Parenteral copper is usually given as copper histidine 250 \u03bcg sc bid to age 1 yr, then 250 \u03bcg sc once/day\n until age 3 yr; monitoring kidney function is essential during treatment. Despite early treatment, many\n children have abnormal neurodevelopment.\n Acquired Copper Toxicity\n Acquired copper toxicity can result from ingesting or absorbing excess copper (eg, from ingesting an\n acidic food or beverage that has had prolonged contact with a copper container). Self-limited\n gastroenteritis with nausea, vomiting, and diarrhea may occur.\n [Table 5-2. Guidelines for Daily Intake of Minerals]\n More severe toxicity results from ingestion (usually with suicidal intent) of gram quantities of a copper salt\n (eg, copper sulfate) or from absorption of large amounts through the skin (eg, if compresses saturated\n with a solution of a copper salt are applied to large areas of burned skin). Hemolytic anemia and anuria\n can result and may be fatal.\n Indian childhood cirrhosis, non-Indian childhood cirrhosis, and idiopathic copper toxicity are probably\n identical disorders in which excess copper causes cirrhosis. All seem to be caused by ingesting milk that\n has been boiled or stored in corroded copper or brass vessels. Recent studies suggest that idiopathic\n copper toxicity may develop only in infants with an unknown genetic defect.\n Diagnosis usually requires liver biopsy, which shows Mallory hyalin bodies.\n Treatment\n \u2022 Chelation\n                                                                                                        100",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 5. Mineral Deficiency &amp; Toxicity\n\n# Inherited Copper Deficiency (Menkes Syndrome)\n\nInherited copper deficiency occurs in male infants who inherit a mutant X-linked gene. Incidence is about 1 in 50,000 live births. Copper is deficient in the liver, serum, and essential copper proteins, including cytochrome-c oxidase, ceruloplasmin, and lysyl oxidase.\n\nSymptoms are severe intellectual disability, vomiting, diarrhea, protein-losing enteropathy, hypopigmentation, bone changes, and arterial rupture; the hair is sparse, steely, or kinky.\n\n# Diagnosis\n\n- Serum copper and ceruloplasmin levels\n- Serum levels of dopamine, norepinephrine, dihydroxyphenylacetic acid, and dihydroxyphenylglycol in infants at risk\n\nDiagnosis is based on low copper and ceruloplasmin levels in serum, although these tests are not always reliable. Because early diagnosis and treatment seem to result in a better prognosis, the disorder is ideally detected before age 2 wk. However, diagnostic accuracy of these tests is limited. Thus, infants at risk (eg, those with a family history) can be screened by measuring dopamine, norepinephrine, dihydroxyphenylacetic acid, and dihydroxyphenylglycol in serum. A dihydroxyphenylacetic acid:dihydroxyphenylglycol ratio of &gt; 4 seems to indicate deficiency, and a dopamine:norepinephrine ratio of &gt; 0.2 seems to confirm it.\n\n# Treatment\n\n- Copper histidine\n\nParenteral copper is usually given as copper histidine 250 \u03bcg sc bid to age 1 yr, then 250 \u03bcg sc once/day until age 3 yr; monitoring kidney function is essential during treatment. Despite early treatment, many children have abnormal neurodevelopment.\n\n# Acquired Copper Toxicity\n\nAcquired copper toxicity can result from ingesting or absorbing excess copper (eg, from ingesting an acidic food or beverage that has had prolonged contact with a copper container). Self-limited gastroenteritis with nausea, vomiting, and diarrhea may occur.\n\n| More severe toxicity results from ingestion (usually with suicidal intent) of gram quantities of a copper salt (eg, copper sulfate) or from absorption of large amounts through the skin (eg, if compresses saturated with a solution of a copper salt are applied to large areas of burned skin). Hemolytic anemia and anuria can result and may be fatal. |                                |\n| ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------ |\n| Indian childhood cirrhosis                                                                                                                                                                                                                                                                                                                                  | non-Indian childhood cirrhosis |\n| and idiopathic copper toxicity are probably identical disorders in which excess copper causes cirrhosis. All seem to be caused by ingesting milk that has been boiled or stored in corroded copper or brass vessels. Recent studies suggest that idiopathic copper toxicity may develop only in infants with an unknown genetic defect.                     |                                |\n\nDiagnosis usually requires liver biopsy, which shows Mallory hyalin bodies.\n\n# Treatment\n\n- Chelation",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 170.18
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "md": "# Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "bBox": {
                        "x": 365,
                        "y": 30.72,
                        "w": 178,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Inherited Copper Deficiency (Menkes Syndrome)",
                    "md": "# Inherited Copper Deficiency (Menkes Syndrome)",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 141,
                        "h": 38
                    }
                },
                {
                    "type": "text",
                    "value": "Inherited copper deficiency occurs in male infants who inherit a mutant X-linked gene. Incidence is about 1 in 50,000 live births. Copper is deficient in the liver, serum, and essential copper proteins, including cytochrome-c oxidase, ceruloplasmin, and lysyl oxidase.\n\nSymptoms are severe intellectual disability, vomiting, diarrhea, protein-losing enteropathy, hypopigmentation, bone changes, and arterial rupture; the hair is sparse, steely, or kinky.",
                    "md": "Inherited copper deficiency occurs in male infants who inherit a mutant X-linked gene. Incidence is about 1 in 50,000 live births. Copper is deficient in the liver, serum, and essential copper proteins, including cytochrome-c oxidase, ceruloplasmin, and lysyl oxidase.\n\nSymptoms are severe intellectual disability, vomiting, diarrhea, protein-losing enteropathy, hypopigmentation, bone changes, and arterial rupture; the hair is sparse, steely, or kinky.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 476,
                        "h": 126
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 188.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Serum copper and ceruloplasmin levels\n- Serum levels of dopamine, norepinephrine, dihydroxyphenylacetic acid, and dihydroxyphenylglycol in infants at risk\n\nDiagnosis is based on low copper and ceruloplasmin levels in serum, although these tests are not always reliable. Because early diagnosis and treatment seem to result in a better prognosis, the disorder is ideally detected before age 2 wk. However, diagnostic accuracy of these tests is limited. Thus, infants at risk (eg, those with a family history) can be screened by measuring dopamine, norepinephrine, dihydroxyphenylacetic acid, and dihydroxyphenylglycol in serum. A dihydroxyphenylacetic acid:dihydroxyphenylglycol ratio of &gt; 4 seems to indicate deficiency, and a dopamine:norepinephrine ratio of &gt; 0.2 seems to confirm it.",
                    "md": "- Serum copper and ceruloplasmin levels\n- Serum levels of dopamine, norepinephrine, dihydroxyphenylacetic acid, and dihydroxyphenylglycol in infants at risk\n\nDiagnosis is based on low copper and ceruloplasmin levels in serum, although these tests are not always reliable. Because early diagnosis and treatment seem to result in a better prognosis, the disorder is ideally detected before age 2 wk. However, diagnostic accuracy of these tests is limited. Thus, infants at risk (eg, those with a family history) can be screened by measuring dopamine, norepinephrine, dihydroxyphenylacetic acid, and dihydroxyphenylglycol in serum. A dihydroxyphenylacetic acid:dihydroxyphenylglycol ratio of &gt; 4 seems to indicate deficiency, and a dopamine:norepinephrine ratio of &gt; 0.2 seems to confirm it.",
                    "bBox": {
                        "x": 55,
                        "y": 188.9,
                        "w": 481,
                        "h": 557
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 378.9,
                        "w": 51,
                        "h": 367
                    }
                },
                {
                    "type": "text",
                    "value": "- Copper histidine\n\nParenteral copper is usually given as copper histidine 250 \u03bcg sc bid to age 1 yr, then 250 \u03bcg sc once/day until age 3 yr; monitoring kidney function is essential during treatment. Despite early treatment, many children have abnormal neurodevelopment.",
                    "md": "- Copper histidine\n\nParenteral copper is usually given as copper histidine 250 \u03bcg sc bid to age 1 yr, then 250 \u03bcg sc once/day until age 3 yr; monitoring kidney function is essential during treatment. Despite early treatment, many children have abnormal neurodevelopment.",
                    "bBox": {
                        "x": 55,
                        "y": 378.9,
                        "w": 480,
                        "h": 367
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Acquired Copper Toxicity",
                    "md": "# Acquired Copper Toxicity",
                    "bBox": {
                        "x": 55,
                        "y": 479.9,
                        "w": 127,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Acquired copper toxicity can result from ingesting or absorbing excess copper (eg, from ingesting an acidic food or beverage that has had prolonged contact with a copper container). Self-limited gastroenteritis with nausea, vomiting, and diarrhea may occur.",
                    "md": "Acquired copper toxicity can result from ingesting or absorbing excess copper (eg, from ingesting an acidic food or beverage that has had prolonged contact with a copper container). Self-limited gastroenteritis with nausea, vomiting, and diarrhea may occur.",
                    "bBox": {
                        "x": 55,
                        "y": 479.9,
                        "w": 456,
                        "h": 63
                    }
                },
                {
                    "type": "table",
                    "rows": [
                        [
                            "More severe toxicity results from ingestion (usually with suicidal intent) of gram quantities of a copper salt (eg, copper sulfate) or from absorption of large amounts through the skin (eg, if compresses saturated with a solution of a copper salt are applied to large areas of burned skin). Hemolytic anemia and anuria can result and may be fatal.",
                            ""
                        ],
                        [
                            "Indian childhood cirrhosis",
                            "non-Indian childhood cirrhosis"
                        ],
                        [
                            "and idiopathic copper toxicity are probably identical disorders in which excess copper causes cirrhosis. All seem to be caused by ingesting milk that has been boiled or stored in corroded copper or brass vessels. Recent studies suggest that idiopathic copper toxicity may develop only in infants with an unknown genetic defect.",
                            ""
                        ]
                    ],
                    "md": "| More severe toxicity results from ingestion (usually with suicidal intent) of gram quantities of a copper salt (eg, copper sulfate) or from absorption of large amounts through the skin (eg, if compresses saturated with a solution of a copper salt are applied to large areas of burned skin). Hemolytic anemia and anuria can result and may be fatal. |                                |\n| ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------ |\n| Indian childhood cirrhosis                                                                                                                                                                                                                                                                                                                                  | non-Indian childhood cirrhosis |\n| and idiopathic copper toxicity are probably identical disorders in which excess copper causes cirrhosis. All seem to be caused by ingesting milk that has been boiled or stored in corroded copper or brass vessels. Recent studies suggest that idiopathic copper toxicity may develop only in infants with an unknown genetic defect.                     |                                |",
                    "isPerfectTable": true,
                    "csv": "\"More severe toxicity results from ingestion (usually with suicidal intent) of gram quantities of a copper salt (eg, copper sulfate) or from absorption of large amounts through the skin (eg, if compresses saturated with a solution of a copper salt are applied to large areas of burned skin). Hemolytic anemia and anuria can result and may be fatal.\",\"\"\n\"Indian childhood cirrhosis\",\"non-Indian childhood cirrhosis\"\n\"and idiopathic copper toxicity are probably identical disorders in which excess copper causes cirrhosis. All seem to be caused by ingesting milk that has been boiled or stored in corroded copper or brass vessels. Recent studies suggest that idiopathic copper toxicity may develop only in infants with an unknown genetic defect.\",\"\"",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 493,
                        "h": 777
                    }
                },
                {
                    "type": "text",
                    "value": "Diagnosis usually requires liver biopsy, which shows Mallory hyalin bodies.",
                    "md": "Diagnosis usually requires liver biopsy, which shows Mallory hyalin bodies.",
                    "bBox": {
                        "x": 55,
                        "y": 188.9,
                        "w": 342,
                        "h": 531
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 378.9,
                        "w": 51,
                        "h": 367
                    }
                },
                {
                    "type": "text",
                    "value": "- Chelation",
                    "md": "- Chelation",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.979
        },
        {
            "page": 49,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition               Chapter 5. Mineral Deficiency &amp; Toxicity\n \u2022 Supportive measures\n For copper toxicity due to ingesting grams of copper, prompt gastric lavage is done. Copper toxicity that\n causes complications such as hemolytic anemia, anuria, or hepatotoxicity is also treated with either oral\n penicillamine 250 mg q 6 h to 750 mg q 12 h (1000 to 1500 mg/day in 2 to 4 doses) or dimercaprol 3 to 5\n mg/kg IM q 4 h for 2 days, then q 4 to 6 h (see also\n Table 340-4 and copper salts in\n Table 340-8). If used early, hemodialysis may be effective. Occasionally, copper toxicity is fatal despite\n treatment.\n Inherited Copper Toxicity\n (Wilson's Disease)\n Inherited copper toxicity results in accumulation of copper in the liver and other organs. Hepatic\n or neurologic symptoms develop. Diagnosis is based on a low serum ceruloplasmin level, high\n urinary excretion of copper, and sometimes liver biopsy results. Treatment consists of a low-\n copper diet and chelation, usually with penicillamine or dimercaprol.\n Wilson's disease is a progressive disorder of copper metabolism that affects 1 person in 30,000. Affected\n people are homozygous for the mutant recessive gene, located on chromosome 13. Heterozygous\n carriers, who constitute about 1.1% of the population, are asymptomatic.\n Pathophysiology\n The genetic defect impairs copper transport. The impaired transport decreases copper secretion into the\n bile, thus causing the copper overload and resultant accumulation in the liver, which begins at birth. The\n impaired transport also interferes with incorporation of copper into the copper protein ceruloplasmin, thus\n decreasing serum levels of ceruloplasmin.\n Hepatic fibrosis develops, ultimately causing cirrhosis. Copper diffuses out of the liver into the blood, then\n into other tissues. It is most destructive to the brain but also damages the kidneys and reproductive\n organs and causes hemolytic anemia. Some copper is deposited in Descemet's membrane of the cornea,\n causing Kayser-Fleischer rings.\n Symptoms and Signs\n Symptoms usually develop between ages 5 and 40. In almost half of patients, particularly adolescents,\n the first symptom is hepatitis\u2014acute, chronic active, or fulminant. But hepatitis may develop at any time.\n In about 40% of patients, particularly young adults, the first symptoms reflect CNS involvement. Motor\n deficits are common, including any combination of tremors, dystonia, dysarthria, dysphagia, chorea,\n drooling, and incoordination. Sometimes the first symptoms are cognitive or psychiatric abnormalities. In 5\n to 10% of patients, the first symptom is incidentally noted gold or greenish gold Kayser-Fleischer rings or\n crescents (due to copper deposits in the cornea), amenorrhea or repeated miscarriages, or hematuria.\n Diagnosis\n \u2022 Slit-lamp examination for Kayser-Fleischer rings\n \u2022 Serum ceruloplasmin and 24-h urinary copper excretion\n \u2022 Sometimes confirmation by penicillamine provocation test or liver biopsy\n Wilson's disease should be suspected in people &lt; 40 with any of the following:\n \u2022 An unexplained hepatic, neurologic, or psychiatric disorder\n \u2022 An unexplained persistent elevation in hepatic transaminases\n                                                                                                       101",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 5. Mineral Deficiency &amp; Toxicity\n\n# Supportive measures\n\nFor copper toxicity due to ingesting grams of copper, prompt gastric lavage is done. Copper toxicity that causes complications such as hemolytic anemia, anuria, or hepatotoxicity is also treated with either oral penicillamine 250 mg q 6 h to 750 mg q 12 h (1000 to 1500 mg/day in 2 to 4 doses) or dimercaprol 3 to 5 mg/kg IM q 4 h for 2 days, then q 4 to 6 h (see also Table 340-4 and copper salts in Table 340-8). If used early, hemodialysis may be effective. Occasionally, copper toxicity is fatal.\n\n# Inherited Copper Toxicity (Wilson's Disease)\n\nInherited copper toxicity results in accumulation of copper in the liver and other organs. Hepatic or neurologic symptoms develop. Diagnosis is based on a low serum ceruloplasmin level, high urinary excretion of copper, and sometimes liver biopsy results. Treatment consists of a low-copper diet and chelation, usually with penicillamine or dimercaprol.\n\nWilson's disease is a progressive disorder of copper metabolism that affects 1 person in 30,000. Affected people are homozygous for the mutant recessive gene, located on chromosome 13. Heterozygous carriers, who constitute about 1.1% of the population, are asymptomatic.\n\n# Pathophysiology\n\nThe genetic defect impairs copper transport. The impaired transport decreases copper secretion into the bile, thus causing the copper overload and resultant accumulation in the liver, which begins at birth. The impaired transport also interferes with incorporation of copper into the copper protein ceruloplasmin, thus decreasing serum levels of ceruloplasmin.\n\nHepatic fibrosis develops, ultimately causing cirrhosis. Copper diffuses out of the liver into the blood, then into other tissues. It is most destructive to the brain but also damages the kidneys and reproductive organs and causes hemolytic anemia. Some copper is deposited in Descemet's membrane of the cornea, causing Kayser-Fleischer rings.\n\n# Symptoms and Signs\n\nSymptoms usually develop between ages 5 and 40. In almost half of patients, particularly adolescents, the first symptom is hepatitis\u2014acute, chronic active, or fulminant. But hepatitis may develop at any time. In about 40% of patients, particularly young adults, the first symptoms reflect CNS involvement. Motor deficits are common, including any combination of tremors, dystonia, dysarthria, dysphagia, chorea, drooling, and incoordination. Sometimes the first symptoms are cognitive or psychiatric abnormalities. In 5 to 10% of patients, the first symptom is incidentally noted gold or greenish gold Kayser-Fleischer rings or crescents (due to copper deposits in the cornea), amenorrhea or repeated miscarriages, or hematuria.\n\n# Diagnosis\n\n- Slit-lamp examination for Kayser-Fleischer rings\n- Serum ceruloplasmin and 24-h urinary copper excretion\n- Sometimes confirmation by penicillamine provocation test or liver biopsy\n\nWilson's disease should be suspected in people &amp;lt; 40 with any of the following:\n\n- An unexplained hepatic, neurologic, or psychiatric disorder\n- An unexplained persistent elevation in hepatic transaminases",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 601.18
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "md": "# Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "bBox": {
                        "x": 365,
                        "y": 30.72,
                        "w": 178,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Supportive measures",
                    "md": "# Supportive measures",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "For copper toxicity due to ingesting grams of copper, prompt gastric lavage is done. Copper toxicity that causes complications such as hemolytic anemia, anuria, or hepatotoxicity is also treated with either oral penicillamine 250 mg q 6 h to 750 mg q 12 h (1000 to 1500 mg/day in 2 to 4 doses) or dimercaprol 3 to 5 mg/kg IM q 4 h for 2 days, then q 4 to 6 h (see also Table 340-4 and copper salts in Table 340-8). If used early, hemodialysis may be effective. Occasionally, copper toxicity is fatal.",
                    "md": "For copper toxicity due to ingesting grams of copper, prompt gastric lavage is done. Copper toxicity that causes complications such as hemolytic anemia, anuria, or hepatotoxicity is also treated with either oral penicillamine 250 mg q 6 h to 750 mg q 12 h (1000 to 1500 mg/day in 2 to 4 doses) or dimercaprol 3 to 5 mg/kg IM q 4 h for 2 days, then q 4 to 6 h (see also Table 340-4 and copper salts in Table 340-8). If used early, hemodialysis may be effective. Occasionally, copper toxicity is fatal.",
                    "bBox": {
                        "x": 55,
                        "y": 74.9,
                        "w": 477,
                        "h": 62
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Inherited Copper Toxicity (Wilson's Disease)",
                    "md": "# Inherited Copper Toxicity (Wilson's Disease)",
                    "bBox": {
                        "x": 55,
                        "y": 175.9,
                        "w": 126,
                        "h": 37
                    }
                },
                {
                    "type": "text",
                    "value": "Inherited copper toxicity results in accumulation of copper in the liver and other organs. Hepatic or neurologic symptoms develop. Diagnosis is based on a low serum ceruloplasmin level, high urinary excretion of copper, and sometimes liver biopsy results. Treatment consists of a low-copper diet and chelation, usually with penicillamine or dimercaprol.\n\nWilson's disease is a progressive disorder of copper metabolism that affects 1 person in 30,000. Affected people are homozygous for the mutant recessive gene, located on chromosome 13. Heterozygous carriers, who constitute about 1.1% of the population, are asymptomatic.",
                    "md": "Inherited copper toxicity results in accumulation of copper in the liver and other organs. Hepatic or neurologic symptoms develop. Diagnosis is based on a low serum ceruloplasmin level, high urinary excretion of copper, and sometimes liver biopsy results. Treatment consists of a low-copper diet and chelation, usually with penicillamine or dimercaprol.\n\nWilson's disease is a progressive disorder of copper metabolism that affects 1 person in 30,000. Affected people are homozygous for the mutant recessive gene, located on chromosome 13. Heterozygous carriers, who constitute about 1.1% of the population, are asymptomatic.",
                    "bBox": {
                        "x": 55,
                        "y": 175.9,
                        "w": 482,
                        "h": 456
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Pathophysiology",
                    "md": "# Pathophysiology",
                    "bBox": {
                        "x": 55,
                        "y": 340.9,
                        "w": 84,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "The genetic defect impairs copper transport. The impaired transport decreases copper secretion into the bile, thus causing the copper overload and resultant accumulation in the liver, which begins at birth. The impaired transport also interferes with incorporation of copper into the copper protein ceruloplasmin, thus decreasing serum levels of ceruloplasmin.\n\nHepatic fibrosis develops, ultimately causing cirrhosis. Copper diffuses out of the liver into the blood, then into other tissues. It is most destructive to the brain but also damages the kidneys and reproductive organs and causes hemolytic anemia. Some copper is deposited in Descemet's membrane of the cornea, causing Kayser-Fleischer rings.",
                    "md": "The genetic defect impairs copper transport. The impaired transport decreases copper secretion into the bile, thus causing the copper overload and resultant accumulation in the liver, which begins at birth. The impaired transport also interferes with incorporation of copper into the copper protein ceruloplasmin, thus decreasing serum levels of ceruloplasmin.\n\nHepatic fibrosis develops, ultimately causing cirrhosis. Copper diffuses out of the liver into the blood, then into other tissues. It is most destructive to the brain but also damages the kidneys and reproductive organs and causes hemolytic anemia. Some copper is deposited in Descemet's membrane of the cornea, causing Kayser-Fleischer rings.",
                    "bBox": {
                        "x": 55,
                        "y": 365.9,
                        "w": 482,
                        "h": 114
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Symptoms and Signs",
                    "md": "# Symptoms and Signs",
                    "bBox": {
                        "x": 55,
                        "y": 492.9,
                        "w": 107,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Symptoms usually develop between ages 5 and 40. In almost half of patients, particularly adolescents, the first symptom is hepatitis\u2014acute, chronic active, or fulminant. But hepatitis may develop at any time. In about 40% of patients, particularly young adults, the first symptoms reflect CNS involvement. Motor deficits are common, including any combination of tremors, dystonia, dysarthria, dysphagia, chorea, drooling, and incoordination. Sometimes the first symptoms are cognitive or psychiatric abnormalities. In 5 to 10% of patients, the first symptom is incidentally noted gold or greenish gold Kayser-Fleischer rings or crescents (due to copper deposits in the cornea), amenorrhea or repeated miscarriages, or hematuria.",
                    "md": "Symptoms usually develop between ages 5 and 40. In almost half of patients, particularly adolescents, the first symptom is hepatitis\u2014acute, chronic active, or fulminant. But hepatitis may develop at any time. In about 40% of patients, particularly young adults, the first symptoms reflect CNS involvement. Motor deficits are common, including any combination of tremors, dystonia, dysarthria, dysphagia, chorea, drooling, and incoordination. Sometimes the first symptoms are cognitive or psychiatric abnormalities. In 5 to 10% of patients, the first symptom is incidentally noted gold or greenish gold Kayser-Fleischer rings or crescents (due to copper deposits in the cornea), amenorrhea or repeated miscarriages, or hematuria.",
                    "bBox": {
                        "x": 55,
                        "y": 517.9,
                        "w": 482,
                        "h": 88
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 619.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Slit-lamp examination for Kayser-Fleischer rings\n- Serum ceruloplasmin and 24-h urinary copper excretion\n- Sometimes confirmation by penicillamine provocation test or liver biopsy\n\nWilson's disease should be suspected in people &amp;lt; 40 with any of the following:\n\n- An unexplained hepatic, neurologic, or psychiatric disorder\n- An unexplained persistent elevation in hepatic transaminases",
                    "md": "- Slit-lamp examination for Kayser-Fleischer rings\n- Serum ceruloplasmin and 24-h urinary copper excretion\n- Sometimes confirmation by penicillamine provocation test or liver biopsy\n\nWilson's disease should be suspected in people &amp;lt; 40 with any of the following:\n\n- An unexplained hepatic, neurologic, or psychiatric disorder\n- An unexplained persistent elevation in hepatic transaminases",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.992
        },
        {
            "page": 50,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition               Chapter 5. Mineral Deficiency &amp; Toxicity\n \u2022 A sibling, parent, or cousin with Wilson's disease\n \u2022 Fulminant hepatitis\n If Wilson's disease is suspected, slit-lamp examination for Kayser-Fleischer rings is required, and serum\n ceruloplasmin and copper levels and 24-h urinary copper excretion are measured. Transaminase levels\n are also often measured; high levels are consistent with the diagnosis.\n Kayser-Fleischer rings: These rings plus typical motor neurologic abnormalities or a decrease in\n ceruloplasmin are nearly pathognomonic for Wilson's disease. Rarely, these rings occur in other liver\n disorders (eg, biliary atresia, primary biliary cirrhosis), but ceruloplasmin levels should be unaffected.\n Ceruloplasmin: Serum ceruloplasmin (normally 20 to 35 mg/dL) is usually low in Wilson's disease but\n can be normal. It can also be low in heterozygous carriers and those with other liver disorders (eg, viral\n hepatitis, drug- or alcohol-induced liver disease). A low ceruloplasmin level in a patient with a Kayser-\n Fleischer ring is diagnostic. Also, a level of &lt; 5 mg/dL is highly suggestive regardless of clinical findings.\n Serum copper: Despite the copper accumulation in the body, serum copper levels are decreased\n because of the decreased ceruloplasmin levels.\n Urinary copper excretion: In Wilson's disease, 24-h urinary copper excretion (normally, \u2264 30 \u03bcg/day) is\n usually &gt; 100 \u03bcg/day. If serum ceruloplasmin is low and urinary copper excretion is high, diagnosis is\n clear. If levels are equivocal, measuring urinary copper excretion after penicillamine is given\n (penicillamine provocation test) may confirm the diagnosis; this test is not usually done in adults because\n cutoff values are not well-established.\n Liver biopsy: In unclear cases (eg, elevated transaminases, no Kayser-Fleischer rings, indeterminate\n values for ceruloplasmin and urinary copper), the diagnosis is made by doing a liver biopsy to measure\n hepatic copper concentration. However, false-negative results may occur because of a sampling error\n (due to large variations in copper concentrations in the liver) or fulminant hepatitis (causing necrosis that\n releases large amounts of copper).\n Screening: Because early treatment is most effective, screening is indicated for anyone who has a\n sibling, cousin, or parent with Wilson's disease. Screening consists of a slit-lamp examination and\n measurement of transaminase levels, serum copper and ceruloplasmin, and 24-h urine copper excretion.\n If any results are abnormal, liver biopsy is done to measure hepatic copper concentration. Infants should\n not be tested until after age 1 yr because ceruloplasmin levels are low during the first few months of life.\n Children &lt; 6 yr with normal test results should be retested 5 to 10 yr later.\n Genetic testing is under investigation.\n Prognosis\n Prognosis is usually good, unless disease is advanced before treatment begins. Untreated Wilson's\n disease is fatal, usually by age 30.\n Treatment\n \u2022 Penicillamine or another chelating drug if needed to remove accumulated copper\n \u2022 Low-copper diet\n \u2022 For maintenance, lifelong low-dose chelation therapy or oral zinc\n Continual, lifelong treatment is mandatory regardless of whether symptoms are present. Accumulated\n copper should be removed with chelating drugs. A low-copper diet (eg, avoiding beef liver, cashews,\n black-eyed peas, vegetable juice, shellfish, mushrooms, and cocoa) and use of either low-dose chelation\n                                                                                                       102",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 5. Mineral Deficiency &amp; Toxicity\n\n\u2022 A sibling, parent, or cousin with Wilson's disease\n\n\u2022 Fulminant hepatitis\n\nIf Wilson's disease is suspected, slit-lamp examination for Kayser-Fleischer rings is required, and serum ceruloplasmin and copper levels and 24-h urinary copper excretion are measured. Transaminase levels are also often measured; high levels are consistent with the diagnosis.\n\n# Kayser-Fleischer rings:\n\nThese rings plus typical motor neurologic abnormalities or a decrease in ceruloplasmin are nearly pathognomonic for Wilson's disease. Rarely, these rings occur in other liver disorders (eg, biliary atresia, primary biliary cirrhosis), but ceruloplasmin levels should be unaffected.\n\n# Ceruloplasmin:\n\nSerum ceruloplasmin (normally 20 to 35 mg/dL) is usually low in Wilson's disease but can be normal. It can also be low in heterozygous carriers and those with other liver disorders (eg, viral hepatitis, drug- or alcohol-induced liver disease). A low ceruloplasmin level in a patient with a Kayser-Fleischer ring is diagnostic. Also, a level of &lt; 5 mg/dL is highly suggestive regardless of clinical findings.\n\n# Serum copper:\n\nDespite the copper accumulation in the body, serum copper levels are decreased because of the decreased ceruloplasmin levels.\n\n# Urinary copper excretion:\n\nIn Wilson's disease, 24-h urinary copper excretion (normally, \u2264 30 \u03bcg/day) is usually &gt; 100 \u03bcg/day. If serum ceruloplasmin is low and urinary copper excretion is high, diagnosis is clear. If levels are equivocal, measuring urinary copper excretion after penicillamine is given (penicillamine provocation test) may confirm the diagnosis; this test is not usually done in adults because cutoff values are not well-established.\n\n# Liver biopsy:\n\nIn unclear cases (eg, elevated transaminases, no Kayser-Fleischer rings, indeterminate values for ceruloplasmin and urinary copper), the diagnosis is made by doing a liver biopsy to measure hepatic copper concentration. However, false-negative results may occur because of a sampling error (due to large variations in copper concentrations in the liver) or fulminant hepatitis (causing necrosis that releases large amounts of copper).\n\n# Screening:\n\nBecause early treatment is most effective, screening is indicated for anyone who has a sibling, cousin, or parent with Wilson's disease. Screening consists of a slit-lamp examination and measurement of transaminase levels, serum copper and ceruloplasmin, and 24-h urine copper excretion. If any results are abnormal, liver biopsy is done to measure hepatic copper concentration. Infants should not be tested until after age 1 yr because ceruloplasmin levels are low during the first few months of life. Children &lt; 6 yr with normal test results should be retested 5 to 10 yr later. Genetic testing is under investigation.\n\n# Prognosis\n\nPrognosis is usually good, unless disease is advanced before treatment begins. Untreated Wilson's disease is fatal, usually by age 30.\n\n# Treatment\n\n\u2022 Penicillamine or another chelating drug if needed to remove accumulated copper\n\n\u2022 Low-copper diet\n\n\u2022 For maintenance, lifelong low-dose chelation therapy or oral zinc\n\nContinual, lifelong treatment is mandatory regardless of whether symptoms are present. Accumulated copper should be removed with chelating drugs. A low-copper diet (eg, avoiding beef liver, cashews, black-eyed peas, vegetable juice, shellfish, mushrooms, and cocoa) and use of either low-dose chelation.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "md": "# Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "bBox": {
                        "x": 365,
                        "y": 30.72,
                        "w": 178,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "\u2022 A sibling, parent, or cousin with Wilson's disease\n\n\u2022 Fulminant hepatitis\n\nIf Wilson's disease is suspected, slit-lamp examination for Kayser-Fleischer rings is required, and serum ceruloplasmin and copper levels and 24-h urinary copper excretion are measured. Transaminase levels are also often measured; high levels are consistent with the diagnosis.",
                    "md": "\u2022 A sibling, parent, or cousin with Wilson's disease\n\n\u2022 Fulminant hepatitis\n\nIf Wilson's disease is suspected, slit-lamp examination for Kayser-Fleischer rings is required, and serum ceruloplasmin and copper levels and 24-h urinary copper excretion are measured. Transaminase levels are also often measured; high levels are consistent with the diagnosis.",
                    "bBox": {
                        "x": 55,
                        "y": 61.9,
                        "w": 474,
                        "h": 88
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Kayser-Fleischer rings:",
                    "md": "# Kayser-Fleischer rings:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "These rings plus typical motor neurologic abnormalities or a decrease in ceruloplasmin are nearly pathognomonic for Wilson's disease. Rarely, these rings occur in other liver disorders (eg, biliary atresia, primary biliary cirrhosis), but ceruloplasmin levels should be unaffected.",
                    "md": "These rings plus typical motor neurologic abnormalities or a decrease in ceruloplasmin are nearly pathognomonic for Wilson's disease. Rarely, these rings occur in other liver disorders (eg, biliary atresia, primary biliary cirrhosis), but ceruloplasmin levels should be unaffected.",
                    "bBox": {
                        "x": 55,
                        "y": 175.9,
                        "w": 460,
                        "h": 25
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Ceruloplasmin:",
                    "md": "# Ceruloplasmin:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Serum ceruloplasmin (normally 20 to 35 mg/dL) is usually low in Wilson's disease but can be normal. It can also be low in heterozygous carriers and those with other liver disorders (eg, viral hepatitis, drug- or alcohol-induced liver disease). A low ceruloplasmin level in a patient with a Kayser-Fleischer ring is diagnostic. Also, a level of &lt; 5 mg/dL is highly suggestive regardless of clinical findings.",
                    "md": "Serum ceruloplasmin (normally 20 to 35 mg/dL) is usually low in Wilson's disease but can be normal. It can also be low in heterozygous carriers and those with other liver disorders (eg, viral hepatitis, drug- or alcohol-induced liver disease). A low ceruloplasmin level in a patient with a Kayser-Fleischer ring is diagnostic. Also, a level of &lt; 5 mg/dL is highly suggestive regardless of clinical findings.",
                    "bBox": {
                        "x": 55,
                        "y": 226.9,
                        "w": 474,
                        "h": 37
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Serum copper:",
                    "md": "# Serum copper:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Despite the copper accumulation in the body, serum copper levels are decreased because of the decreased ceruloplasmin levels.",
                    "md": "Despite the copper accumulation in the body, serum copper levels are decreased because of the decreased ceruloplasmin levels.",
                    "bBox": {
                        "x": 55,
                        "y": 289.9,
                        "w": 218,
                        "h": 12
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Urinary copper excretion:",
                    "md": "# Urinary copper excretion:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "In Wilson's disease, 24-h urinary copper excretion (normally, \u2264 30 \u03bcg/day) is usually &gt; 100 \u03bcg/day. If serum ceruloplasmin is low and urinary copper excretion is high, diagnosis is clear. If levels are equivocal, measuring urinary copper excretion after penicillamine is given (penicillamine provocation test) may confirm the diagnosis; this test is not usually done in adults because cutoff values are not well-established.",
                    "md": "In Wilson's disease, 24-h urinary copper excretion (normally, \u2264 30 \u03bcg/day) is usually &gt; 100 \u03bcg/day. If serum ceruloplasmin is low and urinary copper excretion is high, diagnosis is clear. If levels are equivocal, measuring urinary copper excretion after penicillamine is given (penicillamine provocation test) may confirm the diagnosis; this test is not usually done in adults because cutoff values are not well-established.",
                    "bBox": {
                        "x": 55,
                        "y": 327.9,
                        "w": 478,
                        "h": 50
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Liver biopsy:",
                    "md": "# Liver biopsy:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "In unclear cases (eg, elevated transaminases, no Kayser-Fleischer rings, indeterminate values for ceruloplasmin and urinary copper), the diagnosis is made by doing a liver biopsy to measure hepatic copper concentration. However, false-negative results may occur because of a sampling error (due to large variations in copper concentrations in the liver) or fulminant hepatitis (causing necrosis that releases large amounts of copper).",
                    "md": "In unclear cases (eg, elevated transaminases, no Kayser-Fleischer rings, indeterminate values for ceruloplasmin and urinary copper), the diagnosis is made by doing a liver biopsy to measure hepatic copper concentration. However, false-negative results may occur because of a sampling error (due to large variations in copper concentrations in the liver) or fulminant hepatitis (causing necrosis that releases large amounts of copper).",
                    "bBox": {
                        "x": 55,
                        "y": 403.9,
                        "w": 476,
                        "h": 50
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Screening:",
                    "md": "# Screening:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Because early treatment is most effective, screening is indicated for anyone who has a sibling, cousin, or parent with Wilson's disease. Screening consists of a slit-lamp examination and measurement of transaminase levels, serum copper and ceruloplasmin, and 24-h urine copper excretion. If any results are abnormal, liver biopsy is done to measure hepatic copper concentration. Infants should not be tested until after age 1 yr because ceruloplasmin levels are low during the first few months of life. Children &lt; 6 yr with normal test results should be retested 5 to 10 yr later. Genetic testing is under investigation.",
                    "md": "Because early treatment is most effective, screening is indicated for anyone who has a sibling, cousin, or parent with Wilson's disease. Screening consists of a slit-lamp examination and measurement of transaminase levels, serum copper and ceruloplasmin, and 24-h urine copper excretion. If any results are abnormal, liver biopsy is done to measure hepatic copper concentration. Infants should not be tested until after age 1 yr because ceruloplasmin levels are low during the first few months of life. Children &lt; 6 yr with normal test results should be retested 5 to 10 yr later. Genetic testing is under investigation.",
                    "bBox": {
                        "x": 55,
                        "y": 479.9,
                        "w": 477,
                        "h": 177
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Prognosis",
                    "md": "# Prognosis",
                    "bBox": {
                        "x": 55,
                        "y": 581.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Prognosis is usually good, unless disease is advanced before treatment begins. Untreated Wilson's disease is fatal, usually by age 30.",
                    "md": "Prognosis is usually good, unless disease is advanced before treatment begins. Untreated Wilson's disease is fatal, usually by age 30.",
                    "bBox": {
                        "x": 55,
                        "y": 581.9,
                        "w": 454,
                        "h": 75
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 644.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "\u2022 Penicillamine or another chelating drug if needed to remove accumulated copper\n\n\u2022 Low-copper diet\n\n\u2022 For maintenance, lifelong low-dose chelation therapy or oral zinc\n\nContinual, lifelong treatment is mandatory regardless of whether symptoms are present. Accumulated copper should be removed with chelating drugs. A low-copper diet (eg, avoiding beef liver, cashews, black-eyed peas, vegetable juice, shellfish, mushrooms, and cocoa) and use of either low-dose chelation.",
                    "md": "\u2022 Penicillamine or another chelating drug if needed to remove accumulated copper\n\n\u2022 Low-copper diet\n\n\u2022 For maintenance, lifelong low-dose chelation therapy or oral zinc\n\nContinual, lifelong treatment is mandatory regardless of whether symptoms are present. Accumulated copper should be removed with chelating drugs. A low-copper diet (eg, avoiding beef liver, cashews, black-eyed peas, vegetable juice, shellfish, mushrooms, and cocoa) and use of either low-dose chelation.",
                    "bBox": {
                        "x": 55,
                        "y": 644.9,
                        "w": 478,
                        "h": 139
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.997
        },
        {
            "page": 51,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition               Chapter 5. Mineral Deficiency &amp; Toxicity\n therapy or oral zinc can prevent copper from accumulating.\n Penicillamine is the most commonly used chelating drug but has considerable toxicity (eg, fever, rash,\n neutropenia, thrombocytopenia, proteinuria). Cross-reactivity may occur in people with penicillin allergy.\n Patients &gt; 5 yr are given oral doses of 62.5 mg q 6 h to 250 mg q 12 h (250 to 500 mg/day in 2 to 4\n doses) and slowly increased to a maximum of 250 mg q 6 h to 750 mg q 12 h (1000 to 1500 mg/day in 2\n to 4 doses). Younger children are given 10 mg/kg bid or 6.7 mg/kg tid (20 mg/kg/d) po. Pyridoxine 25 mg\n po once/day is given with penicillamine. Occasionally, use of penicillamine is associated with worsening\n neurologic symptoms.\n Trientine hydrochloride is an alternative treatment to penicillamine. Doses are 375 to 750 mg po bid or\n 250 to 500 mg po tid (750 to 1500 mg/day).\n Zinc acetate 50 mg po tid can prevent reaccumulation of copper in patients who cannot tolerate\n penicillamine or trientine or who have neurologic symptoms that do not respond to the other drugs.\n (CAUTION: Penicillamine or trientine must not be given with zinc because either drug can bind zinc,\n forming a compound with no therapeutic effect.)\n Poor long-term adherence to drug therapy is common. After 1 to 5 yr of therapy, lower dose maintenance\n drug therapy can be considered. Regular follow-up care with an expert in liver disease is recommended.\n Liver transplantation may be lifesaving for patients who have Wilson's disease and fulminant hepatic\n failure or severe hepatic insufficiency refractory to drugs.\n Fluorine\n Most of the body's fluorine (F) is contained in bones and teeth. Fluoride (the ionic form of fluorine) is\n widely distributed in nature. The main source of fluoride is fluoridated drinking water.\n Deficiency: Fluorine deficiency can lead to dental caries and possibly osteoporosis. Fluoridation of\n water that contains &lt; 1 ppm (the ideal) reduces the incidence of dental caries. If a child's drinking water is\n not fluoridated, oral fluoride supplements can be prescribed.\n Toxicity: Excess fluorine can accumulate in teeth and bones, causing fluorosis. Drinking water\n containing &gt; 10 ppm is a common cause. Permanent teeth that develop during high fluoride intake are\n most likely to be affected. Exposure must be much greater to affect deciduous teeth.\n The earliest signs are chalky white, irregularly distributed patches on the surface of the enamel; these\n patches become stained yellow or brown, producing a characteristic mottled appearance. Severe toxicity\n weakens the enamel, pitting its surface. Bony changes, including osteosclerosis, exostoses of the spine,\n and genu valgum, can develop but only in adults after prolonged high intake of fluoride.\n No tests to diagnose toxicity are available.\n Treatment involves reducing fluoride intake; eg, in areas with high fluoride water levels, patients should\n not drink fluoridated water or take fluoride supplements. Children should always be told not to swallow\n fluoridated toothpastes.\n Iodine\n In the body, iodine (I) is involved primarily in the synthesis of 2 thyroid hormones, thyroxine (T4) and\n triiodothyronine (T3). Iodine occurs in the environment and in the diet primarily as iodide. In adults, about\n 80% of the iodide absorbed is trapped by the thyroid gland. Most environmental iodine occurs in\n seawater as iodide; a small amount enters the atmosphere and, through rain, enters ground water and\n soil near the sea. Thus, people living far from the sea and at higher altitudes are at particular risk of\n deficiency. Fortifying table salt with iodide (typically 70 \u03bcg/g) helps ensure adequate intake (150 \u03bcg/day).\n Requirements are higher for pregnant (220 \u03bcg/day) and breastfeeding (290 \u03bcg/day) women.\n                                                                                                       103",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 5. Mineral Deficiency &amp; Toxicity\n\nTherapy or oral zinc can prevent copper from accumulating. Penicillamine is the most commonly used chelating drug but has considerable toxicity (eg, fever, rash, neutropenia, thrombocytopenia, proteinuria). Cross-reactivity may occur in people with penicillin allergy. Patients &gt; 5 yr are given oral doses of 62.5 mg q 6 h to 250 mg q 12 h (250 to 500 mg/day in 2 to 4 doses) and slowly increased to a maximum of 250 mg q 6 h to 750 mg q 12 h (1000 to 1500 mg/day in 2 to 4 doses). Younger children are given 10 mg/kg bid or 6.7 mg/kg tid (20 mg/kg/d) po. Pyridoxine 25 mg po once/day is given with penicillamine. Occasionally, use of penicillamine is associated with worsening neurologic symptoms.\n\nTrientine hydrochloride is an alternative treatment to penicillamine. Doses are 375 to 750 mg po bid or 250 to 500 mg po tid (750 to 1500 mg/day). Zinc acetate 50 mg po tid can prevent reaccumulation of copper in patients who cannot tolerate penicillamine or trientine or who have neurologic symptoms that do not respond to the other drugs. (CAUTION: Penicillamine or trientine must not be given with zinc because either drug can bind zinc, forming a compound with no therapeutic effect.)\n\nPoor long-term adherence to drug therapy is common. After 1 to 5 yr of therapy, lower dose maintenance drug therapy can be considered. Regular follow-up care with an expert in liver disease is recommended. Liver transplantation may be lifesaving for patients who have Wilson's disease and fulminant hepatic failure or severe hepatic insufficiency refractory to drugs.\n\n# Fluorine\n\nMost of the body's fluorine (F) is contained in bones and teeth. Fluoride (the ionic form of fluorine) is widely distributed in nature. The main source of fluoride is fluoridated drinking water.\n\n# Deficiency:\n\nFluorine deficiency can lead to dental caries and possibly osteoporosis. Fluoridation of water that contains &lt; 1 ppm (the ideal) reduces the incidence of dental caries. If a child's drinking water is not fluoridated, oral fluoride supplements can be prescribed.\n\n# Toxicity:\n\nExcess fluorine can accumulate in teeth and bones, causing fluorosis. Drinking water containing &gt; 10 ppm is a common cause. Permanent teeth that develop during high fluoride intake are most likely to be affected. Exposure must be much greater to affect deciduous teeth.\n\nThe earliest signs are chalky white, irregularly distributed patches on the surface of the enamel; these patches become stained yellow or brown, producing a characteristic mottled appearance. Severe toxicity weakens the enamel, pitting its surface. Bony changes, including osteosclerosis, exostoses of the spine, and genu valgum, can develop but only in adults after prolonged high intake of fluoride. No tests to diagnose toxicity are available.\n\nTreatment involves reducing fluoride intake; eg, in areas with high fluoride water levels, patients should not drink fluoridated water or take fluoride supplements. Children should always be told not to swallow fluoridated toothpastes.\n\n# Iodine\n\nIn the body, iodine (I) is involved primarily in the synthesis of 2 thyroid hormones, thyroxine (T4) and triiodothyronine (T3). Iodine occurs in the environment and in the diet primarily as iodide. In adults, about 80% of the iodide absorbed is trapped by the thyroid gland. Most environmental iodine occurs in seawater as iodide; a small amount enters the atmosphere and, through rain, enters ground water and soil near the sea. Thus, people living far from the sea and at higher altitudes are at particular risk of deficiency. Fortifying table salt with iodide (typically 70 \u03bcg/g) helps ensure adequate intake (150 \u03bcg/day). Requirements are higher for pregnant (220 \u03bcg/day) and breastfeeding (290 \u03bcg/day) women.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "md": "# Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "bBox": {
                        "x": 365,
                        "y": 30.72,
                        "w": 178,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "Therapy or oral zinc can prevent copper from accumulating. Penicillamine is the most commonly used chelating drug but has considerable toxicity (eg, fever, rash, neutropenia, thrombocytopenia, proteinuria). Cross-reactivity may occur in people with penicillin allergy. Patients &gt; 5 yr are given oral doses of 62.5 mg q 6 h to 250 mg q 12 h (250 to 500 mg/day in 2 to 4 doses) and slowly increased to a maximum of 250 mg q 6 h to 750 mg q 12 h (1000 to 1500 mg/day in 2 to 4 doses). Younger children are given 10 mg/kg bid or 6.7 mg/kg tid (20 mg/kg/d) po. Pyridoxine 25 mg po once/day is given with penicillamine. Occasionally, use of penicillamine is associated with worsening neurologic symptoms.\n\nTrientine hydrochloride is an alternative treatment to penicillamine. Doses are 375 to 750 mg po bid or 250 to 500 mg po tid (750 to 1500 mg/day). Zinc acetate 50 mg po tid can prevent reaccumulation of copper in patients who cannot tolerate penicillamine or trientine or who have neurologic symptoms that do not respond to the other drugs. (CAUTION: Penicillamine or trientine must not be given with zinc because either drug can bind zinc, forming a compound with no therapeutic effect.)\n\nPoor long-term adherence to drug therapy is common. After 1 to 5 yr of therapy, lower dose maintenance drug therapy can be considered. Regular follow-up care with an expert in liver disease is recommended. Liver transplantation may be lifesaving for patients who have Wilson's disease and fulminant hepatic failure or severe hepatic insufficiency refractory to drugs.",
                    "md": "Therapy or oral zinc can prevent copper from accumulating. Penicillamine is the most commonly used chelating drug but has considerable toxicity (eg, fever, rash, neutropenia, thrombocytopenia, proteinuria). Cross-reactivity may occur in people with penicillin allergy. Patients &gt; 5 yr are given oral doses of 62.5 mg q 6 h to 250 mg q 12 h (250 to 500 mg/day in 2 to 4 doses) and slowly increased to a maximum of 250 mg q 6 h to 750 mg q 12 h (1000 to 1500 mg/day in 2 to 4 doses). Younger children are given 10 mg/kg bid or 6.7 mg/kg tid (20 mg/kg/d) po. Pyridoxine 25 mg po once/day is given with penicillamine. Occasionally, use of penicillamine is associated with worsening neurologic symptoms.\n\nTrientine hydrochloride is an alternative treatment to penicillamine. Doses are 375 to 750 mg po bid or 250 to 500 mg po tid (750 to 1500 mg/day). Zinc acetate 50 mg po tid can prevent reaccumulation of copper in patients who cannot tolerate penicillamine or trientine or who have neurologic symptoms that do not respond to the other drugs. (CAUTION: Penicillamine or trientine must not be given with zinc because either drug can bind zinc, forming a compound with no therapeutic effect.)\n\nPoor long-term adherence to drug therapy is common. After 1 to 5 yr of therapy, lower dose maintenance drug therapy can be considered. Regular follow-up care with an expert in liver disease is recommended. Liver transplantation may be lifesaving for patients who have Wilson's disease and fulminant hepatic failure or severe hepatic insufficiency refractory to drugs.",
                    "bBox": {
                        "x": 55,
                        "y": 48.9,
                        "w": 477,
                        "h": 292
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Fluorine",
                    "md": "# Fluorine",
                    "bBox": {
                        "x": 55,
                        "y": 354.9,
                        "w": 41,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Most of the body's fluorine (F) is contained in bones and teeth. Fluoride (the ionic form of fluorine) is widely distributed in nature. The main source of fluoride is fluoridated drinking water.",
                    "md": "Most of the body's fluorine (F) is contained in bones and teeth. Fluoride (the ionic form of fluorine) is widely distributed in nature. The main source of fluoride is fluoridated drinking water.",
                    "bBox": {
                        "x": 55,
                        "y": 354.9,
                        "w": 456,
                        "h": 50
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Deficiency:",
                    "md": "# Deficiency:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Fluorine deficiency can lead to dental caries and possibly osteoporosis. Fluoridation of water that contains &lt; 1 ppm (the ideal) reduces the incidence of dental caries. If a child's drinking water is not fluoridated, oral fluoride supplements can be prescribed.",
                    "md": "Fluorine deficiency can lead to dental caries and possibly osteoporosis. Fluoridation of water that contains &lt; 1 ppm (the ideal) reduces the incidence of dental caries. If a child's drinking water is not fluoridated, oral fluoride supplements can be prescribed.",
                    "bBox": {
                        "x": 55,
                        "y": 354.9,
                        "w": 482,
                        "h": 100
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Toxicity:",
                    "md": "# Toxicity:",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Excess fluorine can accumulate in teeth and bones, causing fluorosis. Drinking water containing &gt; 10 ppm is a common cause. Permanent teeth that develop during high fluoride intake are most likely to be affected. Exposure must be much greater to affect deciduous teeth.\n\nThe earliest signs are chalky white, irregularly distributed patches on the surface of the enamel; these patches become stained yellow or brown, producing a characteristic mottled appearance. Severe toxicity weakens the enamel, pitting its surface. Bony changes, including osteosclerosis, exostoses of the spine, and genu valgum, can develop but only in adults after prolonged high intake of fluoride. No tests to diagnose toxicity are available.\n\nTreatment involves reducing fluoride intake; eg, in areas with high fluoride water levels, patients should not drink fluoridated water or take fluoride supplements. Children should always be told not to swallow fluoridated toothpastes.",
                    "md": "Excess fluorine can accumulate in teeth and bones, causing fluorosis. Drinking water containing &gt; 10 ppm is a common cause. Permanent teeth that develop during high fluoride intake are most likely to be affected. Exposure must be much greater to affect deciduous teeth.\n\nThe earliest signs are chalky white, irregularly distributed patches on the surface of the enamel; these patches become stained yellow or brown, producing a characteristic mottled appearance. Severe toxicity weakens the enamel, pitting its surface. Bony changes, including osteosclerosis, exostoses of the spine, and genu valgum, can develop but only in adults after prolonged high intake of fluoride. No tests to diagnose toxicity are available.\n\nTreatment involves reducing fluoride intake; eg, in areas with high fluoride water levels, patients should not drink fluoridated water or take fluoride supplements. Children should always be told not to swallow fluoridated toothpastes.",
                    "bBox": {
                        "x": 55,
                        "y": 354.9,
                        "w": 477,
                        "h": 290
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Iodine",
                    "md": "# Iodine",
                    "bBox": {
                        "x": 55,
                        "y": 658.9,
                        "w": 31,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "In the body, iodine (I) is involved primarily in the synthesis of 2 thyroid hormones, thyroxine (T4) and triiodothyronine (T3). Iodine occurs in the environment and in the diet primarily as iodide. In adults, about 80% of the iodide absorbed is trapped by the thyroid gland. Most environmental iodine occurs in seawater as iodide; a small amount enters the atmosphere and, through rain, enters ground water and soil near the sea. Thus, people living far from the sea and at higher altitudes are at particular risk of deficiency. Fortifying table salt with iodide (typically 70 \u03bcg/g) helps ensure adequate intake (150 \u03bcg/day). Requirements are higher for pregnant (220 \u03bcg/day) and breastfeeding (290 \u03bcg/day) women.",
                    "md": "In the body, iodine (I) is involved primarily in the synthesis of 2 thyroid hormones, thyroxine (T4) and triiodothyronine (T3). Iodine occurs in the environment and in the diet primarily as iodide. In adults, about 80% of the iodide absorbed is trapped by the thyroid gland. Most environmental iodine occurs in seawater as iodide; a small amount enters the atmosphere and, through rain, enters ground water and soil near the sea. Thus, people living far from the sea and at higher altitudes are at particular risk of deficiency. Fortifying table salt with iodide (typically 70 \u03bcg/g) helps ensure adequate intake (150 \u03bcg/day). Requirements are higher for pregnant (220 \u03bcg/day) and breastfeeding (290 \u03bcg/day) women.",
                    "bBox": {
                        "x": 55,
                        "y": 658.9,
                        "w": 478,
                        "h": 118
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.996
        },
        {
            "page": 52,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition               Chapter 5. Mineral Deficiency &amp; Toxicity\n Iodine Deficiency\n Deficiency is rare in areas where iodized salt is used but common worldwide. Iodine deficiency develops\n when iodide intake is &lt; 20 \u03bcg/day. In mild or moderate deficiency, the thyroid gland, influenced by thyroid-\n stimulating hormone (TSH), hypertrophies to concentrate iodide in itself, resulting in colloid goiter.\n Usually, patients remain euthyroid; however, severe iodine deficiency in adults may cause hypothyroidism\n (endemic myxedema). It can decrease fertility and increase risk of stillbirth, spontaneous abortion, and\n prenatal and infant mortality. Severe maternal iodine deficiency retards fetal growth and brain\n development, sometimes resulting in birth defects, and, in infants, causes cretinism, which may include\n intellectual disability, deaf-mutism, difficulty walking, short stature, and sometimes hypothyroidism.\n Diagnosis\n \u2022 Assessment of thyroid structure and function\n Diagnosis in adults and children is usually based on thyroid function, examination for goiter, and imaging\n tests identifying abnormalities in thyroid function and structure (see p.\n 776). All neonates should be screened by measuring the TSH level.\n Treatment\n \u2022 Iodide with or without levothyroxine\n Infants with iodine deficiency are given L-thyroxine 3 \u03bcg/kg po once/day for a week plus iodide 50 to 90\n \u03bcg po once/day for several weeks to quickly restore a euthyroid state. Children are treated with iodide 90\n to 120 \u03bcg once/day. Adults are given iodide 150 \u03bcg once/day. Iodine deficiency can also be treated by\n giving levothyroxine. Serum TSH levels are monitored in all patients until the levels are normal (ie, &lt; 5\n \u03bcIU/mL).\n Iodine Toxicity\n Chronic toxicity may develop when intake is &gt; 1.1 mg/day. Most people who ingest excess amounts of\n iodine remain euthyroid. Some people who ingest excess amounts of iodine, particularly those who were\n previously deficient, develop hyperthyroidism (Jod-Basedow phenomenon). Paradoxically, excess uptake\n of iodine by the thyroid may inhibit thyroid hormone synthesis (called Wolff-Chaikoff effect). Thus, iodine\n toxicity can eventually cause iodide goiter, hypothyroidism, or myxedema. Very large amounts of iodide\n may cause a brassy taste in the mouth, increased salivation, GI irritation, and acneiform skin lesions.\n Patients exposed to frequent large amounts of radiographic contrast dyes or the drug amiodarone also\n need to have their thyroid function monitored.\n Diagnosis is usually based on thyroid function and imaging test findings (see p. 776), which are\n correlated with clinical data. Iodine excretion may be more specific but is not usually measured. Treatment\n consists of correcting thyroid abnormalities and, if intake is excessive, dietary modification.\n Iron\n Iron (Fe) is a component of hemoglobin, myoglobin, and many enzymes in the body. Heme iron, contained\n mainly in animal products, is absorbed much better than nonheme iron (eg, in plants and grains), which\n accounts for &gt; 85% of iron in the average diet. However, absorption of nonheme iron is increased when it\n is consumed with animal protein and vitamin C.\n Deficiency: Iron deficiency is one of the most common mineral deficiencies in the world. It may result\n from the following:\n \u2022 Inadequate iron intake, common in infants, adolescent girls, and pregnant women\n \u2022 Malabsorption (eg, celiac sprue)\n                                                                                                       104",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 5. Mineral Deficiency &amp; Toxicity\n\n# Iodine Deficiency\n\nDeficiency is rare in areas where iodized salt is used but common worldwide. Iodine deficiency develops when iodide intake is &amp;lt; 20 \u03bcg/day. In mild or moderate deficiency, the thyroid gland, influenced by thyroid-stimulating hormone (TSH), hypertrophies to concentrate iodide in itself, resulting in colloid goiter. Usually, patients remain euthyroid; however, severe iodine deficiency in adults may cause hypothyroidism (endemic myxedema). It can decrease fertility and increase risk of stillbirth, spontaneous abortion, and prenatal and infant mortality. Severe maternal iodine deficiency retards fetal growth and brain development, sometimes resulting in birth defects, and, in infants, causes cretinism, which may include intellectual disability, deaf-mutism, difficulty walking, short stature, and sometimes hypothyroidism.\n\n# Diagnosis\n\n- Assessment of thyroid structure and function\n\nDiagnosis in adults and children is usually based on thyroid function, examination for goiter, and imaging tests identifying abnormalities in thyroid function and structure (see p. 776). All neonates should be screened by measuring the TSH level.\n\n# Treatment\n\n- Iodide with or without levothyroxine\n\nInfants with iodine deficiency are given L-thyroxine 3 \u03bcg/kg po once/day for a week plus iodide 50 to 90 \u03bcg po once/day for several weeks to quickly restore a euthyroid state. Children are treated with iodide 90 to 120 \u03bcg once/day. Adults are given iodide 150 \u03bcg once/day. Iodine deficiency can also be treated by giving levothyroxine. Serum TSH levels are monitored in all patients until the levels are normal (ie, &amp;lt; 5 \u03bcIU/mL).\n\n# Iodine Toxicity\n\nChronic toxicity may develop when intake is &amp;gt; 1.1 mg/day. Most people who ingest excess amounts of iodine remain euthyroid. Some people who ingest excess amounts of iodine, particularly those who were previously deficient, develop hyperthyroidism (Jod-Basedow phenomenon). Paradoxically, excess uptake of iodine by the thyroid may inhibit thyroid hormone synthesis (called Wolff-Chaikoff effect). Thus, iodine toxicity can eventually cause iodide goiter, hypothyroidism, or myxedema. Very large amounts of iodide may cause a brassy taste in the mouth, increased salivation, GI irritation, and acneiform skin lesions. Patients exposed to frequent large amounts of radiographic contrast dyes or the drug amiodarone also need to have their thyroid function monitored.\n\nDiagnosis is usually based on thyroid function and imaging test findings (see p. 776), which are correlated with clinical data. Iodine excretion may be more specific but is not usually measured. Treatment consists of correcting thyroid abnormalities and, if intake is excessive, dietary modification.\n\n# Iron\n\nIron (Fe) is a component of hemoglobin, myoglobin, and many enzymes in the body. Heme iron, contained mainly in animal products, is absorbed much better than nonheme iron (eg, in plants and grains), which accounts for &amp;gt; 85% of iron in the average diet. However, absorption of nonheme iron is increased when it is consumed with animal protein and vitamin C.\n\n# Deficiency\n\nIron deficiency is one of the most common mineral deficiencies in the world. It may result from the following:\n\n- Inadequate iron intake, common in infants, adolescent girls, and pregnant women\n- Malabsorption (eg, celiac sprue)",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 172.18
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "md": "# Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "bBox": {
                        "x": 365,
                        "y": 30.72,
                        "w": 178,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Iodine Deficiency",
                    "md": "# Iodine Deficiency",
                    "bBox": {
                        "x": 55,
                        "y": 50.9,
                        "w": 87,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Deficiency is rare in areas where iodized salt is used but common worldwide. Iodine deficiency develops when iodide intake is &amp;lt; 20 \u03bcg/day. In mild or moderate deficiency, the thyroid gland, influenced by thyroid-stimulating hormone (TSH), hypertrophies to concentrate iodide in itself, resulting in colloid goiter. Usually, patients remain euthyroid; however, severe iodine deficiency in adults may cause hypothyroidism (endemic myxedema). It can decrease fertility and increase risk of stillbirth, spontaneous abortion, and prenatal and infant mortality. Severe maternal iodine deficiency retards fetal growth and brain development, sometimes resulting in birth defects, and, in infants, causes cretinism, which may include intellectual disability, deaf-mutism, difficulty walking, short stature, and sometimes hypothyroidism.",
                    "md": "Deficiency is rare in areas where iodized salt is used but common worldwide. Iodine deficiency develops when iodide intake is &amp;lt; 20 \u03bcg/day. In mild or moderate deficiency, the thyroid gland, influenced by thyroid-stimulating hormone (TSH), hypertrophies to concentrate iodide in itself, resulting in colloid goiter. Usually, patients remain euthyroid; however, severe iodine deficiency in adults may cause hypothyroidism (endemic myxedema). It can decrease fertility and increase risk of stillbirth, spontaneous abortion, and prenatal and infant mortality. Severe maternal iodine deficiency retards fetal growth and brain development, sometimes resulting in birth defects, and, in infants, causes cretinism, which may include intellectual disability, deaf-mutism, difficulty walking, short stature, and sometimes hypothyroidism.",
                    "bBox": {
                        "x": 55,
                        "y": 50.9,
                        "w": 482,
                        "h": 126
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Diagnosis",
                    "md": "# Diagnosis",
                    "bBox": {
                        "x": 55,
                        "y": 190.9,
                        "w": 50,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Assessment of thyroid structure and function\n\nDiagnosis in adults and children is usually based on thyroid function, examination for goiter, and imaging tests identifying abnormalities in thyroid function and structure (see p. 776). All neonates should be screened by measuring the TSH level.",
                    "md": "- Assessment of thyroid structure and function\n\nDiagnosis in adults and children is usually based on thyroid function, examination for goiter, and imaging tests identifying abnormalities in thyroid function and structure (see p. 776). All neonates should be screened by measuring the TSH level.",
                    "bBox": {
                        "x": 55,
                        "y": 190.9,
                        "w": 476,
                        "h": 88
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Treatment",
                    "md": "# Treatment",
                    "bBox": {
                        "x": 55,
                        "y": 291.9,
                        "w": 51,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "- Iodide with or without levothyroxine\n\nInfants with iodine deficiency are given L-thyroxine 3 \u03bcg/kg po once/day for a week plus iodide 50 to 90 \u03bcg po once/day for several weeks to quickly restore a euthyroid state. Children are treated with iodide 90 to 120 \u03bcg once/day. Adults are given iodide 150 \u03bcg once/day. Iodine deficiency can also be treated by giving levothyroxine. Serum TSH levels are monitored in all patients until the levels are normal (ie, &amp;lt; 5 \u03bcIU/mL).",
                    "md": "- Iodide with or without levothyroxine\n\nInfants with iodine deficiency are given L-thyroxine 3 \u03bcg/kg po once/day for a week plus iodide 50 to 90 \u03bcg po once/day for several weeks to quickly restore a euthyroid state. Children are treated with iodide 90 to 120 \u03bcg once/day. Adults are given iodide 150 \u03bcg once/day. Iodine deficiency can also be treated by giving levothyroxine. Serum TSH levels are monitored in all patients until the levels are normal (ie, &amp;lt; 5 \u03bcIU/mL).",
                    "bBox": {
                        "x": 55,
                        "y": 50.9,
                        "w": 479,
                        "h": 354
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Iodine Toxicity",
                    "md": "# Iodine Toxicity",
                    "bBox": {
                        "x": 55,
                        "y": 418.9,
                        "w": 73,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Chronic toxicity may develop when intake is &amp;gt; 1.1 mg/day. Most people who ingest excess amounts of iodine remain euthyroid. Some people who ingest excess amounts of iodine, particularly those who were previously deficient, develop hyperthyroidism (Jod-Basedow phenomenon). Paradoxically, excess uptake of iodine by the thyroid may inhibit thyroid hormone synthesis (called Wolff-Chaikoff effect). Thus, iodine toxicity can eventually cause iodide goiter, hypothyroidism, or myxedema. Very large amounts of iodide may cause a brassy taste in the mouth, increased salivation, GI irritation, and acneiform skin lesions. Patients exposed to frequent large amounts of radiographic contrast dyes or the drug amiodarone also need to have their thyroid function monitored.\n\nDiagnosis is usually based on thyroid function and imaging test findings (see p. 776), which are correlated with clinical data. Iodine excretion may be more specific but is not usually measured. Treatment consists of correcting thyroid abnormalities and, if intake is excessive, dietary modification.",
                    "md": "Chronic toxicity may develop when intake is &amp;gt; 1.1 mg/day. Most people who ingest excess amounts of iodine remain euthyroid. Some people who ingest excess amounts of iodine, particularly those who were previously deficient, develop hyperthyroidism (Jod-Basedow phenomenon). Paradoxically, excess uptake of iodine by the thyroid may inhibit thyroid hormone synthesis (called Wolff-Chaikoff effect). Thus, iodine toxicity can eventually cause iodide goiter, hypothyroidism, or myxedema. Very large amounts of iodide may cause a brassy taste in the mouth, increased salivation, GI irritation, and acneiform skin lesions. Patients exposed to frequent large amounts of radiographic contrast dyes or the drug amiodarone also need to have their thyroid function monitored.\n\nDiagnosis is usually based on thyroid function and imaging test findings (see p. 776), which are correlated with clinical data. Iodine excretion may be more specific but is not usually measured. Treatment consists of correcting thyroid abnormalities and, if intake is excessive, dietary modification.",
                    "bBox": {
                        "x": 55,
                        "y": 190.9,
                        "w": 483,
                        "h": 404
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Iron",
                    "md": "# Iron",
                    "bBox": {
                        "x": 55,
                        "y": 608.9,
                        "w": 20,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Iron (Fe) is a component of hemoglobin, myoglobin, and many enzymes in the body. Heme iron, contained mainly in animal products, is absorbed much better than nonheme iron (eg, in plants and grains), which accounts for &amp;gt; 85% of iron in the average diet. However, absorption of nonheme iron is increased when it is consumed with animal protein and vitamin C.",
                    "md": "Iron (Fe) is a component of hemoglobin, myoglobin, and many enzymes in the body. Heme iron, contained mainly in animal products, is absorbed much better than nonheme iron (eg, in plants and grains), which accounts for &amp;gt; 85% of iron in the average diet. However, absorption of nonheme iron is increased when it is consumed with animal protein and vitamin C.",
                    "bBox": {
                        "x": 55,
                        "y": 608.9,
                        "w": 482,
                        "h": 75
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Deficiency",
                    "md": "# Deficiency",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Iron deficiency is one of the most common mineral deficiencies in the world. It may result from the following:\n\n- Inadequate iron intake, common in infants, adolescent girls, and pregnant women\n- Malabsorption (eg, celiac sprue)",
                    "md": "Iron deficiency is one of the most common mineral deficiencies in the world. It may result from the following:\n\n- Inadequate iron intake, common in infants, adolescent girls, and pregnant women\n- Malabsorption (eg, celiac sprue)",
                    "bBox": {
                        "x": 55,
                        "y": 608.9,
                        "w": 84,
                        "h": 113
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.997
        },
        {
            "page": 53,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition              Chapter 5. Mineral Deficiency &amp; Toxicity\n \u2022 Chronic bleeding\n Chronic bleeding due to colon cancer is a serious cause in middle-aged people and the elderly.\n When deficiency is advanced, microcytic anemia develops (see p. 924).\n In addition to anemia, iron deficiency may cause pica (a craving for nonfoods) and spoon nails and is\n associated with restless leg syndrome. Rarely, iron deficiency causes dysphagia due to postcricoid\n esophageal web.\n Diagnosis involves CBC, serum ferritin, and possibly measurement of transferrin saturation (iron\n capacity).\n All people with moderate or severe iron deficiency and some people with mild deficiency require iron\n supplementation.\n Toxicity: Iron may accumulate in the body because of\n \u2022 Iron therapy given in excessive amounts or for too long\n \u2022 Repeated blood transfusions\n \u2022 Chronic alcoholism\n \u2022 Overdose of iron\n Iron overload can also result from an inherited iron overload disease (hemochromatosis\u2014see p. 1032), a\n potentially fatal but easily treatable genetic disorder in which too much iron is absorbed.\n Hemochromatosis affects &gt; 1 million Americans.\n An overdose of iron is toxic (see p. 3341), causing vomiting, diarrhea, and damage to the intestine and\n other organs.\n Diagnosis is similar to that for iron deficiency.\n Treatment often involves deferoxamine, which binds with iron and is excreted in urine.\n Manganese\n Manganese (Mn), necessary for healthy bone structure, is a component of several enzyme systems,\n including manganese-specific glycosyltransferases and phosphoenolpyruvate carboxykinase. Median\n intake is between 1.6 and 2.3 mg/day; absorption is 5 to 10%.\n Deficiency has not been conclusively documented, although one experimental case in a volunteer\n resulted in transient dermatitis, hypocholesterolemia, and increased alkaline phosphatase levels.\n Toxicity is usually limited to people who mine and refine ore; prolonged exposure causes neurologic\n symptoms resembling those of parkinsonism or Wilson's disease.\n Molybdenum\n Molybdenum (Mo) is a component of coenzymes necessary for the activity of xanthine oxidase, sulfite\n oxidase, and aldehyde oxidase.\n Genetic and nutritional deficiencies of molybdenum have been reported but are rare. Genetic sulfite\n oxidase deficiency was described in 1967 in a child. It resulted from the inability to form the molybdenum\n coenzyme despite the presence of adequate molybdenum. The deficiency caused intellectual disability,\n seizures, opisthotonus, and lens dislocation.\n                                                                                                      105",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 5. Mineral Deficiency &amp; Toxicity\n\n# Chronic bleeding\n\nChronic bleeding due to colon cancer is a serious cause in middle-aged people and the elderly. When deficiency is advanced, microcytic anemia develops (see p. 924). In addition to anemia, iron deficiency may cause pica (a craving for nonfoods) and spoon nails and is associated with restless leg syndrome. Rarely, iron deficiency causes dysphagia due to postcricoid esophageal web.\n\nDiagnosis involves CBC, serum ferritin, and possibly measurement of transferrin saturation (iron capacity). All people with moderate or severe iron deficiency and some people with mild deficiency require iron supplementation.\n\n# Toxicity\n\nIron may accumulate in the body because of:\n\n- Iron therapy given in excessive amounts or for too long\n- Repeated blood transfusions\n- Chronic alcoholism\n- Overdose of iron\n\nIron overload can also result from an inherited iron overload disease (hemochromatosis\u2014see p. 1032), a potentially fatal but easily treatable genetic disorder in which too much iron is absorbed. Hemochromatosis affects &gt; 1 million Americans. An overdose of iron is toxic (see p. 3341), causing vomiting, diarrhea, and damage to the intestine and other organs. Diagnosis is similar to that for iron deficiency. Treatment often involves deferoxamine, which binds with iron and is excreted in urine.\n\n# Manganese\n\nManganese (Mn), necessary for healthy bone structure, is a component of several enzyme systems, including manganese-specific glycosyltransferases and phosphoenolpyruvate carboxykinase. Median intake is between 1.6 and 2.3 mg/day; absorption is 5 to 10%.\n\nDeficiency has not been conclusively documented, although one experimental case in a volunteer resulted in transient dermatitis, hypocholesterolemia, and increased alkaline phosphatase levels. Toxicity is usually limited to people who mine and refine ore; prolonged exposure causes neurologic symptoms resembling those of parkinsonism or Wilson's disease.\n\n# Molybdenum\n\nMolybdenum (Mo) is a component of coenzymes necessary for the activity of xanthine oxidase, sulfite oxidase, and aldehyde oxidase. Genetic and nutritional deficiencies of molybdenum have been reported but are rare. Genetic sulfite oxidase deficiency was described in 1967 in a child. It resulted from the inability to form the molybdenum coenzyme despite the presence of adequate molybdenum. The deficiency caused intellectual disability, seizures, opisthotonus, and lens dislocation.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "md": "# Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "bBox": {
                        "x": 365,
                        "y": 30.72,
                        "w": 178,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chronic bleeding",
                    "md": "# Chronic bleeding",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Chronic bleeding due to colon cancer is a serious cause in middle-aged people and the elderly. When deficiency is advanced, microcytic anemia develops (see p. 924). In addition to anemia, iron deficiency may cause pica (a craving for nonfoods) and spoon nails and is associated with restless leg syndrome. Rarely, iron deficiency causes dysphagia due to postcricoid esophageal web.\n\nDiagnosis involves CBC, serum ferritin, and possibly measurement of transferrin saturation (iron capacity). All people with moderate or severe iron deficiency and some people with mild deficiency require iron supplementation.",
                    "md": "Chronic bleeding due to colon cancer is a serious cause in middle-aged people and the elderly. When deficiency is advanced, microcytic anemia develops (see p. 924). In addition to anemia, iron deficiency may cause pica (a craving for nonfoods) and spoon nails and is associated with restless leg syndrome. Rarely, iron deficiency causes dysphagia due to postcricoid esophageal web.\n\nDiagnosis involves CBC, serum ferritin, and possibly measurement of transferrin saturation (iron capacity). All people with moderate or severe iron deficiency and some people with mild deficiency require iron supplementation.",
                    "bBox": {
                        "x": 55,
                        "y": 74.9,
                        "w": 460,
                        "h": 164
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Toxicity",
                    "md": "# Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Iron may accumulate in the body because of:\n\n- Iron therapy given in excessive amounts or for too long\n- Repeated blood transfusions\n- Chronic alcoholism\n- Overdose of iron\n\nIron overload can also result from an inherited iron overload disease (hemochromatosis\u2014see p. 1032), a potentially fatal but easily treatable genetic disorder in which too much iron is absorbed. Hemochromatosis affects &gt; 1 million Americans. An overdose of iron is toxic (see p. 3341), causing vomiting, diarrhea, and damage to the intestine and other organs. Diagnosis is similar to that for iron deficiency. Treatment often involves deferoxamine, which binds with iron and is excreted in urine.",
                    "md": "Iron may accumulate in the body because of:\n\n- Iron therapy given in excessive amounts or for too long\n- Repeated blood transfusions\n- Chronic alcoholism\n- Overdose of iron\n\nIron overload can also result from an inherited iron overload disease (hemochromatosis\u2014see p. 1032), a potentially fatal but easily treatable genetic disorder in which too much iron is absorbed. Hemochromatosis affects &gt; 1 million Americans. An overdose of iron is toxic (see p. 3341), causing vomiting, diarrhea, and damage to the intestine and other organs. Diagnosis is similar to that for iron deficiency. Treatment often involves deferoxamine, which binds with iron and is excreted in urine.",
                    "bBox": {
                        "x": 55,
                        "y": 378.9,
                        "w": 478,
                        "h": 126
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Manganese",
                    "md": "# Manganese",
                    "bBox": {
                        "x": 55,
                        "y": 517.9,
                        "w": 57,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Manganese (Mn), necessary for healthy bone structure, is a component of several enzyme systems, including manganese-specific glycosyltransferases and phosphoenolpyruvate carboxykinase. Median intake is between 1.6 and 2.3 mg/day; absorption is 5 to 10%.\n\nDeficiency has not been conclusively documented, although one experimental case in a volunteer resulted in transient dermatitis, hypocholesterolemia, and increased alkaline phosphatase levels. Toxicity is usually limited to people who mine and refine ore; prolonged exposure causes neurologic symptoms resembling those of parkinsonism or Wilson's disease.",
                    "md": "Manganese (Mn), necessary for healthy bone structure, is a component of several enzyme systems, including manganese-specific glycosyltransferases and phosphoenolpyruvate carboxykinase. Median intake is between 1.6 and 2.3 mg/day; absorption is 5 to 10%.\n\nDeficiency has not been conclusively documented, although one experimental case in a volunteer resulted in transient dermatitis, hypocholesterolemia, and increased alkaline phosphatase levels. Toxicity is usually limited to people who mine and refine ore; prolonged exposure causes neurologic symptoms resembling those of parkinsonism or Wilson's disease.",
                    "bBox": {
                        "x": 55,
                        "y": 517.9,
                        "w": 463,
                        "h": 139
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Molybdenum",
                    "md": "# Molybdenum",
                    "bBox": {
                        "x": 55,
                        "y": 669.9,
                        "w": 65,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Molybdenum (Mo) is a component of coenzymes necessary for the activity of xanthine oxidase, sulfite oxidase, and aldehyde oxidase. Genetic and nutritional deficiencies of molybdenum have been reported but are rare. Genetic sulfite oxidase deficiency was described in 1967 in a child. It resulted from the inability to form the molybdenum coenzyme despite the presence of adequate molybdenum. The deficiency caused intellectual disability, seizures, opisthotonus, and lens dislocation.",
                    "md": "Molybdenum (Mo) is a component of coenzymes necessary for the activity of xanthine oxidase, sulfite oxidase, and aldehyde oxidase. Genetic and nutritional deficiencies of molybdenum have been reported but are rare. Genetic sulfite oxidase deficiency was described in 1967 in a child. It resulted from the inability to form the molybdenum coenzyme despite the presence of adequate molybdenum. The deficiency caused intellectual disability, seizures, opisthotonus, and lens dislocation.",
                    "bBox": {
                        "x": 55,
                        "y": 669.9,
                        "w": 476,
                        "h": 114
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.996
        },
        {
            "page": 54,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition              Chapter 5. Mineral Deficiency &amp; Toxicity\n Molybdenum deficiency resulting in sulfite toxicity occurred in a patient receiving long-term TPN.\n Symptoms were tachycardia, tachypnea, headache, nausea, vomiting, and coma. Laboratory tests\n showed high levels of sulfite and xanthine and low levels of sulfate and uric acid in the blood and urine.\n Ammonium molybdate 300 \u03bcg/day IV caused dramatic recovery.\n A case of molybdenum toxicity may have occurred in 1961; it caused goutlike symptoms and\n abnormalities of the GI tract, liver, and kidneys.\n Selenium\n Selenium (Se) is a part of the enzyme glutathione peroxidase, which metabolizes hydro-peroxides formed\n from polyunsaturated fatty acids. Selenium is also a part of the enzymes that deiodinate thyroid\n hormones. Generally, selenium acts as an antioxidant that works with vitamin E. Some epidemiologic\n studies associate low selenium levels with cancer. In children with Down syndrome, selenium\n supplements may help prevent bacterial infections. Plasma levels vary from 8 to 25 \u03bcg/dL, depending on\n selenium intake. Diagnosis is usually clinical; sometimes blood glutathione peroxidase is measured.\n Deficiency: Deficiency is rare, even in New Zealand and Finland, where selenium intake is 30 to 50\n \u03bcg/day, compared with 100 to 250 \u03bcg/day in the US and Canada. In certain areas of China, where intake\n averages 10 to 15 \u03bcg/day, selenium deficiency predisposes patients to Keshan disease, an endemic viral\n cardiomyopathy affecting primarily children and young women. This cardiomyopathy can be prevented\n but not cured by sodium selenite supplements of 50 \u03bcg/day po. Patients receiving long-term TPN have\n developed selenium deficiency with muscle pain and tenderness that responded to a selenomethionine\n supplement. In Siberian Russia and China, growing children with selenium deficiency may develop\n chronic osteoarthropathy (Kashin-Beck disease). Selenium deficiency may contribute synergistically with\n iodine deficiency to the development of goiter and hypothyroidism.\n Diagnosis is made clinically or sometimes by measuring glutathione peroxidase activity or plasma\n selenium, but neither of these tests is readily available. Treatment consists of sodium selenite 100 \u03bcg/day\n po.\n Toxicity: At high doses (&gt; 900 \u03bcg/day), selenium causes toxicity. Manifestations include hair loss,\n abnormal nails, dermatitis, peripheral neuropathy, nausea, diarrhea, fatigue, irritability, and a garlic odor of\n the breath. Toxic levels of plasma selenium are not well defined.\n Zinc\n Zinc (Zn) is contained mainly in bones, teeth, hair, skin, liver, muscle, leukocytes, and testes. Zinc is a\n component of several hundred enzymes, including many nicotinamide adenine dinucleotide (NADH)\n dehydrogenases, RNA and DNA polymerases, and DNA transcription factors as well as alkaline\n phosphatase, superoxide dismutase, and carbonic anhydrase. A diet high in fiber and phytate (eg, in\n whole-grain bread) reduces zinc absorption.\n Deficiency: Dietary deficiency is unlikely in healthy people. Secondary zinc deficiency can develop in the\n following:\n \u2022 Some patients with hepatic insufficiency (because the ability to retain zinc is lost)\n \u2022 Patients taking diuretics\n \u2022 Patients with diabetes mellitus, sickle cell disease, chronic renal failure, or malabsorption\n \u2022 Patients with stressful conditions (eg, sepsis, burns, head injury)\n \u2022 Elderly institutionalized and homebound patients (common)\n Maternal zinc deficiency may cause fetal malformations and low birth weight.\n                                                                                                     106",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 5. Mineral Deficiency &amp; Toxicity\n\n# Molybdenum\n\nMolybdenum deficiency resulting in sulfite toxicity occurred in a patient receiving long-term TPN. Symptoms were tachycardia, tachypnea, headache, nausea, vomiting, and coma. Laboratory tests showed high levels of sulfite and xanthine and low levels of sulfate and uric acid in the blood and urine. Ammonium molybdate 300 \u03bcg/day IV caused dramatic recovery. A case of molybdenum toxicity may have occurred in 1961; it caused goutlike symptoms and abnormalities of the GI tract, liver, and kidneys.\n\n# Selenium\n\nSelenium (Se) is a part of the enzyme glutathione peroxidase, which metabolizes hydro-peroxides formed from polyunsaturated fatty acids. Selenium is also a part of the enzymes that deiodinate thyroid hormones. Generally, selenium acts as an antioxidant that works with vitamin E. Some epidemiologic studies associate low selenium levels with cancer. In children with Down syndrome, selenium supplements may help prevent bacterial infections. Plasma levels vary from 8 to 25 \u03bcg/dL, depending on selenium intake. Diagnosis is usually clinical; sometimes blood glutathione peroxidase is measured.\n\n# Deficiency\n\nDeficiency is rare, even in New Zealand and Finland, where selenium intake is 30 to 50 \u03bcg/day, compared with 100 to 250 \u03bcg/day in the US and Canada. In certain areas of China, where intake averages 10 to 15 \u03bcg/day, selenium deficiency predisposes patients to Keshan disease, an endemic viral cardiomyopathy affecting primarily children and young women. This cardiomyopathy can be prevented but not cured by sodium selenite supplements of 50 \u03bcg/day po. Patients receiving long-term TPN have developed selenium deficiency with muscle pain and tenderness that responded to a selenomethionine supplement. In Siberian Russia and China, growing children with selenium deficiency may develop chronic osteoarthropathy (Kashin-Beck disease). Selenium deficiency may contribute synergistically with iodine deficiency to the development of goiter and hypothyroidism. Diagnosis is made clinically or sometimes by measuring glutathione peroxidase activity or plasma selenium, but neither of these tests is readily available. Treatment consists of sodium selenite 100 \u03bcg/day po.\n\n# Toxicity\n\nAt high doses (&gt; 900 \u03bcg/day), selenium causes toxicity. Manifestations include hair loss, abnormal nails, dermatitis, peripheral neuropathy, nausea, diarrhea, fatigue, irritability, and a garlic odor of the breath. Toxic levels of plasma selenium are not well defined.\n\n# Zinc\n\nZinc (Zn) is contained mainly in bones, teeth, hair, skin, liver, muscle, leukocytes, and testes. Zinc is a component of several hundred enzymes, including many nicotinamide adenine dinucleotide (NADH) dehydrogenases, RNA and DNA polymerases, and DNA transcription factors as well as alkaline phosphatase, superoxide dismutase, and carbonic anhydrase. A diet high in fiber and phytate (eg, in whole-grain bread) reduces zinc absorption.\n\n# Deficiency\n\nDietary deficiency is unlikely in healthy people. Secondary zinc deficiency can develop in the following:\n\n- Some patients with hepatic insufficiency (because the ability to retain zinc is lost)\n- Patients taking diuretics\n- Patients with diabetes mellitus, sickle cell disease, chronic renal failure, or malabsorption\n- Patients with stressful conditions (eg, sepsis, burns, head injury)\n- Elderly institutionalized and homebound patients (common)\n\nMaternal zinc deficiency may cause fetal malformations and low birth weight.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "md": "# Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "bBox": {
                        "x": 365,
                        "y": 30.72,
                        "w": 178,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Molybdenum",
                    "md": "# Molybdenum",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Molybdenum deficiency resulting in sulfite toxicity occurred in a patient receiving long-term TPN. Symptoms were tachycardia, tachypnea, headache, nausea, vomiting, and coma. Laboratory tests showed high levels of sulfite and xanthine and low levels of sulfate and uric acid in the blood and urine. Ammonium molybdate 300 \u03bcg/day IV caused dramatic recovery. A case of molybdenum toxicity may have occurred in 1961; it caused goutlike symptoms and abnormalities of the GI tract, liver, and kidneys.",
                    "md": "Molybdenum deficiency resulting in sulfite toxicity occurred in a patient receiving long-term TPN. Symptoms were tachycardia, tachypnea, headache, nausea, vomiting, and coma. Laboratory tests showed high levels of sulfite and xanthine and low levels of sulfate and uric acid in the blood and urine. Ammonium molybdate 300 \u03bcg/day IV caused dramatic recovery. A case of molybdenum toxicity may have occurred in 1961; it caused goutlike symptoms and abnormalities of the GI tract, liver, and kidneys.",
                    "bBox": {
                        "x": 55,
                        "y": 61.9,
                        "w": 471,
                        "h": 88
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Selenium",
                    "md": "# Selenium",
                    "bBox": {
                        "x": 55,
                        "y": 162.9,
                        "w": 48,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Selenium (Se) is a part of the enzyme glutathione peroxidase, which metabolizes hydro-peroxides formed from polyunsaturated fatty acids. Selenium is also a part of the enzymes that deiodinate thyroid hormones. Generally, selenium acts as an antioxidant that works with vitamin E. Some epidemiologic studies associate low selenium levels with cancer. In children with Down syndrome, selenium supplements may help prevent bacterial infections. Plasma levels vary from 8 to 25 \u03bcg/dL, depending on selenium intake. Diagnosis is usually clinical; sometimes blood glutathione peroxidase is measured.",
                    "md": "Selenium (Se) is a part of the enzyme glutathione peroxidase, which metabolizes hydro-peroxides formed from polyunsaturated fatty acids. Selenium is also a part of the enzymes that deiodinate thyroid hormones. Generally, selenium acts as an antioxidant that works with vitamin E. Some epidemiologic studies associate low selenium levels with cancer. In children with Down syndrome, selenium supplements may help prevent bacterial infections. Plasma levels vary from 8 to 25 \u03bcg/dL, depending on selenium intake. Diagnosis is usually clinical; sometimes blood glutathione peroxidase is measured.",
                    "bBox": {
                        "x": 55,
                        "y": 162.9,
                        "w": 479,
                        "h": 101
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Deficiency",
                    "md": "# Deficiency",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Deficiency is rare, even in New Zealand and Finland, where selenium intake is 30 to 50 \u03bcg/day, compared with 100 to 250 \u03bcg/day in the US and Canada. In certain areas of China, where intake averages 10 to 15 \u03bcg/day, selenium deficiency predisposes patients to Keshan disease, an endemic viral cardiomyopathy affecting primarily children and young women. This cardiomyopathy can be prevented but not cured by sodium selenite supplements of 50 \u03bcg/day po. Patients receiving long-term TPN have developed selenium deficiency with muscle pain and tenderness that responded to a selenomethionine supplement. In Siberian Russia and China, growing children with selenium deficiency may develop chronic osteoarthropathy (Kashin-Beck disease). Selenium deficiency may contribute synergistically with iodine deficiency to the development of goiter and hypothyroidism. Diagnosis is made clinically or sometimes by measuring glutathione peroxidase activity or plasma selenium, but neither of these tests is readily available. Treatment consists of sodium selenite 100 \u03bcg/day po.",
                    "md": "Deficiency is rare, even in New Zealand and Finland, where selenium intake is 30 to 50 \u03bcg/day, compared with 100 to 250 \u03bcg/day in the US and Canada. In certain areas of China, where intake averages 10 to 15 \u03bcg/day, selenium deficiency predisposes patients to Keshan disease, an endemic viral cardiomyopathy affecting primarily children and young women. This cardiomyopathy can be prevented but not cured by sodium selenite supplements of 50 \u03bcg/day po. Patients receiving long-term TPN have developed selenium deficiency with muscle pain and tenderness that responded to a selenomethionine supplement. In Siberian Russia and China, growing children with selenium deficiency may develop chronic osteoarthropathy (Kashin-Beck disease). Selenium deficiency may contribute synergistically with iodine deficiency to the development of goiter and hypothyroidism. Diagnosis is made clinically or sometimes by measuring glutathione peroxidase activity or plasma selenium, but neither of these tests is readily available. Treatment consists of sodium selenite 100 \u03bcg/day po.",
                    "bBox": {
                        "x": 55,
                        "y": 162.9,
                        "w": 481,
                        "h": 279
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Toxicity",
                    "md": "# Toxicity",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "At high doses (&gt; 900 \u03bcg/day), selenium causes toxicity. Manifestations include hair loss, abnormal nails, dermatitis, peripheral neuropathy, nausea, diarrhea, fatigue, irritability, and a garlic odor of the breath. Toxic levels of plasma selenium are not well defined.",
                    "md": "At high doses (&gt; 900 \u03bcg/day), selenium causes toxicity. Manifestations include hair loss, abnormal nails, dermatitis, peripheral neuropathy, nausea, diarrhea, fatigue, irritability, and a garlic odor of the breath. Toxic levels of plasma selenium are not well defined.",
                    "bBox": {
                        "x": 55,
                        "y": 162.9,
                        "w": 483,
                        "h": 329
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Zinc",
                    "md": "# Zinc",
                    "bBox": {
                        "x": 55,
                        "y": 505.9,
                        "w": 21,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Zinc (Zn) is contained mainly in bones, teeth, hair, skin, liver, muscle, leukocytes, and testes. Zinc is a component of several hundred enzymes, including many nicotinamide adenine dinucleotide (NADH) dehydrogenases, RNA and DNA polymerases, and DNA transcription factors as well as alkaline phosphatase, superoxide dismutase, and carbonic anhydrase. A diet high in fiber and phytate (eg, in whole-grain bread) reduces zinc absorption.",
                    "md": "Zinc (Zn) is contained mainly in bones, teeth, hair, skin, liver, muscle, leukocytes, and testes. Zinc is a component of several hundred enzymes, including many nicotinamide adenine dinucleotide (NADH) dehydrogenases, RNA and DNA polymerases, and DNA transcription factors as well as alkaline phosphatase, superoxide dismutase, and carbonic anhydrase. A diet high in fiber and phytate (eg, in whole-grain bread) reduces zinc absorption.",
                    "bBox": {
                        "x": 55,
                        "y": 505.9,
                        "w": 464,
                        "h": 88
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Deficiency",
                    "md": "# Deficiency",
                    "bBox": {
                        "x": 0,
                        "y": 0,
                        "w": 595,
                        "h": 842
                    }
                },
                {
                    "type": "text",
                    "value": "Dietary deficiency is unlikely in healthy people. Secondary zinc deficiency can develop in the following:\n\n- Some patients with hepatic insufficiency (because the ability to retain zinc is lost)\n- Patients taking diuretics\n- Patients with diabetes mellitus, sickle cell disease, chronic renal failure, or malabsorption\n- Patients with stressful conditions (eg, sepsis, burns, head injury)\n- Elderly institutionalized and homebound patients (common)\n\nMaternal zinc deficiency may cause fetal malformations and low birth weight.",
                    "md": "Dietary deficiency is unlikely in healthy people. Secondary zinc deficiency can develop in the following:\n\n- Some patients with hepatic insufficiency (because the ability to retain zinc is lost)\n- Patients taking diuretics\n- Patients with diabetes mellitus, sickle cell disease, chronic renal failure, or malabsorption\n- Patients with stressful conditions (eg, sepsis, burns, head injury)\n- Elderly institutionalized and homebound patients (common)\n\nMaternal zinc deficiency may cause fetal malformations and low birth weight.",
                    "bBox": {
                        "x": 55,
                        "y": 505.9,
                        "w": 349,
                        "h": 278
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.995
        },
        {
            "page": 55,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition               Chapter 5. Mineral Deficiency &amp; Toxicity\n Zinc deficiency in children causes impaired growth and impaired taste (hypogeusia). Other symptoms and\n signs in children include delayed sexual maturation and hypogonadism. In children or adults, symptoms\n include hypogonadism, alopecia, impaired immunity, anorexia, dermatitis, night blindness, anemia,\n lethargy, and impaired wound healing.\n Zinc deficiency should be suspected in undernourished patients with typical symptoms or signs. However,\n because many of the symptoms and signs are nonspecific, clinical diagnosis of mild zinc deficiency is\n difficult. Laboratory diagnosis is also difficult. Low albumin levels, common in zinc deficiency, make serum\n zinc levels difficult to interpret; diagnosis usually requires the combination of low levels of zinc in serum\n and increased urinary zinc excretion. If available, isotope studies can measure zinc status more\n accurately.\n Treatment consists of elemental zinc 15 to 120 mg/day po until symptoms and signs resolve.\n Acrodermatitis enteropathica (a rare, once fatal autosomal recessive disorder) causes malabsorption\n of zinc. Psoriasiform dermatitis develops around the eyes, nose, and mouth; on the buttocks; and in an\n acral distribution. The disorder also causes hair loss, paronychia, impaired immunity, recurrent infection,\n impaired growth, and diarrhea. Symptoms and signs usually develop after infants are weaned from breast\n milk. In such cases, doctors suspect the diagnosis. If deficiency is diagnosed, zinc sulfate 30 to 150\n mg/day po usually results in complete remission.\n Toxicity: The recommended upper limit for zinc intake is 40 mg/day. Toxicity is rare. Ingesting doses of\n elemental zinc ranging from 100 to 150 mg/day for prolonged periods interferes with copper metabolism\n and causes low blood copper levels, RBC microcytosis, neutropenia, and impaired immunity; higher\n doses should be given only for short periods of time and the patient should be followed closely. Ingesting\n larger amounts (200 to 800 mg/day), usually by consuming acidic food or drink from a galvanized (zinc-\n coated) container, can cause anorexia, vomiting, and diarrhea. Metal fume fever, also called brass-\n founders' ague or zinc shakes, is caused by inhaling industrial zinc oxide fumes; it results in neurologic\n damage. Symptoms usually resolve after 12 to 24 h in a zinc-free environment.\n                                                                                                       107",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 5. Mineral Deficiency &amp; Toxicity\n\nZinc deficiency in children causes impaired growth and impaired taste (hypogeusia). Other symptoms and signs in children include delayed sexual maturation and hypogonadism. In children or adults, symptoms include hypogonadism, alopecia, impaired immunity, anorexia, dermatitis, night blindness, anemia, lethargy, and impaired wound healing.\n\nZinc deficiency should be suspected in undernourished patients with typical symptoms or signs. However, because many of the symptoms and signs are nonspecific, clinical diagnosis of mild zinc deficiency is difficult. Laboratory diagnosis is also difficult. Low albumin levels, common in zinc deficiency, make serum zinc levels difficult to interpret; diagnosis usually requires the combination of low levels of zinc in serum and increased urinary zinc excretion. If available, isotope studies can measure zinc status more accurately.\n\nTreatment consists of elemental zinc 15 to 120 mg/day po until symptoms and signs resolve.\n\nAcrodermatitis enteropathica (a rare, once fatal autosomal recessive disorder) causes malabsorption of zinc. Psoriasiform dermatitis develops around the eyes, nose, and mouth; on the buttocks; and in an acral distribution. The disorder also causes hair loss, paronychia, impaired immunity, recurrent infection, impaired growth, and diarrhea. Symptoms and signs usually develop after infants are weaned from breast milk. In such cases, doctors suspect the diagnosis. If deficiency is diagnosed, zinc sulfate 30 to 150 mg/day po usually results in complete remission.\n\nToxicity: The recommended upper limit for zinc intake is 40 mg/day. Toxicity is rare. Ingesting doses of elemental zinc ranging from 100 to 150 mg/day for prolonged periods interferes with copper metabolism and causes low blood copper levels, RBC microcytosis, neutropenia, and impaired immunity; higher doses should be given only for short periods of time and the patient should be followed closely. Ingesting larger amounts (200 to 800 mg/day), usually by consuming acidic food or drink from a galvanized (zinc-coated) container, can cause anorexia, vomiting, and diarrhea. Metal fume fever, also called brass-founders' ague or zinc shakes, is caused by inhaling industrial zinc oxide fumes; it results in neurologic damage. Symptoms usually resolve after 12 to 24 h in a zinc-free environment.",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "md": "# Chapter 5. Mineral Deficiency &amp; Toxicity",
                    "bBox": {
                        "x": 365,
                        "y": 30.72,
                        "w": 178,
                        "h": 11
                    }
                },
                {
                    "type": "text",
                    "value": "Zinc deficiency in children causes impaired growth and impaired taste (hypogeusia). Other symptoms and signs in children include delayed sexual maturation and hypogonadism. In children or adults, symptoms include hypogonadism, alopecia, impaired immunity, anorexia, dermatitis, night blindness, anemia, lethargy, and impaired wound healing.\n\nZinc deficiency should be suspected in undernourished patients with typical symptoms or signs. However, because many of the symptoms and signs are nonspecific, clinical diagnosis of mild zinc deficiency is difficult. Laboratory diagnosis is also difficult. Low albumin levels, common in zinc deficiency, make serum zinc levels difficult to interpret; diagnosis usually requires the combination of low levels of zinc in serum and increased urinary zinc excretion. If available, isotope studies can measure zinc status more accurately.\n\nTreatment consists of elemental zinc 15 to 120 mg/day po until symptoms and signs resolve.\n\nAcrodermatitis enteropathica (a rare, once fatal autosomal recessive disorder) causes malabsorption of zinc. Psoriasiform dermatitis develops around the eyes, nose, and mouth; on the buttocks; and in an acral distribution. The disorder also causes hair loss, paronychia, impaired immunity, recurrent infection, impaired growth, and diarrhea. Symptoms and signs usually develop after infants are weaned from breast milk. In such cases, doctors suspect the diagnosis. If deficiency is diagnosed, zinc sulfate 30 to 150 mg/day po usually results in complete remission.\n\nToxicity: The recommended upper limit for zinc intake is 40 mg/day. Toxicity is rare. Ingesting doses of elemental zinc ranging from 100 to 150 mg/day for prolonged periods interferes with copper metabolism and causes low blood copper levels, RBC microcytosis, neutropenia, and impaired immunity; higher doses should be given only for short periods of time and the patient should be followed closely. Ingesting larger amounts (200 to 800 mg/day), usually by consuming acidic food or drink from a galvanized (zinc-coated) container, can cause anorexia, vomiting, and diarrhea. Metal fume fever, also called brass-founders' ague or zinc shakes, is caused by inhaling industrial zinc oxide fumes; it results in neurologic damage. Symptoms usually resolve after 12 to 24 h in a zinc-free environment.",
                    "md": "Zinc deficiency in children causes impaired growth and impaired taste (hypogeusia). Other symptoms and signs in children include delayed sexual maturation and hypogonadism. In children or adults, symptoms include hypogonadism, alopecia, impaired immunity, anorexia, dermatitis, night blindness, anemia, lethargy, and impaired wound healing.\n\nZinc deficiency should be suspected in undernourished patients with typical symptoms or signs. However, because many of the symptoms and signs are nonspecific, clinical diagnosis of mild zinc deficiency is difficult. Laboratory diagnosis is also difficult. Low albumin levels, common in zinc deficiency, make serum zinc levels difficult to interpret; diagnosis usually requires the combination of low levels of zinc in serum and increased urinary zinc excretion. If available, isotope studies can measure zinc status more accurately.\n\nTreatment consists of elemental zinc 15 to 120 mg/day po until symptoms and signs resolve.\n\nAcrodermatitis enteropathica (a rare, once fatal autosomal recessive disorder) causes malabsorption of zinc. Psoriasiform dermatitis develops around the eyes, nose, and mouth; on the buttocks; and in an acral distribution. The disorder also causes hair loss, paronychia, impaired immunity, recurrent infection, impaired growth, and diarrhea. Symptoms and signs usually develop after infants are weaned from breast milk. In such cases, doctors suspect the diagnosis. If deficiency is diagnosed, zinc sulfate 30 to 150 mg/day po usually results in complete remission.\n\nToxicity: The recommended upper limit for zinc intake is 40 mg/day. Toxicity is rare. Ingesting doses of elemental zinc ranging from 100 to 150 mg/day for prolonged periods interferes with copper metabolism and causes low blood copper levels, RBC microcytosis, neutropenia, and impaired immunity; higher doses should be given only for short periods of time and the patient should be followed closely. Ingesting larger amounts (200 to 800 mg/day), usually by consuming acidic food or drink from a galvanized (zinc-coated) container, can cause anorexia, vomiting, and diarrhea. Metal fume fever, also called brass-founders' ague or zinc shakes, is caused by inhaling industrial zinc oxide fumes; it results in neurologic damage. Symptoms usually resolve after 12 to 24 h in a zinc-free environment.",
                    "bBox": {
                        "x": 55,
                        "y": 61.9,
                        "w": 482,
                        "h": 367
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.996
        },
        {
            "page": 56,
            "text": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition        Chapter 6. Obesity &amp; the Metabolic Syndrome\n Chapter 6. Obesity and the Metabolic Syndrome\n Obesity\n Obesity is excess body fat; consequences depend not only on the absolute amount but also on\n the distribution of the fat. Complications include cardiovascular disorders, diabetes mellitus,\n many cancers, cholelithiasis, fatty liver and cirrhosis, osteoarthritis, reproductive disorders in\n men and women, psychologic disorders, and premature death. Diagnosis is based on body\n mass index (BMI\u2014calculated from height and weight) and waist circumference. BP, fasting\n plasma glucose, and lipid levels should be measured. Treatment includes physical activity,\n dietary and behavioral modification, and sometimes drugs or surgery.\n Prevalence of obesity in the US is high and is increasing, particularly among children and adolescents\n (see\n Table 6-1).\n Prevalence is more than twice as high at age 55 as at age 20. Obesity is twice as common among women\n in a lower socioeconomic group as among those in a higher group. Prevalence among black and white\n men does not differ significantly, but it is higher among black women than white women. More than 50%\n of black women \u2265 40 yr are obese; &gt; 80% are overweight.\n In the US, obesity and its complications cause as many as 300,000 premature deaths each year, making\n it second only to cigarette smoking as a preventable cause of death.\n [Table 6-1. Changes in Prevalence of Obesity According to Nhanes]\n Etiology\n Almost all cases of obesity result from a combination of genetic predisposition and a chronic imbalance\n between energy intake, energy utilization for basic metabolic processes, and energy expenditure from\n physical activity.\n Genetic factors: Heritability of BMI is about 66%. Genetic factors may affect the many signaling\n molecules and receptors used by parts of the hypothalamus and GI tract to regulate food intake (see\n Sidebar 6-1). Rarely, obesity results from abnormal levels of peptides that regulate food intake (eg, leptin)\n or abnormalities in their receptors (eg, melanocortin-4 receptor).\n Genetic factors also regulate energy expenditure, including BMR, diet-induced thermogenesis, and\n nonvoluntary activity-associated thermogenesis. Genetic factors may have a greater effect on the\n distribution of body fat, particularly abdominal fat (see Metabolic Syndrome on p. 64), than on the amount\n of body fat.\n Environmental factors: Weight is gained when caloric intake exceeds energy needs. Important\n determinants of energy intake include portion sizes and the energy density of the food. High-fat foods,\n processed foods, and diets high in refined carbohydrates, soft drinks, fruit juices, and alcohol promote\n weight gain. Diets high in fresh fruit and vegetables, fiber, and complex carbohydrates, with water as the\n main fluid consumed, minimize weight gain. A sedentary lifestyle promotes weight gain.\n Regulatory factors: Prenatal maternal obesity, prenatal maternal smoking, intrauterine growth\n restriction, and insufficient sleep can disturb weight regulation. About 15% of women permanently gain \u2265\n 20 lb with each pregnancy. Obesity that persists beyond early childhood makes weight loss in later life\n more difficult.\n Drugs, including corticosteroids, lithium, traditional antidepressants (tricyclics, tetracyclics, and\n monoamine oxidase inhibitors [MAOIs]), benzodiazepines, and antipsychotic drugs, often cause weight\n gain.\n Uncommonly, weight gain is caused by one of the following disorders:\n                                                                                                     108",
            "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition\n\n# Chapter 6. Obesity and the Metabolic Syndrome\n\n# Obesity\n\nObesity is excess body fat; consequences depend not only on the absolute amount but also on the distribution of the fat. Complications include cardiovascular disorders, diabetes mellitus, many cancers, cholelithiasis, fatty liver and cirrhosis, osteoarthritis, reproductive disorders in men and women, psychologic disorders, and premature death. Diagnosis is based on body mass index (BMI\u2014calculated from height and weight) and waist circumference. BP, fasting plasma glucose, and lipid levels should be measured. Treatment includes physical activity, dietary and behavioral modification, and sometimes drugs or surgery.\n\nPrevalence of obesity in the US is high and is increasing, particularly among children and adolescents (see Table 6-1). Prevalence is more than twice as high at age 55 as at age 20. Obesity is twice as common among women in a lower socioeconomic group as among those in a higher group. Prevalence among black and white men does not differ significantly, but it is higher among black women than white women. More than 50% of black women \u2265 40 yr are obese; &gt; 80% are overweight.\n\nIn the US, obesity and its complications cause as many as 300,000 premature deaths each year, making it second only to cigarette smoking as a preventable cause of death.\n\n# Etiology\n\nAlmost all cases of obesity result from a combination of genetic predisposition and a chronic imbalance between energy intake, energy utilization for basic metabolic processes, and energy expenditure from physical activity.\n\nGenetic factors: Heritability of BMI is about 66%. Genetic factors may affect the many signaling molecules and receptors used by parts of the hypothalamus and GI tract to regulate food intake (see Sidebar 6-1). Rarely, obesity results from abnormal levels of peptides that regulate food intake (eg, leptin) or abnormalities in their receptors (eg, melanocortin-4 receptor).\n\nGenetic factors also regulate energy expenditure, including BMR, diet-induced thermogenesis, and nonvoluntary activity-associated thermogenesis. Genetic factors may have a greater effect on the distribution of body fat, particularly abdominal fat (see Metabolic Syndrome on p. 64), than on the amount of body fat.\n\nEnvironmental factors: Weight is gained when caloric intake exceeds energy needs. Important determinants of energy intake include portion sizes and the energy density of the food. High-fat foods, processed foods, and diets high in refined carbohydrates, soft drinks, fruit juices, and alcohol promote weight gain. Diets high in fresh fruit and vegetables, fiber, and complex carbohydrates, with water as the main fluid consumed, minimize weight gain. A sedentary lifestyle promotes weight gain.\n\nRegulatory factors: Prenatal maternal obesity, prenatal maternal smoking, intrauterine growth restriction, and insufficient sleep can disturb weight regulation. About 15% of women permanently gain \u2265 20 lb with each pregnancy. Obesity that persists beyond early childhood makes weight loss in later life more difficult.\n\nDrugs, including corticosteroids, lithium, traditional antidepressants (tricyclics, tetracyclics, and monoamine oxidase inhibitors [MAOIs]), benzodiazepines, and antipsychotic drugs, often cause weight gain.\n\nUncommonly, weight gain is caused by one of the following disorders:",
            "images": [],
            "charts": [],
            "items": [
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "md": "# The Merck Manual of Diagnosis &amp; Therapy, 19th Edition",
                    "bBox": {
                        "x": 51,
                        "y": 30.72,
                        "w": 249,
                        "h": 11
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Chapter 6. Obesity and the Metabolic Syndrome",
                    "md": "# Chapter 6. Obesity and the Metabolic Syndrome",
                    "bBox": {
                        "x": 55,
                        "y": 54.9,
                        "w": 240,
                        "h": 37
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Obesity",
                    "md": "# Obesity",
                    "bBox": {
                        "x": 55,
                        "y": 79.9,
                        "w": 39,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Obesity is excess body fat; consequences depend not only on the absolute amount but also on the distribution of the fat. Complications include cardiovascular disorders, diabetes mellitus, many cancers, cholelithiasis, fatty liver and cirrhosis, osteoarthritis, reproductive disorders in men and women, psychologic disorders, and premature death. Diagnosis is based on body mass index (BMI\u2014calculated from height and weight) and waist circumference. BP, fasting plasma glucose, and lipid levels should be measured. Treatment includes physical activity, dietary and behavioral modification, and sometimes drugs or surgery.\n\nPrevalence of obesity in the US is high and is increasing, particularly among children and adolescents (see Table 6-1). Prevalence is more than twice as high at age 55 as at age 20. Obesity is twice as common among women in a lower socioeconomic group as among those in a higher group. Prevalence among black and white men does not differ significantly, but it is higher among black women than white women. More than 50% of black women \u2265 40 yr are obese; &gt; 80% are overweight.\n\nIn the US, obesity and its complications cause as many as 300,000 premature deaths each year, making it second only to cigarette smoking as a preventable cause of death.",
                    "md": "Obesity is excess body fat; consequences depend not only on the absolute amount but also on the distribution of the fat. Complications include cardiovascular disorders, diabetes mellitus, many cancers, cholelithiasis, fatty liver and cirrhosis, osteoarthritis, reproductive disorders in men and women, psychologic disorders, and premature death. Diagnosis is based on body mass index (BMI\u2014calculated from height and weight) and waist circumference. BP, fasting plasma glucose, and lipid levels should be measured. Treatment includes physical activity, dietary and behavioral modification, and sometimes drugs or surgery.\n\nPrevalence of obesity in the US is high and is increasing, particularly among children and adolescents (see Table 6-1). Prevalence is more than twice as high at age 55 as at age 20. Obesity is twice as common among women in a lower socioeconomic group as among those in a higher group. Prevalence among black and white men does not differ significantly, but it is higher among black women than white women. More than 50% of black women \u2265 40 yr are obese; &gt; 80% are overweight.\n\nIn the US, obesity and its complications cause as many as 300,000 premature deaths each year, making it second only to cigarette smoking as a preventable cause of death.",
                    "bBox": {
                        "x": 55,
                        "y": 79.9,
                        "w": 483,
                        "h": 265
                    }
                },
                {
                    "type": "heading",
                    "lvl": 1,
                    "value": "Etiology",
                    "md": "# Etiology",
                    "bBox": {
                        "x": 55,
                        "y": 383.9,
                        "w": 41,
                        "h": 12
                    }
                },
                {
                    "type": "text",
                    "value": "Almost all cases of obesity result from a combination of genetic predisposition and a chronic imbalance between energy intake, energy utilization for basic metabolic processes, and energy expenditure from physical activity.\n\nGenetic factors: Heritability of BMI is about 66%. Genetic factors may affect the many signaling molecules and receptors used by parts of the hypothalamus and GI tract to regulate food intake (see Sidebar 6-1). Rarely, obesity results from abnormal levels of peptides that regulate food intake (eg, leptin) or abnormalities in their receptors (eg, melanocortin-4 receptor).\n\nGenetic factors also regulate energy expenditure, including BMR, diet-induced thermogenesis, and nonvoluntary activity-associated thermogenesis. Genetic factors may have a greater effect on the distribution of body fat, particularly abdominal fat (see Metabolic Syndrome on p. 64), than on the amount of body fat.\n\nEnvironmental factors: Weight is gained when caloric intake exceeds energy needs. Important determinants of energy intake include portion sizes and the energy density of the food. High-fat foods, processed foods, and diets high in refined carbohydrates, soft drinks, fruit juices, and alcohol promote weight gain. Diets high in fresh fruit and vegetables, fiber, and complex carbohydrates, with water as the main fluid consumed, minimize weight gain. A sedentary lifestyle promotes weight gain.\n\nRegulatory factors: Prenatal maternal obesity, prenatal maternal smoking, intrauterine growth restriction, and insufficient sleep can disturb weight regulation. About 15% of women permanently gain \u2265 20 lb with each pregnancy. Obesity that persists beyond early childhood makes weight loss in later life more difficult.\n\nDrugs, including corticosteroids, lithium, traditional antidepressants (tricyclics, tetracyclics, and monoamine oxidase inhibitors [MAOIs]), benzodiazepines, and antipsychotic drugs, often cause weight gain.\n\nUncommonly, weight gain is caused by one of the following disorders:",
                    "md": "Almost all cases of obesity result from a combination of genetic predisposition and a chronic imbalance between energy intake, energy utilization for basic metabolic processes, and energy expenditure from physical activity.\n\nGenetic factors: Heritability of BMI is about 66%. Genetic factors may affect the many signaling molecules and receptors used by parts of the hypothalamus and GI tract to regulate food intake (see Sidebar 6-1). Rarely, obesity results from abnormal levels of peptides that regulate food intake (eg, leptin) or abnormalities in their receptors (eg, melanocortin-4 receptor).\n\nGenetic factors also regulate energy expenditure, including BMR, diet-induced thermogenesis, and nonvoluntary activity-associated thermogenesis. Genetic factors may have a greater effect on the distribution of body fat, particularly abdominal fat (see Metabolic Syndrome on p. 64), than on the amount of body fat.\n\nEnvironmental factors: Weight is gained when caloric intake exceeds energy needs. Important determinants of energy intake include portion sizes and the energy density of the food. High-fat foods, processed foods, and diets high in refined carbohydrates, soft drinks, fruit juices, and alcohol promote weight gain. Diets high in fresh fruit and vegetables, fiber, and complex carbohydrates, with water as the main fluid consumed, minimize weight gain. A sedentary lifestyle promotes weight gain.\n\nRegulatory factors: Prenatal maternal obesity, prenatal maternal smoking, intrauterine growth restriction, and insufficient sleep can disturb weight regulation. About 15% of women permanently gain \u2265 20 lb with each pregnancy. Obesity that persists beyond early childhood makes weight loss in later life more difficult.\n\nDrugs, including corticosteroids, lithium, traditional antidepressants (tricyclics, tetracyclics, and monoamine oxidase inhibitors [MAOIs]), benzodiazepines, and antipsychotic drugs, often cause weight gain.\n\nUncommonly, weight gain is caused by one of the following disorders:",
                    "bBox": {
                        "x": 55,
                        "y": 79.9,
                        "w": 482,
                        "h": 709
                    }
                }
            ],
            "status": "OK",
            "originalOrientationAngle": 0,
            "links": [],
            "width": 595,
            "height": 842,
            "triggeredAutoMode": false,
            "parsingMode": "accurate",
            "structuredData": null,
            "noStructuredContent": false,
            "noTextContent": false,
            "confidence": 0.966
        }
    ],
    "job_metadata": {
        "credits_used": 0,
        "job_credits_usage": 0,
        "job_pages": 0,
        "job_auto_mode_triggered_pages": 0,
        "job_is_cache_hit": true
    },
    "job_id": "3727e792-2ec8-4cdc-9be4-6dc5dd920a62",
    "file_path": "Nutritional Medical Reference/Nutritional Disorders.pdf"
}
</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Extracting Tables from Parsed JSON Objects</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[21]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Initialize dictionaries to store page texts and tables</span>
<span class="n">page_texts</span><span class="p">,</span> <span class="n">tables</span> <span class="o">=</span> <span class="p">{},</span> <span class="p">{}</span>

<span class="c1"># Extract tables from the parsed JSON objects</span>
<span class="k">for</span> <span class="n">obj</span> <span class="ow">in</span> <span class="n">json_objs</span><span class="p">:</span>
    <span class="n">json_list</span> <span class="o">=</span> <span class="n">obj</span><span class="p">[</span><span class="s1">'pages'</span><span class="p">]</span>
    <span class="n">name</span> <span class="o">=</span> <span class="n">obj</span><span class="p">[</span><span class="s2">"file_path"</span><span class="p">]</span><span class="o">.</span><span class="n">split</span><span class="p">(</span><span class="s2">"/"</span><span class="p">)[</span><span class="o">-</span><span class="mi">1</span><span class="p">]</span>  <span class="c1"># Extract the file name</span>
    <span class="n">page_texts</span><span class="p">[</span><span class="n">name</span><span class="p">]</span> <span class="o">=</span> <span class="p">{}</span>  <span class="c1"># Initialize dictionary for page texts</span>
    <span class="n">tables</span><span class="p">[</span><span class="n">name</span><span class="p">]</span> <span class="o">=</span> <span class="p">{}</span>  <span class="c1"># Initialize dictionary for tables</span>

    <span class="k">for</span> <span class="n">json_item</span> <span class="ow">in</span> <span class="n">json_list</span><span class="p">:</span>
        <span class="k">for</span> <span class="n">component</span> <span class="ow">in</span> <span class="n">json_item</span><span class="p">[</span><span class="s1">'items'</span><span class="p">]:</span>
            <span class="k">if</span> <span class="n">component</span><span class="p">[</span><span class="s1">'type'</span><span class="p">]</span> <span class="o">==</span> <span class="s1">'table'</span><span class="p">:</span>  <span class="c1"># Check if the component is a table</span>
                <span class="n">tables</span><span class="p">[</span><span class="n">name</span><span class="p">][</span><span class="n">json_item</span><span class="p">[</span><span class="s1">'page'</span><span class="p">]]</span> <span class="o">=</span> <span class="n">component</span><span class="p">[</span><span class="s1">'rows'</span><span class="p">]</span>  <span class="c1"># Store table rows</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Displaying Extracted Tables</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[22]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Display extracted tables for each PDF</span>
<span class="k">for</span> <span class="n">file_name</span><span class="p">,</span> <span class="n">file_tables</span> <span class="ow">in</span> <span class="n">tables</span><span class="o">.</span><span class="n">items</span><span class="p">():</span>
    <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"Tables from </span><span class="si">{</span><span class="n">file_name</span><span class="si">}</span><span class="s2">:"</span><span class="p">)</span>
    <span class="k">for</span> <span class="n">page_num</span><span class="p">,</span> <span class="n">table_rows</span> <span class="ow">in</span> <span class="n">file_tables</span><span class="o">.</span><span class="n">items</span><span class="p">():</span>
        <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"  Page </span><span class="si">{</span><span class="n">page_num</span><span class="si">}</span><span class="s2">:"</span><span class="p">)</span>
        <span class="k">for</span> <span class="n">row</span> <span class="ow">in</span> <span class="n">table_rows</span><span class="p">:</span>
            <span class="nb">print</span><span class="p">(</span><span class="n">row</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Tables from Nutritional Disorders.pdf:
  Page 1:
['Food', 'Glycemic Index']
['Glucose', '100']
['Sucrose', '65']
['Starches', 'Variable']
['Fiber', '0']
  Page 4:
  Page 17:
['Men:', 'kcal / day = 66 + (13.7  wt[kg]) + (5  height[cm]) - (6.8  age)']
['Women:', 'kcal / day = 665 + (9.6  wt[kg]) + (1.8  height[cm]) - (4.7  age)']
  Page 24:
  Page 35:
['Inadequate absorption', 'Decreased acid secretion (elderly)']
['Blind loop syndrome', 'Fish tapeworm infestation']
['Inflammatory bowel disease', 'Surgical removal of ileal absorptive sites']
['Chronic pancreatitis', 'Gastric surgery']
['Malabsorption syndromes', 'AIDS']
['Use of certain drugs', '(e.g., antacids, metformin)']
['Repeated exposure to nitrous oxide', 'Genetic disorder (Imerslund-Graesbeck syndrome)']
  Page 48:
['More severe toxicity results from ingestion (usually with suicidal intent) of gram quantities of a copper salt (eg, copper sulfate) or from absorption of large amounts through the skin (eg, if compresses saturated with a solution of a copper salt are applied to large areas of burned skin). Hemolytic anemia and anuria can result and may be fatal.', '']
['Indian childhood cirrhosis', 'non-Indian childhood cirrhosis']
['and idiopathic copper toxicity are probably identical disorders in which excess copper causes cirrhosis. All seem to be caused by ingesting milk that has been boiled or stored in corroded copper or brass vessels. Recent studies suggest that idiopathic copper toxicity may develop only in infants with an unknown genetic defect.', '']
</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h2 id="1.4-Semantic-Chunking-and-Structured-Retrieval"><strong>1.4 Semantic Chunking and Structured Retrieval</strong><a class="anchor-link" href="#1.4-Semantic-Chunking-and-Structured-Retrieval"></a></h2>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="1.4.1-PDF-Parsing-and-Text-Chunking-Using-SemanticChunker"><strong>1.4.1 PDF Parsing and Text Chunking Using SemanticChunker</strong><a class="anchor-link" href="#1.4.1-PDF-Parsing-and-Text-Chunking-Using-SemanticChunker"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Initialize ChromaDB Client</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[23]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Initialize ChromaDB client</span>
<span class="n">chromadb_client</span> <span class="o">=</span> <span class="n">chromadb</span><span class="o">.</span><span class="n">EphemeralClient</span><span class="p">()</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Initialize the SemanticChunker with percentile breakpoint type and adjusted threshold</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[24]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="n">semantic_text_splitter</span> <span class="o">=</span> <span class="n">SemanticChunker</span><span class="p">(</span>
    <span class="n">embedding_model</span><span class="p">,</span>
    <span class="n">breakpoint_threshold_type</span><span class="o">=</span><span class="s1">'percentile'</span><span class="p">,</span>
    <span class="n">breakpoint_threshold_amount</span><span class="o">=</span><span class="mi">80</span>
<span class="p">)</span>
<span class="c1"># This initializes the semantic text splitter, controlling how text is divided into meaningful chunks.</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Text Chunking Using SemanticChunker</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[25]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="kn">import</span><span class="w"> </span><span class="nn">os</span>

<span class="c1"># Step 1: Define the folder containing the documents</span>
<span class="n">folder_path</span> <span class="o">=</span> <span class="s2">"Nutritional Medical Reference"</span>

<span class="c1"># Step 2: Initialize an empty list to store all semantic chunks</span>
<span class="n">semantic_chunks</span> <span class="o">=</span> <span class="p">[]</span>

<span class="c1"># Step 3: Initialize the PyPDFDirectoryLoader for the folder</span>
<span class="n">pdf_loader</span> <span class="o">=</span> <span class="n">PyPDFDirectoryLoader</span><span class="p">(</span><span class="n">folder_path</span><span class="p">)</span>

<span class="c1"># Step 4: Load and split PDF documents into chunks using SemanticChunker</span>
<span class="n">chunks</span> <span class="o">=</span> <span class="n">pdf_loader</span><span class="o">.</span><span class="n">load_and_split</span><span class="p">(</span><span class="n">semantic_text_splitter</span><span class="p">)</span>

<span class="c1"># Step 5: Extend the semantic_chunks list with the chunks from this folder</span>
<span class="n">semantic_chunks</span><span class="o">.</span><span class="n">extend</span><span class="p">(</span><span class="n">chunks</span><span class="p">)</span>

<span class="c1"># Step 6: Get the total number of chunks</span>
<span class="nb">len</span><span class="p">(</span><span class="n">semantic_chunks</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child jp-OutputArea-executeResult">
<div class="jp-OutputPrompt jp-OutputArea-prompt">Out[25]:</div>
<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain" tabindex="0">
<pre>402</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="1.4.2-Creating-and-Storing-Document-Chunks-in-Chroma-Vectorstore"><strong>1.4.2 Creating and Storing Document Chunks in Chroma Vectorstore</strong><a class="anchor-link" href="#1.4.2-Creating-and-Storing-Document-Chunks-in-Chroma-Vectorstore"></a></h3>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[26]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Add IDs to the semantic chunks</span>
<span class="n">semantic_chunks</span> <span class="o">=</span> <span class="p">[</span><span class="n">Document</span><span class="p">(</span><span class="nb">id</span><span class="o">=</span><span class="n">i</span><span class="p">,</span> <span class="n">page_content</span> <span class="o">=</span> <span class="n">d</span><span class="o">.</span><span class="n">page_content</span><span class="p">,</span> <span class="n">metadata</span> <span class="o">=</span> <span class="n">d</span><span class="o">.</span><span class="n">metadata</span><span class="p">)</span> <span class="k">for</span> <span class="n">i</span><span class="p">,</span> <span class="n">d</span> <span class="ow">in</span> <span class="nb">enumerate</span><span class="p">(</span><span class="n">semantic_chunks</span><span class="p">)]</span>

<span class="c1"># Plot a histogram of the number of characters in each semantic chunk</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">matplotlib.pyplot</span><span class="w"> </span><span class="k">as</span><span class="w"> </span><span class="nn">plt</span>

<span class="n">chunk_lengths</span> <span class="o">=</span> <span class="p">[</span><span class="nb">len</span><span class="p">(</span><span class="n">chunk</span><span class="o">.</span><span class="n">page_content</span><span class="p">)</span> <span class="k">for</span> <span class="n">chunk</span> <span class="ow">in</span> <span class="n">semantic_chunks</span><span class="p">]</span>
<span class="n">plt</span><span class="o">.</span><span class="n">hist</span><span class="p">(</span><span class="n">chunk_lengths</span><span class="p">,</span> <span class="n">bins</span><span class="o">=</span><span class="mi">25</span><span class="p">,</span> <span class="n">edgecolor</span><span class="o">=</span><span class="s1">'black'</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">xlabel</span><span class="p">(</span><span class="s1">'Chunk Length'</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">ylabel</span><span class="p">(</span><span class="s1">'Frequency'</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">title</span><span class="p">(</span><span class="s1">'Number of Characters in Each Semantic Chunk'</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">show</span><span class="p">()</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedImage jp-OutputArea-output" tabindex="0">
<img alt="No description has been provided for this image" class="" src="data:image/png;base64,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
"/>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Store the document chunks in Chroma vectorstore in batches</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[27]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="n">batch_size</span> <span class="o">=</span> <span class="mi">100</span>  <span class="c1"># Adjust the batch size as needed</span>
<span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="nb">len</span><span class="p">(</span><span class="n">semantic_chunks</span><span class="p">),</span> <span class="n">batch_size</span><span class="p">):</span>
    <span class="n">batch</span> <span class="o">=</span> <span class="n">semantic_chunks</span><span class="p">[</span><span class="n">i</span> <span class="p">:</span> <span class="n">i</span> <span class="o">+</span> <span class="n">batch_size</span><span class="p">]</span>
    <span class="n">semanticstore</span> <span class="o">=</span> <span class="n">Chroma</span><span class="o">.</span><span class="n">from_documents</span><span class="p">(</span>
        <span class="n">batch</span><span class="p">,</span>
        <span class="n">embedding_model</span><span class="p">,</span>
        <span class="n">collection_name</span><span class="o">=</span><span class="s2">"semantic_chunks"</span><span class="p">,</span>
        <span class="n">persist_directory</span><span class="o">=</span><span class="s1">'./nutritional_db'</span>
    <span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Perform similarity search in the vectorstore</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[28]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Example user query</span>
<span class="n">user_input</span> <span class="o">=</span> <span class="s2">"what are differnt types of essential macronutrients?"</span>

<span class="c1"># Perform similarity search in the vectorstore</span>
<span class="n">docs</span> <span class="o">=</span> <span class="n">semanticstore</span><span class="o">.</span><span class="n">similarity_search</span><span class="p">(</span><span class="n">user_input</span><span class="p">,</span> <span class="n">k</span><span class="o">=</span><span class="mi">5</span><span class="p">)</span>

<span class="c1"># Display retrieved documents</span>
<span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="n">docs</span><span class="p">:</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"Source:"</span><span class="p">,</span> <span class="n">i</span><span class="o">.</span><span class="n">metadata</span><span class="p">[</span><span class="s1">'source'</span><span class="p">])</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"Page:"</span><span class="p">,</span> <span class="n">i</span><span class="o">.</span><span class="n">metadata</span><span class="p">[</span><span class="s1">'page'</span><span class="p">],</span> <span class="s2">"</span><span class="se">\n</span><span class="s2">"</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="n">i</span><span class="o">.</span><span class="n">page_content</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Source: Nutritional Medical Reference/Nutritional Disorders.pdf
Page: 0 

9
). Excess intake of macronutrients can lead to obesity (see p. 56
) and related disorders; excess intake of
micro-nutrients can be toxic. Also, the balance of various types of nutrients, such as how much
usaturated vs saturated fat is consumed, can influence the development of disorders. Macronutrients
Macronutrients constitute the bulk of the diet and supply energy and many essential nutrients. Carbohydrates, proteins (including essential amino acids), fats (including essential fatty acids),
macrominerals, and water are macronutrients. Carbohydrates, fats, and proteins are interchangeable as
sources of energy; fats yield 9 kcal/g (37.8 kJ/g); proteins and carbohydrates yield 4 kcal/g (16.8 kJ/g). Carbohydrates:
 Dietary carbohydrates are broken down into glucose and other monosaccharides.
Source: Nutritional Medical Reference/Nutritional Disorders.pdf
Page: 0 

Nutrients that cannot be synthesized by the body
and thus must be derived from the diet are considered essential. They include vitamins, minerals, some
amino acids, and some fatty acids. Nutrients that the body can synthesize from other compounds,
although they may also be derived from the diet, are considered nonessential. Macronutrients are
required by the body in relatively large amounts; micronutrients are needed in minute amounts. Lack of nutrients can result in deficiency syndromes (eg, kwashiorkor, pellagra) or other disorders (see p.
Source: Nutritional Medical Reference/Nutritional Disorders.pdf
Page: 2 

[
Table 1-4. Recommended Dietary Reference Intakes* for Some Macronutrients, Food and Nutrition
Board, Institute of Medicine of the National Academies]
Micronutrients
Vitamins and minerals required in minute amounts (trace minerals) are micronutrients (see 
Chs. 4
 and 
5
).
Source: Nutritional Medical Reference/Nutritional Disorders.pdf
Page: 1 

Water:
 Water is considered a macronutrient because it is required in amounts of 1 mL/kcal (0.24 mL/kJ)
of energy expended, or about 2500 mL/day. Needs vary with fever, physical activity, and changes in
climate and humidity.
Source: Nutritional Medical Reference/Nutritional Disorders.pdf
Page: 1 

Essential Amino Acid Requirements in mg/kg Body Weight]
Requirements for EFAs vary by age. Adults require amounts of linoleic acid equal to at least 2% of total
caloric needs and linolenic acid equal to at least 0.5%. Vegetable oils provide linoleic acid and linolenic
acid. Oils made from safflower, sunflower, corn, soya, primrose, pumpkin, and wheat germ provide large
amounts of linoleic acid. Marine fish oils and oils made from flax-seeds, pumpkin, soy, and canola provide
large amounts of linolenic acid. Marine fish oils also provide some other 

-3 fatty acids in large amounts. Macrominerals:
 Na, Cl, K, Ca, P, and Mg are required in relatively large amounts per day (see
Tables 1-3
,
1-4
, and
5-2
).
</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="1.4.3-Structured-Retrieval-Using-Self-Query-Retriever"><strong>1.4.3 Structured Retrieval Using Self-Query Retriever</strong><a class="anchor-link" href="#1.4.3-Structured-Retrieval-Using-Self-Query-Retriever"></a></h3>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[29]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Define metadata fields for structured retrieval</span>
<span class="n">metadata_field_info</span> <span class="o">=</span> <span class="p">[</span>
    <span class="n">AttributeInfo</span><span class="p">(</span>
        <span class="n">name</span><span class="o">=</span><span class="s2">"Category"</span><span class="p">,</span>
        <span class="n">description</span><span class="o">=</span><span class="s2">"Category of the nutritional disorder (e.g., Undernutrition, Vitamin Deficiency, Obesity, etc.)"</span><span class="p">,</span>
        <span class="nb">type</span><span class="o">=</span><span class="s2">"string"</span>
    <span class="p">),</span>
    <span class="n">AttributeInfo</span><span class="p">(</span>
        <span class="n">name</span><span class="o">=</span><span class="s2">"DisorderType"</span><span class="p">,</span>
        <span class="n">description</span><span class="o">=</span><span class="s2">"Specific type of nutritional disorder (e.g., Protein-Energy Malnutrition, Scurvy, Rickets, etc.)"</span><span class="p">,</span>
        <span class="nb">type</span><span class="o">=</span><span class="s2">"string"</span>
    <span class="p">),</span>
    <span class="n">AttributeInfo</span><span class="p">(</span>
        <span class="n">name</span><span class="o">=</span><span class="s2">"Page"</span><span class="p">,</span>
        <span class="n">description</span><span class="o">=</span><span class="s2">"Page within the nutritional medical reference document that the information belongs to"</span><span class="p">,</span>
        <span class="nb">type</span><span class="o">=</span><span class="s2">"integer"</span>
    <span class="p">)</span>
<span class="p">]</span>

<span class="c1"># Describe the content of the document</span>
<span class="n">document_content_description</span> <span class="o">=</span> <span class="s2">"information mentioned in the research paper"</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Initialize the self-querying retriever for semantic chunks and perform structutred retrieval</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[30]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="n">structured_retriever</span> <span class="o">=</span> <span class="n">SelfQueryRetriever</span><span class="o">.</span><span class="n">from_llm</span><span class="p">(</span>
    <span class="n">llm</span><span class="p">,</span>
    <span class="n">semanticstore</span><span class="p">,</span>
    <span class="n">document_content_description</span><span class="p">,</span>
    <span class="n">metadata_field_info</span>
<span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[31]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Example user query</span>
<span class="n">user_input</span> <span class="o">=</span> <span class="s2">"what are differnt types of essential macronutrients?"</span>

<span class="c1"># Perform structured retrieval using self-querying retriever</span>
<span class="n">structured_retriever</span><span class="o">.</span><span class="n">invoke</span><span class="p">(</span><span class="n">user_input</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child jp-OutputArea-executeResult">
<div class="jp-OutputPrompt jp-OutputArea-prompt">Out[31]:</div>
<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain" tabindex="0">
<pre>[Document(metadata={'page': 0, 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf'}, page_content='9\n). Excess intake of macronutrients can lead to obesity (see p. 56\n) and related disorders; excess intake of\nmicro-nutrients can be toxic. Also, the balance of various types of nutrients, such as how much\nusaturated vs saturated fat is consumed, can influence the development of disorders. Macronutrients\nMacronutrients constitute the bulk of the diet and supply energy and many essential nutrients. Carbohydrates, proteins (including essential amino acids), fats (including essential fatty acids),\nmacrominerals, and water are macronutrients. Carbohydrates, fats, and proteins are interchangeable as\nsources of energy; fats yield 9 kcal/g (37.8 kJ/g); proteins and carbohydrates yield 4 kcal/g (16.8 kJ/g). Carbohydrates:\n Dietary carbohydrates are broken down into glucose and other monosaccharides.'),
 Document(metadata={'page': 0, 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf'}, page_content='Nutrients that cannot be synthesized by the body\nand thus must be derived from the diet are considered essential. They include vitamins, minerals, some\namino acids, and some fatty acids. Nutrients that the body can synthesize from other compounds,\nalthough they may also be derived from the diet, are considered nonessential. Macronutrients are\nrequired by the body in relatively large amounts; micronutrients are needed in minute amounts. Lack of nutrients can result in deficiency syndromes (eg, kwashiorkor, pellagra) or other disorders (see p.'),
 Document(metadata={'page': 1, 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf'}, page_content='Water:\n Water is considered a macronutrient because it is required in amounts of 1 mL/kcal (0.24 mL/kJ)\nof energy expended, or about 2500 mL/day. Needs vary with fever, physical activity, and changes in\nclimate and humidity.'),
 Document(metadata={'page': 2, 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf'}, page_content='[\nTable 1-4. Recommended Dietary Reference Intakes* for Some Macronutrients, Food and Nutrition\nBoard, Institute of Medicine of the National Academies]\nMicronutrients\nVitamins and minerals required in minute amounts (trace minerals) are micronutrients (see \nChs. 4\n and \n5\n).')]</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h2 id="1.5-Creating-Hypothetical-Questions-and-Storing-in-Chroma-Vectorstore"><strong>1.5 Creating Hypothetical Questions and Storing in Chroma Vectorstore</strong><a class="anchor-link" href="#1.5-Creating-Hypothetical-Questions-and-Storing-in-Chroma-Vectorstore"></a></h2>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="1.5.1-Generating-Hypothetical-Questions-for-Text-Semantic-Chunks"><strong>1.5.1 Generating Hypothetical Questions for Text Semantic Chunks</strong><a class="anchor-link" href="#1.5.1-Generating-Hypothetical-Questions-for-Text-Semantic-Chunks"></a></h3>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[32]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="n">hypothetical_text_questions_prompt</span> <span class="o">=</span> <span class="s2">"""</span>
<span class="s2">Generate a list of exactly 3 hypothetical questions that the below nutritional disorder document could be used to answer:</span>
<span class="si">{doc}</span>
<span class="s2">Generate only a list of questions. Do not mention anything before or after the list.</span>
<span class="s2">If the content cannot answer any questions, return an empty list.</span>
<span class="s2">Ensure that the questions are specific to the causes, symptoms, or treatment of the nutritional disorder discussed in the document.</span>
<span class="s2">"""</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[33]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Generate hypothetical questions for each semantic chunk and store them in a structured format.</span>

<span class="c1"># List to store documents with hypothetical questions</span>
<span class="n">hyp_docs</span> <span class="o">=</span> <span class="p">[]</span>

<span class="c1"># Generate hypothetical questions for each semantic chunk</span>
<span class="k">for</span> <span class="n">i</span><span class="p">,</span> <span class="n">document</span> <span class="ow">in</span> <span class="nb">enumerate</span><span class="p">(</span><span class="n">semantic_chunks</span><span class="p">):</span>
    <span class="k">try</span><span class="p">:</span>
        <span class="c1"># Invoke the LLM to generate questions based on the chunk content</span>
        <span class="n">response</span> <span class="o">=</span> <span class="n">llm</span><span class="o">.</span><span class="n">invoke</span><span class="p">(</span><span class="n">hypothetical_text_questions_prompt</span><span class="o">.</span><span class="n">format</span><span class="p">(</span><span class="n">doc</span><span class="o">=</span><span class="n">document</span><span class="o">.</span><span class="n">page_content</span><span class="p">))</span>
        <span class="n">questions</span> <span class="o">=</span> <span class="n">response</span><span class="o">.</span><span class="n">content</span>
    <span class="k">except</span> <span class="ne">Exception</span> <span class="k">as</span> <span class="n">e</span><span class="p">:</span>
        <span class="nb">print</span><span class="p">(</span><span class="n">e</span><span class="p">)</span>
        <span class="n">questions</span> <span class="o">=</span> <span class="s2">"NA"</span>

    <span class="c1"># Create metadata for the generated questions</span>
    <span class="n">questions_metadata</span> <span class="o">=</span> <span class="p">{</span>
            <span class="s1">'original_content'</span><span class="p">:</span> <span class="n">document</span><span class="o">.</span><span class="n">page_content</span><span class="p">,</span>
            <span class="s1">'source'</span><span class="p">:</span> <span class="n">document</span><span class="o">.</span><span class="n">metadata</span><span class="p">[</span><span class="s1">'source'</span><span class="p">],</span>
            <span class="s1">'page'</span><span class="p">:</span> <span class="n">document</span><span class="o">.</span><span class="n">metadata</span><span class="p">[</span><span class="s1">'page'</span><span class="p">],</span>
            <span class="s1">'type'</span><span class="p">:</span> <span class="s1">'text'</span>
    <span class="p">}</span>

    <span class="c1"># Create and store the document containing generated questions</span>
    <span class="n">hyp_docs</span><span class="o">.</span><span class="n">append</span><span class="p">(</span>
      <span class="n">Document</span><span class="p">(</span>
          <span class="nb">id</span><span class="o">=</span><span class="nb">str</span><span class="p">(</span><span class="n">i</span><span class="p">),</span>
          <span class="n">page_content</span><span class="o">=</span><span class="n">questions</span><span class="p">,</span>
          <span class="n">metadata</span><span class="o">=</span><span class="n">questions_metadata</span>
      <span class="p">)</span>
    <span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
</pre>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[34]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="nb">print</span><span class="p">(</span><span class="n">hyp_docs</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>[Document(id='0', metadata={'original_content': '1 - Nutritional Disorders\nChapter 1. Nutrition: General Considerations\nIntroduction\nNutrition is the science of food and its relationship to health. Nutrients are chemicals in foods that are\nused by the body for growth, maintenance, and energy.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 0, 'type': 'text'}, page_content='1. What are the primary nutrients involved in the prevention of nutritional disorders?  \n2. How can deficiencies in essential vitamins and minerals lead to specific nutritional disorders?  \n3. What dietary changes are recommended for individuals diagnosed with a nutritional disorder?  '), Document(id='1', metadata={'original_content': 'Nutrients that cannot be synthesized by the body\nand thus must be derived from the diet are considered essential. They include vitamins, minerals, some\namino acids, and some fatty acids. Nutrients that the body can synthesize from other compounds,\nalthough they may also be derived from the diet, are considered nonessential. Macronutrients are\nrequired by the body in relatively large amounts; micronutrients are needed in minute amounts. Lack of nutrients can result in deficiency syndromes (eg, kwashiorkor, pellagra) or other disorders (see p.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 0, 'type': 'text'}, page_content='1. What are the symptoms and causes of deficiency syndromes like kwashiorkor and pellagra?  \n2. How do essential nutrients differ from nonessential nutrients in terms of dietary requirements?  \n3. What treatment options are available for individuals suffering from nutrient deficiencies related to essential vitamins and minerals?  '), Document(id='2', metadata={'original_content': '9\n). Excess intake of macronutrients can lead to obesity (see p. 56\n) and related disorders; excess intake of\nmicro-nutrients can be toxic. Also, the balance of various types of nutrients, such as how much\nusaturated vs saturated fat is consumed, can influence the development of disorders. Macronutrients\nMacronutrients constitute the bulk of the diet and supply energy and many essential nutrients. Carbohydrates, proteins (including essential amino acids), fats (including essential fatty acids),\nmacrominerals, and water are macronutrients. Carbohydrates, fats, and proteins are interchangeable as\nsources of energy; fats yield 9 kcal/g (37.8 kJ/g); proteins and carbohydrates yield 4 kcal/g (16.8 kJ/g). Carbohydrates:\n Dietary carbohydrates are broken down into glucose and other monosaccharides.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 0, 'type': 'text'}, page_content='1. How does an excess intake of macronutrients contribute to the development of obesity and its related disorders?\n2. What are the potential health risks associated with the excessive consumption of specific micronutrients?\n3. In what ways can the balance between saturated and unsaturated fats impact the onset of nutritional disorders?'), Document(id='3', metadata={'original_content': 'Carbohydrates increase blood glucose levels, supplying energy. Simple carbohydrates are composed of\nsmall molecules, generally monosaccharides or disaccharides, which increase blood glucose levels\nrapidly. Complex carbohydrates are composed of larger molecules, which are broken down into\nmonosaccharides. Complex carbohydrates increase blood glucose levels more slowly but for a longer\ntime. Glucose and sucrose are simple carbohydrates; starches and fiber are complex carbohydrates. The glycemic index measures how rapidly consumption of a carbohydrate increases plasma glucose\nlevels. Values range from 1 (the slowest increase) to 100 (the fastest increase, equivalent to pure glucose\nsee\nTable 1-1\n). However, the actual rate of increase also depends on what foods are consumed with the\ncarbohydrate.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 0, 'type': 'text'}, page_content='1. How do simple carbohydrates affect blood glucose levels compared to complex carbohydrates in individuals with insulin resistance?  \n2. What role does the glycemic index play in managing blood glucose levels for people with diabetes?  \n3. What dietary changes can be made to reduce the rapid increase of blood glucose levels after consuming carbohydrates?  '), Document(id='4', metadata={'original_content': 'Carbohydrates with a high glycemic index may increase plasma glucose to high levels rapidly. It is\nhypothesized that, as a result, insulin levels increase, inducing hypoglycemia and hunger, which tends to\nlead to consumption of excess calories and weight gain. Carbohydrates with a low glycemic index\nincrease plasma glucose levels slowly, resulting in lower postprandial insulin levels and less hunger,\nwhich probably makes consumption of excess calories less likely. These effects are predicted to result in\na more favorable lipid profile and a decreased risk of obesity, diabetes mellitus, and complications of\ndiabetes if present.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 0, 'type': 'text'}, page_content='1. How do high glycemic index carbohydrates contribute to weight gain and obesity through their effects on insulin levels and hunger?  \n2. What role do low glycemic index carbohydrates play in managing plasma glucose levels and reducing the risk of diabetes complications?  \n3. In what ways can dietary choices involving glycemic index influence the lipid profile of individuals at risk for diabetes mellitus?  '), Document(id='5', metadata={'original_content': 'Proteins:\n Dietary proteins are broken down into peptides and amino acids.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 0, 'type': 'text'}, page_content='[]'), Document(id='6', metadata={'original_content': 'Proteins are required for\ntissue maintenance, replacement, function, and growth. However, if the body is not getting enough\ncalories from dietary sources or tissue stores (particularly of fat), protein may be used for energy. As the body uses dietary protein for tissue production, there is a net gain of protein (positive nitrogen\nbalance). During catabolic\n[\nTable 1-1. Glycemic Index of Some Foods]\nstates (eg, starvation, infections, burns), more protein may be used (because body tissues are broken\ndown) than is absorbed, resulting in a net loss of protein (negative nitrogen balance). Nitrogen balance is\nbest determined by subtracting the amount of nitrogen excreted in urine and feces from the amount of\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 1.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 0, 'type': 'text'}, page_content='1. What are the effects of prolonged starvation on protein utilization in the body?  \n2. How does a negative nitrogen balance impact tissue repair and growth during periods of infection or burn injury?  \n3. What dietary changes can be made to prevent a negative nitrogen balance in individuals with high protein needs?  '), Document(id='7', metadata={'original_content': 'Nutrition: General Considerations\n53', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 0, 'type': 'text'}, page_content='1. What are the common causes of nutritional deficiencies in adults?\n2. What symptoms might indicate a person is suffering from a specific nutritional disorder?\n3. What treatment options are available for individuals diagnosed with a nutritional disorder?'), Document(id='8', metadata={'original_content': 'nitrogen consumed. Of the 20 amino acids, 9 are essential amino acids (EAAs); they cannot be synthesized and must be\nobtained from the diet. All people require 8 EAAs; infants also require histidine. The weight-adjusted requirement for dietary protein correlates with growth rate, which decreases from\ninfancy until adulthood. The daily dietary protein requirement decreases from 2.2 g/kg in 3-mo-old infants\nto 1.2 g/kg in 5-yr-old children and to 0.8 g/kg in adults. Protein requirements correspond to EAA\nrequirements (see\nTable 1-2\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 1, 'type': 'text'}, page_content='1. What are the daily dietary protein requirements for infants compared to adults, and how do these requirements change as a person grows?  \n2. Why are essential amino acids (EAAs) crucial for growth, and what are the specific EAAs that must be obtained from the diet?  \n3. How does a deficiency in essential amino acids affect growth rates in infants and children?  '), Document(id='9', metadata={'original_content': 'Adults trying to increase muscle mass need very little extra protein beyond the requirements in\nthe table.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 1, 'type': 'text'}, page_content='1. How much additional protein do adults need to effectively increase muscle mass beyond the standard dietary requirements?  \n2. What are the potential consequences of consuming excessive protein for adults looking to build muscle?  \n3. Are there specific dietary sources of protein that are more beneficial for adults trying to gain muscle mass?  '), Document(id='10', metadata={'original_content': "The amino acid composition of protein varies widely. Biological value (BV) reflects the similarity in amino\nacid composition of protein to that of animal tissues; thus, BV indicates what percentage of a dietary\nprotein provides EAAs for the body. A perfect match is egg protein, with a value of 100. Animal proteins in\nmilk and meat have a high BV (~90); proteins in cereal and vegetables have a lower BV (~40), and some\nderived proteins (eg, gelatin) have a BV of 0. The extent to which dietary proteins supply each other's\nmissing amino acids (complementarity) determines the overall BV of the diet. The recommended daily\nallowances (RDA) for protein assumes that the average mixed diet has a BV of 70. Fats:\n Fats are broken down into fatty acids and glycerol.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 1, 'type': 'text'}, page_content='1. How does the biological value (BV) of different protein sources affect the dietary needs for essential amino acids in individuals following a vegetarian or vegan diet?  \n2. What are the potential health implications of consuming protein sources with low biological value, such as gelatin or certain plant proteins, in terms of amino acid deficiencies?  \n3. How can individuals improve the overall biological value of their diet if they primarily consume low BV proteins like cereals and vegetables?  '), Document(id='11', metadata={'original_content': 'Fats are required for tissue growth and hormone\nproduction. Saturated fatty acids, common in animal fats, tend to be solid at room temperature. Except for\npalm and coconut oils, fats derived from plants tend to be liquid at room temperature; these fats contain\nhigh levels of monounsaturated fatty acids or polyunsaturated fatty acids (PUFAs). Partial hydrogenation of unsaturated fatty acids (as occurs during food manufacturing) produces trans\nfatty acids, which are solid or semisolid at room temperature. In the US, the main dietary source of trans\nfatty acids is partially hydrogenated vegetable oils, used in manufacturing certain foods (eg, cookies,\ncrackers, chips) to prolong shelf-life. Trans fatty acids may elevate LDL cholesterol and lower HDL; they\nmay also independently increase the risk of coronary artery disease. Essential fatty acids (EFAs) are linoleic acid, an \n\n-6 (n-6) fatty acid, and linolenic acid, an \n\n-3 (n-3) fatty\nacid. Other \n\n-6 acids (eg, arachidonic acid) and other \n\n-3 fatty acids (eg, eicosapentaenoic acid,\ndocosahexaenoic acid) are required by the body but can be synthesized from EFAs. EFAs (see also p. 19\n) are needed for the formation of various eicosanoids (biologically active lipids),\nincluding prostaglandins, thromboxanes, prostacyclins, and leukotrienes. Consumption of \n\n-3 fatty acids\nmay decrease the risk of coronary artery disease.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 1, 'type': 'text'}, page_content='1. How do trans fatty acids impact cholesterol levels and the risk of coronary artery disease?  \n2. What are the consequences of a deficiency in essential fatty acids on eicosanoid production in the body?  \n3. How can increasing the intake of -3 fatty acids potentially benefit cardiovascular health?  '), Document(id='12', metadata={'original_content': '[\nTable 1-2.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 1, 'type': 'text'}, page_content='[]'), Document(id='13', metadata={'original_content': 'Essential Amino Acid Requirements in mg/kg Body Weight]\nRequirements for EFAs vary by age. Adults require amounts of linoleic acid equal to at least 2% of total\ncaloric needs and linolenic acid equal to at least 0.5%. Vegetable oils provide linoleic acid and linolenic\nacid. Oils made from safflower, sunflower, corn, soya, primrose, pumpkin, and wheat germ provide large\namounts of linoleic acid. Marine fish oils and oils made from flax-seeds, pumpkin, soy, and canola provide\nlarge amounts of linolenic acid. Marine fish oils also provide some other \n\n-3 fatty acids in large amounts. Macrominerals:\n Na, Cl, K, Ca, P, and Mg are required in relatively large amounts per day (see\nTables 1-3\n,\n1-4\n, and\n5-2\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 1, 'type': 'text'}, page_content='1. What are the essential fatty acid requirements for adults in terms of percentage of total caloric needs?\n2. Which vegetable oils are recommended for providing linoleic acid and linolenic acid?\n3. How do deficiencies in essential fatty acids affect overall health and nutrition in adults?'), Document(id='14', metadata={'original_content': 'Water:\n Water is considered a macronutrient because it is required in amounts of 1 mL/kcal (0.24 mL/kJ)\nof energy expended, or about 2500 mL/day. Needs vary with fever, physical activity, and changes in\nclimate and humidity.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 1, 'type': 'text'}, page_content='1. How does increased physical activity affect daily water requirements?\n2. What are the symptoms of dehydration related to inadequate water intake?\n3. How should water intake be adjusted for individuals experiencing fever?'), Document(id='15', metadata={'original_content': '[\nTable 1-3.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 1, 'type': 'text'}, page_content='1. What are the common causes of the nutritional disorder outlined in the document?\n2. What symptoms should one look for to identify the nutritional disorder mentioned?\n3. What treatment options are available for managing the nutritional disorder described?'), Document(id='16', metadata={'original_content': 'Macrominerals]\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 1. Nutrition: General Considerations\n54', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 1, 'type': 'text'}, page_content='1. What are the common causes of macromineral deficiencies in the diet?\n2. What symptoms might indicate an excess of certain macrominerals in the body?\n3. What treatment options are available for individuals suffering from macromineral imbalances?'), Document(id='17', metadata={'original_content': '[\nTable 1-4. Recommended Dietary Reference Intakes* for Some Macronutrients, Food and Nutrition\nBoard, Institute of Medicine of the National Academies]\nMicronutrients\nVitamins and minerals required in minute amounts (trace minerals) are micronutrients (see \nChs. 4\n and \n5\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 2, 'type': 'text'}, page_content='1. What are the recommended dietary reference intakes for essential micronutrients to prevent deficiencies?\n2. How do deficiencies in specific micronutrients affect overall health and lead to nutritional disorders?\n3. What dietary changes can be made to increase the intake of necessary vitamins and minerals to address a nutritional disorder?'), Document(id='18', metadata={'original_content': 'Water-soluble vitamins\n are vitamin C (ascorbic acid) and 8 members of the vitamin B complex: biotin,\nfolate, niacin, pantothenic acid, riboflavin (vitamin B\n2\n), thiamin (vitamin B\n1\n), vitamin B\n6\n (pyridoxine), and\nvitamin B\n12\n (cobalamin). Fat-soluble vitamins\n are vitamins A (retinol), D (cholecalciferol and ergocalciferol), E (\n\n-tocopherol), and\nK (phylloquinone and menaquinone). Only vitamins A, E, and B\n12\n are stored to any significant extent in the body; the other vitamins must be\nconsumed regularly to maintain tissue health. Essential trace minerals\n include chromium, copper, iodine, iron, manganese, molybdenum, selenium,\nand zinc. Except for chromium, each of these is incorporated into enzymes or hormones required in\nmetabolism. Except for deficiencies of iron and zinc, micromineral deficiencies are uncommon in\ndeveloped countries (see \nCh. 5\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 2, 'type': 'text'}, page_content='1. What are the key differences between water-soluble and fat-soluble vitamins in terms of storage and dietary requirements?  \n2. Which vitamins must be consumed regularly to maintain tissue health and why are they essential?  \n3. How do deficiencies in trace minerals, such as iron and zinc, manifest in individuals living in developed countries?  '), Document(id='19', metadata={'original_content': 'Other minerals (eg, aluminum, arsenic, boron, cobalt, fluoride, nickel, silicon, vanadium) have not been\nproved essential for people. Fluoride, although not essential, helps prevent tooth decay by forming a\ncompound with Ca (CaF\n2\n), which stabilizes the mineral matrix in teeth. All trace minerals are toxic at high levels, and some (arsenic, nickel, and chromium) may cause cancer. Other Dietary Substances\nThe daily human diet typically contains as many as 100,000 chemicals (eg, coffee contains 1000). Of\nthese, only 300 are nutrients, only some of which are essential.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 2, 'type': 'text'}, page_content='1. What role does fluoride play in dental health and how does it contribute to the prevention of tooth decay?  \n2. What are the potential health risks associated with high levels of trace minerals such as arsenic and nickel in the diet?  \n3. How do the non-essential dietary substances in our daily diet impact overall health and nutrition?  '), Document(id='20', metadata={'original_content': "However, many nonnutrients in foods are\nuseful. For example, food additives (eg, preservatives, emulsifiers, antioxidants, stabilizers) improve the\nproduction and stability of foods. Trace components (eg, spices, flavors, odors, colors, phytochemicals,\nmany other natural products) improve appearance and taste. Fiber:\n Fiber occurs in various forms (eg, cellulose, hemicellulose, pectin, gums). It \nincreases GI motility,\nprevents constipation, and helps control diverticular disease. Fiber is thought to accelerate the elimination\nof cancer-causing substances produced by bacteria in the large intestine. Epidemiologic evidence\nsuggests an association between colon cancer and low fiber intake and a beneficial effect of fiber in\npatients with functional bowel disorders, Crohn's disease, obesity, and hemorrhoids. Soluble fiber\n(present in fruits, vegetables, oats, barley, and legumes) reduces the postprandial increase in blood\nglucose and insulin and can reduce cholesterol levels. The typical Western diet is low in fiber (about 12 g/day) because of a high intake of highly refined wheat\nflour and a low intake of fruits and vegetables.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 2, 'type': 'text'}, page_content='1. How does a low fiber intake contribute to the development of colon cancer?  \n2. What role does soluble fiber play in managing blood glucose and cholesterol levels?  \n3. What are the potential health benefits of increasing fiber consumption for individuals with functional bowel disorders?  '), Document(id='21', metadata={'original_content': 'Increasing fiber intake to about 30 g/day by consuming\nmore vegetables, fruits, and high-fiber cereals and grains is generally recommended. However, very high\nfiber intake may reduce absorption of certain minerals. Nutritional Requirements\nGood nutrition aims to achieve and maintain a desirable body composition and high potential for physical\nand mental work.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 2, 'type': 'text'}, page_content='1. What are the potential risks of consuming excessive fiber in relation to mineral absorption?\n2. How can individuals increase their fiber intake to meet the recommended 30 g/day while maintaining a balanced diet?\n3. What role does fiber play in achieving and maintaining desirable body composition and overall health?'), Document(id='22', metadata={'original_content': 'Balancing energy intake with energy expenditure is necessary for a desirable body\nweight. Energy expenditure depends on age, sex, weight (see \nTable 1-4\n), and metabolic and physical\nactivity. If energy intake exceeds expenditure, weight is gained. Taking in about 100 calories/day more\nthan needed results in a weight gain of about 4 to 5 kg in a year. If energy intake is less than expenditure,\nweight is lost.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 2, 'type': 'text'}, page_content="1. How does an imbalance between energy intake and expenditure lead to weight gain or loss?  \n2. What factors influence an individual's energy expenditure?  \n3. What is the estimated weight gain associated with a daily excess of 100 calories over a year?  "), Document(id='23', metadata={'original_content': 'The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 1.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 2, 'type': 'text'}, page_content='1. What are the common causes of vitamin deficiency disorders as outlined in the Merck Manual of Diagnosis &amp; Therapy?\n2. What symptoms are typically associated with malnutrition in adults according to the manual?\n3. What treatment options are recommended for individuals diagnosed with nutritional deficiencies?'), Document(id='24', metadata={'original_content': 'Nutrition: General Considerations\n55', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 2, 'type': 'text'}, page_content='1. What are the common causes of nutritional deficiencies in adults?  \n2. What symptoms might indicate a person is suffering from a nutritional disorder?  \n3. What treatment options are available for individuals diagnosed with a nutritional disorder?  '), Document(id='25', metadata={'original_content': 'Daily dietary requirements for essential nutrients also depend on age, sex, weight, and metabolic and\nphysical activity. Every 5 yr, the Food and Nutrition Board of the National Academy of Sciences/National\nResearch Council and the US Department of Agriculture (USDA) issues the dietary reference intakes\n(DRIs) for protein, energy, and some vitamins and minerals (see \nTables 1-4\n,\n4-1\n, and \n5-2\n). For vitamins and minerals about which less is known, safe and adequate daily dietary\nintakes are estimated.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 3, 'type': 'text'}, page_content="1. How do daily dietary requirements for essential nutrients vary based on an individual's age and sex?\n2. What are the potential health consequences of not meeting the dietary reference intakes (DRIs) for vitamins and minerals?\n3. How can physical activity levels influence the necessary intake of protein and energy in a person's diet?"), Document(id='26', metadata={'original_content': 'Pregnant women (see p.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 3, 'type': 'text'}, page_content='1. What are the common nutritional deficiencies that can occur during pregnancy, and how do they impact maternal and fetal health?\n2. What symptoms should pregnant women be aware of that may indicate a nutritional disorder?\n3. What dietary recommendations can be made to prevent nutritional disorders in pregnant women?'), Document(id='27', metadata={'original_content': '2608\n) and infants (see p. 2703\n) have special nutritional needs. The USDA publishes the Food Guide Pyramid, which specifies the number of recommended daily\nservings of various food groups. The recommendations are individualized based on age, sex, and\nphysical activity (see\nTable 1-5\n). Generally, the recommended intake decreases with aging because physical activity tends to\ndecrease, resulting in less energy expended. The new Food Guide Pyramid emphasizes the following:\n Increasing consumption of whole grains\n Increasing consumption of vegetables and fruits\n Substituting fat-free or low-fat milk products (or equivalents) for whole-fat milk products\n Reducing consumption of saturated fats and trans fatty acids\n Exercising regularly\nAdequate fluid intake is also important. Fats should constitute  30% of total calories, and saturated and trans fatty acids should constitute &lt;\n10%.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 3, 'type': 'text'}, page_content='1. What are the specific dietary recommendations for infants to meet their nutritional needs according to the Food Guide Pyramid?  \n2. How does aging affect the recommended daily intake of food groups as outlined in the Food Guide Pyramid?  \n3. What role does regular exercise play in achieving the dietary goals set by the Food Guide Pyramid?  '), Document(id='28', metadata={'original_content': 'Excess intake of saturated fats contributes to atherosclerosis. Substituting polyunsaturated fatty\nacids for saturated fats can decrease the risk of atherosclerosis. Routine use of nutritional supplements is\nnot necessary or beneficial; some supplements can be harmful.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 3, 'type': 'text'}, page_content='1. How does excess intake of saturated fats contribute to the development of atherosclerosis?\n2. What are the benefits of substituting polyunsaturated fatty acids for saturated fats in relation to atherosclerosis risk?\n3. Are there any nutritional supplements that can worsen the condition of atherosclerosis?'), Document(id='29', metadata={'original_content': 'For example, excess vitamin A can lead to\nhypervitaminosis A, with headaches, osteoporosis, and rash. Nutrition in Clinical Medicine\nNutritional deficiencies can often worsen health outcomes (whether a disorder is present or not), and\nsome disorders (eg, malabsorption) can cause nutritional deficiencies. Also, many patients (eg, elderly\npatients during acute hospitalization) have unsuspected nutritional deficiencies that require treatment. Many medical centers have multi-disciplinary nutrition support teams of physicians, nurses, dietitians, and\npharmacists to help the clinician prevent, diagnose, and treat occult nutritional deficiencies. Overnutrition may contribute to chronic disorders, such as cancer, hypertension, obesity, diabetes\nmellitus, and coronary artery disease. Dietary restrictions are necessary in many hereditary metabolic\ndisorders (eg, galactosemia, phenylketonuria). Evaluation of Nutritional Status\nIndications for nutritional evaluation include undesirable body weight or body composition, suspicion of\nspecific deficiencies or toxicities\n[\nTable 1-5. Recommended Dietary Intake for 40-yr-Olds with Moderate Physical Activity*]\nof essential nutrients, and, in infants and children, insufficient growth or development. Nutritional status\nshould be evaluated routinely as part of the clinical examination for infants and children, the elderly,\npeople taking several drugs, people with psychiatric disorders, and people with systemic disorders that\nlast longer than several days. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 1.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 3, 'type': 'text'}, page_content='1. What are the potential health consequences of vitamin A toxicity, and how can they be identified in patients?\n2. How can malabsorption disorders lead to specific nutritional deficiencies, and what symptoms should clinicians look for?\n3. What dietary restrictions are necessary for managing hereditary metabolic disorders like galactosemia and phenylketonuria?'), Document(id='30', metadata={'original_content': 'Nutrition: General Considerations\n56', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 3, 'type': 'text'}, page_content='1. What are the common causes of the nutritional disorder discussed in the document?\n2. What symptoms should one look for to identify the nutritional disorder?\n3. What treatment options are available for managing the nutritional disorder?'), Document(id='31', metadata={'original_content': 'Evaluating general nutritional status includes history, physical examination, and sometimes tests. If\nundernutrition is suspected, laboratory tests (eg, albumin levels) and skin tests for delayed\nhypersensitivity may be done (see p. 13\n). Body composition analysis (eg, skinfold measurements, bioelectrical impedance analysis) is used to\nestimate percentage of body fat and to evaluate obesity (see p. 58\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 4, 'type': 'text'}, page_content='1. What laboratory tests are commonly used to confirm suspected undernutrition in patients?  \n2. How can body composition analysis help in evaluating obesity and its related health risks?  \n3. What role do skin tests for delayed hypersensitivity play in assessing nutritional status?  '), Document(id='32', metadata={'original_content': 'History includes questions about dietary intake, weight change, and risk factors for nutritional deficiencies\nand a focused review of systems (see\nTable 2-1\n on p. 11\n). A dietitian can obtain a more detailed dietary history. It usually includes a list of foods\neaten within the previous 24 h and a food questionnaire. A food diary may be used to record all foods\neaten. The weighed ad libitum diet, in which the patient weighs and writes down all foods consumed, is\nthe most accurate record. A complete physical examination, including measurement of height and weight and distribution of body\nfat, should be done. Body mass index (BMI)weight(kg)/height(m)\n2\n, which adjusts weight for height (see\nTable 6-2\n on p. 59\n), is more accurate than height and weight tables.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 4, 'type': 'text'}, page_content="1. What dietary factors may contribute to the risk of developing nutritional deficiencies in patients?\n2. How can a food diary help in identifying specific nutritional deficiencies in an individual?\n3. What role does body mass index (BMI) play in assessing a patient's risk for nutritional-related health issues?"), Document(id='33', metadata={'original_content': 'There are standards for growth and\nweight gain in infants, children, and adolescents (see p.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 4, 'type': 'text'}, page_content='1. What are the common causes of growth delays in infants and children related to nutritional disorders?\n2. What symptoms should parents look for that may indicate their child is experiencing a nutritional disorder affecting weight gain?\n3. What treatment options are available for adolescents struggling with nutritional disorders that impact their growth and development?'), Document(id='34', metadata={'original_content': '2756\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 4, 'type': 'text'}, page_content='1. What are the common causes of the nutritional disorder outlined in the document?\n2. What symptoms should one look for to identify the nutritional disorder mentioned?\n3. What treatment options are available for managing the nutritional disorder described?'), Document(id='35', metadata={'original_content': "Distribution of body fat is important. Disproportionate truncal obesity (ie, waist/hip ratio &gt; 0.8) is\nassociated with cardiovascular and cerebrovascular disorders, hypertension, and diabetes mellitus more\noften than fat located elsewhere. Measuring waist circumference in patients with a BMI of &lt; 35 helps\ndetermine whether they have truncal obesity and helps predict risk of diabetes, hypertension,\nhypercholesterolemia, and cardiovascular disorders. Risk is increased if waist circumference is &gt; 102 cm\n(&gt; 40 in) in men or &gt; 88 cm (&gt; 35 in) in women. Nutrient-Drug Interactions\nNutrition can affect the body's response to drugs; conversely, drugs can affect the body's nutrition.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 4, 'type': 'text'}, page_content='1. How does disproportionate truncal obesity impact the risk of developing cardiovascular diseases and diabetes mellitus?\n2. What waist circumference measurements indicate an increased risk for hypertension and hypercholesterolemia in men and women?\n3. In patients with a BMI of &lt; 35, how can measuring waist circumference help in predicting the risk of truncal obesity-related health issues?'), Document(id='36', metadata={'original_content': 'Foods can enhance, delay, or decrease drug absorption. Foods impair absorption of many antibiotics. They can alter metabolism of drugs; eg, high-protein diets can accelerate metabolism of certain drugs by\nstimulating \ncytochrome P-450. Eating grapefruit can inhibit cytochrome P-450 34A, slowing metabolism of\nsome drugs (eg, amiodarone, carbamazepine, cyclosporine, certain Ca channel blockers). Diets that alter\nthe bacterial flora may markedly affect the overall metabolism of certain drugs.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 4, 'type': 'text'}, page_content='1. How can high-protein diets influence the metabolism of specific medications in patients?  \n2. What effects does grapefruit consumption have on the absorption and metabolism of certain drugs?  \n3. In what ways can changes in bacterial flora due to diet impact drug metabolism and effectiveness?  '), Document(id='37', metadata={'original_content': "Some foods affect the\nbody's response to drugs. For example, tyramine, a component of cheese and a potent vasoconstrictor,\ncan cause hypertensive crisis in some patients who take monoamine oxidase inhibitors and eat cheese. Nutritional deficiencies can affect drug absorption and metabolism. Severe energy and protein\ndeficiencies reduce enzyme tissue concentrations and may impair the response to drugs by reducing\nabsorption or protein binding and causing liver dysfunction. Changes in the GI tract can impair absorption\nand affect the response to a drug. Deficiency of Ca, Mg, or zinc may impair drug metabolism. Vitamin C\ndeficiency decreases activity of drug-metabolizing enzymes, especially in the elderly. Many drugs affect appetite, food absorption, and tissue metabolism (see\nTable 1-6\n).", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 4, 'type': 'text'}, page_content='1. How does tyramine in foods like cheese interact with monoamine oxidase inhibitors, and what are the potential consequences of this interaction for patients?  \n2. In what ways can severe energy and protein deficiencies influence drug absorption and metabolism in the body?  \n3. What role do deficiencies in calcium, magnesium, or zinc play in drug metabolism and overall drug efficacy?  '), Document(id='38', metadata={'original_content': 'Some drugs (eg, metoclopramide) increase GI motility, decreasing food absorption. Other\ndrugs (eg, opioids, anticholinergics) decrease GI motility. Some drugs are better tolerated if taken with\nfood.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 4, 'type': 'text'}, page_content='1. How do different medications affect gastrointestinal motility and nutrient absorption?\n2. What types of drugs should be taken with food to improve tolerance and reduce gastrointestinal side effects?\n3. What are the potential consequences of decreased gastrointestinal motility on nutritional status?'), Document(id='39', metadata={'original_content': 'Certain drugs affect mineral metabolism. For example, diuretics, especially thiazides, and corticosteroids\ncan deplete body K, increasing susceptibility to digoxin-induced cardiac arrhythmias. Repeated use of\nlaxatives may deplete K. Cortisol, desoxycorticosterone, and aldosterone cause marked Na and water\nretention, at least temporarily; retention is much less with prednisone, prednisolone, and some other\ncorticosteroid analogs. Sulfonylureas and lithium can impair the uptake or release of iodine by the thyroid.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 4, 'type': 'text'}, page_content='1. How do thiazide diuretics affect potassium levels in the body and what are the potential consequences for cardiac health?  \n2. What impact do corticosteroids have on sodium and water retention compared to other steroid analogs?  \n3. In what ways can sulfonylureas and lithium influence iodine metabolism in the thyroid gland?  '), Document(id='40', metadata={'original_content': 'Oral contraceptives can lower blood zinc levels and increase copper levels. Certain antibiotics (eg,\ntetracyclines) reduce iron absorption, as can certain foods (eg, vegetables, tea, bran).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 4, 'type': 'text'}, page_content='1. How do oral contraceptives affect zinc and copper levels in the body?  \n2. What impact do tetracyclines have on iron absorption, and how can this affect overall nutrition?  \n3. Which foods should be avoided to improve iron absorption when taking certain antibiotics?  '), Document(id='41', metadata={'original_content': 'Certain drugs affect vitamin absorption or metabolism. Ethanol impairs thiamin utilization, and isoniazid\ninterferes with niacin and pyridoxine metabolism. Ethanol and oral contraceptives inhibit folate (folic acid)\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 1. Nutrition: General Considerations\n57', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 4, 'type': 'text'}, page_content='1. How does ethanol consumption impact thiamin utilization in the body?\n2. What effects do oral contraceptives have on folate absorption and metabolism?\n3. In what ways does isoniazid interfere with the metabolism of niacin and pyridoxine?'), Document(id='42', metadata={'original_content': 'absorption. Most patients receiving phenytoin, phenobarbital, primidone, or phenothiazines develop folate\ndeficiency, probably because hepatic microsomal drug-metabolizing enzymes are affected. Folate\nsupplements may\n[\nTable 1-6. Effects of Some Drugs on Nutrition]\nmake phenytoin less effective. Anticonvulsants can cause vitamin D deficiency. Malabsorption of vitamin\nB\n12\n can occur with use of aminosalicylic acid, slow-release K iodide, colchicine, trifluoperazine, ethanol,\nand oral contraceptives. Oral contraceptives with a high progestin dose can cause depression, probably\nbecause of metabolically induced tryptophan deficiency.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 5, 'type': 'text'}, page_content='1. How do anticonvulsants like phenytoin and phenobarbital contribute to folate deficiency in patients?  \n2. What are the potential consequences of vitamin D deficiency caused by the use of anticonvulsants?  \n3. In what ways can oral contraceptives with high progestin doses lead to depression due to tryptophan deficiency?'), Document(id='43', metadata={'original_content': 'Food Additives and Contaminants\nAdditives:\n Chemicals are often combined with foods to facilitate their processing and preservation or to\nenhance their desirability.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 5, 'type': 'text'}, page_content='1. What potential health risks are associated with the consumption of food additives in processed foods?\n2. How can individuals identify food additives that may trigger allergic reactions or intolerances?\n3. What measures can be taken to minimize exposure to harmful food contaminants during food preparation and storage?'), Document(id='44', metadata={'original_content': 'Only amounts of additives shown to be safe by laboratory tests are permitted in\ncommercially prepared foods. Weighing the benefits of additives (eg, reduced waste, increased variety of available foods, protection\nagainst food-borne illness) against the risks is often complex. For example, nitrite, which is used in cured\nmeats, inhibits the growth of \nClostridium botulinum\n and improves flavor. However, nitrite converts to\nnitrosamines, which are carcinogens in animals. On the other hand, the amount of nitrite added to cured\nmeat is small compared with the amount from naturally occurring food nitrates converted to nitrite by the\nsalivary glands. Dietary vitamin C can reduce nitrite formation in the GI tract. Rarely, some additives (eg,\nsulfites) cause food hypersensitivity (allergy) reactions.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 5, 'type': 'text'}, page_content='1. What are the potential health risks associated with the consumption of nitrites in cured meats?\n2. How does dietary vitamin C affect nitrite formation in the gastrointestinal tract?\n3. What are the common food hypersensitivity reactions caused by additives like sulfites?'), Document(id='45', metadata={'original_content': 'Most of these reactions are caused by ordinary\nfoods (see p. 1118\n). Contaminants:\n Sometimes limited amounts of contaminants are allowed in foods because the\ncontaminants cannot be completely eliminated without damaging the foods. Common contaminants are\npesticides, heavy metals (lead, cadmium, mercury), nitrates (in green leafy vegetables), aflatoxins (in nuts\nand milk), growth-promoting hormones (in dairy products and meat), animal hairs and feces, and insect\nparts. FDA-estimated safe levels are levels that have not caused illness or adverse effects in people.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 5, 'type': 'text'}, page_content='1. What specific contaminants are commonly found in everyday foods, and how can they impact human health?  \n2. How do FDA-estimated safe levels of contaminants in food ensure consumer safety?  \n3. What are the potential health effects of consuming foods contaminated with heavy metals such as lead and mercury?  '), Document(id='46', metadata={'original_content': 'However,\ndemonstrating a causal relationship between extremely low level exposures and adverse effects is\ndifficult; long-term adverse effects, although unlikely, are still possible. Safe levels are often determined\nby consensus rather than by hard evidence.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 5, 'type': 'text'}, page_content='1. What are the potential long-term adverse effects of extremely low level exposures to certain nutrients in individuals with nutritional disorders?  \n2. How are safe exposure levels for nutrients determined in the absence of conclusive evidence?  \n3. What challenges exist in establishing a causal relationship between low nutrient levels and specific adverse health effects?  '), Document(id='47', metadata={'original_content': 'The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 1. Nutrition: General Considerations\n58', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 5, 'type': 'text'}, page_content='1. What are the common causes of malnutrition in adults, and how can they be addressed?\n2. What symptoms should one look for to identify a vitamin deficiency disorder?\n3. What treatment options are available for individuals diagnosed with protein-energy malnutrition?'), Document(id='48', metadata={'original_content': 'Chapter 2. Undernutrition\nIntroduction\nUndernutrition is a form of malnutrition. (Malnutrition also includes overnutritionsee \nCh. 6\n). Undernutrition can result from inadequate ingestion of nutrients, malabsorption, impaired\nmetabolism, loss of nutrients due to diarrhea, or increased nutritional requirements (as occurs\nin cancer or infection). Undernutrition progresses in stages; each stage usually takes\nconsiderable time to develop. First, nutrient levels in blood and tissues change, followed by\nintracellular changes in biochemical functions and structure. Ultimately, symptoms and signs\nappear. Risk Factors\nUndernutrition is associated with many disorders and circumstances, including poverty and social\ndeprivation. Risk is also greater at certain times (ie, during infancy, early childhood, adolescence,\npregnancy, breastfeeding, and old age).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 6, 'type': 'text'}, page_content='1. What are the primary causes of undernutrition and how do they lead to nutrient deficiencies in the body?  \n2. What stages does undernutrition progress through before symptoms and signs become apparent?  \n3. How do specific life stages, such as infancy and old age, increase the risk of undernutrition?  '), Document(id='49', metadata={'original_content': 'Infancy and childhood:\n Infants and children are particularly susceptible to undernutrition because of\ntheir high demand for energy and essential nutrients. Because vitamin K does not readily cross the\nplacenta, neonates may be deficient, so all are given a single injection of vitamin K within 1 h of birth to\nprevent hemorrhagic disease of the newborn, a life-threatening disorder (see pp. 46\n and\n2783\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 6, 'type': 'text'}, page_content='1. What are the potential consequences of vitamin K deficiency in neonates?  \n2. Why are infants and children particularly vulnerable to undernutrition?  \n3. How does the administration of vitamin K shortly after birth help prevent hemorrhagic disease of the newborn?  '), Document(id='50', metadata={'original_content': 'Infants fed only breast milk, which is typically low in vitamin D, are given supplemental vitamin D;\nthey can develop vitamin B\n12\n deficiency if the mother is a vegan. Inadequately fed infants and children\nare at risk of protein-energy undernutrition (PEUpreviously called protein-energy malnutrition) and\ndeficiencies of iron, folate (folic acid), vitamins A and C, copper, and zinc. During adolescence, nutritional\nrequirements increase because the growth rate accelerates.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 6, 'type': 'text'}, page_content='1. What are the potential consequences of a vegan mother breastfeeding her infant in terms of vitamin B12 deficiency?\n2. How can inadequate nutrition in infants and children lead to protein-energy undernutrition (PEU)?\n3. What specific vitamins and minerals are infants and children at risk of being deficient in due to inadequate feeding?'), Document(id='51', metadata={'original_content': 'Anorexia nervosa (see p. 1535\n) may affect\nadolescent girls in particular.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 6, 'type': 'text'}, page_content='1. What are the common psychological causes of anorexia nervosa in adolescent girls?\n2. What symptoms should parents look for to identify anorexia nervosa in their daughters?\n3. What treatment options are available for adolescent girls diagnosed with anorexia nervosa?'), Document(id='52', metadata={'original_content': 'Pregnancy and breastfeeding:\n Requirements for nutrients increase during pregnancy and\nbreastfeeding. Aberrations of diet, including pica (consumption of nonnutritive substances, such as clay\nand charcoal), may occur during \npregnancy. Anemia due to iron deficiency is common, as is anemia due\nto folate deficiency, especially among women who have taken oral contraceptives.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 6, 'type': 'text'}, page_content='1. What are the common nutritional deficiencies that can occur during pregnancy and breastfeeding, and how can they be addressed?\n2. How does pica affect the nutritional status of pregnant women, and what are the potential health implications?\n3. What are the symptoms of iron and folate deficiency anemia in pregnant women, and what treatments are recommended?'), Document(id='53', metadata={'original_content': 'Vitamin D deficiency is\ncommon during late pregnancy, predisposing the child to decreased bone mass. Old age:\n Agingeven when disease or dietary deficiency is absentleads to sarcopenia (progressive\nloss of lean body mass), starting after age 40 and eventually amounting to a muscle loss of about 10 kg\n(22 lb) in men and 5 kg (11 lb) in women. Undernutrition contributes to sarcopenia, and sarcopenia\naccounts for many of the complications of undernutrition (eg, decreased nitrogen balance, increased\nsusceptibility to infections). Causes of sarcopenia include the following:\n Decreased physical activity\n Decreased food intake\n Increased levels of cytokines (particularly interleukin-6)\n Decreased levels of growth hormone and mechano growth factor (insulin-like growth factor-3)\n In men, decreasing androgen levels\nAging decreases basal metabolic rate (due mainly to decreased fat-free mass), total body weight, height,\nand skeletal mass; aging increases mean body fat (as a percentage of body weight) to about 30% (from\n20%) in men and to 40% (from 27%) in women. From age 20 to 80, food intake decreases, especially in men.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 6, 'type': 'text'}, page_content='1. What are the main causes of sarcopenia in older adults, and how do they contribute to muscle loss?  \n2. How does vitamin D deficiency during late pregnancy affect the bone health of the child?  \n3. What role does decreased food intake play in the progression of sarcopenia among the elderly?  '), Document(id='54', metadata={'original_content': "Anorexia due to aging itself has many\ncauses, including reduced adaptive relaxation of the stomach's fundus, increased release and activity of\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 2. Undernutrition\n59", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 6, 'type': 'text'}, page_content='1. What physiological changes in the stomach contribute to anorexia in the aging population?  \n2. How does the increased release and activity of certain hormones affect appetite in elderly individuals?  \n3. What therapeutic approaches are recommended for managing anorexia related to aging?  '), Document(id='55', metadata={'original_content': 'cholecystokinin (which produces satiation), and increased leptin (an anorectic hormone produced by fat\ncells). Diminished taste and smell can decrease eating pleasure but usually decrease food intake only\nslightly. Anorexia may have other causes (eg, loneliness, inability to shop or prepare meals, dementia,\nsome chronic disorders, use of certain drugs).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 7, 'type': 'text'}, page_content='1. What role do hormones like cholecystokinin and leptin play in the regulation of appetite and satiety in individuals with anorexia?  \n2. How can diminished taste and smell impact food intake and eating behaviors in patients with anorexia?  \n3. What are some non-biological factors that may contribute to the development of anorexia, such as loneliness or cognitive impairments?  '), Document(id='56', metadata={'original_content': 'Depression is a common cause. Occasionally, anorexia\nnervosa (sometimes called anorexia tardive in the elderly), paranoia, or mania interferes with eating. Dental problems limit the ability to chew and subsequently to digest foods. Swallowing difficulties (eg, due\nto strokes, other neurologic disorders, esophageal candidiasis, or xerostomia) are common. Poverty or\nfunctional impairment limits access to nutrients. The institutionalized elderly are at particular risk of PEU. They are often confused and may be unable to\nexpress hunger or preferences for foods.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 7, 'type': 'text'}, page_content='1. What psychological conditions can interfere with the eating habits of elderly individuals, potentially leading to poor nutritional intake?  \n2. How do dental problems affect the nutritional status of older adults, particularly in relation to their ability to chew and digest food?  \n3. What factors contribute to the increased risk of protein-energy undernutrition (PEU) in institutionalized elderly populations?  '), Document(id='57', metadata={'original_content': 'They may be physically unable to feed themselves.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 7, 'type': 'text'}, page_content='1. What are the common causes that may lead to an individual being physically unable to feed themselves in cases of nutritional disorders?  \n2. What symptoms might indicate that a person is struggling with self-feeding due to a nutritional disorder?  \n3. What treatment options are available for individuals who are physically unable to feed themselves because of a nutritional disorder?  '), Document(id='58', metadata={'original_content': 'Chewing or\nswallowing may be very slow, making it tedious for another person to feed them enough food. In the elderly, particularly the institutionalized elderly, inadequate intake and often decreased absorption\nor synthesis of vitamin D, increased demand for vitamin D, and inadequate exposure to sunshine\ncontribute to osteomalacia (see p. 41\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 7, 'type': 'text'}, page_content='1. What are the contributing factors to osteomalacia in the elderly, particularly those who are institutionalized?  \n2. How does decreased synthesis of vitamin D affect the nutritional status of elderly individuals?  \n3. What dietary interventions can help improve vitamin D intake and absorption in elderly patients with osteomalacia?  '), Document(id='59', metadata={'original_content': 'Disorders and medical procedures:\n Diabetes, some chronic disorders that affect the GI tract, intestinal\nresection, and certain other GI surgical procedures tend to impair absorption of fat-soluble vitamins,\nvitamin B\n12\n, Ca, and iron. Gluten enteropathy, pancreatic insufficiency, or other disorders can result in\nmalabsorption. Decreased absorption possibly contributes to iron deficiency and osteoporosis. Liver\ndisorders impair storage of vitamins A and B\n12\n and interfere with metabolism of protein and energy\nsources. Renal insufficiency predisposes to protein, iron, and vitamin D deficiencies. Anorexia causes\nsome patients with cancer or depression and many with AIDS to consume inadequate amounts of food. Infections, trauma, hyperthyroidism, extensive burns, and prolonged fever increase metabolic demands. Any condition that increases cytokines may be accompanied by muscle loss, lipolysis, low albumin levels,\nand anorexia. Vegetarian diets:\n Iron deficiency can occur in ovo-lacto vegetarians (although such a diet can be\ncompatible with good health). Vegans may develop vitamin B\n12\n deficiency unless they consume yeast\nextracts or Asian-style fermented foods. Their intake of Ca, iron, and zinc also tends to be low.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 7, 'type': 'text'}, page_content='1. How do gastrointestinal disorders affect the absorption of fat-soluble vitamins and minerals in patients with diabetes?  \n2. What are the potential nutritional deficiencies faced by individuals with renal insufficiency, and how can they be managed?  \n3. What dietary adjustments should vegans consider to prevent vitamin B12 deficiency and ensure adequate intake of calcium, iron, and zinc?  '), Document(id='60', metadata={'original_content': 'A fruit-only\ndiet is not recommended because it is deficient in protein, Na, and many micronutrients. Fad diets:\n Some fad diets result in vitamin, mineral, and protein deficiencies; cardiac, renal, and\nmetabolic disorders; and sometimes death. Very low calorie diets (&lt; 400 kcal/day) cannot sustain health\nfor long. Drugs and nutritional supplements:\n Many drugs (eg, appetite suppressants, digoxin) decrease\nappetite; others impair nutrient absorption or metabolism. Some drugs (eg, stimulants) have catabolic\neffects. Certain drugs can impair absorption of many nutrients; eg, anticonvulsants can impair absorption\nof vitamins. Alcohol or drug dependency:\n Patients with alcohol or drug dependency may neglect their nutritional\nneeds. Absorption and metabolism of nutrients may also be impaired. IV drug addicts typically become\nundernourished, as do\n[\nTable 2-1. Symptoms and Signs of Nutritional Deficiency]\nalcoholics who consume  1 quart of hard liquor/day. Alcoholism can cause deficiencies of Mg, zinc, and\ncertain vitamins, including thiamin. Symptoms and Signs\nSymptoms vary depending on the cause and type of undernutrition (see p.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 7, 'type': 'text'}, page_content='1. What are the potential health risks associated with following a fruit-only diet?\n2. How can alcohol dependency affect nutrient absorption and lead to deficiencies?\n3. What are the consequences of very low-calorie diets on overall health and nutrient intake?'), Document(id='61', metadata={'original_content': '15\n and \nChs.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 7, 'type': 'text'}, page_content='[]'), Document(id='62', metadata={'original_content': '4\n and \n5\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 7, 'type': 'text'}, page_content='1. What are the common causes of the nutritional disorder described in the document?  \n2. What symptoms should one look for to identify this nutritional disorder?  \n3. What treatment options are available for managing the nutritional disorder mentioned?  '), Document(id='63', metadata={'original_content': 'Evaluation\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 2. Undernutrition\n60', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 7, 'type': 'text'}, page_content='1. What are the common causes of undernutrition in adults, as outlined in the Merck Manual?\n2. What symptoms are typically associated with undernutrition in children?\n3. What treatment options are recommended for patients diagnosed with undernutrition?'), Document(id='64', metadata={'original_content': 'Diagnosis is based on results of medical and diet histories, physical examination, body composition\nanalysis (see p. 58\n), and selected laboratory tests.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 8, 'type': 'text'}, page_content='1. What laboratory tests are commonly used to diagnose the nutritional disorder described in the document?  \n2. How can body composition analysis contribute to the diagnosis of the nutritional disorder?  \n3. What role do medical and diet histories play in identifying the symptoms of the nutritional disorder?  '), Document(id='65', metadata={'original_content': 'History:\n History should include questions about dietary intake (see\nFig. 2-1\n), recent changes in weight, and risk factors for undernutrition, including drug and alcohol use. Unintentional loss of  10% of usual body weight during a 3-mo period indicates a high probability of\nundernutrition. Social history should include questions about whether money is available for food and\nwhether the patient can shop and cook. Review of systems should focus on symptoms of nutritional deficiencies (see \nTable 2-1\n). For example,\nimpaired night vision may indicate vitamin A deficiency. Physical examination:\n Physical examination should include measurement of height and weight,\ninspection of body fat distribution, and anthropometric measurements of lean body mass.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 8, 'type': 'text'}, page_content='1. What dietary changes have you made in the last three months that may have contributed to weight loss or nutritional deficiencies?  \n2. Have you experienced any symptoms such as impaired night vision, which could indicate a vitamin A deficiency?  \n3. Are you facing any financial difficulties that affect your ability to purchase food and maintain a balanced diet?  '), Document(id='66', metadata={'original_content': "Body mass\nindex (BMI = weight(kg)/height(m)\n2\n) adjusts weight for height (see\nTable 6-2\n on p. 59\n). If weight is &lt; 80% of what is predicted for the patient's height or if BMI is  18,\nundernutrition should be suspected. Although these findings are useful in diagnosing undernutrition and\nare acceptably sensitive, they lack specificity.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 8, 'type': 'text'}, page_content='1. What are the potential health risks associated with a BMI of 18 or lower in adults?\n2. How can one determine if a patient is experiencing undernutrition based on their weight relative to their height?\n3. What are the recommended treatment strategies for individuals diagnosed with undernutrition?'), Document(id='67', metadata={'original_content': '[\nFig.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 8, 'type': 'text'}, page_content='[]'), Document(id='68', metadata={'original_content': "2-1. Mini nutritional assessment.]\nThe mid upper arm muscle area estimates lean body mass. This area is derived from the triceps skinfold\nthickness (TSF) and mid upper arm circumference. Both are measured at the same site, with the patient's\nright arm in a relaxed position. The average mid upper arm circumference is about 32  5 cm for men and\n28  6 cm for women. The formula for calculating the mid upper arm muscle area in cm\n2\n is as follows:\nThis formula corrects the upper arm area for fat and bone. Average values for the mid upper arm muscle\narea are 54  11 cm\n2\n for men and 30  7 cm\n2\n for women. A value &lt; 75% of this standard (depending on\nage) indicates depletion of lean body mass (see\nTable 2-2\n).", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 8, 'type': 'text'}, page_content='1. How can the mid upper arm muscle area measurements help in assessing lean body mass depletion in patients?\n2. What are the implications of having a mid upper arm muscle area value below the standard threshold for men and women?\n3. What factors could contribute to variations in mid upper arm circumference and triceps skinfold thickness measurements among different individuals?'), Document(id='69', metadata={'original_content': 'This measurement may be affected by physical activity, genetic factors, and age-related\nmuscle loss.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 8, 'type': 'text'}, page_content='1. How do physical activity levels influence the measurement of muscle mass in individuals with nutritional disorders?  \n2. What genetic factors can affect muscle loss in older adults suffering from nutritional deficiencies?  \n3. How can age-related muscle loss be mitigated through dietary changes in individuals with nutritional disorders?  '), Document(id='70', metadata={'original_content': "Physical examination should focus on signs of specific nutritional deficiencies. Signs of PEU (eg, edema,\nmuscle wasting, skin changes) should be sought. Examination should also focus on signs of conditions\nthat could predispose to nutritional deficiencies, such as dental problems. Mental status should be\nassessed, because depression and cognitive impairment can lead to weight loss. The widely used Subjective Global Assessment (SGA) uses information from the patient history (eg,\nweight loss, change in intake, GI symptoms), physical examination findings (eg, loss of muscle and\nsubcutaneous fat, edema, ascites), and the clinician's judgment of the patient's nutritional status. The\nMini Nutritional Assessment (MNA) has been validated and is widely used, especially for elderly patients\n(see \nFig. 2-1\n). The Simplified Nutrition Assessment Questionnaire (SNAQ), a simple, validated method of\npredicting future weight loss, may be used (see\nFig. 2-2\n).", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 8, 'type': 'text'}, page_content="1. What physical examination signs should be assessed to identify specific nutritional deficiencies in a patient with suspected PEU?  \n2. How can mental status impact a patient's nutritional status and contribute to weight loss?  \n3. What are the differences between the Subjective Global Assessment (SGA) and the Mini Nutritional Assessment (MNA) in evaluating nutritional status?  "), Document(id='71', metadata={'original_content': "Testing:\n The extent of laboratory testing needed is unclear and may depend on the patient's\ncircumstances. If the cause is obvious and correctable (eg, a wilderness survival situation), testing is\nprobably of little benefit.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 8, 'type': 'text'}, page_content='1. What factors should be considered when determining the need for laboratory testing in a patient with a nutritional disorder?  \n2. In what situations might laboratory testing for a nutritional disorder be deemed unnecessary?  \n3. How can the identification of an obvious and correctable cause of a nutritional disorder influence the management plan for the patient?  '), Document(id='72', metadata={'original_content': 'Other patients may require more detailed evaluation. Serum albumin measurement is the laboratory test most often used. Decreases in albumin and other\nproteins (eg, prealbumin [transthyretin], transferrin, retinol-binding protein) may indicate protein deficiency\nor PEU. As undernutrition progresses, albumin decreases slowly; prealbumin, transferrin, and retinol-\nbinding protein decrease rapidly. Albumin measurement is inexpensive and predicts morbidity and\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 2. Undernutrition\n61', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 8, 'type': 'text'}, page_content="1. What laboratory tests can be used to evaluate protein deficiency in patients with undernutrition?  \n2. How do serum albumin levels change as undernutrition progresses, and what does this indicate about the patient's condition?  \n3. What is the significance of measuring prealbumin, transferrin, and retinol-binding protein in the context of diagnosing protein-energy undernutrition (PEU)?  "), Document(id='73', metadata={'original_content': 'mortality better than measurement of the other proteins. However, the correlation of albumin with\nmorbidity and mortality may be related to nonnutritional as well as nutritional factors. Inflammation\nproduces cytokines that cause albumin and other nutritional protein markers to extravasate, decreasing\nserum levels. Because prealbumin, transferrin, and retinol-binding protein decrease more rapidly during\nstarvation than does albumin, their measurements are sometimes used to diagnose or assess the severity\nof acute starvation. However, whether they are more sensitive or specific than albumin is unclear. Total lymphocyte count, which often decreases as undernutrition progresses, may be determined. Undernutrition causes a marked decline in CD4+ T lymphocytes, so this count may not be useful in\npatients who have AIDS. Skin tests using antigens can detect impaired cell-mediated immunity in PEU and in some other disorders\nof undernutrition (see p. 1098\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 9, 'type': 'text'}, page_content='1. How do inflammatory cytokines affect serum albumin levels in patients with undernutrition?\n2. What is the role of prealbumin, transferrin, and retinol-binding protein in diagnosing acute starvation compared to albumin?\n3. Why might total lymphocyte count be an unreliable indicator of undernutrition in patients with AIDS?'), Document(id='74', metadata={'original_content': 'Other laboratory tests, such as measuring vitamin and mineral levels, are used selectively to diagnose\nspecific deficiencies.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 9, 'type': 'text'}, page_content='1. What specific laboratory tests are used to diagnose vitamin and mineral deficiencies in patients?\n2. How do the symptoms of nutritional deficiencies vary based on specific vitamin or mineral shortages?\n3. What treatment options are available for individuals diagnosed with specific vitamin and mineral deficiencies?'), Document(id='75', metadata={'original_content': '[\nTable 2-2.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 9, 'type': 'text'}, page_content='[]'), Document(id='76', metadata={'original_content': 'Mid Upper Arm Muscle Area in Adults]\n[\nFigure 2-2. Simplified Nutrition Assessment Questionnaire (SNAQ).]\nProtein-Energy Undernutrition\nProtein-energy undernutrition (PEU), previously called protein-energy malnutrition, is an energy\ndeficit due to chronic deficiency of all macronutrients. It commonly includes deficiencies of\nmany micronutrients.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 9, 'type': 'text'}, page_content='1. What are the common causes of protein-energy undernutrition in adults?\n2. What symptoms might indicate that an adult is experiencing protein-energy undernutrition?\n3. What treatment options are available for an adult diagnosed with protein-energy undernutrition?'), Document(id='77', metadata={'original_content': 'PEU can be sudden and total (starvation) or gradual. Severity ranges from\nsubclinical deficiencies to obvious wasting (with edema, hair loss, and skin atrophy) to\nstarvation.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 9, 'type': 'text'}, page_content='1. What are the common symptoms associated with progressive protein-energy undernutrition (PEU) that can indicate a deficiency?  \n2. How can starvation contribute to the development of severe protein-energy undernutrition (PEU)?  \n3. What treatment options are available for individuals experiencing obvious wasting due to protein-energy undernutrition (PEU)?  '), Document(id='78', metadata={'original_content': 'Multiple organ systems are often impaired.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 9, 'type': 'text'}, page_content='1. What are the common causes of multiple organ impairment in individuals with nutritional disorders?  \n2. What specific symptoms might indicate that multiple organ systems are affected due to a nutritional deficiency?  \n3. What treatment options are available to address the impairment of multiple organ systems caused by nutritional disorders?  '), Document(id='79', metadata={'original_content': 'Diagnosis usually involves laboratory\ntesting, including serum albumin. Treatment consists of correcting fluid and electrolyte deficits\nwith IV solutions, then gradually replenishing nutrients, orally if possible. In developed countries, PEU is common among the institutionalized elderly (although often not suspected)\nand among patients with disorders that decrease appetite or impair nutrient digestion, absorption, or\nmetabolism. In developing countries, PEU affects children who do not consume enough calories or\nprotein. Classification and Etiology\nPEU is graded as mild, moderate, or severe. Grade is determined by calculating weight as a percentage\nof expected weight for length or height using international standards (normal, 90 to 110%; mild PEU, 85 to\n90%; moderate, 75 to 85%; severe, &lt;75%). PEU may be primary or secondary.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 9, 'type': 'text'}, page_content='1. What laboratory tests are used to diagnose Protein-Energy Undernutrition (PEU) and how do they inform the treatment plan?\n2. What are the primary and secondary causes of Protein-Energy Undernutrition (PEU) in both developed and developing countries?\n3. How is the severity of Protein-Energy Undernutrition (PEU) determined and what are the implications for treatment based on its classification?'), Document(id='80', metadata={'original_content': 'Primary PEU is caused by inadequate nutrient intake. Secondary PEU\nresults from disorders or drugs that interfere with nutrient use. Primary PEU:\n Worldwide, primary PEU occurs mostly in children and the elderly who lack access to\nnutrients, although a common cause in the elderly is depression. PEU can also result from fasting or\nanorexia nervosa. Child or elder abuse may be a cause. In children, chronic primary PEU has 2 common forms: marasmus and kwashiorkor. The form depends on\nthe balance of nonprotein and protein sources of energy. Starvation is an acute severe form of primary\nPEU. Marasmus (also called the dry form of PEU) causes weight loss and depletion of fat and muscle. In\ndeveloping countries, marasmus is the most common form of PEU in children. Kwashiorkor (also called the wet, swollen, or edematous form) is associated with premature abandonment\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 2. Undernutrition\n62', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 9, 'type': 'text'}, page_content='1. What are the primary causes of primary protein-energy undernutrition (PEU) in children and the elderly?\n2. How can disorders or medications lead to secondary protein-energy undernutrition (PEU)?\n3. What are the distinguishing symptoms and characteristics of marasmus compared to kwashiorkor in children?'), Document(id='81', metadata={'original_content': 'of breastfeeding, which typically occurs when a younger sibling is born, displacing the older child from the\nbreast. So children with kwashiorkor tend to be older than those with marasmus. Kwashiorkor may also\nresult from an acute illness, often gastroenteritis or another infection (probably secondary to cytokine\nrelease), in a child who already has PEU. A diet that is more deficient in protein than energy may be more\nlikely to cause kwashiorkor than marasmus. Less common than marasmus, kwashiorkor tends to be\nconfined to specific parts of the world, such as rural Africa, the Caribbean, and the Pacific islands. In\nthese areas, staple foods (eg, yams, cassavas, sweet potatoes, green bananas) are low in protein and\nhigh in carbohydrates. In kwashiorkor, cell membranes leak, causing extravasation of intravascular fluid\nand protein, resulting in peripheral edema. Starvation is a complete lack of nutrients.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 10, 'type': 'text'}, page_content='1. What are the primary dietary deficiencies that lead to the development of kwashiorkor in children?  \n2. How does kwashiorkor differ in age of onset compared to marasmus, and what factors contribute to this difference?  \n3. What are the physiological effects of kwashiorkor on cell membranes and fluid balance in the body?  '), Document(id='82', metadata={'original_content': "It occasionally occurs when food is available (as in fasting or\nanorexia nervosa) but usually occurs because food is unavailable (eg, during famine or wilderness\nexposure). Secondary PEU:\n This type most commonly results from the following:\n Disorders that affect GI function: These disorders can interfere with digestion (eg, pancreatic\ninsufficiency), absorption (eg, enteritis, enteropathy), or lymphatic transport of nutrients (eg,\nretroperitoneal fibrosis, Milroy's disease).  Wasting disorders: In wasting disorders (eg, AIDS, cancer) and renal failure, catabolism causes cytokine\nexcess, resulting in undernutrition via anorexia and cachexia (wasting of muscle and fat). End-stage\nheart failure can cause cardiac cachexia, a severe form of undernutrition; mortality rate is particularly\nhigh. Factors contributing to cardiac cachexia may include passive hepatic congestion (causing\nanorexia), edema of the intestinal tract (impairing absorption), and, in advanced disease, increased O\n2\nrequirement due to anaerobic metabolism. Wasting disorders can decrease appetite or impair\nmetabolism of nutrients.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 10, 'type': 'text'}, page_content='1. What are the primary causes of primary energy undernutrition (PEU) in individuals with anorexia nervosa or during periods of fasting?\n2. How do gastrointestinal disorders like pancreatic insufficiency and enteropathy contribute to secondary PEU?\n3. What role does cardiac cachexia play in the nutritional status of patients with end-stage heart failure, and what are its implications for treatment?'), Document(id='83', metadata={'original_content': ' Conditions that increase metabolic demands: These conditions include infections, hyperthyroidism,\npheochromocytoma, other endocrine disorders, burns, trauma, surgery, and other critical illnesses. Pathophysiology\nThe initial metabolic response is decreased metabolic rate.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 10, 'type': 'text'}, page_content='1. How do infections and burns affect the metabolic demands of an individual?\n2. What role does hyperthyroidism play in increasing metabolic rate, and how can it be managed nutritionally?\n3. What are the implications of trauma and surgery on a patients nutritional status and metabolic response?'), Document(id='84', metadata={'original_content': 'To supply energy, the body first breaks down\nadipose tissue. However, later when these tissues are depleted, the body may use protein for energy,\nresulting in a negative nitrogen balance. Visceral organs and muscle are broken down and decrease in\nweight.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 10, 'type': 'text'}, page_content='1. What are the consequences of the body using protein for energy during prolonged energy depletion?  \n2. How does a negative nitrogen balance affect muscle and organ health?  \n3. What are the signs that indicate the body is breaking down adipose tissue for energy?'), Document(id='85', metadata={'original_content': 'Loss of organ weight is greatest in the liver and intestine, intermediate in the heart and kidneys,\nand least in the nervous system. Symptoms and Signs\nSymptoms of moderate PEU can be constitutional or involve specific organ systems. Apathy and irritability\nare common.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 10, 'type': 'text'}, page_content='1. What are the common symptoms associated with moderate Protein-Energy Undernutrition (PEU)?\n2. Which organ systems are most affected by the loss of organ weight in individuals with PEU?\n3. How does the severity of PEU influence the behavioral symptoms such as apathy and irritability?'), Document(id='86', metadata={'original_content': 'The patient is weak, and work capacity decreases.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 10, 'type': 'text'}, page_content='1. What nutritional deficiencies could lead to weakness and decreased work capacity in patients?\n2. How can dietary interventions improve strength and enhance work capacity in individuals experiencing these symptoms?\n3. What are the common symptoms associated with nutritional disorders that might cause weakness and reduced physical performance?'), Document(id='87', metadata={'original_content': 'Cognition and sometimes\nconsciousness are impaired. Temporary lactose deficiency and achlorhydria develop. Diarrhea is common\nand can be aggravated by deficiency of intestinal disaccharidases, especially lactase (see p. 157\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 10, 'type': 'text'}, page_content='1. What are the cognitive and consciousness-related symptoms associated with lactose deficiency and achlorhydria?\n2. How does a deficiency of intestinal disaccharidases, particularly lactase, contribute to diarrhea in individuals with this nutritional disorder?\n3. What treatment options are available to manage the symptoms of lactose deficiency and achlorhydria?'), Document(id='88', metadata={'original_content': 'Gonadal tissues atrophy. PEU can cause amenorrhea in women and loss of libido in men and women. Wasting of fat and muscle is common in all forms of PEU. In adult volunteers who fasted for 30 to 40\ndays, weight loss was marked (25% of initial weight). If starvation is more prolonged, weight loss may\nreach 50% in adults and possibly more in children. In adults, cachexia is most obvious in areas where prominent fat depots normally exist. Muscles shrink\nand bones protrude. The skin becomes thin, dry, inelastic, pale, and cold. The hair is dry and falls out\neasily, becoming sparse. Wound healing is impaired.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 10, 'type': 'text'}, page_content='1. What are the potential consequences of prolonged protein-energy undernutrition (PEU) on reproductive health in men and women?  \n2. How does starvation affect muscle mass and body fat distribution in adults compared to children?  \n3. What are the observable physical changes in the skin and hair of individuals suffering from severe nutritional disorders like PEU?  '), Document(id='89', metadata={'original_content': 'In elderly patients, risk of hip fractures and pressure\n(decubitus) ulcers increases. With acute or chronic severe PEU, heart size and cardiac output decrease; pulse slows\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 2. Undernutrition\n63', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 10, 'type': 'text'}, page_content='1. What are the potential consequences of acute or chronic severe protein-energy undernutrition (PEU) in elderly patients?\n2. How does severe protein-energy undernutrition contribute to an increased risk of hip fractures in the elderly?\n3. What interventions can be implemented to prevent pressure ulcers in elderly patients with protein-energy undernutrition?'), Document(id='90', metadata={'original_content': '[\nTable 2-3. Values Commonly Used to Grade the Severity of Protein-Energy Undernutrition]\nand BP falls. Respiratory rate and vital capacity decrease.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 11, 'type': 'text'}, page_content='1. What are the physiological symptoms associated with severe protein-energy undernutrition as indicated in the document?  \n2. How does protein-energy undernutrition affect vital signs such as blood pressure and respiratory rate?  \n3. What grading system is used to assess the severity of protein-energy undernutrition?  '), Document(id='91', metadata={'original_content': 'Body temperature falls, sometimes contributing\nto death. Edema, anemia, jaundice, and petechiae can develop. Liver, kidney, or heart failure may occur. Cell-mediated immunity is impaired, increasing susceptibility to infections. Bacterial infections (eg,\npneumonia, gastroenteritis, otitis media, UTIs, sepsis) are common in both forms of PEU. Infections result\nin release of cytokines, which cause anorexia, worsen muscle wasting, and cause a marked decrease in\nserum albumin levels. Marasmus in infants causes hunger, weight loss, growth retardation, and wasting of subcutaneous fat\nand muscle. Ribs and facial bones appear prominent.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 11, 'type': 'text'}, page_content='1. What are the common symptoms associated with protein-energy undernutrition (PEU) in infants and adults?  \n2. How does the impairment of cell-mediated immunity in PEU increase the risk of infections?  \n3. What are the potential consequences of untreated marasmus in infants?  '), Document(id='92', metadata={'original_content': 'Loose, thin skin hangs in folds. Kwashiorkor is characterized by peripheral and periorbital edema. The abdomen protrudes because\nabdominal muscles are weakened, the intestine is distended, the liver enlarges, and ascites is present. The skin is dry, thin, and wrinkled; it can become hyperpigmented and fissured and later hypopigmented,\nfriable, and atrophic.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 11, 'type': 'text'}, page_content='1. What are the primary symptoms associated with Kwashiorkor and how do they manifest in the skin and abdomen?  \n2. How does the weakening of abdominal muscles contribute to the symptoms observed in individuals with Kwashiorkor?  \n3. What are the potential skin changes that occur in patients suffering from Kwashiorkor over time?  '), Document(id='93', metadata={'original_content': 'Skin in different areas of the body may be affected at different times. The hair can\nbecome thin, reddish brown, or gray. Scalp hair falls out easily, eventually becoming sparse, but eyelash\nhair may grow excessively. Alternating episodes of undernutrition and adequate nutrition may cause the\nhair to have a dramatic "striped flag" appearance. Affected children may be apathetic but become irritable\nwhen held.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 11, 'type': 'text'}, page_content='1. What are the typical symptoms of the nutritional disorder that affects hair and skin in children?\n2. How does alternating between undernutrition and adequate nutrition contribute to the "striped flag" appearance of hair?\n3. What behavioral changes might be observed in children affected by this nutritional disorder when they are held?'), Document(id='94', metadata={'original_content': 'Total starvation is fatal in 8 to 12 wk. Thus, certain symptoms of PEU do not have time to develop. Diagnosis\n Diagnosis usually based on history\n To determine severity: BMI, serum albumin, total lymphocyte count, CD4+ count, serum transferrin\n To diagnose complications and consequences: CBC, electrolytes, BUN, glucose, Ca, Mg, phosphate\nDiagnosis can be based on history when dietary intake is markedly inadequate. The cause of inadequate\nintake, particularly in children, needs to be identified.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 11, 'type': 'text'}, page_content='1. What laboratory tests are used to assess the severity of Protein-Energy Undernutrition (PEU) in patients?\n2. How does total starvation impact the development of symptoms associated with Protein-Energy Undernutrition?\n3. What factors should be considered when diagnosing the cause of inadequate dietary intake in children with Protein-Energy Undernutrition?'), Document(id='95', metadata={'original_content': 'In children and adolescents, child abuse and\nanorexia nervosa should be considered. Physical examination findings can usually confirm the diagnosis.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 11, 'type': 'text'}, page_content='1. What physical examination findings may indicate a diagnosis of anorexia nervosa in children and adolescents?\n2. How can child abuse be differentiated from anorexia nervosa in young patients?\n3. What are the potential psychological factors contributing to the development of anorexia nervosa in children and adolescents?'), Document(id='96', metadata={'original_content': 'Laboratory tests are required if dietary\nhistory does not clearly indicate inadequate caloric intake. Measurement of serum albumin, total\nlymphocyte count, CD4+ T lymphocytes, transferrin, and response to skin antigens may help determine\nthe severity of PEU (see \nTable 2-3\n) or confirm the diagnosis in borderline cases. Many other test results\nmay be abnormal: eg, decreased levels of hormones, vitamins, lipids, cholesterol, prealbumin, insulin\ngrowth factor-1, fibronectin, and retinol-binding protein. Urinary creatine and methylhistidine levels can be\nused to gauge the degree of muscle wasting. Because protein catabolism slows, urinary urea level also\ndecreases.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 11, 'type': 'text'}, page_content='1. What laboratory tests can help confirm a diagnosis of protein-energy undernutrition (PEU) when dietary history is inconclusive?  \n2. How can urine creatine and methylhistidine levels be utilized to assess muscle wasting in patients suspected of having PEU?  \n3. What specific abnormalities in serum levels might indicate the severity of protein-energy undernutrition?  '), Document(id='97', metadata={'original_content': 'These findings rarely affect treatment. Laboratory tests are required to identify causes of suspected secondary PEU. C-reactive protein or\nsoluble interleukin-2 receptor should be measured when the cause of undernutrition \nis unclear; these\nmeasurements can help determine whether there is cytokine excess. Thyroid function tests may also be\ndone.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 11, 'type': 'text'}, page_content='1. What laboratory tests are recommended for identifying the causes of suspected secondary protein-energy undernutrition (PEU)?\n2. How can measuring C-reactive protein or soluble interleukin-2 receptor levels aid in diagnosing the underlying causes of undernutrition?\n3. When should thyroid function tests be considered in the evaluation of a patient with suspected undernutrition?'), Document(id='98', metadata={'original_content': 'Other laboratory tests can detect associated abnormalities that may require treatment. Serum\nelectrolytes, BUN, glucose, and possibly levels of Ca, Mg, and phosphate should be measured. Levels of\nserum glucose, electrolytes (especially K, occasionally Na), phosphate, Ca, and Mg are usually low. BUN\nis often low unless renal failure is present. Metabolic acidosis may be present. CBC is usually obtained;\nnormocytic anemia (usually due to protein deficiency) or microcytic anemia (due to simultaneous iron\ndeficiency) is usually present. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 2.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 11, 'type': 'text'}, page_content='1. What laboratory tests are essential for diagnosing the nutritional disorder described, and what specific abnormalities do they typically reveal?  \n2. How might low serum electrolytes and metabolic acidosis contribute to the symptoms associated with this nutritional disorder?  \n3. What treatment options are available for managing normocytic or microcytic anemia related to protein or iron deficiencies in patients with this nutritional disorder?  '), Document(id='99', metadata={'original_content': 'Undernutrition\n64', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 11, 'type': 'text'}, page_content='1. What are the primary causes of undernutrition in children?\n2. What symptoms should be monitored to identify undernutrition in adults?\n3. What treatment options are available for individuals suffering from undernutrition?'), Document(id='100', metadata={'original_content': 'Stool cultures should be obtained and checked for ova and parasites if diarrhea is severe or does not\nresolve with treatment. Sometimes urinalysis, urine culture, blood cultures, tuberculin testing, and a chest\nx-ray are used to diagnose occult infections because people with PEU may have a muted response to\ninfections. Prognosis\nChildren:\n In children, mortality varies from 5 to 40%.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 12, 'type': 'text'}, page_content="1. What diagnostic tests should be performed if a child with protein-energy undernutrition (PEU) presents with severe diarrhea that does not improve with treatment?  \n2. How does protein-energy undernutrition (PEU) affect the body's response to infections in children?  \n3. What is the range of mortality rates for children diagnosed with protein-energy undernutrition (PEU)?  "), Document(id='101', metadata={'original_content': 'Mortality rates are lower in children with mild PEU\nand those given intensive care. Death in the first days of treatment is usually due to electrolyte deficits,\nsepsis, hypothermia, or heart failure. Impaired consciousness, jaundice, petechiae, hyponatremia, and\npersistent diarrhea are ominous signs.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 12, 'type': 'text'}, page_content='1. What are the common causes of death in children undergoing treatment for mild protein-energy undernutrition (PEU) within the first days of care?  \n2. What are the ominous signs that indicate a worsening condition in children with mild PEU?  \n3. How does intensive care impact the mortality rates of children diagnosed with mild PEU?  '), Document(id='102', metadata={'original_content': 'Resolution of apathy, edema, and anorexia is a favorable sign. Recovery is more rapid in kwashiorkor than in marasmus. Long-term effects of PEU in children are not fully documented. Some children develop chronic\nmalabsorption and pancreatic insufficiency. In very young children, mild intellectual disability may develop\nand persist until at least school age. Permanent cognitive impairment may occur, depending on the\nduration, severity, and age at onset of PEU. Adults:\n In adults, PEU can result in morbidity and mortality (eg, progressive weight loss increases\nmortality rate for elderly patients in nursing homes). In elderly patients, PEU increases the risk of\nmorbidity and mortality due to surgery, infections, or other disorders.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 12, 'type': 'text'}, page_content='1. What are the signs of recovery in children suffering from kwashiorkor and marasmus?  \n2. How does protein-energy undernutrition (PEU) affect cognitive development in very young children?  \n3. What are the potential long-term health consequences of PEU in elderly patients?  '), Document(id='103', metadata={'original_content': 'Except when organ failure occurs,\ntreatment is uniformly successful. Treatment\n Usually, oral feeding\n Possibly avoidance of lactose (eg, if persistent diarrhea suggests lactose intolerance)\n Supportive care (eg, environmental changes, assistance with feeding, orexigenic drugs)\n For children, feeding delayed 24 to 48 h\nWorldwide, the most important preventive strategy is to reduce poverty and improve nutritional education\nand public health measures. Mild or moderate PEU, including brief starvation, can be treated by providing a balanced diet, preferably\norally. Liquid oral food supplements (usually lactose-free) can be used when solid food cannot be\nadequately ingested.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 12, 'type': 'text'}, page_content='1. What are the recommended treatment options for mild or moderate protein-energy undernutrition (PEU) in children?  \n2. How can lactose intolerance be managed in individuals experiencing persistent diarrhea associated with nutritional disorders?  \n3. What role do environmental changes and supportive care play in the treatment of nutritional disorders?  '), Document(id='104', metadata={'original_content': "Diarrhea often complicates oral feeding because starvation makes the GI tract more\nlikely to move bacteria into Peyer's patches, facilitating infectious diarrhea. If diarrhea persists\n(suggesting lactose intolerance), yogurt-based rather than milk-based formulas are given because people\nwith lactose intolerance can tolerate yogurt. Patients should also be given a multivitamin supplement.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 12, 'type': 'text'}, page_content='1. How does starvation affect the gastrointestinal tract in relation to bacterial movement and the risk of infectious diarrhea?  \n2. What dietary adjustments should be made for patients with diarrhea who may have lactose intolerance?  \n3. Why is it important to provide a multivitamin supplement to patients experiencing persistent diarrhea?  '), Document(id='105', metadata={'original_content': 'Severe PEU or prolonged starvation requires treatment in a hospital with a controlled diet. The first\npriority is to correct fluid and electrolyte abnormalities (see \nCh.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 12, 'type': 'text'}, page_content='1. What are the recommended methods for correcting fluid and electrolyte abnormalities in patients with severe protein-energy undernutrition (PEU) or prolonged starvation?  \n2. What are the potential complications of untreated severe PEU or prolonged starvation that may require hospitalization?  \n3. How does a controlled diet contribute to the treatment of severe PEU or prolonged starvation in a hospital setting?  '), Document(id='106', metadata={'original_content': '97\n) and treat infections. Next is to supply\nmacronutrients orally or, if necessary (eg, when swallowing is difficult), through a feeding tube, a\nnasogastric tube (usually), or a gastrostomy tube. Parenteral nutrition is indicated if malabsorption is\nsevere (see p. 23\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 12, 'type': 'text'}, page_content='1. What are the indications for using a feeding tube in the treatment of nutritional disorders?\n2. How does parenteral nutrition address severe malabsorption issues?\n3. What macronutrients are essential for oral supplementation in patients with swallowing difficulties?'), Document(id='107', metadata={'original_content': 'Other treatments may be needed to correct specific deficiencies, which may become evident as weight\nincreases. To avoid deficiencies, patients should take micronutrients at about twice the recommended\ndaily allowance (RDA) until recovery is complete. Children:\n Underlying disorders should be treated. For children with diarrhea, feeding may be delayed 24\nto 48 h to avoid making the diarrhea worse; during this interval, children require oral or IV rehydration. Feedings are given often (6 to 12 times/day) but, to avoid overwhelming the limited intestinal absorptive\ncapacity, are limited to small amounts (&lt; 100 mL). During the first week, milk-based formulas with\nsupplements added are usually given in progressively increasing amounts; after a week, the full amounts\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 2. Undernutrition\n65', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 12, 'type': 'text'}, page_content='1. What micronutrients should be taken at twice the recommended daily allowance to prevent deficiencies during recovery from undernutrition?  \n2. How should feeding be managed in children experiencing diarrhea to avoid exacerbating the condition?  \n3. What is the recommended feeding frequency and volume for children recovering from undernutrition in the initial stages of treatment?  '), Document(id='108', metadata={'original_content': "of 175 kcal/kg and 4 g of protein/kg can be given. Twice the RDA of micronutrients should be given,\nusing commercial multivitamin supplements. After 4 wk, the formula can be replaced with whole milk plus\ncod liver oil and solid foods, including eggs, fruit, meats, and yeast. Energy distribution among macronutrients should be about 16% protein, 50% fat, and 34% carbohydrate. An example is a combination of powdered cow's skimmed milk (110 g), sucrose (100 g), vegetable oil (70\ng), and water (900 mL). Many other formulas (eg, whole [full-fat] fresh milk plus corn oil and maltodextrin)\ncan be used. Milk powders used in formulas are diluted with water. Usually, supplements should be added to formulas:\n Mg 0.4 mEq/kg/day IM is given for 7 days.  B-complex vitamins at twice the RDA are given parenterally for the first 3 days, usually with vitamin A,\nphosphorus, zinc, manganese, copper, iodine, fluoride, molybdenum, and selenium.  Because absorption of oral iron is poor in children with PEU, oral or IM iron supplementation may be\nnecessary. Parents are taught about nutritional requirements.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 13, 'type': 'text'}, page_content='1. What are the recommended macronutrient distributions for a child diagnosed with protein-energy undernutrition (PEU)?\n2. How should micronutrient supplementation be managed during the treatment of protein-energy undernutrition in children?\n3. What dietary changes should be implemented after the initial 4 weeks of treatment for a child with protein-energy undernutrition?'), Document(id='109', metadata={'original_content': 'Adults:\n Underlying disorders should be treated. For example, if AIDS or cancer results in excess cytokine\nproduction, megestrol acetate or medroxyprogesterone may improve food intake. However, because\nthese drugs dramatically decrease testosterone in men (possibly causing muscle loss), testosterone\nshould be replaced. Because these drugs can cause adrenal insufficiency, they should be used only\nshort-term (&lt; 3 mo).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 13, 'type': 'text'}, page_content='1. What treatments are recommended for improving food intake in adults with nutritional disorders caused by excess cytokine production due to underlying conditions like AIDS or cancer?  \n2. How do megestrol acetate and medroxyprogesterone affect testosterone levels in men, and what are the potential consequences of this effect?  \n3. Why should megestrol acetate and medroxyprogesterone be used only for a short duration in the treatment of nutritional disorders?  '), Document(id='110', metadata={'original_content': 'In patients with functional limitations, home delivery of meals and feeding assistance are key. An orexigenic drug, such as the cannabis extract dronabinol, should be given to patients with anorexia\nwhen no cause is obvious or to patients at the end of life when anorexia impairs quality of life. An\nanabolic steroid (eg, enanthate, nandrolone, testosterone) or growth hormone can benefit patients with\ncachexia due to renal failure and possibly elderly patients (eg, by increasing lean body mass or possibly\nby improving function). Correction of PEU in adults generally resembles that in children; feedings are often limited to small\namounts.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 13, 'type': 'text'}, page_content='1. What role do home-delivered meals and feeding assistance play in managing patients with functional limitations and nutritional disorders?  \n2. In what scenarios is the use of dronabinol indicated for patients suffering from anorexia?  \n3. How can anabolic steroids or growth hormone be utilized in the treatment of cachexia in patients with renal failure or the elderly?  '), Document(id='111', metadata={'original_content': 'However, for most adults, feeding does not need to be delayed.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 13, 'type': 'text'}, page_content='1. What are the potential consequences of delaying feeding in adults with nutritional disorders?\n2. Are there specific conditions under which feeding should be delayed in adults?\n3. What are the recommended feeding protocols for adults with nutritional disorders?'), Document(id='112', metadata={'original_content': 'A commercial formula for oral\nfeeding can be used. Daily nutrient supply should be given at a rate of 60 kcal/kg and 1.2 to 2 g of\nprotein/kg. If liquid oral supplements are used with solid food, they should be given at least 1 h before\nmeals so that the amount of food eaten at the meal is not reduced. Treatment of institutionalized elderly patients with PEU requires multiple interventions:\n Environmental measures (eg, making the dining area more attractive)\n Feeding assistance\n Changes in diet (eg, use of food enhancers and caloric supplements between meals)\n Treatment of depression and other underlying disorders\n Use of orexigenics, anabolic steroids, or both\nThe long-term use of gastrostomy tube feeding is essential for patients with severe dysphagia; its use in\npatients with dementia is controversial. Increasing evidence supports the avoidance of unpalatable\ntherapeutic diets (eg, low salt, diabetic, low cholesterol) in institutionalized patients because these diets\ndecrease food intake and may cause severe PEU. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 2.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 13, 'type': 'text'}, page_content='1. What are the recommended daily nutrient requirements for patients with protein-energy undernutrition (PEU) in an institutional setting?\n2. How can environmental measures be implemented to improve food intake among elderly patients with PEU?\n3. What are the potential benefits and controversies surrounding the use of gastrostomy tube feeding in patients with dementia who experience dysphagia?'), Document(id='113', metadata={'original_content': 'Undernutrition\n66', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 13, 'type': 'text'}, page_content='1. What are the common causes of undernutrition in children and adults?\n2. What symptoms should one look for to identify undernutrition?\n3. What are the recommended treatment strategies for individuals suffering from undernutrition?'), Document(id='114', metadata={'original_content': 'Complications of treatment:\n Treatment of PEU can cause complications (refeeding syndrome),\nincluding fluid overload, electrolyte deficits, hyperglycemia, cardiac arrhythmias, and diarrhea. Diarrhea is\nusually mild and resolves; however, diarrhea in patients with severe PEU occasionally causes severe\ndehydration or death. Causes of diarrhea (eg, sorbitol used in elixir tube feedings, \nClostridium difficile\n if\nthe patient has received an antibiotic) may be correctable. Osmotic diarrhea due to excess calories is rare\nin adults and should be considered only when other causes have been excluded. Because PEU can impair cardiac and renal function, hydration can cause intravascular volume overload. Treatment decreases extra-cellular K and Mg.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 14, 'type': 'text'}, page_content='1. What are the potential complications associated with the treatment of Protein-Energy Undernutrition (PEU)?\n2. How can electrolyte deficits occur during the treatment of PEU, and what symptoms should be monitored?\n3. What factors might contribute to diarrhea in patients undergoing treatment for severe PEU?'), Document(id='115', metadata={'original_content': 'Depletion of K or Mg may cause arrhythmias. Carbohydrate metabolism that occurs during treatment stimulates insulin release, which drives phosphate\ninto cells. Hypophosphatemia can cause muscle weakness, paresthesias, seizures, coma, and\narrhythmias. Because phosphate levels can change rapidly during parenteral feeding, levels should be\nmeasured regularly. During treatment, endogenous insulin may become ineffective, leading to hyperglycemia.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 14, 'type': 'text'}, page_content='1. What are the potential symptoms of hypophosphatemia related to muscle function and neurological status?  \n2. How does carbohydrate metabolism during treatment affect insulin release and phosphate levels in the body?  \n3. Why is it important to regularly monitor phosphate levels during parenteral feeding?  '), Document(id='116', metadata={'original_content': 'Dehydration\nand hyperosmolarity can result.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 14, 'type': 'text'}, page_content='1. What are the primary causes of dehydration and hyperosmolarity in individuals with nutritional disorders?  \n2. What symptoms should one look out for that may indicate dehydration and hyperosmolarity?  \n3. What treatment options are available for managing dehydration and hyperosmolarity in affected individuals?  '), Document(id='117', metadata={'original_content': 'Fatal ventricular arrhythmias can develop, possibly caused by a\nprolonged QT interval. Carnitine Deficiency\nCarnitine deficiency results from inadequate intake of or inability to metabolize the amino acid\ncarnitine. It can cause a heterogeneous group of disorders.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 14, 'type': 'text'}, page_content='1. What are the potential causes of carnitine deficiency and how does it relate to prolonged QT interval and ventricular arrhythmias?  \n2. What symptoms are commonly associated with carnitine deficiency and how might they impact cardiac health?  \n3. What treatment options are available for individuals diagnosed with carnitine deficiency to prevent complications such as fatal ventricular arrhythmias?  '), Document(id='118', metadata={'original_content': 'Muscle metabolism is impaired,\ncausing myopathy, hypoglycemia, or cardiomyopathy. Infants typically present with\nhypoglycemic, hypoketotic encephalopathy. Most often, treatment consists of dietary L-\ncarnitine. The amino acid carnitine is required for the transport of long-chain fatty acyl coenzyme A (CoA) esters\ninto myocyte mitochondria, where they are oxidized for energy. Carnitine is obtained from foods,\nparticularly animal-based foods, and via endogenous synthesis. Causes of carnitine deficiency include the following:\n Inadequate intake (eg, due to fad diets, lack of access, or long-term TPN)\n Inability to metabolize carnitine due to enzyme deficiencies (eg, carnitine palmitoyltransferase deficiency,\nmethylmalonicaciduria, propionicacidemia, isovalericacidemia)\n Decreased endogenous synthesis of carnitine due to a severe liver disorder\n Excess loss of carnitine due to diarrhea, diuresis, or hemodialysis\n A hereditary disorder in which carnitine leaks from renal tubules\n Increased requirements for carnitine when ketosis is present or demand for fat oxidation is high (eg,\nduring a critical illness such as sepsis or major burns; after major surgery of the GI tract)\n Decreased muscle carnitine levels due to mitochondrial impairment (eg, due to use of zidovudine)\n Use of valproate\nThe deficiency may be generalized (systemic) or may affect mainly muscle (myopathic). Symptoms and Signs\nSymptoms and the age at which symptoms appear depend on the cause. Carnitine deficiency may cause\nmuscle necrosis, myoglobinuria, lipid-storage myopathy, hypoglycemia, fatty liver, and hyperammonemia\nwith muscle aches, fatigue, confusion, and cardiomyopathy. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 2.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 14, 'type': 'text'}, page_content='1. What are the potential causes of carnitine deficiency that could lead to muscle metabolism impairment and associated symptoms?  \n2. How does dietary L-carnitine treatment help manage symptoms of myopathy and hypoglycemia in infants with carnitine deficiency?  \n3. What are the signs and symptoms associated with generalized vs. myopathic carnitine deficiency?  '), Document(id='119', metadata={'original_content': 'Undernutrition\n67', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 14, 'type': 'text'}, page_content='1. What are the common causes of undernutrition in different age groups?\n2. What symptoms should one look for to identify undernutrition in children?\n3. What dietary changes or interventions are recommended for the treatment of undernutrition?'), Document(id='120', metadata={'original_content': 'Diagnosis\nIn neonates, carnitine palmitoyltransferase deficiency is diagnosed using mass spectrometry to screen\nblood. Prenatal diagnosis may be possible using amniotic villous cells. In adults, the definitive diagnosis is\nbased on acylcarnitine levels in serum, urine, and tissues (muscle and liver for systemic deficiency;\nmuscle only for myopathic deficiency). Treatment\n Avoidance of fasting and strenuous exercise\n Dietary interventions, based on cause\nCarnitine deficiency due to inadequate dietary intake, increased requirements, excess losses, decreased\nsynthesis, or (sometimes) enzyme deficiencies can be treated by giving L-carnitine 25 mg/kg po q 6 h. All patients must avoid fasting and strenuous exercise.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 15, 'type': 'text'}, page_content='1. What are the potential causes of carnitine deficiency in adults, and how do they differ from those in neonates?\n2. How is carnitine palmitoyltransferase deficiency diagnosed in both neonates and adults?\n3. What dietary interventions are recommended for patients diagnosed with carnitine palmitoyltransferase deficiency?'), Document(id='121', metadata={'original_content': 'Consuming uncooked cornstarch at bedtime\nprevents early morning hypoglycemia. Some patients require supplementation with medium-chain\ntriglycerides and essential fatty acids (eg, linoleic acid, linolenic acid).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 15, 'type': 'text'}, page_content='1. How does consuming uncooked cornstarch at bedtime help prevent early morning hypoglycemia in patients?  \n2. What role do medium-chain triglycerides and essential fatty acids play in the management of hypoglycemia?  \n3. Are there specific symptoms that indicate a patient might benefit from supplementation with essential fatty acids?'), Document(id='122', metadata={'original_content': 'Patients with a fatty acid oxidation\ndisorder require a high-carbohydrate, low-fat diet. Essential Fatty Acid Deficiency\nEssential fatty acid (EFA) deficiency is rare, occurring most often in infants fed diets deficient in\nEFAs. Signs include scaly dermatitis, alopecia, thrombocytopenia, and, in children, growth\nretardation.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 15, 'type': 'text'}, page_content='1. What are the common signs and symptoms of essential fatty acid deficiency in infants?  \n2. How can a high-carbohydrate, low-fat diet help manage fatty acid oxidation disorders?  \n3. What dietary changes can prevent essential fatty acid deficiency in infants?  '), Document(id='123', metadata={'original_content': 'Diagnosis is clinical.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 15, 'type': 'text'}, page_content='[]'), Document(id='124', metadata={'original_content': 'Dietary replenishment of EFAs reverses the deficiency. The EFAs linoleic and linolenic acid are substrates for the endogenous synthesis of other fatty acids that\nare needed for many physiologic processes, including maintaining the integrity of skin and cell\nmembranes and synthesizing prostaglandins and leukotrienes. For example, eicosapentaenoic acid and\ndocosahexaenoic acid, synthesized from EFAs, are important components of the brain and retina. For EFA deficiency to develop, dietary intake must be very low.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 15, 'type': 'text'}, page_content='1. What dietary factors contribute to the development of essential fatty acid (EFA) deficiency?  \n2. How does EFA deficiency affect the integrity of skin and cell membranes?  \n3. What role do eicosapentaenoic acid and docosahexaenoic acid play in the brain and retina, and how can their synthesis be supported?  '), Document(id='125', metadata={'original_content': "Even small amounts of EFAs can prevent\nEFA deficiency. Cow's milk has only about 25% of the linoleic acid in human milk, but when ingested in\nnormal amounts, it has enough linoleic acid to prevent EFA deficiency. Total fat intake of people in many\ndeveloping countries may be very low, but the fat is often vegetable based, with large amounts of linoleic\nacid and enough linolenic acid to prevent EFA deficiency. Babies fed a formula low in linoleic acid, such as a skim-milk formula, can develop EFA deficiency. EFA\ndeficiency used to result from long-term TPN if fat was not included. But now, most TPN solutions include\nfat emulsions to prevent EFA deficiency. In patients with fat malabsorption or increased metabolic needs\n(eg, because of surgery, multiple trauma, or burns), laboratory evidence of EFA deficiency may be\npresent without clinical signs. Dermatitis due to EFA deficiency is generalized and scaly; in infants, it can resemble congenital\nichthyosis. The dermatitis increases water loss from the skin. Diagnosis is usually clinical; however, laboratory assays are now available in large research centers. Treatment consists of dietary EFAs, reversing the deficiency. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 2.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 15, 'type': 'text'}, page_content='1. What dietary factors can contribute to EFA deficiency in infants fed formula?\n2. How can EFA deficiency manifest in patients with fat malabsorption or increased metabolic needs?\n3. What are the clinical signs and symptoms associated with EFA deficiency dermatitis?'), Document(id='126', metadata={'original_content': 'Undernutrition\n68', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 15, 'type': 'text'}, page_content='1. What are the primary causes of undernutrition in different populations?\n2. What are the common symptoms associated with undernutrition in children and adults?\n3. What treatment options are available for individuals suffering from undernutrition?'), Document(id='127', metadata={'original_content': 'Chapter 3. Nutritional Support\nIntroduction\nMany undernourished patients need nutritional support, which aims to increase lean body mass. Oral\nfeeding can be difficult for some patients with anorexia or with eating or absorption problems. Behavioral\nmeasures that sometimes enhance oral intake include the following:\n Encouraging patients to eat\n Heating or seasoning foods\n Providing favorite or strongly flavored foods\n Encouraging patients to eat small portions\n Scheduling around meals\n Assisting patients with feeding\nIf behavioral measures are ineffective, nutritional supportoral, enteral tube, or parenteral nutritionis\nindicated, except sometimes for dying or severely demented patients (see p. 25\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 16, 'type': 'text'}, page_content='1. What behavioral measures can be implemented to encourage patients with anorexia to increase their oral intake of food?  \n2. When should nutritional support be considered for patients who have difficulty with oral feeding due to eating or absorption problems?  \n3. In what situations might nutritional support not be indicated for patients who are severely demented or dying?  '), Document(id='128', metadata={'original_content': "Predicting Nutritional Requirements\nNutritional requirements are predicted so that interventions can be planned. Requirements can be\nestimated by formulas or measured by indirect calorimetry. Indirect calorimetry requires use of a metabolic\ncart (a closed rebreathing system that determines energy expenditure based on total CO\n2\n production),\nwhich requires special expertise and is not always available. Thus, total energy expenditure (TEE) and\nprotein requirements usually are estimated. Energy expenditure:\n TEE varies based on the patient's weight, activity level, and degree of metabolic\nstress (metabolic demands); TEE ranges from 25 kcal/kg/day for people who are sedentary and not under\nstress to about 40 kcal/kg/day for people who are critically ill. TEE equals the sum of\n Resting metabolic rate (RMR, or resting energy expenditure rate), which is normally about 70% of TEE\n Energy dissipated by metabolism of food (10% of TEE)\n Energy expended during physical activity (20% of TEE)\nUndernutrition can decrease RMR up to 20%. Conditions that increase metabolic stress (eg, critical\nillness, infection, inflammation, trauma, surgery) can increase RMR but rarely by &gt; 50%.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 16, 'type': 'text'}, page_content="1. How do variations in a patient's weight and activity level influence their total energy expenditure (TEE) in different nutritional disorders?  \n2. What are the potential effects of critical illness on resting metabolic rate (RMR) and total energy expenditure (TEE) in patients experiencing undernutrition?  \n3. How can indirect calorimetry provide more accurate measurements of nutritional requirements compared to estimated formulas in patients with metabolic stress?  "), Document(id='129', metadata={'original_content': 'The Mifflin-St. Jeor equation estimates RMR more precisely and with fewer errors than the commonly\nused Harris-Benedict equation, usually providing results that are within 20% of those measured by\nindirect calorimetry. The Mifflin-St. Jeor equation estimates RMR as follows:\nMen\n: kcal / day = 66 + (13.7  wt[kg]) + (5  height[cm]) - (6.8  age)\nWomen\n: kcal / day = 665 + (9.6  wt[kg]) + (1.8  height[cm]) - (4.7  age)\nTEE can be estimated by adding about 10% (for sedentary people) to about 40% (for people who are\ncritically ill) to RMR. Protein requirements:\n For healthy people, protein requirements are estimated at 0.8 g/kg/day.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 16, 'type': 'text'}, page_content='1. How can the Mifflin-St. Jeor equation be used to determine the caloric needs of a critically ill patient compared to a sedentary individual?  \n2. What are the implications of protein intake below the recommended 0.8 g/kg/day for healthy individuals?  \n3. How does the accuracy of the Mifflin-St. Jeor equation in estimating RMR impact dietary planning for individuals with nutritional disorders?  '), Document(id='130', metadata={'original_content': 'However, for patients with metabolic stress or kidney failure and for elderly patients, requirements may be\nhigher (see\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 3.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 16, 'type': 'text'}, page_content='1. How do metabolic stress and kidney failure impact nutritional requirements in patients?  \n2. What adjustments should be made to dietary plans for elderly patients experiencing metabolic stress?  \n3. What are the implications of higher nutritional requirements for patients with kidney failure when planning their treatment?  '), Document(id='131', metadata={'original_content': 'Nutritional Support\n69', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 16, 'type': 'text'}, page_content='1. What are the common causes of the nutritional disorder described in the document?  \n2. What symptoms should one look for to identify this nutritional disorder?  \n3. What treatment options are available for managing the nutritional disorder?  '), Document(id='132', metadata={'original_content': 'Table 3-1\n). Assessing Response to Nutritional Support\nThere is no gold standard to assess response. Clinicians commonly use indicators of lean body mass\nsuch as the following:\n Body mass index (BMI)\n Body composition analysis\n Body fat distribution (see pp. 11\n and \n58\n)\nNitrogen balance, response to skin antigens, muscle strength measurement, and indirect calorimetry can\nalso be used.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 17, 'type': 'text'}, page_content='1. How can body composition analysis be utilized to assess the effectiveness of nutritional support in patients with malnutrition?  \n2. What role does nitrogen balance play in evaluating the response to nutritional interventions?  \n3. In what ways can changes in muscle strength measurement indicate improvements in nutritional status?  '), Document(id='133', metadata={'original_content': '[\nTable 3-1. Estimated Adult Daily Protein Requirement]\nNitrogen balance,\n which reflects the balance between protein needs and supplies, is the difference\nbetween amount of nitrogen ingested and amount lost. A positive balance (ie, more ingested than lost)\nimplies adequate intake. Precise measurement is impractical, but estimates help assess response to\nnutritional support. Nitrogen intake is estimated from protein intake: nitrogen (g) equals protein (g)/6.25. Estimated nitrogen losses consist of urinary nitrogen losses (estimated by measuring urea nitrogen\ncontent of an accurately obtained 24-h urine collection) plus stool losses (estimated at 1 g/day if stool is\nproduced; negligible if stool is not produced) plus insensible and other unmeasured losses (estimated at\n3 g). Response to skin antigens\n, a measure of delayed hypersensitivity, often increases to normal as\nundernourished patients respond to nutritional support.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 17, 'type': 'text'}, page_content="1. How can nitrogen balance be used to assess the adequacy of protein intake in adults?  \n2. What are the implications of having a positive nitrogen balance for an individual's nutritional status?  \n3. How does nutritional support affect the response to skin antigens in undernourished patients?  "), Document(id='134', metadata={'original_content': 'However, other factors can affect response to\nskin antigens. Muscle strength\n indirectly reflects increases in lean body mass.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 17, 'type': 'text'}, page_content="1. How does muscle strength relate to lean body mass in individuals with nutritional disorders?  \n2. What factors can influence the body's response to skin antigens in the context of nutritional disorders?  \n3. Are there specific nutritional interventions that can improve muscle strength and lean body mass in patients with nutritional deficiencies?"), Document(id='135', metadata={'original_content': 'It can be measured quantitatively, by\nhand-grip dynamometry, or electrophysiologically (typically by stimulating the ulnar nerve with an\nelectrode). Levels of acute-phase reactant\n serum proteins (particularly short-lived proteins such as prealbumin\n[transthyretin], retinol-binding protein, and transferrin) sometimes correlate with improved nutritional\nstatus, but these levels correlate better with inflammatory conditions. Enteral Tube Nutrition\nEnteral tube nutrition is indicated for patients who have a functioning GI tract but cannot ingest enough\nnutrients orally because they are unable or unwilling to take oral feedings.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 17, 'type': 'text'}, page_content='1. What methods can be used to assess muscle strength in patients with nutritional disorders?  \n2. How do levels of acute-phase reactant serum proteins relate to nutritional status in the context of inflammation?  \n3. In what situations is enteral tube nutrition recommended for patients with a functioning gastrointestinal tract?  '), Document(id='136', metadata={'original_content': 'Compared with parenteral\nnutrition, enteral nutrition has the following advantages:\n Better preservation of the structure and function of the GI tract\n Lower cost\n Probably fewer complications, particularly infections\nSpecific indications\n for enteral nutrition include the following:\n Prolonged anorexia\n Severe protein-energy undernutrition\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 3. Nutritional Support\n70', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 17, 'type': 'text'}, page_content='1. What are the advantages of enteral nutrition over parenteral nutrition in patients with prolonged anorexia?  \n2. How does enteral nutrition help in preserving the structure and function of the gastrointestinal tract in cases of severe protein-energy undernutrition?  \n3. What are the potential complications associated with parenteral nutrition compared to enteral nutrition?  '), Document(id='137', metadata={'original_content': " Coma or depressed sensorium\n Liver failure\n Inability to take oral feedings due to head or neck trauma or neurologic disorders\n Critical illnesses (eg, burns) causing metabolic stress\nOther indications may include bowel preparation for surgery in seriously ill or undernourished patients,\nclosure of enterocutaneous fistulas, and small-bowel adaptation after massive intestinal resection or in\ndisorders that may cause malabsorption (eg, Crohn's disease). Procedure:\n If tube feeding is needed for  4 to 6 wk, a small-caliber, soft nasogastric or nasoenteric (eg,\nnasoduodenal) tube made of silicone or polyurethane is usually used.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 18, 'type': 'text'}, page_content='1. What nutritional interventions are recommended for patients in a coma or with a depressed sensorium who cannot take oral feedings?  \n2. How can tube feeding be utilized in patients experiencing liver failure as a result of critical illnesses?  \n3. What are the indications for using a nasogastric or nasoenteric tube in patients with bowel preparation needs prior to surgery?  '), Document(id='138', metadata={'original_content': 'If a nasal injury or deformity makes\nnasal placement difficult, an orogastric or other oroenteric tube can be placed. Tube feeding for &gt; 4 to 6 wk usually requires a gastrostomy or jejunostomy tube, placed endoscopically,\nsurgically, or radiologically. Choice depends on physician capabilities and patient preference. Jejunostomy tubes are useful for patients with contraindications to gastrostomy (eg, gastrectomy, bowel\nobstruction proximal to the jejunum). However, these tubes do not pose less risk of tracheobronchial\naspiration than gastrostomy tubes, as is often thought. Jejunostomy tubes are easily dislodged and are\nusually used only for inpatients. Feeding tubes are surgically placed if endoscopic and radiologic placement is unavailable, technically\nimpossible, or unsafe (eg, because of overlying bowel).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 18, 'type': 'text'}, page_content='1. What are the indications for using a jejunostomy tube over a gastrostomy tube in patients with nutritional disorders?\n2. What risks are associated with the use of jejunostomy tubes for enteral feeding in patients with nasal injuries?\n3. How does the placement method of feeding tubes affect the risk of tracheobronchial aspiration in patients requiring long-term nutrition support?'), Document(id='139', metadata={'original_content': 'Open or laparoscopic techniques can be used. Formulas:\n Liquid formulas commonly used include feeding modules and polymeric or other specialized\nformulas.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 18, 'type': 'text'}, page_content='1. What are the benefits of using liquid formulas in the treatment of nutritional disorders?  \n2. How do open and laparoscopic techniques differ in the management of nutritional disorders?  \n3. What types of specialized formulas are available for patients with specific nutritional needs?'), Document(id='140', metadata={'original_content': 'Feeding modules\n are commercially available products that contain a single nutrient, such as proteins,\nfats, or carbohydrates. Feeding modules may be used individually to treat a specific deficiency or\ncombined with other formulas to completely satisfy nutritional requirements. Polymeric formulas\n (including blenderized food and milk-based or lactose-free commercial formulas)\nare commercially available and generally provide a complete, balanced diet. For oral or tube feedings,\nthey are usually preferred to feeding modules. In hospitalized patients, lactose-free formulas are the most\ncommonly used polymeric formulas. However, milk-based formulas tend to taste better than lactose-free\nformulas. Patients with lactose intolerance may be able to tolerate milk-based formulas given slowly by\ncontinuous infusion. Specialized formulas\n include hydrolyzed protein or sometimes amino acid formulas, which are used for\npatients who have difficulty digesting complex proteins.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 18, 'type': 'text'}, page_content='1. What types of feeding modules are available for treating specific nutrient deficiencies in patients with nutritional disorders?  \n2. How do polymeric formulas differ from feeding modules in terms of providing a balanced diet for patients?  \n3. What considerations should be taken into account when selecting a formula for patients with lactose intolerance?  '), Document(id='141', metadata={'original_content': 'However, these formulas are expensive and\nusually unnecessary. Most patients with pancreatic insufficiency, if \ngiven enzymes, and most patients with\nmalabsorption can digest complex proteins. Other specialized formulas (eg, calorie- and protein-dense\nformulas for patients whose fluids are restricted, fiber-enriched formulas for constipated patients) may be\nhelpful. Administration:\n Patients should be sitting upright at 30 to 45 during tube feeding and for 1 to 2 h\nafterward to minimize incidence of nosocomial aspiration pneumonia and to allow gravity to help propel\nthe food. Tube feedings are given in boluses several times a day or by continuous infusion.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 18, 'type': 'text'}, page_content='1. What are the potential benefits of using specialized formulas for patients with pancreatic insufficiency or malabsorption issues?  \n2. How should patients be positioned during tube feeding to reduce the risk of aspiration pneumonia?  \n3. What are the differences between bolus and continuous infusion methods of tube feeding in patients with nutritional disorders?  '), Document(id='142', metadata={'original_content': 'Bolus feeding\nis more physiologic and may be preferred for patients with diabetes. Continuous infusion is necessary if\nboluses cause nausea.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 18, 'type': 'text'}, page_content='1. What are the advantages of bolus feeding for patients with diabetes compared to continuous infusion?  \n2. What potential side effects might occur if bolus feeding causes nausea in patients?  \n3. Under what circumstances should continuous infusion be considered over bolus feeding in diabetic patients?  '), Document(id='143', metadata={'original_content': '[\nTable 3-2. Complications of Enteral Tube Nutrition]\nFor bolus feeding, total daily volume is divided into 4 to 6 separate feedings, which are injected through\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 3. Nutritional Support\n71', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 18, 'type': 'text'}, page_content='1. What complications can arise from bolus feeding in patients receiving enteral tube nutrition?\n2. How does the total daily volume of enteral nutrition influence the risk of complications during bolus feeding?\n3. What are the recommended practices for administering bolus feedings to minimize complications in enteral tube nutrition?'), Document(id='144', metadata={'original_content': 'the tube with a syringe or infused by gravity from an elevated bag. After feedings, the tube is flushed with\nwater to prevent clogging. Nasogastric or nasoduodenal tube feeding\n often causes diarrhea initially; thus, feedings are usually\nstarted with small amounts of dilute preparations and increased as tolerated. Most formulas contain 0.5,\n1, or 2 kcal/mL.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 19, 'type': 'text'}, page_content='1. What are the initial feeding strategies for patients receiving nasogastric or nasoduodenal tube feeding to minimize diarrhea?  \n2. How should tube feedings be adjusted if a patient experiences diarrhea during nasogastric or nasoduodenal tube feeding?  \n3. What are the typical caloric concentrations found in tube feeding formulas?  '), Document(id='145', metadata={'original_content': 'Formulas with higher caloric concentration (less water per calorie) may cause decreased\ngastric emptying and thus higher gastric residuals than when more dilute formulas with the same number\nof calories are used. Initially, a 1-kcal/mL commercially prepared solution may be given undiluted at 50\nmL/h or, if patients have not been fed for a while, at 25 mL/h.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 19, 'type': 'text'}, page_content='1. How does the caloric concentration of enteral formulas affect gastric emptying in patients receiving tube feeding?  \n2. What are the potential consequences of using a 1-kcal/mL formula at a higher infusion rate on gastric residuals in critically ill patients?  \n3. In what situations should a more dilute formula be preferred over a higher caloric concentration formula to prevent complications associated with gastric residuals?  '), Document(id='146', metadata={'original_content': 'Usually, these solutions do not supply\nenough water, particularly if vomiting, diarrhea, sweating, or fever has increased water loss. Extra water\nis supplied as boluses via the feeding tube or IV. After a few days, the rate or concentration can be\nincreased as needed to meet caloric and water needs. Jejunostomy tube feeding\n requires greater dilution and smaller volumes. Feeding usually begins at a\nconcentration of  0.5 kcal/mL and a rate of 25 mL/h.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 19, 'type': 'text'}, page_content="1. What are the recommended methods to ensure adequate hydration in patients with increased water loss due to vomiting or diarrhea during tube feeding?\n2. How should the concentration and rate of jejunostomy tube feeding be adjusted over time to meet a patient's caloric and water needs?\n3. What initial concentration and feeding rate should be used when starting tube feeding for patients requiring jejunostomy?"), Document(id='147', metadata={'original_content': 'After a few days, concentrations and volumes can\nbe increased to eventually meet caloric and water needs. Usually, the maximum that can be tolerated is\n0.8 kcal/mL at 125 mL/h, providing 2400 kcal/day. Complications:\n Complications are common and can be serious (see \nTable 3-2\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 19, 'type': 'text'}, page_content='1. What are the potential complications associated with increasing caloric and water intake in patients with this nutritional disorder?  \n2. How does the maximum tolerated concentration of 0.8 kcal/mL impact the treatment plan for individuals with this nutritional disorder?  \n3. What is the recommended volume of intake per hour to meet daily caloric needs for patients affected by this nutritional disorder?  '), Document(id='148', metadata={'original_content': 'Total Parenteral Nutrition\nParenteral nutrition is by definition given IV. Partial parenteral nutrition\n supplies only part of daily nutritional requirements, supplementing oral\nintake. Many hospitalized patients are given dextrose or amino acid solutions by this method. Total parenteral nutrition\n (TPN) supplies all daily nutritional requirements. TPN can be used in the\nhospital or at home. Because TPN solutions are concentrated and can cause thrombosis of peripheral\nveins, a central venous catheter is usually required. Parenteral nutrition should not be used routinely in patients with an intact GI tract.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 19, 'type': 'text'}, page_content='1. What are the indications for using total parenteral nutrition (TPN) in patients with gastrointestinal issues?  \n2. What are the potential complications associated with the use of total parenteral nutrition (TPN)?  \n3. How does total parenteral nutrition (TPN) differ from partial parenteral nutrition in terms of nutritional delivery?  '), Document(id='149', metadata={'original_content': "Compared with enteral\nnutrition, it causes more complications, does not preserve GI tract structure and function as well, and is\nmore expensive. Indications:\n TPN may be the only feasible option for patients who do not have a functioning GI tract or\nwho have disorders requiring complete bowel rest, such as the following:\n Some stages of Crohn's disease or ulcerative colitis\n Bowel obstruction\n Certain pediatric GI disorders (eg, congenital GI anomalies, prolonged diarrhea regardless of its cause)\n Short bowel syndrome due to surgery\nNutritional content:\n TPN requires water (30 to 40 mL/kg/day), energy (30 to 60 kcal/kg/day, depending\non energy expenditure), amino acids (1 to 2.0 g/kg/day, depending on the degree of catabolism), essential\nfatty acids, vitamins, and minerals (see\nTable 3-3\n). Children who need TPN may have different fluid requirements and need more energy (up to\n120 kcal/kg/day) and amino acids (up to 2.5 or 3.5 g/kg/day). Basic TPN solutions are prepared using sterile techniques, usually in liter batches according to standard\nformulas. Normally, 2 L/day of the standard solution is needed.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 19, 'type': 'text'}, page_content='1. What are the primary indications for using total parenteral nutrition (TPN) in patients with gastrointestinal disorders?  \n2. How does total parenteral nutrition (TPN) compare to enteral nutrition in terms of complications and preservation of GI tract function?  \n3. What are the specific nutritional requirements for children receiving total parenteral nutrition (TPN) compared to adults?  '), Document(id='150', metadata={'original_content': 'Solutions may be modified based on\nlaboratory results, underlying disorders, hypermetabolism, or other factors. Most calories are supplied as carbohydrate. Typically, about 4 to 5 mg/kg/day of dextrose is given. Standard solutions contain up to about 25% dextrose, but the amount and concentration depend on other\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 3. Nutritional Support\n72', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 19, 'type': 'text'}, page_content='1. What factors should be considered when determining the appropriate dextrose concentration for a patient receiving nutritional support?  \n2. How do underlying disorders influence the caloric requirements and solutions for patients with nutritional disorders?  \n3. In cases of hypermetabolism, how might the administration of dextrose differ from standard nutritional solutions?  '), Document(id='151', metadata={'original_content': 'factors, such as metabolic needs and the proportion of caloric needs that are supplied by lipids. Commercially available lipid emulsions are often added to supply essential fatty acids and triglycerides;\n20 to 30% of total calories are usually supplied as lipids. However, withholding lipids and their calories\nmay help obese patients mobilize endogenous fat stores, increasing insulin sensitivity. Solutions:\n Many solutions are commonly used.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 20, 'type': 'text'}, page_content="1. How do lipid emulsions impact the metabolic needs of patients and their caloric intake?  \n2. In what ways can withholding lipids from a patient's diet improve insulin sensitivity in obese individuals?  \n3. What are the essential fatty acids and triglycerides provided by commercially available lipid emulsions, and why are they important for nutritional treatment?  "), Document(id='152', metadata={'original_content': "Electrolytes can be added to meet the patient's needs. Solutions vary depending on other disorders present and patient age, as for the following:\n For renal insufficiency not being treated with dialysis or for liver failure: Reduced protein content and a\nhigh percentage of essential amino acids\n For heart or kidney failure: Limited volume (liquid) intake\n \nFor respiratory failure: A lipid emulsion that provides most of nonprotein calories to minimize CO\n2\nproduction by carbohydrate metabolism\n For neonates: Lower dextrose concentrations (17 to 18%)\nBeginning TPN administration:\n Because the central venous catheter needs to remain in place for a\nlong time, strict sterile technique must be used during insertion and maintenance. The TPN line should\nnot be used for any other purpose.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 20, 'type': 'text'}, page_content='1. What specific dietary modifications are recommended for patients with renal insufficiency who are not on dialysis?\n2. How does the management of total parenteral nutrition (TPN) differ for patients with heart failure compared to those with liver failure?\n3. What precautions should be taken when administering TPN to neonates to ensure their safety and nutritional needs are met?'), Document(id='153', metadata={'original_content': 'External tubing should be changed every 24 h with the first bag of the\nday. In-line filters have not been shown to decrease complications. Dressings should be kept sterile and\nare usually changed every 48 h using strict sterile techniques. If TPN is given outside the hospital,\npatients must be taught to recognize symptoms of infection, and qualified home nursing must be\narranged. The solution is started slowly at 50% of the calculated requirements, using 5% dextrose to make up the\nbalance of fluid requirements. Energy and nitrogen should be given simultaneously. The amount of\nregular insulin given (added directly to the TPN solution) depends on the plasma glucose level; if the\nlevel is normal and the final solution contains 25% dextrose, the usual starting dose is 5 to 10 units of\nregular insulin/L of TPN fluid. Monitoring:\n Progress should be followed on a flowchart.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 20, 'type': 'text'}, page_content="1. What are the recommended practices for changing external tubing and dressings in patients receiving TPN to minimize infection risk?  \n2. How should insulin be adjusted in a TPN solution based on the patient's plasma glucose levels?  \n3. What steps should be taken to educate patients receiving TPN at home about recognizing symptoms of infection?  "), Document(id='154', metadata={'original_content': 'An interdisciplinary nutrition team, if available,\nshould monitor patients. Weight, CBC, electrolytes, and BUN should be monitored often (eg, daily for\ninpatients). Plasma glucose should be monitored every 6 h until patients and glucose levels become\nstable. Fluid intake and output should be monitored continuously. When patients become stable, blood\ntests can be done much less often. Liver function tests should be done. Plasma proteins (eg, serum albumin, possibly transthyretin or retinol-\nbinding protein), PT, plasma and urine osmolality, and Ca, Mg, and phosphate should be measured\ntwice/wk. Changes in transthyretin and retinol-binding protein reflect overall clinical status rather than\nnutritional status alone. If possible, blood tests should not be done during glucose infusion.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 20, 'type': 'text'}, page_content='1. What specific laboratory tests should be monitored daily for inpatients experiencing a nutritional disorder?\n2. How frequently should plasma glucose levels be monitored in patients until they become stable?\n3. What indicators should be assessed to evaluate the overall clinical status of patients with nutritional disorders?'), Document(id='155', metadata={'original_content': 'Full nutritional\nassessment (including BMI calculation and anthropometric measurementssee pp. 11\n and \n58\n) should be\nrepeated at 2-wk intervals.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 20, 'type': 'text'}, page_content='1. How can regular BMI calculations and anthropometric measurements help monitor the progress of a nutritional disorder over time?  \n2. What specific anthropometric measurements are most indicative of nutritional deficiencies in patients?  \n3. What are the potential symptoms of nutritional disorders that should be assessed during a full nutritional evaluation?  '), Document(id='156', metadata={'original_content': 'Complications:\n About 5 to 10% of patients have complications related to central venous access.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 20, 'type': 'text'}, page_content='1. What are the potential complications associated with central venous access in nutritional disorder patients?  \n2. How frequently do complications arise in patients receiving central venous access for nutritional support?  \n3. What measures can be taken to minimize complications related to central venous access in patients with nutritional disorders?  '), Document(id='157', metadata={'original_content': '[\nTable 3-3. Basic Adult Daily Requirements for Total Parenteral Nutrition]\nCatheter-related sepsis occurs in about  50% of patients. Glucose abnormalities (hyperglycemia or\nhypoglycemia) or liver dysfunction occurs in &gt; 90% of patients.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 20, 'type': 'text'}, page_content='1. What are the potential complications associated with catheter use in patients receiving total parenteral nutrition?\n2. How do glucose abnormalities manifest in patients undergoing total parenteral nutrition?\n3. What treatment options are available for managing liver dysfunction in patients on total parenteral nutrition?'), Document(id='158', metadata={'original_content': 'Glucose abnormalities\n are common. Hyperglycemia can be avoided by monitoring plasma glucose\noften, adjusting the insulin dose in the TPN solution and giving subcutaneous insulin as needed. Hypoglycemia can be precipitated by suddenly stopping constant concentrated dextrose infusions. Treatment depends on the degree of hypoglycemia. Short-term hypoglycemia may be reversed with 50%\ndextrose IV; more prolonged hypoglycemia may require infusion of 5 or 10% dextrose for 24 h before\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 3. Nutritional Support\n73', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 20, 'type': 'text'}, page_content='1. What are the recommended methods for monitoring and managing hyperglycemia in patients receiving TPN (Total Parenteral Nutrition)?\n2. How can sudden cessation of concentrated dextrose infusions lead to hypoglycemia, and what are the symptoms to watch for?\n3. What are the treatment options for short-term versus prolonged hypoglycemia in patients?'), Document(id='159', metadata={'original_content': 'resuming TPN via the central venous catheter. Hepatic complications\n include liver dysfunction, painful hepatomegaly, and hyperammonemia. They can\ndevelop at any age but are most common among infants, particularly premature ones (whose liver is\nimmature).  Liver dysfunction may be transient, evidenced by increased transaminases, bilirubin, and alkaline\nphosphatase; it commonly occurs when TPN is started. Delayed or persistent elevations may result\nfrom excess amino acids.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 21, 'type': 'text'}, page_content='1. What are the common hepatic complications associated with resuming TPN via a central venous catheter in infants?\n2. How can liver dysfunction manifest in patients receiving TPN, and what laboratory values indicate its presence?\n3. What factors contribute to the development of hyperammonemia in patients on TPN?'), Document(id='160', metadata={'original_content': 'Pathogenesis is unknown, but cholestasis and inflammation may contribute. Progressive fibrosis occasionally develops. Reducing protein delivery may help.  Painful hepatomegaly suggests fat accumulation; carbohydrate delivery should be reduced.  Hyperammonemia can develop in infants, causing lethargy, twitching, and generalized seizures. Arginine\nsupplementation at 0.5 to 1.0 mmol/kg/day can correct it. If infants develop any hepatic complication, limiting amino acids to 1.0 g/kg/day may be necessary. Abnormalities of serum electrolytes and minerals\n should be corrected by modifying subsequent\ninfusions or, if correction is urgently required, by beginning appropriate peripheral vein infusions.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 21, 'type': 'text'}, page_content='1. What are the potential contributing factors to the pathogenesis of the nutritional disorder described, particularly regarding cholestasis and inflammation?  \n2. How can arginine supplementation help manage hyperammonemia in infants, and what is the recommended dosage?  \n3. What dietary modifications should be made for infants experiencing painful hepatomegaly and potential hepatic complications?  '), Document(id='161', metadata={'original_content': 'Vitamin\nand mineral deficiencies are rare when solutions are given correctly. Elevated BUN may reflect\ndehydration, which can be corrected by giving free water as 5% dextrose via a peripheral vein. Volume overload\n (suggested by &gt; 1 kg/day weight gain) may occur when patients have high daily\nenergy requirements and thus require large fluid volumes. Metabolic bone disease\n, or bone demineralization (osteoporosis or osteomalacia), develops in some\npatients given TPN for &gt; 3 mo.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 21, 'type': 'text'}, page_content='1. What are the potential consequences of prolonged total parenteral nutrition (TPN) on bone health?\n2. How can dehydration be identified and addressed in patients receiving TPN?\n3. What factors might contribute to volume overload in patients with high daily energy requirements on TPN?'), Document(id='162', metadata={'original_content': 'The mechanism is unknown. Advanced disease can cause severe\nperiarticular, lower-extremity, and back pain. Temporarily or permanently stopping TPN is the only known\ntreatment. Adverse reactions to lipid emulsions\n (eg, dyspnea, cutaneous allergic reactions, nausea, headache,\nback pain, sweating, dizziness) are uncommon but may occur early, particularly if lipids are given at &gt; 1.0\nkcal/kg/h. Temporary hyperlipidemia may occur, particularly in patients with kidney or liver failure;\ntreatment is usually not required. Delayed adverse reactions to lipid emulsions include hepatomegaly, mild\nelevation of liver enzymes, splenomegaly, thrombocytopenia, leukopenia, and, especially in premature\ninfants with respiratory distress syndrome, pulmonary function abnormalities. Temporarily or permanently\nslowing or stopping lipid emulsion infusion may prevent or minimize these adverse reactions. Gallbladder complications\n include cholelithiasis, gallbladder sludge, and cholecystitis. These\ncomplications can be caused or worsened by prolonged gallbladder stasis. Stimulating contraction by\nproviding about 20 to 30% of calories as fat and stopping glucose infusion several hours a day is helpful.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 21, 'type': 'text'}, page_content='1. What are the potential adverse reactions to lipid emulsions used in total parenteral nutrition (TPN), and how can they be minimized?\n2. How can gallbladder complications associated with prolonged gallbladder stasis be prevented in patients receiving TPN?\n3. What symptoms might indicate advanced disease related to the nutritional disorder described, and what is the recommended treatment approach?'), Document(id='163', metadata={'original_content': 'Oral or enteral intake also helps.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 21, 'type': 'text'}, page_content='1. What role does oral or enteral intake play in the management of the nutritional disorder?  \n2. What are the potential symptoms that indicate the need for enhanced oral or enteral intake in patients?  \n3. How can oral or enteral intake be adjusted to improve nutritional outcomes for individuals with this disorder?'), Document(id='164', metadata={'original_content': 'Treatment with metronidazole, ursodeoxycholic acid, phenobarbital, or\ncholecystokinin helps some patients with cholestasis. Nutritional Support for Dying or Severely Demented Patients\nAnorexia or loss of appetite is common among dying patients (see p.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 21, 'type': 'text'}, page_content='1. What medications are commonly used to treat cholestasis and how do they work?\n2. How does anorexia manifest in dying or severely demented patients?\n3. What nutritional support options are available for patients experiencing appetite loss due to cholestasis?'), Document(id='165', metadata={'original_content': '3485\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 21, 'type': 'text'}, page_content='[]'), Document(id='166', metadata={'original_content': 'Behavioral measures (eg,\nusing flexible feeding schedules, feeding slowly, giving small portions or favorite or strongly flavored\nfoods) can often increase oral intake. A small amount of a favorite alcoholic drink, given 30 min before\nmeals, may also help. Certain antidepressants, megestrol acetate, and dronabinol may stimulate appetite. Metoclopramide enhances gastric emptying, but it may take 1 to 2 wk to reach peak effectiveness. Advanced dementia eventually leads to inability to eat; sometimes affected patients are given tube\nfeedings.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 21, 'type': 'text'}, page_content='1. What behavioral strategies can be employed to increase oral intake in individuals with nutritional disorders?  \n2. How can medications like megestrol acetate and dronabinol be used to stimulate appetite in patients?  \n3. What are the potential benefits of using tube feedings for patients with advanced dementia who can no longer eat?  '), Document(id='167', metadata={'original_content': 'However, there is no convincing evidence that tube feedings prolong life, provide comfort,\nimprove function, or prevent complications (eg, aspiration, pressure ulcers). Tube feedings and parenteral nutrition cause discomfort and are usually not indicated for patients who\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 3. Nutritional Support\n74', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 21, 'type': 'text'}, page_content='1. What are the potential complications associated with tube feedings and parenteral nutrition in patients who do not require them?  \n2. How does the discomfort caused by tube feedings impact the quality of life for patients?  \n3. In what situations might tube feedings be considered unnecessary or contraindicated for patients?  '), Document(id='168', metadata={'original_content': 'are dying or too demented to eat. Forgoing nutritional support may be difficult for family members to\naccept, but they should understand that patients are usually more comfortable eating and drinking as they\nchoose. Sips of water and easy-to-swallow foods may be useful. Supportive care, including good oral\nhygiene (eg, brushing the teeth, moistening the oral cavity with swabs and ice chips as needed, applying\nlip salve), can physically and psychologically comfort the patients and the family members who provide\nthe care. Counseling may help family members who are dealing with anxieties about whether to use invasive\nnutritional support.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 22, 'type': 'text'}, page_content='1. What are the recommended supportive care measures for patients who are unable to eat due to severe dementia or terminal illness?\n2. How can family members manage their anxieties about forgoing invasive nutritional support for a loved one in a deteriorating condition?\n3. What types of easy-to-swallow foods and drinks can be provided to patients who are still able to consume them but have difficulty eating?'), Document(id='169', metadata={'original_content': 'The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 3. Nutritional Support\n75', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 22, 'type': 'text'}, page_content='1. What are the common causes of malnutrition as outlined in the Merck Manual of Diagnosis &amp; Therapy?\n2. What symptoms should clinicians look for when diagnosing nutritional deficiencies?\n3. What treatment options are recommended for patients suffering from severe malnutrition?'), Document(id='170', metadata={'original_content': 'Chapter 4. Vitamin Deficiency, Dependency, and Toxicity\nIntroduction\nVitamins may be fat soluble (vitamins A, D, E, and K) or water soluble (B vitamins and vitamin C). The B\nvitamins include biotin, folate, niacin, pantothenic acid, riboflavin (B\n2\n), thiamin (B\n1\n), B\n6\n (eg, pyridoxine),\nand B\n12\n (cobalamins). For dietary requirements, sources, functions, effects of deficiencies and toxicities,\nblood levels, and usual therapeutic dosages for vitamins, see\nTables 4-1\n and\n4-2\n.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 23, 'type': 'text'}, page_content='1. What are the symptoms and health effects associated with a deficiency of vitamin B12 in the body?  \n2. How can excessive intake of vitamin A lead to toxicity, and what are the associated symptoms?  \n3. What dietary sources are recommended to prevent folate deficiency, and what are the potential consequences of this deficiency?  '), Document(id='171', metadata={'original_content': 'Dietary requirements for vitamins (and other nutrients) are expressed as daily recommended intake (DRI). There are 3 types of DRI:\n \nRecommended daily allowance (RDA):\n RDAs are set to meet the needs of 97 to 98% of healthy\npeople.  \nAdequate intake (AI):\n When data to calculate an RDA are insufficient, AIs are based on observed or\nexperimentally determined estimates of nutrient intake by healthy people.  \nTolerable upper intake level (UL):\n ULs are the largest amount of a nutrient that most adults can\ningest daily without risk of adverse health effects. In developed countries, vitamin deficiencies result mainly from poverty, food faddism, drugs (see p.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 23, 'type': 'text'}, page_content='1. What are the daily recommended intake levels for essential vitamins and how do they differ between RDA, AI, and UL?  \n2. How can poverty contribute to vitamin deficiencies in developed countries?  \n3. What are the potential health risks associated with exceeding the tolerable upper intake level of certain vitamins?  '), Document(id='172', metadata={'original_content': '7\n and\nTable 4-3\n), alcoholism, or prolonged and inadequately supplemented parenteral feeding. Mild vitamin\ndeficiency is common among frail and institutionalized elderly people who have protein-energy\nundernutrition. In developing countries, deficiencies can result from lack of access to nutrients.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 23, 'type': 'text'}, page_content='1. What are the common causes of vitamin deficiency in frail and institutionalized elderly individuals?  \n2. How does prolonged and inadequately supplemented parenteral feeding contribute to nutritional disorders?  \n3. What are the potential consequences of vitamin deficiency in developing countries?  '), Document(id='173', metadata={'original_content': 'Deficiencies of water-soluble vitamins (except vitamin B\n12\n) may develop after weeks to months of\nundernutrition. Deficiencies of fat-soluble vitamins and of vitamin B\n12\n take &gt; 1 yr to develop because the\nbody stores them in relatively large amounts. Intake of vitamins sufficient to prevent classic vitamin\ndeficiencies (like scurvy or beriberi) may not be adequate for optimum health. This area remains one of\ncontroversy and active research. Vitamin dependency results from a genetic defect involving metabolism of a vitamin. In some cases,\nvitamin doses as high as 1000 times the DRI improve function of the altered metabolic pathway. Vitamin\ntoxicity (hypervitaminosis) usually results from taking megadoses of vitamin A, D, C, B\n6\n, or niacin. Because many people eat irregularly, foods alone may provide suboptimal amounts of some vitamins.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 23, 'type': 'text'}, page_content='1. What are the potential health effects of prolonged undernutrition leading to deficiencies in water-soluble vitamins?\n2. How does vitamin dependency due to genetic defects affect the metabolism of certain vitamins in the body?\n3. What are the signs and symptoms of vitamin toxicity resulting from excessive intake of fat-soluble vitamins?'), Document(id='174', metadata={'original_content': 'In\nthese cases, the risk of certain cancers or other disorders may be increased.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 23, 'type': 'text'}, page_content='1. What nutritional deficiencies are linked to an increased risk of certain cancers?  \n2. How can dietary changes mitigate the risk of disorders associated with nutrient imbalances?  \n3. What are the symptoms that may indicate a nutritional disorder leading to higher cancer risk?  '), Document(id='175', metadata={'original_content': 'Because of this risk, routine\ndaily multivitamin supplements are sometimes recommended. Biotin and Pantothenic Acid\nBiotin acts as a coenzyme for carboxylation reactions essential to fat and carbohydrate metabolism. Adequate intake for adults is 30 \n\ng/day. Pantothenic acid is widely distributed in foods; it is an essential\ncomponent of coenzyme A. Adults probably require about 5 mg/day. A beneficial role for pantothenic acid\nsupplementation in lipid metabolism, RA, or athletic performance remains unproved. Isolated deficiency of\nbiotin or pantothenic acid virtually never occurs. Folate\nFolate (folic acid) is now added to enriched grain foods in the US. Folate is also plentiful in various plant\nfoods and meats, but its bioavailability is greater when it is in supplements\n[\nTable 4-1. Recommended Daily Intakes for Vitamins]\nor enriched foods than when it occurs naturally in food.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 23, 'type': 'text'}, page_content='1. What are the recommended daily intakes of biotin and pantothenic acid for adults, and what roles do they play in metabolism?  \n2. How does the bioavailability of folate differ between natural food sources and supplements or enriched foods?  \n3. What are the potential benefits of routine daily multivitamin supplementation in relation to the risk of nutritional deficiencies?  '), Document(id='176', metadata={'original_content': 'The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 23, 'type': 'text'}, page_content='1. What are the common causes of vitamin D deficiency and how can it be diagnosed?  \n2. What are the key symptoms associated with iron deficiency anemia?  \n3. What treatment options are available for individuals suffering from scurvy?'), Document(id='177', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n76', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 23, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiency disorders?  \n2. How can excessive intake of vitamins lead to toxicity, and what are the potential health consequences?  \n3. What treatment options are available for individuals suffering from vitamin dependency?  '), Document(id='178', metadata={'original_content': 'Folates are involved in RBC maturation and synthesis of purines and pyrimidines. They are required for\ndevelopment of the fetal nervous system. Absorption occurs in the duodenum and upper jejunum. Enterohepatic circulation of folate occurs.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 24, 'type': 'text'}, page_content='1. What role do folates play in the maturation of red blood cells and synthesis of nucleotides?  \n2. How does folate deficiency affect fetal nervous system development?  \n3. What are the implications of impaired absorption of folates in the duodenum and upper jejunum?  '), Document(id='179', metadata={'original_content': 'Folate supplements\n[\nTable 4-2. Sources, Functions, and Effects of Vitamins]\ndo not protect against coronary artery disease or stroke (by lowering homocysteine levels); their role in\nreducing the risk of various cancers is unclear. The upper limit for folate intake is 1000 \n\ng; higher doses\n(up to 5 mg) are recommended for women who have had a baby with a neural tube defect. Folate is\nessentially nontoxic.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 24, 'type': 'text'}, page_content='1. What is the recommended upper limit for folate intake for the general population and for women who have had a baby with a neural tube defect?  \n2. How does folate supplementation influence the risk of coronary artery disease and stroke?  \n3. What are the potential effects of folate on cancer risk according to current research?  '), Document(id='180', metadata={'original_content': 'Folate Deficiency\nFolate deficiency is common. It may result from inadequate intake, malabsorption, or use of various drugs. Deficiency causes megaloblastic anemia (indistinguishable from that due to vitamin B\n12\n deficiency). Maternal deficiency increases the risk of neural tube birth defects.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 24, 'type': 'text'}, page_content='1. What are the common causes of folate deficiency?  \n2. How does folate deficiency contribute to the development of megaloblastic anemia?  \n3. What are the potential risks associated with maternal folate deficiency during pregnancy?  '), Document(id='181', metadata={'original_content': 'Diagnosis requires laboratory testing\nto confirm. Measurement of neutrophil hypersegmentation is sensitive and readily available. Treatment\nwith oral folate is usually successful.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 24, 'type': 'text'}, page_content='1. What laboratory tests are necessary to confirm the diagnosis of neutrophil hypersegmentation?  \n2. What are the common symptoms associated with neutrophil hypersegmentation?  \n3. How effective is oral folate in treating neutrophil hypersegmentation?  '), Document(id='182', metadata={'original_content': 'Etiology and Pathophysiology\nThe most common causes are inadequate intake (usually in patients with undernutrition or alcoholism),\nincreased demand (eg, due to pregnancy or breastfeeding), and impaired absorption (eg, in tropical\nsprue, due to certain drugs). Deficiency can also result from inadequate bioavailability and increased\nexcretion (see\nTable 4-4\n). Prolonged cooking destroys folate, predisposing to inadequate intake. Intake is sometimes barely\nadequate (eg, in alcoholics). Liver stores provide only a several-month supply. Alcohol interferes with folate absorption, metabolism, renal excretion, and enterohepatic reabsorption, as\nwell as intake. 5-Fluorouracil, metformin, methotrexate, phenobarbital, phenytoin, sulfasalazine,\ntriamterene, and trimethoprim impair folate metabolism. In the US, many dietary staples (eg, cereals, grain products) are routinely enriched with folate, tending to\nreduce risk of deficiency.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 24, 'type': 'text'}, page_content='1. What are the common causes of folate deficiency in individuals with undernutrition or alcoholism?  \n2. How does prolonged cooking affect the bioavailability of folate in foods?  \n3. What medications are known to impair folate metabolism and potentially lead to deficiency?  '), Document(id='183', metadata={'original_content': '[\nTable 4-3. Potential Vitamin-Drug Interactions]\nSymptoms and Signs\nFolate deficiency may cause glossitis, diarrhea, depression, and confusion. Anemia may develop\ninsidiously and, because of compensatory mechanisms, be more severe than symptoms suggest.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 24, 'type': 'text'}, page_content="1. What symptoms are associated with folate deficiency, and how can they affect a patient's quality of life?  \n2. How can the presence of glossitis in a patient indicate a potential folate deficiency?  \n3. What are the compensatory mechanisms in anemia that may cause the condition to be more severe than the symptoms suggest?"), Document(id='184', metadata={'original_content': 'Folate deficiency during pregnancy increases the risk of fetal neural tube defects and perhaps other brain\ndefects (see p. 2992\n). Diagnosis\n CBC and serum vitamin B\n12\n and folate levels\nCBC may indicate megaloblastic anemia indistinguishable from that of vitamin B\n12\n deficiency. If serum\nfolate is &lt; 3 \n\ng/L or ng/mL (&lt; 7 nmol/L), deficiency is likely.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 24, 'type': 'text'}, page_content='1. What are the potential consequences of folate deficiency during pregnancy on fetal development?  \n2. How can folate deficiency be diagnosed and what laboratory tests are commonly used?  \n3. What are the differences in symptoms between folate deficiency and vitamin B12 deficiency in pregnant women?  '), Document(id='185', metadata={'original_content': 'Serum folate reflects folate status unless\nintake has recently increased or decreased. If intake has changed, erythrocyte (RBC) folate level better\nreflects tissue stores. A level of &lt; 140 \n\ng/L or ng/mL (&lt; 305 nmol/L) indicates inadequate status. Also, an\nincrease in the homocysteine level suggests tissue folate deficiency (but the level is also affected by\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n77', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 24, 'type': 'text'}, page_content='1. What serum folate level indicates inadequate folate status, and how does it relate to erythrocyte folate levels?  \n2. How does an increase in homocysteine levels correlate with tissue folate deficiency?  \n3. In what situations would erythrocyte folate levels be a more accurate indicator of folate status than serum folate levels?  '), Document(id='186', metadata={'original_content': 'vitamin B\n12\n and vitamin B\n6\n levels, renal insufficiency, and genetic factors). A normal methylmalonic acid\n(MMA) level may differentiate folate deficiency from vitamin B\n12\n deficiency because MMA levels rise in\nvitamin B\n12\n deficiency but not in folate deficiency. Treatment\n Supplemental oral folate\nFolate 400 to 1000 \n\ng po once/day replenishes tissues and is usually successful even if deficiency has\nresulted from malabsorption.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 25, 'type': 'text'}, page_content='1. How can methylmalonic acid levels be used to differentiate between vitamin B12 deficiency and folate deficiency?  \n2. What role do renal insufficiency and genetic factors play in the development of vitamin B12 and B6 deficiencies?  \n3. What is the recommended dosage of supplemental oral folate for treating folate deficiency due to malabsorption?  '), Document(id='187', metadata={'original_content': 'The normal requirement is 400 \n\ng/day.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 25, 'type': 'text'}, page_content='1. What are the potential causes of a deficiency in the nutrient that has a normal requirement of 400 g/day?  \n2. What symptoms might indicate that an individual is not meeting their daily requirement of 400 g of the nutrient?  \n3. What treatment options are available for someone with a deficiency in the nutrient that requires 400 g/day?'), Document(id='188', metadata={'original_content': '[\nTable 4-4. Causes of Folate Deficiency]\n(CAUTION: \nIn patients with megaloblastic anemia, vitamin B\n12\n deficiency must be ruled out before\ntreating with folate. If vitamin B\n12\n deficiency is present, folate supplementation can alleviate the\nanemia but does not reverse and may even worsen neurologic deficits\n.) For pregnant women, the\nrecommended daily allowance (RDA) is 600 \n\ng/day. For women who have had a fetus or infant with a\nneural tube defect, the recommended dose is 1000 to 5000 \n\ng/day.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 25, 'type': 'text'}, page_content='1. What are the potential consequences of treating megaloblastic anemia with folate if vitamin B12 deficiency is present?  \n2. What is the recommended daily allowance of folate for pregnant women, and how does it differ for those with a history of neural tube defects?  \n3. What are the signs or symptoms of folate deficiency that may indicate the need for supplementation?  '), Document(id='189', metadata={'original_content': 'Niacin\nNiacin (nicotinic acid, nicotinamide) derivatives include nicotinamide adenine dinucleotide (NAD) and\nnicotinamide adenine dinucleotide phosphate (NADP), which are coenzymes in oxidation-reduction\nreactions.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 25, 'type': 'text'}, page_content='1. What are the primary functions of niacin in the body, particularly in relation to coenzymes like NAD and NADP?\n2. What nutritional deficiencies can lead to niacin-related disorders, and what are the common causes of such deficiencies?\n3. What are the potential symptoms associated with niacin deficiency in individuals?'), Document(id='190', metadata={'original_content': 'They are vital in cell metabolism. Because dietary tryptophan can be metabolized to niacin,\nfoods rich in tryptophan (eg, dairy products) can compensate for inadequate dietary niacin. Niacin Deficiency\nDietary niacin deficiency (causing pellagra) is uncommon in developed countries. Clinical\nmanifestations include the "three Ds": localized pigmented rash (dermatitis); gastroenteritis\n(diarrhea); and widespread neurologic deficits, including cognitive decline (dementia). Diagnosis is usually clinical, and dietary supplementation (oral or, if needed, IM) is usually\nsuccessful. Etiology\nPrimary deficiency results from extremely inadequate intake of both niacin and tryptophan, which usually\noccurs in areas where maize (Indian corn) constitutes a substantial part of the diet. Bound niacin, found in\nmaize, is not assimilated in the GI tract unless it has been previously treated with alkali, as when tortillas\nare prepared. Corn protein is also deficient in tryptophan. The high incidence of pellagra in India among\npeople who eat millet with a high leucine content has led to the hypothesis that amino acid imbalance may\ncontribute to deficiency. Deficiencies of protein and many B vitamins commonly accompany primary niacin\ndeficiency.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 25, 'type': 'text'}, page_content='1. What are the clinical manifestations of niacin deficiency, and how do they relate to the "three Ds"?\n2. How can dietary tryptophan help prevent niacin deficiency in individuals with inadequate dietary niacin?\n3. What dietary factors contribute to the primary deficiency of niacin, particularly in regions where maize is a staple food?'), Document(id='191', metadata={'original_content': 'Secondary deficiency may be due to diarrhea, cirrhosis, or alcoholism. Pellagra also may occur in\ncarcinoid syndrome (tryptophan is diverted to form 5-hydroxytryptophan and serotonin) and in Hartnup\ndisease (absorption of tryptophan by the intestine and kidneys is defective). Symptoms and Signs\nPellagra is characterized by skin, mucous membrane, CNS, and GI symptoms. Advanced pellagra can\ncause a symmetric photosensitive rash, stomatitis, glossitis, diarrhea, and mental aberrations. Symptoms\nmay appear alone or in combination.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 25, 'type': 'text'}, page_content='1. What are the potential causes of secondary deficiency leading to pellagra?\n2. What are the common symptoms and signs associated with advanced pellagra?\n3. How does carcinoid syndrome contribute to the development of pellagra?'), Document(id='192', metadata={'original_content': 'Skin symptoms\n include several types of lesions, which are usually bilaterally symmetric. The distribution\nof lesionsat pressure points or sun-exposed skinis more pathognomonic than the form of the lesions. Lesions can develop in a glovelike distribution on the hands (pellagrous glove) or in a boot-shaped\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n78', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 25, 'type': 'text'}, page_content='1. What are the characteristic skin lesions associated with specific vitamin deficiencies, and how do they present in different areas of the body?\n2. How does the distribution of skin lesions in nutritional disorders differ from other dermatological conditions?\n3. What treatment options are available for skin symptoms associated with vitamin deficiencies?'), Document(id='193', metadata={'original_content': "distribution on the feet and legs (pellagrous boot). Sunlight causes Casal's necklace and butterfly-shaped\nlesions on the face. Mucous membrane symptoms\n affect primarily the mouth but may also affect the vagina and urethra.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 26, 'type': 'text'}, page_content='1. What are the specific skin lesions associated with the nutritional disorder described, and where do they typically appear on the body?\n2. How does exposure to sunlight influence the symptoms of this nutritional disorder?\n3. What mucous membrane symptoms are commonly observed in individuals affected by this condition?'), Document(id='194', metadata={'original_content': 'Glossitis and stomatitis characterize acute deficiency. As the deficiency progresses, the tongue and oral\nmucous membranes become reddened, followed by pain in the mouth, increased salivation, and edema of\nthe tongue. Ulcerations may appear, especially under the tongue, on the mucosa of the lower lip, and\nopposite the molar teeth. GI symptoms\n early in the deficiency include burning in the pharynx and esophagus and abdominal\ndiscomfort and distention. Constipation is common.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 26, 'type': 'text'}, page_content='1. What are the early symptoms of acute deficiency that lead to glossitis and stomatitis?\n2. How does the progression of deficiency affect the oral mucous membranes and tongue?\n3. What gastrointestinal symptoms are commonly associated with the early stages of this nutritional deficiency?'), Document(id='195', metadata={'original_content': 'Later, nausea, vomiting, and diarrhea may occur.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 26, 'type': 'text'}, page_content='1. What are the potential symptoms associated with this nutritional disorder?\n2. What causes nausea and vomiting in individuals with this nutritional disorder?\n3. How can diarrhea related to this nutritional disorder be effectively managed?'), Document(id='196', metadata={'original_content': 'Diarrhea is often bloody because of bowel hyperemia and ulceration. CNS symptoms\n include psychosis, encephalopathy (characterized by impaired consciousness), and\ncognitive decline (dementia). Psychosis is characterized by memory impairment, disorientation, confusion,\nand confabulation; the predominant symptom may be excitement, depression, mania, delirium, or\nparanoia. Diagnosis\n Clinical evaluation\nDiagnosis is clinical and may be straightforward when skin and mouth lesions, diarrhea, delirium, and\ndementia occur simultaneously.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 26, 'type': 'text'}, page_content='1. What are the common CNS symptoms associated with diarrhea resulting from bowel hyperemia and ulceration?  \n2. How can clinicians differentiate between psychosis and other cognitive impairments in patients presenting with diarrhea and dementia?  \n3. What clinical signs should be evaluated to diagnose the nutritional disorder linked to bloody diarrhea and neurological symptoms?  '), Document(id='197', metadata={'original_content': 'More often, the presentation is not so specific. Differentiating the CNS\nchanges from those in thiamin deficiency is difficult. A history of a diet lacking niacin and tryptophan may\nhelp establish the diagnosis. A favorable response to treatment with niacin can usually \nconfirm it.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 26, 'type': 'text'}, page_content='1. What are the common symptoms associated with a deficiency of niacin and tryptophan?  \n2. How can a history of dietary habits aid in diagnosing niacin deficiency?  \n3. What is the typical treatment response when administering niacin for a deficiency?  '), Document(id='198', metadata={'original_content': 'If\navailable, laboratory testing can help confirm the diagnosis, particularly when the diagnosis is otherwise\nunclear. Urinary excretion of N\n1\n-methylnicotinamide (NMN) is decreased; &lt; 0.8 mg/day (&lt; 5.8 \n\nmol/day)\nsuggests a niacin deficiency. Treatment\n Nicotinamide and other nutrients\nBecause multiple deficiencies are common, a balanced diet, including other B vitamins (particularly\nriboflavin and pyridoxine), is needed. Nicotinamide is usually used to treat deficiency, because\nnicotinamide, unlike nicotinic acid (the most common form of niacin), does not cause flushing, itching,\nburning, or tingling sensations. Nicotinamide is given in doses ranging from 40 to 250 mg/day po in\ndivided doses 3 to 4 times a day. Niacin Toxicity\nNiacin (nicotinic acid) in large amounts is sometimes used to lower low-density lipoprotein\n(LDL) cholesterol and triglyceride levels and to increase high-density lipoprotein (HDL)\ncholesterol levels. Symptoms may include flushing and, rarely, hepatotoxicity. Immediate- and sustained-release preparations of niacin (but not nicotinamide) may improve lipid levels. Flushing, which is prostaglandin-mediated, is more common with immediate-release preparations. It may\nbe more intense after alcohol ingestion, aerobic activity, sun exposure, and consumption of spicy foods. Flushing is minimized if niacin is taken after meals or if aspirin (325 mg) is taken 30 to 45 min before\nniacin. The chance of severe flushing can be reduced by starting immediate-release niacin at a low dose\n(eg, 50 mg tid) and increasing it very slowly. At intermediate doses (1000 mg/day), triglyceride levels\ndecrease 15 to 20%, and HDL cholesterol levels increase 15 to 30%. Reductions in LDL cholesterol are\nmodest (&lt; 10%). Higher doses of niacin (3000 mg/day) reduce LDL cholesterol 15 to 20% but may cause\njaundice, abdominal discomfort, blurred vision, worsening of hyperglycemia, and precipitation of\npreexisting gout. People with a liver disorder probably should not take high-dose niacin.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 26, 'type': 'text'}, page_content='1. What laboratory tests can help confirm a diagnosis of niacin deficiency and what specific urinary excretion levels indicate this deficiency?  \n2. What are the differences in side effects between nicotinic acid and nicotinamide when used as treatment for niacin deficiency?  \n3. What are the potential risks and symptoms associated with high-dose niacin therapy for lipid management?  '), Document(id='199', metadata={'original_content': 'Hepatotoxicity may be more common with some sustained-release preparations.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 26, 'type': 'text'}, page_content='1. What are the potential risks of using sustained-release preparations in patients with hepatotoxicity?\n2. How can one identify symptoms of hepatotoxicity associated with certain medication formulations?\n3. What treatment options are available for managing hepatotoxicity resulting from sustained-release medications?'), Document(id='200', metadata={'original_content': 'Some authorities\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n79', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 26, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiencies as outlined in the Merck Manual of Diagnosis &amp; Therapy?  \n2. How does vitamin dependency develop, and what are its potential health implications?  \n3. What treatment options are recommended for addressing vitamin toxicity according to the Merck Manual?  '), Document(id='201', metadata={'original_content': 'recommend checking levels of uric acid, serum glucose, and plasma transaminases every 6 to 8 wk until\nthe dose of niacin has been stabilized. Riboflavin\nRiboflavin (vitamin B\n2\n) is involved in carbohydrate metabolism as an essential coenzyme in many\noxidation-reduction reactions.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 27, 'type': 'text'}, page_content='1. What are the potential side effects of niacin that necessitate the monitoring of uric acid, serum glucose, and plasma transaminases levels?  \n2. How does riboflavin deficiency affect carbohydrate metabolism and what symptoms might manifest as a result?  \n3. What is the recommended frequency for monitoring patients on niacin therapy, and why is it important for managing their treatment?  '), Document(id='202', metadata={'original_content': 'Riboflavin is essentially nontoxic.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 27, 'type': 'text'}, page_content='1. What are the potential causes of riboflavin deficiency in individuals?\n2. What symptoms may indicate a riboflavin deficiency in a patient?\n3. What treatment options are available for correcting riboflavin deficiency?'), Document(id='203', metadata={'original_content': 'Riboflavin Deficiency\nRiboflavin deficiency usually occurs with other B-vitamin deficiencies. Symptoms and signs\ninclude sore throat, lesions of the lips and mucosa of the mouth, glossitis, conjunctivitis,\nseborrheic dermatitis, and normochromicnormocytic anemia. Diagnosis is usually clinical. Treatment consists of oral or, if needed, IM riboflavin. Primary riboflavin deficiency results from inadequate intake of fortified cereals, milk, and other animal\nproducts. The most common causes of secondary deficiency are chronic diarrhea, malabsorption\nsyndromes, liver disorders, hemodialysis, peritoneal dialysis, long-term use of barbiturates, and chronic\nalcoholism. Symptoms and Signs\nThe most common signs are pallor and maceration of the mucosa at the angles of the mouth (angular\nstomatitis) and vermilion surfaces of the lips (cheilosis), eventually replaced by superficial linear fissures. The fissures can become infected with \nCandida albicans\n, causing grayish white lesions (perleche). The\ntongue may appear magenta. Seborrheic dermatitis develops, usually affecting the nasolabial folds, ears,\neyelids, and scrotum or labia majora. These areas become red, scaly, and greasy.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 27, 'type': 'text'}, page_content='1. What are the primary causes of riboflavin deficiency and how do they differ from secondary causes?  \n2. What specific symptoms and signs are associated with riboflavin deficiency?  \n3. How is riboflavin deficiency treated, and what are the potential routes of administration?  '), Document(id='204', metadata={'original_content': 'Rarely, neovascularization and keratitis of the cornea occur, causing lacrimation and photophobia. Diagnosis\nThe lesions characteristic of riboflavin deficiency are nonspecific. Riboflavin deficiency should be\nsuspected if characteristic signs develop in a patient with other B vitamin deficiencies. Diagnosis can be\nconfirmed by a therapeutic trial or laboratory testing, usually by measuring urinary excretion of riboflavin. Treatment\nRiboflavin 5 to 10 mg/day po is given until recovery. Other water-soluble vitamins should also be given.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 27, 'type': 'text'}, page_content='1. What are the characteristic symptoms of riboflavin deficiency that may lead to suspected diagnosis?\n2. How can riboflavin deficiency be confirmed through laboratory testing?\n3. What is the recommended treatment regimen for a patient diagnosed with riboflavin deficiency?'), Document(id='205', metadata={'original_content': 'Thiamin\nThiamin (vitamin B\n1\n) is widely available in the diet. Thiamin is involved in carbohydrate, fat, amino acid,\nglucose, and alcohol metabolism. Thiamin is essentially nontoxic. Thiamin Deficiency\nThiamin deficiency (causing beriberi) is most common among people subsisting on white rice\nor highly refined carbohydrates in developing countries and among alcoholics. Symptoms\ninclude diffuse polyneuropathy, high-output heart failure, and Wernicke-Korsakoff syndrome. Thiamin is given to help diagnose and treat the deficiency. Etiology\nPrimary thiamin deficiency is caused by inadequate intake of thiamin. It is commonly due to a diet of\nhighly refined carbohydrates (eg, polished rice, white flour, white sugar). It also develops when intake of\nother nutrients is inadequate; it often occurs with other B vitamin deficiencies.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 27, 'type': 'text'}, page_content='1. What are the primary dietary causes of thiamin deficiency leading to beriberi?\n2. What symptoms are associated with thiamin deficiency, particularly in cases of Wernicke-Korsakoff syndrome?\n3. How is thiamin administered for the diagnosis and treatment of thiamin deficiency?'), Document(id='206', metadata={'original_content': 'The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 27, 'type': 'text'}, page_content='1. What are the common causes of vitamin D deficiency as outlined in the Merck Manual of Diagnosis &amp; Therapy, 19th Edition?\n2. What symptoms are associated with iron deficiency anemia according to the nutritional disorder document?\n3. What treatment options are recommended for managing malnutrition in adults as described in the Merck Manual?'), Document(id='207', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n80', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 27, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiencies and how can they be identified?\n2. What treatments are available for individuals suffering from vitamin dependency?\n3. What are the potential health risks associated with vitamin toxicity and how can they be prevented?'), Document(id='208', metadata={'original_content': 'Secondary thiamin deficiency is caused by increased demand (eg, due to hyperthyroidism, pregnancy,\nbreastfeeding, strenuous exercise, or fever), impaired absorption (eg, due to prolonged diarrhea), or\nimpaired metabolism (eg, due to hepatic insufficiency). In alcoholics, many mechanisms contribute to\nthiamin deficiency; they include decreased intake, impaired absorption and use, increased demand, and\npossibly an apoenzyme defect. Pathophysiology\nDeficiency causes degeneration of peripheral nerves, thalamus, mammillary bodies, and cerebellum. Cerebral blood flow is markedly reduced, and vascular resistance is increased.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 28, 'type': 'text'}, page_content='1. What are the common causes of secondary thiamin deficiency in individuals with hyperthyroidism?  \n2. How does prolonged diarrhea contribute to the impaired absorption of thiamin?  \n3. What neurological symptoms are associated with thiamin deficiency due to its effects on the peripheral nerves and brain structures?  '), Document(id='209', metadata={'original_content': 'The heart may become dilated; muscle fibers become swollen, fragmented, and vacuolized, with\ninterstitial spaces dilated by fluid. Vasodilation occurs and can result in edema in the feet and legs. Arteriovenous shunting of blood increases. Eventually, high-output heart failure may occur.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 28, 'type': 'text'}, page_content='1. What are the physiological changes that occur in the heart due to nutritional deficiencies leading to dilated cardiomyopathy?\n2. How does vasodilation contribute to edema in the feet and legs in patients with this nutritional disorder?\n3. What treatments are available to manage high-output heart failure resulting from this nutritional disorder?'), Document(id='210', metadata={'original_content': 'Symptoms and Signs\nEarly symptoms are nonspecific: fatigue, irritability, poor memory, sleep disturbances, precordial pain,\nanorexia, and abdominal discomfort. Dry beriberi\n refers to peripheral neurologic deficits due to thiamin deficiency. These deficits are bilateral\nand roughly symmetric, occurring in a stocking-glove distribution.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 28, 'type': 'text'}, page_content='1. What are the early symptoms associated with thiamin deficiency?\n2. How does dry beriberi manifest in patients with thiamin deficiency?\n3. What are the key neurological deficits observed in individuals suffering from dry beriberi?'), Document(id='211', metadata={'original_content': "They affect predominantly the lower\nextremities, beginning with paresthesias in the toes, burning in the feet (particularly severe at night),\nmuscle cramps in the calves, pains in the legs, and plantar dysesthesias. Calf muscle tenderness,\ndifficulty rising from a squatting position, and decreased vibratory sensation in the toes are early signs. Muscle wasting occurs. Continued deficiency worsens polyneuropathy, which can eventually affect the\narms. Wernicke-Korsakoff syndrome,\n which combines Wernicke's encephalopathy (see p.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 28, 'type': 'text'}, page_content='1. What are the early signs and symptoms of the nutritional disorder affecting the lower extremities?  \n2. How does continued deficiency lead to the progression of polyneuropathy in this nutritional disorder?  \n3. What treatment options are available for individuals experiencing symptoms like paresthesias, muscle cramps, and decreased vibratory sensation due to this nutritional disorder?  '), Document(id='212', metadata={'original_content': "1522\n) and\nKorsakoff's psychosis (see p. 1523\n), occurs in some alcoholics who do not consume foods fortified with\nthiamin. Wernicke's encephalopathy consists of psychomotor slowing or apathy, nystagmus, ataxia,\nophthalmoplegia, impaired consciousness, and, if untreated, coma and death. It probably results from\nsevere acute deficiency superimposed on chronic deficiency. Korsakoff's psychosis consists of mental\nconfusion, dysphonia, and confabulation with impaired memory of recent events. It probably results from\nchronic deficiency and may develop after repeated episodes of Wernicke's encephalopathy. Cardiovascular (wet) beriberi\n is myocardial disease due to thiamin deficiency. The first effects are\nvasodilation, tachycardia, a wide pulse pressure, sweating, warm skin, and lactic acidosis.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 28, 'type': 'text'}, page_content="1. What are the key symptoms of Wernicke's encephalopathy and how does it relate to thiamin deficiency in alcoholics?  \n2. How does chronic thiamin deficiency contribute to the development of Korsakoff's psychosis?  \n3. What cardiovascular symptoms are associated with wet beriberi due to thiamin deficiency?  "), Document(id='213', metadata={'original_content': 'Later, heart\nfailure develops, causing orthopnea and pulmonary and peripheral edema.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 28, 'type': 'text'}, page_content='1. What nutritional deficiencies could lead to the development of heart failure characterized by orthopnea and edema?  \n2. How can dietary modifications help manage the symptoms of heart failure, such as pulmonary and peripheral edema?  \n3. What are the potential long-term effects of untreated nutritional disorders on cardiovascular health, specifically in relation to heart failure?  '), Document(id='214', metadata={'original_content': 'Vasodilation can continue,\nsometimes resulting in shock. Infantile beriberi\n occurs in infants (usually by age 3 to 4 wk) who are breastfed by thiamin-deficient\nmothers. Heart failure (which may occur suddenly), aphonia, and absent deep tendon reflexes are\ncharacteristic. Because thiamin is necessary for glucose metabolism, glucose infusions may precipitate or worsen\nsymptoms of deficiency in thiamin-deficient people. Diagnosis\n Favorable response to thiamin\nDiagnosis is usually based on a favorable response to treatment with thiamin in a patient with symptoms\nor signs of deficiency. Similar bilateral lower-extremity polyneuropathies due to other disorders (eg,\ndiabetes, alcoholism, vitamin B\n12\n deficiency, heavy metal poisoning) do not respond to thiamin. Single-\nnerve neuritides (mononeuropathieseg, sciatica) and multiple mononeuropathies (mononeuritis\nmultiplex) are unlikely to result from thiamin deficiency. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 28, 'type': 'text'}, page_content='1. What are the key symptoms of infantile beriberi in infants breastfed by thiamin-deficient mothers?\n2. How can a favorable response to thiamin treatment be used to diagnose thiamin deficiency?\n3. What complications may arise from glucose infusions in individuals with thiamin deficiency?'), Document(id='215', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n81', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 28, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiency in adults?  \n2. How can vitamin toxicity occur, and what are its potential health effects?  \n3. What dietary changes can help prevent vitamin dependency in individuals with chronic health conditions?  '), Document(id='216', metadata={'original_content': 'Electrolytes, including Mg, should be measured to exclude other causes. For confirmation in equivocal\ncases, erythrocyte transketolase activity and 24-h urinary thiamin excretion may be measured. Diagnosis of cardiovascular beriberi can be difficult if other disorders that cause heart failure are present. A therapeutic trial of thiamin can help.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 29, 'type': 'text'}, page_content='1. What laboratory tests should be performed to confirm a diagnosis of cardiovascular beriberi when symptoms are present?  \n2. How can a therapeutic trial of thiamin aid in the diagnosis of cardiovascular beriberi?  \n3. What role do electrolytes, such as magnesium, play in the diagnosis of cardiovascular beriberi?  '), Document(id='217', metadata={'original_content': 'Treatment\n Supplemental thiamin, with dose based on clinical manifestations\nEnsuring that dietary supplies of thiamin are adequate is important regardless of symptoms. Because IV\nglucose can worsen thiamin deficiency, alcoholics and others at risk of thiamin deficiency should receive\nIV thiamin 100 mg before receiving IV glucose solutions. For mild polyneuropathy, thiamin 10 to 20 mg po once/day is given for 2 wk. For moderate or advanced\nneuropathy, the dose is 20 to 30 mg/day; it should be continued for several weeks after symptoms\ndisappear. For edema and congestion due to cardiovascular beriberi, thiamin 100 mg IV once/day is given\nfor several days. Heart failure is also treated. For Wernicke-Korsakoff syndrome, thiamin 50 to 100 mg IM or IV bid must usually be given for several\ndays, followed by 10 to 20 mg once/day until a therapeutic response is obtained. Anaphylactic reactions\nto IV thiamin are rare. Symptoms of ophthalmoplegia may resolve in a day; improvement in patients with\nKorsakoff psychosis may take 1 to 3 mo. Recovery from neurologic deficits is often incomplete in\nWernicke-Korsakoff syndrome and in other forms of thiamin deficiency. Because thiamin deficiency often occurs with other B vitamin deficiencies, multiple water-soluble vitamins\nare usually given for several weeks. Patients should continue to consume a nutritious diet, supplying 1 to\n2 times the daily recommended intake of vitamins; all alcohol intake should stop.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 29, 'type': 'text'}, page_content='1. What is the recommended dosage of thiamin for a patient with moderate polyneuropathy?  \n2. How should thiamin deficiency be managed in patients at risk, such as alcoholics, before administering IV glucose?  \n3. What are the treatment protocols for Wernicke-Korsakoff syndrome regarding thiamin administration?  '), Document(id='218', metadata={'original_content': "Vitamin A\nVitamin A (retinol) is required for the formation of rhodopsin, a photoreceptor pigment in the retina. Vitamin\nA helps maintain epithelial tissues. Normally, the liver stores 80 to 90% of the body's vitamin A.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 29, 'type': 'text'}, page_content="1. What are the potential symptoms of vitamin A deficiency related to vision and epithelial tissue health?  \n2. How does the liver's storage capacity for vitamin A affect the body's overall vitamin A levels?  \n3. What are the dietary sources that can help prevent vitamin A deficiency?  "), Document(id='219', metadata={'original_content': 'To use\nvitamin A, the body releases it into the circulation bound to prealbumin (transthyretin) and retinol-binding\nprotein. \n-Carotene and other provitamin carotenoids, contained in green leafy and yellow vegetables\nand deep- or bright-colored fruits, are converted to vitamin A. Carotenoids are absorbed better from\nvegetables when they are cooked or homogenized and served with some fats or oils. Retinol activity equivalents (RAE) were developed because provitamin A carotenoids have less vitamin A\nactivity than preformed vitamin A; 1 \n\ng retinol = 3.33 IU. Synthetic vitamin analogs (retinoids) are being used increasingly in dermatology.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 29, 'type': 'text'}, page_content="1. How does the body's mechanism for utilizing vitamin A differ between preformed vitamin A and provitamin A carotenoids?\n2. What dietary factors enhance the absorption of carotenoids and their conversion to vitamin A in the body?\n3. What role do synthetic vitamin A analogs (retinoids) play in the treatment of skin disorders?"), Document(id='220', metadata={'original_content': 'The possible protective\nrole of \n\n-carotene, retinol, and retinoids against some epithelial cancers is under study. However, risk of\ncertain cancers may be increased after \n\n-carotene supplementation. Vitamin A Deficiency\nVitamin A deficiency can result from inadequate intake, fat malabsorption, or liver disorders.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 29, 'type': 'text'}, page_content='1. What are the potential health risks associated with -carotene supplementation in relation to cancer?\n2. What causes vitamin A deficiency and how can it be identified?\n3. What treatment options are available for individuals suffering from vitamin A deficiency?'), Document(id='221', metadata={'original_content': 'Deficiency impairs immunity and hematopoiesis and causes rashes and typical ocular effects\n(eg, xerophthalmia, night blindness). Diagnosis is based on typical ocular findings and low\nvitamin A levels. Treatment consists of vitamin A given orally or, if symptoms are severe or\nmalabsorption is the cause, parenterally. Etiology\nPrimary vitamin A deficiency is usually caused by prolonged dietary deprivation. It is endemic in areas\nsuch as southern and eastern Asia, where rice, devoid of \n\n-carotene, is the staple food.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 29, 'type': 'text'}, page_content='1. What are the typical symptoms associated with vitamin A deficiency, particularly regarding ocular health?\n2. How can vitamin A deficiency impact the immune system and blood cell production?\n3. What treatment options are available for individuals diagnosed with severe vitamin A deficiency?'), Document(id='222', metadata={'original_content': 'Xerophthalmia\ndue to primary deficiency is a common cause of blindness among young children in developing countries. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 29, 'type': 'text'}, page_content='1. What are the primary causes of xerophthalmia in young children in developing countries?\n2. What symptoms should be monitored to diagnose xerophthalmia effectively?\n3. What treatment options are available for children suffering from xerophthalmia due to vitamin A deficiency?'), Document(id='223', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n82', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 29, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiencies, and how can they be identified?  \n2. What factors can lead to vitamin dependency, and what are the potential consequences of this condition?  \n3. How can vitamin toxicity occur, and what treatment options are available for someone experiencing it?'), Document(id='224', metadata={'original_content': 'Secondary vitamin A deficiency may be due to decreased bioavailability of provitamin A carotenoids or to\ninterference with absorption, storage, or transport of vitamin A. Interference with absorption or storage is\nlikely in sprue, cystic fibrosis, pancreatic insufficiency, duodenal bypass, chronic diarrhea, bile duct\nobstruction, giardiasis, and cirrhosis. Vitamin A deficiency is common in prolonged protein-energy\nundernutrition not only because the diet is deficient but also because vitamin A storage and transport is\ndefective. In children with complicated measles, vitamin A can shorten the duration of the disorder and\nreduce the severity of symptoms and risk of death. Symptoms and Signs\nImpaired dark adaptation of the eyes, which can lead to night blindness, is an early symptom.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 30, 'type': 'text'}, page_content='1. What are the potential causes of secondary vitamin A deficiency related to gastrointestinal disorders?\n2. How does prolonged protein-energy undernutrition contribute to vitamin A deficiency in children?\n3. In what ways can administering vitamin A impact the prognosis of children with complicated measles?'), Document(id='225', metadata={'original_content': "Xerophthalmia (which is nearly pathognomonic) results from keratinization of the eyes. It involves drying\n(xerosis) and thickening of the conjunctivae and corneas. Superficial foamy patches composed of\nepithelial debris and secretions on the exposed bulbar conjunctiva (Bitot's spots) develop. In advanced\ndeficiency, the cornea becomes hazy and can develop erosions, which can lead to its destruction\n(keratomalacia). Keratinization of the skin and of the mucous membranes in the respiratory, GI, and urinary tracts can\noccur.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 30, 'type': 'text'}, page_content="1. What are the primary symptoms associated with xerophthalmia and how do they progress in severity?  \n2. How does a deficiency in vitamin A lead to the development of Bitot's spots in the conjunctiva?  \n3. What treatment options are available for individuals suffering from advanced xerophthalmia and keratomalacia?"), Document(id='226', metadata={'original_content': 'Drying, scaling, and follicular thickening of the skin and respiratory infections can result.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 30, 'type': 'text'}, page_content='1. What nutritional deficiencies could lead to drying, scaling, and follicular thickening of the skin?  \n2. How do respiratory infections relate to the symptoms of this nutritional disorder?  \n3. What treatments are recommended for managing the skin symptoms associated with this nutritional disorder?  '), Document(id='227', metadata={'original_content': 'Immunity\nis generally impaired. The younger the patient, the more severe are the effects of vitamin A deficiency. Growth retardation and\ninfections are common among children. Mortality rate can exceed 50% in children with severe vitamin A\ndeficiency. Diagnosis\n Serum retinol levels, clinical evaluation, and response to vitamin A\nOcular findings suggest the diagnosis. Dark adaptation can be impaired in other disorders (eg, zinc\ndeficiency, retinitis pigmentosa, severe refractive errors, cataracts, diabetic retinopathy). If dark\nadaptation is impaired, rod scotometry and electroretinography are done to determine whether vitamin A\ndeficiency is the cause. Serum levels of retinol are measured. Normal range is 28 to 86 \n\ng/dL (1 to 3 \n\nmol/L). However, levels\ndecrease only after the deficiency is advanced because the liver contains large stores of vitamin A. Also,\ndecreased levels may result from acute infection, which causes retinol-binding protein and transthyretin\n(also called prealbumin) levels to decrease transiently. A therapeutic trial of vitamin A may help confirm\nthe diagnosis.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 30, 'type': 'text'}, page_content='1. What are the common symptoms of vitamin A deficiency in children, and how can it affect their overall health and growth?  \n2. How can healthcare professionals diagnose vitamin A deficiency, and what tests are used to assess serum retinol levels?  \n3. What therapeutic interventions are available for treating severe vitamin A deficiency, particularly in pediatric patients?  '), Document(id='228', metadata={'original_content': 'Prevention\nThe diet should include dark green leafy vegetables, deep- or bright-colored fruits (eg, papayas,\noranges), carrots, and yellow vegetables (eg, squash, pumpkin). Vitamin A-fortified milk and cereals, liver,\negg yolks, and fish liver oils are helpful.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 30, 'type': 'text'}, page_content='1. What foods should be included in the diet to prevent vitamin A deficiency?  \n2. How can the consumption of dark green leafy vegetables impact overall nutritional health?  \n3. What role do vitamin A-fortified products play in preventing nutritional disorders?  '), Document(id='229', metadata={'original_content': 'Carotenoids are absorbed better when consumed with some\ndietary fat. If milk allergy is suspected in infants, they should be given adequate vitamin A in formula\nfeedings. In developing countries, prophylactic supplements of vitamin A palmitate in oil 60,000 RAE\n(200,000 IU) po every 6 mo are advised for all children between 1 and 5 yr of age; infants &lt; 6 mo can be\ngiven a one-time dose of 15,000 RAE (50,000 IU), and those aged 6 to 12 mo can be given a one-time\ndose of 30,000 RAE (100,000 IU). Treatment\n Vitamin A palmitate\nDietary deficiency is traditionally treated with vitamin A palmitate in oil 60,000 IU po once/day for 2 days,\nfollowed by 4500 IU po once/day. If vomiting or malabsorption is present or xerophthalmia is probable, a\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 30, 'type': 'text'}, page_content='1. How can the absorption of carotenoids be enhanced in infants with a suspected milk allergy?  \n2. What are the recommended vitamin A supplementation dosages for children in developing countries aged 1 to 5 years?  \n3. What is the treatment protocol for dietary vitamin A deficiency in adults experiencing symptoms such as vomiting or malabsorption?  '), Document(id='230', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n83', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 30, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiency and how can they be identified?\n2. What factors contribute to vitamin dependency, and how can it be managed effectively?\n3. What are the signs of vitamin toxicity, and what steps should be taken if someone experiences them?'), Document(id='231', metadata={'original_content': 'dose of 50,000 IU for infants &lt; 6 mo, 100,000 IU for infants 6 to 12 mo, or 200,000 IU for children &gt; 12 mo\nand adults should be given for 2 days, with a third dose at least 2 wk later. The same doses are\nrecommended for infants and children with complicated measles. Infants born of HIV-positive mothers\nshould receive 50,000 IU (15,000 RAE) within 48 h of birth. Prolonged daily administration of large doses,\nespecially to infants, must be avoided because toxicity may result. For pregnant or breastfeeding women, prophylactic or therapeutic doses should not exceed 10,000 IU\n(3000 RAE)/day to avoid possible damage to the fetus or infant. Vitamin A Toxicity\nVitamin A toxicity can be acute (usually due to accidental ingestion by children) or chronic. Both\ntypes usually cause headache and increased intracranial pressure. Acute toxicity also causes\nnausea and vomiting. Chronic toxicity also causes changes in skin, hair, and nails; abnormal\nliver test results; and, in a fetus, birth defects. Diagnosis is usually clinical.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 31, 'type': 'text'}, page_content='1. What are the recommended dosages of vitamin A for infants and children with complicated measles?\n2. What are the potential symptoms of acute and chronic vitamin A toxicity in children?\n3. How should vitamin A supplementation be managed for pregnant or breastfeeding women to avoid toxicity?'), Document(id='232', metadata={'original_content': 'Unless birth defects\nare present, adjusting the dose almost always leads to complete recovery. Acute vitamin A toxicity in children may result from taking large doses (&gt; 100,000 RAE [&gt; 300,000 IU]),\nusually accidentally. In adults, acute toxicity has occurred when arctic explorers ingested polar bear or\nseal livers, which contain several million units of vitamin A. Chronic toxicity in older children and adults usually develops after doses of &gt; 30,000 RAE (&gt; 100,000\nIU)/day have been taken for months. Megavitamin therapy is a possible cause, as are massive daily\ndoses (50,000 to 120,000 RAE [150,000 to 350,000 IU]) of vitamin A \nor its metabolites, which are\nsometimes given for nodular acne or other skin disorders. Adults who consume &gt; 1500 RAE (&gt; 4500\nIU)/day of vitamin A may develop osteoporosis. Infants who are given excessive doses (6,000 to 20,000\nRAE [18,000 to 60,000 IU]/day) of water-miscible vitamin A may develop toxicity within a few weeks. Birth\ndefects occur in children of women receiving isotretinoin (which is related to vitamin A) for acne treatment\nduring pregnancy. Although carotene is converted to vitamin A in the body, excessive ingestion of carotene causes\ncarotenemia, not vitamin A toxicity.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 31, 'type': 'text'}, page_content='1. What are the potential sources of acute vitamin A toxicity in children and adults?  \n2. How can chronic vitamin A toxicity develop in older children and adults, and what are the associated risks?  \n3. What precautions should pregnant women take regarding vitamin A intake to prevent birth defects?  '), Document(id='233', metadata={'original_content': 'Carotenemia is usually asymptomatic but may lead to carotenodermia,\nin which the skin becomes yellow. When taken as a supplement, \n\n-carotene has been associated with\nincreased cancer risk; risk does not seem to increase when carotenoids are consumed in fruits and\nvegetables. Symptoms and Signs\nAlthough symptoms may vary, headache and rash usually develop during acute or chronic toxicity.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 31, 'type': 'text'}, page_content='1. What are the potential symptoms of carotenemia and how does it progress to carotenodermia?\n2. What risks are associated with -carotene supplementation compared to consuming carotenoids from fruits and vegetables?\n3. What symptoms might indicate acute or chronic toxicity related to carotenoid consumption?'), Document(id='234', metadata={'original_content': 'Acute\ntoxicity causes increased intracranial pressure. Drowsiness, irritability, abdominal pain, nausea, and\nvomiting are common. Sometimes the skin subsequently peels. Early symptoms of chronic toxicity are sparsely distributed, coarse hair; alopecia of the eyebrows; dry,\nrough skin; dry eyes; and cracked lips. Later, severe headache, pseudotumor cerebri, and generalized\nweakness develop.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 31, 'type': 'text'}, page_content='1. What are the acute symptoms associated with toxicity that can lead to increased intracranial pressure?\n2. How do the symptoms of chronic toxicity differ from those of acute toxicity?\n3. What are the potential long-term effects of nutritional toxicity on hair and skin health?'), Document(id='235', metadata={'original_content': 'Cortical hyperostosis of bone and arthralgia may occur, especially in children. Fractures may occur easily, especially in the elderly. In children, toxicity can cause pruritus, anorexia, and\nfailure to thrive.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 31, 'type': 'text'}, page_content='1. What are the potential symptoms of cortical hyperostosis in children?\n2. How does toxicity related to this nutritional disorder manifest in pediatric patients?\n3. What complications are associated with this disorder in elderly individuals?'), Document(id='236', metadata={'original_content': 'Hepatomegaly and splenomegaly may occur. In carotenodermia, the skin (but not the sclera) becomes deep yellow, especially on the palms and soles. Diagnosis\n Clinical evaluation\nDiagnosis is clinical.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 31, 'type': 'text'}, page_content='1. What are the clinical signs that indicate the presence of carotenodermia in a patient?\n2. How can hepatomegaly and splenomegaly be differentiated from other conditions during a clinical evaluation?\n3. What dietary factors might contribute to the development of carotenodermia?'), Document(id='237', metadata={'original_content': 'Blood vitamin levels correlate poorly with toxicity.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 31, 'type': 'text'}, page_content='1. What are the potential causes of poor correlation between blood vitamin levels and toxicity symptoms in individuals?\n2. How might the symptoms of vitamin toxicity present in patients with normal blood vitamin levels?\n3. What treatment options are available for managing symptoms of vitamin toxicity despite normal blood vitamin level readings?'), Document(id='238', metadata={'original_content': 'However, if clinical diagnosis is\nequivocal, laboratory testing may help. In vitamin A toxicity, fasting serum retinol levels may increase from\nnormal (28 to 86 \n\ng/dL [1 to 3 \n\nmol/L]) to &gt; 100 \n\ng/dL (&gt; 3.49 \n\nmol/L), sometimes to &gt; 2000 \n\ng/dL (&gt; 69.8\n\nmol/L). Hypercalcemia is common.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 31, 'type': 'text'}, page_content='1. What laboratory tests can help confirm a diagnosis of vitamin A toxicity when clinical symptoms are unclear?  \n2. What are the typical serum retinol level ranges associated with vitamin A toxicity?  \n3. What symptoms might indicate hypercalcemia in a patient with vitamin A toxicity?  '), Document(id='239', metadata={'original_content': 'The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n84', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 31, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiency and how can they be differentiated from other health conditions?  \n2. What diagnostic tests are recommended for identifying specific vitamin deficiencies?  \n3. What treatment options are available for patients suffering from vitamin toxicity?'), Document(id='240', metadata={'original_content': 'Differentiating vitamin A toxicity from other disorders may be difficult. Carotenodermia may also occur in\nsevere hypothyroidism and anorexia nervosa, possibly because carotene is converted to vitamin A more\nslowly. Prognosis\nComplete recovery usually occurs if vitamin A ingestion stops.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 32, 'type': 'text'}, page_content='1. What are the distinguishing symptoms of vitamin A toxicity compared to carotenodermia in hypothyroidism and anorexia nervosa?  \n2. How does the conversion rate of carotene to vitamin A differ in individuals with severe hypothyroidism?  \n3. What steps should be taken for the treatment of vitamin A toxicity to ensure complete recovery?  '), Document(id='241', metadata={'original_content': 'Symptoms and signs of chronic toxicity\nusually disappear within 1 to 4 wk. However, birth defects in the fetus of a mother who has taken\nmegadoses of vitamin A are not reversible.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 32, 'type': 'text'}, page_content='1. What are the symptoms and signs associated with chronic vitamin A toxicity?  \n2. How long does it typically take for symptoms of chronic vitamin A toxicity to resolve?  \n3. What are the potential consequences of a pregnant woman taking megadoses of vitamin A?  '), Document(id='242', metadata={'original_content': 'Treatment\nVitamin A is stopped. Vitamin B\n6\nVitamin B\n6\n includes a group of closely related compounds: pyridoxine, pyridoxal, and pyridoxamine. They\nare metabolized in the body to pyridoxal phosphate, which acts as a coenzyme in many important\nreactions in blood, CNS, and skin metabolism. Vitamin B\n6\n is important in heme and nucleic acid\nbiosynthesis and in lipid, carbohydrate, and amino acid metabolism. Vitamin B\n6\n Deficiency and Dependency\nBecause vitamin B\n6\n is present in most foods, dietary deficiency is rare.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 32, 'type': 'text'}, page_content='1. What are the potential consequences of stopping vitamin A treatment in individuals with vitamin B6 deficiency?\n2. How does a deficiency in vitamin B6 affect blood and central nervous system metabolism?\n3. What dietary sources are rich in vitamin B6 to prevent deficiency?'), Document(id='243', metadata={'original_content': 'Secondary deficiency\nmay result from various conditions. Symptoms can include peripheral neuropathy, a pellagra-\nlike syndrome, anemia, and seizures, which, particularly in infants, may not resolve when\ntreated with anticonvulsants. Impaired metabolism (dependency) is rare; it causes various\nsymptoms, including seizures, intellectual disability, and anemia. Diagnosis is usually clinical;\nno laboratory test readily assesses vitamin B\n6\n status.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 32, 'type': 'text'}, page_content='1. What are the common symptoms associated with secondary deficiency of vitamin B6?  \n2. How can peripheral neuropathy and anemia be linked to secondary deficiency?  \n3. What treatment options are available for seizures caused by impaired metabolism related to vitamin B6 deficiency?'), Document(id='244', metadata={'original_content': 'Treatment consists of giving oral vitamin\nB\n6\n and, when possible, treating the cause. Dietary deficiency, though rare, can develop because extensive processing can deplete foods of vitamin\nB\n6\n. Secondary deficiency most often results from protein-energy undernutrition, malabsorption,\nalcoholism, use of pyridoxine-inactivating drugs (eg, anticonvulsants, isoniazid, cycloserine, hydralazine,\ncorticosteroids, penicillamine), or excessive loss. Rarely, it results from increased metabolic demand (eg,\nin hyperthyroidism). Rare inborn errors of metabolism can affect pyridoxine metabolism. The role of vitamin B\n6\n deficiency in increasing plasma homocysteine levels and in contributing to vascular\ndisorders is under study. Symptoms and Signs\nDeficiency causes a pellagra-like syndrome, with seborrheic dermatitis, glossitis, and cheilosis, and, in\nadults, can cause depression, confusion, EEG abnormalities, and seizures. Rarely, deficiency or\ndependency causes seizures in infants.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 32, 'type': 'text'}, page_content='1. What are the common causes of vitamin B6 deficiency in adults, and how do they differ from dietary deficiencies?  \n2. What specific symptoms are associated with vitamin B6 deficiency in infants compared to adults?  \n3. How does vitamin B6 deficiency contribute to increased plasma homocysteine levels and what potential vascular disorders are being studied in relation to this deficiency?  '), Document(id='245', metadata={'original_content': 'Seizures, particularly in infants, may be refractory to treatment\nwith anticonvulsants. Normocytic, microcytic, or sideroblastic anemia can also develop. Diagnosis\n Clinical evaluation\nVitamin B\n6\n deficiency should be considered in any infant who has seizures, any patient who has seizures\nrefractory to treatment with anticonvulsants, and any patient with deficiencies of other B vitamins,\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n85', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 32, 'type': 'text'}, page_content='1. What are the potential consequences of Vitamin B6 deficiency in infants experiencing seizures?\n2. How can Vitamin B6 deficiency be diagnosed in patients with refractory seizures?\n3. What other B vitamin deficiencies should be evaluated in patients presenting with seizures?'), Document(id='246', metadata={'original_content': 'particularly in patients with alcoholism or protein-energy undernutrition.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 33, 'type': 'text'}, page_content="1. What are the common symptoms of nutritional disorders in patients with alcoholism?  \n2. How does protein-energy undernutrition affect the body's ability to recover from alcohol-related health issues?  \n3. What treatment options are recommended for individuals suffering from nutritional disorders due to alcoholism or protein-energy undernutrition?  "), Document(id='247', metadata={'original_content': 'Diagnosis is usually clinical. There is no single accepted laboratory test of vitamin B\n6\n status; measurement of serum pyridoxal\nphosphate is most common. Treatment\n Pyridoxine\n Elimination of risk factors when possible\nFor secondary deficiency, causes (eg, use of pyridoxine-inactivating drugs, malabsorption) should be\ncorrected if possible. Usually, pyridoxine 50 to 100 mg po once/day corrects the deficiency in adults. Most\npeople taking isoniazid should also be given pyridoxine 30 to 50 mg/day. For deficiency due to increased\nmetabolic demand, amounts larger than the daily recommended intake may be required. For most cases\nof inborn errors of metabolism, high doses of pyridoxine may be effective. Vitamin B\n6\n Toxicity\nThe ingestion of megadoses (&gt; 500 mg/day) of pyridoxine (eg, taken to treat carpal tunnel syndrome or\npremenstrual syndrome although efficacy is unproved) may cause peripheral neuropathy with deficits in a\nstocking-glove distribution, including progressive sensory ataxia and severe impairment of position and\nvibration senses. Senses of touch, temperature, and pain are less affected.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 33, 'type': 'text'}, page_content='1. What are the common causes of vitamin B6 deficiency and how can they be corrected?  \n2. What symptoms are associated with vitamin B6 toxicity, and at what dosage does toxicity typically occur?  \n3. How is vitamin B6 deficiency diagnosed and what is the standard treatment regimen for adults?  '), Document(id='248', metadata={'original_content': 'Motor and central nervous\nsystems are usually intact.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 33, 'type': 'text'}, page_content='1. What nutritional deficiencies can lead to symptoms affecting motor and central nervous system function despite their intact status?  \n2. How can the symptoms of a nutritional disorder manifest in patients with otherwise healthy motor and central nervous systems?  \n3. What treatments are recommended for addressing nutritional disorders that do not directly impact the motor and central nervous systems?  '), Document(id='249', metadata={'original_content': 'Diagnosis is clinical. Treatment is to stop taking vitamin B\n6\n. Recovery is slow and, for some patients,\nincomplete. Vitamin B\n12\nCobalamin is a general term for compounds with biologic vitamin B\n12\n activity. These compounds are\ninvolved in nucleic acid metabolism, methyl transfer, and myelin synthesis and repair.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 33, 'type': 'text'}, page_content='1. What are the potential symptoms associated with vitamin B6 toxicity that may lead to a clinical diagnosis?  \n2. How does the discontinuation of vitamin B6 affect the recovery process in patients?  \n3. What role does vitamin B12 play in nucleic acid metabolism and myelin synthesis?  '), Document(id='250', metadata={'original_content': "They are necessary\nfor the formation of normal RBCs. Food-bound vitamin B\n12\n is released in the stomach's acid environment and is bound to R protein\n(haptocorrin). Pancreatic enzymes cleave this B\n12\n complex (B\n12\n-R protein) in the small intestine. After\ncleavage, intrinsic factor, secreted by parietal cells in the gastric mucosa, binds with vitamin B\n12\n. Intrinsic\nfactor is required for absorption of vitamin B\n12\n, which takes place in the terminal ileum. Vitamin B\n12\n in plasma is bound to transcobalamins I and II.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 33, 'type': 'text'}, page_content='1. What role does intrinsic factor play in the absorption of vitamin B12, and what might happen if it is deficient?  \n2. How can a deficiency in vitamin B12 affect the formation of red blood cells (RBCs)?  \n3. What types of foods are rich in vitamin B12, and how can individuals ensure they are getting enough of this nutrient?  '), Document(id='251', metadata={'original_content': 'Transcobalamin II is responsible for delivering\nvitamin B\n12\n to tissues. The liver stores large amounts of vitamin B\n12\n. Enterohepatic reabsorption helps\nretain vitamin B\n12\n. Liver vitamin B\n12\n stores can normally sustain physiologic needs for 3 to 5 yr if B\n12\nintake stops (eg, in people who become vegans) and for months to 1 yr if enterohepatic reabsorption\ncapacity is absent. Large amounts of vitamin B\n12\n seem to be nontoxic but are not recommended for regular use (ie, as a\ngeneral tonic).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 33, 'type': 'text'}, page_content="1. What role does Transcobalamin II play in the delivery of vitamin B12 to the body's tissues, and how might deficiencies in this protein affect B12 levels?\n2. How does enterohepatic reabsorption contribute to the maintenance of vitamin B12 levels in the body, and what factors could impair this process?\n3. What are the potential consequences of long-term vitamin B12 deficiency in individuals who have stopped consuming dietary sources of this nutrient, such as vegans?"), Document(id='252', metadata={'original_content': 'Vitamin B\n12\n Deficiency\nDietary vitamin B\n12\n deficiency usually results from inadequate absorption, but deficiency can\ndevelop in vegans who do not take vitamin supplements. Deficiency causes megaloblastic\nanemia, damage to the white matter of the spinal cord and brain, and peripheral neuropathy. Diagnosis is usually made by measuring serum vitamin B\n12\n levels.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 33, 'type': 'text'}, page_content='1. What are the common causes of vitamin B12 deficiency in individuals following a vegan diet?\n2. What symptoms are associated with megaloblastic anemia resulting from vitamin B12 deficiency?\n3. How is vitamin B12 deficiency diagnosed in patients?'), Document(id='253', metadata={'original_content': 'The Schilling test helps\ndetermine etiology. Treatment consists of oral or parenteral vitamin B\n12\n. Folate (folic acid)\nshould not be used instead of vitamin B\n12\n because folate may alleviate the anemia but allow\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n86', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 33, 'type': 'text'}, page_content='1. What role does the Schilling test play in diagnosing vitamin B12 deficiency?  \n2. Why is it important to treat vitamin B12 deficiency with vitamin B12 rather than folate?  \n3. What are the potential consequences of using folate to treat anemia caused by vitamin B12 deficiency?  '), Document(id='254', metadata={'original_content': 'neurologic deficits to progress. Etiology\nInadequate vitamin B\n12\n intake is possible in vegans but is otherwise unlikely. Breastfed babies of vegan\nmothers may develop vitamin B\n12\n deficiency by age 4 to 6 mo because their\n[\nTable 4-5. Causes of Vitamin B\n12\n Deficiency]\nliver stores (which are normally extensive) are limited and their rapid growth rate results in high demand.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 34, 'type': 'text'}, page_content='1. What are the potential causes of vitamin B12 deficiency in breastfed infants of vegan mothers?  \n2. How can inadequate vitamin B12 intake affect neurological development in infants?  \n3. What dietary recommendations can be made to prevent vitamin B12 deficiency in vegans?  '), Document(id='255', metadata={'original_content': 'Vitamin B\n12\n deficiency usually results from inadequate absorption (see \nTable 4-5\n and p. 153\n), which, in\nthe elderly, most commonly results from decreased acid secretion. In such cases, crystalline vitamin B\n12\n(such as that available in vitamin supplements) can be absorbed, but food-bound vitamin B\n12\n is not\nliberated and absorbed normally. Inadequate absorption may occur in blind loop syndrome (with\novergrowth of bacteria) or fish tapeworm infestation; in these cases, bacteria or parasites use ingested\nvitamin B\n12\n so that less is available for absorption. Vitamin B\n12\n absorption may be inadequate if ileal\nabsorptive sites are destroyed by inflammatory bowel disease or are surgically removed. Less common\ncauses of inadequate vitamin B\n12\n absorption include chronic pancreatitis, gastric surgery, malabsorption\nsyndromes, AIDS, use of certain drugs (eg, antacids, metformin), repeated exposure to nitrous oxide, and\na genetic disorder causing malabsorption in the ileum (Imerslund-Graesbeck syndrome). Pernicious anemia\n is often used synonymously with vitamin B\n12\n deficiency. However, pernicious\nanemia specifically refers to anemia resulting from vitamin B\n12\n deficiency caused by an autoimmune\nmetaplastic atrophic gastritis with loss of intrinsic factor (see p. 133\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 34, 'type': 'text'}, page_content='1. What are the common causes of vitamin B12 deficiency in the elderly, particularly related to absorption issues?\n2. How does pernicious anemia differ from general vitamin B12 deficiency in terms of its underlying mechanism?\n3. What role do certain medical conditions, such as inflammatory bowel disease or chronic pancreatitis, play in the absorption of vitamin B12?'), Document(id='256', metadata={'original_content': 'Patients with classic pernicious\nanemia, most commonly younger adults, are at increased risk of stomach and other GI cancers. Subacute combined degeneration\n refers to degenerative changes in the nervous system due to\nvitamin B\n12\n deficiency; they affect mostly brain and spinal cord white matter. Demyelinating or axonal\nperipheral neuropathies can occur.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 34, 'type': 'text'}, page_content='1. What are the potential neurological complications associated with vitamin B12 deficiency in patients with classic pernicious anemia?\n2. How does pernicious anemia increase the risk of gastrointestinal cancers in younger adults?\n3. What treatment options are available for managing subacute combined degeneration due to vitamin B12 deficiency?'), Document(id='257', metadata={'original_content': 'Symptoms and Signs\nAnemia usually develops insidiously.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 34, 'type': 'text'}, page_content='1. What are the common symptoms associated with anemia as it develops over time?\n2. How can the insidious onset of anemia be differentiated from other similar nutritional disorders?\n3. What are the potential underlying causes of anemia that may lead to its gradual development?'), Document(id='258', metadata={'original_content': 'It is often more severe than its symptoms indicate because its slow\nevolution allows physiologic adaptation. Occasionally, splenomegaly and hepatomegaly occur. Various GI\nsymptoms, including weight loss and poorly localized abdominal pain, may occur. Glossitis, usually\ndescribed as burning of the tongue, is uncommon. Neurologic symptoms develop independently from and often without hematologic abnormalities.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 34, 'type': 'text'}, page_content='1. What are the potential gastrointestinal symptoms associated with this nutritional disorder?\n2. How can splenomegaly and hepatomegaly manifest in patients with this condition?\n3. What neurologic symptoms might develop in individuals with this nutritional disorder, and how do they relate to hematologic abnormalities?'), Document(id='259', metadata={'original_content': 'In early\nstages, decreased position and vibratory sensation in the extremities is accompanied by mild to moderate\nweakness and hyporeflexia. In later stages, spasticity, extensor plantar responses, greater loss of position\nand vibratory sensation in the lower extremities, and ataxia emerge. These deficits may develop in a\nstocking-glove distribution. Tactile, pain, and temperature sensations are usually spared but may be\ndifficult to assess in the elderly.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 34, 'type': 'text'}, page_content='1. What are the early symptoms of the nutritional disorder described in the document?\n2. How do the symptoms of this nutritional disorder progress in later stages?\n3. What types of sensory sensations are typically preserved in individuals with this nutritional disorder?'), Document(id='260', metadata={'original_content': "Some patients are also irritable and mildly depressed. Paranoia (megaloblastic madness), delirium,\nconfusion, spastic ataxia, and, at times, postural hypotension may occur in advanced cases. The\nconfusion may be difficult to differentiate from age-related dementias, such as Alzheimer's disease. Diagnosis\n CBC and vitamin B\n12\n and folate levels\n Sometimes methylmalonic acid levels or Schilling test\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n87", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 34, 'type': 'text'}, page_content="1. What are the psychological symptoms associated with advanced vitamin B12 deficiency?\n2. How can confusion caused by vitamin B12 deficiency be differentiated from Alzheimer's disease?\n3. What diagnostic tests are used to confirm a vitamin B12 deficiency in patients exhibiting neurological symptoms?"), Document(id='261', metadata={'original_content': 'Diagnosis is based on CBC and vitamin B\n12\n and folate levels. It is important to remember that severe\nneurologic disease may occur without anemia or macrocytosis. CBC detects megaloblastic anemia.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 35, 'type': 'text'}, page_content='1. What are the potential neurological symptoms associated with vitamin B12 deficiency that may occur without the presence of anemia?  \n2. How does megaloblastic anemia manifest in patients with low folate levels compared to those with low vitamin B12 levels?  \n3. What treatment options are available for individuals diagnosed with megaloblastic anemia due to vitamin B12 or folate deficiency?  '), Document(id='262', metadata={'original_content': 'Tissue deficiency and macrocytic indexes may precede the\ndevelopment of anemia. A vitamin B\n12\n level &lt; 200 pg/mL (&lt; 145 pmol/L) indicates vitamin B\n12\n deficiency. The folate level is measured because vitamin B\n12\n deficiency must be differentiated from folate deficiency\nas a cause of megaloblastic anemia; folate supplementation can mask vitamin B\n12\n deficiency and may\nalleviate megaloblastic anemia but allow the neurologic deficits to progress or even accelerate. When clinical judgment suggests vitamin B\n12\n deficiency but the vitamin B\n12\n level is low-normal (200 to\n350 pg/mL [145 to 260 pmol/L]) or hematologic indexes are normal, other tests can be done. Measuring\nserum methylmalonic acid (MMA) levels may be useful. An elevated MMA level supports vitamin B\n12\ndeficiency but may be due to renal failure. MMA levels can also be used to monitor the response to\ntreatment. MMA levels remain normal in folate deficiency; homocysteine levels may be elevated with\neither vitamin B\n12\n or folate deficiency. Less commonly, holotranscobalamin II (transcobalamin II-B\n12\ncomplex) content is measured; when holotranscobalamin II is &lt; 40 pg/mL (&lt; 30 pmol/L), vitamin B\n12\n is\ndeficient. After deficiency is diagnosed, additional tests may be indicated for younger adults but usually not for the\nelderly. Unless dietary vitamin B\n12\n is obviously inadequate, measurement of serum gastrin levels or\nautoantibodies to intrinsic factor may be done; sensitivity and specificity of these tests may be poor. Schilling test:\n The Schilling test is useful only if diagnosing intrinsic factor deficiency is important, as in\nclassic pernicious anemia. This test is not necessary for most elderly patients.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 35, 'type': 'text'}, page_content='1. What are the differences in laboratory findings between vitamin B12 deficiency and folate deficiency in cases of megaloblastic anemia?  \n2. How can elevated serum methylmalonic acid (MMA) levels assist in diagnosing vitamin B12 deficiency?  \n3. When is the Schilling test indicated for evaluating vitamin B12 deficiency, and why might it not be necessary for elderly patients?  '), Document(id='263', metadata={'original_content': 'The Schilling test\nmeasures absorption of free radiolabeled vitamin B\n12\n. Radiolabeled vitamin B\n12\n is given orally, followed\nin 1 to 6 h by 1000 \n\ng (1 mg) of parenteral vitamin B\n12\n, which reduces uptake of radiolabeled vitamin\nB\n12\n by the liver. Absorbed radiolabeled vitamin B\n12\n is excreted in urine, which is collected for 24 h. The\namount excreted is measured, and the percentage of total radiolabeled vitamin B\n12\n is determined. If\nabsorption is normal,  9% of the dose given appears in the urine. Reduced urinary excretion (&lt; 5% if\nkidney function is normal) indicates inadequate vitamin B\n12\n absorption. Improved absorption with the\nsubsequent addition of intrinsic factor to radiolabeled vitamin B\n12\n confirms the diagnosis of pernicious\nanemia. The test is often difficult to do or interpret because of incomplete urine collection or renal\ninsufficiency. In addition, because the Schilling test does not measure absorption of protein-bound vitamin\nB\n12\n, the test does not detect defective liberation of vitamin B\n12\n from foods, which is common among the\nelderly. The Schilling test repletes vitamin B\n12\n and can mask deficiency, so it should be done only after all\nother diagnostic tests and therapeutic trials. If malabsorption is identified, the Schilling test can be repeated after a 2-wk trial of an oral antibiotic. If\nantibiotic therapy corrects malabsorption, the likely cause is intestinal overgrowth of bacteria (eg, blind-\nloop syndrome). Treatment\n Supplemental vitamin B\n12\nVitamin B\n12\n 1000 to 2000 \n\ng po can be given once/day to patients who do not have severe deficiency or\nneurologic symptoms or signs.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 35, 'type': 'text'}, page_content='1. How does the Schilling test determine whether a patient has pernicious anemia or another cause of vitamin B12 deficiency?\n2. What are the implications of reduced urinary excretion of radiolabeled vitamin B12 in the Schilling test results?\n3. How can antibiotic therapy affect the results of the Schilling test in patients suspected of having intestinal overgrowth?'), Document(id='264', metadata={'original_content': 'A nasal gel preparation of vitamin B\n12\n is available at a higher price.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 35, 'type': 'text'}, page_content='1. What are the potential benefits of using a nasal gel preparation of vitamin B12 for individuals with vitamin B12 deficiency?\n2. How does the nasal gel preparation of vitamin B12 compare to traditional oral supplements in terms of absorption and effectiveness?\n3. What are the symptoms of vitamin B12 deficiency that may warrant the use of a nasal gel preparation?'), Document(id='265', metadata={'original_content': 'Large\noral doses can be absorbed by mass action, even when intrinsic factor is absent.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 35, 'type': 'text'}, page_content='1. How do large oral doses of vitamin B12 affect absorption in individuals lacking intrinsic factor?  \n2. What are the potential symptoms of vitamin B12 deficiency in the absence of intrinsic factor?  \n3. What treatment options are available for individuals with intrinsic factor deficiency to ensure adequate vitamin B12 absorption?'), Document(id='266', metadata={'original_content': 'If the MMA level\n(sometimes used to monitor treatment) does not decrease, patients may not be taking vitamin B\n12\n. For\nmore severe deficiency, vitamin B\n12\n 1 mg IM is usually given 1 to 4 times/wk for several weeks until\nhematologic abnormalities are corrected; then it is given once/mo. Although hematologic abnormalities are usually corrected within 6 wk (reticulocyte count should improve\nwithin 1 wk), resolution of neurologic symptoms may take much longer.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 35, 'type': 'text'}, page_content='1. What are the implications of an unchanged MMA level in patients being treated for vitamin B12 deficiency?  \n2. How frequently should vitamin B12 be administered via intramuscular injection in cases of severe deficiency?  \n3. What is the expected timeline for the resolution of hematologic abnormalities and neurologic symptoms in patients receiving vitamin B12 treatment?'), Document(id='267', metadata={'original_content': 'Neurologic symptoms that persist\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 35, 'type': 'text'}, page_content='1. What are the potential nutritional deficiencies that can lead to persistent neurologic symptoms?  \n2. How can specific dietary changes help alleviate neurologic symptoms associated with nutritional disorders?  \n3. What diagnostic tests are recommended to identify the underlying nutritional causes of persistent neurologic symptoms?  '), Document(id='268', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n88', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 35, 'type': 'text'}, page_content='1. What are the common causes of vitamin deficiency and how can they be prevented?  \n2. What symptoms might indicate a vitamin dependency in an individual?  \n3. What are the potential health risks associated with vitamin toxicity and how can it be treated?  '), Document(id='269', metadata={'original_content': 'for months or years become irreversible. In most elderly people with vitamin B\n12\n deficiency and dementia,\ncognition does not improve after treatment. Vitamin B\n12\n treatment must be continued for life unless the\npathophysiologic mechanism for the deficiency is corrected. Infants of vegan mothers should receive supplemental vitamin B\n12\n from birth. Vitamin C\nVitamin C (ascorbic acid) plays a role in collagen, carnitine, hormone, and amino acid formation. It is\nessential for wound healing and facilitates recovery from burns. Vitamin C is also an antioxidant, supports\nimmune function, and facilitates the absorption of iron. Vitamin C Deficiency\nIn developed countries, vitamin C deficiency can occur as part of general undernutrition, but\nsevere deficiency (causing scurvy) is uncommon. Symptoms include fatigue, depression, and\nconnective tissue defects (eg, gingivitis, petechiae, rash, internal bleeding, impaired wound\nhealing).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 36, 'type': 'text'}, page_content='1. What are the long-term cognitive effects of untreated vitamin B12 deficiency in elderly individuals?  \n2. How can vitamin C deficiency manifest in individuals, and what are its common symptoms?  \n3. What treatment recommendations are there for infants born to vegan mothers to prevent vitamin B12 deficiency?  '), Document(id='270', metadata={'original_content': 'In infants and children, bone growth may be impaired.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 36, 'type': 'text'}, page_content='1. What are the potential causes of impaired bone growth in infants and children?\n2. What symptoms might indicate that an infant or child is experiencing impaired bone growth?\n3. What treatments are available to address impaired bone growth in infants and children?'), Document(id='271', metadata={'original_content': 'Diagnosis is usually clinical. Treatment consists of oral vitamin C. Severe deficiency results in scurvy, a disorder characterized by hemorrhagic manifestations and abnormal\nosteoid and dentin formation. Etiology\nIn adults, primary deficiency is usually due to inadequate diet. The need for dietary vitamin C is increased\nby febrile illnesses, inflammatory disorders (particularly diarrheal disorders), achlorhydria, smoking,\nthyrotoxicosis, iron deficiency, cold or heat stress, surgery, burns, and protein deficiency. Heat (eg,\nsterilization of formulas, cooking) can destroy some of the vitamin C in food. Pathophysiology\nFormation of intercellular cement substances in connective tissues, bones, and dentin is defective,\nresulting in weakened capillaries with subsequent hemorrhage and defects in bone and related\nstructures.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 36, 'type': 'text'}, page_content="1. What dietary factors can lead to a primary deficiency of vitamin C in adults?  \n2. What are the clinical manifestations associated with severe vitamin C deficiency, such as scurvy?  \n3. How does smoking influence the body's need for dietary vitamin C?  "), Document(id='272', metadata={'original_content': 'Bone tissue formation becomes impaired, which, in children, causes bone lesions and poor bone growth. Fibrous tissue forms between the diaphysis and the epiphysis, and costochondral junctions enlarge. Densely calcified fragments of cartilage are embedded in the fibrous tissue. Subperiosteal hemorrhages,\nsometimes due to small fractures, may occur in children or adults. Symptoms and Signs\nIn adults, symptoms develop after weeks to months of vitamin C depletion. Lassitude, weakness,\nirritability, weight loss, and vague myalgias and arthralgias may develop early.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 36, 'type': 'text'}, page_content='1. What are the early symptoms of vitamin C depletion in adults that may indicate impaired bone tissue formation?  \n2. How does vitamin C deficiency lead to the formation of fibrous tissue in bone growth among children?  \n3. What potential complications arise from subperiosteal hemorrhages related to vitamin C deficiency in both children and adults?  '), Document(id='273', metadata={'original_content': 'Later, symptoms related to defects in connective tissues develop. Follicular hyperkeratosis, coiled hair,\nand perifollicular hemorrhages may develop. Gums may become swollen, purple, spongy, and friable; they\nbleed easily in severe deficiency. Eventually, teeth become loose and avulsed.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 36, 'type': 'text'}, page_content='1. What are the symptoms associated with severe deficiencies in connective tissues as mentioned in the document?\n2. How does the deficiency described affect oral health, particularly the condition of the gums and teeth?\n3. What specific skin and hair symptoms might indicate a nutritional disorder related to connective tissue defects?'), Document(id='274', metadata={'original_content': 'Secondary infections may\ndevelop. Wounds heal poorly and tear easily, and spontaneous hemorrhages may occur, especially as\necchymoses in the skin of the lower limbs or as bulbar conjunctival hemorrhage. Other symptoms and signs include femoral neuropathy due to hemorrhage into femoral sheaths (which\nmay mimic deep venous thrombosis), lower-extremity edema, and painful bleeding or effusions within\njoints. Diagnosis\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 36, 'type': 'text'}, page_content='1. What are the common symptoms associated with the nutritional disorder that leads to spontaneous hemorrhages and poor wound healing?  \n2. How can femoral neuropathy related to this nutritional disorder be differentiated from deep venous thrombosis?  \n3. What are the potential secondary infections that may arise as a result of the nutritional disorder described?  '), Document(id='275', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n89', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 36, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiency disorders, and how can they be identified?  \n2. How can excessive intake of vitamins lead to toxicity, and what are the signs to watch for?  \n3. What dietary changes or supplements can be recommended to address vitamin dependency issues?  '), Document(id='276', metadata={'original_content': ' Usually, skin or gingival findings and risk factors\nDiagnosis is usually made clinically in a patient who has skin or gingival signs and is at risk of vitamin C\ndeficiency. Laboratory confirmation may be available.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 37, 'type': 'text'}, page_content='1. What are the common skin and gingival signs associated with vitamin C deficiency?\n2. What risk factors increase the likelihood of developing vitamin C deficiency?\n3. How is vitamin C deficiency diagnosed clinically in patients exhibiting skin or gingival symptoms?'), Document(id='277', metadata={'original_content': 'Anemia is common.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 37, 'type': 'text'}, page_content='1. What are the common causes of anemia?\n2. What symptoms should one look out for to identify anemia?\n3. What dietary changes can help in the treatment of anemia?'), Document(id='278', metadata={'original_content': 'Bleeding, coagulation, and PT\nare normal. Skeletal x-rays can help diagnose childhood (but not adult) scurvy. Changes are most evident at the ends\nof long bones, particularly at the knee.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 37, 'type': 'text'}, page_content='1. What are the key symptoms of childhood scurvy that can be identified through skeletal x-rays?\n2. How does the diagnosis of childhood scurvy differ from that of adult scurvy, particularly in terms of skeletal changes?\n3. What nutritional deficiencies lead to the development of scurvy in children?'), Document(id='279', metadata={'original_content': "Early changes resemble atrophy. Loss of trabeculae results in a\nground-glass appearance. The cortex thins. A line of calcified, irregular cartilage (white line of Fraenkel)\nmay be visible at the metaphysis. A zone of rarefaction or a linear fracture proximal and parallel to the\nwhite line may be visible as only a triangular defect at the bone's lateral margin but is specific. The\nepiphysis may be compressed.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 37, 'type': 'text'}, page_content='1. What are the early symptoms associated with the atrophy of trabeculae in nutritional disorders?\n2. How does the ground-glass appearance of bones correlate with nutritional deficiencies?\n3. What treatment options are available for managing the complications of bone rarefaction and compression of the epiphysis in nutritional disorders?'), Document(id='280', metadata={'original_content': 'Healing subperiosteal hemorrhages may elevate and calcify the\nperiosteum. Laboratory diagnosis, which requires measuring blood ascorbic acid, is sometimes done at academic\ncenters. Levels of &lt; 0.6 mg/dL (&lt; 34 \n\nmol/L) are considered marginal; levels of &lt; 0.2 mg/dL (&lt; 11 \n\nmol/L)\nindicate vitamin C deficiency. Measurement of ascorbic acid levels in the WBC-platelet layer of\ncentrifuged blood is not widely available or standardized. In adults, scurvy must be differentiated from arthritis, hemorrhagic disorders, gingivitis, and protein-energy\nundernutrition. Hyperkeratotic hair follicles with surrounding hyperemia or hemorrhage are almost\npathognomonic. Bleeding gums, conjunctival hemorrhages, most petechiae, and ecchymoses are\nnonspecific. Treatment\n Nutritious diet with supplemental ascorbic acid\nFor scurvy in adults, ascorbic acid 100 to 500 mg po tid is given for 1 to 2 wk, until signs disappear, and\nfollowed by a nutritious diet supplying 1 to 2 times the daily recommended intake. In scurvy, therapeutic\ndoses \nof ascorbic acid restore the functions of vitamin C in a few days. The symptoms and signs usually\ndisappear over 1 to 2 wk.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 37, 'type': 'text'}, page_content='1. What are the specific symptoms that indicate a vitamin C deficiency in adults, and how can they be differentiated from other conditions like arthritis or gingivitis?\n2. How is the severity of vitamin C deficiency assessed through blood ascorbic acid levels, and what are the implications of different level ranges?\n3. What dietary recommendations and supplementation are necessary for the effective treatment of scurvy in adults?'), Document(id='281', metadata={'original_content': 'Chronic gingivitis with extensive subcutaneous hemorrhage persists longer. Prevention\nVitamin C 75 mg po once/day for women and 90 mg po once/day for men prevents deficiency. Smokers\nshould consume an additional 35 mg/day.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 37, 'type': 'text'}, page_content='1. What is the recommended daily intake of Vitamin C for men and women to prevent chronic gingivitis and its associated symptoms?  \n2. How does smoking influence the daily Vitamin C requirements to prevent nutritional deficiencies?  \n3. What are the potential consequences of Vitamin C deficiency in relation to chronic gingivitis and subcutaneous hemorrhage?  '), Document(id='282', metadata={'original_content': "Five servings of most fruits and vegetables (recommended\ndaily) provide &gt; 200 mg of vitamin C. Vitamin C Toxicity\nThe upper limit for vitamin C intake is 2000 mg/day. Up to 10 g/day of vitamin C are sometimes taken for\nunproven health benefits, such as preventing or shortening the duration of viral infections or slowing or\nreversing the progression of cancer or atherosclerosis. Such doses may acidify the urine, cause nausea\nand diarrhea, interfere with the healthy antioxidant-prooxidant balance in the body, and, in patients with\nthalassemia or hemochromatosis, promote iron overload. Intake below the upper limit does not have toxic\neffects in healthy adults. Vitamin D\nVitamin D has 2 main forms: D\n2\n (ergocalciferol) and D\n3\n (cholecalciferol); the latter is the naturally\noccurring form and the form used for low-dose supplementation. Vitamin D\n3\n is synthesized in skin by\nexposure to direct sunlight (ultraviolet B radiation) and obtained in the diet chiefly in fish liver oils and salt\nwater fish. In some developed countries, milk and other foods are fortified with vitamin D. Human breast\nmilk is low in vitamin D, containing an average of only 10% of the amount in fortified cow's milk. Requirements for vitamin D increase with age because skin synthesis declines.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 37, 'type': 'text'}, page_content='1. What are the potential health risks associated with excessive intake of vitamin C beyond the recommended daily limit?  \n2. How does vitamin D synthesis in the skin change with age, and what implications does this have for older adults?  \n3. What dietary sources can provide adequate levels of vitamin D for individuals, especially those who may not get enough sunlight exposure?  '), Document(id='283', metadata={'original_content': 'Sunscreen use and dark\nskin pigmentation also reduce skin synthesis of vitamin D. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 37, 'type': 'text'}, page_content="1. How does the use of sunscreen affect vitamin D synthesis in individuals with dark skin pigmentation?  \n2. What role does skin pigmentation play in the body's ability to produce vitamin D when exposed to sunlight?  \n3. Are there specific recommendations for vitamin D supplementation in people with dark skin who regularly use sunscreen?  "), Document(id='284', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n90', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 37, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiency and how can they be differentiated from those of vitamin toxicity?  \n2. What factors contribute to an increased risk of vitamin dependency in individuals?  \n3. How can one effectively treat and manage vitamin toxicity in patients?  '), Document(id='285', metadata={'original_content': 'Vitamin D is a prohormone with several active metabolites that act as hormones. Vitamin D is metabolized\nby the liver to 25(OH)D, which is then converted by the kidneys to 1,25(OH)\n2\nD (1,25-\ndihydroxycholecalciferol, calcitriol, or active vitamin D hormone). 25(OH)D, the major circulating form, has\nsome metabolic activity, but 1,25(OH)\n2\nD is the most metabolically active. The conversion to 1,25(OH)\n2\nD\nis regulated by its own concentration, parathyroid hormone (PTH), and serum concentrations of Ca and\nphosphate. [\nTable 4-6. Actions of Vitamin D and its Metabolites]\nVitamin D affects many organ systems (see \nTable 4-6\n), but mainly it increases Ca and phosphate\nabsorption from the intestine and promotes normal bone formation and mineralization. Vitamin D and\nrelated analogs may be used to treat psoriasis, hypoparathyroidism, renal osteodystrophy, and possibly\nleukemia and breast, prostate, and colon cancers; they may also be used for immunosuppression. Vitamin D Deficiency and Dependency\nInadequate exposure to sunlight predisposes to vitamin D deficiency.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 38, 'type': 'text'}, page_content='1. What are the potential health consequences of vitamin D deficiency in relation to bone formation and mineralization?\n2. How does inadequate exposure to sunlight contribute to the development of vitamin D deficiency?\n3. In what ways can vitamin D and its metabolites be used as treatment options for conditions like hypoparathyroidism and renal osteodystrophy?'), Document(id='286', metadata={'original_content': 'Deficiency impairs bone\nmineralization, causing rickets in children and osteomalacia in adults and possibly contributing\nto osteoporosis. Treatment usually consists of oral vitamin D; Ca and phosphate are\nsupplemented as needed.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 38, 'type': 'text'}, page_content='1. What are the symptoms of rickets in children and osteomalacia in adults due to vitamin D deficiency?  \n2. How does vitamin D deficiency contribute to the development of osteoporosis?  \n3. What treatments are typically recommended for individuals diagnosed with rickets or osteomalacia?  '), Document(id='287', metadata={'original_content': 'Prevention is often possible.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 38, 'type': 'text'}, page_content='1. What dietary changes can help prevent the onset of this nutritional disorder?\n2. What are the early symptoms that indicate the presence of this nutritional disorder?\n3. What treatment options are available for individuals diagnosed with this nutritional disorder?'), Document(id='288', metadata={'original_content': 'Rarely, hereditary disorders cause\nimpaired metabolism of vitamin D (dependency). Vitamin D deficiency is a common cause of rickets and osteomalacia, but these disorders may also result\nfrom other conditions, such as various renal tubular disorders, familial hypophosphatemic (vitamin D-\nresistant) rickets (see p. 2991\n), chronic metabolic acidosis, hypoparathyroidism (which reduces vitamin D\nabsorption), inadequate dietary Ca, and disorders or drugs that impair the mineralization of bone matrix. Vitamin D deficiency causes hypocalcemia, which stimulates production of PTH, causing\nhyperparathyroidism. Hyperparathyroidism increases absorption, bone mobilization, and renal\nconservation of Ca but increases excretion of phosphate. As a result, the serum level of Ca may be\nnormal, but because of hypophosphatemia, bone mineralization is impaired. Etiology\nVitamin D deficiency may result from the following.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 38, 'type': 'text'}, page_content='1. What hereditary disorders can lead to impaired metabolism of vitamin D and how do they affect bone health?\n2. How does chronic metabolic acidosis contribute to vitamin D deficiency and its associated disorders?\n3. In what ways can hyperparathyroidism affect calcium and phosphate levels in patients with vitamin D deficiency?'), Document(id='289', metadata={'original_content': 'Inadequate exposure or intake:\n Inadequate direct sunlight exposure (or sunscreen use) and\ninadequate intake usually occur simultaneously to result in clinical deficiency. Susceptible people include\nthe elderly (who are often undernourished and are not exposed to enough sunlight), and certain\ncommunities (eg, women and children who are confined to the home or who wear clothing that covers the\nentire body and face). Inadequate vitamin D stores are common among the elderly, particularly those who\nare house-bound, institutionalized, or hospitalized or who have had a hip fracture. Recommended direct\nsunlight exposure is 5 to 15 min (suberythemal dose) to arms and legs, or face, arms and hands, at least\n3 times a week. Reduced absorption:\n Malabsorption can deprive the body of dietary vitamin D; only a small amount of\n25(OH)D is recirculated enterohepatically.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 38, 'type': 'text'}, page_content='1. What are the primary factors contributing to vitamin D deficiency in the elderly population?  \n2. How does inadequate sunlight exposure relate to malabsorption issues in vitamin D?  \n3. What recommendations can be made to improve vitamin D intake for individuals who are house-bound or wear clothing that covers their skin?  '), Document(id='290', metadata={'original_content': 'Abnormal metabolism:\n Vitamin D deficiency may result from defects in the production of 25(OH)D or\n1,25(OH)\n2\nD. People with a chronic renal disorder commonly develop rickets or osteomalacia because\nrenal production of 1,25 (OH)\n2\nD is decreased and phosphate levels are elevated. Hepatic dysfunction\ncan also interfere with production of active vitamin D metabolites. Type I hereditary vitamin D-dependent rickets is an autosomal recessive disorder characterized by absent\nor defective conversion of 25(OH)D to 1,25(OH)\n2\nD in the kidneys. X-linked familial hypophosphatemia\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 38, 'type': 'text'}, page_content='1. What are the potential causes of vitamin D deficiency related to renal dysfunction?\n2. How does Type I hereditary vitamin D-dependent rickets affect the metabolism of vitamin D in the body?\n3. What are the symptoms and treatment options for individuals with osteomalacia due to vitamin D deficiency?'), Document(id='291', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n91', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 38, 'type': 'text'}, page_content='1. What are the common symptoms associated with a vitamin deficiency, and how can they be identified?  \n2. What factors can lead to vitamin dependency, and what are the potential health implications?  \n3. How can vitamin toxicity occur, and what treatment options are available for managing its effects?  '), Document(id='292', metadata={'original_content': 'reduces vitamin D synthesis in the kidneys. Many anticonvulsants and glucocorticoid use increase the\nneed for vitamin D supplementation. Resistance to effects of vitamin D:\n Type II hereditary vitamin D-dependent rickets has several forms\nand is due to mutations in the 1,25(OH)\n2\nD receptor.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 39, 'type': 'text'}, page_content="1. How do anticonvulsants and glucocorticoids affect the body's requirement for vitamin D supplementation?  \n2. What are the genetic mutations associated with Type II hereditary vitamin D-dependent rickets?  \n3. What are the potential symptoms of resistance to the effects of vitamin D in individuals with Type II hereditary vitamin D-dependent rickets?  "), Document(id='293', metadata={'original_content': 'This receptor affects the metabolism of gut, kidney,\nbone, and other cells.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 39, 'type': 'text'}, page_content="1. How does the dysfunction of this receptor influence metabolic processes in the gut and kidney?  \n2. What symptoms might arise from an imbalance in the receptor's activity affecting bone health?  \n3. What treatment options are available to address the metabolic disturbances caused by this receptor in various tissues?  "), Document(id='294', metadata={'original_content': 'In this disorder, 1,25(OH)\n2\nD is abundant but ineffective because the receptor is not\nfunctional. Symptoms and Signs\nVitamin D deficiency can cause muscle aches, muscle weakness, and bone pain at any age. Vitamin D deficiency in a pregnant woman causes deficiency in the fetus. Occasionally, deficiency severe\nenough to cause maternal osteomalacia results in rickets with metaphyseal lesions in neonates. In young\ninfants, rickets causes softening of the entire skull (craniotabes). When palpated, the occiput and\nposterior parietal bones feel like a ping pong ball. In older infants with rickets, sitting and crawling are\ndelayed, as is fontanelle closure; there is bossing of the skull and costochondral thickening. Costochondral thickening can look like beadlike prominences along the lateral chest wall (rachitic rosary). In children 1 to 4 yr, epiphyseal cartilage at the lower ends of the radius, ulna, tibia, and fibula enlarges;\nkyphoscoliosis develops, and walking is delayed.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 39, 'type': 'text'}, page_content='1. What are the potential consequences of vitamin D deficiency during pregnancy for both the mother and the fetus?\n2. How does vitamin D deficiency manifest in young infants, and what specific symptoms should caregivers look for?\n3. What are the long-term developmental implications of untreated rickets in children aged 1 to 4 years?'), Document(id='295', metadata={'original_content': 'In older children and adolescents, walking is painful; in\nextreme cases, deformities such as bowlegs and knock-knees develop. Tetany is caused by hypocalcemia and may accompany infantile or adult vitamin D deficiency. Tetany may\ncause paresthesias of the lips, tongue, and fingers; carpopedal and facial spasm; and, if very severe,\nseizures. Maternal deficiency can cause tetany in neonates. Osteomalacia predisposes to fractures.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 39, 'type': 'text'}, page_content='1. What are the potential deformities that can develop in older children and adolescents due to vitamin D deficiency?\n2. How does hypocalcemia contribute to the development of tetany in both infants and adults?\n3. What are the symptoms associated with severe tetany, and how can it affect individuals with maternal vitamin D deficiency?'), Document(id='296', metadata={'original_content': 'In the elderly, hip fractures may result from only minimal trauma. Diagnosis\n Levels of 25(OH)D (D\n2\n+D\n3\n)\nDiagnosis may be suspected based on any of the following:\n A history of inadequate sunlight exposure or dietary intake\n Symptoms and signs of rickets, osteomalacia, or neonatal tetany\n Characteristic bone changes seen on x-ray\nX-rays of the radius and ulna plus serum levels of Ca, phosphate, alkaline phosphatase, PTH, and\n25(OH)D are needed to differentiate vitamin D deficiency from other causes of bone demineralization. Assessment of vitamin D status and serologic tests for syphilis can be considered for infants with\ncraniotabes based on the history and physical, but most cases of craniotabes resolve spontaneously. Rickets can be distinguished from chondrodystrophy because the latter is characterized by a large head,\nshort extremities, thick bones, and normal serum Ca, phosphate, and alkaline phosphatase levels. Tetany due to infantile rickets may be clinically indistinguishable from seizures due to other causes. Blood\ntests and clinical history may help distinguish them.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 39, 'type': 'text'}, page_content='1. What are the common symptoms of rickets in the elderly, and how can they be distinguished from other conditions?\n2. How can inadequate sunlight exposure contribute to the diagnosis of vitamin D deficiency in elderly patients?\n3. What diagnostic tests are necessary to differentiate vitamin D deficiency from other causes of bone demineralization?'), Document(id='297', metadata={'original_content': 'Bone changes, seen on x-rays, precede clinical signs. In rickets, changes are most evident at the lower\nends of the radius and ulna. The diaphyseal ends lose their sharp, clear outline; they are cup-shaped and\nshow a spotty or fringy rarefaction. Later, because the ends of the radius and ulna have become\nnoncalcified and radiolucent, the distance between them and the metacarpal bones appears increased. The bone matrix elsewhere also becomes more radiolucent. Characteristic deformities result from the\nbones bending at the cartilage-shaft junction because the shaft is weak. As healing begins, a thin white\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 39, 'type': 'text'}, page_content='1. What are the early radiographic changes associated with rickets, particularly at the lower ends of the radius and ulna?  \n2. How do the bone deformities in rickets develop due to weakness at the cartilage-shaft junction?  \n3. What is the significance of the radiolucent appearance of the bone matrix in the diagnosis of rickets?  '), Document(id='298', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n92', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 39, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiency, and how can they impact overall health?\n2. What dietary changes can be made to address a vitamin deficiency and prevent its recurrence?\n3. How can excessive intake of vitamins lead to toxicity, and what are the potential health risks associated with it?'), Document(id='299', metadata={'original_content': "line of calcification appears at the epiphysis, becoming denser and thicker as calcification proceeds. Later, the bone matrix becomes calcified and opacified at the subperiosteal level. In adults, bone demineralization, particularly in the spine, pelvis, and lower extremities, can be seen on x-\nrays; the fibrous lamellae can also be seen, and incomplete ribbonlike areas of demineralization\n(pseudofractures, Looser's lines, Milkman's syndrome) appear in the cortex. Because levels of serum 25(OH)D reflect body stores of vitamin D and correlate with symptoms and signs\nof vitamin D deficiency better than levels of other vitamin D metabolites, 25(OH)D (D\n2\n+D\n3\n) measurement\nis generally considered the best way to diagnose deficiency.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 40, 'type': 'text'}, page_content='1. What are the characteristic x-ray findings associated with vitamin D deficiency in adults, particularly in terms of bone demineralization and pseudofractures?  \n2. How does the level of serum 25(OH)D correlate with the symptoms of vitamin D deficiency, and why is it considered the best diagnostic measure?  \n3. What are the potential consequences of prolonged vitamin D deficiency on bone health, particularly in relation to calcification and the development of fibrous lamellae?  '), Document(id='300', metadata={'original_content': 'Goal 25(OH)D levels are 30 to 40 ng/mL\n(about 75 to 100 nmol/L); whether higher levels may be beneficial remains uncertain. If the diagnosis is unclear, serum levels of 1,25(OH)\n2\nD and urinary Ca concentration can be measured. In\nsevere deficiency, serum 1,25(OH)\n2\nD is abnormally low, usually undetectable. Urinary Ca is low in all\nforms of the deficiency except those associated with acidosis. In vitamin D deficiency, serum Ca may be low or, because of secondary hyperparathyroidism, may be\nnormal. Serum phosphate usually decreases, and serum alkaline phosphatase usually increases. Serum\nPTH is elevated. Type I hereditary vitamin D-dependent rickets results in normal serum 25(OH)D, low serum 1,25(OH)\n2\nD\nand Ca, and normal or low serum phosphate. Treatment\n Correction of Ca and phosphate deficiencies\n Supplemental vitamin D\nCa deficiency (which is common) and phosphate deficiency should be corrected. As long as Ca and\nphosphate intake is adequate, adults with osteomalacia and children with uncomplicated rickets can be\ncured by giving vitamin D 40 \n\ng (1600 IU) po once/day. Serum 25(OH)D and 1,25(OH)\n2\nD begin to\nincrease within 1 or 2 days.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 40, 'type': 'text'}, page_content='1. What are the serum levels of 1,25(OH)2D and urinary calcium concentration indicative of severe vitamin D deficiency?\n2. How does secondary hyperparathyroidism affect serum calcium levels in individuals with vitamin D deficiency?\n3. What is the recommended treatment regimen for adults with osteomalacia due to vitamin D deficiency?'), Document(id='301', metadata={'original_content': 'Serum Ca and phosphate increase and serum alkaline phosphatase\ndecreases within about 10 days. During the 3rd wk, enough Ca and phosphate are deposited in bones to\nbe visible on x-rays. After about 1 mo, the dose can usually be reduced gradually to the usual\nmaintenance level of 10 to 15 \n\ng (400 to 600 IU) once/day. If tetany is present, vitamin D should be\nsupplemented with IV Ca salts for up to 1 wk (see p. 841\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 40, 'type': 'text'}, page_content='1. What changes in serum calcium and phosphate levels indicate the effectiveness of treatment for the nutritional disorder discussed in the document?  \n2. How does the supplementation of vitamin D and intravenous calcium salts help in the management of tetany associated with this nutritional disorder?  \n3. What is the typical timeframe for the deposition of calcium and phosphate in bones to become visible on x-rays after starting treatment?  '), Document(id='302', metadata={'original_content': 'Elderly patients may need 25 to  50 \n\ng (1000\nto  2000 IU) daily to maintain a 25(OH)D level &gt; 30 ng/mL (&gt; 75 nmol/L); this dose is higher than the\nrecommended daily allowance (RDA) for people &gt; 70 yr (600 IU) and may exceed the current upper limit\nof 2000 IU/day. Because rickets and osteomalacia due to defective production of vitamin D metabolites are vitamin D-\nresistant, they do not respond to the doses usually effective for rickets due to inadequate intake.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 40, 'type': 'text'}, page_content='1. What is the recommended daily allowance of vitamin D for elderly patients over 70 years old, and how does it compare to the amount needed to maintain adequate 25(OH)D levels?  \n2. Why do patients with rickets and osteomalacia caused by defective production of vitamin D metabolites not respond to standard vitamin D supplementation?  \n3. What are the potential risks associated with elderly patients exceeding the upper limit of 2000 IU/day of vitamin D?  '), Document(id='303', metadata={'original_content': 'Endocrinologic evaluation is required because treatment depends on the specific defect. When 25(OH)D\nproduction is defective, vitamin D 50 \n\ng (2000 IU) once/day increases serum levels and results in clinical\nimprovement. Patients with kidney disorders often need 1,25(OH)\n2\nD supplementation. Type I hereditary vitamin D-dependent rickets responds to 1,25(OH)\n2\nD 1 to 2 \n\ng po once/day. Some\npatients with type II hereditary vitamin D-dependent rickets respond to very high doses (eg, 10 to 24\n\ng/day) of 1,25(OH)\n2\nD; others require long-term infusions of Ca. Prevention\nDietary counseling is particularly important in communities whose members are at risk of vitamin D\ndeficiency. Fortifying unleavened chapati flour with vitamin D (125 \n\ng/kg) has been effective among Indian\nimmigrants in Britain. The benefits of sunlight exposure for vitamin D status must be weighed against the\nincreased skin damage and skin cancer risks.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 40, 'type': 'text'}, page_content='1. What are the specific treatments for patients with type I hereditary vitamin D-dependent rickets?\n2. How does the supplementation of 1,25(OH)2D differ between patients with kidney disorders and those with hereditary vitamin D-dependent rickets?\n3. What dietary interventions can help prevent vitamin D deficiency in at-risk communities?'), Document(id='304', metadata={'original_content': 'The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 40, 'type': 'text'}, page_content='1. What are the most common causes of vitamin D deficiency as outlined in the Merck Manual of Diagnosis &amp; Therapy?  \n2. What symptoms are typically associated with iron deficiency anemia according to the Merck Manual?  \n3. What treatment options are recommended for patients with malnutrition in the Merck Manual of Diagnosis &amp; Therapy?'), Document(id='305', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n93', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 40, 'type': 'text'}, page_content='1. What are the common symptoms associated with a vitamin deficiency, and how can they be identified?  \n2. What are the potential health risks of vitamin toxicity, and what causes it?  \n3. How can dietary changes or supplements be used to treat vitamin dependency?  '), Document(id='306', metadata={'original_content': 'increased skin damage and skin cancer risks. All breastfed infants should be given supplemental vitamin D 5 \n\ng (200 IU) once/day from birth to 6 mo; at\n6 mo, a more diversified diet is available. For adolescents at risk, a single IM dose of ergocalciferol 2.5\nmg (100,000 IU) given in the fall can maintain adequate 25(OH)D levels throughout the winter. The\nrecommended daily allowance (RDA) for vitamin D is 400 IU for people aged 51 to 70 and \n600 IU for\nthose &gt;70; many consider this intake too low, and the 2005 Dietary Guidelines for Americans\nrecommends that healthy older adults consume 1000 IU/day. Vitamin D Toxicity\nUsually, vitamin D toxicity results from taking excessive amounts.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 41, 'type': 'text'}, page_content='1. What are the potential consequences of vitamin D deficiency in infants and adolescents concerning skin health?  \n2. How much vitamin D should older adults consume daily to reduce the risk of skin damage and skin cancer?  \n3. What are the symptoms and risks associated with vitamin D toxicity?  '), Document(id='307', metadata={'original_content': 'Marked hypercalcemia\ncommonly causes symptoms. Diagnosis is typically based on elevated blood levels of 25(OH)D. Treatment consists of stopping vitamin D, restricting dietary Ca, restoring intravascular volume\ndeficits, and, if toxicity is severe, giving corticosteroids or bisphosphonates. Because synthesis of 1,25(OH)\n2\nD (the most active metabolite of vitamin D) is tightly regulated, vitamin D\ntoxicity usually occurs only if excessive doses (prescription or megavitamin) are taken. Vitamin D 1000 \n\ng\n(40,000 IU)/day causes toxicity within 1 to 4 mo in infants. In adults, taking 1250 \n\ng (50,000 IU)/day for\nseveral months can cause toxicity. Vitamin D toxicity can occur iatrogenically when hypoparathyroidism is\ntreated too aggressively (see p.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 41, 'type': 'text'}, page_content='1. What are the common symptoms associated with marked hypercalcemia due to vitamin D toxicity?\n2. How is the diagnosis of vitamin D toxicity confirmed through blood tests?\n3. What treatment options are available for managing severe cases of vitamin D toxicity?'), Document(id='308', metadata={'original_content': '844\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 41, 'type': 'text'}, page_content='[]'), Document(id='309', metadata={'original_content': 'Symptoms and Signs\nThe main symptoms result from hypercalcemia. Anorexia, nausea, and vomiting can develop, often\nfollowed by polyuria, polydipsia, weakness, nervousness, pruritus, and eventually renal failure. Proteinuria, urinary casts, azotemia, and metastatic calcifications (particularly in the kidneys) can develop. Diagnosis\n Hypercalcemia plus risk factors or elevated serum 25(OH)D levels\nA history of excessive vitamin D intake may be the only clue differentiating vitamin D toxicity from other\ncauses of hypercalcemia. Elevated serum Ca levels of 12 to 16 mg/dL (3 to 4 mmol/L) are a constant\nfinding when toxic symptoms occur. Serum 25(OH)D levels are usually elevated &gt; 150 ng/mL (&gt; 375\nnmol/L). Levels of 1,25(OH)\n2\nD, which need not be measured to confirm the diagnosis, may be normal. Serum Ca should be measured often (weekly at first, then monthly) in all patients receiving large doses of\nvitamin D, particularly the potent 1,25(OH)\n2\nD. Treatment\n IV hydration plus corticosteroids or bisphosphonates\nAfter stopping vitamin D intake, hydration with IV normal saline and corticosteroids or bisphosphonates\n(which inhibit bone resorption) are used to reduce blood Ca levels. Kidney damage or metastatic calcifications, if present, may be irreversible.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 41, 'type': 'text'}, page_content='1. What are the common symptoms associated with hypercalcemia due to excessive vitamin D intake?  \n2. How can one differentiate between vitamin D toxicity and other causes of hypercalcemia?  \n3. What treatment options are available for managing hypercalcemia resulting from vitamin D toxicity?  '), Document(id='310', metadata={'original_content': 'Vitamin E\nVitamin E is a group of compounds (including tocopherols and tocotrienols) that have similar biologic\nactivities.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 41, 'type': 'text'}, page_content='1. What are the potential causes of Vitamin E deficiency in individuals?\n2. What symptoms might indicate a deficiency in Vitamin E?\n3. How can Vitamin E deficiency be treated or managed effectively?'), Document(id='311', metadata={'original_content': 'The most biologically active is \n\n-tocopherol, but \n\n-, \n\n-, and \n\n-tocopherols, 4 tocotrienols, and\nseveral stereoisomers may also have important biologic activity. These compounds act as antioxidants,\nwhich prevent lipid peroxidation of polyunsaturated fatty acids in cellular membranes. Plasma tocopherol\nlevels vary with total plasma lipid levels. Normally, the plasma \n\n-tocopherol level is 5 to 20 \n\ng/mL (11.6 to\n46.4 \n\nmol/L). High-dose vitamin E supplements do not protect against cardiovascular disorders;whether\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 41, 'type': 'text'}, page_content='1. What is the role of -tocopherol and other tocopherols in preventing lipid peroxidation in cellular membranes?  \n2. How do plasma tocopherol levels correlate with total plasma lipid levels in the body?  \n3. Why do high-dose vitamin E supplements fail to protect against cardiovascular disorders?  '), Document(id='312', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n94', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 41, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiency and how can they be identified?\n2. What factors can lead to vitamin dependency in individuals, and how does it affect their health?\n3. What are the signs of vitamin toxicity, and what treatment options are available to address it?'), Document(id='313', metadata={'original_content': "supplements can protect against Alzheimer's disease, tardive dyskinesia, and prostate cancer among\nsmokers is controversial. Although the amount of vitamin E in many fortified foods and supplements is given in IU, current\nrecommendations are to use mg. Vitamin E Deficiency\nDietary vitamin E deficiency is common in developing countries; deficiency among adults in\ndeveloped countries is uncommon and usually due to fat malabsorption. The main symptoms\nare hemolytic anemia and neurologic deficits. Diagnosis is based on measuring the ratio of\nplasma \n\n-tocopherol to total plasma lipids; a low ratio suggests vitamin E deficiency. Treatment\nconsists of oral vitamin E, given in high doses if there are neurologic deficits or if deficiency\nresults from malabsorption. Vitamin E deficiency causes fragility of RBCs and degeneration of neurons, particularly peripheral axons\nand posterior column neurons. Etiology\nIn developing countries, the most common cause is inadequate intake of vitamin E.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 42, 'type': 'text'}, page_content='1. What are the main symptoms associated with vitamin E deficiency in adults, and how does it typically manifest in developing countries?  \n2. How is vitamin E deficiency diagnosed, and what does a low plasma -tocopherol to total plasma lipids ratio indicate?  \n3. What are the recommended treatment options for individuals diagnosed with vitamin E deficiency, particularly in cases involving neurologic deficits?  '), Document(id='314', metadata={'original_content': 'In developed\ncountries, the most common causes are disorders that cause fat malabsorption, including\nabetalipoproteinemia (Bassen-Kornzweig syndrome, due to genetic absence of apolipoprotein B), chronic\ncholestatic \nhepatobiliary disease, pancreatitis, short bowel syndrome, and cystic fibrosis. A rare genetic\nform of vitamin E deficiency without fat malabsorption results from defective liver metabolism. Symptoms and Signs\nThe main symptoms are mild hemolytic anemia and nonspecific neurologic deficits. Abetalipoproteinemia\nresults in progressive neuropathy and retinopathy in the first 2 decades of life (see p.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 42, 'type': 'text'}, page_content='1. What are the primary causes of fat malabsorption leading to nutritional disorders in developed countries?  \n2. What symptoms and signs are associated with abetalipoproteinemia and vitamin E deficiency?  \n3. How does the progression of neuropathy and retinopathy manifest in individuals with abetalipoproteinemia during the first two decades of life?  '), Document(id='315', metadata={'original_content': '904\n). Vitamin E deficiency may contribute to retinopathy of prematurity (also called retrolental fibroplasia) in\npremature infants and to some cases of intraventricular and subependymal hemorrhage in neonates. Affected premature neonates have muscle weakness. In children, chronic cholestatic hepatobiliary disease or cystic fibrosis causes neurologic deficits, including\nspinocerebellar ataxia with loss of deep tendon reflexes, truncal and limb ataxia, loss of vibration and\nposition senses, ophthalmoplegia, muscle weakness, ptosis, and dysarthria. In adults with malabsorption, vitamin E deficiency very rarely causes spinocerebellar ataxia because\nadults have large vitamin E stores in adipose tissue. Diagnosis\n Low \n\n-tocopherol level or low ratio of serum \n\n-tocopherol to serum lipids\nWithout a history of inadequate intake or a predisposing condition, vitamin E deficiency is unlikely.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 42, 'type': 'text'}, page_content='1. What are the potential neurological symptoms associated with vitamin E deficiency in children with chronic cholestatic hepatobiliary disease or cystic fibrosis?\n2. How does vitamin E deficiency contribute to retinopathy of prematurity in premature infants?\n3. What laboratory findings are indicative of vitamin E deficiency in affected individuals?'), Document(id='316', metadata={'original_content': 'Confirmation usually requires measuring the vitamin level.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 42, 'type': 'text'}, page_content='1. What vitamin deficiency can be confirmed through measuring vitamin levels in patients?  \n2. What are the common symptoms associated with low vitamin levels?  \n3. What treatment options are available for individuals diagnosed with a vitamin deficiency?  '), Document(id='317', metadata={'original_content': 'Measuring RBC hemolysis in response to\nperoxide can suggest the diagnosis but is nonspecific. Hemolysis increases as vitamin E deficiency\nimpairs RBC stability. Measuring the serum \n\n-tocopherol level is the most direct method of diagnosis. In adults, vitamin E\ndeficiency is suggested if the \n\n-tocopherol level is &lt; 5 \n\ng/mL (&lt; 11.6 \n\nmol/L). Because abnormal lipid\nlevels can affect vitamin E status, a low ratio of serum \n\n-tocopherol to lipids (&lt; 0.8 mg/g total lipid) is the\nmost accurate indicator in adults with hyperlipidemia. In children and adults with abetalipoproteinemia, serum \n\n-tocopherol levels are usually undetectable. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 42, 'type': 'text'}, page_content='1. How does vitamin E deficiency lead to increased RBC hemolysis, and what are the implications for diagnosis?  \n2. What are the recommended serum -tocopherol levels for diagnosing vitamin E deficiency in adults, and how can lipid levels influence this measurement?  \n3. In cases of abetalipoproteinemia, what can be expected regarding serum -tocopherol levels, and how does this condition affect vitamin E status?  '), Document(id='318', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n95', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 42, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiency, and how can they be identified?  \n2. What factors contribute to vitamin dependency in individuals, and how can it be addressed?  \n3. What are the potential health risks of vitamin toxicity, and what treatment options are available for those affected?  '), Document(id='319', metadata={'original_content': 'Treatment\n Supplemental \n\n-tocopherol\nIf malabsorption causes clinically evident deficiency, \n\n-tocopherol 15 to 25 mg/kg po once/day should be\ngiven. However, larger doses given by injection are required to treat neuropathy during its early stages or\nto overcome the defect of absorption and transport in abetalipoproteinemia. Prevention\nAlthough premature neonates may require supplementation, human milk and commercial formulas have\nenough vitamin E for full-term neonates. Vitamin E Toxicity\nMany adults take relatively large amounts of vitamin E (\n\n-tocopherol 400 to 800 mg/day) for months to\nyears without any apparent harm. Occasionally, muscle weakness, fatigue, nausea, and diarrhea occur.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 43, 'type': 'text'}, page_content='1. What is the recommended dosage of -tocopherol for treating clinically evident deficiency due to malabsorption?\n2. How does the treatment for neuropathy differ from the standard supplementation of -tocopherol in patients with abetalipoproteinemia?\n3. What are the potential side effects associated with high doses of vitamin E supplementation in adults?'), Document(id='320', metadata={'original_content': 'The most significant risk is bleeding.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 43, 'type': 'text'}, page_content='1. What are the potential causes of bleeding associated with this nutritional disorder?\n2. What symptoms might indicate that a person is experiencing bleeding due to this nutritional disorder?\n3. What treatment options are available to manage bleeding related to this nutritional disorder?'), Document(id='321', metadata={'original_content': 'However, bleeding is uncommon unless the dose is &gt; 1000 mg/day\nor the patient takes oral coumarin or warfarin. Thus, the upper limit for adults aged 19 yr is 1000 mg for\nany form of \n\n-tocopherol. Recent analyses of previous studies report that high vitamin E intakes may\nincrease the risk of hemorrhagic stroke and premature death.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 43, 'type': 'text'}, page_content='1. What are the potential risks associated with high vitamin E intake in adults, particularly regarding hemorrhagic stroke and premature death?  \n2. How does the dosage of vitamin E affect the likelihood of bleeding in patients taking anticoagulants like coumarin or warfarin?  \n3. What is the recommended upper limit of vitamin E intake for adults aged 19 and older to avoid adverse health effects?  '), Document(id='322', metadata={'original_content': 'Vitamin K\nVitamin K\n1\n (phylloquinone) is dietary vitamin K.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 43, 'type': 'text'}, page_content='1. What dietary sources are rich in Vitamin K and how can they help prevent Vitamin K deficiency?\n2. What are the common symptoms associated with a deficiency in Vitamin K?\n3. How can Vitamin K supplementation be used as a treatment for individuals with low levels of this vitamin?'), Document(id='323', metadata={'original_content': 'Dietary fat enhances its absorption. Infant formulas\ncontain supplemental vitamin K. Vitamin K\n2\n refers to a group of compounds (menaquinones) synthesized\nby bacteria in the intestinal tract; the amount synthesized does not satisfy the vitamin K requirement. Vitamin K controls the formation of coagulation factors II (prothrombin), VII, IX, and X in the liver. Other\ncoagulation factors dependent on vitamin K are protein C, protein S, and protein Z; proteins C and S are\nanticoagulants. Metabolic pathways conserve vitamin K. Once vitamin K has participated in formation of\ncoagulation factors, the reaction product, vitamin K epoxide, is enzymatically converted to the active form,\nvitamin K hydroquinone. The actions of vitamin K-dependent proteins require Ca. The vitamin K-dependent proteins, osteocalcin\nand matrix \n\n-carboxy-glutamyl (Gla) protein, may have important roles in bone and other tissues. Forms of\nvitamin K are common therapy for osteoporosis in Japan and other countries. Vitamin K Deficiency\nVitamin K deficiency results from extremely inadequate intake, fat malabsorption, or use of\ncoumarin anticoagulants. Deficiency is particularly common among breastfed infants. It impairs\nclotting.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 43, 'type': 'text'}, page_content='1. What are the primary causes of vitamin K deficiency in infants, and how does it impact their clotting ability?  \n2. How do dietary fat and gut bacteria contribute to the absorption and synthesis of vitamin K in the body?  \n3. What role does vitamin K play in the treatment of osteoporosis, and how is it utilized in therapy?  '), Document(id='324', metadata={'original_content': 'Diagnosis is suspected based on routine coagulation study findings and confirmed by\nresponse to vitamin K. Treatment consists of vitamin K given orally or, when fat malabsorption\nis the cause or risk of bleeding is high, parenterally. Vitamin K deficiency decreases levels of prothrombin and other vitamin K-dependent coagulation factors,\ncausing defective coagulation and, potentially, bleeding. Etiology\nWorldwide, vitamin K deficiency causes infant morbidity and mortality. Vitamin K deficiency causes\nhemorrhagic disease of the newborn, which usually occurs 1 to 7 days postpartum. In affected neonates,\nbirth trauma can cause intracranial hemorrhage. Neonates are prone to vitamin K deficiency because of\nthe following:\n The placenta transmits lipids and vitamin K relatively poorly. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 43, 'type': 'text'}, page_content='1. What are the common causes of vitamin K deficiency in newborns, and how does it relate to their coagulation status?  \n2. What symptoms might indicate a vitamin K deficiency in infants, particularly in the context of hemorrhagic disease?  \n3. How is vitamin K deficiency treated in neonates, and what factors influence the choice between oral and parenteral administration?  '), Document(id='325', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n96', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 43, 'type': 'text'}, page_content="1. What are the common causes of vitamin deficiency in adults?  \n2. What symptoms might indicate a vitamin toxicity condition?  \n3. How can vitamin dependency affect an individual's overall health?  "), Document(id='326', metadata={'original_content': " The neonatal liver is immature with respect to prothrombin synthesis.  Breast milk is low in vitamin K, containing about 2.5 \n\ng/L (cow's milk contains 5000 \n\ng/L).  The neonatal gut is sterile during the first few days of life. Late hemorrhagic disease (occurring 3 to 8 wk postpartum) is usually associated with breastfeeding,\nmalabsorption, or a liver disorder. If the mother has taken phenytoin anticonvulsants, coumarin\nanticoagulants, or cephalosporin antibiotics, the risk of both types of hemorrhagic disease is increased. In healthy adults, dietary vitamin K deficiency is uncommon because vitamin K is widely distributed in\ngreen vegetables and the bacteria of the normal gut synthesize menaquinones. However, biliary\nobstruction, malabsorption, cystic fibrosis, and resection of the small intestine can contribute to vitamin K\ndeficiency. Coumarin anticoagulants interfere with the synthesis of vitamin K-dependent coagulation proteins (factors\nII, VII, IX, and X) in the liver. Certain antibiotics (particularly some cephalosporins and other broad-\nspectrum antibiotics), salicylates, megadoses of vitamin E, and hepatic insufficiency increase risk of\nbleeding in patients with vitamin K deficiency. Symptoms and Signs\nBleeding is the usual manifestation.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 44, 'type': 'text'}, page_content='1. What are the potential causes of late hemorrhagic disease in neonates, particularly in relation to breastfeeding and maternal medications?  \n2. How does the immaturity of the neonatal liver affect prothrombin synthesis and the risk of bleeding disorders?  \n3. What role do dietary sources of vitamin K and gut bacteria play in preventing vitamin K deficiency in healthy adults compared to neonates?  '), Document(id='327', metadata={'original_content': 'Easy bruisability and mucosal bleeding (especially epistaxis, GI\nhemorrhage, menorrhagia, and hematuria) can occur. Blood may ooze from puncture sites or incisions. Hemorrhagic disease of the newborn and late hemorrhagic disease in infants may cause cutaneous, GI,\nintrathoracic, or, in the worst cases, intracranial bleeding. If obstructive jaundice develops, bleedingif it\noccursusually begins after the 4th or 5th day.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 44, 'type': 'text'}, page_content='1. What are the common causes of easy bruisability and mucosal bleeding in infants?\n2. How does obstructive jaundice affect the timing and severity of bleeding in newborns?\n3. What are the potential complications of late hemorrhagic disease in infants?'), Document(id='328', metadata={'original_content': 'It may begin as a slow ooze from a surgical incision, the\ngums, the nose, or GI mucosa, or it may begin as massive bleeding into the GI tract. Diagnosis\n Usually, prolonged PT that decreases after phytonadione\nVitamin K deficiency or antagonism (due to coumarin anticoagulants) is suspected when abnormal\nbleeding occurs in a patient at risk. Blood coagulation studies can preliminarily confirm the diagnosis. PT,\nusually reported as the INR, is prolonged, but PTT, thrombin time, platelet count, bleeding time, and\nlevels of fibrinogen, fibrin-split products, and D-dimer are normal. If phytonadione (USP generic name for\nvitamin K\n1\n) 1 mg IV significantly decreases PT within 2 to 6 h, a liver disorder is not the likely cause, and\nthe diagnosis of vitamin K deficiency is confirmed. Some centers can detect vitamin K deficiency more\ndirectly by measuring the serum vitamin level.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 44, 'type': 'text'}, page_content='1. What are the common symptoms of vitamin K deficiency that may indicate abnormal bleeding in a patient?  \n2. How can the administration of phytonadione help differentiate between vitamin K deficiency and liver disorders in patients with prolonged PT?  \n3. What coagulation studies are typically performed to diagnose vitamin K deficiency and what results would indicate a deficiency?  '), Document(id='329', metadata={'original_content': 'The serum level of vitamin K\n1\n ranges from 0.2 to 1.0 ng/mL\nin healthy people consuming adequate quantities of vitamin K\n1\n (50 to 150 \n\ng/day). Knowing vitamin K\nintake can help interpret serum levels; recent intake affects levels in serum but not in tissues.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 44, 'type': 'text'}, page_content='1. How does inadequate dietary intake of vitamin K affect serum levels in individuals?\n2. What are the potential symptoms of vitamin K deficiency in relation to serum levels?\n3. How can recent vitamin K intake influence the interpretation of serum vitamin K levels in clinical assessments?'), Document(id='330', metadata={'original_content': 'More sensitive indicators of vitamin K status, such as PIVKA (\nP\nrotein \nI\nnduced in \nV\nitamin \nK A\nbsence or\nA\nntagonism) and under-carboxylated osteocalcin, are under study. Treatment\n Phytonadione\nWhenever possible, phytonadione should be given po or sc.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 44, 'type': 'text'}, page_content='1. What are the more sensitive indicators of vitamin K status, and how do they relate to diagnosing vitamin K deficiency?  \n2. What is the recommended route of administration for phytonadione in the treatment of vitamin K deficiency?  \n3. How does under-carboxylated osteocalcin serve as a marker for assessing vitamin K status in individuals?  '), Document(id='331', metadata={'original_content': 'The usual adult dose is 5 to 20 mg. (Rarely,\neven when phytonadione is correctly diluted and given slowly, IV replacement can result in anaphylaxis or\nanaphylactoid reactions.) INR usually decreases within 6 to 12 h. The dose may be repeated in 6 to 8 h if\nINR has not decreased satisfactorily. Phytonadione 2.5 to 10 mg po is indicated for \nnonemergency\ncorrection of a prolonged INR in patients taking anticoagulants. Correction usually occurs within 6 to 8 h.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 44, 'type': 'text'}, page_content='1. What is the recommended dosage range of phytonadione for correcting a prolonged INR in patients on anticoagulants?  \n2. What potential adverse reactions can occur with intravenous administration of phytonadione?  \n3. How quickly can one expect a decrease in INR levels after administering phytonadione?  '), Document(id='332', metadata={'original_content': 'When only partial correction of INR is desirable (eg, when INR should remain slightly elevated because of\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency &amp; Toxicity\n97', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 44, 'type': 'text'}, page_content='1. What dietary modifications can be made to maintain a slightly elevated INR in patients requiring partial correction?  \n2. What vitamin deficiencies are associated with abnormal INR levels?  \n3. How can vitamin toxicity impact INR levels in patients on anticoagulant therapy?  '), Document(id='333', metadata={'original_content': 'a prosthetic heart valve), lower doses (eg, 1 to 2.5 mg) of phytonadione can be given. In infants, bleeding due to deficiency can be corrected by giving phytonadione 1 mg sc or IM once. The\ndose is repeated if INR remains elevated. Higher doses may be necessary if the mother has been taking\noral anticoagulants. Prevention\nPhytonadione 0.5 to 1 mg IM (or 0.3 mg/kg for preterm infants) is recommended for all neonates within 6 h\nof birth to reduce the incidence of intracranial hemorrhage due to birth trauma and of classic hemorrhagic\ndisease of the newborn (increased bleeding risks 1 to 7 days after birth). It is also used prophylactically\nbefore surgery. Some clinicians recommend that pregnant women taking anticonvulsants receive\nphytonadione 10 mg po once/day for the 1 mo or 20 mg po once/day for the 2 wk before delivery. The low\nvitamin K\n1\n content in breast milk can be increased by increasing maternal dietary intake of phylloquinone\nto 5 mg/day. Vitamin K Toxicity\nVitamin K\n1\n (phylloquinone) is not toxic when consumed orally, even in large amounts.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 45, 'type': 'text'}, page_content='1. What is the recommended dosage of phytonadione for neonates within the first 6 hours of birth to prevent hemorrhagic disease?  \n2. How can maternal dietary intake of phylloquinone affect vitamin K levels in breast milk?  \n3. What are the indications for administering phytonadione to pregnant women who are taking anticonvulsants?  '), Document(id='334', metadata={'original_content': 'However,\nmenadione (a synthetic, water-soluble vitamin K precursor) can cause toxicity and should not be used to\ntreat vitamin K deficiency. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 4.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 45, 'type': 'text'}, page_content='1. What are the potential risks associated with using menadione for treating vitamin K deficiency?  \n2. How does vitamin K deficiency manifest in individuals?  \n3. What alternative treatments are recommended for vitamin K deficiency instead of menadione?  '), Document(id='335', metadata={'original_content': 'Vitamin Deficiency, Dependency &amp; Toxicity\n98', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 45, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin deficiency, and how can they be identified?\n2. What are the potential health risks of excessive vitamin intake, and how can vitamin toxicity be managed?\n3. What dietary changes can be recommended to address vitamin dependency and prevent deficiencies?'), Document(id='336', metadata={'original_content': 'Chapter 5. Mineral Deficiency and Toxicity\nIntroduction\nSix macrominerals are required by people in gram amounts. Four (Na, K, Ca, and Mg) are cations; two (Cl\nand P) are accompanying anions (see p.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 46, 'type': 'text'}, page_content='1. What are the common symptoms associated with a deficiency in macrominerals such as calcium and magnesium?  \n2. How can excessive intake of sodium lead to toxicity, and what are the potential health consequences?  \n3. What dietary changes can be implemented to prevent mineral deficiencies in individuals at risk?  '), Document(id='337', metadata={'original_content': '820\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 46, 'type': 'text'}, page_content='[]'), Document(id='338', metadata={'original_content': "Daily requirements range from 0.3 to 2.0 g. Bone, muscle,\nheart, and brain function depend on these minerals. Nine trace minerals (microminerals) are required by people in minute amounts: chromium, copper, iodine,\niron, fluorine, manganese, molybdenum, selenium, and zinc. (For sources, functions, effects of deficiency\nand toxicity, and dietary requirements, see\nTables 5-1\n and\n5-2\n.) All trace minerals are toxic at high levels; some minerals (arsenic, nickel, and chromium) may be\ncarcinogens. Mineral deficiencies (except of iodine, iron, and zinc) do not often develop spontaneously in adults on\nordinary diets; infants are more vulnerable because their growth is rapid and intake varies. Trace mineral\nimbalances can result from hereditary disorders (eg, hemochromatosis, Wilson's disease), kidney dialysis,\nparenteral nutrition, or restrictive diets prescribed for people with inborn errors of metabolism. Chromium\nOnly 1 to 3% of biologically active trivalent chromium (Cr) is absorbed. Normal plasma levels are 0.05 to\n0.50 \n\ng/L (1.0 to 9.6 nmol/L). Chromium potentiates insulin activity and increases the growth rate in\nundernourished children.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 46, 'type': 'text'}, page_content="1. What are the potential health effects of chromium deficiency in infants, and how does it differ from adults?  \n2. What dietary sources can help prevent trace mineral imbalances, particularly for chromium, copper, and zinc?  \n3. How can hereditary disorders like hemochromatosis and Wilson's disease affect the body's absorption and utilization of trace minerals?  "), Document(id='339', metadata={'original_content': 'Supplements do not enhance muscle size or strength in men. Deficiency:\n Four patients receiving long-term TPN developed possible chromium deficiency, with\nglucose intolerance, weight loss, ataxia, and peripheral neuropathy. Symptoms resolved in 3 who were\ngiven trivalent chromium 150 to 250 mg.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 46, 'type': 'text'}, page_content='1. What are the symptoms associated with chromium deficiency in patients receiving long-term TPN?  \n2. How does chromium supplementation affect glucose intolerance and peripheral neuropathy in individuals with deficiency?  \n3. What is the recommended dosage of trivalent chromium for treating chromium deficiency in patients?  '), Document(id='340', metadata={'original_content': "Toxicity:\n High doses of trivalent chromium given parenterally cause skin irritation, but lower doses given\norally are not toxic. Exposure to hexavalent chromium (CrO\n3\n) in the workplace may irritate the skin, lungs,\nand GI tract and may cause perforation of the nasal septum and lung carcinoma. Copper\nCopper is a component of many body proteins; almost all of the body's copper is bound to copper\nproteins.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 46, 'type': 'text'}, page_content='1. What are the health effects of exposure to hexavalent chromium in the workplace?\n2. How does trivalent chromium toxicity differ between parenteral and oral administration?\n3. What role does copper play in the body, and what are the potential consequences of copper deficiency?'), Document(id='341', metadata={'original_content': 'Unbound (free) copper ions are toxic. Genetic mechanisms control the incorporation of copper\ninto apoproteins and the processes that prevent toxic accumulation of copper in the body. Copper\nabsorbed in excess of metabolic requirements is excreted through bile. [\nTable 5-1. Trace Minerals]\nAcquired Copper Deficiency\nIf the genetic mechanisms controlling copper metabolism are normal, dietary deficiency rarely causes\nclinically significant copper deficiency. The only reported causes are kwashiorkor, persistent infantile\ndiarrhea (usually associated with a diet limited to milk), severe malabsorption (as in sprue), and excessive\nzinc intake. Deficiency may cause neutropenia, impaired bone calcification, and hypochromic anemia not responsive\nto iron supplements. Diagnosis is based on low serum levels of copper and ceruloplasmin, although these tests are not always\nreliable. Treatment is directed at the cause, and copper 1.5 to 3 mg/day po (usually as copper sulfate) is\ngiven. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 5.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 46, 'type': 'text'}, page_content='1. What dietary factors can lead to acquired copper deficiency in individuals with normal genetic mechanisms for copper metabolism?  \n2. What are the potential symptoms of copper deficiency, and how can it be differentiated from iron deficiency anemia?  \n3. What is the recommended treatment protocol for a patient diagnosed with acquired copper deficiency?  '), Document(id='342', metadata={'original_content': 'Mineral Deficiency &amp; Toxicity\n99', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 46, 'type': 'text'}, page_content='1. What are the common symptoms associated with mineral deficiencies in the body?  \n2. How can mineral toxicity occur, and what are its potential health effects?  \n3. What dietary changes or supplements can be recommended to address specific mineral deficiencies?  '), Document(id='343', metadata={'original_content': 'Inherited Copper Deficiency\n(Menkes Syndrome)\nInherited copper deficiency occurs in male infants who inherit a mutant X-linked gene. Incidence is about\n1 in 50,000 live births. Copper is deficient in the liver, serum, and essential copper proteins, including\ncytochrome-c oxidase, ceruloplasmin, and lysyl oxidase. Symptoms are severe intellectual disability, vomiting, diarrhea, protein-losing enteropathy,\nhypopigmentation, bone changes, and arterial rupture; the hair is sparse, steely, or kinky. Diagnosis\n Serum copper and ceruloplasmin levels\n Serum levels of dopamine, norepinephrine, dihydroxyphenylacetic acid, and dihydroxyphenylglycol in\ninfants at risk\nDiagnosis is based on low copper and ceruloplasmin levels in serum, although these tests are not always\nreliable. Because early diagnosis and treatment seem to result in a better prognosis, the disorder is\nideally detected before age 2 wk.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 47, 'type': 'text'}, page_content='1. What are the primary symptoms associated with inherited copper deficiency in male infants diagnosed with Menkes Syndrome?  \n2. How is inherited copper deficiency diagnosed in infants, and what specific serum levels are measured?  \n3. What is the importance of early diagnosis and treatment for infants at risk of inherited copper deficiency?'), Document(id='344', metadata={'original_content': 'However, diagnostic accuracy of these tests is limited. Thus, infants at\nrisk (eg, those with a family history) can be screened by measuring dopamine, norepinephrine,\ndihydroxyphenylacetic acid, and dihydroxyphenylglycol in serum. A dihydroxyphenylacetic\nacid:dihydroxyphenylglycol ratio of &gt; 4 seems to indicate deficiency, and a dopamine:norepinephrine ratio\nof &gt; 0.2 seems to confirm it. Treatment\n Copper histidine\nParenteral copper is usually given as copper histidine 250 \n\ng sc bid to age 1 yr, then 250 \n\ng sc once/day\nuntil age 3 yr; monitoring kidney function is essential during treatment. Despite early treatment, many\nchildren have abnormal neurodevelopment.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 47, 'type': 'text'}, page_content='1. What biochemical markers are used to screen infants at risk for the nutritional disorder mentioned in the document?\n2. How is the treatment regimen for copper deficiency in infants structured, and what is the importance of monitoring during this treatment?\n3. What are the potential neurodevelopmental outcomes for children treated early for the nutritional disorder discussed?'), Document(id='345', metadata={'original_content': 'Acquired Copper Toxicity\nAcquired copper toxicity can result from ingesting or absorbing excess copper (eg, from ingesting an\nacidic food or beverage that has had prolonged contact with a copper container). Self-limited\ngastroenteritis with nausea, vomiting, and diarrhea may occur. [\nTable 5-2. Guidelines for Daily Intake of Minerals]\nMore severe toxicity results from ingestion (usually with suicidal intent) of gram quantities of a copper salt\n(eg, copper sulfate) or from absorption of large amounts through the skin (eg, if compresses saturated\nwith a solution of a copper salt are applied to large areas of burned skin). Hemolytic anemia and anuria\ncan result and may be fatal. Indian childhood cirrhosis, non-Indian childhood cirrhosis, and idiopathic copper toxicity are probably\nidentical disorders in which excess copper causes cirrhosis. All seem to be caused by ingesting milk that\nhas been boiled or stored in corroded copper or brass vessels. Recent studies suggest that idiopathic\ncopper toxicity may develop only in infants with an unknown genetic defect. Diagnosis usually requires liver biopsy, which shows Mallory hyalin bodies.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 47, 'type': 'text'}, page_content='1. What are the potential sources of acquired copper toxicity in individuals, particularly related to food storage practices?  \n2. What symptoms are associated with mild versus severe cases of acquired copper toxicity?  \n3. How is acquired copper toxicity diagnosed, and what specific findings are expected in a liver biopsy?  '), Document(id='346', metadata={'original_content': 'Treatment\n Chelation\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 5.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 47, 'type': 'text'}, page_content='1. What is the role of chelation in the treatment of nutritional disorders caused by heavy metal toxicity?\n2. What are the potential symptoms associated with nutritional disorders that may require chelation therapy?\n3. How does the Merck Manual of Diagnosis &amp; Therapy outline the diagnosis of nutritional disorders that necessitate chelation?'), Document(id='347', metadata={'original_content': 'Mineral Deficiency &amp; Toxicity\n100', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 47, 'type': 'text'}, page_content='1. What are the common causes of mineral deficiency in adults?  \n2. What symptoms might indicate a person is experiencing mineral toxicity?  \n3. How can mineral deficiencies be effectively treated through diet or supplements?'), Document(id='348', metadata={'original_content': ' Supportive measures\nFor copper toxicity due to ingesting grams of copper, prompt gastric lavage is done. Copper toxicity that\ncauses complications such as hemolytic anemia, anuria, or hepatotoxicity is also treated with either oral\npenicillamine 250 mg q 6 h to 750 mg q 12 h (1000 to 1500 mg/day in 2 to 4 doses) or dimercaprol 3 to 5\nmg/kg IM q 4 h for 2 days, then q 4 to 6 h (see also\nTable 340-4\n and copper salts in\nTable 340-8\n). If used early, hemodialysis may be effective.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 48, 'type': 'text'}, page_content='1. What are the recommended treatments for severe copper toxicity with complications such as hemolytic anemia or hepatotoxicity?  \n2. How does prompt gastric lavage aid in the management of copper toxicity?  \n3. In what situations is hemodialysis considered effective for treating copper toxicity?  '), Document(id='349', metadata={'original_content': "Occasionally, copper toxicity is fatal despite\ntreatment. Inherited Copper Toxicity\n(Wilson's Disease)\nInherited copper toxicity results in accumulation of copper in the liver and other organs. Hepatic\nor neurologic symptoms develop.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 48, 'type': 'text'}, page_content="1. What are the primary symptoms associated with inherited copper toxicity, specifically Wilson's Disease?  \n2. How does inherited copper toxicity lead to copper accumulation in the liver and other organs?  \n3. What treatment options are available for individuals diagnosed with Wilson's Disease?  "), Document(id='350', metadata={'original_content': "Diagnosis is based on a low serum ceruloplasmin level, high\nurinary excretion of copper, and sometimes liver biopsy results. Treatment consists of a low-\ncopper diet and chelation, usually with penicillamine or dimercaprol. Wilson's disease is a progressive disorder of copper metabolism that affects 1 person in 30,000. Affected\npeople are homozygous for the mutant recessive gene, located on chromosome 13.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 48, 'type': 'text'}, page_content="1. What are the primary diagnostic indicators for Wilson's disease?\n2. How does a low-copper diet help in the management of Wilson's disease?\n3. What genetic factors contribute to the development of Wilson's disease?"), Document(id='351', metadata={'original_content': "Heterozygous\ncarriers, who constitute about 1.1% of the population, are asymptomatic. Pathophysiology\nThe genetic defect impairs copper transport. The impaired transport decreases copper secretion into the\nbile, thus causing the copper overload and resultant accumulation in the liver, which begins at birth. The\nimpaired transport also interferes with incorporation of copper into the copper protein ceruloplasmin, thus\ndecreasing serum levels of ceruloplasmin. Hepatic fibrosis develops, ultimately causing cirrhosis. Copper diffuses out of the liver into the blood, then\ninto other tissues. It is most destructive to the brain but also damages the kidneys and reproductive\norgans and causes hemolytic anemia. Some copper is deposited in Descemet's membrane of the cornea,\ncausing Kayser-Fleischer rings. Symptoms and Signs\nSymptoms usually develop between ages 5 and 40.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 48, 'type': 'text'}, page_content='1. What is the genetic defect responsible for the impaired copper transport in this nutritional disorder?\n2. At what age do symptoms of copper overload typically begin to develop in individuals affected by this condition?\n3. What are the potential complications associated with the accumulation of copper in the liver and other tissues in this disorder?'), Document(id='352', metadata={'original_content': 'In almost half of patients, particularly adolescents,\nthe first symptom is hepatitisacute, chronic active, or fulminant. But hepatitis may develop at any time. In about 40% of patients, particularly young adults, the first symptoms reflect CNS involvement. Motor\ndeficits are common, including any combination of tremors, dystonia, dysarthria, dysphagia, chorea,\ndrooling, and incoordination. Sometimes the first symptoms are cognitive or psychiatric abnormalities.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 48, 'type': 'text'}, page_content='1. What are the common initial symptoms of the nutritional disorder in adolescents and young adults?  \n2. How does the nutritional disorder cause CNS involvement in patients?  \n3. What treatment options are available for managing motor deficits associated with this nutritional disorder?  '), Document(id='353', metadata={'original_content': "In 5\nto 10% of patients, the first symptom is incidentally noted gold or greenish gold Kayser-Fleischer rings or\ncrescents (due to copper deposits in the cornea), amenorrhea or repeated miscarriages, or hematuria. Diagnosis\n Slit-lamp examination for Kayser-Fleischer rings\n Serum ceruloplasmin and 24-h urinary copper excretion\n Sometimes confirmation by penicillamine provocation test or liver biopsy\nWilson's disease should be suspected in people &lt; 40 with any of the following:\n An unexplained hepatic, neurologic, or psychiatric disorder\n An unexplained persistent elevation in hepatic transaminases\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 5. Mineral Deficiency &amp; Toxicity\n101", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 48, 'type': 'text'}, page_content="1. What are the initial symptoms that may indicate the presence of Wilson's disease in patients under 40?\n2. How is Wilson's disease diagnosed through clinical examinations and laboratory tests?\n3. What role do Kayser-Fleischer rings play in the diagnosis of Wilson's disease?"), Document(id='354', metadata={'original_content': " A sibling, parent, or cousin with Wilson's disease\n Fulminant hepatitis\nIf Wilson's disease is suspected, slit-lamp examination for Kayser-Fleischer rings is required, and serum\nceruloplasmin and copper levels and 24-h urinary copper excretion are measured. Transaminase levels\nare also often measured; high levels are consistent with the diagnosis. Kayser-Fleischer rings:\n These rings plus typical motor neurologic abnormalities or a decrease in\nceruloplasmin are nearly pathognomonic for Wilson's disease. Rarely, these rings occur in other liver\ndisorders (eg, biliary atresia, primary biliary cirrhosis), but ceruloplasmin levels should be unaffected. Ceruloplasmin:\n Serum ceruloplasmin (normally 20 to 35 mg/dL) is usually low in Wilson's disease but\ncan be normal. It can also be low in heterozygous carriers and those with other liver disorders (eg, viral\nhepatitis, drug- or alcohol-induced liver disease). A low ceruloplasmin level in a patient with a \nKayser-\nFleischer ring is diagnostic. Also, a level of &lt; 5 mg/dL is highly suggestive regardless of clinical findings.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 49, 'type': 'text'}, page_content="1. What diagnostic tests are necessary to confirm Wilson's disease in a patient with suspected symptoms, such as Kayser-Fleischer rings?  \n2. How do serum ceruloplasmin and copper levels help differentiate between Wilson's disease and other liver disorders like fulminant hepatitis?  \n3. What is the significance of a low ceruloplasmin level in a patient presenting with Kayser-Fleischer rings?  "), Document(id='355', metadata={'original_content': "Serum copper:\n Despite the copper accumulation in the body, serum copper levels are decreased\nbecause of the decreased ceruloplasmin levels. Urinary copper excretion:\n In Wilson's disease, 24-h urinary copper excretion (normally,  30 \n\ng/day) is\nusually &gt; 100 \n\ng/day. If serum ceruloplasmin is low and urinary copper excretion is high, diagnosis is\nclear. If levels are equivocal, measuring urinary copper excretion after penicillamine is given\n(penicillamine provocation test) may confirm the diagnosis; this test is not usually done in adults because\ncutoff values are not well-established. Liver biopsy:\n In unclear cases (eg, elevated transaminases, no Kayser-Fleischer rings, indeterminate\nvalues for ceruloplasmin and urinary copper), the diagnosis is made by doing a liver biopsy to measure\nhepatic copper concentration. However, false-negative results may occur because of a sampling error\n(due to large variations in copper concentrations in the liver) or fulminant hepatitis (causing necrosis that\nreleases large amounts of copper). Screening:\n Because early treatment is most effective, screening is indicated for anyone who has a\nsibling, cousin, or parent with Wilson's disease. Screening consists of a slit-lamp examination and\nmeasurement of transaminase levels, serum copper and ceruloplasmin, and 24-h urine copper excretion.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 49, 'type': 'text'}, page_content="1. What laboratory tests are used to diagnose Wilson's disease in patients with suspected copper metabolism disorders?\n2. How does low serum ceruloplasmin contribute to the clinical presentation of Wilson's disease?\n3. Why is a liver biopsy sometimes necessary in the diagnosis of Wilson's disease, and what factors may affect the accuracy of this test?"), Document(id='356', metadata={'original_content': 'If any results are abnormal, liver biopsy is done to measure hepatic copper concentration. Infants should\nnot be tested until after age 1 yr because ceruloplasmin levels are low during the first few months of life. Children &lt; 6 yr with normal test results should be retested 5 to 10 yr later.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 49, 'type': 'text'}, page_content='1. What are the implications of low ceruloplasmin levels in infants when testing for hepatic copper concentration?\n2. Why is it recommended to retest children under 6 years old for hepatic copper concentration after 5 to 10 years if their initial results are normal?\n3. What are the potential consequences of abnormal liver biopsy results in relation to hepatic copper levels?'), Document(id='357', metadata={'original_content': 'Genetic testing is under investigation.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 49, 'type': 'text'}, page_content='1. What role do genetic factors play in the development of the nutritional disorder being investigated?\n2. What specific symptoms might indicate a genetic predisposition to this nutritional disorder?\n3. How could genetic testing influence the treatment options available for individuals with this nutritional disorder?'), Document(id='358', metadata={'original_content': 'Prognosis\nPrognosis is usually good, unless disease is advanced before treatment begins.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 49, 'type': 'text'}, page_content='1. What factors can lead to an advanced stage of the nutritional disorder before treatment begins?  \n2. What are the common symptoms that indicate the nutritional disorder is progressing?  \n3. What treatment options are available for patients diagnosed with the nutritional disorder at an early stage?  '), Document(id='359', metadata={'original_content': "Untreated Wilson's\ndisease is fatal, usually by age 30. Treatment\n Penicillamine or another chelating drug if needed to remove accumulated copper\n Low-copper diet\n For maintenance, lifelong low-dose chelation therapy or oral zinc\nContinual, lifelong treatment is mandatory regardless of whether symptoms are present. Accumulated\ncopper should be removed with chelating drugs. A low-copper diet (eg, avoiding beef liver, cashews,\nblack-eyed peas, vegetable juice, shellfish, mushrooms, and cocoa) and use of either low-dose chelation\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 5. Mineral Deficiency &amp; Toxicity\n102", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 49, 'type': 'text'}, page_content="1. What are the potential consequences of untreated Wilson's disease if left without treatment?\n2. What dietary restrictions should individuals with Wilson's disease follow to manage their condition effectively?\n3. What are the recommended treatments for removing accumulated copper in patients diagnosed with Wilson's disease?"), Document(id='360', metadata={'original_content': 'therapy or oral zinc can prevent copper from accumulating. Penicillamine is the most commonly used chelating drug but has considerable toxicity (eg, fever, rash,\nneutropenia, thrombocytopenia, proteinuria). Cross-reactivity may occur in people with penicillin allergy.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 50, 'type': 'text'}, page_content='1. What are the potential side effects of using penicillamine as a chelating agent for copper accumulation?  \n2. How can therapy or oral zinc help in managing copper levels in the body?  \n3. Is there a risk of allergic reactions for individuals with a penicillin allergy when using penicillamine?  '), Document(id='361', metadata={'original_content': 'Patients &gt; 5 yr are given oral doses of 62.5 mg q 6 h to 250 mg q 12 h (250 to 500 mg/day in 2 to 4\ndoses) and slowly increased to a maximum of 250 mg q 6 h to 750 mg q 12 h (1000 to 1500 mg/day in 2\nto 4 doses).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 50, 'type': 'text'}, page_content='1. What is the recommended dosage schedule for patients over 5 years old with this nutritional disorder?\n2. How can the dosage of medication be adjusted for patients experiencing inadequate symptom control?\n3. What is the maximum daily dosage for patients over 5 years old with this nutritional disorder?'), Document(id='362', metadata={'original_content': 'Younger children are given 10 mg/kg bid or 6.7 mg/kg tid (20 mg/kg/d) po. Pyridoxine 25 mg\npo once/day is given with penicillamine. Occasionally, use of penicillamine is associated with worsening\nneurologic symptoms. Trientine hydrochloride is an alternative treatment to penicillamine. Doses are 375 to 750 mg po bid or\n250 to 500 mg po tid (750 to 1500 mg/day). Zinc acetate 50 mg po tid can prevent reaccumulation of copper in patients who cannot tolerate\npenicillamine or trientine or who have neurologic symptoms that do not respond to the other drugs. (CAUTION: \nPenicillamine or trientine must not be given with zinc because either drug can bind zinc,\nforming a compound with no therapeutic effect\n.)\nPoor long-term adherence to drug therapy is common. After 1 to 5 yr of therapy, lower dose maintenance\ndrug therapy can be considered.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 50, 'type': 'text'}, page_content='1. What are the recommended dosages of penicillamine and trientine hydrochloride for treating younger children with this nutritional disorder?\n2. How does zinc acetate function in the treatment of patients who cannot tolerate penicillamine or trientine, and what are the precautions associated with its use?\n3. What are the potential neurological side effects associated with the use of penicillamine in the treatment of this nutritional disorder?'), Document(id='363', metadata={'original_content': "Regular follow-up care with an expert in liver disease is recommended. Liver transplantation may be lifesaving for patients who have Wilson's disease and fulminant hepatic\nfailure or severe hepatic insufficiency refractory to drugs. Fluorine\nMost of the body's fluorine (F) is contained in bones and teeth.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 50, 'type': 'text'}, page_content="1. What are the treatment options for patients with Wilson's disease experiencing severe hepatic insufficiency?\n2. How does fluorine contribute to the health of bones and teeth in individuals with liver disease?\n3. What role does regular follow-up care play in managing Wilson's disease?"), Document(id='364', metadata={'original_content': "Fluoride (the ionic form of fluorine) is\nwidely distributed in nature. The main source of fluoride is fluoridated drinking water. Deficiency:\n Fluorine deficiency can lead to dental caries and possibly osteoporosis. Fluoridation of\nwater that contains &lt; 1 ppm (the ideal) reduces the incidence of dental caries. If a child's drinking water is\nnot fluoridated, oral fluoride supplements can be prescribed. Toxicity:\n Excess fluorine can accumulate in teeth and bones, causing fluorosis. Drinking water\ncontaining &gt; 10 ppm is a common cause. Permanent teeth that develop during \nhigh fluoride intake are\nmost likely to be affected.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 50, 'type': 'text'}, page_content='1. What are the potential dental and skeletal health consequences of fluoride deficiency in children?\n2. How does the fluoride concentration in drinking water affect the incidence of dental caries?\n3. What are the symptoms and risks associated with fluoride toxicity, particularly in relation to dental fluorosis?'), Document(id='365', metadata={'original_content': 'Exposure must be much greater to affect deciduous teeth. The earliest signs are chalky white, irregularly distributed patches on the surface of the enamel; these\npatches become stained yellow or brown, producing a characteristic mottled appearance. Severe toxicity\nweakens the enamel, pitting its surface. Bony changes, including osteosclerosis, exostoses of the spine,\nand genu valgum, can develop but only in adults after prolonged high intake of fluoride. No tests to diagnose toxicity are available.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 50, 'type': 'text'}, page_content='1. What are the early signs of fluoride toxicity in children, particularly regarding their deciduous teeth?\n2. How does prolonged high intake of fluoride lead to bony changes in adults?\n3. What are the characteristic appearances of enamel affected by severe fluoride toxicity?'), Document(id='366', metadata={'original_content': 'Treatment involves reducing fluoride intake; eg, in areas with high fluoride water levels, patients should\nnot drink fluoridated water or take fluoride supplements. Children should always be told not to swallow\nfluoridated toothpastes. Iodine\nIn the body, iodine (I) is involved primarily in the synthesis of 2 thyroid hormones, thyroxine (T\n4\n) and\ntriiodothyronine (T\n3\n). Iodine occurs in the environment and in the diet primarily as iodide. In adults, about\n80% of the iodide absorbed is trapped by the thyroid gland. Most environmental iodine occurs in\nseawater as iodide; a small amount enters the atmosphere and, through rain, enters ground water and\nsoil near the sea. Thus, people living far from the sea and at higher altitudes are at particular risk of\ndeficiency. Fortifying table salt with iodide (typically 70 \n\ng/g) helps ensure adequate intake (150 \n\ng/day). Requirements are higher for pregnant (220 \n\ng/day) and breastfeeding (290 \n\ng/day) women.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 50, 'type': 'text'}, page_content='1. What are the potential health risks associated with high fluoride intake in children?  \n2. How can iodine deficiency impact thyroid hormone production in adults?  \n3. What dietary sources are recommended for individuals living far from the sea to prevent iodine deficiency?  '), Document(id='367', metadata={'original_content': 'The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 5.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 50, 'type': 'text'}, page_content='1. What are the common symptoms associated with vitamin D deficiency, as outlined in the Merck Manual of Diagnosis &amp; Therapy?\n2. What treatment options are recommended for managing iron deficiency anemia according to the Merck Manual?\n3. How does malnutrition affect immune function, based on the information in the Merck Manual?'), Document(id='368', metadata={'original_content': 'Mineral Deficiency &amp; Toxicity\n103', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 50, 'type': 'text'}, page_content='1. What are the common symptoms associated with mineral deficiency in adults?\n2. How can excessive intake of certain minerals lead to toxicity, and what are the potential health effects?\n3. What dietary changes can be recommended to prevent mineral deficiencies in children?'), Document(id='369', metadata={'original_content': 'Iodine Deficiency\nDeficiency is rare in areas where iodized salt is used but common worldwide. Iodine deficiency develops\nwhen iodide intake is &lt; 20 \n\ng/day. In mild or moderate deficiency, the thyroid gland, influenced by thyroid-\nstimulating hormone (TSH), hypertrophies to concentrate iodide in itself, resulting in colloid goiter. Usually, patients remain euthyroid; however, severe iodine deficiency in adults may cause hypothyroidism\n(endemic myxedema). It can decrease fertility and increase risk of stillbirth, spontaneous abortion, and\nprenatal and infant mortality. Severe maternal iodine deficiency retards fetal growth and brain\ndevelopment, sometimes resulting in birth defects, and, in infants, causes cretinism, which may include\nintellectual disability, deaf-mutism, difficulty walking, short stature, and sometimes hypothyroidism. Diagnosis\n Assessment of thyroid structure and function\nDiagnosis in adults and children is usually based on thyroid function, examination for goiter, and imaging\ntests identifying abnormalities in thyroid function and structure (see p.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 51, 'type': 'text'}, page_content='1. What are the potential health consequences of severe iodine deficiency during pregnancy for both the mother and the fetus?  \n2. How does iodine deficiency lead to the development of goiter in individuals?  \n3. What diagnostic methods are used to assess thyroid function in individuals suspected of having iodine deficiency?  '), Document(id='370', metadata={'original_content': '776\n).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 51, 'type': 'text'}, page_content='1. What are the common causes of the nutritional disorder described in the document?\n2. What symptoms should one look for to identify this nutritional disorder?\n3. What treatment options are available for managing the nutritional disorder mentioned?'), Document(id='371', metadata={'original_content': 'All neonates should be screened by measuring the TSH level. Treatment\n Iodide with or without levothyroxine\nInfants with iodine deficiency are given L-thyroxine 3 \n\ng/kg po once/day for a week plus iodide 50 to 90\n\ng po once/day for several weeks to quickly restore a euthyroid state. Children are treated with iodide 90\nto 120 \n\ng once/day. Adults are given iodide 150 \n\ng once/day. Iodine deficiency can also be treated by\ngiving levothyroxine. Serum TSH levels are monitored in all patients until the levels are normal (ie, &lt; 5\n\nIU/mL). Iodine Toxicity\nChronic toxicity may develop when intake is &gt; 1.1 mg/day. Most people who ingest excess amounts of\niodine remain euthyroid. Some people who ingest excess amounts of iodine, particularly those who were\npreviously deficient, develop hyperthyroidism (Jod-Basedow phenomenon). Paradoxically, excess uptake\nof iodine by the thyroid may inhibit thyroid hormone synthesis (called Wolff-Chaikoff effect). Thus, iodine\ntoxicity can eventually cause iodide goiter, hypothyroidism, or myxedema. Very large amounts of iodide\nmay cause a brassy taste in the mouth, increased salivation, GI irritation, and acneiform skin lesions. Patients exposed to frequent large amounts of radiographic contrast dyes or the drug amiodarone also\nneed to have their thyroid function monitored.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 51, 'type': 'text'}, page_content='1. What is the recommended treatment protocol for infants diagnosed with iodine deficiency?\n2. What are the potential symptoms and complications associated with chronic iodine toxicity?\n3. How is thyroid function monitored in patients receiving treatment for iodine deficiency?'), Document(id='372', metadata={'original_content': 'Diagnosis is usually based on thyroid function and imaging test findings (see p.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 51, 'type': 'text'}, page_content='1. What imaging tests are typically used to diagnose thyroid-related nutritional disorders?  \n2. How do thyroid function tests contribute to the diagnosis of nutritional disorders?  \n3. What symptoms are commonly associated with thyroid dysfunction in nutritional disorders?  '), Document(id='373', metadata={'original_content': '776\n), which are\ncorrelated with clinical data. Iodine excretion may be more specific but is not usually measured.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 51, 'type': 'text'}, page_content='1. What are the potential clinical implications of low iodine excretion in patients with iodine deficiency?\n2. How can measuring iodine excretion aid in the diagnosis of thyroid-related disorders?\n3. What are the common symptoms associated with iodine deficiency in individuals?'), Document(id='374', metadata={'original_content': 'Treatment\nconsists of correcting thyroid abnormalities and, if intake is excessive, dietary modification. Iron\nIron (Fe) is a component of hemoglobin, myoglobin, and many enzymes in the body.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 51, 'type': 'text'}, page_content='1. What dietary modifications are recommended for individuals with excessive iron intake related to thyroid abnormalities?  \n2. How do thyroid abnormalities impact iron levels in the body?  \n3. What are the symptoms of iron deficiency related to thyroid dysfunction?  '), Document(id='375', metadata={'original_content': 'Heme iron, contained\nmainly in animal products, is absorbed much better than nonheme iron (eg, in plants and grains), which\naccounts for &gt; 85% of iron in the average diet. However, absorption of nonheme iron is increased when it\nis consumed with animal protein and vitamin C. Deficiency:\n Iron deficiency is one of the most common mineral deficiencies in the world. It may result\nfrom the following:\n Inadequate iron intake, common in infants, adolescent girls, and pregnant women\n Malabsorption (eg, celiac sprue)\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 5. Mineral Deficiency &amp; Toxicity\n104', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 51, 'type': 'text'}, page_content='1. What are the primary causes of iron deficiency in different population groups, such as infants, adolescent girls, and pregnant women?  \n2. How does the presence of animal protein and vitamin C affect the absorption of nonheme iron from plant sources?  \n3. What are the potential health consequences of iron deficiency due to malabsorption conditions like celiac sprue?  '), Document(id='376', metadata={'original_content': ' Chronic bleeding\nChronic bleeding due to colon cancer is a serious cause in middle-aged people and the elderly. When deficiency is advanced, microcytic anemia develops (see p.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 52, 'type': 'text'}, page_content='1. What are the potential nutritional deficiencies caused by chronic bleeding from colon cancer in middle-aged and elderly individuals?  \n2. How does chronic bleeding lead to the development of microcytic anemia?  \n3. What treatment options are available for managing anemia resulting from chronic bleeding due to colon cancer?'), Document(id='377', metadata={'original_content': '924\n). In addition to anemia, iron deficiency may cause pica (a craving for nonfoods) and spoon nails and is\nassociated with restless leg syndrome. Rarely, iron deficiency causes dysphagia due to postcricoid\nesophageal web. Diagnosis involves CBC, serum ferritin, and possibly measurement of transferrin saturation (iron\ncapacity).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 52, 'type': 'text'}, page_content='1. What are the common symptoms associated with iron deficiency anemia?\n2. How does iron deficiency contribute to the development of pica?\n3. What diagnostic tests are used to confirm iron deficiency in patients?'), Document(id='378', metadata={'original_content': 'All people with moderate or severe iron deficiency and some people with mild deficiency require iron\nsupplementation. Toxicity:\n Iron may accumulate in the body because of\n Iron therapy given in excessive amounts or for too long\n Repeated blood transfusions\n Chronic alcoholism\n Overdose of iron\nIron overload can also result from an inherited iron overload disease (hemochromatosissee p. 1032\n), a\npotentially fatal but easily treatable genetic disorder in which too much iron is absorbed. Hemochromatosis affects &gt; 1 million Americans. An overdose of iron is toxic (see p. 3341\n), causing vomiting, diarrhea, and damage to the intestine and\nother organs. Diagnosis is similar to that for iron deficiency.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 52, 'type': 'text'}, page_content='1. What are the potential causes of iron overload in the body, and how do they differ from those of iron deficiency?  \n2. What symptoms should be monitored in individuals who are receiving iron supplementation to prevent toxicity?  \n3. How can hemochromatosis be diagnosed and what treatments are available for this genetic disorder?  '), Document(id='379', metadata={'original_content': 'Treatment often involves deferoxamine, which binds with iron and is excreted in urine. Manganese\nManganese (Mn), necessary for healthy bone structure, is a component of several enzyme systems,\nincluding manganese-specific glycosyltransferases and phosphoenolpyruvate carboxykinase. Median\nintake is between 1.6 and 2.3 mg/day; absorption is 5 to 10%.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 52, 'type': 'text'}, page_content='1. What role does manganese play in enzyme systems related to bone health?\n2. What are the typical treatment options for conditions involving excess iron in the body?\n3. How does deferoxamine function in the treatment of iron overload disorders?'), Document(id='380', metadata={'original_content': "Deficiency has not been conclusively documented, although one experimental case in a volunteer\nresulted in transient dermatitis, hypocholesterolemia, and increased alkaline phosphatase levels. Toxicity is usually limited to people who mine and refine ore; prolonged exposure causes neurologic\nsymptoms resembling those of parkinsonism or Wilson's disease. Molybdenum\nMolybdenum (Mo) is a component of coenzymes necessary for the activity of xanthine oxidase, sulfite\noxidase, and aldehyde oxidase. Genetic and nutritional deficiencies of molybdenum have been reported but are rare. Genetic sulfite\noxidase deficiency was described in 1967 in a child. It resulted from the inability to form the molybdenum\ncoenzyme despite the presence of adequate molybdenum. The deficiency caused intellectual disability,\nseizures, opisthotonus, and lens dislocation. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 5.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 52, 'type': 'text'}, page_content='1. What are the potential neurological symptoms associated with prolonged exposure to molybdenum toxicity?\n2. How can a genetic deficiency in sulfite oxidase lead to intellectual disability and seizures in affected individuals?\n3. What are the possible symptoms of molybdenum deficiency observed in experimental cases?'), Document(id='381', metadata={'original_content': 'Mineral Deficiency &amp; Toxicity\n105', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 52, 'type': 'text'}, page_content='NA'), Document(id='382', metadata={'original_content': 'Molybdenum deficiency resulting in sulfite toxicity occurred in a patient receiving long-term TPN. Symptoms were tachycardia, tachypnea, headache, nausea, vomiting, and coma. Laboratory tests\nshowed high levels of sulfite and xanthine and low levels of sulfate and uric acid in the blood and urine. Ammonium molybdate 300 \n\ng/day IV caused dramatic recovery. A case of molybdenum toxicity may have occurred in 1961; it caused goutlike symptoms and\nabnormalities of the GI tract, liver, and kidneys. Selenium\nSelenium (Se) is a part of the enzyme glutathione peroxidase, which metabolizes hydro-peroxides formed\nfrom polyunsaturated fatty acids.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 53, 'type': 'text'}, page_content='NA'), Document(id='383', metadata={'original_content': 'Selenium is also a part of the enzymes that deiodinate thyroid\nhormones. Generally, selenium acts as an antioxidant that works with vitamin E. Some epidemiologic\nstudies associate low selenium levels with cancer. In children with Down syndrome, selenium\nsupplements may help prevent bacterial infections. Plasma levels vary from 8 to 25 \n\ng/dL, depending on\nselenium intake.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 53, 'type': 'text'}, page_content='NA'), Document(id='384', metadata={'original_content': 'Diagnosis is usually clinical; sometimes blood glutathione peroxidase is measured. Deficiency:\n Deficiency is rare, even in New Zealand and Finland, where selenium intake \nis 30 to 50\n\ng/day, compared with 100 to 250 \n\ng/day in the US and Canada. In certain areas of China, where intake\naverages 10 to 15 \n\ng/day, selenium deficiency predisposes patients to Keshan disease, an endemic viral\ncardiomyopathy affecting primarily children and young women. This cardiomyopathy can be prevented\nbut not cured by sodium selenite supplements of 50 \n\ng/day po. Patients receiving long-term TPN have\ndeveloped selenium deficiency with muscle pain and tenderness that responded to a selenomethionine\nsupplement. In Siberian Russia and China, growing children with selenium deficiency may develop\nchronic osteoarthropathy (Kashin-Beck disease).', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 53, 'type': 'text'}, page_content='NA'), Document(id='385', metadata={'original_content': 'Selenium deficiency may contribute synergistically with\niodine deficiency to the development of goiter and hypothyroidism. Diagnosis is made clinically or sometimes by measuring glutathione peroxidase activity or plasma\nselenium, but neither of these tests is readily available.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 53, 'type': 'text'}, page_content='NA'), Document(id='386', metadata={'original_content': 'Treatment consists of sodium selenite 100 \n\ng/day\npo. Toxicity:\n At high doses (&gt; 900 \n\ng/day), selenium causes toxicity. Manifestations include hair loss,\nabnormal nails, dermatitis, peripheral neuropathy, nausea, diarrhea, fatigue, irritability, and a garlic odor of\nthe breath. Toxic levels of plasma selenium are not well defined. Zinc\nZinc (Zn) is contained mainly in bones, teeth, hair, skin, liver, muscle, leukocytes, and testes. Zinc is a\ncomponent of several hundred enzymes, including many nicotinamide adenine dinucleotide (NADH)\ndehydrogenases, RNA and DNA polymerases, and DNA transcription factors as well as alkaline\nphosphatase, superoxide dismutase, and carbonic anhydrase. A diet high in fiber and phytate (eg, in\nwhole-grain bread) reduces zinc absorption.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 53, 'type': 'text'}, page_content='NA'), Document(id='387', metadata={'original_content': 'Deficiency:\n Dietary deficiency is unlikely in healthy people. Secondary zinc deficiency can develop in the\nfollowing:\n Some patients with hepatic insufficiency (because the ability to retain zinc is lost)\n Patients taking diuretics\n Patients with diabetes mellitus, sickle cell disease, chronic renal failure, or malabsorption\n Patients with stressful conditions (eg, sepsis, burns, head injury)\n Elderly institutionalized and homebound patients (common)\nMaternal zinc deficiency may cause fetal malformations and low birth weight. The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 5.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 53, 'type': 'text'}, page_content='NA'), Document(id='388', metadata={'original_content': 'Mineral Deficiency &amp; Toxicity\n106', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 53, 'type': 'text'}, page_content='NA'), Document(id='389', metadata={'original_content': 'Zinc deficiency in children causes impaired growth and impaired taste (hypogeusia). Other symptoms and\nsigns in children include delayed sexual maturation and hypogonadism. In children or adults, symptoms\ninclude hypogonadism, alopecia, impaired immunity, anorexia, dermatitis, night blindness, anemia,\nlethargy, and impaired wound healing. Zinc deficiency should be suspected in undernourished patients with typical symptoms or signs. However,\nbecause many of the symptoms and signs are nonspecific, clinical diagnosis of mild zinc deficiency is\ndifficult. Laboratory diagnosis is also difficult. Low albumin levels, common in zinc deficiency, make serum\nzinc levels difficult to interpret; diagnosis usually requires the combination of low levels of zinc in serum\nand increased urinary zinc excretion. If available, isotope studies can measure zinc status more\naccurately.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 54, 'type': 'text'}, page_content='NA'), Document(id='390', metadata={'original_content': 'Treatment consists of elemental zinc 15 to 120 mg/day po until symptoms and signs resolve. Acrodermatitis enteropathica\n (a rare, once fatal autosomal recessive disorder) causes malabsorption\nof zinc. Psoriasiform dermatitis develops around the eyes, nose, and mouth; on the buttocks; and in an\nacral distribution. The disorder also causes hair loss, paronychia, impaired immunity, recurrent infection,\nimpaired growth, and diarrhea.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 54, 'type': 'text'}, page_content='NA'), Document(id='391', metadata={'original_content': 'Symptoms and signs usually develop after infants are weaned from breast\nmilk.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 54, 'type': 'text'}, page_content='NA'), Document(id='392', metadata={'original_content': "In such cases, doctors suspect the diagnosis. If deficiency is diagnosed, zinc sulfate 30 to 150\nmg/day po usually results in complete remission. Toxicity:\n The recommended upper limit for zinc intake is 40 mg/day. Toxicity is rare. Ingesting doses of\nelemental zinc ranging from 100 to 150 mg/day for prolonged periods interferes with copper metabolism\nand causes low blood copper levels, RBC microcytosis, neutropenia, and impaired immunity; higher\ndoses should be given only for short periods of time and the patient should be followed closely. Ingesting\nlarger amounts (200 to 800 mg/day), usually by consuming acidic food or drink from a galvanized (zinc-\ncoated) container, can cause anorexia, vomiting, and diarrhea. Metal fume fever, also called brass-\nfounders' ague or zinc shakes, is caused by inhaling industrial zinc oxide fumes; it results in neurologic\ndamage. Symptoms usually resolve after 12 to 24 h in a zinc-free environment.", 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 54, 'type': 'text'}, page_content='NA'), Document(id='393', metadata={'original_content': 'The Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 5.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 54, 'type': 'text'}, page_content='NA'), Document(id='394', metadata={'original_content': 'Mineral Deficiency &amp; Toxicity\n107', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 54, 'type': 'text'}, page_content='NA'), Document(id='395', metadata={'original_content': 'Chapter 6. Obesity and the Metabolic Syndrome\nObesity\nObesity is excess body fat; consequences depend not only on the absolute amount but also on\nthe distribution of the fat. Complications include cardiovascular disorders, diabetes mellitus,\nmany cancers, cholelithiasis, fatty liver and cirrhosis, osteoarthritis, reproductive disorders in\nmen and women, psychologic disorders, and premature death.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 55, 'type': 'text'}, page_content='NA'), Document(id='396', metadata={'original_content': 'Diagnosis is based on body\nmass index (BMIcalculated from height and weight) and waist circumference. BP, fasting\nplasma glucose, and lipid levels should be measured. Treatment includes physical activity,\ndietary and behavioral modification, and sometimes drugs or surgery.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 55, 'type': 'text'}, page_content='NA'), Document(id='397', metadata={'original_content': 'Prevalence of obesity in the US is high and is increasing, particularly among children and adolescents\n(see\nTable 6-1\n). Prevalence is more than twice as high at age 55 as at age 20. Obesity is twice as common among women\nin a lower socioeconomic group as among those in a higher group. Prevalence among black and white\nmen does not differ significantly, but it is higher among black women than white women. More than 50%\nof black women  40 yr are obese; &gt; 80% are overweight. In the US, obesity and its complications cause as many as 300,000 premature deaths each year, making\nit second only to cigarette smoking as a preventable cause of death.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 55, 'type': 'text'}, page_content='NA'), Document(id='398', metadata={'original_content': '[\nTable 6-1. Changes in Prevalence of Obesity According to Nhanes]\nEtiology\nAlmost all cases of obesity result from a combination of genetic predisposition and a chronic imbalance\nbetween energy intake, energy utilization for basic metabolic processes, and energy expenditure from\nphysical activity. Genetic factors:\n Heritability of BMI is about 66%. Genetic factors may affect the many signaling\nmolecules and receptors used by parts of the hypothalamus and GI tract to regulate food intake (see\nSidebar 6-1\n). Rarely, obesity results from abnormal levels of peptides that regulate food intake (eg, leptin)\nor abnormalities in their receptors (eg, melanocortin-4 receptor). Genetic factors also regulate energy expenditure, including BMR, diet-induced thermogenesis, and\nnonvoluntary activity-associated thermogenesis. Genetic factors may have a greater effect on the\ndistribution of body fat, particularly abdominal fat (see \nMetabolic Syndrome\n on p. 64\n), than on the amount\nof body fat.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 55, 'type': 'text'}, page_content='NA'), Document(id='399', metadata={'original_content': 'Environmental factors:\n Weight is gained when caloric intake exceeds energy needs. Important\ndeterminants of energy intake include portion sizes and the energy density of the food. High-fat foods,\nprocessed foods, and diets high in refined carbohydrates, soft drinks, fruit juices, and alcohol promote\nweight gain. Diets high in fresh fruit and vegetables, fiber, and complex carbohydrates, with water as the\nmain fluid consumed, minimize weight gain. A sedentary lifestyle promotes weight gain. Regulatory factors:\n Prenatal maternal obesity, prenatal maternal smoking, intrauterine growth\nrestriction, and insufficient sleep can disturb weight regulation. About 15% of women permanently gain \n20 lb with each pregnancy.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 55, 'type': 'text'}, page_content='NA'), Document(id='400', metadata={'original_content': 'Obesity that persists beyond early childhood makes weight loss in later life\nmore difficult. Drugs, including corticosteroids, lithium, traditional antidepressants (tricyclics, tetracyclics, and\nmonoamine oxidase inhibitors [MAOIs]), benzodiazepines, and antipsychotic drugs, often cause weight\ngain. Uncommonly, weight gain is caused by one of the following disorders:\nThe Merck Manual of Diagnosis &amp; Therapy, 19th Edition Chapter 6.', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 55, 'type': 'text'}, page_content='NA'), Document(id='401', metadata={'original_content': 'Obesity &amp; the Metabolic Syndrome\n108', 'source': 'Nutritional Medical Reference/Nutritional Disorders.pdf', 'page': 55, 'type': 'text'}, page_content='NA')]
</pre>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[35]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Function to print a sample document with hypothetical questions</span>
<span class="k">def</span><span class="w"> </span><span class="nf">print_sample</span><span class="p">(</span><span class="n">docs</span><span class="p">,</span> <span class="n">index</span><span class="o">=</span><span class="mi">0</span><span class="p">):</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"ID:</span><span class="se">\n</span><span class="s2">"</span><span class="p">,</span> <span class="n">docs</span><span class="p">[</span><span class="n">index</span><span class="p">]</span><span class="o">.</span><span class="n">id</span><span class="p">,</span> <span class="s2">"</span><span class="se">\n</span><span class="s2">"</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"Metadata:"</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="n">json</span><span class="o">.</span><span class="n">dumps</span><span class="p">(</span><span class="n">docs</span><span class="p">[</span><span class="n">index</span><span class="p">]</span><span class="o">.</span><span class="n">metadata</span><span class="p">,</span> <span class="n">indent</span><span class="o">=</span><span class="mi">4</span><span class="p">),</span> <span class="s2">"</span><span class="se">\n</span><span class="s2">"</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"Hypothetical Questions:</span><span class="se">\n</span><span class="s2">"</span><span class="p">,</span> <span class="n">docs</span><span class="p">[</span><span class="n">index</span><span class="p">]</span><span class="o">.</span><span class="n">page_content</span><span class="p">)</span>

<span class="c1"># Print a sample document</span>
<span class="n">print_sample</span><span class="p">(</span><span class="n">hyp_docs</span><span class="p">,</span> <span class="mi">20</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>ID:
 20 

Metadata:
{
    "original_content": "However, many nonnutrients in foods are\nuseful. For example, food additives (eg, preservatives, emulsifiers, antioxidants, stabilizers) improve the\nproduction and stability of foods. Trace components (eg, spices, flavors, odors, colors, phytochemicals,\nmany other natural products) improve appearance and taste. Fiber:\n Fiber occurs in various forms (eg, cellulose, hemicellulose, pectin, gums). It \nincreases GI motility,\nprevents constipation, and helps control diverticular disease. Fiber is thought to accelerate the elimination\nof cancer-causing substances produced by bacteria in the large intestine. Epidemiologic evidence\nsuggests an association between colon cancer and low fiber intake and a beneficial effect of fiber in\npatients with functional bowel disorders, Crohn's disease, obesity, and hemorrhoids. Soluble fiber\n(present in fruits, vegetables, oats, barley, and legumes) reduces the postprandial increase in blood\nglucose and insulin and can reduce cholesterol levels. The typical Western diet is low in fiber (about 12 g/day) because of a high intake of highly refined wheat\nflour and a low intake of fruits and vegetables.",
    "source": "Nutritional Medical Reference/Nutritional Disorders.pdf",
    "page": 2,
    "type": "text"
} 

Hypothetical Questions:
 1. How does a low fiber intake contribute to the development of colon cancer?  
2. What role does soluble fiber play in managing blood glucose and cholesterol levels?  
3. What are the potential health benefits of increasing fiber consumption for individuals with functional bowel disorders?  
</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="1.5.2-Generating-Hypothetical-Questions-for-Tables"><strong>1.5.2 Generating Hypothetical Questions for Tables</strong><a class="anchor-link" href="#1.5.2-Generating-Hypothetical-Questions-for-Tables"></a></h3>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[36]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Define prompt for generating hypothetical questions for tables</span>
<span class="n">hypothetical_table_questions_prompt</span> <span class="o">=</span> <span class="s2">"""</span>
<span class="s2">Generate a list of exactly 3 hypothetical questions that the below nutritional disorder table could be used to answer:</span>
<span class="si">{table}</span>
<span class="s2">Generate only a list of questions. Do not mention anything before or after the list.</span>
<span class="s2">If the content cannot answer any questions, return an empty list.</span>
<span class="s2">Ensure that the questions are specific to nutritional disorder diagnosis, dietary deficiencies, metabolic disorders, vitamin and mineral imbalances, obesity, and related health conditions.</span>
<span class="s2">"""</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[37]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Generate hypothetical questions for tables in documents and store them as structured metadata.</span>

<span class="c1"># List to store documents with hypothetical questions for tables</span>
<span class="n">hypotheticalq_tables</span>  <span class="o">=</span> <span class="p">[]</span>  <span class="c1"># Initialize an empty list to store generated questions</span>

<span class="c1"># Generate hypothetical questions for each table in the documents</span>
<span class="k">for</span> <span class="n">source</span> <span class="ow">in</span> <span class="n">tables</span><span class="p">:</span>
    <span class="k">for</span> <span class="n">page</span> <span class="ow">in</span> <span class="n">tables</span><span class="p">[</span><span class="n">source</span><span class="p">]:</span>
        <span class="n">table_in_page</span> <span class="o">=</span> <span class="n">tables</span><span class="p">[</span><span class="n">source</span><span class="p">][</span><span class="n">page</span><span class="p">]</span>
        <span class="k">try</span><span class="p">:</span>
            <span class="c1"># Generate questions using the LLM</span>
            <span class="n">response</span> <span class="o">=</span> <span class="n">llm</span><span class="o">.</span><span class="n">invoke</span><span class="p">(</span><span class="n">hypothetical_table_questions_prompt</span><span class="o">.</span><span class="n">format</span><span class="p">(</span><span class="n">table</span><span class="o">=</span><span class="n">table_in_page</span><span class="p">))</span>
            <span class="n">questions</span> <span class="o">=</span> <span class="n">response</span><span class="o">.</span><span class="n">content</span>
        <span class="k">except</span> <span class="ne">Exception</span> <span class="k">as</span> <span class="n">e</span><span class="p">:</span>
            <span class="nb">print</span><span class="p">(</span><span class="n">e</span><span class="p">)</span>
            <span class="n">questions</span> <span class="o">=</span> <span class="s2">"NA"</span>

        <span class="c1"># Metadata for each table</span>
        <span class="n">questions_metadata</span> <span class="o">=</span> <span class="p">{</span>
            <span class="s1">'original_content'</span><span class="p">:</span> <span class="nb">str</span><span class="p">(</span><span class="n">table_in_page</span><span class="p">),</span>
            <span class="s1">'source'</span><span class="p">:</span><span class="n">source</span><span class="p">,</span>
            <span class="s1">'page'</span><span class="p">:</span> <span class="n">page</span><span class="p">,</span>
            <span class="s1">'type'</span><span class="p">:</span> <span class="s1">'table'</span>
        <span class="p">}</span>

        <span class="c1"># Create a Document object for each set of generated questions</span>
        <span class="n">hypotheticalq_tables</span><span class="o">.</span><span class="n">append</span><span class="p">(</span>
          <span class="n">Document</span><span class="p">(</span>
              <span class="nb">id</span> <span class="o">=</span> <span class="s2">"table_"</span><span class="o">+</span> <span class="n">source</span><span class="o">+</span><span class="s2">"_"</span><span class="o">+</span><span class="nb">str</span><span class="p">(</span><span class="n">page</span><span class="p">),</span>
              <span class="n">page_content</span><span class="o">=</span><span class="n">questions</span><span class="p">,</span>
              <span class="n">metadata</span><span class="o">=</span><span class="n">questions_metadata</span>
          <span class="p">)</span>
       <span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
Error code: 429 - {'reason': {'error': 'Rate limit reached for requests!!'}}
</pre>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[38]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Function to print a sample document with hypothetical questions for tables</span>
<span class="k">def</span><span class="w"> </span><span class="nf">print_sample</span><span class="p">(</span><span class="n">docs</span><span class="p">,</span> <span class="n">index</span><span class="o">=</span><span class="mi">0</span><span class="p">):</span>
    <span class="k">if</span> <span class="mi">0</span> <span class="o">&lt;=</span> <span class="n">index</span> <span class="o">&lt;</span> <span class="nb">len</span><span class="p">(</span><span class="n">docs</span><span class="p">):</span>  <span class="c1"># Check if index is within bounds</span>
        <span class="nb">print</span><span class="p">(</span><span class="s2">"ID:</span><span class="se">\n</span><span class="s2">"</span><span class="p">,</span> <span class="n">docs</span><span class="p">[</span><span class="n">index</span><span class="p">]</span><span class="o">.</span><span class="n">id</span><span class="p">,</span> <span class="s2">"</span><span class="se">\n</span><span class="s2">"</span><span class="p">)</span>
        <span class="nb">print</span><span class="p">(</span><span class="s2">"Metadata:"</span><span class="p">)</span>
        <span class="nb">print</span><span class="p">(</span><span class="n">json</span><span class="o">.</span><span class="n">dumps</span><span class="p">(</span><span class="n">docs</span><span class="p">[</span><span class="n">index</span><span class="p">]</span><span class="o">.</span><span class="n">metadata</span><span class="p">,</span> <span class="n">indent</span><span class="o">=</span><span class="mi">4</span><span class="p">),</span> <span class="s2">"</span><span class="se">\n</span><span class="s2">"</span><span class="p">)</span>
        <span class="nb">print</span><span class="p">(</span><span class="s2">"Hypothetical Questions:</span><span class="se">\n</span><span class="s2">"</span><span class="p">,</span> <span class="n">docs</span><span class="p">[</span><span class="n">index</span><span class="p">]</span><span class="o">.</span><span class="n">page_content</span><span class="p">)</span>
    <span class="k">else</span><span class="p">:</span>
        <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"Index </span><span class="si">{</span><span class="n">index</span><span class="si">}</span><span class="s2"> is out of range for the list with length </span><span class="si">{</span><span class="nb">len</span><span class="p">(</span><span class="n">docs</span><span class="p">)</span><span class="si">}</span><span class="s2">."</span><span class="p">)</span>

<span class="c1"># Print a sample document, ensure index is within bounds</span>
<span class="n">print_sample</span><span class="p">(</span><span class="n">hypotheticalq_tables</span><span class="p">,</span> <span class="n">index</span><span class="o">=</span><span class="nb">min</span><span class="p">(</span><span class="mi">5</span><span class="p">,</span> <span class="nb">len</span><span class="p">(</span><span class="n">hypotheticalq_tables</span><span class="p">)</span> <span class="o">-</span> <span class="mi">1</span><span class="p">))</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>ID:
 table_Nutritional Disorders.pdf_48 

Metadata:
{
    "original_content": "[['More severe toxicity results from ingestion (usually with suicidal intent) of gram quantities of a copper salt (eg, copper sulfate) or from absorption of large amounts through the skin (eg, if compresses saturated with a solution of a copper salt are applied to large areas of burned skin). Hemolytic anemia and anuria can result and may be fatal.', ''], ['Indian childhood cirrhosis', 'non-Indian childhood cirrhosis'], ['and idiopathic copper toxicity are probably identical disorders in which excess copper causes cirrhosis. All seem to be caused by ingesting milk that has been boiled or stored in corroded copper or brass vessels. Recent studies suggest that idiopathic copper toxicity may develop only in infants with an unknown genetic defect.', '']]",
    "source": "Nutritional Disorders.pdf",
    "page": 48,
    "type": "table"
} 

Hypothetical Questions:
 NA
</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="1.5.3-Storing-Hypothetical-Chunks-of-documents-and-tables-as-batches-in-Chroma-Vectorstore"><strong>1.5.3 Storing Hypothetical Chunks of documents and tables as batches in Chroma Vectorstore</strong><a class="anchor-link" href="#1.5.3-Storing-Hypothetical-Chunks-of-documents-and-tables-as-batches-in-Chroma-Vectorstore"></a></h3>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[45]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Assign unique IDs to hypothetical questions and store them in the Chroma vector database in batches.</span>

<span class="c1"># Add IDs to the hypothetical questions for text semantic chunks</span>
<span class="n">hyp_chunks</span> <span class="o">=</span> <span class="p">[</span><span class="n">Document</span><span class="p">(</span><span class="nb">id</span><span class="o">=</span><span class="nb">str</span><span class="p">(</span><span class="n">i</span><span class="p">),</span> <span class="n">page_content</span><span class="o">=</span><span class="n">d</span><span class="o">.</span><span class="n">page_content</span><span class="p">,</span> <span class="n">metadata</span><span class="o">=</span><span class="n">d</span><span class="o">.</span><span class="n">metadata</span><span class="p">)</span> <span class="k">for</span> <span class="n">i</span><span class="p">,</span> <span class="n">d</span> <span class="ow">in</span> <span class="nb">enumerate</span><span class="p">(</span><span class="n">hyp_docs</span><span class="p">)]</span>

<span class="c1"># Store the document chunks in Chroma vectorstore in batches</span>
<span class="n">batch_size</span> <span class="o">=</span> <span class="mi">5</span>
<span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="nb">len</span><span class="p">(</span><span class="n">hyp_chunks</span><span class="p">),</span> <span class="n">batch_size</span><span class="p">):</span>
    <span class="n">batch</span> <span class="o">=</span> <span class="n">hyp_chunks</span><span class="p">[</span><span class="n">i</span> <span class="p">:</span> <span class="n">i</span> <span class="o">+</span> <span class="n">batch_size</span><span class="p">]</span>
    <span class="n">hypstore</span> <span class="o">=</span> <span class="n">Chroma</span><span class="o">.</span><span class="n">from_documents</span><span class="p">(</span>
        <span class="n">batch</span><span class="p">,</span>
        <span class="n">embedding_model</span><span class="p">,</span>
        <span class="n">collection_name</span><span class="o">=</span><span class="s2">"hypotheticalq_texts"</span><span class="p">,</span>
        <span class="n">persist_directory</span><span class="o">=</span><span class="s1">'./nutritional_db'</span>
    <span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[46]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Assign unique IDs to hypothetical questions for tables and store them in the Chroma vector database in batches.</span>

<span class="c1"># Add IDs to the hypothetical questions for tables</span>
<span class="n">hypotheticalq_tables_chunks</span> <span class="o">=</span> <span class="p">[</span><span class="n">Document</span><span class="p">(</span><span class="nb">id</span><span class="o">=</span><span class="nb">str</span><span class="p">(</span><span class="n">i</span><span class="p">),</span> <span class="n">page_content</span><span class="o">=</span><span class="n">d</span><span class="o">.</span><span class="n">page_content</span><span class="p">,</span> <span class="n">metadata</span><span class="o">=</span><span class="n">d</span><span class="o">.</span><span class="n">metadata</span><span class="p">)</span> <span class="k">for</span> <span class="n">i</span><span class="p">,</span> <span class="n">d</span> <span class="ow">in</span> <span class="nb">enumerate</span><span class="p">(</span><span class="n">hypotheticalq_tables</span><span class="p">)]</span>

<span class="c1"># Store the table chunks in Chroma vectorstore in batches</span>
<span class="n">batch_size</span> <span class="o">=</span> <span class="mi">2</span>
<span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="nb">len</span><span class="p">(</span><span class="n">hypotheticalq_tables_chunks</span><span class="p">),</span> <span class="n">batch_size</span><span class="p">):</span>
    <span class="n">batch</span> <span class="o">=</span> <span class="n">hypotheticalq_tables_chunks</span><span class="p">[</span><span class="n">i</span> <span class="p">:</span> <span class="n">i</span> <span class="o">+</span> <span class="n">batch_size</span><span class="p">]</span>
    <span class="n">hypstore</span> <span class="o">=</span> <span class="n">Chroma</span><span class="o">.</span><span class="n">from_documents</span><span class="p">(</span>
        <span class="n">batch</span><span class="p">,</span>
        <span class="n">embedding_model</span><span class="p">,</span>
        <span class="n">collection_name</span><span class="o">=</span><span class="s2">"hypotheticalq_tables"</span><span class="p">,</span>
        <span class="n">persist_directory</span><span class="o">=</span><span class="s1">'./nutritional_db'</span>
    <span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>Backing Up the Nutritional Vectorstore to Google Drive</strong></p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[47]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="kn">from</span><span class="w"> </span><span class="nn">google.colab</span><span class="w"> </span><span class="kn">import</span> <span class="n">drive</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">shutil</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">os</span>

<span class="c1"># Mount Google Drive</span>
<span class="n">drive</span><span class="o">.</span><span class="n">mount</span><span class="p">(</span><span class="s1">'/content/drive'</span><span class="p">)</span>

<span class="c1"># Define source and destination paths</span>
<span class="n">source_path</span> <span class="o">=</span> <span class="s1">'./nutritional_db'</span>  <span class="c1"># Complete the code to define the path to your vectorstore directory</span>
<span class="n">destination_path</span> <span class="o">=</span> <span class="s1">'/content/drive/MyDrive/nutritional_db'</span>  <span class="c1"># Complete the code to define the destination path in your Drive</span>

<span class="c1"># Copy the directory to Google Drive</span>
<span class="k">try</span><span class="p">:</span>
    <span class="n">shutil</span><span class="o">.</span><span class="n">copytree</span><span class="p">(</span><span class="n">source_path</span><span class="p">,</span> <span class="n">destination_path</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"Successfully copied '</span><span class="si">{</span><span class="n">source_path</span><span class="si">}</span><span class="s2">' to '</span><span class="si">{</span><span class="n">destination_path</span><span class="si">}</span><span class="s2">'"</span><span class="p">)</span>
<span class="k">except</span> <span class="ne">FileExistsError</span><span class="p">:</span>
    <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"Directory '</span><span class="si">{</span><span class="n">destination_path</span><span class="si">}</span><span class="s2">' already exists. Skipping copy."</span><span class="p">)</span>
<span class="k">except</span> <span class="ne">Exception</span> <span class="k">as</span> <span class="n">e</span><span class="p">:</span>
    <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"Error copying directory: </span><span class="si">{</span><span class="n">e</span><span class="si">}</span><span class="s2">"</span><span class="p">)</span>

<span class="c1"># Verify if the directory was copied successfully</span>
<span class="k">if</span> <span class="n">os</span><span class="o">.</span><span class="n">path</span><span class="o">.</span><span class="n">exists</span><span class="p">(</span><span class="n">destination_path</span><span class="p">):</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"nutritional_db directory exists in your Google Drive."</span><span class="p">)</span>  <span class="c1"># Complete the code to confirm the directory name</span>
<span class="k">else</span><span class="p">:</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"nutritional_db directory was not copied to your Google Drive."</span><span class="p">)</span>  <span class="c1"># Complete the code to confirm the directory name</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount("/content/drive", force_remount=True).
Successfully copied './nutritional_db' to '/content/drive/MyDrive/nutritional_db'
nutritional_db directory exists in your Google Drive.
</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="1.5.4-Initializing-Structured-Retriever-for-Hypothetical-Questions"><strong>1.5.4 Initializing Structured Retriever for Hypothetical Questions</strong><a class="anchor-link" href="#1.5.4-Initializing-Structured-Retriever-for-Hypothetical-Questions"></a></h3>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[48]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Define metadata fields for structured retrieval of hypothetical questions</span>
<span class="n">metadata_field_info</span> <span class="o">=</span> <span class="p">[</span>
    <span class="n">AttributeInfo</span><span class="p">(</span>
        <span class="n">name</span><span class="o">=</span><span class="s2">"Category"</span><span class="p">,</span>
        <span class="n">description</span><span class="o">=</span><span class="s2">"Category of the nutritional disorder (e.g., Undernutrition, Vitamin Deficiency, Obesity, etc.)"</span><span class="p">,</span>
        <span class="nb">type</span><span class="o">=</span><span class="s2">"string"</span>
    <span class="p">),</span>
    <span class="n">AttributeInfo</span><span class="p">(</span>
        <span class="n">name</span><span class="o">=</span><span class="s2">"DisorderType"</span><span class="p">,</span>
        <span class="n">description</span><span class="o">=</span><span class="s2">"Specific type of nutritional disorder (e.g., Protein-Energy Malnutrition, Scurvy, Rickets, etc.)"</span><span class="p">,</span>
        <span class="nb">type</span><span class="o">=</span><span class="s2">"string"</span>
    <span class="p">),</span>
    <span class="n">AttributeInfo</span><span class="p">(</span>
        <span class="n">name</span><span class="o">=</span><span class="s2">"Page"</span><span class="p">,</span>
        <span class="n">description</span><span class="o">=</span><span class="s2">"Page within the nutritional medical reference document that the information belongs to"</span><span class="p">,</span>
        <span class="nb">type</span><span class="o">=</span><span class="s2">"integer"</span>
    <span class="p">),</span>
    <span class="n">AttributeInfo</span><span class="p">(</span>
        <span class="n">name</span><span class="o">=</span><span class="s2">"original_content"</span><span class="p">,</span>
        <span class="n">description</span><span class="o">=</span><span class="s2">"Content in the original chunk"</span><span class="p">,</span>
        <span class="nb">type</span><span class="o">=</span><span class="s2">"string"</span>
    <span class="p">),</span>
    <span class="n">AttributeInfo</span><span class="p">(</span>
        <span class="n">name</span><span class="o">=</span><span class="s2">"type"</span><span class="p">,</span>
        <span class="n">description</span><span class="o">=</span><span class="s2">"Original content type of the embedding. Value can be 'text' or 'table'."</span><span class="p">,</span>
        <span class="nb">type</span><span class="o">=</span><span class="s2">"string"</span>
    <span class="p">)</span>
<span class="p">]</span>

<span class="c1"># Describe the content of the document</span>
<span class="n">document_content_description</span> <span class="o">=</span> <span class="s2">"Questions that the content within the parent chunk can answer"</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[49]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Initialize the self-querying retriever for hypothetical questions</span>
<span class="n">structured_retriever</span> <span class="o">=</span> <span class="n">SelfQueryRetriever</span><span class="o">.</span><span class="n">from_llm</span><span class="p">(</span>
    <span class="n">llm</span><span class="p">,</span>
    <span class="n">hypstore</span><span class="p">,</span>
    <span class="n">document_content_description</span><span class="p">,</span>
    <span class="n">metadata_field_info</span>
<span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[50]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Example user query</span>
<span class="n">user_input</span> <span class="o">=</span> <span class="s2">"What are the symptoms for vitamin B12 deficiency?"</span>

<span class="c1"># Perform structured retrieval using the self-querying retriever</span>
<span class="n">hypothetical_questions_retrieved</span> <span class="o">=</span> <span class="n">structured_retriever</span><span class="o">.</span><span class="n">invoke</span><span class="p">(</span><span class="n">user_input</span><span class="p">)</span>

<span class="c1"># Print sample retrieved documents</span>
<span class="nb">print</span><span class="p">(</span><span class="n">hypothetical_questions_retrieved</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>[Document(metadata={'original_content': "[['Food', 'Glycemic Index'], ['Glucose', '100'], ['Sucrose', '65'], ['Starches', 'Variable'], ['Fiber', '0']]", 'page': 1, 'source': 'Nutritional Disorders.pdf', 'type': 'table'}, page_content='NA'), Document(metadata={'original_content': "[['More severe toxicity results from ingestion (usually with suicidal intent) of gram quantities of a copper salt (eg, copper sulfate) or from absorption of large amounts through the skin (eg, if compresses saturated with a solution of a copper salt are applied to large areas of burned skin). Hemolytic anemia and anuria can result and may be fatal.', ''], ['Indian childhood cirrhosis', 'non-Indian childhood cirrhosis'], ['and idiopathic copper toxicity are probably identical disorders in which excess copper causes cirrhosis. All seem to be caused by ingesting milk that has been boiled or stored in corroded copper or brass vessels. Recent studies suggest that idiopathic copper toxicity may develop only in infants with an unknown genetic defect.', '']]", 'page': 48, 'source': 'Nutritional Disorders.pdf', 'type': 'table'}, page_content='NA'), Document(metadata={'original_content': "[['Inadequate absorption', 'Decreased acid secretion (elderly)'], ['Blind loop syndrome', 'Fish tapeworm infestation'], ['Inflammatory bowel disease', 'Surgical removal of ileal absorptive sites'], ['Chronic pancreatitis', 'Gastric surgery'], ['Malabsorption syndromes', 'AIDS'], ['Use of certain drugs', '(e.g., antacids, metformin)'], ['Repeated exposure to nitrous oxide', 'Genetic disorder (Imerslund-Graesbeck syndrome)']]", 'page': 35, 'source': 'Nutritional Disorders.pdf', 'type': 'table'}, page_content='NA'), Document(metadata={'original_content': '[]', 'page': 24, 'source': 'Nutritional Disorders.pdf', 'type': 'table'}, page_content='NA')]
</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h1 id="Section-2:-Building-an-Intelligent-Nutrition-Disorder-Agent-with-Advanced-Retrieval-and-Safety-Mechanisms"><strong>Section 2: Building an Intelligent Nutrition Disorder Agent with Advanced Retrieval and Safety Mechanisms</strong><a class="anchor-link" href="#Section-2:-Building-an-Intelligent-Nutrition-Disorder-Agent-with-Advanced-Retrieval-and-Safety-Mechanisms"></a></h1>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>In this section, we focus on developing an intelligent Nutrition Disorder Specialist agent that can provide accurate and context-aware responses. We start by building an Advanced Retrieval-Augmented Generation (RAG) Agent Tool, which involves importing necessary libraries, defining the agent's state, expanding queries for better retrieval, and fetching relevant information from the vector store. We then generate responses based on the retrieved context and evaluate their groundedness and precision. If needed, we refine the responses and queries to ensure high-quality outputs. Additionally, we guardrail user input using Llama Guard to ensure safe interactions. Finally, we initialize and run the AI Nutrition Disorder Specialist agent, enabling it to answer nutrition disorder-related questions effectively and safely. This comprehensive setup equips the agent with advanced retrieval mechanisms and ensures safe and informative user interactions.</p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h2 id="2.1-Building-an-Advanced-RAG-Agent-Tool"><strong>2.1 Building an Advanced RAG Agent Tool</strong><a class="anchor-link" href="#2.1-Building-an-Advanced-RAG-Agent-Tool"></a></h2>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.1-Setting-up-embedding-model,-embedding-function,-llm-and-importing-the-required-libraries"><strong>2.1.1 Setting up embedding model, embedding function, llm and importing the required libraries</strong><a class="anchor-link" href="#2.1.1-Setting-up-embedding-model,-embedding-function,-llm-and-importing-the-required-libraries"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>Since we have already created the database and pushed it to do the google drive, we do not need to re run everything, we can directly define the required models and just use it. This saves our time as well as our computational resources.</p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h4 id="2.1.1.1-Importing-the-necessary-libraries"><strong>2.1.1.1 Importing the necessary libraries</strong><a class="anchor-link" href="#2.1.1.1-Importing-the-necessary-libraries"></a></h4>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[1]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Import necessary libraries</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">os</span>  <span class="c1"># Operating system library for file handling</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">typing</span><span class="w"> </span><span class="kn">import</span> <span class="n">Dict</span><span class="p">,</span> <span class="n">List</span><span class="p">,</span> <span class="n">Tuple</span><span class="p">,</span> <span class="n">Any</span>  <span class="c1"># Python typing for function annotations</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_core.runnables</span><span class="w"> </span><span class="kn">import</span> <span class="n">RunnablePassthrough</span>  <span class="c1"># LangChain core library for running pipelines</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.text_splitter</span><span class="w"> </span><span class="kn">import</span> <span class="n">RecursiveCharacterTextSplitter</span>  <span class="c1"># For splitting text documents</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_community.document_loaders</span><span class="w"> </span><span class="kn">import</span> <span class="n">PyPDFLoader</span>  <span class="c1"># PDF document loader</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_community.vectorstores</span><span class="w"> </span><span class="kn">import</span> <span class="n">FAISS</span>  <span class="c1"># FAISS vector store</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.embeddings.openai</span><span class="w"> </span><span class="kn">import</span> <span class="n">OpenAIEmbeddings</span>  <span class="c1"># OpenAI embeddings for text vectors</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.prompts</span><span class="w"> </span><span class="kn">import</span> <span class="n">ChatPromptTemplate</span>  <span class="c1"># Template for chat prompts</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_core.output_parsers</span><span class="w"> </span><span class="kn">import</span> <span class="n">StrOutputParser</span>  <span class="c1"># String output parser</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langgraph.graph</span><span class="w"> </span><span class="kn">import</span> <span class="n">StateGraph</span><span class="p">,</span> <span class="n">END</span>  <span class="c1"># State graph for managing states in LangChain</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">pydantic</span><span class="w"> </span><span class="kn">import</span> <span class="n">BaseModel</span>  <span class="c1"># Pydantic for data validation</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">numpy</span><span class="w"> </span><span class="k">as</span><span class="w"> </span><span class="nn">np</span>  <span class="c1"># Numpy for numerical operations</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">typing</span><span class="w"> </span><span class="kn">import</span> <span class="n">TypedDict</span>  <span class="c1"># Typing for structured data</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[2]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="kn">from</span><span class="w"> </span><span class="nn">google.colab</span><span class="w"> </span><span class="kn">import</span> <span class="n">drive</span>
<span class="n">drive</span><span class="o">.</span><span class="n">mount</span><span class="p">(</span><span class="s1">'/content/drive'</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Mounted at /content/drive
</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h4 id="2.1.1.2-Configuration-Setup"><strong>2.1.1.2 Configuration Setup</strong><a class="anchor-link" href="#2.1.1.2-Configuration-Setup"></a></h4>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[3]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Define a function to read a JSON config file and return its contents as a dictionary.</span>
<span class="k">def</span><span class="w"> </span><span class="nf">read_config</span><span class="p">(</span><span class="n">config_file</span><span class="p">):</span>
<span class="w">  </span><span class="sd">"""Reads a JSON config file and returns a dictionary."""</span>
  <span class="k">with</span> <span class="nb">open</span><span class="p">(</span><span class="n">config_file</span><span class="p">,</span> <span class="s1">'r'</span><span class="p">)</span> <span class="k">as</span> <span class="n">f</span><span class="p">:</span>
    <span class="k">return</span> <span class="n">json</span><span class="o">.</span><span class="n">load</span><span class="p">(</span><span class="n">f</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[8]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Read the configuration files</span>
<span class="n">config</span> <span class="o">=</span> <span class="n">read_config</span><span class="p">(</span><span class="s2">"config_GANLP.json"</span><span class="p">)</span>  <span class="c1">#Copy and paste the path of the config file uploaded in Colab</span>
<span class="n">config2</span> <span class="o">=</span> <span class="n">read_config</span><span class="p">(</span><span class="s2">"config2_emb_tested.json"</span><span class="p">)</span>

<span class="c1"># Extract keys and endpoints from the configuration files</span>
<span class="n">api_key</span> <span class="o">=</span> <span class="n">config</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"API_KEY"</span><span class="p">)</span>
<span class="n">endpoint</span> <span class="o">=</span> <span class="n">config</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"OPENAI_API_BASE"</span><span class="p">)</span>
<span class="n">llamaparse_api_key</span> <span class="o">=</span> <span class="n">config2</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"LLAMA_KEY"</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[9]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Initialize the OpenAI embedding function for Chroma</span>
<span class="n">embedding_function</span> <span class="o">=</span> <span class="n">chromadb</span><span class="o">.</span><span class="n">utils</span><span class="o">.</span><span class="n">embedding_functions</span><span class="o">.</span><span class="n">OpenAIEmbeddingFunction</span><span class="p">(</span>
    <span class="n">api_base</span><span class="o">=</span><span class="n">endpoint</span><span class="p">,</span>
    <span class="n">api_key</span><span class="o">=</span><span class="n">api_key</span><span class="p">,</span>
    <span class="n">model_name</span><span class="o">=</span><span class="s1">'text-embedding-ada-002'</span>
<span class="p">)</span>
<span class="c1"># This initializes the OpenAI embedding function for the Chroma vectorstore, using the provided endpoint and API key.</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[10]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Initialize the OpenAI Embeddings</span>
<span class="n">embedding_model</span> <span class="o">=</span> <span class="n">OpenAIEmbeddings</span><span class="p">(</span>
    <span class="n">openai_api_base</span><span class="o">=</span><span class="n">endpoint</span><span class="p">,</span>
    <span class="n">openai_api_key</span><span class="o">=</span><span class="n">api_key</span><span class="p">,</span>
    <span class="n">model</span><span class="o">=</span><span class="s1">'text-embedding-ada-002'</span>
<span class="p">)</span>
<span class="c1"># This initializes the OpenAI embeddings model using the specified endpoint, API key, and model name.</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[11]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Initialize the Chat OpenAI model</span>
<span class="n">llm</span> <span class="o">=</span> <span class="n">ChatOpenAI</span><span class="p">(</span>
    <span class="n">openai_api_base</span><span class="o">=</span><span class="n">endpoint</span><span class="p">,</span>
    <span class="n">openai_api_key</span><span class="o">=</span><span class="n">api_key</span><span class="p">,</span>
    <span class="n">model</span><span class="o">=</span><span class="s2">"gpt-4o-mini"</span><span class="p">,</span>
    <span class="n">streaming</span><span class="o">=</span><span class="kc">False</span>
<span class="p">)</span>
<span class="c1"># This initializes the Chat OpenAI model using the provided endpoint, API key, deployment name.</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[12]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># set the LLM and embedding model in the LlamaIndex settings.</span>
<span class="n">Settings</span><span class="o">.</span><span class="n">llm</span> <span class="o">=</span> <span class="n">llm</span>
<span class="n">Settings</span><span class="o">.</span><span class="n">embedding</span> <span class="o">=</span> <span class="n">embedding_model</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.2-Define-Agent-State"><strong>2.1.2 Define Agent State</strong><a class="anchor-link" href="#2.1.2-Define-Agent-State"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>The flow we wish to create</p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><img alt="flow-1.jpg" src="data:image/jpeg;base64,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"/></p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>Defines the AgentState class using TypedDict. It represents the state of the AI agent at different stages of the workflow.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[13]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">class</span><span class="w"> </span><span class="nc">AgentState</span><span class="p">(</span><span class="n">TypedDict</span><span class="p">):</span>
    <span class="n">query</span><span class="p">:</span> <span class="nb">str</span>  <span class="c1"># The current user query</span>
    <span class="n">expanded_query</span><span class="p">:</span> <span class="nb">str</span>  <span class="c1"># The expanded version of the user query</span>
    <span class="n">context</span><span class="p">:</span> <span class="n">List</span><span class="p">[</span><span class="n">Dict</span><span class="p">[</span><span class="nb">str</span><span class="p">,</span> <span class="n">Any</span><span class="p">]]</span>  <span class="c1"># Retrieved documents (content and metadata)</span>
    <span class="n">response</span><span class="p">:</span> <span class="nb">str</span>  <span class="c1"># The generated response to the user query</span>
    <span class="n">precision_score</span><span class="p">:</span> <span class="nb">float</span>  <span class="c1"># The precision score of the response</span>
    <span class="n">groundedness_score</span><span class="p">:</span> <span class="nb">float</span>  <span class="c1"># The groundedness score of the response</span>
    <span class="n">groundedness_loop_count</span><span class="p">:</span> <span class="nb">int</span>  <span class="c1"># Counter for groundedness refinement loops</span>
    <span class="n">precision_loop_count</span><span class="p">:</span> <span class="nb">int</span>  <span class="c1"># Counter for precision refinement loops</span>
    <span class="n">feedback</span><span class="p">:</span> <span class="nb">str</span>
    <span class="n">query_feedback</span><span class="p">:</span> <span class="nb">str</span>
    <span class="n">groundedness_check</span><span class="p">:</span> <span class="nb">bool</span>
    <span class="n">loop_max_iter</span><span class="p">:</span> <span class="nb">int</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.3-Expand-Query-for-Better-Retrieval"><strong>2.1.3 Expand Query for Better Retrieval</strong><a class="anchor-link" href="#2.1.3-Expand-Query-for-Better-Retrieval"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>This function expands user queries related to nutrition disorders to improve retrieval accuracy.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[14]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">def</span><span class="w"> </span><span class="nf">expand_query</span><span class="p">(</span><span class="n">state</span><span class="p">):</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Expands the user query to improve retrieval of nutrition disorder-related information.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the user query.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with the expanded query.</span>
<span class="sd">    """</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------Expanding Query---------"</span><span class="p">)</span>
    <span class="n">system_message</span> <span class="o">=</span> <span class="s1">'''You are a query expansion assistant specialized in nutritional and medical information retrieval.</span>

<span class="s1">    Given a short or ambiguous user query, your task is to rewrite or expand it into a more detailed and specific question that would help retrieve relevant medical literature  particularly related to nutritional disorders, dietary deficiencies, vitamin and mineral imbalances, obesity, and metabolic conditions.</span>

<span class="s1">    - Maintain the original intent of the query.</span>
<span class="s1">    - Add medically-relevant context or clarifying terms if appropriate.</span>
<span class="s1">    - Output only the expanded query as a single sentence.</span>

<span class="s1">    Do not include explanations or bullet points.</span>
<span class="s1">    '''</span>


    <span class="n">expand_prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
        <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_message</span><span class="p">),</span>
        <span class="p">(</span><span class="s2">"user"</span><span class="p">,</span> <span class="s2">"Expand this query: </span><span class="si">{query}</span><span class="s2"> using the feedback: </span><span class="si">{query_feedback}</span><span class="s2">"</span><span class="p">)</span>

    <span class="p">])</span>

    <span class="n">chain</span> <span class="o">=</span> <span class="n">expand_prompt</span> <span class="o">|</span> <span class="n">llm</span> <span class="o">|</span> <span class="n">StrOutputParser</span><span class="p">()</span>
    <span class="n">expanded_query</span> <span class="o">=</span> <span class="n">chain</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span><span class="s2">"query"</span><span class="p">:</span> <span class="n">state</span><span class="p">[</span><span class="s1">'query'</span><span class="p">],</span> <span class="s2">"query_feedback"</span><span class="p">:</span><span class="n">state</span><span class="p">[</span><span class="s2">"query_feedback"</span><span class="p">]})</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"expanded_query"</span><span class="p">,</span> <span class="n">expanded_query</span><span class="p">)</span>
    <span class="n">state</span><span class="p">[</span><span class="s2">"expanded_query"</span><span class="p">]</span> <span class="o">=</span> <span class="n">expanded_query</span>
    <span class="k">return</span> <span class="n">state</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.4-Retrieve-Context-from-Vector-Store"><strong>2.1.4 Retrieve Context from Vector Store</strong><a class="anchor-link" href="#2.1.4-Retrieve-Context-from-Vector-Store"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>Fetches relevant insurance-related information from the Chroma vector store based on the expanded or original query.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[15]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Initialize the Chroma vector store for retrieving documents</span>
<span class="n">vector_store</span> <span class="o">=</span> <span class="n">Chroma</span><span class="p">(</span>
    <span class="n">collection_name</span><span class="o">=</span><span class="s2">"semantic_chunks"</span><span class="p">,</span>
    <span class="n">persist_directory</span><span class="o">=</span><span class="s2">"nutritional_db"</span><span class="p">,</span>
    <span class="n">embedding_function</span><span class="o">=</span><span class="n">embedding_model</span>
<span class="p">)</span>

<span class="c1"># Create a retriever from the vector store</span>
<span class="n">retriever</span> <span class="o">=</span> <span class="n">vector_store</span><span class="o">.</span><span class="n">as_retriever</span><span class="p">(</span>
    <span class="n">search_type</span><span class="o">=</span><span class="s1">'similarity'</span><span class="p">,</span>
    <span class="n">search_kwargs</span><span class="o">=</span><span class="p">{</span><span class="s1">'k'</span><span class="p">:</span> <span class="mi">3</span><span class="p">}</span>
<span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[16]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">def</span><span class="w"> </span><span class="nf">retrieve_context</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">AgentState</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">AgentState</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Retrieves context from the vector store using the expanded or original query.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the query and expanded query.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with the retrieved context.</span>
<span class="sd">    """</span>
    <span class="n">query</span> <span class="o">=</span> <span class="n">state</span><span class="p">[</span><span class="s1">'expanded_query'</span><span class="p">]</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"Query used for retrieval:"</span><span class="p">,</span> <span class="n">query</span><span class="p">)</span>  <span class="c1"># Debugging: Print the query</span>

    <span class="c1"># Retrieve documents from the vector store</span>
    <span class="n">docs</span> <span class="o">=</span> <span class="n">retriever</span><span class="o">.</span><span class="n">invoke</span><span class="p">(</span><span class="n">query</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"Retrieved documents:"</span><span class="p">,</span> <span class="n">docs</span><span class="p">)</span>  <span class="c1"># Debugging: Print the raw docs object</span>

    <span class="c1"># Extract both page_content and metadata from each document</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'context'</span><span class="p">]</span> <span class="o">=</span> <span class="p">[</span>
        <span class="p">{</span>
            <span class="s2">"content"</span><span class="p">:</span> <span class="n">doc</span><span class="o">.</span><span class="n">page_content</span><span class="p">,</span>  <span class="c1"># The actual content of the document</span>
            <span class="s2">"metadata"</span><span class="p">:</span> <span class="n">doc</span><span class="o">.</span><span class="n">metadata</span>  <span class="c1"># The metadata (e.g., source, page number, etc.)</span>
        <span class="p">}</span>
        <span class="k">for</span> <span class="n">doc</span> <span class="ow">in</span> <span class="n">docs</span>
    <span class="p">]</span>

    <span class="nb">print</span><span class="p">(</span><span class="s2">"Extracted context with metadata:"</span><span class="p">,</span> <span class="n">state</span><span class="p">[</span><span class="s1">'context'</span><span class="p">])</span>  <span class="c1"># Debugging: Print the extracted context</span>
    <span class="k">return</span> <span class="n">state</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.5-Generate-Response-from-Retrieved-Context"><strong>2.1.5 Generate Response from Retrieved Context</strong><a class="anchor-link" href="#2.1.5-Generate-Response-from-Retrieved-Context"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>This function generates a response based on the retrieved context, focusing on nutrition disorders.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[17]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">def</span><span class="w"> </span><span class="nf">craft_response</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">Dict</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">Dict</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Generates a response using the retrieved context, focusing on nutrition disorders.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the query and retrieved context.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with the generated response.</span>
<span class="sd">    """</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------craft_response---------"</span><span class="p">)</span>
    <span class="n">system_message</span> <span class="o">=</span> <span class="s1">'''</span>
<span class="s1">    You are a helpful medical assistant specialized in nutritional disorders.</span>
<span class="s1">    Given a user's query, retrieved context, and any feedback, generate a concise and accurate answer.</span>

<span class="s1">    Guidelines:</span>
<span class="s1">    - Use only the information present in the context.</span>
<span class="s1">    - Do not hallucinate or assume facts not grounded in the context.</span>
<span class="s1">    - Write clearly and professionally.</span>
<span class="s1">    - If the context is insufficient, say so clearly and avoid making up an answer.</span>
<span class="s1">    '''</span>

    <span class="n">response_prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
        <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_message</span><span class="p">),</span>
        <span class="p">(</span><span class="s2">"user"</span><span class="p">,</span> <span class="s2">"Query: </span><span class="si">{query}</span><span class="se">\n</span><span class="s2">Context: </span><span class="si">{context}</span><span class="se">\n\n</span><span class="s2">feedback: </span><span class="si">{feedback}</span><span class="s2">"</span><span class="p">)</span>
    <span class="p">])</span>

    <span class="n">chain</span> <span class="o">=</span> <span class="n">response_prompt</span> <span class="o">|</span> <span class="n">llm</span>
    <span class="n">response</span> <span class="o">=</span> <span class="n">chain</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span>
        <span class="s2">"query"</span><span class="p">:</span> <span class="n">state</span><span class="p">[</span><span class="s1">'query'</span><span class="p">],</span>
        <span class="s2">"context"</span><span class="p">:</span> <span class="s2">"</span><span class="se">\n</span><span class="s2">"</span><span class="o">.</span><span class="n">join</span><span class="p">([</span><span class="n">doc</span><span class="p">[</span><span class="s2">"content"</span><span class="p">]</span> <span class="k">for</span> <span class="n">doc</span> <span class="ow">in</span> <span class="n">state</span><span class="p">[</span><span class="s1">'context'</span><span class="p">]]),</span>
        <span class="s2">"feedback"</span><span class="p">:</span> <span class="n">state</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"feedback"</span><span class="p">,</span> <span class="s2">""</span><span class="p">)</span>
    <span class="p">})</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'response'</span><span class="p">]</span> <span class="o">=</span> <span class="n">response</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"intermediate response: "</span><span class="p">,</span> <span class="n">response</span><span class="p">)</span>

    <span class="k">return</span> <span class="n">state</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.6-Check-Groundedness"><strong>2.1.6 Check Groundedness</strong><a class="anchor-link" href="#2.1.6-Check-Groundedness"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>This function evaluates whether the response is grounded in the retrieved context.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[18]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">def</span><span class="w"> </span><span class="nf">score_groundedness</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">Dict</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">Dict</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Checks whether the response is grounded in the retrieved context.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the response and context.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with the groundedness score.</span>
<span class="sd">    """</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------check_groundedness---------"</span><span class="p">)</span>
    <span class="n">system_message</span> <span class="o">=</span> <span class="s1">'''</span>
<span class="s1">    You are a scoring assistant.</span>

<span class="s1">    Given a response and its supporting context, rate how well-grounded the response is on a scale from 0.0 to 1.0:</span>

<span class="s1">    - 1.0 = fully grounded (every statement in the response is directly supported by the context)</span>
<span class="s1">    - 0.5 = partially grounded (some statements are supported, some are not)</span>
<span class="s1">    - 0.0 = not grounded (statements are unsupported or hallucinated)</span>

<span class="s1">     Respond with **only the score as a number** (e.g., 0.8). Do not include any explanation or additional text.</span>
<span class="s1">    '''</span>

    <span class="n">groundedness_prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
        <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_message</span><span class="p">),</span>
        <span class="p">(</span><span class="s2">"user"</span><span class="p">,</span> <span class="s2">"Context: </span><span class="si">{context}</span><span class="se">\n</span><span class="s2">Response: </span><span class="si">{response}</span><span class="se">\n\n</span><span class="s2">Groundedness score:"</span><span class="p">)</span>
    <span class="p">])</span>

    <span class="n">chain</span> <span class="o">=</span> <span class="n">groundedness_prompt</span> <span class="o">|</span> <span class="n">llm</span> <span class="o">|</span> <span class="n">StrOutputParser</span><span class="p">()</span>
    <span class="n">groundedness_score</span> <span class="o">=</span> <span class="nb">float</span><span class="p">(</span><span class="n">chain</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span>
        <span class="s2">"context"</span><span class="p">:</span> <span class="s2">"</span><span class="se">\n</span><span class="s2">"</span><span class="o">.</span><span class="n">join</span><span class="p">([</span><span class="n">doc</span><span class="p">[</span><span class="s2">"content"</span><span class="p">]</span> <span class="k">for</span> <span class="n">doc</span> <span class="ow">in</span> <span class="n">state</span><span class="p">[</span><span class="s1">'context'</span><span class="p">]]),</span>
        <span class="s2">"response"</span><span class="p">:</span> <span class="n">state</span><span class="p">[</span><span class="s2">"response"</span><span class="p">]</span>
    <span class="p">}))</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"groundedness_score: "</span><span class="p">,</span> <span class="n">groundedness_score</span><span class="p">)</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'groundedness_loop_count'</span><span class="p">]</span> <span class="o">+=</span> <span class="mi">1</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"#########Groundedness Incremented###########"</span><span class="p">)</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'groundedness_score'</span><span class="p">]</span> <span class="o">=</span> <span class="n">groundedness_score</span>

    <span class="k">return</span> <span class="n">state</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.7-Check-Precision"><strong>2.1.7 Check Precision</strong><a class="anchor-link" href="#2.1.7-Check-Precision"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>This function evaluates whether the response precisely addresses the users query.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[19]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">def</span><span class="w"> </span><span class="nf">check_precision</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">Dict</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">Dict</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Checks whether the response precisely addresses the users query.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the query and response.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with the precision score.</span>
<span class="sd">    """</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------check_precision---------"</span><span class="p">)</span>
    <span class="n">system_message</span> <span class="o">=</span> <span class="s1">'''</span>
<span class="s1">    You are an assistant evaluating how precisely a response answers the given query.</span>

<span class="s1">    Score precision on a scale from 0.0 to 1.0:</span>
<span class="s1">    - 1.0: Direct and highly specific answer to the query, without irrelevant details.</span>
<span class="s1">    - 0.5: Partially addresses the query but lacks clarity or adds some unrelated information.</span>
<span class="s1">    - 0.0: Fails to answer the query or gives a vague or off-topic response.</span>

<span class="s1">    Respond with only the numeric precision score as a decimal (e.g., 0.8).</span>
<span class="s1">    '''</span>

    <span class="n">precision_prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
        <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_message</span><span class="p">),</span>
        <span class="p">(</span><span class="s2">"user"</span><span class="p">,</span> <span class="s2">"Query: </span><span class="si">{query}</span><span class="se">\n</span><span class="s2">Response: </span><span class="si">{response}</span><span class="se">\n\n</span><span class="s2">Precision score:"</span><span class="p">)</span>
    <span class="p">])</span>

    <span class="n">chain</span> <span class="o">=</span> <span class="n">precision_prompt</span> <span class="o">|</span> <span class="n">llm</span> <span class="o">|</span> <span class="n">StrOutputParser</span><span class="p">()</span>
    <span class="n">precision_score</span> <span class="o">=</span> <span class="nb">float</span><span class="p">(</span><span class="n">chain</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span>
        <span class="s2">"query"</span><span class="p">:</span> <span class="n">state</span><span class="p">[</span><span class="s1">'query'</span><span class="p">],</span>
        <span class="s2">"response"</span><span class="p">:</span> <span class="n">state</span><span class="p">[</span><span class="s1">'response'</span><span class="p">]</span>
    <span class="p">}))</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'precision_score'</span><span class="p">]</span> <span class="o">=</span> <span class="n">precision_score</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"precision_score:"</span><span class="p">,</span> <span class="n">precision_score</span><span class="p">)</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'precision_loop_count'</span><span class="p">]</span> <span class="o">+=</span> <span class="mi">1</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"#########Precision Incremented###########"</span><span class="p">)</span>
    <span class="k">return</span> <span class="n">state</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.8-Refine-AI-Response"><strong>2.1.8 Refine AI Response</strong><a class="anchor-link" href="#2.1.8-Refine-AI-Response"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>Provides constructive feedback on the generated response by identifying potential gaps, ambiguities, or missing details. It does not rewrite the response but suggests improvements to enhance accuracy and completeness.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[20]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">def</span><span class="w"> </span><span class="nf">refine_response</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">Dict</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">Dict</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Suggests improvements for the generated response.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the query and response.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with response refinement suggestions.</span>
<span class="sd">    """</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------refine_response---------"</span><span class="p">)</span>

    <span class="n">system_message</span> <span class="o">=</span> <span class="s1">'''</span>
<span class="s1">    You are an assistant specializing in improving medical question-answering responses.</span>

<span class="s1">    Your task is to suggest specific improvements to a given response based on a users original query. Focus on enhancing:</span>

<span class="s1">    - **Accuracy**: Ensure facts align with current medical knowledge and the retrieved context.</span>
<span class="s1">    - **Completeness**: Suggest what's missing or could be clarified.</span>
<span class="s1">    - **Clarity**: Recommend rewording for better readability or precision.</span>

<span class="s1">    Your feedback should be constructive and actionable. Return only suggestions without rewriting the entire response.</span>
<span class="s1">    '''</span>

    <span class="n">refine_response_prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
        <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_message</span><span class="p">),</span>
        <span class="p">(</span><span class="s2">"user"</span><span class="p">,</span> <span class="s2">"Query: </span><span class="si">{query}</span><span class="se">\n</span><span class="s2">Response: </span><span class="si">{response}</span><span class="se">\n\n</span><span class="s2">"</span>
                 <span class="s2">"What improvements can be made to enhance accuracy and completeness?"</span><span class="p">)</span>
    <span class="p">])</span>

    <span class="n">chain</span> <span class="o">=</span> <span class="n">refine_response_prompt</span> <span class="o">|</span> <span class="n">llm</span> <span class="o">|</span> <span class="n">StrOutputParser</span><span class="p">()</span>

    <span class="c1"># Store response suggestions in a structured format</span>
    <span class="n">feedback</span> <span class="o">=</span> <span class="sa">f</span><span class="s2">"Previous Response: </span><span class="si">{</span><span class="n">state</span><span class="p">[</span><span class="s1">'response'</span><span class="p">]</span><span class="si">}</span><span class="se">\n</span><span class="s2">Suggestions: </span><span class="si">{</span><span class="n">chain</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span><span class="s1">'query'</span><span class="p">:</span><span class="w"> </span><span class="n">state</span><span class="p">[</span><span class="s1">'query'</span><span class="p">],</span><span class="w"> </span><span class="s1">'response'</span><span class="p">:</span><span class="w"> </span><span class="n">state</span><span class="p">[</span><span class="s1">'response'</span><span class="p">]})</span><span class="si">}</span><span class="s2">"</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"feedback: "</span><span class="p">,</span> <span class="n">feedback</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"State: </span><span class="si">{</span><span class="n">state</span><span class="si">}</span><span class="s2">"</span><span class="p">)</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'feedback'</span><span class="p">]</span> <span class="o">=</span> <span class="n">feedback</span>
    <span class="k">return</span> <span class="n">state</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.9-Refine-Expanded-Query"><strong>2.1.9 Refine Expanded Query</strong><a class="anchor-link" href="#2.1.9-Refine-Expanded-Query"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>Improves the expanded query by identifying missing details, specific keywords, or scope refinements that can enhance search precision. It does not replace the expanded query but provides structured suggestions for improvement.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[21]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">def</span><span class="w"> </span><span class="nf">refine_query</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">Dict</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">Dict</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Suggests improvements for the expanded query.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the query and expanded query.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with query refinement suggestions.</span>
<span class="sd">    """</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------refine_query---------"</span><span class="p">)</span>
    <span class="n">system_message</span> <span class="o">=</span> <span class="s1">'''</span>
<span class="s1">    You are an assistant that helps improve search queries for medical literature retrieval, specifically in the context of nutritional disorders.</span>

<span class="s1">    Your task is to analyze an original user query and its expanded version, and suggest improvements to the expanded query to make it:</span>

<span class="s1">    - More specific and medically relevant</span>
<span class="s1">    - Better aligned with information retrieval best practices</span>
<span class="s1">    - Clear and unambiguous</span>

<span class="s1">    Focus on clarity, terminology, and contextual relevance. Return only the suggestions. Do not rewrite the query.</span>
<span class="s1">    '''</span>

    <span class="n">refine_query_prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
        <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_message</span><span class="p">),</span>
        <span class="p">(</span><span class="s2">"user"</span><span class="p">,</span> <span class="s2">"Original Query: </span><span class="si">{query}</span><span class="se">\n</span><span class="s2">Expanded Query: </span><span class="si">{expanded_query}</span><span class="se">\n\n</span><span class="s2">"</span>
                 <span class="s2">"What improvements can be made for a better search?"</span><span class="p">)</span>
    <span class="p">])</span>

    <span class="n">chain</span> <span class="o">=</span> <span class="n">refine_query_prompt</span> <span class="o">|</span> <span class="n">llm</span> <span class="o">|</span> <span class="n">StrOutputParser</span><span class="p">()</span>

    <span class="c1"># Store refinement suggestions without modifying the original expanded query</span>
    <span class="n">query_feedback</span> <span class="o">=</span> <span class="sa">f</span><span class="s2">"Previous Expanded Query: </span><span class="si">{</span><span class="n">state</span><span class="p">[</span><span class="s1">'expanded_query'</span><span class="p">]</span><span class="si">}</span><span class="se">\n</span><span class="s2">Suggestions: </span><span class="si">{</span><span class="n">chain</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span><span class="s1">'query'</span><span class="p">:</span><span class="w"> </span><span class="n">state</span><span class="p">[</span><span class="s1">'query'</span><span class="p">],</span><span class="w"> </span><span class="s1">'expanded_query'</span><span class="p">:</span><span class="w"> </span><span class="n">state</span><span class="p">[</span><span class="s1">'expanded_query'</span><span class="p">]})</span><span class="si">}</span><span class="s2">"</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"query_feedback: "</span><span class="p">,</span> <span class="n">query_feedback</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"Groundedness loop count: </span><span class="si">{</span><span class="n">state</span><span class="p">[</span><span class="s1">'groundedness_loop_count'</span><span class="p">]</span><span class="si">}</span><span class="s2">"</span><span class="p">)</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'query_feedback'</span><span class="p">]</span> <span class="o">=</span> <span class="n">query_feedback</span>
    <span class="k">return</span> <span class="n">state</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.10-Groundedness-Evaluation-&amp;-Next-Step-Decision"><strong>2.1.10 Groundedness Evaluation &amp; Next Step Decision</strong><a class="anchor-link" href="#2.1.10-Groundedness-Evaluation-&amp;-Next-Step-Decision"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>Determines if the AI-generated response is sufficiently grounded in the retrieved context. Based on the groundedness score, it decides whether the process should proceed to precision checking or require response refinement.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[22]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">def</span><span class="w"> </span><span class="nf">should_continue_groundedness</span><span class="p">(</span><span class="n">state</span><span class="p">):</span>
<span class="w">    </span><span class="sd">"""Decides if groundedness is sufficient or needs improvement."""</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------should_continue_groundedness---------"</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"groundedness loop count: "</span><span class="p">,</span> <span class="n">state</span><span class="p">[</span><span class="s1">'groundedness_loop_count'</span><span class="p">])</span>

    <span class="k">if</span> <span class="n">state</span><span class="p">[</span><span class="s1">'groundedness_score'</span><span class="p">]</span> <span class="o">&gt;=</span> <span class="mf">0.85</span><span class="p">:</span>  <span class="c1"># Threshold for groundedness</span>
        <span class="nb">print</span><span class="p">(</span><span class="s2">" Groundedness sufficient. Moving to precision check."</span><span class="p">)</span>
        <span class="k">return</span> <span class="s2">"check_precision"</span>
    <span class="k">else</span><span class="p">:</span>
        <span class="k">if</span> <span class="n">state</span><span class="p">[</span><span class="s2">"groundedness_loop_count"</span><span class="p">]</span> <span class="o">&gt;</span> <span class="n">state</span><span class="p">[</span><span class="s1">'loop_max_iter'</span><span class="p">]:</span>
            <span class="nb">print</span><span class="p">(</span><span class="s2">" Maximum iterations reached. Stopping."</span><span class="p">)</span>
            <span class="k">return</span> <span class="s2">"max_iterations_reached"</span>
        <span class="k">else</span><span class="p">:</span>
            <span class="nb">print</span><span class="p">(</span><span class="s2">" Groundedness score too low. Refining response."</span><span class="p">)</span>
            <span class="k">return</span> <span class="s2">"refine_response"</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.11-Precision-Evaluation-&amp;-Next-Step-Decision"><strong>2.1.11 Precision Evaluation &amp; Next Step Decision</strong><a class="anchor-link" href="#2.1.11-Precision-Evaluation-&amp;-Next-Step-Decision"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>Determines if the AI-generated response is sufficiently precise based on the precision score. It helps decide whether the response can pass or if the query needs refinement.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[23]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">def</span><span class="w"> </span><span class="nf">should_continue_precision</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">Dict</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="nb">str</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""Decides if precision is sufficient or needs improvement."""</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------should_continue_precision---------"</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"precision loop count: "</span><span class="p">,</span> <span class="n">state</span><span class="p">[</span><span class="s1">'precision_loop_count'</span><span class="p">])</span>

    <span class="k">if</span> <span class="n">state</span><span class="p">[</span><span class="s1">'precision_score'</span><span class="p">]</span> <span class="o">&gt;=</span> <span class="mf">0.85</span><span class="p">:</span>  <span class="c1"># Threshold for precision</span>
        <span class="nb">print</span><span class="p">(</span><span class="s2">" Precision sufficient. Passing."</span><span class="p">)</span>
        <span class="k">return</span> <span class="s2">"pass"</span>
    <span class="k">else</span><span class="p">:</span>
        <span class="k">if</span> <span class="n">state</span><span class="p">[</span><span class="s1">'precision_loop_count'</span><span class="p">]</span> <span class="o">&gt;</span> <span class="n">state</span><span class="p">[</span><span class="s1">'loop_max_iter'</span><span class="p">]:</span>
            <span class="nb">print</span><span class="p">(</span><span class="s2">" Maximum iterations reached. Stopping."</span><span class="p">)</span>
            <span class="k">return</span> <span class="s2">"max_iterations_reached"</span>
        <span class="k">else</span><span class="p">:</span>
            <span class="nb">print</span><span class="p">(</span><span class="s2">" Precision score too low. Refining query."</span><span class="p">)</span>
            <span class="k">return</span> <span class="s2">"refine_query"</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.12-Defining-the-state-where-max-iterations-reached"><strong>2.1.12 Defining the state where max iterations reached</strong><a class="anchor-link" href="#2.1.12-Defining-the-state-where-max-iterations-reached"></a></h3>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[24]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">def</span><span class="w"> </span><span class="nf">max_iterations_reached</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">AgentState</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">AgentState</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""Handles the case where max iterations are reached."""</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'response'</span><span class="p">]</span> <span class="o">=</span> <span class="s2">"We need more context to provide an accurate answer."</span>
    <span class="k">return</span> <span class="n">state</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.13-Define-AI-Workflow-for-Insurance-Agent"><strong>2.1.13 Define AI Workflow for Insurance Agent</strong><a class="anchor-link" href="#2.1.13-Define-AI-Workflow-for-Insurance-Agent"></a></h3>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[25]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="kn">from</span><span class="w"> </span><span class="nn">langgraph.graph</span><span class="w"> </span><span class="kn">import</span> <span class="n">END</span><span class="p">,</span> <span class="n">StateGraph</span><span class="p">,</span> <span class="n">START</span>

<span class="k">def</span><span class="w"> </span><span class="nf">create_workflow</span><span class="p">()</span> <span class="o">-&gt;</span> <span class="n">StateGraph</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""Creates the updated workflow for the AI nutrition agent."""</span>
    <span class="n">workflow</span> <span class="o">=</span> <span class="n">StateGraph</span><span class="p">(</span><span class="nb">dict</span><span class="p">)</span>

    <span class="c1"># Add processing nodes</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"expand_query"</span><span class="p">,</span> <span class="n">expand_query</span><span class="p">)</span>                      <span class="c1"># Step 1</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"retrieve_context"</span><span class="p">,</span> <span class="n">retrieve_context</span><span class="p">)</span>              <span class="c1"># Step 2</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"craft_response"</span><span class="p">,</span> <span class="n">craft_response</span><span class="p">)</span>                  <span class="c1"># Step 3</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"score_groundedness"</span><span class="p">,</span> <span class="n">score_groundedness</span><span class="p">)</span>          <span class="c1"># Step 4</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"refine_response"</span><span class="p">,</span> <span class="n">refine_response</span><span class="p">)</span>                <span class="c1"># Step 5</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"check_precision"</span><span class="p">,</span> <span class="n">check_precision</span><span class="p">)</span>                <span class="c1"># Step 6</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"refine_query"</span><span class="p">,</span> <span class="n">refine_query</span><span class="p">)</span>                      <span class="c1"># Step 7</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"max_iterations_reached"</span><span class="p">,</span> <span class="k">lambda</span> <span class="n">x</span><span class="p">:</span> <span class="n">x</span><span class="p">)</span>             <span class="c1"># Step 8  exit handler (no-op)</span>

    <span class="c1"># Main flow edges</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="n">START</span><span class="p">,</span> <span class="s2">"expand_query"</span><span class="p">)</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="s2">"expand_query"</span><span class="p">,</span> <span class="s2">"retrieve_context"</span><span class="p">)</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="s2">"retrieve_context"</span><span class="p">,</span> <span class="s2">"craft_response"</span><span class="p">)</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="s2">"craft_response"</span><span class="p">,</span> <span class="s2">"score_groundedness"</span><span class="p">)</span>

    <span class="c1"># Conditional edges based on groundedness check</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_conditional_edges</span><span class="p">(</span>
        <span class="s2">"score_groundedness"</span><span class="p">,</span>
        <span class="n">should_continue_groundedness</span><span class="p">,</span>
        <span class="p">{</span>
            <span class="s2">"check_precision"</span><span class="p">:</span> <span class="s2">"check_precision"</span><span class="p">,</span>         <span class="c1"># If grounded enough</span>
            <span class="s2">"refine_response"</span><span class="p">:</span> <span class="s2">"refine_response"</span><span class="p">,</span>         <span class="c1"># If not grounded</span>
            <span class="s2">"max_iterations_reached"</span><span class="p">:</span> <span class="s2">"max_iterations_reached"</span>  <span class="c1"># Too many loops</span>
        <span class="p">}</span>
    <span class="p">)</span>

    <span class="c1"># Re-craft response after refining it</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="s2">"refine_response"</span><span class="p">,</span> <span class="s2">"craft_response"</span><span class="p">)</span>

    <span class="c1"># Conditional edges based on precision check</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_conditional_edges</span><span class="p">(</span>
        <span class="s2">"check_precision"</span><span class="p">,</span>
        <span class="n">should_continue_precision</span><span class="p">,</span>  <span class="c1"># Function to decide precision flow</span>
        <span class="p">{</span>
            <span class="s2">"pass"</span><span class="p">:</span> <span class="n">END</span><span class="p">,</span>
            <span class="s2">"refine_query"</span><span class="p">:</span> <span class="s2">"refine_query"</span><span class="p">,</span>
            <span class="s2">"max_iterations_reached"</span><span class="p">:</span> <span class="s2">"max_iterations_reached"</span>
        <span class="p">}</span>
    <span class="p">)</span>

    <span class="c1"># Re-expand and re-process refined queries</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="s2">"refine_query"</span><span class="p">,</span> <span class="s2">"expand_query"</span><span class="p">)</span>

    <span class="c1"># Exit when max loop count is reached</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="s2">"max_iterations_reached"</span><span class="p">,</span> <span class="n">END</span><span class="p">)</span>

    <span class="k">return</span> <span class="n">workflow</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>Defines the end-to-end workflow for the insurance agent using a StateGraph. The workflow ensures the AI agent follows a structured approach, refining queries, retrieving relevant data, generating responses, and validating them for accuracy before finalizing the response.</p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.1.14-Visualising-the-flow"><strong>2.1.14 Visualising the flow</strong><a class="anchor-link" href="#2.1.14-Visualising-the-flow"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>Uses the workflow graph to compile and generate a visual representation of the workflow in the form of a flowchart</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[26]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="n">WORKFLOW_APP</span> <span class="o">=</span> <span class="n">create_workflow</span><span class="p">()</span><span class="o">.</span><span class="n">compile</span><span class="p">()</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[27]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="kn">from</span><span class="w"> </span><span class="nn">IPython.display</span><span class="w"> </span><span class="kn">import</span> <span class="n">Image</span><span class="p">,</span> <span class="n">display</span>

<span class="n">display</span><span class="p">(</span><span class="n">Image</span><span class="p">(</span><span class="n">WORKFLOW_APP</span><span class="o">.</span><span class="n">get_graph</span><span class="p">()</span><span class="o">.</span><span class="n">draw_mermaid_png</span><span class="p">()))</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedImage jp-OutputArea-output" tabindex="0">
<img alt="No description has been provided for this image" class="" src="data:image/jpeg;base64,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
"/>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p><strong>2.1.15 Agentic RAG Execution Function</strong></p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>This function runs an agentic RAG-based workflow to generate context-aware responses by refining user queries, retrieving relevant knowledge, and ensuring precision and groundedness.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[28]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="kn">from</span><span class="w"> </span><span class="nn">datetime</span><span class="w"> </span><span class="kn">import</span> <span class="n">datetime</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_core.tools</span><span class="w"> </span><span class="kn">import</span> <span class="n">tool</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.agents</span><span class="w"> </span><span class="kn">import</span> <span class="n">create_tool_calling_agent</span><span class="p">,</span> <span class="n">AgentExecutor</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_core.prompts</span><span class="w"> </span><span class="kn">import</span> <span class="n">ChatPromptTemplate</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[29]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="nd">@tool</span>
<span class="k">def</span><span class="w"> </span><span class="nf">agentic_rag</span><span class="p">(</span><span class="n">query</span><span class="p">:</span> <span class="nb">str</span><span class="p">):</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Runs the RAG-based agent with conversation history for context-aware responses.</span>

<span class="sd">    Args:</span>
<span class="sd">        query (str): The current user query.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict[str, Any]: The updated state with the generated response and conversation history.</span>
<span class="sd">    """</span>
    <span class="c1"># Initialize state with necessary parameters</span>
    <span class="n">inputs</span> <span class="o">=</span> <span class="p">{</span>
        <span class="s2">"query"</span><span class="p">:</span> <span class="n">query</span><span class="p">,</span>                         <span class="c1"># User's question</span>
        <span class="s2">"expanded_query"</span><span class="p">:</span> <span class="s2">""</span><span class="p">,</span>                   <span class="c1"># Will be filled by expand_query step</span>
        <span class="s2">"context"</span><span class="p">:</span> <span class="p">[],</span>                          <span class="c1"># Retrieved docs (initially empty)</span>
        <span class="s2">"response"</span><span class="p">:</span> <span class="s2">""</span><span class="p">,</span>                         <span class="c1"># Will be generated during workflow</span>
        <span class="s2">"precision_score"</span><span class="p">:</span> <span class="mf">0.0</span><span class="p">,</span>                 <span class="c1"># Initialized to zero</span>
        <span class="s2">"groundedness_score"</span><span class="p">:</span> <span class="mf">0.0</span><span class="p">,</span>              <span class="c1"># Initialized to zero</span>
        <span class="s2">"groundedness_loop_count"</span><span class="p">:</span> <span class="mi">0</span><span class="p">,</span>           <span class="c1"># Count how many times grounding refinement occurred</span>
        <span class="s2">"precision_loop_count"</span><span class="p">:</span> <span class="mi">0</span><span class="p">,</span>              <span class="c1"># Count how many times precision refinement occurred</span>
        <span class="s2">"feedback"</span><span class="p">:</span> <span class="s2">""</span><span class="p">,</span>                         <span class="c1"># Feedback after response refinement</span>
        <span class="s2">"query_feedback"</span><span class="p">:</span> <span class="s2">""</span><span class="p">,</span>                   <span class="c1"># Feedback after query refinement</span>
        <span class="s2">"loop_max_iter"</span><span class="p">:</span> <span class="mi">3</span>                      <span class="c1"># Max loop iterations for groundedness/precision</span>
    <span class="p">}</span>

    <span class="n">output</span> <span class="o">=</span> <span class="n">WORKFLOW_APP</span><span class="o">.</span><span class="n">invoke</span><span class="p">(</span><span class="n">inputs</span><span class="p">)</span>

    <span class="k">return</span> <span class="n">output</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[30]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="n">agentic_rag</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span><span class="s2">"query"</span><span class="p">:</span> <span class="s2">"What are the symptoms of vitamin D deficiency?"</span><span class="p">})</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>---------Expanding Query---------
expanded_query What are the common clinical symptoms and health consequences associated with vitamin D deficiency in adults and children?
Query used for retrieval: What are the common clinical symptoms and health consequences associated with vitamin D deficiency in adults and children?
Retrieved documents: []
Extracted context with metadata: []
---------craft_response---------
intermediate response:  content='The context does not provide information regarding the symptoms of vitamin D deficiency. Therefore, I cannot provide an answer based on the available information.' response_metadata={'token_usage': {'completion_tokens': 27, 'prompt_tokens': 117, 'total_tokens': 144, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'finish_reason': 'stop', 'logprobs': None} id='run-774a22b7-3311-4864-aa1c-de70c623267c-0' usage_metadata={'input_tokens': 117, 'output_tokens': 27, 'total_tokens': 144}
---------check_groundedness---------
groundedness_score:  1.0
#########Groundedness Incremented###########
---------should_continue_groundedness---------
groundedness loop count:  1
 Groundedness sufficient. Moving to precision check.
---------check_precision---------
precision_score: 0.0
#########Precision Incremented###########
---------should_continue_precision---------
precision loop count:  1
 Precision score too low. Refining query.
---------refine_query---------
query_feedback:  Previous Expanded Query: What are the common clinical symptoms and health consequences associated with vitamin D deficiency in adults and children?
Suggestions: 1. Specify the age groups more clearly by using terms like "pediatric" for children and "adult" for adults.
2. Include "clinical manifestations" instead of "common clinical symptoms" for precision.
3. Add "pathophysiological implications" to encompass health consequences.
4. Mention specific populations if relevant, such as "at-risk populations" or "elderly."
5. Consider including "diagnosis" or "assessment" to focus on clinical evaluation.
6. Include "epidemiology" to address prevalence and risk factors associated with vitamin D deficiency.
7. Use "vitamin D insufficiency" along with "deficiency" to capture a broader range of literature.
Groundedness loop count: 1
---------Expanding Query---------
expanded_query What are the clinical manifestations, pathophysiological implications, and epidemiology of vitamin D deficiency and insufficiency in pediatric and adult populations, particularly among at-risk groups such as the elderly, along with considerations for diagnosis and assessment?
Query used for retrieval: What are the clinical manifestations, pathophysiological implications, and epidemiology of vitamin D deficiency and insufficiency in pediatric and adult populations, particularly among at-risk groups such as the elderly, along with considerations for diagnosis and assessment?
Retrieved documents: []
Extracted context with metadata: []
---------craft_response---------
intermediate response:  content='The context provided does not include specific information regarding the symptoms of vitamin D deficiency. Therefore, I cannot provide an answer based on the given context.' response_metadata={'token_usage': {'completion_tokens': 29, 'prompt_tokens': 117, 'total_tokens': 146, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'finish_reason': 'stop', 'logprobs': None} id='run-81a22573-464f-4728-8b88-e2b23168864c-0' usage_metadata={'input_tokens': 117, 'output_tokens': 29, 'total_tokens': 146}
---------check_groundedness---------
groundedness_score:  1.0
#########Groundedness Incremented###########
---------should_continue_groundedness---------
groundedness loop count:  2
 Groundedness sufficient. Moving to precision check.
---------check_precision---------
precision_score: 0.0
#########Precision Incremented###########
---------should_continue_precision---------
precision loop count:  2
 Precision score too low. Refining query.
---------refine_query---------
query_feedback:  Previous Expanded Query: What are the clinical manifestations, pathophysiological implications, and epidemiology of vitamin D deficiency and insufficiency in pediatric and adult populations, particularly among at-risk groups such as the elderly, along with considerations for diagnosis and assessment?
Suggestions: 1. Specify "clinical manifestations" to "clinical manifestations and symptoms" for clarity.
2. Replace "pathophysiological implications" with "pathophysiology" to streamline the terminology.
3. Clarify "epidemiology" by adding "prevalence and risk factors" to focus on relevant details.
4. Change "pediatric and adult populations" to "pediatric and adult populations experiencing vitamin D deficiency" for specificity.
5. Define "at-risk groups" more clearly by including specific examples of risk factors.
6. Include "diagnosis criteria" instead of just "diagnosis" for precision.
7. Reorganize the query into a clearer list format for improved readability.
Groundedness loop count: 2
---------Expanding Query---------
expanded_query What are the clinical manifestations and symptoms, pathophysiology, prevalence and risk factors, and diagnosis criteria of vitamin D deficiency in pediatric and adult populations experiencing deficiencies, particularly among at-risk groups such as the elderly, individuals with limited sun exposure, and those with malabsorption disorders?
Query used for retrieval: What are the clinical manifestations and symptoms, pathophysiology, prevalence and risk factors, and diagnosis criteria of vitamin D deficiency in pediatric and adult populations experiencing deficiencies, particularly among at-risk groups such as the elderly, individuals with limited sun exposure, and those with malabsorption disorders?
Retrieved documents: []
Extracted context with metadata: []
---------craft_response---------
intermediate response:  content='The context does not provide information about the symptoms of vitamin D deficiency. Therefore, I cannot answer your query accurately. If you need specific details, please provide additional information or context.' response_metadata={'token_usage': {'completion_tokens': 36, 'prompt_tokens': 117, 'total_tokens': 153, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'finish_reason': 'stop', 'logprobs': None} id='run-3781e6f7-4628-43a4-82c2-67e5de396bea-0' usage_metadata={'input_tokens': 117, 'output_tokens': 36, 'total_tokens': 153}
---------check_groundedness---------
groundedness_score:  1.0
#########Groundedness Incremented###########
---------should_continue_groundedness---------
groundedness loop count:  3
 Groundedness sufficient. Moving to precision check.
---------check_precision---------
precision_score: 0.0
#########Precision Incremented###########
---------should_continue_precision---------
precision loop count:  3
 Precision score too low. Refining query.
---------refine_query---------
query_feedback:  Previous Expanded Query: What are the clinical manifestations and symptoms, pathophysiology, prevalence and risk factors, and diagnosis criteria of vitamin D deficiency in pediatric and adult populations experiencing deficiencies, particularly among at-risk groups such as the elderly, individuals with limited sun exposure, and those with malabsorption disorders?
Suggestions: 1. Specify "clinical manifestations" to include "signs and symptoms" for clarity.
2. Replace "prevalence and risk factors" with "epidemiology and associated risk factors" for precision.
3. Clarify "diagnosis criteria" to "diagnostic criteria and guidelines" for specificity.
4. Remove "experiencing deficiencies" as it is redundant; the term "deficiency" already implies this.
5. Consider adding "laboratory assessment" to encompass diagnostic methods.
6. Use "pediatric and adult populations" more succinctly by stating "all age groups."
7. Specify "malabsorption disorders" by including examples like "celiac disease or Crohn's disease."
8. Include "intervention strategies" to address potential management of vitamin D deficiency.
9. Utilize "Vitamin D deficiency" consistently throughout for uniformity.
Groundedness loop count: 3
---------Expanding Query---------
expanded_query What are the clinical manifestations, signs and symptoms, pathophysiology, epidemiology, associated risk factors, diagnostic criteria and guidelines, laboratory assessment methods, and intervention strategies for Vitamin D deficiency in all age groups, particularly among at-risk populations such as the elderly, individuals with limited sun exposure, and those with malabsorption disorders like celiac disease or Crohn's disease?
Query used for retrieval: What are the clinical manifestations, signs and symptoms, pathophysiology, epidemiology, associated risk factors, diagnostic criteria and guidelines, laboratory assessment methods, and intervention strategies for Vitamin D deficiency in all age groups, particularly among at-risk populations such as the elderly, individuals with limited sun exposure, and those with malabsorption disorders like celiac disease or Crohn's disease?
Retrieved documents: []
Extracted context with metadata: []
---------craft_response---------
intermediate response:  content='The context does not provide information on the symptoms of vitamin D deficiency. Therefore, I cannot answer your question.' response_metadata={'token_usage': {'completion_tokens': 22, 'prompt_tokens': 117, 'total_tokens': 139, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'finish_reason': 'stop', 'logprobs': None} id='run-a7cc35e9-acaa-4862-bb14-4380fa34cc93-0' usage_metadata={'input_tokens': 117, 'output_tokens': 22, 'total_tokens': 139}
---------check_groundedness---------
groundedness_score:  1.0
#########Groundedness Incremented###########
---------should_continue_groundedness---------
groundedness loop count:  4
 Groundedness sufficient. Moving to precision check.
---------check_precision---------
precision_score: 0.0
#########Precision Incremented###########
---------should_continue_precision---------
precision loop count:  4
 Maximum iterations reached. Stopping.
</pre>
</div>
</div>
<div class="jp-OutputArea-child jp-OutputArea-executeResult">
<div class="jp-OutputPrompt jp-OutputArea-prompt">Out[30]:</div>
<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain" tabindex="0">
<pre>{'query': 'What are the symptoms of vitamin D deficiency?',
 'expanded_query': "What are the clinical manifestations, signs and symptoms, pathophysiology, epidemiology, associated risk factors, diagnostic criteria and guidelines, laboratory assessment methods, and intervention strategies for Vitamin D deficiency in all age groups, particularly among at-risk populations such as the elderly, individuals with limited sun exposure, and those with malabsorption disorders like celiac disease or Crohn's disease?",
 'context': [],
 'response': AIMessage(content='The context does not provide information on the symptoms of vitamin D deficiency. Therefore, I cannot answer your question.', response_metadata={'token_usage': {'completion_tokens': 22, 'prompt_tokens': 117, 'total_tokens': 139, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'finish_reason': 'stop', 'logprobs': None}, id='run-a7cc35e9-acaa-4862-bb14-4380fa34cc93-0', usage_metadata={'input_tokens': 117, 'output_tokens': 22, 'total_tokens': 139}),
 'precision_score': 0.0,
 'groundedness_score': 1.0,
 'groundedness_loop_count': 4,
 'precision_loop_count': 4,
 'feedback': '',
 'query_feedback': 'Previous Expanded Query: What are the clinical manifestations and symptoms, pathophysiology, prevalence and risk factors, and diagnosis criteria of vitamin D deficiency in pediatric and adult populations experiencing deficiencies, particularly among at-risk groups such as the elderly, individuals with limited sun exposure, and those with malabsorption disorders?\nSuggestions: 1. Specify "clinical manifestations" to include "signs and symptoms" for clarity.\n2. Replace "prevalence and risk factors" with "epidemiology and associated risk factors" for precision.\n3. Clarify "diagnosis criteria" to "diagnostic criteria and guidelines" for specificity.\n4. Remove "experiencing deficiencies" as it is redundant; the term "deficiency" already implies this.\n5. Consider adding "laboratory assessment" to encompass diagnostic methods.\n6. Use "pediatric and adult populations" more succinctly by stating "all age groups."\n7. Specify "malabsorption disorders" by including examples like "celiac disease or Crohn\'s disease."\n8. Include "intervention strategies" to address potential management of vitamin D deficiency.\n9. Utilize "Vitamin D deficiency" consistently throughout for uniformity.',
 'loop_max_iter': 3}</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h2 id="2.2-Guardrailing-the-Input-Provided-by-the-User"><strong>2.2 Guardrailing the Input Provided by the User</strong><a class="anchor-link" href="#2.2-Guardrailing-the-Input-Provided-by-the-User"></a></h2>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.2.1-Importing-Necessary-Libraries"><strong>2.2.1 Importing Necessary Libraries</strong><a class="anchor-link" href="#2.2.1-Importing-Necessary-Libraries"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>To get the Key follow the below steps</p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>Click on this <a href="https://console.groq.com/login">Link</a>, and click login with Google.<img alt="image.png" src="data:image/png;base64,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"/></p>
<p>On logging in, you will be taken to this page.Click on "API KEYS" as highlighted.<img alt="image.png" src="data:image/png;base64,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"/>
On clicking on API Keys, you will be landing on this page. Click On Create API Keys
<img alt="image.png" src="data:image/png;base64,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"/>
Choose a suitable name for your API, for example we chose "llama-guard-api" for this case and click on submit.
<img alt="Screenshot 2025-01-29 115904.png" src="data:image/png;base64,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"/>
After clicking on submit, your API key will be displayed, click on Copy.
<img alt="image.png" src="data:image/png;base64,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"/>
Paste this key in config.json as mentioned in the following format:-
"LLAMA_API_KEY":"Your key"</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[31]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Import libraries for handling user input filtering and accessing user data</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">groq</span><span class="w"> </span><span class="kn">import</span> <span class="n">Groq</span>  <span class="c1"># Llama Guard client for filtering user input</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">google.colab</span><span class="w"> </span><span class="kn">import</span> <span class="n">userdata</span>  <span class="c1"># Access user-specific data securely</span>

<span class="c1"># Retrieve the Llama API key from user data</span>
<span class="n">llama_api_key</span> <span class="o">=</span> <span class="n">userdata</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s1">'LLAMA_API_KEY'</span><span class="p">)</span>

<span class="c1"># Initialize the Llama Guard client with the API key</span>
<span class="n">llama_guard_client</span> <span class="o">=</span> <span class="n">Groq</span><span class="p">(</span><span class="n">api_key</span><span class="o">=</span><span class="n">llama_api_key</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h3 id="2.2.2-Defining-the-Filter-Input-with-Llama-Guard-Function"><strong>2.2.2 Defining the Filter Input with Llama Guard Function</strong><a class="anchor-link" href="#2.2.2-Defining-the-Filter-Input-with-Llama-Guard-Function"></a></h3>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>This function takes user input and checks whether the given input is safe enough or not</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[32]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Function to filter user input with Llama Guard</span>
<span class="k">def</span><span class="w"> </span><span class="nf">filter_input_with_llama_guard</span><span class="p">(</span><span class="n">user_input</span><span class="p">,</span> <span class="n">model</span><span class="o">=</span><span class="s2">"llama-guard-3-8b"</span><span class="p">):</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Filters user input using Llama Guard to ensure it is safe.</span>

<span class="sd">    Parameters:</span>
<span class="sd">    - user_input: The input provided by the user.</span>
<span class="sd">    - model: The Llama Guard model to be used for filtering (default is "llama-guard-3-8b").</span>

<span class="sd">    Returns:</span>
<span class="sd">    - The filtered and safe input.</span>
<span class="sd">    """</span>
    <span class="k">try</span><span class="p">:</span>
        <span class="c1"># Create a request to Llama Guard to filter the user input</span>
        <span class="n">response</span> <span class="o">=</span> <span class="n">llama_guard_client</span><span class="o">.</span><span class="n">chat</span><span class="o">.</span><span class="n">completions</span><span class="o">.</span><span class="n">create</span><span class="p">(</span>
            <span class="n">messages</span><span class="o">=</span><span class="p">[{</span><span class="s2">"role"</span><span class="p">:</span> <span class="s2">"user"</span><span class="p">,</span> <span class="s2">"content"</span><span class="p">:</span> <span class="n">user_input</span><span class="p">}],</span>
            <span class="n">model</span><span class="o">=</span><span class="n">model</span><span class="p">,</span>
        <span class="p">)</span>
        <span class="c1"># Return the filtered input</span>
        <span class="k">return</span> <span class="n">response</span><span class="o">.</span><span class="n">choices</span><span class="p">[</span><span class="mi">0</span><span class="p">]</span><span class="o">.</span><span class="n">message</span><span class="o">.</span><span class="n">content</span><span class="o">.</span><span class="n">strip</span><span class="p">()</span>
    <span class="k">except</span> <span class="ne">Exception</span> <span class="k">as</span> <span class="n">e</span><span class="p">:</span>
        <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"Error with Llama Guard: </span><span class="si">{</span><span class="n">e</span><span class="si">}</span><span class="s2">"</span><span class="p">)</span>
        <span class="k">return</span> <span class="kc">None</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h2 id="2.3-Adding-Memory-to-the-Chatbot"><strong>2.3 Adding Memory to the Chatbot</strong><a class="anchor-link" href="#2.3-Adding-Memory-to-the-Chatbot"></a></h2>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>At the Current Moment, there is some issue with Azure Open AI integration with mem0. For the time being, we will use mem0 API. Note that, you can use Mem0 with many open source models. Check out <a href="https://docs.mem0.ai/components/llms/models/openai">Mem0 Docs</a></p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>Get the Mem0 API key by following instruction <a href="https://docs.mem0.ai/quickstart#get-api-key">here</a> and add it to colab secrets.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[33]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="kn">from</span><span class="w"> </span><span class="nn">mem0</span><span class="w"> </span><span class="kn">import</span> <span class="n">MemoryClient</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">google.colab</span><span class="w"> </span><span class="kn">import</span> <span class="n">userdata</span>

<span class="c1"># No modifications are required as this code does not contain tunable parameters.</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[48]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">class</span><span class="w"> </span><span class="nc">NutritionBot</span><span class="p">:</span>
    <span class="k">def</span><span class="w"> </span><span class="fm">__init__</span><span class="p">(</span><span class="bp">self</span><span class="p">):</span>
<span class="w">        </span><span class="sd">"""</span>
<span class="sd">        Initialize the NutritionBot class, setting up memory, the LLM client, tools, and the agent executor.</span>
<span class="sd">        """</span>

        <span class="c1"># Initialize a memory client to store and retrieve customer interactions</span>
        <span class="bp">self</span><span class="o">.</span><span class="n">memory</span> <span class="o">=</span> <span class="n">MemoryClient</span><span class="p">(</span><span class="n">api_key</span><span class="o">=</span><span class="n">userdata</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"mem0"</span><span class="p">))</span>  <span class="c1"># Complete the code to define the memory client API key</span>

        <span class="c1"># Initialize the OpenAI client using the provided credentials</span>
        <span class="bp">self</span><span class="o">.</span><span class="n">client</span> <span class="o">=</span> <span class="n">ChatOpenAI</span><span class="p">(</span>
            <span class="n">model_name</span><span class="o">=</span><span class="s2">"gpt-4o-mini"</span><span class="p">,</span>  <span class="c1"># Specify the model to use (e.g., GPT-4 optimized version)</span>
            <span class="n">api_key</span><span class="o">=</span> <span class="n">config</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"API_KEY"</span><span class="p">),</span>  <span class="c1"># API key for authentication</span>
            <span class="n">base_url</span><span class="o">=</span><span class="n">config</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"OPENAI_API_BASE"</span><span class="p">),</span>
            <span class="n">temperature</span><span class="o">=</span><span class="mi">0</span>  <span class="c1"># Controls randomness in responses; 0 ensures deterministic results</span>
        <span class="p">)</span>

        <span class="c1"># Define tools available to the chatbot, such as web search</span>
        <span class="n">tools</span> <span class="o">=</span> <span class="p">[</span><span class="n">agentic_rag</span><span class="p">]</span>

        <span class="c1"># Define the system prompt to set the behavior of the chatbot</span>
        <span class="n">system_prompt</span> <span class="o">=</span> <span class="s2">"""You are a caring and knowledgeable Medical Support Agent, specializing in nutrition disorder-related guidance. Your goal is to provide accurate, empathetic, and tailored nutritional recommendations while ensuring a seamless customer experience.</span>
<span class="s2">                          Guidelines for Interaction:</span>
<span class="s2">                          Maintain a polite, professional, and reassuring tone.</span>
<span class="s2">                          Show genuine empathy for customer concerns and health challenges.</span>
<span class="s2">                          Reference past interactions to provide personalized and consistent advice.</span>
<span class="s2">                          Engage with the customer by asking about their food preferences, dietary restrictions, and lifestyle before offering recommendations.</span>
<span class="s2">                          Ensure consistent and accurate information across conversations.</span>
<span class="s2">                          If any detail is unclear or missing, proactively ask for clarification.</span>
<span class="s2">                          Always use the agentic_rag tool to retrieve up-to-date and evidence-based nutrition insights.</span>
<span class="s2">                          Keep track of ongoing issues and follow-ups to ensure continuity in support.</span>
<span class="s2">                          Your primary goal is to help customers make informed nutrition decisions that align with their health conditions and personal preferences.</span>

<span class="s2">        """</span>

        <span class="c1"># Build the prompt template for the agent</span>
        <span class="n">prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
            <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_prompt</span><span class="p">),</span>  <span class="c1"># System instructions</span>
            <span class="p">(</span><span class="s2">"human"</span><span class="p">,</span> <span class="s2">"</span><span class="si">{input}</span><span class="s2">"</span><span class="p">),</span>  <span class="c1"># Placeholder for human input</span>
            <span class="p">(</span><span class="s2">"placeholder"</span><span class="p">,</span> <span class="s2">"</span><span class="si">{agent_scratchpad}</span><span class="s2">"</span><span class="p">)</span>  <span class="c1"># Placeholder for intermediate reasoning steps</span>
        <span class="p">])</span>

        <span class="c1"># Create an agent capable of interacting with tools and executing tasks</span>
        <span class="n">agent</span> <span class="o">=</span> <span class="n">create_tool_calling_agent</span><span class="p">(</span><span class="bp">self</span><span class="o">.</span><span class="n">client</span><span class="p">,</span> <span class="n">tools</span><span class="p">,</span> <span class="n">prompt</span><span class="p">)</span>

        <span class="c1"># Wrap the agent in an executor to manage tool interactions and execution flow</span>
        <span class="bp">self</span><span class="o">.</span><span class="n">agent_executor</span> <span class="o">=</span> <span class="n">AgentExecutor</span><span class="p">(</span><span class="n">agent</span><span class="o">=</span><span class="n">agent</span><span class="p">,</span> <span class="n">tools</span><span class="o">=</span><span class="n">tools</span><span class="p">,</span> <span class="n">verbose</span><span class="o">=</span><span class="kc">True</span><span class="p">)</span>


    <span class="k">def</span><span class="w"> </span><span class="nf">store_customer_interaction</span><span class="p">(</span><span class="bp">self</span><span class="p">,</span> <span class="n">user_id</span><span class="p">:</span> <span class="nb">str</span><span class="p">,</span> <span class="n">message</span><span class="p">:</span> <span class="nb">str</span><span class="p">,</span> <span class="n">response</span><span class="p">:</span> <span class="nb">str</span><span class="p">,</span> <span class="n">metadata</span><span class="p">:</span> <span class="n">Dict</span> <span class="o">=</span> <span class="kc">None</span><span class="p">):</span>
<span class="w">        </span><span class="sd">"""</span>
<span class="sd">        Store customer interaction in memory for future reference.</span>

<span class="sd">        Args:</span>
<span class="sd">            user_id (str): Unique identifier for the customer.</span>
<span class="sd">            message (str): Customer's query or message.</span>
<span class="sd">            response (str): Chatbot's response.</span>
<span class="sd">            metadata (Dict, optional): Additional metadata for the interaction.</span>
<span class="sd">        """</span>
        <span class="k">if</span> <span class="n">metadata</span> <span class="ow">is</span> <span class="kc">None</span><span class="p">:</span>
            <span class="n">metadata</span> <span class="o">=</span> <span class="p">{}</span>

        <span class="c1"># Add a timestamp to the metadata for tracking purposes</span>
        <span class="n">metadata</span><span class="p">[</span><span class="s2">"timestamp"</span><span class="p">]</span> <span class="o">=</span> <span class="n">datetime</span><span class="o">.</span><span class="n">now</span><span class="p">()</span><span class="o">.</span><span class="n">isoformat</span><span class="p">()</span>

        <span class="c1"># Format the conversation for storage</span>
        <span class="n">conversation</span> <span class="o">=</span> <span class="p">[</span>
            <span class="p">{</span><span class="s2">"role"</span><span class="p">:</span> <span class="s2">"user"</span><span class="p">,</span> <span class="s2">"content"</span><span class="p">:</span> <span class="n">message</span><span class="p">},</span>
            <span class="p">{</span><span class="s2">"role"</span><span class="p">:</span> <span class="s2">"assistant"</span><span class="p">,</span> <span class="s2">"content"</span><span class="p">:</span> <span class="n">response</span><span class="p">}</span>
        <span class="p">]</span>

        <span class="c1"># Store the interaction in the memory client</span>
        <span class="bp">self</span><span class="o">.</span><span class="n">memory</span><span class="o">.</span><span class="n">add</span><span class="p">(</span>
            <span class="n">conversation</span><span class="p">,</span>
            <span class="n">user_id</span><span class="o">=</span><span class="n">user_id</span><span class="p">,</span>
            <span class="n">output_format</span><span class="o">=</span><span class="s2">"v1.1"</span><span class="p">,</span>
            <span class="n">metadata</span><span class="o">=</span><span class="n">metadata</span>
        <span class="p">)</span>


    <span class="k">def</span><span class="w"> </span><span class="nf">get_relevant_history</span><span class="p">(</span><span class="bp">self</span><span class="p">,</span> <span class="n">user_id</span><span class="p">:</span> <span class="nb">str</span><span class="p">,</span> <span class="n">query</span><span class="p">:</span> <span class="nb">str</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">List</span><span class="p">[</span><span class="n">Dict</span><span class="p">]:</span>
<span class="w">        </span><span class="sd">"""</span>
<span class="sd">        Retrieve past interactions relevant to the current query.</span>

<span class="sd">        Args:</span>
<span class="sd">            user_id (str): Unique identifier for the customer.</span>
<span class="sd">            query (str): The customer's current query.</span>

<span class="sd">        Returns:</span>
<span class="sd">            List[Dict]: A list of relevant past interactions.</span>
<span class="sd">        """</span>
        <span class="k">return</span> <span class="bp">self</span><span class="o">.</span><span class="n">memory</span><span class="o">.</span><span class="n">search</span><span class="p">(</span>
            <span class="n">query</span><span class="o">=</span><span class="n">query</span><span class="p">,</span>  <span class="c1"># Search for interactions related to the query</span>
            <span class="n">user_id</span><span class="o">=</span><span class="n">user_id</span><span class="p">,</span>  <span class="c1"># Restrict search to the specific user</span>
            <span class="n">limit</span><span class="o">=</span><span class="mi">5</span>
        <span class="p">)</span>


    <span class="k">def</span><span class="w"> </span><span class="nf">handle_customer_query</span><span class="p">(</span><span class="bp">self</span><span class="p">,</span> <span class="n">user_id</span><span class="p">:</span> <span class="nb">str</span><span class="p">,</span> <span class="n">query</span><span class="p">:</span> <span class="nb">str</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="nb">str</span><span class="p">:</span>
<span class="w">        </span><span class="sd">"""</span>
<span class="sd">        Process a customer's query and provide a response, taking into account past interactions.</span>

<span class="sd">        Args:</span>
<span class="sd">            user_id (str): Unique identifier for the customer.</span>
<span class="sd">            query (str): Customer's query.</span>

<span class="sd">        Returns:</span>
<span class="sd">            str: Chatbot's response.</span>
<span class="sd">        """</span>

        <span class="c1"># Retrieve relevant past interactions for context</span>
        <span class="n">relevant_history</span> <span class="o">=</span> <span class="bp">self</span><span class="o">.</span><span class="n">get_relevant_history</span><span class="p">(</span><span class="n">user_id</span><span class="p">,</span> <span class="n">query</span><span class="p">)</span>

        <span class="c1"># Build a context string from the relevant history</span>
        <span class="n">context</span> <span class="o">=</span> <span class="s2">"Previous relevant interactions:</span><span class="se">\n</span><span class="s2">"</span>
        <span class="k">for</span> <span class="n">memory</span> <span class="ow">in</span> <span class="n">relevant_history</span><span class="p">:</span>
            <span class="n">context</span> <span class="o">+=</span> <span class="sa">f</span><span class="s2">"Customer: </span><span class="si">{</span><span class="n">memory</span><span class="p">[</span><span class="s1">'memory'</span><span class="p">]</span><span class="si">}</span><span class="se">\n</span><span class="s2">"</span>  <span class="c1"># Customer's past messages</span>
            <span class="n">context</span> <span class="o">+=</span> <span class="sa">f</span><span class="s2">"Support: </span><span class="si">{</span><span class="n">memory</span><span class="p">[</span><span class="s1">'memory'</span><span class="p">]</span><span class="si">}</span><span class="se">\n</span><span class="s2">"</span>  <span class="c1"># Chatbot's past responses</span>
            <span class="n">context</span> <span class="o">+=</span> <span class="s2">"---</span><span class="se">\n</span><span class="s2">"</span>

        <span class="c1"># Print context for debugging purposes</span>
        <span class="nb">print</span><span class="p">(</span><span class="s2">"Context: "</span><span class="p">,</span> <span class="n">context</span><span class="p">)</span>

        <span class="c1"># Prepare a prompt combining past context and the current query</span>
        <span class="n">prompt</span> <span class="o">=</span> <span class="sa">f</span><span class="s2">"""</span>
<span class="s2">        Context:</span>
<span class="s2">        </span><span class="si">{</span><span class="n">context</span><span class="si">}</span>

<span class="s2">        Current customer query: </span><span class="si">{</span><span class="n">query</span><span class="si">}</span>

<span class="s2">        Provide a helpful response that takes into account any relevant past interactions.</span>
<span class="s2">        """</span>

        <span class="c1"># Generate a response using the agent</span>
        <span class="n">response</span> <span class="o">=</span> <span class="bp">self</span><span class="o">.</span><span class="n">agent_executor</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span><span class="s2">"input"</span><span class="p">:</span> <span class="n">prompt</span><span class="p">})</span>

        <span class="c1"># Store the current interaction for future reference</span>
        <span class="bp">self</span><span class="o">.</span><span class="n">store_customer_interaction</span><span class="p">(</span>
            <span class="n">user_id</span><span class="o">=</span><span class="n">user_id</span><span class="p">,</span>
            <span class="n">message</span><span class="o">=</span><span class="n">query</span><span class="p">,</span>
            <span class="n">response</span><span class="o">=</span><span class="n">response</span><span class="p">[</span><span class="s2">"output"</span><span class="p">],</span>
            <span class="n">metadata</span><span class="o">=</span><span class="p">{</span><span class="s2">"type"</span><span class="p">:</span> <span class="s2">"support_query"</span><span class="p">}</span>
        <span class="p">)</span>

        <span class="c1"># Return the chatbot's response</span>
        <span class="k">return</span> <span class="n">response</span><span class="p">[</span><span class="s1">'output'</span><span class="p">]</span>
</pre></div>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<ol>
<li>Assume a User Persona and Specify Preferences</li>
</ol>
<p>Example:</p>
<p>Persona Name: Samay</p>
<p>Preferences: Enjoys dining at iconic city restaurants and exploring internet-famous eateries.</p>
<p>Task: Plan an itinerary that aligns with Samay's preferences, including suitable hotel recommendations.</p>
<p>Action: After completing the task, end the session by typing "exit."</p>
<ol start="2">
<li>Initiate a New Session with a Different Persona</li>
</ol>
<p>Example:</p>
<p>Persona Name: Jay
Preferences: Prefers vibrant nightlife and is interested in top party destinations, disregarding typical sunrise and sunset spots.
Task: Identify locations renowned for exceptional parties.</p>
<p>Action: After completing the task, end the session by typing "exit."</p>
<ol start="3">
<li>Re-engage as the Initial Persona (Samay) for a New Destination</li>
</ol>
<p>Task: Request an itinerary for a different city without specifying preferences. The system should automatically generate a plan tailored to Samay's known interests.</p>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h2 id="2.4-Initializing-and-Using-the-AI-Nutrition-Disorder-Specailaist-Agent"><strong>2.4 Initializing and Using the AI Nutrition Disorder Specailaist Agent</strong><a class="anchor-link" href="#2.4-Initializing-and-Using-the-AI-Nutrition-Disorder-Specailaist-Agent"></a></h2>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[49]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="k">def</span><span class="w"> </span><span class="nf">nutrition_disorder_agent</span><span class="p">():</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    A conversational agent that answers nutrition disorder-related questions</span>
<span class="sd">    using a RAG-based workflow with safety filtering and user session handling.</span>
<span class="sd">    """</span>

    <span class="nb">print</span><span class="p">(</span><span class="s2">"Welcome to the Nutrition Disorder Specialist Agent!"</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"You can ask me anything about nutrition disorders, such as symptoms, causes, treatments, and more."</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"Type 'exit' to end the conversation.</span><span class="se">\n</span><span class="s2">"</span><span class="p">)</span>

    <span class="n">chatbot</span> <span class="o">=</span> <span class="n">NutritionBot</span><span class="p">()</span>    <span class="c1"># Initialize chatbot instance</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"Login by providing customer name"</span><span class="p">)</span>  <span class="c1"># This provides a way to initiate a chat as different users.</span>
    <span class="n">user_id</span> <span class="o">=</span> <span class="nb">input</span><span class="p">()</span>  <span class="c1"># Get user ID for tracking conversation sessions</span>

    <span class="k">while</span> <span class="kc">True</span><span class="p">:</span>
        <span class="c1"># Get user input</span>
        <span class="nb">print</span><span class="p">(</span><span class="s2">"How can I help you?"</span><span class="p">)</span>
        <span class="n">user_query</span> <span class="o">=</span> <span class="nb">input</span><span class="p">(</span><span class="s2">"You: "</span><span class="p">)</span>

        <span class="c1"># Define the logic for exitting the loop' [if user types in exit]</span>
        <span class="k">if</span> <span class="n">user_query</span><span class="o">.</span><span class="n">lower</span><span class="p">()</span> <span class="o">==</span> <span class="s2">"exit"</span><span class="p">:</span>
            <span class="nb">print</span><span class="p">(</span><span class="s2">"Agent: Goodbye! Feel free to return if you have more questions."</span><span class="p">)</span>
            <span class="k">break</span>

        <span class="c1"># Filter input through Llama Guard - returns "SAFE" or "UNSAFE"</span>
        <span class="n">filtered_result</span> <span class="o">=</span> <span class="n">filter_input_with_llama_guard</span><span class="p">(</span><span class="n">user_query</span><span class="p">)</span>  <span class="c1"># Call function to filter input</span>
        <span class="n">filtered_result</span> <span class="o">=</span> <span class="n">filtered_result</span><span class="o">.</span><span class="n">strip</span><span class="p">()</span><span class="o">.</span><span class="n">upper</span><span class="p">()</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="s2">"</span><span class="se">\n</span><span class="s2">"</span><span class="p">,</span> <span class="s2">" "</span><span class="p">)</span>
        <span class="nb">print</span><span class="p">(</span><span class="n">filtered_result</span><span class="p">)</span>

        <span class="k">if</span> <span class="n">filtered_result</span> <span class="ow">in</span> <span class="p">[</span><span class="s2">"SAFE"</span><span class="p">,</span> <span class="s2">"S6"</span><span class="p">,</span> <span class="s2">"S7"</span><span class="p">]:</span>  <span class="c1"># You need to by pass some cases like "S6" and "S7" so that it can work effectively.</span>
            <span class="c1"># Process the user query using the RAG workflow</span>
            <span class="k">try</span><span class="p">:</span>
                <span class="n">response</span> <span class="o">=</span> <span class="n">chatbot</span><span class="o">.</span><span class="n">handle_customer_query</span><span class="p">(</span><span class="n">user_id</span><span class="p">,</span> <span class="n">user_query</span><span class="p">)</span>  <span class="c1"># Call chatbot handler function</span>
                <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"Agent: </span><span class="si">{</span><span class="n">response</span><span class="si">}</span><span class="se">\n</span><span class="s2">"</span><span class="p">)</span>

            <span class="k">except</span> <span class="ne">Exception</span> <span class="k">as</span> <span class="n">e</span><span class="p">:</span>
                <span class="nb">print</span><span class="p">(</span><span class="s2">"Agent: Sorry, I encountered an error while processing your query. Please try again."</span><span class="p">)</span>
                <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"Error: </span><span class="si">{</span><span class="n">e</span><span class="si">}</span><span class="se">\n</span><span class="s2">"</span><span class="p">)</span>
        <span class="k">else</span><span class="p">:</span>
            <span class="nb">print</span><span class="p">(</span><span class="s2">"Agent: I apologize, but I cannot process that input as it may be inappropriate. Please try again."</span><span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[50]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="n">nutrition_disorder_agent</span><span class="p">()</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Welcome to the Nutrition Disorder Specialist Agent!
You can ask me anything about nutrition disorders, such as symptoms, causes, treatments, and more.
Type 'exit' to end the conversation.

Login by providing customer name
Samay
How can I help you?
You: Vitamin types
SAFE
Context:  Previous relevant interactions:



<span class="ansi-bold">&gt; Entering new AgentExecutor chain...</span>
<span class="ansi-green-intense-fg ansi-bold">
Invoking: `agentic_rag` with `{'query': 'Vitamin types'}`


</span>---------Expanding Query---------
expanded_query What are the different types of vitamins, their functions in the body, and the potential health consequences of deficiencies in each type?
Query used for retrieval: What are the different types of vitamins, their functions in the body, and the potential health consequences of deficiencies in each type?
Retrieved documents: []
Extracted context with metadata: []
---------craft_response---------
intermediate response:  content='The context provided does not contain any information about vitamin types. Therefore, I am unable to provide an answer regarding vitamin types. If you have a specific question or need information on a particular aspect of vitamins, please let me know!' response_metadata={'token_usage': {'completion_tokens': 46, 'prompt_tokens': 111, 'total_tokens': 157, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'finish_reason': 'stop', 'logprobs': None} id='run-9db3b013-1693-45f7-b4fa-2c10cda4b070-0' usage_metadata={'input_tokens': 111, 'output_tokens': 46, 'total_tokens': 157}
---------check_groundedness---------
groundedness_score:  1.0
#########Groundedness Incremented###########
---------should_continue_groundedness---------
groundedness loop count:  1
 Groundedness sufficient. Moving to precision check.
---------check_precision---------
precision_score: 0.0
#########Precision Incremented###########
---------should_continue_precision---------
precision loop count:  1
 Precision score too low. Refining query.
---------refine_query---------
query_feedback:  Previous Expanded Query: What are the different types of vitamins, their functions in the body, and the potential health consequences of deficiencies in each type?
Suggestions: 1. Specify the types of vitamins (e.g., fat-soluble, water-soluble) to narrow down the search context.
2. Include specific health conditions or deficiencies associated with each vitamin to enhance relevance.
3. Use medical terminology (e.g., "hypovitaminosis" for deficiencies) for clarity.
4. Consider adding "clinical implications" to focus on the health consequences in a medical context.
5. Clarify if the search is for human health or other species to avoid ambiguity.
Groundedness loop count: 1
---------Expanding Query---------
expanded_query What are the different types of vitamins, specifically fat-soluble and water-soluble vitamins, their physiological functions in the human body, the clinical implications of hypovitaminosis for each type, and the associated health conditions resulting from deficiencies?
Query used for retrieval: What are the different types of vitamins, specifically fat-soluble and water-soluble vitamins, their physiological functions in the human body, the clinical implications of hypovitaminosis for each type, and the associated health conditions resulting from deficiencies?
Retrieved documents: []
Extracted context with metadata: []
---------craft_response---------
intermediate response:  content='The context provided does not contain any information about vitamin types. Therefore, I cannot provide an answer regarding vitamin types. If you have specific questions about vitamins or need information on a particular type, please let me know!' response_metadata={'token_usage': {'completion_tokens': 43, 'prompt_tokens': 111, 'total_tokens': 154, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'finish_reason': 'stop', 'logprobs': None} id='run-61ebe241-95f7-4a73-bd16-bda07eccdb87-0' usage_metadata={'input_tokens': 111, 'output_tokens': 43, 'total_tokens': 154}
---------check_groundedness---------
groundedness_score:  1.0
#########Groundedness Incremented###########
---------should_continue_groundedness---------
groundedness loop count:  2
 Groundedness sufficient. Moving to precision check.
---------check_precision---------
precision_score: 0.0
#########Precision Incremented###########
---------should_continue_precision---------
precision loop count:  2
 Precision score too low. Refining query.
---------refine_query---------
query_feedback:  Previous Expanded Query: What are the different types of vitamins, specifically fat-soluble and water-soluble vitamins, their physiological functions in the human body, the clinical implications of hypovitaminosis for each type, and the associated health conditions resulting from deficiencies?
Suggestions: 1. Specify the types of vitamins by including "vitamin classification" to clarify the focus on fat-soluble and water-soluble categories.
2. Include "mechanisms of action" alongside "physiological functions" to enhance the understanding of how vitamins operate in the body.
3. Use "clinical consequences" instead of "clinical implications" for clearer terminology regarding the effects of hypovitaminosis.
4. Replace "associated health conditions" with "specific health disorders" to target particular medical conditions linked to deficiencies.
5. Consider adding "treatment options" for hypovitaminosis to provide a comprehensive overview of clinical management.
6. Clarify "deficiencies" by specifying "nutritional deficiencies" to emphasize the context of vitamin insufficiency.
Groundedness loop count: 2
---------Expanding Query---------
expanded_query What are the classifications of vitamins, specifically fat-soluble and water-soluble vitamins, their mechanisms of action and physiological functions in the human body, the clinical consequences of hypovitaminosis for each type, the specific health disorders resulting from nutritional deficiencies, and the treatment options available for managing these vitamin deficiencies?
Query used for retrieval: What are the classifications of vitamins, specifically fat-soluble and water-soluble vitamins, their mechanisms of action and physiological functions in the human body, the clinical consequences of hypovitaminosis for each type, the specific health disorders resulting from nutritional deficiencies, and the treatment options available for managing these vitamin deficiencies?
Retrieved documents: []
Extracted context with metadata: []
---------craft_response---------
intermediate response:  content="The context provided does not contain any information about vitamin types. Therefore, I cannot provide an answer regarding vitamin types. If you have specific questions or if there's additional context, please share!" response_metadata={'token_usage': {'completion_tokens': 37, 'prompt_tokens': 111, 'total_tokens': 148, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'finish_reason': 'stop', 'logprobs': None} id='run-15c8528f-7144-4dc3-85b4-3cb919626fc7-0' usage_metadata={'input_tokens': 111, 'output_tokens': 37, 'total_tokens': 148}
---------check_groundedness---------
groundedness_score:  1.0
#########Groundedness Incremented###########
---------should_continue_groundedness---------
groundedness loop count:  3
 Groundedness sufficient. Moving to precision check.
---------check_precision---------
precision_score: 0.0
#########Precision Incremented###########
---------should_continue_precision---------
precision loop count:  3
 Precision score too low. Refining query.
---------refine_query---------
query_feedback:  Previous Expanded Query: What are the classifications of vitamins, specifically fat-soluble and water-soluble vitamins, their mechanisms of action and physiological functions in the human body, the clinical consequences of hypovitaminosis for each type, the specific health disorders resulting from nutritional deficiencies, and the treatment options available for managing these vitamin deficiencies?
Suggestions: 1. Specify the types of vitamins: Instead of "vitamin types," specify "fat-soluble vitamins (A, D, E, K) and water-soluble vitamins (B-complex, C)" for clarity.
2. Replace "classifications of vitamins" with "classification of vitamins into fat-soluble and water-soluble categories" for precision.
3. Use "mechanisms of action and physiological roles" instead of "mechanisms of action and physiological functions" to align with common terminology.
4. Clarify "clinical consequences of hypovitaminosis" by specifying "clinical consequences of hypovitaminosis for fat-soluble and water-soluble vitamins."
5. Instead of "specific health disorders resulting from nutritional deficiencies," specify "health disorders associated with deficiencies of fat-soluble and water-soluble vitamins."
6. Use "evidence-based treatment options for vitamin deficiencies" to emphasize the importance of scientifically supported approaches.
7. Consider breaking the query into distinct components or using bullet points to enhance readability and focus on specific aspects, such as classification, mechanisms, clinical consequences, health disorders, and treatment options.
Groundedness loop count: 3
---------Expanding Query---------
expanded_query What are the classifications of vitamins into fat-soluble vitamins (A, D, E, K) and water-soluble vitamins (B-complex, C), including their mechanisms of action and physiological roles in the human body, the clinical consequences of hypovitaminosis for each category, the health disorders associated with deficiencies of these vitamins, and the evidence-based treatment options available for managing these vitamin deficiencies?
Query used for retrieval: What are the classifications of vitamins into fat-soluble vitamins (A, D, E, K) and water-soluble vitamins (B-complex, C), including their mechanisms of action and physiological roles in the human body, the clinical consequences of hypovitaminosis for each category, the health disorders associated with deficiencies of these vitamins, and the evidence-based treatment options available for managing these vitamin deficiencies?
Retrieved documents: []
Extracted context with metadata: []
---------craft_response---------
intermediate response:  content='The context provided does not contain any information regarding vitamin types. Therefore, I cannot provide an answer to your query. Please provide more specific details or context for further assistance.' response_metadata={'token_usage': {'completion_tokens': 34, 'prompt_tokens': 111, 'total_tokens': 145, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_62a23a81ef', 'finish_reason': 'stop', 'logprobs': None} id='run-a0f18b30-52ca-46c2-97e1-46ea50e8c3e9-0' usage_metadata={'input_tokens': 111, 'output_tokens': 34, 'total_tokens': 145}
---------check_groundedness---------
groundedness_score:  1.0
#########Groundedness Incremented###########
---------should_continue_groundedness---------
groundedness loop count:  4
 Groundedness sufficient. Moving to precision check.
---------check_precision---------
precision_score: 0.0
#########Precision Incremented###########
---------should_continue_precision---------
precision loop count:  4
 Maximum iterations reached. Stopping.
<span class="ansi-cyan-intense-fg ansi-bold">{'query': 'Vitamin types', 'expanded_query': 'What are the classifications of vitamins into fat-soluble vitamins (A, D, E, K) and water-soluble vitamins (B-complex, C), including their mechanisms of action and physiological roles in the human body, the clinical consequences of hypovitaminosis for each category, the health disorders associated with deficiencies of these vitamins, and the evidence-based treatment options available for managing these vitamin deficiencies?', 'context': [], 'response': AIMessage(content='The context provided does not contain any information regarding vitamin types. Therefore, I cannot provide an answer to your query. Please provide more specific details or context for further assistance.', response_metadata={'token_usage': {'completion_tokens': 34, 'prompt_tokens': 111, 'total_tokens': 145, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_62a23a81ef', 'finish_reason': 'stop', 'logprobs': None}, id='run-a0f18b30-52ca-46c2-97e1-46ea50e8c3e9-0', usage_metadata={'input_tokens': 111, 'output_tokens': 34, 'total_tokens': 145}), 'precision_score': 0.0, 'groundedness_score': 1.0, 'groundedness_loop_count': 4, 'precision_loop_count': 4, 'feedback': '', 'query_feedback': 'Previous Expanded Query: What are the classifications of vitamins, specifically fat-soluble and water-soluble vitamins, their mechanisms of action and physiological functions in the human body, the clinical consequences of hypovitaminosis for each type, the specific health disorders resulting from nutritional deficiencies, and the treatment options available for managing these vitamin deficiencies?\nSuggestions: 1. Specify the types of vitamins: Instead of "vitamin types," specify "fat-soluble vitamins (A, D, E, K) and water-soluble vitamins (B-complex, C)" for clarity.\n2. Replace "classifications of vitamins" with "classification of vitamins into fat-soluble and water-soluble categories" for precision.\n3. Use "mechanisms of action and physiological roles" instead of "mechanisms of action and physiological functions" to align with common terminology.\n4. Clarify "clinical consequences of hypovitaminosis" by specifying "clinical consequences of hypovitaminosis for fat-soluble and water-soluble vitamins."\n5. Instead of "specific health disorders resulting from nutritional deficiencies," specify "health disorders associated with deficiencies of fat-soluble and water-soluble vitamins."\n6. Use "evidence-based treatment options for vitamin deficiencies" to emphasize the importance of scientifically supported approaches.\n7. Consider breaking the query into distinct components or using bullet points to enhance readability and focus on specific aspects, such as classification, mechanisms, clinical consequences, health disorders, and treatment options.', 'loop_max_iter': 3}</span><span class="ansi-green-intense-fg ansi-bold">It seems that your query about vitamin types is quite broad. To provide you with the most accurate and helpful information, could you please specify if you're interested in:

1. **Fat-soluble vitamins** (A, D, E, K) or **water-soluble vitamins** (B-complex, C)?
2. Any specific health concerns or conditions you might have that relate to vitamin deficiencies?
3. Your dietary preferences or restrictions that might affect your vitamin intake?

This will help me tailor the information to your needs!</span>

<span class="ansi-bold">&gt; Finished chain.</span>
Agent: It seems that your query about vitamin types is quite broad. To provide you with the most accurate and helpful information, could you please specify if you're interested in:

1. **Fat-soluble vitamins** (A, D, E, K) or **water-soluble vitamins** (B-complex, C)?
2. Any specific health concerns or conditions you might have that relate to vitamin deficiencies?
3. Your dietary preferences or restrictions that might affect your vitamin intake?

This will help me tailor the information to your needs!

How can I help you?
You: exit
Agent: Goodbye! Feel free to return if you have more questions.
</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<h1 id="Section-3:-Getting-Your-App-Live-on-Hugging-Face-Docker-Spaces"><strong>Section 3: Getting Your App Live on Hugging Face Docker Spaces</strong><a class="anchor-link" href="#Section-3:-Getting-Your-App-Live-on-Hugging-Face-Docker-Spaces"></a></h1>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[78]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="o">%%</span><span class="n">writefile</span> <span class="n">app</span><span class="o">.</span><span class="n">py</span>

<span class="c1"># Import necessary libraries</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">os</span>  <span class="c1"># Interacting with the operating system (reading/writing files)</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">chromadb</span>  <span class="c1"># High-performance vector database for storing/querying dense vectors</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">dotenv</span><span class="w"> </span><span class="kn">import</span> <span class="n">load_dotenv</span>  <span class="c1"># Loading environment variables from a .env file</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">json</span>  <span class="c1"># Parsing and handling JSON data</span>

<span class="c1"># LangChain imports</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_core.documents</span><span class="w"> </span><span class="kn">import</span> <span class="n">Document</span>  <span class="c1"># Document data structures</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_core.runnables</span><span class="w"> </span><span class="kn">import</span> <span class="n">RunnablePassthrough</span>  <span class="c1"># LangChain core library for running pipelines</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_core.output_parsers</span><span class="w"> </span><span class="kn">import</span> <span class="n">StrOutputParser</span>  <span class="c1"># String output parser</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.prompts</span><span class="w"> </span><span class="kn">import</span> <span class="n">ChatPromptTemplate</span>  <span class="c1"># Template for chat prompts</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.chains.query_constructor.base</span><span class="w"> </span><span class="kn">import</span> <span class="n">AttributeInfo</span>  <span class="c1"># Base classes for query construction</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.retrievers.self_query.base</span><span class="w"> </span><span class="kn">import</span> <span class="n">SelfQueryRetriever</span>  <span class="c1"># Base classes for self-querying retrievers</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.retrievers.document_compressors</span><span class="w"> </span><span class="kn">import</span> <span class="n">LLMChainExtractor</span><span class="p">,</span> <span class="n">CrossEncoderReranker</span>  <span class="c1"># Document compressors</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.retrievers</span><span class="w"> </span><span class="kn">import</span> <span class="n">ContextualCompressionRetriever</span>  <span class="c1"># Contextual compression retrievers</span>

<span class="c1"># LangChain community &amp; experimental imports</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_community.vectorstores</span><span class="w"> </span><span class="kn">import</span> <span class="n">Chroma</span>  <span class="c1"># Implementations of vector stores like Chroma</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_community.document_loaders</span><span class="w"> </span><span class="kn">import</span> <span class="n">PyPDFDirectoryLoader</span><span class="p">,</span> <span class="n">PyPDFLoader</span>  <span class="c1"># Document loaders for PDFs</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_community.cross_encoders</span><span class="w"> </span><span class="kn">import</span> <span class="n">HuggingFaceCrossEncoder</span>  <span class="c1"># Cross-encoders from HuggingFace</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_experimental.text_splitter</span><span class="w"> </span><span class="kn">import</span> <span class="n">SemanticChunker</span>  <span class="c1"># Experimental text splitting methods</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.text_splitter</span><span class="w"> </span><span class="kn">import</span> <span class="p">(</span>
    <span class="n">CharacterTextSplitter</span><span class="p">,</span>  <span class="c1"># Splitting text by characters</span>
    <span class="n">RecursiveCharacterTextSplitter</span>  <span class="c1"># Recursive splitting of text by characters</span>
<span class="p">)</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_core.tools</span><span class="w"> </span><span class="kn">import</span> <span class="n">tool</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.agents</span><span class="w"> </span><span class="kn">import</span> <span class="n">create_tool_calling_agent</span><span class="p">,</span> <span class="n">AgentExecutor</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_core.prompts</span><span class="w"> </span><span class="kn">import</span> <span class="n">ChatPromptTemplate</span>

<span class="c1"># LangChain OpenAI imports</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_openai</span><span class="w"> </span><span class="kn">import</span> <span class="n">ChatOpenAI</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain_openai</span><span class="w"> </span><span class="kn">import</span> <span class="n">AzureOpenAIEmbeddings</span><span class="p">,</span> <span class="n">AzureChatOpenAI</span>  <span class="c1"># OpenAI embeddings and models</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langchain.embeddings.openai</span><span class="w"> </span><span class="kn">import</span> <span class="n">OpenAIEmbeddings</span>  <span class="c1"># OpenAI embeddings for text vectors</span>

<span class="c1"># LlamaParse &amp; LlamaIndex imports</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">llama_parse</span><span class="w"> </span><span class="kn">import</span> <span class="n">LlamaParse</span>  <span class="c1"># Document parsing library</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">llama_index.core</span><span class="w"> </span><span class="kn">import</span> <span class="n">Settings</span><span class="p">,</span> <span class="n">SimpleDirectoryReader</span>  <span class="c1"># Core functionalities of the LlamaIndex</span>

<span class="c1"># LangGraph import</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">langgraph.graph</span><span class="w"> </span><span class="kn">import</span> <span class="n">StateGraph</span><span class="p">,</span> <span class="n">END</span><span class="p">,</span> <span class="n">START</span>  <span class="c1"># State graph for managing states in LangChain</span>

<span class="c1"># Pydantic import</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">pydantic</span><span class="w"> </span><span class="kn">import</span> <span class="n">BaseModel</span>  <span class="c1"># Pydantic for data validation</span>

<span class="c1"># Typing imports</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">typing</span><span class="w"> </span><span class="kn">import</span> <span class="n">Dict</span><span class="p">,</span> <span class="n">List</span><span class="p">,</span> <span class="n">Tuple</span><span class="p">,</span> <span class="n">Any</span><span class="p">,</span> <span class="n">TypedDict</span>  <span class="c1"># Python typing for function annotations</span>

<span class="c1"># Other utilities</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">numpy</span><span class="w"> </span><span class="k">as</span><span class="w"> </span><span class="nn">np</span>  <span class="c1"># Numpy for numerical operations</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">groq</span><span class="w"> </span><span class="kn">import</span> <span class="n">Groq</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">mem0</span><span class="w"> </span><span class="kn">import</span> <span class="n">MemoryClient</span>
<span class="kn">import</span><span class="w"> </span><span class="nn">streamlit</span><span class="w"> </span><span class="k">as</span><span class="w"> </span><span class="nn">st</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">datetime</span><span class="w"> </span><span class="kn">import</span> <span class="n">datetime</span>

<span class="c1"># Fetch secrets from Hugging Face Spaces</span>
<span class="n">api_key</span> <span class="o">=</span> <span class="n">os</span><span class="o">.</span><span class="n">environ</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s1">'API_KEY'</span><span class="p">)</span>
<span class="n">endpoint</span> <span class="o">=</span> <span class="n">os</span><span class="o">.</span><span class="n">environ</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s1">'OPENAI_API_BASE'</span><span class="p">)</span>
<span class="n">llama_api_key</span> <span class="o">=</span> <span class="n">os</span><span class="o">.</span><span class="n">environ</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s1">'GROQ_API_KEY'</span><span class="p">)</span>
<span class="n">MEM0_api_key</span> <span class="o">=</span> <span class="n">os</span><span class="o">.</span><span class="n">environ</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s1">'mem0'</span><span class="p">)</span>

<span class="c1"># Initialize the OpenAI embedding function for Chroma</span>
<span class="n">embedding_function</span> <span class="o">=</span> <span class="n">chromadb</span><span class="o">.</span><span class="n">utils</span><span class="o">.</span><span class="n">embedding_functions</span><span class="o">.</span><span class="n">OpenAIEmbeddingFunction</span><span class="p">(</span>
    <span class="n">api_base</span><span class="o">=</span><span class="n">endpoint</span><span class="p">,</span> <span class="c1"># Complete the code to define the API base endpoint</span>
    <span class="n">api_key</span><span class="o">=</span><span class="n">api_key</span><span class="p">,</span> <span class="c1"># Complete the code to define the API key</span>
    <span class="n">model_name</span><span class="o">=</span><span class="s1">'text-embedding-ada-002'</span> <span class="c1"># This is a fixed value and does not need modification</span>
<span class="p">)</span>

<span class="c1"># This initializes the OpenAI embedding function for the Chroma vectorstore, using the provided endpoint and API key.</span>

<span class="c1"># Initialize the OpenAI Embeddings</span>
<span class="n">embedding_model</span> <span class="o">=</span> <span class="n">OpenAIEmbeddings</span><span class="p">(</span>
    <span class="n">openai_api_base</span><span class="o">=</span><span class="n">endpoint</span><span class="p">,</span>
    <span class="n">openai_api_key</span><span class="o">=</span><span class="n">api_key</span><span class="p">,</span>
    <span class="n">model</span><span class="o">=</span><span class="s1">'text-embedding-ada-002'</span>
<span class="p">)</span>


<span class="c1"># Initialize the Chat OpenAI model</span>
<span class="n">llm</span> <span class="o">=</span> <span class="n">ChatOpenAI</span><span class="p">(</span>
    <span class="n">openai_api_base</span><span class="o">=</span><span class="n">endpoint</span><span class="p">,</span>
    <span class="n">openai_api_key</span><span class="o">=</span><span class="n">api_key</span><span class="p">,</span>
    <span class="n">model</span><span class="o">=</span><span class="s2">"gpt-4o-mini"</span><span class="p">,</span>
    <span class="n">streaming</span><span class="o">=</span><span class="kc">False</span>
<span class="p">)</span>

<span class="c1"># set the LLM and embedding model in the LlamaIndex settings.</span>
<span class="n">Settings</span><span class="o">.</span><span class="n">llm</span> <span class="o">=</span> <span class="n">llm</span>
<span class="n">Settings</span><span class="o">.</span><span class="n">embedding</span> <span class="o">=</span> <span class="n">embedding_model</span>

<span class="c1">#================================Creating Langgraph agent======================#</span>

<span class="k">class</span><span class="w"> </span><span class="nc">AgentState</span><span class="p">(</span><span class="n">TypedDict</span><span class="p">):</span>
    <span class="n">query</span><span class="p">:</span> <span class="nb">str</span>  <span class="c1"># The current user query</span>
    <span class="n">expanded_query</span><span class="p">:</span> <span class="nb">str</span>  <span class="c1"># The expanded version of the user query</span>
    <span class="n">context</span><span class="p">:</span> <span class="n">List</span><span class="p">[</span><span class="n">Dict</span><span class="p">[</span><span class="nb">str</span><span class="p">,</span> <span class="n">Any</span><span class="p">]]</span>  <span class="c1"># Retrieved documents (content and metadata)</span>
    <span class="n">response</span><span class="p">:</span> <span class="nb">str</span>  <span class="c1"># The generated response to the user query</span>
    <span class="n">precision_score</span><span class="p">:</span> <span class="nb">float</span>  <span class="c1"># The precision score of the response</span>
    <span class="n">groundedness_score</span><span class="p">:</span> <span class="nb">float</span>  <span class="c1"># The groundedness score of the response</span>
    <span class="n">groundedness_loop_count</span><span class="p">:</span> <span class="nb">int</span>  <span class="c1"># Counter for groundedness refinement loops</span>
    <span class="n">precision_loop_count</span><span class="p">:</span> <span class="nb">int</span>  <span class="c1"># Counter for precision refinement loops</span>
    <span class="n">feedback</span><span class="p">:</span> <span class="nb">str</span>
    <span class="n">query_feedback</span><span class="p">:</span> <span class="nb">str</span>
    <span class="n">groundedness_check</span><span class="p">:</span> <span class="nb">bool</span>
    <span class="n">loop_max_iter</span><span class="p">:</span> <span class="nb">int</span>

<span class="k">def</span><span class="w"> </span><span class="nf">expand_query</span><span class="p">(</span><span class="n">state</span><span class="p">):</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Expands the user query to improve retrieval of nutrition disorder-related information.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the user query.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with the expanded query.</span>
<span class="sd">    """</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------Expanding Query---------"</span><span class="p">)</span>
    <span class="n">system_message</span> <span class="o">=</span> <span class="s1">'''You are a query expansion assistant specialized in nutritional and medical information retrieval.</span>

<span class="s1">    Given a short or ambiguous user query, your task is to rewrite or expand it into a more detailed and specific question that would help retrieve relevant medical literature  particularly related to nutritional disorders, dietary deficiencies, vitamin and mineral imbalances, obesity, and metabolic conditions.</span>

<span class="s1">    - Maintain the original intent of the query.</span>
<span class="s1">    - Add medically-relevant context or clarifying terms if appropriate.</span>
<span class="s1">    - Output only the expanded query as a single sentence.</span>

<span class="s1">    Do not include explanations or bullet points.</span>
<span class="s1">    '''</span>


    <span class="n">expand_prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
        <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_message</span><span class="p">),</span>
        <span class="p">(</span><span class="s2">"user"</span><span class="p">,</span> <span class="s2">"Expand this query: </span><span class="si">{query}</span><span class="s2"> using the feedback: </span><span class="si">{query_feedback}</span><span class="s2">"</span><span class="p">)</span>

    <span class="p">])</span>

    <span class="n">chain</span> <span class="o">=</span> <span class="n">expand_prompt</span> <span class="o">|</span> <span class="n">llm</span> <span class="o">|</span> <span class="n">StrOutputParser</span><span class="p">()</span>
    <span class="n">expanded_query</span> <span class="o">=</span> <span class="n">chain</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span><span class="s2">"query"</span><span class="p">:</span> <span class="n">state</span><span class="p">[</span><span class="s1">'query'</span><span class="p">],</span> <span class="s2">"query_feedback"</span><span class="p">:</span><span class="n">state</span><span class="p">[</span><span class="s2">"query_feedback"</span><span class="p">]})</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"expanded_query"</span><span class="p">,</span> <span class="n">expanded_query</span><span class="p">)</span>
    <span class="n">state</span><span class="p">[</span><span class="s2">"expanded_query"</span><span class="p">]</span> <span class="o">=</span> <span class="n">expanded_query</span>
    <span class="k">return</span> <span class="n">state</span>

<span class="c1"># Initialize the Chroma vector store for retrieving documents</span>
<span class="n">vector_store</span> <span class="o">=</span> <span class="n">Chroma</span><span class="p">(</span>
    <span class="n">collection_name</span><span class="o">=</span><span class="s2">"semantic_chunks"</span><span class="p">,</span>
    <span class="n">persist_directory</span><span class="o">=</span><span class="s2">"nutritional_db"</span><span class="p">,</span>
    <span class="n">embedding_function</span><span class="o">=</span><span class="n">embedding_model</span>
<span class="p">)</span>

<span class="c1"># Create a retriever from the vector store</span>
<span class="n">retriever</span> <span class="o">=</span> <span class="n">vector_store</span><span class="o">.</span><span class="n">as_retriever</span><span class="p">(</span>
    <span class="n">search_type</span><span class="o">=</span><span class="s1">'similarity'</span><span class="p">,</span>
    <span class="n">search_kwargs</span><span class="o">=</span><span class="p">{</span><span class="s1">'k'</span><span class="p">:</span> <span class="mi">3</span><span class="p">}</span>
<span class="p">)</span>

<span class="k">def</span><span class="w"> </span><span class="nf">retrieve_context</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">AgentState</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">AgentState</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Retrieves context from the vector store using the expanded or original query.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the query and expanded query.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with the retrieved context.</span>
<span class="sd">    """</span>
    <span class="n">query</span> <span class="o">=</span> <span class="n">state</span><span class="p">[</span><span class="s1">'expanded_query'</span><span class="p">]</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"Query used for retrieval:"</span><span class="p">,</span> <span class="n">query</span><span class="p">)</span>  <span class="c1"># Debugging: Print the query</span>

    <span class="c1"># Retrieve documents from the vector store</span>
    <span class="n">docs</span> <span class="o">=</span> <span class="n">retriever</span><span class="o">.</span><span class="n">invoke</span><span class="p">(</span><span class="n">query</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"Retrieved documents:"</span><span class="p">,</span> <span class="n">docs</span><span class="p">)</span>  <span class="c1"># Debugging: Print the raw docs object</span>

    <span class="c1"># Extract both page_content and metadata from each document</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'context'</span><span class="p">]</span> <span class="o">=</span> <span class="p">[</span>
        <span class="p">{</span>
            <span class="s2">"content"</span><span class="p">:</span> <span class="n">doc</span><span class="o">.</span><span class="n">page_content</span><span class="p">,</span>  <span class="c1"># The actual content of the document</span>
            <span class="s2">"metadata"</span><span class="p">:</span> <span class="n">doc</span><span class="o">.</span><span class="n">metadata</span>  <span class="c1"># The metadata (e.g., source, page number, etc.)</span>
        <span class="p">}</span>
        <span class="k">for</span> <span class="n">doc</span> <span class="ow">in</span> <span class="n">docs</span>
    <span class="p">]</span>

    <span class="nb">print</span><span class="p">(</span><span class="s2">"Extracted context with metadata:"</span><span class="p">,</span> <span class="n">state</span><span class="p">[</span><span class="s1">'context'</span><span class="p">])</span>  <span class="c1"># Debugging: Print the extracted context</span>
    <span class="k">return</span> <span class="n">state</span>

<span class="k">def</span><span class="w"> </span><span class="nf">craft_response</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">Dict</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">Dict</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Generates a response using the retrieved context, focusing on nutrition disorders.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the query and retrieved context.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with the generated response.</span>
<span class="sd">    """</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------craft_response---------"</span><span class="p">)</span>
    <span class="n">system_message</span> <span class="o">=</span> <span class="s1">'''</span>
<span class="s1">    You are a helpful medical assistant specialized in nutritional disorders.</span>
<span class="s1">    Given a user's query, retrieved context, and any feedback, generate a concise and accurate answer.</span>

<span class="s1">    Guidelines:</span>
<span class="s1">    - Use only the information present in the context.</span>
<span class="s1">    - Do not hallucinate or assume facts not grounded in the context.</span>
<span class="s1">    - Write clearly and professionally.</span>
<span class="s1">    - If the context is insufficient, say so clearly and avoid making up an answer.</span>
<span class="s1">    '''</span>

    <span class="n">response_prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
        <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_message</span><span class="p">),</span>
        <span class="p">(</span><span class="s2">"user"</span><span class="p">,</span> <span class="s2">"Query: </span><span class="si">{query}</span><span class="se">\n</span><span class="s2">Context: </span><span class="si">{context}</span><span class="se">\n\n</span><span class="s2">feedback: </span><span class="si">{feedback}</span><span class="s2">"</span><span class="p">)</span>
    <span class="p">])</span>

    <span class="n">chain</span> <span class="o">=</span> <span class="n">response_prompt</span> <span class="o">|</span> <span class="n">llm</span>
    <span class="n">response</span> <span class="o">=</span> <span class="n">chain</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span>
        <span class="s2">"query"</span><span class="p">:</span> <span class="n">state</span><span class="p">[</span><span class="s1">'query'</span><span class="p">],</span>
        <span class="s2">"context"</span><span class="p">:</span> <span class="s2">"</span><span class="se">\n</span><span class="s2">"</span><span class="o">.</span><span class="n">join</span><span class="p">([</span><span class="n">doc</span><span class="p">[</span><span class="s2">"content"</span><span class="p">]</span> <span class="k">for</span> <span class="n">doc</span> <span class="ow">in</span> <span class="n">state</span><span class="p">[</span><span class="s1">'context'</span><span class="p">]]),</span>
        <span class="s2">"feedback"</span><span class="p">:</span> <span class="n">state</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"feedback"</span><span class="p">,</span> <span class="s2">""</span><span class="p">)</span>
    <span class="p">})</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'response'</span><span class="p">]</span> <span class="o">=</span> <span class="n">response</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"intermediate response: "</span><span class="p">,</span> <span class="n">response</span><span class="p">)</span>

    <span class="k">return</span> <span class="n">state</span>


<span class="k">def</span><span class="w"> </span><span class="nf">score_groundedness</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">Dict</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">Dict</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Checks whether the response is grounded in the retrieved context.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the response and context.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with the groundedness score.</span>
<span class="sd">    """</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------check_groundedness---------"</span><span class="p">)</span>
    <span class="n">system_message</span> <span class="o">=</span> <span class="s1">'''</span>
<span class="s1">    You are a scoring assistant.</span>

<span class="s1">    Given a response and its supporting context, rate how well-grounded the response is on a scale from 0.0 to 1.0:</span>

<span class="s1">    - 1.0 = fully grounded (every statement in the response is directly supported by the context)</span>
<span class="s1">    - 0.5 = partially grounded (some statements are supported, some are not)</span>
<span class="s1">    - 0.0 = not grounded (statements are unsupported or hallucinated)</span>

<span class="s1">     Respond with **only the score as a number** (e.g., 0.8). Do not include any explanation or additional text.</span>
<span class="s1">    '''</span>

    <span class="n">groundedness_prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
        <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_message</span><span class="p">),</span>
        <span class="p">(</span><span class="s2">"user"</span><span class="p">,</span> <span class="s2">"Context: </span><span class="si">{context}</span><span class="se">\n</span><span class="s2">Response: </span><span class="si">{response}</span><span class="se">\n\n</span><span class="s2">Groundedness score:"</span><span class="p">)</span>
    <span class="p">])</span>

    <span class="n">chain</span> <span class="o">=</span> <span class="n">groundedness_prompt</span> <span class="o">|</span> <span class="n">llm</span> <span class="o">|</span> <span class="n">StrOutputParser</span><span class="p">()</span>
    <span class="n">groundedness_score</span> <span class="o">=</span> <span class="nb">float</span><span class="p">(</span><span class="n">chain</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span>
        <span class="s2">"context"</span><span class="p">:</span> <span class="s2">"</span><span class="se">\n</span><span class="s2">"</span><span class="o">.</span><span class="n">join</span><span class="p">([</span><span class="n">doc</span><span class="p">[</span><span class="s2">"content"</span><span class="p">]</span> <span class="k">for</span> <span class="n">doc</span> <span class="ow">in</span> <span class="n">state</span><span class="p">[</span><span class="s1">'context'</span><span class="p">]]),</span>
        <span class="s2">"response"</span><span class="p">:</span> <span class="n">state</span><span class="p">[</span><span class="s2">"response"</span><span class="p">]</span>
    <span class="p">}))</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"groundedness_score: "</span><span class="p">,</span> <span class="n">groundedness_score</span><span class="p">)</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'groundedness_loop_count'</span><span class="p">]</span> <span class="o">+=</span> <span class="mi">1</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"#########Groundedness Incremented###########"</span><span class="p">)</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'groundedness_score'</span><span class="p">]</span> <span class="o">=</span> <span class="n">groundedness_score</span>

    <span class="k">return</span> <span class="n">state</span>


<span class="k">def</span><span class="w"> </span><span class="nf">check_precision</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">Dict</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">Dict</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Checks whether the response precisely addresses the users query.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the query and response.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with the precision score.</span>
<span class="sd">    """</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------check_precision---------"</span><span class="p">)</span>
    <span class="n">system_message</span> <span class="o">=</span> <span class="s1">'''</span>
<span class="s1">    You are an assistant evaluating how precisely a response answers the given query.</span>

<span class="s1">    Score precision on a scale from 0.0 to 1.0:</span>
<span class="s1">    - 1.0: Direct and highly specific answer to the query, without irrelevant details.</span>
<span class="s1">    - 0.5: Partially addresses the query but lacks clarity or adds some unrelated information.</span>
<span class="s1">    - 0.0: Fails to answer the query or gives a vague or off-topic response.</span>

<span class="s1">    Respond with only the numeric precision score as a decimal (e.g., 0.8).</span>
<span class="s1">    '''</span>

    <span class="n">precision_prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
        <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_message</span><span class="p">),</span>
        <span class="p">(</span><span class="s2">"user"</span><span class="p">,</span> <span class="s2">"Query: </span><span class="si">{query}</span><span class="se">\n</span><span class="s2">Response: </span><span class="si">{response}</span><span class="se">\n\n</span><span class="s2">Precision score:"</span><span class="p">)</span>
    <span class="p">])</span>

    <span class="n">chain</span> <span class="o">=</span> <span class="n">precision_prompt</span> <span class="o">|</span> <span class="n">llm</span> <span class="o">|</span> <span class="n">StrOutputParser</span><span class="p">()</span>
    <span class="n">precision_score</span> <span class="o">=</span> <span class="nb">float</span><span class="p">(</span><span class="n">chain</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span>
        <span class="s2">"query"</span><span class="p">:</span> <span class="n">state</span><span class="p">[</span><span class="s1">'query'</span><span class="p">],</span>
        <span class="s2">"response"</span><span class="p">:</span> <span class="n">state</span><span class="p">[</span><span class="s1">'response'</span><span class="p">]</span>
    <span class="p">}))</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'precision_score'</span><span class="p">]</span> <span class="o">=</span> <span class="n">precision_score</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"precision_score:"</span><span class="p">,</span> <span class="n">precision_score</span><span class="p">)</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'precision_loop_count'</span><span class="p">]</span> <span class="o">+=</span> <span class="mi">1</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"#########Precision Incremented###########"</span><span class="p">)</span>
    <span class="k">return</span> <span class="n">state</span>


<span class="k">def</span><span class="w"> </span><span class="nf">refine_response</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">Dict</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">Dict</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Suggests improvements for the generated response.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the query and response.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with response refinement suggestions.</span>
<span class="sd">    """</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------refine_response---------"</span><span class="p">)</span>

    <span class="n">system_message</span> <span class="o">=</span> <span class="s1">'''</span>
<span class="s1">    You are an assistant specializing in improving medical question-answering responses.</span>

<span class="s1">    Your task is to suggest specific improvements to a given response based on a users original query. Focus on enhancing:</span>

<span class="s1">    - **Accuracy**: Ensure facts align with current medical knowledge and the retrieved context.</span>
<span class="s1">    - **Completeness**: Suggest what's missing or could be clarified.</span>
<span class="s1">    - **Clarity**: Recommend rewording for better readability or precision.</span>

<span class="s1">    Your feedback should be constructive and actionable. Return only suggestions without rewriting the entire response.</span>
<span class="s1">    '''</span>

    <span class="n">refine_response_prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
        <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_message</span><span class="p">),</span>
        <span class="p">(</span><span class="s2">"user"</span><span class="p">,</span> <span class="s2">"Query: </span><span class="si">{query}</span><span class="se">\n</span><span class="s2">Response: </span><span class="si">{response}</span><span class="se">\n\n</span><span class="s2">"</span>
                 <span class="s2">"What improvements can be made to enhance accuracy and completeness?"</span><span class="p">)</span>
    <span class="p">])</span>

    <span class="n">chain</span> <span class="o">=</span> <span class="n">refine_response_prompt</span> <span class="o">|</span> <span class="n">llm</span> <span class="o">|</span> <span class="n">StrOutputParser</span><span class="p">()</span>

    <span class="c1"># Store response suggestions in a structured format</span>
    <span class="n">feedback</span> <span class="o">=</span> <span class="sa">f</span><span class="s2">"Previous Response: </span><span class="si">{</span><span class="n">state</span><span class="p">[</span><span class="s1">'response'</span><span class="p">]</span><span class="si">}</span><span class="se">\n</span><span class="s2">Suggestions: </span><span class="si">{</span><span class="n">chain</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span><span class="s1">'query'</span><span class="p">:</span><span class="w"> </span><span class="n">state</span><span class="p">[</span><span class="s1">'query'</span><span class="p">],</span><span class="w"> </span><span class="s1">'response'</span><span class="p">:</span><span class="w"> </span><span class="n">state</span><span class="p">[</span><span class="s1">'response'</span><span class="p">]})</span><span class="si">}</span><span class="s2">"</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"feedback: "</span><span class="p">,</span> <span class="n">feedback</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"State: </span><span class="si">{</span><span class="n">state</span><span class="si">}</span><span class="s2">"</span><span class="p">)</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'feedback'</span><span class="p">]</span> <span class="o">=</span> <span class="n">feedback</span>
    <span class="k">return</span> <span class="n">state</span>


<span class="k">def</span><span class="w"> </span><span class="nf">refine_query</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">Dict</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">Dict</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Suggests improvements for the expanded query.</span>

<span class="sd">    Args:</span>
<span class="sd">        state (Dict): The current state of the workflow, containing the query and expanded query.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict: The updated state with query refinement suggestions.</span>
<span class="sd">    """</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------refine_query---------"</span><span class="p">)</span>
    <span class="n">system_message</span> <span class="o">=</span> <span class="s1">'''</span>
<span class="s1">    You are an assistant that helps improve search queries for medical literature retrieval, specifically in the context of nutritional disorders.</span>

<span class="s1">    Your task is to analyze an original user query and its expanded version, and suggest improvements to the expanded query to make it:</span>

<span class="s1">    - More specific and medically relevant</span>
<span class="s1">    - Better aligned with information retrieval best practices</span>
<span class="s1">    - Clear and unambiguous</span>

<span class="s1">    Focus on clarity, terminology, and contextual relevance. Return only the suggestions. Do not rewrite the query.</span>
<span class="s1">    '''</span>

    <span class="n">refine_query_prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
        <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_message</span><span class="p">),</span>
        <span class="p">(</span><span class="s2">"user"</span><span class="p">,</span> <span class="s2">"Original Query: </span><span class="si">{query}</span><span class="se">\n</span><span class="s2">Expanded Query: </span><span class="si">{expanded_query}</span><span class="se">\n\n</span><span class="s2">"</span>
                 <span class="s2">"What improvements can be made for a better search?"</span><span class="p">)</span>
    <span class="p">])</span>

    <span class="n">chain</span> <span class="o">=</span> <span class="n">refine_query_prompt</span> <span class="o">|</span> <span class="n">llm</span> <span class="o">|</span> <span class="n">StrOutputParser</span><span class="p">()</span>

    <span class="c1"># Store refinement suggestions without modifying the original expanded query</span>
    <span class="n">query_feedback</span> <span class="o">=</span> <span class="sa">f</span><span class="s2">"Previous Expanded Query: </span><span class="si">{</span><span class="n">state</span><span class="p">[</span><span class="s1">'expanded_query'</span><span class="p">]</span><span class="si">}</span><span class="se">\n</span><span class="s2">Suggestions: </span><span class="si">{</span><span class="n">chain</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span><span class="s1">'query'</span><span class="p">:</span><span class="w"> </span><span class="n">state</span><span class="p">[</span><span class="s1">'query'</span><span class="p">],</span><span class="w"> </span><span class="s1">'expanded_query'</span><span class="p">:</span><span class="w"> </span><span class="n">state</span><span class="p">[</span><span class="s1">'expanded_query'</span><span class="p">]})</span><span class="si">}</span><span class="s2">"</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"query_feedback: "</span><span class="p">,</span> <span class="n">query_feedback</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"Groundedness loop count: </span><span class="si">{</span><span class="n">state</span><span class="p">[</span><span class="s1">'groundedness_loop_count'</span><span class="p">]</span><span class="si">}</span><span class="s2">"</span><span class="p">)</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'query_feedback'</span><span class="p">]</span> <span class="o">=</span> <span class="n">query_feedback</span>
    <span class="k">return</span> <span class="n">state</span>


<span class="k">def</span><span class="w"> </span><span class="nf">should_continue_groundedness</span><span class="p">(</span><span class="n">state</span><span class="p">):</span>
<span class="w">    </span><span class="sd">"""Decides if groundedness is sufficient or needs improvement."""</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------should_continue_groundedness---------"</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"groundedness loop count: "</span><span class="p">,</span> <span class="n">state</span><span class="p">[</span><span class="s1">'groundedness_loop_count'</span><span class="p">])</span>

    <span class="k">if</span> <span class="n">state</span><span class="p">[</span><span class="s1">'groundedness_score'</span><span class="p">]</span> <span class="o">&gt;=</span> <span class="mf">0.85</span><span class="p">:</span>  <span class="c1"># Threshold for groundedness</span>
        <span class="nb">print</span><span class="p">(</span><span class="s2">" Groundedness sufficient. Moving to precision check."</span><span class="p">)</span>
        <span class="k">return</span> <span class="s2">"check_precision"</span>
    <span class="k">else</span><span class="p">:</span>
        <span class="k">if</span> <span class="n">state</span><span class="p">[</span><span class="s2">"groundedness_loop_count"</span><span class="p">]</span> <span class="o">&gt;</span> <span class="n">state</span><span class="p">[</span><span class="s1">'loop_max_iter'</span><span class="p">]:</span>
            <span class="nb">print</span><span class="p">(</span><span class="s2">" Maximum iterations reached. Stopping."</span><span class="p">)</span>
            <span class="k">return</span> <span class="s2">"max_iterations_reached"</span>
        <span class="k">else</span><span class="p">:</span>
            <span class="nb">print</span><span class="p">(</span><span class="s2">" Groundedness score too low. Refining response."</span><span class="p">)</span>
            <span class="k">return</span> <span class="s2">"refine_response"</span>

<span class="k">def</span><span class="w"> </span><span class="nf">should_continue_precision</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">Dict</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="nb">str</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""Decides if precision is sufficient or needs improvement."""</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"---------should_continue_precision---------"</span><span class="p">)</span>
    <span class="nb">print</span><span class="p">(</span><span class="s2">"precision loop count: "</span><span class="p">,</span> <span class="n">state</span><span class="p">[</span><span class="s1">'precision_loop_count'</span><span class="p">])</span>

    <span class="k">if</span> <span class="n">state</span><span class="p">[</span><span class="s1">'precision_score'</span><span class="p">]</span> <span class="o">&gt;=</span> <span class="mf">0.85</span><span class="p">:</span>  <span class="c1"># Threshold for precision</span>
        <span class="nb">print</span><span class="p">(</span><span class="s2">" Precision sufficient. Passing."</span><span class="p">)</span>
        <span class="k">return</span> <span class="s2">"pass"</span>
    <span class="k">else</span><span class="p">:</span>
        <span class="k">if</span> <span class="n">state</span><span class="p">[</span><span class="s1">'precision_loop_count'</span><span class="p">]</span> <span class="o">&gt;</span> <span class="n">state</span><span class="p">[</span><span class="s1">'loop_max_iter'</span><span class="p">]:</span>
            <span class="nb">print</span><span class="p">(</span><span class="s2">" Maximum iterations reached. Stopping."</span><span class="p">)</span>
            <span class="k">return</span> <span class="s2">"max_iterations_reached"</span>
        <span class="k">else</span><span class="p">:</span>
            <span class="nb">print</span><span class="p">(</span><span class="s2">" Precision score too low. Refining query."</span><span class="p">)</span>
            <span class="k">return</span> <span class="s2">"refine_query"</span>


<span class="k">def</span><span class="w"> </span><span class="nf">max_iterations_reached</span><span class="p">(</span><span class="n">state</span><span class="p">:</span> <span class="n">AgentState</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">AgentState</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""Handles the case where max iterations are reached."""</span>
    <span class="n">state</span><span class="p">[</span><span class="s1">'response'</span><span class="p">]</span> <span class="o">=</span> <span class="s2">"We need more context to provide an accurate answer."</span>
    <span class="k">return</span> <span class="n">state</span>

<span class="kn">from</span><span class="w"> </span><span class="nn">langgraph.graph</span><span class="w"> </span><span class="kn">import</span> <span class="n">END</span><span class="p">,</span> <span class="n">StateGraph</span><span class="p">,</span> <span class="n">START</span>

<span class="k">def</span><span class="w"> </span><span class="nf">create_workflow</span><span class="p">()</span> <span class="o">-&gt;</span> <span class="n">StateGraph</span><span class="p">:</span>
<span class="w">    </span><span class="sd">"""Creates the updated workflow for the AI nutrition agent."""</span>
    <span class="n">workflow</span> <span class="o">=</span> <span class="n">StateGraph</span><span class="p">(</span><span class="nb">dict</span><span class="p">)</span>

    <span class="c1"># Add processing nodes</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"expand_query"</span><span class="p">,</span> <span class="n">expand_query</span><span class="p">)</span>                      <span class="c1"># Step 1</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"retrieve_context"</span><span class="p">,</span> <span class="n">retrieve_context</span><span class="p">)</span>              <span class="c1"># Step 2</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"craft_response"</span><span class="p">,</span> <span class="n">craft_response</span><span class="p">)</span>                  <span class="c1"># Step 3</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"score_groundedness"</span><span class="p">,</span> <span class="n">score_groundedness</span><span class="p">)</span>          <span class="c1"># Step 4</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"refine_response"</span><span class="p">,</span> <span class="n">refine_response</span><span class="p">)</span>                <span class="c1"># Step 5</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"check_precision"</span><span class="p">,</span> <span class="n">check_precision</span><span class="p">)</span>                <span class="c1"># Step 6</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"refine_query"</span><span class="p">,</span> <span class="n">refine_query</span><span class="p">)</span>                      <span class="c1"># Step 7</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_node</span><span class="p">(</span><span class="s2">"max_iterations_reached"</span><span class="p">,</span> <span class="k">lambda</span> <span class="n">x</span><span class="p">:</span> <span class="n">x</span><span class="p">)</span>             <span class="c1"># Step 8  exit handler (no-op)</span>

    <span class="c1"># Main flow edges</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="n">START</span><span class="p">,</span> <span class="s2">"expand_query"</span><span class="p">)</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="s2">"expand_query"</span><span class="p">,</span> <span class="s2">"retrieve_context"</span><span class="p">)</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="s2">"retrieve_context"</span><span class="p">,</span> <span class="s2">"craft_response"</span><span class="p">)</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="s2">"craft_response"</span><span class="p">,</span> <span class="s2">"score_groundedness"</span><span class="p">)</span>

    <span class="c1"># Conditional edges based on groundedness check</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_conditional_edges</span><span class="p">(</span>
        <span class="s2">"score_groundedness"</span><span class="p">,</span>
        <span class="n">should_continue_groundedness</span><span class="p">,</span>
        <span class="p">{</span>
            <span class="s2">"check_precision"</span><span class="p">:</span> <span class="s2">"check_precision"</span><span class="p">,</span>         <span class="c1"># If grounded enough</span>
            <span class="s2">"refine_response"</span><span class="p">:</span> <span class="s2">"refine_response"</span><span class="p">,</span>         <span class="c1"># If not grounded</span>
            <span class="s2">"max_iterations_reached"</span><span class="p">:</span> <span class="s2">"max_iterations_reached"</span>  <span class="c1"># Too many loops</span>
        <span class="p">}</span>
    <span class="p">)</span>

    <span class="c1"># Re-craft response after refining it</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="s2">"refine_response"</span><span class="p">,</span> <span class="s2">"craft_response"</span><span class="p">)</span>

    <span class="c1"># Conditional edges based on precision check</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_conditional_edges</span><span class="p">(</span>
        <span class="s2">"check_precision"</span><span class="p">,</span>
        <span class="n">should_continue_precision</span><span class="p">,</span>  <span class="c1"># Function to decide precision flow</span>
        <span class="p">{</span>
            <span class="s2">"pass"</span><span class="p">:</span> <span class="n">END</span><span class="p">,</span>
            <span class="s2">"refine_query"</span><span class="p">:</span> <span class="s2">"refine_query"</span><span class="p">,</span>
            <span class="s2">"max_iterations_reached"</span><span class="p">:</span> <span class="s2">"max_iterations_reached"</span>
        <span class="p">}</span>
    <span class="p">)</span>

    <span class="c1"># Re-expand and re-process refined queries</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="s2">"refine_query"</span><span class="p">,</span> <span class="s2">"expand_query"</span><span class="p">)</span>

    <span class="c1"># Exit when max loop count is reached</span>
    <span class="n">workflow</span><span class="o">.</span><span class="n">add_edge</span><span class="p">(</span><span class="s2">"max_iterations_reached"</span><span class="p">,</span> <span class="n">END</span><span class="p">)</span>

    <span class="k">return</span> <span class="n">workflow</span>

<span class="c1">#=========================== Defining the agentic rag tool ====================#</span>

<span class="n">WORKFLOW_APP</span> <span class="o">=</span> <span class="n">create_workflow</span><span class="p">()</span><span class="o">.</span><span class="n">compile</span><span class="p">()</span>

<span class="nd">@tool</span>
<span class="k">def</span><span class="w"> </span><span class="nf">agentic_rag</span><span class="p">(</span><span class="n">query</span><span class="p">:</span> <span class="nb">str</span><span class="p">):</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Runs the RAG-based agent with conversation history for context-aware responses.</span>

<span class="sd">    Args:</span>
<span class="sd">        query (str): The current user query.</span>

<span class="sd">    Returns:</span>
<span class="sd">        Dict[str, Any]: The updated state with the generated response and conversation history.</span>
<span class="sd">    """</span>
    <span class="c1"># Initialize state with necessary parameters</span>
    <span class="n">inputs</span> <span class="o">=</span> <span class="p">{</span>
        <span class="s2">"query"</span><span class="p">:</span> <span class="n">query</span><span class="p">,</span>                         <span class="c1"># User's question</span>
        <span class="s2">"expanded_query"</span><span class="p">:</span> <span class="s2">""</span><span class="p">,</span>                   <span class="c1"># Will be filled by expand_query step</span>
        <span class="s2">"context"</span><span class="p">:</span> <span class="p">[],</span>                          <span class="c1"># Retrieved docs (initially empty)</span>
        <span class="s2">"response"</span><span class="p">:</span> <span class="s2">""</span><span class="p">,</span>                         <span class="c1"># Will be generated during workflow</span>
        <span class="s2">"precision_score"</span><span class="p">:</span> <span class="mf">0.0</span><span class="p">,</span>                 <span class="c1"># Initialized to zero</span>
        <span class="s2">"groundedness_score"</span><span class="p">:</span> <span class="mf">0.0</span><span class="p">,</span>              <span class="c1"># Initialized to zero</span>
        <span class="s2">"groundedness_loop_count"</span><span class="p">:</span> <span class="mi">0</span><span class="p">,</span>           <span class="c1"># Count how many times grounding refinement occurred</span>
        <span class="s2">"precision_loop_count"</span><span class="p">:</span> <span class="mi">0</span><span class="p">,</span>              <span class="c1"># Count how many times precision refinement occurred</span>
        <span class="s2">"feedback"</span><span class="p">:</span> <span class="s2">""</span><span class="p">,</span>                         <span class="c1"># Feedback after response refinement</span>
        <span class="s2">"query_feedback"</span><span class="p">:</span> <span class="s2">""</span><span class="p">,</span>                   <span class="c1"># Feedback after query refinement</span>
        <span class="s2">"loop_max_iter"</span><span class="p">:</span> <span class="mi">3</span>                      <span class="c1"># Max loop iterations for groundedness/precision</span>
    <span class="p">}</span>

    <span class="n">output</span> <span class="o">=</span> <span class="n">WORKFLOW_APP</span><span class="o">.</span><span class="n">invoke</span><span class="p">(</span><span class="n">inputs</span><span class="p">)</span>

    <span class="k">return</span> <span class="n">output</span>

<span class="c1">#================================ Guardrails ===========================#</span>
<span class="c1"># Initialize the Llama Guard client with the API key</span>
<span class="n">llama_guard_client</span> <span class="o">=</span> <span class="n">Groq</span><span class="p">(</span><span class="n">api_key</span><span class="o">=</span><span class="n">llama_api_key</span><span class="p">)</span>

<span class="c1"># Function to filter user input with Llama Guard</span>
<span class="k">def</span><span class="w"> </span><span class="nf">filter_input_with_llama_guard</span><span class="p">(</span><span class="n">user_input</span><span class="p">,</span> <span class="n">model</span><span class="o">=</span><span class="s2">"llama-guard-3-8b"</span><span class="p">):</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    Filters user input using Llama Guard to ensure it is safe.</span>

<span class="sd">    Parameters:</span>
<span class="sd">    - user_input: The input provided by the user.</span>
<span class="sd">    - model: The Llama Guard model to be used for filtering (default is "llama-guard-3-8b").</span>

<span class="sd">    Returns:</span>
<span class="sd">    - The filtered and safe input.</span>
<span class="sd">    """</span>
    <span class="k">try</span><span class="p">:</span>
        <span class="c1"># Create a request to Llama Guard to filter the user input</span>
        <span class="n">response</span> <span class="o">=</span> <span class="n">llama_guard_client</span><span class="o">.</span><span class="n">chat</span><span class="o">.</span><span class="n">completions</span><span class="o">.</span><span class="n">create</span><span class="p">(</span>
            <span class="n">messages</span><span class="o">=</span><span class="p">[{</span><span class="s2">"role"</span><span class="p">:</span> <span class="s2">"user"</span><span class="p">,</span> <span class="s2">"content"</span><span class="p">:</span> <span class="n">user_input</span><span class="p">}],</span>
            <span class="n">model</span><span class="o">=</span><span class="n">model</span><span class="p">,</span>
        <span class="p">)</span>
        <span class="c1"># Return the filtered input</span>
        <span class="k">return</span> <span class="n">response</span><span class="o">.</span><span class="n">choices</span><span class="p">[</span><span class="mi">0</span><span class="p">]</span><span class="o">.</span><span class="n">message</span><span class="o">.</span><span class="n">content</span><span class="o">.</span><span class="n">strip</span><span class="p">()</span>
    <span class="k">except</span> <span class="ne">Exception</span> <span class="k">as</span> <span class="n">e</span><span class="p">:</span>
        <span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s2">"Error with Llama Guard: </span><span class="si">{</span><span class="n">e</span><span class="si">}</span><span class="s2">"</span><span class="p">)</span>
        <span class="k">return</span> <span class="kc">None</span>

<span class="c1">#============================= Adding Memory to the agent using mem0 ===============================#</span>

<span class="k">class</span><span class="w"> </span><span class="nc">NutritionBot</span><span class="p">:</span>
    <span class="k">def</span><span class="w"> </span><span class="fm">__init__</span><span class="p">(</span><span class="bp">self</span><span class="p">):</span>
<span class="w">        </span><span class="sd">"""</span>
<span class="sd">        Initialize the NutritionBot class, setting up memory, the LLM client, tools, and the agent executor.</span>
<span class="sd">        """</span>

        <span class="c1"># Initialize a memory client to store and retrieve customer interactions</span>
        <span class="bp">self</span><span class="o">.</span><span class="n">memory</span> <span class="o">=</span> <span class="n">MemoryClient</span><span class="p">(</span><span class="n">api_key</span><span class="o">=</span><span class="n">os</span><span class="o">.</span><span class="n">environ</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"mem0"</span><span class="p">))</span>  <span class="c1"># Complete the code to define the memory client API key</span>

        <span class="c1"># Initialize the OpenAI client using the provided credentials</span>
        <span class="bp">self</span><span class="o">.</span><span class="n">client</span> <span class="o">=</span> <span class="n">ChatOpenAI</span><span class="p">(</span>
            <span class="n">model_name</span><span class="o">=</span><span class="s2">"gpt-4o-mini"</span><span class="p">,</span>  <span class="c1"># Specify the model to use (e.g., GPT-4 optimized version)</span>
            <span class="n">api_key</span><span class="o">=</span> <span class="n">os</span><span class="o">.</span><span class="n">environ</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"API_KEY"</span><span class="p">),</span>  <span class="c1"># API key for authentication</span>
            <span class="n">base_url</span><span class="o">=</span><span class="n">os</span><span class="o">.</span><span class="n">environ</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"OPENAI_API_BASE"</span><span class="p">),</span>
            <span class="n">temperature</span><span class="o">=</span><span class="mi">0</span>  <span class="c1"># Controls randomness in responses; 0 ensures deterministic results</span>
        <span class="p">)</span>

        <span class="c1"># Define tools available to the chatbot, such as web search</span>
        <span class="n">tools</span> <span class="o">=</span> <span class="p">[</span><span class="n">agentic_rag</span><span class="p">]</span>

        <span class="c1"># Define the system prompt to set the behavior of the chatbot</span>
        <span class="n">system_prompt</span> <span class="o">=</span> <span class="s2">"""You are a caring and knowledgeable Medical Support Agent, specializing in nutrition disorder-related guidance. Your goal is to provide accurate, empathetic, and tailored nutritional recommendations while ensuring a seamless customer experience.</span>
<span class="s2">                          Guidelines for Interaction:</span>
<span class="s2">                          Maintain a polite, professional, and reassuring tone.</span>
<span class="s2">                          Show genuine empathy for customer concerns and health challenges.</span>
<span class="s2">                          Reference past interactions to provide personalized and consistent advice.</span>
<span class="s2">                          Engage with the customer by asking about their food preferences, dietary restrictions, and lifestyle before offering recommendations.</span>
<span class="s2">                          Ensure consistent and accurate information across conversations.</span>
<span class="s2">                          If any detail is unclear or missing, proactively ask for clarification.</span>
<span class="s2">                          Always use the agentic_rag tool to retrieve up-to-date and evidence-based nutrition insights.</span>
<span class="s2">                          Keep track of ongoing issues and follow-ups to ensure continuity in support.</span>
<span class="s2">                          Your primary goal is to help customers make informed nutrition decisions that align with their health conditions and personal preferences.</span>

<span class="s2">        """</span>

        <span class="c1"># Build the prompt template for the agent</span>
        <span class="n">prompt</span> <span class="o">=</span> <span class="n">ChatPromptTemplate</span><span class="o">.</span><span class="n">from_messages</span><span class="p">([</span>
            <span class="p">(</span><span class="s2">"system"</span><span class="p">,</span> <span class="n">system_prompt</span><span class="p">),</span>  <span class="c1"># System instructions</span>
            <span class="p">(</span><span class="s2">"human"</span><span class="p">,</span> <span class="s2">"</span><span class="si">{input}</span><span class="s2">"</span><span class="p">),</span>  <span class="c1"># Placeholder for human input</span>
            <span class="p">(</span><span class="s2">"placeholder"</span><span class="p">,</span> <span class="s2">"</span><span class="si">{agent_scratchpad}</span><span class="s2">"</span><span class="p">)</span>  <span class="c1"># Placeholder for intermediate reasoning steps</span>
        <span class="p">])</span>

        <span class="c1"># Create an agent capable of interacting with tools and executing tasks</span>
        <span class="n">agent</span> <span class="o">=</span> <span class="n">create_tool_calling_agent</span><span class="p">(</span><span class="bp">self</span><span class="o">.</span><span class="n">client</span><span class="p">,</span> <span class="n">tools</span><span class="p">,</span> <span class="n">prompt</span><span class="p">)</span>

        <span class="c1"># Wrap the agent in an executor to manage tool interactions and execution flow</span>
        <span class="bp">self</span><span class="o">.</span><span class="n">agent_executor</span> <span class="o">=</span> <span class="n">AgentExecutor</span><span class="p">(</span><span class="n">agent</span><span class="o">=</span><span class="n">agent</span><span class="p">,</span> <span class="n">tools</span><span class="o">=</span><span class="n">tools</span><span class="p">,</span> <span class="n">verbose</span><span class="o">=</span><span class="kc">True</span><span class="p">)</span>


    <span class="k">def</span><span class="w"> </span><span class="nf">store_customer_interaction</span><span class="p">(</span><span class="bp">self</span><span class="p">,</span> <span class="n">user_id</span><span class="p">:</span> <span class="nb">str</span><span class="p">,</span> <span class="n">message</span><span class="p">:</span> <span class="nb">str</span><span class="p">,</span> <span class="n">response</span><span class="p">:</span> <span class="nb">str</span><span class="p">,</span> <span class="n">metadata</span><span class="p">:</span> <span class="n">Dict</span> <span class="o">=</span> <span class="kc">None</span><span class="p">):</span>
<span class="w">        </span><span class="sd">"""</span>
<span class="sd">        Store customer interaction in memory for future reference.</span>

<span class="sd">        Args:</span>
<span class="sd">            user_id (str): Unique identifier for the customer.</span>
<span class="sd">            message (str): Customer's query or message.</span>
<span class="sd">            response (str): Chatbot's response.</span>
<span class="sd">            metadata (Dict, optional): Additional metadata for the interaction.</span>
<span class="sd">        """</span>
        <span class="k">if</span> <span class="n">metadata</span> <span class="ow">is</span> <span class="kc">None</span><span class="p">:</span>
            <span class="n">metadata</span> <span class="o">=</span> <span class="p">{}</span>

        <span class="c1"># Add a timestamp to the metadata for tracking purposes</span>
        <span class="n">metadata</span><span class="p">[</span><span class="s2">"timestamp"</span><span class="p">]</span> <span class="o">=</span> <span class="n">datetime</span><span class="o">.</span><span class="n">now</span><span class="p">()</span><span class="o">.</span><span class="n">isoformat</span><span class="p">()</span>

        <span class="c1"># Format the conversation for storage</span>
        <span class="n">conversation</span> <span class="o">=</span> <span class="p">[</span>
            <span class="p">{</span><span class="s2">"role"</span><span class="p">:</span> <span class="s2">"user"</span><span class="p">,</span> <span class="s2">"content"</span><span class="p">:</span> <span class="n">message</span><span class="p">},</span>
            <span class="p">{</span><span class="s2">"role"</span><span class="p">:</span> <span class="s2">"assistant"</span><span class="p">,</span> <span class="s2">"content"</span><span class="p">:</span> <span class="n">response</span><span class="p">}</span>
        <span class="p">]</span>

        <span class="c1"># Store the interaction in the memory client</span>
        <span class="bp">self</span><span class="o">.</span><span class="n">memory</span><span class="o">.</span><span class="n">add</span><span class="p">(</span>
            <span class="n">conversation</span><span class="p">,</span>
            <span class="n">user_id</span><span class="o">=</span><span class="n">user_id</span><span class="p">,</span>
            <span class="n">output_format</span><span class="o">=</span><span class="s2">"v1.1"</span><span class="p">,</span>
            <span class="n">metadata</span><span class="o">=</span><span class="n">metadata</span>
        <span class="p">)</span>


    <span class="k">def</span><span class="w"> </span><span class="nf">get_relevant_history</span><span class="p">(</span><span class="bp">self</span><span class="p">,</span> <span class="n">user_id</span><span class="p">:</span> <span class="nb">str</span><span class="p">,</span> <span class="n">query</span><span class="p">:</span> <span class="nb">str</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="n">List</span><span class="p">[</span><span class="n">Dict</span><span class="p">]:</span>
<span class="w">        </span><span class="sd">"""</span>
<span class="sd">        Retrieve past interactions relevant to the current query.</span>

<span class="sd">        Args:</span>
<span class="sd">            user_id (str): Unique identifier for the customer.</span>
<span class="sd">            query (str): The customer's current query.</span>

<span class="sd">        Returns:</span>
<span class="sd">            List[Dict]: A list of relevant past interactions.</span>
<span class="sd">        """</span>
        <span class="k">return</span> <span class="bp">self</span><span class="o">.</span><span class="n">memory</span><span class="o">.</span><span class="n">search</span><span class="p">(</span>
            <span class="n">query</span><span class="o">=</span><span class="n">query</span><span class="p">,</span>  <span class="c1"># Search for interactions related to the query</span>
            <span class="n">user_id</span><span class="o">=</span><span class="n">user_id</span><span class="p">,</span>  <span class="c1"># Restrict search to the specific user</span>
            <span class="n">limit</span><span class="o">=</span><span class="mi">5</span>
        <span class="p">)</span>


    <span class="k">def</span><span class="w"> </span><span class="nf">handle_customer_query</span><span class="p">(</span><span class="bp">self</span><span class="p">,</span> <span class="n">user_id</span><span class="p">:</span> <span class="nb">str</span><span class="p">,</span> <span class="n">query</span><span class="p">:</span> <span class="nb">str</span><span class="p">)</span> <span class="o">-&gt;</span> <span class="nb">str</span><span class="p">:</span>
<span class="w">        </span><span class="sd">"""</span>
<span class="sd">        Process a customer's query and provide a response, taking into account past interactions.</span>

<span class="sd">        Args:</span>
<span class="sd">            user_id (str): Unique identifier for the customer.</span>
<span class="sd">            query (str): Customer's query.</span>

<span class="sd">        Returns:</span>
<span class="sd">            str: Chatbot's response.</span>
<span class="sd">        """</span>

        <span class="c1"># Retrieve relevant past interactions for context</span>
        <span class="n">relevant_history</span> <span class="o">=</span> <span class="bp">self</span><span class="o">.</span><span class="n">get_relevant_history</span><span class="p">(</span><span class="n">user_id</span><span class="p">,</span> <span class="n">query</span><span class="p">)</span>

        <span class="c1"># Build a context string from the relevant history</span>
        <span class="n">context</span> <span class="o">=</span> <span class="s2">"Previous relevant interactions:</span><span class="se">\n</span><span class="s2">"</span>
        <span class="k">for</span> <span class="n">memory</span> <span class="ow">in</span> <span class="n">relevant_history</span><span class="p">:</span>
            <span class="n">context</span> <span class="o">+=</span> <span class="sa">f</span><span class="s2">"Customer: </span><span class="si">{</span><span class="n">memory</span><span class="p">[</span><span class="s1">'memory'</span><span class="p">]</span><span class="si">}</span><span class="se">\n</span><span class="s2">"</span>  <span class="c1"># Customer's past messages</span>
            <span class="n">context</span> <span class="o">+=</span> <span class="sa">f</span><span class="s2">"Support: </span><span class="si">{</span><span class="n">memory</span><span class="p">[</span><span class="s1">'memory'</span><span class="p">]</span><span class="si">}</span><span class="se">\n</span><span class="s2">"</span>  <span class="c1"># Chatbot's past responses</span>
            <span class="n">context</span> <span class="o">+=</span> <span class="s2">"---</span><span class="se">\n</span><span class="s2">"</span>

        <span class="c1"># Print context for debugging purposes</span>
        <span class="nb">print</span><span class="p">(</span><span class="s2">"Context: "</span><span class="p">,</span> <span class="n">context</span><span class="p">)</span>

        <span class="c1"># Prepare a prompt combining past context and the current query</span>
        <span class="n">prompt</span> <span class="o">=</span> <span class="sa">f</span><span class="s2">"""</span>
<span class="s2">        Context:</span>
<span class="s2">        </span><span class="si">{</span><span class="n">context</span><span class="si">}</span>

<span class="s2">        Current customer query: </span><span class="si">{</span><span class="n">query</span><span class="si">}</span>

<span class="s2">        Provide a helpful response that takes into account any relevant past interactions.</span>
<span class="s2">        """</span>

        <span class="c1"># Generate a response using the agent</span>
        <span class="n">response</span> <span class="o">=</span> <span class="bp">self</span><span class="o">.</span><span class="n">agent_executor</span><span class="o">.</span><span class="n">invoke</span><span class="p">({</span><span class="s2">"input"</span><span class="p">:</span> <span class="n">prompt</span><span class="p">})</span>

        <span class="c1"># Store the current interaction for future reference</span>
        <span class="bp">self</span><span class="o">.</span><span class="n">store_customer_interaction</span><span class="p">(</span>
            <span class="n">user_id</span><span class="o">=</span><span class="n">user_id</span><span class="p">,</span>
            <span class="n">message</span><span class="o">=</span><span class="n">query</span><span class="p">,</span>
            <span class="n">response</span><span class="o">=</span><span class="n">response</span><span class="p">[</span><span class="s2">"output"</span><span class="p">],</span>
            <span class="n">metadata</span><span class="o">=</span><span class="p">{</span><span class="s2">"type"</span><span class="p">:</span> <span class="s2">"support_query"</span><span class="p">}</span>
        <span class="p">)</span>

        <span class="c1"># Return the chatbot's response</span>
        <span class="k">return</span> <span class="n">response</span><span class="p">[</span><span class="s1">'output'</span><span class="p">]</span>

<span class="c1">#=====================User Interface using streamlit ===========================#</span>

<span class="k">def</span><span class="w"> </span><span class="nf">nutrition_disorder_streamlit</span><span class="p">():</span>
<span class="w">    </span><span class="sd">"""</span>
<span class="sd">    A Streamlit-based UI for the Nutrition Disorder Specialist Agent.</span>
<span class="sd">    """</span>
    <span class="n">st</span><span class="o">.</span><span class="n">title</span><span class="p">(</span><span class="s2">"Nutrition Disorder Specialist"</span><span class="p">)</span>
    <span class="n">st</span><span class="o">.</span><span class="n">write</span><span class="p">(</span><span class="s2">"Ask me anything about nutrition disorders, symptoms, causes, treatments, and more."</span><span class="p">)</span>
    <span class="n">st</span><span class="o">.</span><span class="n">write</span><span class="p">(</span><span class="s2">"Type 'exit' to end the conversation."</span><span class="p">)</span>

    <span class="c1"># Initialize session state for chat history and user_id if they don't exist</span>
    <span class="k">if</span> <span class="s1">'chat_history'</span> <span class="ow">not</span> <span class="ow">in</span> <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="p">:</span>
        <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">chat_history</span> <span class="o">=</span> <span class="p">[]</span>
    <span class="k">if</span> <span class="s1">'user_id'</span> <span class="ow">not</span> <span class="ow">in</span> <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="p">:</span>
        <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">user_id</span> <span class="o">=</span> <span class="kc">None</span>

    <span class="c1"># Login form: Only if user is not logged in</span>
    <span class="k">if</span> <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">user_id</span> <span class="ow">is</span> <span class="kc">None</span><span class="p">:</span>
        <span class="k">with</span> <span class="n">st</span><span class="o">.</span><span class="n">form</span><span class="p">(</span><span class="s2">"login_form"</span><span class="p">,</span> <span class="n">clear_on_submit</span><span class="o">=</span><span class="kc">True</span><span class="p">):</span>
            <span class="n">user_id</span> <span class="o">=</span> <span class="n">st</span><span class="o">.</span><span class="n">text_input</span><span class="p">(</span><span class="s2">"Please enter your name to begin:"</span><span class="p">)</span>
            <span class="n">submit_button</span> <span class="o">=</span> <span class="n">st</span><span class="o">.</span><span class="n">form_submit_button</span><span class="p">(</span><span class="s2">"Login"</span><span class="p">)</span>
            <span class="k">if</span> <span class="n">submit_button</span> <span class="ow">and</span> <span class="n">user_id</span><span class="p">:</span>
                <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">user_id</span> <span class="o">=</span> <span class="n">user_id</span>
                <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">chat_history</span><span class="o">.</span><span class="n">append</span><span class="p">({</span>
                    <span class="s2">"role"</span><span class="p">:</span> <span class="s2">"assistant"</span><span class="p">,</span>
                    <span class="s2">"content"</span><span class="p">:</span> <span class="sa">f</span><span class="s2">"Welcome, </span><span class="si">{</span><span class="n">user_id</span><span class="si">}</span><span class="s2">! How can I help you with nutrition disorders today?"</span>
                <span class="p">})</span>
                <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">login_submitted</span> <span class="o">=</span> <span class="kc">True</span>  <span class="c1"># Set flag to trigger rerun</span>
        <span class="k">if</span> <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s2">"login_submitted"</span><span class="p">,</span> <span class="kc">False</span><span class="p">):</span>
            <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">pop</span><span class="p">(</span><span class="s2">"login_submitted"</span><span class="p">)</span>
            <span class="n">st</span><span class="o">.</span><span class="n">rerun</span><span class="p">()</span>
    <span class="k">else</span><span class="p">:</span>
        <span class="c1"># Display chat history</span>
        <span class="k">for</span> <span class="n">message</span> <span class="ow">in</span> <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">chat_history</span><span class="p">:</span>
            <span class="k">with</span> <span class="n">st</span><span class="o">.</span><span class="n">chat_message</span><span class="p">(</span><span class="n">message</span><span class="p">[</span><span class="s2">"role"</span><span class="p">]):</span>
                <span class="n">st</span><span class="o">.</span><span class="n">write</span><span class="p">(</span><span class="n">message</span><span class="p">[</span><span class="s2">"content"</span><span class="p">])</span>

        <span class="c1"># Chat input with custom placeholder text</span>
        <span class="n">user_query</span> <span class="o">=</span> <span class="n">st</span><span class="o">.</span><span class="n">chat_input</span><span class="p">(</span> <span class="s2">"Type your question here (or 'exit' to end)..."</span><span class="p">)</span>
        <span class="k">if</span> <span class="n">user_query</span><span class="p">:</span>
            <span class="k">if</span> <span class="n">user_query</span><span class="o">.</span><span class="n">lower</span><span class="p">()</span> <span class="o">==</span> <span class="s2">"exit"</span><span class="p">:</span>
                <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">chat_history</span><span class="o">.</span><span class="n">append</span><span class="p">({</span><span class="s2">"role"</span><span class="p">:</span> <span class="s2">"user"</span><span class="p">,</span> <span class="s2">"content"</span><span class="p">:</span> <span class="s2">"exit"</span><span class="p">})</span>
                <span class="k">with</span> <span class="n">st</span><span class="o">.</span><span class="n">chat_message</span><span class="p">(</span><span class="s2">"user"</span><span class="p">):</span>
                    <span class="n">st</span><span class="o">.</span><span class="n">write</span><span class="p">(</span><span class="s2">"exit"</span><span class="p">)</span>
                <span class="n">goodbye_msg</span> <span class="o">=</span> <span class="s2">"Goodbye! Feel free to return if you have more questions about nutrition disorders."</span>
                <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">chat_history</span><span class="o">.</span><span class="n">append</span><span class="p">({</span><span class="s2">"role"</span><span class="p">:</span> <span class="s2">"assistant"</span><span class="p">,</span> <span class="s2">"content"</span><span class="p">:</span> <span class="n">goodbye_msg</span><span class="p">})</span>
                <span class="k">with</span> <span class="n">st</span><span class="o">.</span><span class="n">chat_message</span><span class="p">(</span><span class="s2">"assistant"</span><span class="p">):</span>
                    <span class="n">st</span><span class="o">.</span><span class="n">write</span><span class="p">(</span><span class="n">goodbye_msg</span><span class="p">)</span>
                <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">user_id</span> <span class="o">=</span> <span class="kc">None</span>
                <span class="n">st</span><span class="o">.</span><span class="n">rerun</span><span class="p">()</span>
                <span class="k">return</span>

            <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">chat_history</span><span class="o">.</span><span class="n">append</span><span class="p">({</span><span class="s2">"role"</span><span class="p">:</span> <span class="s2">"user"</span><span class="p">,</span> <span class="s2">"content"</span><span class="p">:</span> <span class="n">user_query</span><span class="p">})</span>
            <span class="k">with</span> <span class="n">st</span><span class="o">.</span><span class="n">chat_message</span><span class="p">(</span><span class="s2">"user"</span><span class="p">):</span>
                <span class="n">st</span><span class="o">.</span><span class="n">write</span><span class="p">(</span><span class="n">user_query</span><span class="p">)</span>

            <span class="c1"># Filter input using Llama Guard</span>
            <span class="n">filtered_result</span> <span class="o">=</span> <span class="n">filter_input_with_llama_guard</span><span class="p">(</span><span class="n">user_query</span><span class="p">)</span>
            <span class="n">filtered_result</span> <span class="o">=</span> <span class="n">filtered_result</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="s2">"</span><span class="se">\n</span><span class="s2">"</span><span class="p">,</span> <span class="s2">" "</span><span class="p">)</span>  <span class="c1"># Normalize the result</span>

            <span class="c1"># Check if input is safe based on allowed statuses</span>
            <span class="k">if</span> <span class="n">filtered_result</span> <span class="ow">in</span> <span class="p">[</span><span class="s2">"safe"</span><span class="p">,</span> <span class="s2">"unsafe S7"</span><span class="p">,</span> <span class="s2">"unsafe S6"</span><span class="p">]:</span>
                <span class="k">try</span><span class="p">:</span>
                    <span class="k">if</span> <span class="s1">'chatbot'</span> <span class="ow">not</span> <span class="ow">in</span> <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="p">:</span>
                        <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">chatbot</span> <span class="o">=</span> <span class="n">NutritionBot</span><span class="p">()</span>
                    <span class="n">response</span> <span class="o">=</span> <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">chatbot</span><span class="o">.</span><span class="n">handle_customer_query</span><span class="p">(</span><span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">user_id</span><span class="p">,</span> <span class="n">user_query</span><span class="p">)</span>
                    <span class="n">st</span><span class="o">.</span><span class="n">write</span><span class="p">(</span><span class="n">response</span><span class="p">)</span>
                    <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">chat_history</span><span class="o">.</span><span class="n">append</span><span class="p">({</span><span class="s2">"role"</span><span class="p">:</span> <span class="s2">"assistant"</span><span class="p">,</span> <span class="s2">"content"</span><span class="p">:</span> <span class="n">response</span><span class="p">})</span>
                <span class="k">except</span> <span class="ne">Exception</span> <span class="k">as</span> <span class="n">e</span><span class="p">:</span>
                    <span class="n">error_msg</span> <span class="o">=</span> <span class="sa">f</span><span class="s2">"Sorry, I encountered an error while processing your query. Please try again. Error: </span><span class="si">{</span><span class="nb">str</span><span class="p">(</span><span class="n">e</span><span class="p">)</span><span class="si">}</span><span class="s2">"</span>
                    <span class="n">st</span><span class="o">.</span><span class="n">write</span><span class="p">(</span><span class="n">error_msg</span><span class="p">)</span>
                    <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">chat_history</span><span class="o">.</span><span class="n">append</span><span class="p">({</span><span class="s2">"role"</span><span class="p">:</span> <span class="s2">"assistant"</span><span class="p">,</span> <span class="s2">"content"</span><span class="p">:</span> <span class="n">error_msg</span><span class="p">})</span>
            <span class="k">else</span><span class="p">:</span>
                <span class="n">inappropriate_msg</span> <span class="o">=</span> <span class="s2">"I apologize, but I cannot process that input as it may be inappropriate. Please try again."</span>
                <span class="n">st</span><span class="o">.</span><span class="n">write</span><span class="p">(</span><span class="n">inappropriate_msg</span><span class="p">)</span>
                <span class="n">st</span><span class="o">.</span><span class="n">session_state</span><span class="o">.</span><span class="n">chat_history</span><span class="o">.</span><span class="n">append</span><span class="p">({</span><span class="s2">"role"</span><span class="p">:</span> <span class="s2">"assistant"</span><span class="p">,</span> <span class="s2">"content"</span><span class="p">:</span> <span class="n">inappropriate_msg</span><span class="p">})</span>

<span class="k">if</span> <span class="vm">__name__</span> <span class="o">==</span> <span class="s2">"__main__"</span><span class="p">:</span>
    <span class="n">nutrition_disorder_streamlit</span><span class="p">()</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Overwriting app.py
</pre>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[65]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="o">%%</span><span class="n">writefile</span> <span class="n">requirements</span><span class="o">.</span><span class="n">txt</span>

<span class="n">openai</span><span class="o">==</span><span class="mf">1.55.3</span>
<span class="n">langchain</span><span class="o">==</span><span class="mf">0.2.7</span>
<span class="n">langchain</span><span class="o">-</span><span class="n">community</span><span class="o">==</span><span class="mf">0.2.7</span>
<span class="n">langchain</span><span class="o">-</span><span class="n">huggingface</span><span class="o">==</span><span class="mf">0.0.3</span>
<span class="n">langchain</span><span class="o">-</span><span class="n">experimental</span><span class="o">==</span><span class="mf">0.0.62</span>
<span class="n">langchain</span><span class="o">-</span><span class="n">openai</span><span class="o">==</span><span class="mf">0.1.14</span>
<span class="n">chromadb</span><span class="o">==</span><span class="mf">0.5.3</span>
<span class="n">sentence</span><span class="o">-</span><span class="n">transformers</span><span class="o">==</span><span class="mf">3.0.1</span>
<span class="n">python</span><span class="o">-</span><span class="n">dotenv</span><span class="o">==</span><span class="mf">1.0.1</span>
<span class="n">lark</span><span class="o">==</span><span class="mf">1.1.9</span>
<span class="n">llama</span><span class="o">-</span><span class="n">index</span><span class="o">-</span><span class="n">core</span>
<span class="n">llama</span><span class="o">-</span><span class="n">parse</span><span class="o">==</span><span class="mf">0.5.11</span>
<span class="n">llama</span><span class="o">-</span><span class="n">index</span><span class="o">-</span><span class="n">readers</span><span class="o">-</span><span class="n">file</span>
<span class="n">llama</span><span class="o">-</span><span class="n">index</span><span class="o">-</span><span class="n">llms</span><span class="o">-</span><span class="n">langchain</span>
<span class="n">langgraph</span>
<span class="n">groq</span>
<span class="n">mem0ai</span>
<span class="n">streamlit</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Overwriting requirements.txt
</pre>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[66]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="o">%%</span><span class="n">writefile</span> <span class="n">Dockerfile</span>

<span class="n">FROM</span> <span class="n">python</span><span class="p">:</span><span class="mf">3.9</span>

<span class="n">RUN</span> <span class="n">useradd</span> <span class="o">-</span><span class="n">m</span> <span class="o">-</span><span class="n">u</span> <span class="mi">1000</span> <span class="n">user</span>
<span class="n">USER</span> <span class="n">user</span>
<span class="n">ENV</span> <span class="n">PATH</span><span class="o">=</span><span class="s2">"/home/user/.local/bin:$PATH"</span>

<span class="n">WORKDIR</span> <span class="o">/</span><span class="n">app</span>

<span class="n">COPY</span> <span class="o">--</span><span class="n">chown</span><span class="o">=</span><span class="n">user</span> <span class="o">./</span><span class="n">requirements</span><span class="o">.</span><span class="n">txt</span> <span class="n">requirements</span><span class="o">.</span><span class="n">txt</span>
<span class="n">RUN</span> <span class="n">pip</span> <span class="n">install</span> <span class="o">--</span><span class="n">no</span><span class="o">-</span><span class="n">cache</span><span class="o">-</span><span class="nb">dir</span> <span class="o">--</span><span class="n">upgrade</span> <span class="o">-</span><span class="n">r</span> <span class="n">requirements</span><span class="o">.</span><span class="n">txt</span>

<span class="n">COPY</span> <span class="o">--</span><span class="n">chown</span><span class="o">=</span><span class="n">user</span> <span class="o">.</span> <span class="o">/</span><span class="n">app</span>

<span class="c1"># Start the Streamlit app on port 7860</span>
<span class="n">CMD</span> <span class="p">[</span><span class="s2">"streamlit"</span><span class="p">,</span> <span class="s2">"run"</span><span class="p">,</span> <span class="s2">"app.py"</span><span class="p">,</span> <span class="s2">"--server.address=0.0.0.0"</span><span class="p">,</span> <span class="s2">"--server.port=7860"</span><span class="p">]</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>Overwriting Dockerfile
</pre>
</div>
</div>
</div>
</div>
</div>
<div class="jp-Cell jp-MarkdownCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput" data-mime-type="text/markdown">
<p>Let's upload these files to huggingface spaces.</p>
<p>Add your HF_TOKEN in colab secrets.</p>
<p>Make sure you have initiated a huggingface space before this. Replace the repo name below. Configure all the secrets as used in the app.py file.</p>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[67]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="kn">from</span><span class="w"> </span><span class="nn">huggingface_hub</span><span class="w"> </span><span class="kn">import</span> <span class="n">HfApi</span>
<span class="kn">from</span><span class="w"> </span><span class="nn">google.colab</span><span class="w"> </span><span class="kn">import</span> <span class="n">userdata</span>

<span class="n">api</span> <span class="o">=</span>  <span class="n">HfApi</span><span class="p">(</span>
    <span class="n">token</span><span class="o">=</span><span class="n">userdata</span><span class="o">.</span><span class="n">get</span><span class="p">(</span><span class="s1">'HF_TOKEN'</span><span class="p">)</span>
<span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[68]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Mention your HF space repo id</span>
<span class="n">HF_repo_id</span> <span class="o">=</span>  <span class="s2">"madhjosh/GL_Project_3"</span>
</pre></div>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[69]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="n">api</span><span class="o">.</span><span class="n">upload_file</span><span class="p">(</span>
    <span class="n">path_or_fileobj</span><span class="o">=</span><span class="s2">"requirements.txt"</span><span class="p">,</span>
    <span class="n">path_in_repo</span><span class="o">=</span><span class="s2">"requirements.txt"</span><span class="p">,</span>
    <span class="n">repo_id</span><span class="o">=</span> <span class="n">HF_repo_id</span><span class="p">,</span>
    <span class="n">repo_type</span><span class="o">=</span><span class="s2">"space"</span><span class="p">,</span>
<span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="application/vnd.jupyter.stderr" tabindex="0">
<pre>No files have been modified since last commit. Skipping to prevent empty commit.
WARNING:huggingface_hub.hf_api:No files have been modified since last commit. Skipping to prevent empty commit.
</pre>
</div>
</div>
<div class="jp-OutputArea-child jp-OutputArea-executeResult">
<div class="jp-OutputPrompt jp-OutputArea-prompt">Out[69]:</div>
<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain" tabindex="0">
<pre>CommitInfo(commit_url='https://huggingface.co/spaces/madhjosh/GL_Project_3/commit/0a9a91aa41e7bba7e3e4c6728aeaeae60cccdd4c', commit_message='Upload requirements.txt with huggingface_hub', commit_description='', oid='0a9a91aa41e7bba7e3e4c6728aeaeae60cccdd4c', pr_url=None, repo_url=RepoUrl('https://huggingface.co/spaces/madhjosh/GL_Project_3', endpoint='https://huggingface.co', repo_type='space', repo_id='madhjosh/GL_Project_3'), pr_revision=None, pr_num=None)</pre>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[79]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="n">api</span><span class="o">.</span><span class="n">upload_file</span><span class="p">(</span>
    <span class="n">path_or_fileobj</span><span class="o">=</span><span class="s2">"app.py"</span><span class="p">,</span>
    <span class="n">path_in_repo</span><span class="o">=</span><span class="s2">"app.py"</span><span class="p">,</span>
    <span class="n">repo_id</span><span class="o">=</span> <span class="n">HF_repo_id</span><span class="p">,</span>
    <span class="n">repo_type</span><span class="o">=</span><span class="s2">"space"</span><span class="p">,</span>
<span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child jp-OutputArea-executeResult">
<div class="jp-OutputPrompt jp-OutputArea-prompt">Out[79]:</div>
<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain" tabindex="0">
<pre>CommitInfo(commit_url='https://huggingface.co/spaces/madhjosh/GL_Project_3/commit/921bfc4bab0d5f82358ba3ddfa8fab0c12beafbd', commit_message='Upload app.py with huggingface_hub', commit_description='', oid='921bfc4bab0d5f82358ba3ddfa8fab0c12beafbd', pr_url=None, repo_url=RepoUrl('https://huggingface.co/spaces/madhjosh/GL_Project_3', endpoint='https://huggingface.co', repo_type='space', repo_id='madhjosh/GL_Project_3'), pr_revision=None, pr_num=None)</pre>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[60]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="n">api</span><span class="o">.</span><span class="n">upload_folder</span><span class="p">(</span>
    <span class="n">folder_path</span><span class="o">=</span><span class="s2">"nutritional_db"</span><span class="p">,</span>
    <span class="n">path_in_repo</span><span class="o">=</span><span class="s2">"nutritional_db"</span><span class="p">,</span>
    <span class="n">repo_id</span><span class="o">=</span> <span class="n">HF_repo_id</span><span class="p">,</span>
    <span class="n">repo_type</span><span class="o">=</span><span class="s2">"space"</span><span class="p">,</span>
<span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child">
<div class="jp-OutputPrompt jp-OutputArea-prompt"></div>
<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain" tabindex="0">
<pre>chroma.sqlite3:   0%|          | 0.00/156k [00:00&lt;?, ?B/s]</pre>
</div>
</div>
<div class="jp-OutputArea-child jp-OutputArea-executeResult">
<div class="jp-OutputPrompt jp-OutputArea-prompt">Out[60]:</div>
<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain" tabindex="0">
<pre>CommitInfo(commit_url='https://huggingface.co/spaces/madhjosh/GL_Project_3/commit/ae077283ebb633c05b51873351c8d80cfa8acc72', commit_message='Upload folder using huggingface_hub', commit_description='', oid='ae077283ebb633c05b51873351c8d80cfa8acc72', pr_url=None, repo_url=RepoUrl('https://huggingface.co/spaces/madhjosh/GL_Project_3', endpoint='https://huggingface.co', repo_type='space', repo_id='madhjosh/GL_Project_3'), pr_revision=None, pr_num=None)</pre>
</div>
</div>
</div>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell">
<div class="jp-Cell-inputWrapper" tabindex="0">
<div class="jp-Collapser jp-InputCollapser jp-Cell-inputCollapser">
</div>
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In[61]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
<div class="cm-editor cm-s-jupyter">
<div class="highlight hl-python"><pre><span></span><span class="c1"># Upload Dockerfile</span>
<span class="n">api</span><span class="o">.</span><span class="n">upload_file</span><span class="p">(</span>
    <span class="n">path_or_fileobj</span><span class="o">=</span><span class="s2">"Dockerfile"</span><span class="p">,</span>
    <span class="n">path_in_repo</span><span class="o">=</span><span class="s2">"Dockerfile"</span><span class="p">,</span>
    <span class="n">repo_id</span><span class="o">=</span> <span class="n">HF_repo_id</span><span class="p">,</span>  <span class="c1"># Replace with your username and space name</span>
    <span class="n">repo_type</span><span class="o">=</span><span class="s2">"space"</span>
<span class="p">)</span>
</pre></div>
</div>
</div>
</div>
</div>
<div class="jp-Cell-outputWrapper">
<div class="jp-Collapser jp-OutputCollapser jp-Cell-outputCollapser">
</div>
<div class="jp-OutputArea jp-Cell-outputArea">
<div class="jp-OutputArea-child jp-OutputArea-executeResult">
<div class="jp-OutputPrompt jp-OutputArea-prompt">Out[61]:</div>
<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain" tabindex="0">
<pre>CommitInfo(commit_url='https://huggingface.co/spaces/madhjosh/GL_Project_3/commit/3248102fde0717e15bfa24e9b5fdf2e0279b8172', commit_message='Upload Dockerfile with huggingface_hub', commit_description='', oid='3248102fde0717e15bfa24e9b5fdf2e0279b8172', pr_url=None, repo_url=RepoUrl('https://huggingface.co/spaces/madhjosh/GL_Project_3', endpoint='https://huggingface.co', repo_type='space', repo_id='madhjosh/GL_Project_3'), pr_revision=None, pr_num=None)</pre>
</div>
</div>
</div>
</div>
</div>
</main>
</body>
</html>
